May 11-14, 2009 PACIFICO YOKOHAMA, JAPANA BS T R A CT S

n Invited Lecture (IL)....................................

.........................

KN01-13............................

O001-176n Keynote Lecture (KN)n Oral Presentation (0)n Poster Presentation (P)- 49 -

IL01-04................

P001-318

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

IL01
STEM CELLS AND CANCER STEM CELLS
Toshio Suda, M.D.

Invited Lecture (IL)The Sakaguchi Laboratory of Developmental Biology, School of Medicine, Keio University
The quiescent state is thought to be a characteristic property for the maintenance of hematopoietic stem cells (HSCs).
Interaction of HSCs with their particular microenvironments, known as the stem cell niches, is critical for adult hematopoiesis in
the bone marrow (BM). We demonstrate that quiescent HSCs adhere to osteoblasts (OBs) in the niche through the Tie2/
Angiopoietin-1 and/or mpl/thrombopoietin. Since Ang-1 enhanced the expression of N-cadherin in HSCs and induced the cell.
adhesion to bone, we examined the role of N-cadherin in vivo. When HSC cells transfected with dominant negative N-cadherin,
which lacks extracellular domain, HSC cells can reach bone marrow but not enter the osteoblastic niche, resulting in the defectin hematopoietic reconstitution.
When the BM is ablated during BM transplantation or after treatment with myelosuppressive agents, the quiescent HSCs enter
the cell cycle and proliferate to supply progenitors of committed hematopoietic cells. We found that reactive oxygen species(ROS) induce the exit of HSCs from the niche after 5-FU injection through down-regulation of N-cadherin. Similarly, ROS waselevated after serial BM transplantation, and up-regulation of MAPK p38 and INK4A was detected only in HSCs. In vivo
treatment of recipients with anti-oxidant or p38 MAPK inhibitor restored exhaustion of HSCs in the repeated BM transplantation.
We are now studying the cellular metabolic changes of HSCs. I will show that the metabolism of quiescent stem cells is
glycolysis-dependent in the hypoxic niche, while that of proliferating progenitors are mitochondria-dependent, using HIF-1a/VHLdefficient mice.
Moreover, I want to discuss the therapeutic strategy targeting the niche of cancer cells.
References
1. Kubota Y, Hirashima M, Kishi K, Stewart CL, Suda T. Leukemia inhibitory factor regulates microvessel density by modulating
oxygen-dependent VEGF expression in mice. J Clin Invest. 2008 Jul 1;118(7):2393-2403.
2. Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, Miyamoto K, Yoshiwara H,
Hosokawa K, Nakamura Y, Gomei Y, Iwasaki H, Hayashi Y, Matsuzaki Y, Nakayama K, Ikeda Y, Hata A, Chiba S, Nakayama KI,
Suda T. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes
Dev. 2008 Apr 15;22(8):986-91.
3. Suda T, Arai F. Wnt signaling in the niche. Cell. 2008;132:729-30.
4. Takubo K, Ohmura M, Azuma M, Nagamatsu G, Yamada W, Arai F, Hirao A , Suda T. Stem Cell Defects in ATM-Deficient
Undifferentiated Spermatogonia through DNA Damage-Induced Cell-Cycle Arrest Cell Stem Cell. 2008;2:170-182.
5. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, Gomei Y, Iwasaki H, Matsuoka S, Miyamoto K, Miyazaki H,
Takahashi T, Suda T. Thrombopoietin/MPL Signaling Regulates Hematopoietic Stem Cell Quiescence and Interaction with the
Osteoblastic Niche. Cell Stem Cell. 2007;1:685-697.
6. Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S, Matsuoka S, Miyamoto T, Ito K, Ohmura M, Chen C, Hosokawa K,
Nakauchi H, Nakayama K, Nakayama KI, Harada M, Motoyama N, Suda T, Hirao A. Foxo3a Is Essential for Maintenance of theHematopoietic Stem Cell Pool. Cell Stem Cell. 2007;1:101-112.
7. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, Ohmura M, Naka K, Hosokawa K, Ikeda Y, Suda T. Reactive oxygen
species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006 Apr;12(4):446-451.
8. Suda T, Arai F, Hirao A. Hematopoietic stem cells and their niche. Trends Immunol. 2005 Aug;26(8):426-33. Review.
9. Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, Nomiyama K, Hosokawa K, Sakurada K, Nakagata N, Ikeda Y, Mak
TW, Suda T. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004 Oct
21;431(7011):997-1002.
10. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY and Suda T. Tie2/Angiopoietin-1 Signaling Regulates
Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche. Cell. 2004 Jul 23;118(2):149-61.

IL02
Gliolan in the therapy of malignant gliomas: Quo vadis?
Walter Stummer
University of Düsseldorf
Gliolan (ALA) has been developed and approved in Europe for intra-operative identification of malignant gliomas by inducing
fluorescent porphyrins in these tumors. Data from the pivotal approval study has consequently increased the understanding forthe principle value of cytoreductive surgery in malignant gliomas. Since then, novel data has been collected which underlines thevalue of cytoreductive surgery in the context of recently approved adjuvant therapies such as BCNU-wafers or concomitantradiochemotherapy with temozolomide. On the other hand, ALA-derived porphyrins are potent photosensitizers with efficacy forphotodynamic therapy and demonstrate preliminary efficacy for stereotactic phototherapy of malignant gliomas. Preliminary
experimental evidence indicates immnostimulation to play a role in mediating this efficacy. Finally, ALA-induced tumor porphyrins
may be of value in other tumors relevant to neurosurgeons, such as pituitary adenomas, medulloblastoms, meningiomas orspinal chord tumors.

- 50 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

IL03
Engineering T cells for adoptive therapy
Carmine Carpenito, Michael Milone, Richard Carroll, James Riley and Carl June

IL04
Brain Tumor Stem Cells: New Insights and Challenges in Human andMouse Models
Peter Dirks
Associate Professor of Neurosurgery Dept. of Surgery, Brain Tumour Research Centre, University of Toronto
Human brain tumors appear to have a hierarchical cellular organisation, suggestive of a stem cell foundation. We have recently
derived adherent cell lines with high efficiency from human malignant glioma that display stem cell properties and initiate highgrade gliomas following xenotransplantation. Significantly, these cell lines from different tumors exhibit divergent gene expression
signatures and differentiation behaviour that correlate with specific neural progenitor subtypes. The diversity of gliomas may
therefore reflect distinct cancer stem cell phenotypes.
Adherent brain tumor stem cell lines offer significant experimental advantages compared to ‘sphere’ based cultures, and provide
a simplified model enabling refined studies of cancer stem cell behaviour.
In addition, it remains unclear if genetically engineered mouse models of cancer recapitulate the functional heterogeneity
observed in their human counterparts. We demonstrate medulloblastomas arising from Patched1 (Ptc1+/-)deficient micecontain a subpopulation of cells that demonstrate a neural precursor phenotype, show clonogenic and multilineage
differentiation capacity, wild-type Patched-1 expression, and the ability to initiate tumors following allogeneic orthotopic
transplantation. The normal neural stem cell surface antigen CD15 enriches for the in vitro clonogenic and in vivo tumorigenic
potential from uncultured medulloblastomas supporting the existence of a cancer stem cell hierarchy in this clinically relevantmouse model of cancer. Interestingly, the cell that drives the growth of these tumors has a stem cell phenotype, lending further
support to a potential cell of origin of these tumors from normal cerebellar neural stem cells, or acquisition of a stem cell
phenotype as part of the neoplastic transformation process from lineage restricted progenitors.
I will present these recent data along with my current perspectives on cancer stem cell research, particularly the challenges thefield faces moving forward.

- 51 -­­

Invited Lecture (IL)Abramson Cancer Center, University of Pennsylvania
Adoptive cell transfer immunotherapy is based on the infusion of tumor reactive T cells into patients with cancer. This approach
has multiple advantages compared to other forms of immunotherapy. It is possible to administer large numbers of highly
selected cells with high avidity for tumor specific antigens that are required for CNS tumors, and the cells can be activated exvivo to exhibit anti-tumor effector function and thus do not depend on activating stimuli at the tumor site. The exact cell
subpopulations and effective functions that are required for cancer regression in vivo can be identified and it is possible tomanipulate the host prior to cell transfer to provide an altered environment for the transferred cells. We are exploring the use ofengineered T cells bearing chimeric receptors. As a model for non-immunogenic tumors, we are targeting the surface
membrane glycoprotein mesothelin is a promising target for the immunotherapy of mesothelioma, ovarian, and pancreatictumors due to the uniform overexpression of mesothelin and the benign phenotype of mesothelin null mice. We hypothesize that
previous trials of adoptive immunotherapy for cancer that have used CTL have failed due to poor trafficking to sites of tumor, andinsufficient effector functions to self antigens. Our preclinical data indicates that use of lentiviral engineered T cells with chimeric
receptors that incorporate a ‘tumor resistance genotype’ should have improved function for cancer immunotherapy. We havetested mesothelin redirected T cells in humanized mouse models bearing tumor xenografts. The T cells are able to eradicate
large, well established tumors at an E:T ratio of at least 1:70 in vivo. Three routes of administration with redirected T cells havebeen tested in mice bearing xenografted flank tumors. The intraperitoneal route was found to be inferior to intravenous or direct
intratumoral injection of the redirected T cells. Long term engraftment of the redirected T cells correlates with antitumor efficacy.
This strategy could be adopted to CNS tumors, where the engineered T cells could prove to have resistance to the highly
immunosuppressive tumor microenvironment that is characteristic of glioblastoma.
References:
1. Carpenito C, Milone MC, Hassan,R., Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda
SM et al 2009. Control of large established tumor xenografts with genetically re-targeted human T cells containing CD28 andCD137 domains. Proc Natl Acad Sci U S A 106:3360-3365.
2. Milone MC, Fish,J., Carpenito C, Carroll RG, Binder GK, Teachey,D., Samanta M, Lakhal M, Danet-Desnoyers G, Gloss B
et al 2009. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells andincreased anti-leukemic efficacy in vivo. Mol Ther. In press.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

KN01
SURGERY ON PATIENTS WITH SYMPTOMATIC LOW GRADE GLIOMA IN CRITICAL BRAIN AREA
Christianto B. Lumenta, M.D., Ph.D., Matthias Krammer, M.D., David Schul, M.D., Moni Lehl, M.D.

Keynote Lecture (KN)

Department of Neurosurgery, Bogenhausen Academic Teaching Hospital, Technuical University of Munich,Englschalkinger Str. 77, 81925 Munich – GERMANY
Objective: Up to now there still has been no therapeutic standard for the heterogenic groups of low grade gliomas (LGG).
Our tumor data bank demonstrates an incidence of 5 -10% LGG among averaged 180 primary surgically treated brain
tumors per year with an increasing tendency. In this manuscript we describe our operative procedure and its results onpatients with symptomatic LGG in critical brain area.
Methods: The analysis revealed 30 patients with LGG who were operated on in the last 3 years. Most patients had diffuse
astrocytoma WHO grade 2 (15 patients). Rare tumors such as ganglioglioma (4), central neurocytoma (2) andsubependymoma (2) were also diagnosed during this period. The tumor was mostly localized perisylvian (15) less inventricle (5), brainstem (5), central region (4) or basal ganglia (1). All patients were operated on with navigation support,
endoscopic- microsurgical technique and intraoperative neurophysiologic monitoring (IOM) of different modalities. Since
2007 the morphologic data ha been fused with the functional one (fMRI, DTI as well as PET) for navigation setting.
Results: Total excision could be achieved in 17 patients. Subtotal (11)or part resection (2) has had to be performed due tothe functional data and the IOM results. Temporary worsening of the neurological finding occurred in 18 patients for several
days. The examination 3 months after surgery and later on demonstrates, however, an improvement status in comparison
to that before surgery in 25 patients. During this period no recurrence surgery was needed. The seizures improve in 10/ 13
patients with or without antiepileptic drugs but in decreased dosage.
Conclusion: Our results show that LGG in critical area can be operated on safely with good outcome thus improvement of
the quality of life. This therapeutic option using modern morphologic and functional data should be offered to patients withsymptomatic LGG

KN02
The Role of MicroRNAs in Malignant Glioma
Chiocca EA, Godlewski J, Nowicki MO, Bronisz A, Otsuki A, Ray-Chaudhury A, Newton HB,
Novo G, Lawler S
Dardinger Laboratory for Neuro-Oncology and Neurosciences, Departments of Neurology, Neurosurgery, andPathology, The Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute,
Columbus, Ohio, USA
MicroRNA’s (miR’s) are recently described small non-protein-coding RNA molecules that are involved in the modulation ofprotein synthesis, via binding to complementary mRNA. They are also known to modify the activity of oncogenes andtumor suppressor genes of tumors, such as glioblastoma multiforme (GBM), the most common and deadly form of brain
cancer. Using microarray analysis and quantitative RT-PCR, we have noted that miR-128, which is normally abundant innormal brain tissue, is significantly under-expressed in GBM tumor samples (18.75-fold reduction). Ectopic expression of
miR-128 using oligonucleotide precursor or lentiviral vector reduced glioma cells growth considerably – both in vitro (U87,
U251) in vivo (flank), as well as in models that enrich for glioma “stem-like” cells. Direct effects on several target genes
functionally linked to regulation of oncogenic growth related processes, as well as impact exerted on stem cell – like selfrenewal will be discussed. Another characteristic of gliomas is invasion into normal tissues. miR-451 was noted to have themost profound change in expression during the invasion process (relative signal strength drop from 2.753 to 0.000) when
we compared invading vs. non-invading glioma cells. This down-regulation during invasion was corroborated in a numberof glioma cell lines. In over-expression experiments, cells treated with pre-miR-451 or stably expressing pri-miR-451
demonstrated significantly reduced migratory behavior during invasion assay experiments. Potential targets of miR-451,
involved in migration/invasion processes, will be discussed and validated. In concluiosn, miR’s are important modulatorsof GBM proliferation and invasion, and have the potential to be used as diagnostic or therapeutic agents.

- 52 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANKN03
COMPREHENSIVE GENOMIC CHARACTERIZATION OF GLIOBLASTOMA: THE CANCERGENOME ATLAS EFFORT.
W. K. Cavenee, Ph.D.
Professor, University of California-San Diego
Director, Ludwig Institute for Cancer Research- San Diego Branch, La Jolla, CA 92093-0660

KN04
The future treatment of anaplastic glioma: lessons from NOA-04 andbeyondWolfgang Wick1
Department of Neurooncology, University of Heidelberg, Heidelberg, Germany

1

The common practice of care for anaplastic astrocytoma (AA) is to use postoperative radiotherapy alone or to embark on
regimens developed for the treatment of malignant gliomas in general. Can and should the increase in survival gained byradiochemotherapy with temozolomide (TMZ) in glioblastoma be extrapolated to patients with AA. Taking the evidence on
nitrosourea-based therapy from the glioma meta-analysis, it would seem reasonable to suggest that a similar survival
benefit might be seen amongst AA patients. However, there are concerns regarding late neurotoxicity related to theadministration of concurrent radiochemotherapy, especially for patients who are living long enough to experience theseunwanted sequelae. In the early 1990s, physicians began treating most AO patients with procarbazine, lomustine (CCNU),
and vincristine (PCV) chemotherapy not only at recurrence but also at diagnosis in combination with or without
radiotherapy, despite the lack of convincing data supporting this practice. In the United States, the prospective randomized
Phase III Radiation Therapy Oncology Group (RTOG) study (R9402) compared radiotherapy with and without preceding
PCV. The contemporaneous study of the European Organization for Research and Treatment of Cancer (EORTC) (26951)
used the same comparators but completed radiotherapy before commencing PCV. Both trials showed increased
progression-free survival (PFS) but not overall survival (OS) in patients receiving radiochemotherapy, gained at the cost of
relevant toxicity with the PCV regimen. Deletion of 1p and 19q may predict a superior outcome in AO and anaplastic
oligoastrocytoma (AOA) in response to genotoxic treatments but not in patients with low-grade oligodendroglial tumors
treated with surgery alone. To date, it has still remained unclear whether the combined1p/19q deletions simply represent a
molecular signature in anaplastic gliomas, which reflects a favorable natural biological behavior, or whether these markers
are mechanistically related to response to therapy. The NOA-04 phase III, multicenter, open-label trial compared theefficacy and safety of radiotherapy versus chemotherapy (PCV or temozolomide) in 318 patients with newly diagnosed,
supratentorial anaplastic gliomas of WHO grade III. In addition, the clinical significance of 1p/19q deletion and MGMT
promoter methylation in these tumors was assessed in a translational study. Median time-to-treatment failure (TTF), PFS,
and OS were not different between arms. Patients with an astrocytic tumor had a worse TTF. Oligoastrocytic tumors sharethe same favourable risks of pure oligodendroglioma. Combined 1p/19q deletion and hypermethylation of the MGMT genepromoter provided a large risk reduction for TTF and PFS irrespective of histology and treatment. In conclusion, there is an
identical clinical course of anaplastic oligodendroglioma and oligoastrocytoma. The favourable impact of anoligodendroglial component was as strong as detecting combined 1p/19q deletion in the tumor tissue. MGMT promoter
methylation was associated with prolonged PFS also in the radiotherapy arm A. Initial therapy in all anaplastic gliomas could
possibly be either temozolomide or radiotherapy. The next challenges include intensifying therapy for anaplastic gliomas
with unfavourable prognosis (e.g. no MGMT methylation, no combined 1p/19q deletion) and optimizing treatment foranaplastic gliomas with favourable prognosis without increasing toxicity. Trials basically testing radiochemotherapy withtemozolomide separate for these entities are ongoing. Further, it will be important to test novel agents also in anaplastic
gliomas, especially if influence on differentiation, angiogenesis or invasiveness can be postulated with a potential of
influencing malignant progression.

- 53 -­­

Keynote Lecture (KN)

Background: Advances in understanding the genetic basis of cancer have led to the identification of molecules that are
specifically expressed or mutated in tumors. Such molecules represent targets for therapy whose targeting might be
expected to have increased selectivity for tumor cells compared to normal tissue with resultant enhancements in effect andreductions in the non-specific toxicities that lead to chemotherapeutic side effects. In order to provide a large-scale
comprehensive catalogue of such targets, the National Institutes of Health have initiated The Cancer Genome Atlas project
and the first cancer to be subjected to this multi-center analysis is glioblastoma multiforme. The purpose of this lecture is toreview the progress this effort has made.
Methods and Results: The purpose of the TCGA is to catalogue and discover major cancer-causing genome alterations inlarge cohorts of human tumors through integrated multi-dimensional analyses. To this end, a committee screened
retrospective biospecimen repositories for possible inclusion and each of these was then reviewed at the Biospecimen
Core Resource. This resulted in approximately 35% of candidates being included in the initial studies (n=206). Thesesamples were considered to be of sufficient quality and size to be entered into the analysis stage. Various parameters werethen examined: DNA copy number by high-resolution comparative genomic hybridization, gene and microRNA expression
was determined on several platforms, loss of heterozygosity was determined using single nucleotide polymorphism arrays,
cancer-specific DNA methylation in CpG islands and promoters of 2305 genes was determined using Golden Gate
technologies, and 91 matched normal-tumor pairs were subjected to Sanger sequencing of 601 selected genes. All of thisinformation was then entered into a large database for statistical analysis in the Data Coordinating Center (http://
cancergenome.nih.gov/) that has various levels of public accessibility. The major findings from this effort are: 1) it is possible
to perform a comprehensive, multi-institution, multi-investigator effort and the structure to accomplish this has now been
established; 2) genes that were previously found to be targets of the oncogenic process such as EGFR, PDGFRA, MDM2,
CDK4/6, CDKN2A/B, PTEN, RAS and AKT were found to have significant levels of alterations in this larger dataset; 3) new
potential targets such as NF1, ERBB2, MET, PIK3R1 were discovered; 4) an interaction between MGMT promoter
methylation and a hypermutator phenotype was uncovered with clinical significance for the application of alkylating
tharapeutics.
Conclusions: These results demonstrate the value of a large comprehensive genetic analysis of tumors, particularly
glioblastoma multiforme. The alterations that were uncovered in this way suggest a limited number of signaling/metabolic
pathways that are likely to be defective in tumors and furthermore that targeting pathways rather than specific molecules
may be a reasonable approach in future.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

KN05
MR Metabolic and Physiological Imaging of Patients with Glioma
Sarah J. Nelson, PhD
University of California, San Francisco

Keynote Lecture (KN)MR imaging is an important technology that is of interest for diagnosing, planning focal therapy, evaluating treatment effects
and assessing prognosis for patients with glioma. Despite the widespread application of conventional anatomic imaging
techniques, there is a critical need for more advanced methods that are able to characterize biological properties of thelesion and surrounding normal brain. This is particularly important for understanding the effects of combination therapies,
which influence proliferation and angiogenesis, as opposed to having a direct effect on cell viability. A number of advancedin vivo MR imaging methodologies are being evaluated in the clinic to see which combination of parameters are the most
relevant for evaluating patients with gliomas.
Anatomic Parameters: In addition to optimizing the acquisition times and resolution of anatomic images with standard
contrast mechanisms, high resolution T2*weighted magnitude and phase images are being acquired with 3T and 7T wholebody scanners. These images visualize heterogeneity in the region of T2 hyperintensity caused by local changes insusceptibility due to hemorrhage and other treatment effects. Using either the phase image alone or by the applying postprocessing methods to generate susceptibility weighted data it is possible to visualize small veins and hence examine
differences between the tumor and surrounding tissue.
Vascular Parameters: To further measures changes in vascular properties, data acquisition and analysis techniques havebeen developed to measure arterial spin labeling, Dynamic Contrast Enhanced (DCE) and Perfusion Weighted (PW)
Images. The latter two methods utilize changes in T1-weighted or T2*-weighted images during and after an injection ofGadolinium to estimate parametric maps of with vascular density and permeability. This is particularly important for theevaluation and quantification of measures of response for patients receiving anti-angiogenic therapies.
Structural Parameters: Degradation in the normal architecture of the brain can be evaluated using Diffusion Tensor
Imaging. This gives information about the change in the magnitude of the apparent diffusion coefficient of water (ADC), as
well as utilizing the directional properties of the diffusion tensor to mapping of connectivity using tractography. The ADC
measurements have been reported as being linked to tumor cellularity and as being an early predictor of treatment
effectiveness. The tractography is being used routinely for pre-operative analysis of the disruption in normal tissue structurecaused by the tumor and for surgical planning.
Metabolic Parameters: The use of MR spectroscopy methods has been a major focus of our brain tumor research. 1-H
spectroscopy has been shown to highlight areas of metabolically abnormal, non-enhancing tumor that are important forassessing disease burden, treatment planning and assessing treatment response. Of particular interest are the spatial
extent of areas where both the spectral peak corresponding to choline containing compounds and the peaks from lactate
and/or lipid are elevated. Quantitative measures of these regions have been shown to be predictive of poor outcome inpatients with GBM. More recent studies using very rapid spectroscopy acquisitions following the injection of hyperpolarized
C-13 agents have shown promise for monitoring metabolically active lactate.

KN06
Brain tumor initiation and development, influence of cancer stem-like cells.
Rolf Bjerkvig
NorLux Neuro-Oncology, Department of Biomedicine, University of Bergen, Norway and Centre Recherche PublicSanté, Luxembourg
The molecular events that lead to the cancer-initiating cell involve critical mutations in genes regulating normal cell growthand differentiation. Cancer stem cells, or cancer initiating cells have been described in the context of acute myeloid
leukemia, breast, brain, bone, lung, melanoma and prostate. Yet, there is emerging evidence for that tumor initiation may
occur also from tumor cells that are not defined as cancer stem cells. The origin of the cancer initiating cell and theirmechanisms of progression are not clear. At present there are two main models of cancer development 1) The hierarchicalmodel that suggests that tumours are generated and maintained by a small subset of undifferentiated cancer stem cells
that are able to self renew and differentiate into the bulk tumour population, and 2) The stochastic model implying thattumor progression is the result of acquired genetic variability within the original clone allowing sequential selection of moreaggressive subclones.
The strongest evidence for a hierarchical model comes from studies of Leukemia. For other tumors, however, the evidence
is less clear. It has often been a problem to identify a clear-cut marker that defines the cancer stem cell. For brain tumors,recent evidence show that also CD133- cells can be tumorigenic indicating that CD133 is not a unique marker for cancer
stem cells in the CNS. Therefore, it is not clear if brain tumor development follow a hierachical or stochastic model ofprogression..
What is clear is that within tumors, there are tumor cells that express and behave as stem cells. These cells can as normal
stem cells, adapt to new micro-environments and may well represent the most resistant cells to therapy. Based on theiradaptability and differentiation capacities they can most likely not be defined by a specific marker. To what extent theenvironment and epigenetic factors influence the cancer stem like cells deserves further studies. In conclusion, increased
knowledge of developmental aspects in relation to self-renewal and differentiation, both under normal and deregulated
conditions, will probably shed more light on the mechanisms that lead to tumor initiation and progression.

- 54 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANKN07
Can we Develop Management Strategies for Adults and Children withPrimary Brain Tumors in Low Income Countries?
Jonathan L. Finlay
Keck School of Medicine, University of Southern California, USA and the International Outreach Committee, Society of
Neuro-oncology.

KN08
Involvement of VEGF-VEGFR System in the Progression of Cancer including
Brain Tumors.
Masabumi Shibuya
Department of Molecular Oncology, Tokyo Medical and Dental University, Tokyo Japan
An endothelial cell-specific growth factor VEGF (VEGF-A) is deeply involved in physiological as well as most of thepathological angiogenesis detected in cancer and arthritis. VEGF-A binds and activates two tyrosine kinase (TK) receptors,
VEGFR-1 (Flt-1) and -2 (KDR/Flk-1). VEGFR-2 has a 10-fold higher kinase activity compared to that of VEGFR-1, whereas
VEGFR-1 has a strong affinity to VEGF-A. The major signaling pathway from VEGFR-2 has recently been clarified. However,the possible role of VEGFR-1 and its signaling are not fully understood yet.
1. A unique signaling of VEGFR-2 for angiogenesis.
First, I will briefly summarize the signaling of VEGFR-2, the major positive signal transducer for angiogenesis. We found that
VEGFR-2 activates a unique signaling, PLCγ-PKC(C-kinase)-Raf-MAP kinase pathway for DNA synthesis in endothelial
cells. Ras-activation was only minor for this downstream signaling from VEGFR-2. Also, we have shown that a single
autophosphorylation site 1175PY (phosphotyrosine. 1173-position in mice) is critical for this pathway. 1173F/F mutant micedied at E8.5-9.0 with a severe defect on vasculogenesis, indicating that this pathway is important for angiogenesis in vivo,
and a good target for suppression of tumor angiogenesis.
2. An important role of VEGFR-1 in tumor growth and metastasis.
VEGFR-1 gene knockout mice are embryonic lethal due to an overgrowth of blood vessels at E8.5, suggesting a negativerole of VEGFR-1 in early embryogenesis. We showed that VEGFR-1 ligand-binding domain [VEGFR-1 TK-/-] rescues thislethality. Since VEGFR-1 TK-/- mice develop essentially normal angiogenesis, these mice are useful to study the role of
VEGFR-1 signals at adult stages in disease models such as cancer. We found that in various tumors, tumor growth andangiogenesis are significantly lower in VEGFR-1 TK-/- mice compared with that in the wild type mice mostly due to a defectof macrophage recruitment from bone marrow. In collaboration with us, Kerber et al. also showed a slower growth ofgliomas in VEGFR-1 TK-/- mice.
VEGFR-1 is expressed not only in vascular endothelial cells but in macrophages, suggesting that VEGFR-1 plays animportant role in the promotion of tumors including glioma via activation of macrophage-lineage cells. Finally I will discuss
on a possible increase in tumor aggressiveness after low oxygen-nutrition stress.

- 55 -­­

Keynote Lecture (KN)

The Problem: About 200,000 primary brain tumors are diagnosed world-wide each year, 70% in low income countries.
The cure rates for several cancers of both children and adults have improved markedly in high income countries in recent
decades. However, substantial improvements in the cure of patients with primary brain tumors remain an elusive goal evenin high income countries, except for those with “pediatric” brain tumors such as medulloblastomas, ependymomas,
pilocytic astrocytomas and germ cell tumors. Quality of life has improved for many brain tumor patients in high income
countries, even in the absence of improved cure rates, through introduction of advanced imaging, neurosurgical and more
focused radiotherapeutic technologies.
Concerted efforts in recent years in several low income countries throughout the world, mainly focused on children withleukemias and lymphomas, have produced remarkably speedy and dramatic improvements in cure rates. However, suchtumors do not require neurosurgical, imaging and radiotherapeutic skills and technology to improve outcome.
No single approach can be employed in tackling the problem of patients with brain tumors in low income countries: first,
there is tremendous heterogeneity of resources amongst low income countries: one cannot compare Paraguay with Brazil,
the Congo with the Republic of South Africa, or Cambodia with Thailand. Any and all efforts must be placed within thecontext of the major prevailing health issues of the particular country: malnutrition, sanitation and water supply, infectious
disease (including but not confined to HIV-AIDS), immunization. Efforts must recognize that in the majority of low income
countries, some 35-60% of the population will be less than 21 years of age – necessitating a substantial “pediatric” focus.
Finally, for several countries, one cannot even begin to consider definitive treatment of brain cancer when there is a total
absence of potent analgesics, anticonvulsants or even dexamethasone…….One cannot address improving neurosurgicalskills in so many countries who have fewer than one neurosurgeon for 12 million people (70% of African countries, at least)
when WHO recommends one per 100,000 people. One cannot address radiotherapeutic techniques when 90% of theAfrican continent has less than one machine for 30 million people –and where expertise lags even further behind availabilityof equipment.
The Solution: (a) The “Big Picture” - Creation of a global patchwork quilt………triaging of efforts, avoidance of duplication,
maximizing economy of effort, serving to connect interested/enthusiastic individuals/programs with emerging countries’
programs. (b) The details – Palliative care/quality of life strategies for malignant glial tumors; neurosurgical/neurooncological training in and establishment of regional centers; establishment of satellite centers affiliated with regional
centers to facilitate decentralization of supportive and acute care; development and adaptation of radiotherapy avoiding
treatment strategies for “pediatric” brain cancers.
The WFNO Mini-Symposium on Developing Strategies for Brain Tumor management will endeavor to address several
aspects of this “solution” already in operation in different parts of the world.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

KN09
EGFR signaling through an Akt/SREBP1-dependent, rapamycin-resistantpathway sensitizes glioblastomas to anti-lipogenic therapy
Deliang Guo, Akio Iwanami, Daisuke Kuga, Julie Dang, H. Ian Robbins, Minesh Mehta,
John Kuhn, Michael Prados, Steve Horvath, Caius Radu, Timothy F. Cloughesy,
Paul S. Mischel
ABSTRACT
Glioblastoma, the most common malignant brain tumor, is amongst the most lethal and difficult cancers to treat. Although
EGFR-mutations are frequent in glioblastoma, their clinical relevance is poorly understood. Unexpectedly, studies of tumors
from patients treated with the EGFR-inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocationof the master transcriptional regulator of fatty acid synthesis, SREBP1. We show that this response is mediated by Akt, but
surprisingly clinical data from rapamycin-treated patients shows that SREBP1 activation is independent of the mTORC1,
potentially explaining its poor efficacy in the treatment of such tumors. The importance of these observations areunderscored by the finding that non-EGFR-activated glioblastomas are resistant to inhibition of fatty acid synthesis whereas
introduction of an activated EGFR-allele sensitizes tumor xenografts in mice to cell death, which is augmented by the HMGCoA reductase inhibitor atorvastatin. These results identify a novel EGFR-mediated pro-survival metabolic pathway,
suggesting a promising approach for treating EGFR-activated glioblastomas.

Keynote Lecture (KN)

KN10MANAGEMENT OF YOUNG CHILDREN NEWLY-DIAGNOSED WITH CENTRAL NERVOUS
SYSTEM (CNS) EMBRYONAL TUMORS: 18 YEARS OF THREE SEQUENTIAL IRRADIATIONAVOIDING CHEMOTHERAPY STUDIES - THE “HEAD START” PROTOCOLS
Jonathan L Finlay1, Kelley Haley1, Girish Dhall1, Jason Fangusaro1, Susan Chi1, Jeffrey Allen2,
Stephen Sands3, Richard Sposto1, Sharon Gardner2
1Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California,
USA 2New York University School, of Medicine, New York, NY , USA 3Columbia Babies Hospital, Columbia University,
New York, USA

Study Purpose: To improve the survival and quality of life for young children with newly-diagnosed primary malignant CNS
embryonal tumors through a strategy of relatively brief and intensive chemotherapy (<5 months duration), followed bymyeloablative chemotherapy in an effort to avoid CNS irradiation.
Study Design: Since 1991, three sequential prospective non-randomized multi-center feasibility studies have been
conducted. In the first study, “Head Start” I (1991-1997) eligible children received a single treatment strategy: Induction
chemotherapy of vincristine, cisplatin, cyclophosphamide and etoposide administered every 21-28 days for 5 cycles(Regimen A). This was followed by a single cycle of myeloablative chemotherapy (thiotepa, carboplatin and etoposide) andrescue with autologous hematopoietic progenitor cells. In the subsequent “Head Start” II (1997-2003) study, patients withlocalized medulloblastoma/PNET received the “Head Start” I Induction Regimen A, while patients with AT/RT or metastatic
tumor received a modified Induction Regimen A2 intensified with high dose systemic methotrexate (HD-MTX, 400mg/Kg).
In the current “Head Start” III study (2003 to present), all patients receive the same new Induction Regimen D, which
includes 3 cycles of Regimen A2 (cycles 1, 3 and 5), alternating with two new cycles (cycles 2 and 4), in which HD-MTX
and cisplatin are deleted, and replaced by oral etoposide and oral temozolomide.
Summary of Results: In children with medulloblastoma, gross total resection of localized primary tumor, absence ofdissemination and desmoplastic histology conferred highly favorable irradiation-free 5-year overall survivals (OS) of 73%(classical) and 88% (desmoplastic). The use of HD-MTX in the “Head Start”II protocol produced markedly improved 5-year
EFS (45%) and OS (53%) for children with disseminated medulloblastoma, exceeding even the 5-year EFS of 29% forchildren with localized but incompletely resected medulloblastoma who did not receive HD-MTX. For this reason, the “HeadStart” III regimen incorporates HD-MTX for all children. For children with supratentorial PNET (sPNET), the only statisticallysignificant prognostic factor was location; children with pineal region PNET (pineoblastoma) experienced poorer outcome
than those with non-pineal sPNET (EFS of 15% versus 44% and OS of 25% versus 62%). The small group of patients withbrainstem PNET represents the first reported cures (2/6 patients) of this rare entity. For children with AT/RT, the addition of
HD-MTX in “Head Start” II resulted in an overall significant improvement in 5-year EFS (43%) and OS (54%), but only forpatients with localized disease at diagnosis. Prospective longitudinal follow-up, including formal quality of life,
neuropsychological, endocrine and audiometric assessments of the surviving patients is ongoing, and has now been
completed for “Head Start” I and II. Neuropsychological studies document preserved quality of life and intellectual
functioning for those children who avoided irradiation, including children who received HD-MTX. Hearing loss continues tobe the major long-term morbidity of treatment, and seems magnified by the use of ototoxic antibiotics during treatment.
Endocrine studies have identified only rare isolated examples of growth or thyroid dysfunction requiring hormonal
replacement therapy. Second malignancies have not been identified in patients receiving only protocol chemotherapy
without CNS irradiation.
Conclusions: The "Head Start" protocols have demonstrated significant improvements in both the survival and quality oflife of young children with CNS embryonal tumors, compared with previously published treatment regimens.

- 56 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANKN11
The chemotherapeutic management of low grade gliomas
Eric Bouffet
The Hospital for Sick Children, Toronto- 57 -­­

Keynote Lecture (KN)

Low grade gliomas (LGG) account for the largest group of brain tumours in the paediatric age, representing approximately
one third of all childhood brain tumours. These tumours can arise in any part of the nervous system. Subtypes of LGG are
distinguished by their histological features, but all LGGs are classified as World Health Organization (WHO) grade I or II.
LGG are usually slow growing although for reasons that are not completely clear, some of these tumours may show
aggressive behaviour and/or have erratic growth rates, particularly in young children with hypothalamic/chiasmatic gliomas.
Surgery is the treatment of choice of resectable tumours and is often curative in these instances. However, a large numberof paediatric LGG arise in areas where the role of surgery is limited, due to the risk of morbidity associated with attempts ataggressive resection. Radiation therapy to such tumours has demonstrated evidence of benefit, with objective radiographic
responses often for long periods of time, although the use of radiation therapy in young children results in serious long-termsequelae, including permanent neurocognitive and neuroendocrine deficits, as well as an increased risk of vasculopathy
and second malignancy. It is now clear that chemotherapy can delay the need for radiation therapy. Over the past decade,the upfront use of chemotherapy has become standard therapy for children and infants with unresectable tumours.
Various regimens have been tested, both in chemotherapy naïve patients and in patient with recurrence after previous
radiation and/or chemotherapy. Carboplatin is one of the most effective agents against low-grade gliomas. The regimen of
weekly carboplatin and vincristine has been extensively piloted and is considered by many to be the standard
chemotherapeutic regimen for young children with unresectable low-grade gliomas. Other regimens have been suggested,
and the choice between different options is often a challenge for paediatric oncologists. Beside the efficacy, the decision
should take into account various factors such as short and long term toxicity, the route and schedule of administration andthe cost.
Recent prospective studies have shown that a majority of children (up to 70%) will require additional treatments after a firstline of chemotherapy. The management of these children who do not respond to upfront chemotherapy or show
progression after a first line of treatment is challenging. Traditionally, radiation has been offered as a “salvage treatment”,
regardless of the age of the patient. Increasingly chemotherapy is being been considered in this context, particularly when
young age predicts significant neuro-intellectual deficits with the use of radiation. Several studies are ongoing, looking at
new agents or combinations in children with recurrent LGG. How many lines of chemotherapy can be used withoutcompromising long term outcome is still unclear. It appears however that the use of multiple lines of chemotherapy is
possible and that the need for radiation can be reduced to a small proportion of children.
Recently, biological studies have suggested that it might be possible to predict the behaviour of paediatric LGG byevaluating the proliferation index (mib-1 or Ki-67), microvessel density, or telomere length. Evaluation of these parameters inprospective protocols is ongoing and the results of these studies may potentially influence the chemotherapeutic
management of patients with low risk and high risk features.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

KN12Neuropsychological Functioning and Outcome for Brain Tumor Patients
Stephen A. Sands, Psy.D.
Assistant Professor of Pediatrics and Psychiatry
Columbia University Medical Center, New York, New York 10032

Keynote Lecture (KN)

Survival rates for those diagnosed with brain tumors have generally improved with advances in surgery, radiation therapy,
and chemotherapy. As a result, understanding the long-term impact of therapy including the neurocognitive andpsychological effects of cancer treatment are important. Most brain tumor survivors who achieve durable survival often
present with various deficits. Significant sequelae, including intellectual decline, as well as variable attention-concentration,
slow processing speed and motor deficits have been observed as a result of treatment, with specific risk factors including
young age at the time of treatment, higher dose and larger brain volume involved in radiotherapy, and longer follow-up.
Cranial irradiation has been associated white matter changes, particularly in the frontal cortex. Consequently, a young childtreated for Medulloblastoma with craniospinal radiation will likely experience more adverse late effects as compared with anadolescent treated for a CNS germinoma with focal radiotherapy. In an effort to preserve intellectual functioning and qualityof life, many current treatment studies are utilizing reduced doses and volumes of radiotherapy, while others are employing
postoperative chemotherapy to delay or avoid radiation therapy.
Despite “benign” histology and lower toxicity of treatments for low grade tumors that are commonly limited to maximal
surgical resection, these tumors are associated with increased risk for late effects in both cerebellar and supratentorial
locations given their slow growing and infiltrative presentation. In contrast, high-grade gliomas are a group of CNS tumors
characterized by heterogeneity and a typically poor treatment response to surgery, chemotherapy and radiotherapy.
Consequently, newly emerging treatment regimens often involve significant toxicities which necessitate the sequential
measurement of quality of life by both patient- and caregiver-report as a primary outcome in conjunction with length ofsurvival.
Two prominent pediatric multi-center intervention studies in the U.S. involved the use of Methylphenidate (Ritalin)
medication and the other utilized a Cognitive Remediation Training Program in order to address symptoms such asattention, memory and academic achievement difficulties following treatment for pediatric cancer and the results havedemonstrated modest effect sizes. Similarly, recent adult studies have reported encouraging pilot data in response topatients using substances such as Donepezil (Aricept), Modafinil (Provigil) and Ginkgo biloba.
Emotional effects from the treatment of a brain tumor vary depending on the patient, diagnosis, location of disease,treatment type, family dynamics and pre-existing psychological conditions. Some studies indicate that brain tumor
survivors are at no greater risk for long term emotional sequelae than would normally be expected in a healthy population
with lower levels of psychological distress, better psychological health, lower levels of aggressiveness, antisocial behavior
and substance abuse than case controls. However, other survivor studies have identified social difficulties in withdrawal,
isolation and poor social competence attributed to physical appearance, functional impairments, and reduced time withpeers. Thus, while information about brain tumor patients’ social-emotional and behavioral functioning continues toemerge, there does appear to be an increased risk for deficit in certain domains of physical and psychosocial functioning.
Consequently, there is currently a change underway in research orientation from cancer treatment as a necessarily
pathology-inducing experience but rather focusing upon the skills and resilience of patients and families who were
struggling with a difficult situation. As such, it is important to identify risk factors in patients and families in order to tailor
interventions to minimize the psychological sequelae in brain tumor survivors.
In sum, neuropsychological, social-emotional, behavioral and quality of life evaluations and interventions provide a range ofbenefits to the field of neuro oncology including the assessment of functioning prior to treatment, as well as measuring theneurocognitive impact between treatment regimens and facilitating the psychological transition through treatment andbeyond into survivorship.

KN13
primary central nervous system lymphoma
Antonio M. Omuro, MD
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Chemotherapy, with or without radiotherapy, is the mainstay of treatment for primary central nervous system lymphoma(PCNSL). High-dose methotrexate (MTX) is the most effective drug, and is used in doses of 1-8 g/m2 either as a single
agent or in combination with other drugs such as corticosteroids, cytarabine, procarbazine, vincristine, carmustine,
lomustine, thiotepa, cyclophosphamide, temozolomide, and rituximab. To date, an overwhelming number of different
regimens utilizing high-dose MTX have been reported. However, given the lack of randomized trials, the optimal treatment
remains controversial. Varying methodology makes the comparison of available studies extremely difficult; however, somecommon themes can be found throughout literature. Treatment paradigms vary considerably according to the patient’s
age. Most studies support the use of chemotherapy-only treatments for elderly patients (> 60 years), given the high risks ofneurotoxicity associated with radiotherapy. However, the prognosis remains poor independent of the chemotherapy
chosen, and less toxic regimens might be preferable for such elderly patients. Conversely, the goal of treatment in younger
patients (< 60 years) is a cure, and a more aggressive approach seems warranted. Growing evidence suggests that
commonly used chemotherapy-only regimens for younger PCNSL patients are associated with increased relapse rates that
may not justify deferral of radiotherapy. Thus, a significant focus of research has been the development of intensified
chemotherapy regimens that could replace radiotherapy. Several ongoing studies are evaluating the role of high-dose
chemotherapy with stem cell rescue utilizing drugs that penetrate the blood-brain barrier. An important feature of thesestudies is the inclusion of thorough neuropsychological evaluation in order to evaluate the long-term cognitive outcomes.
Another important venue of investigation is trying to identify molecular predictors of aggressiveness, as well as markers of
biological predisposition for neurotoxicity, which would allow more judicious therapeutic decisions.

- 58 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO001
NG2 EXPRESSION ESTABLISHES A LINK BETWEEN NEURAL PRECURSORS AND
CANCER STEM CELLS IN GLIOBLASTOMAThis Abstract nominated the Hoshino Award.
Please refer to P049 on page 146.

O002
A SINGLE CD133-POSITIVE CELL IS CAPABLE OF PRODUCING GLIOMA POPULATION DIVERSITY
Akio Soeda1, Myung-Jin Park1, Dae-Hee Lee1, Arlan Mintz2, Johnathan Engh2,
Toru Iwama3, Takahiro Kunisada4, Ian F. Pollack1,2, Amin B. Kassam1,2, Deric M. Park1,2
Brain Tumor Program, University of Pittsburgh Cancer InstituteDepartment of Neurological Surgery, University of Pittsbugh3
Department of Neurosurgery, Gifu University School of Medicine, Gifu, Japan
4
Department of Tissue and Organ Development Regeneration and Advanced Medical Science, Giful University
1
2

O003
ANALYSIS OF CANCER STEM CELLS IN GENETICALLY-INDUCED BRAIN TUMORS
Hideyuki Saya1
Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan

1

Tumors are thought to contain a small population of cells, designated cancer stem cells (CSCs), that possess the ability
both to self-renew and to differentiate and that play a key role in the initiation and maintenance of cancer. However, whether
CSCs arise from multipotent immature cells or differentiating cells has remained unclear. Moreover, the minimal repertoire ofgenetic changes required for the generation of CSCs is unknown. The establishment of CSCs from cells of various
differentiation stages by genetic manipulation might be expected to provide insight into these questions.
We have now established mouse malignant brain tumor models by overexpressing c-MYC or RasV12 in neural stem cells/
multipotent progenitor cells derived from subventricular zone of mouse with a homozygous deletion of the Ink4a/Arf locus(Ink4aKO mice). Tumors induced by c-MYC are histologically different from those induced by RasV12, suggesting that
pathological phenotype of tumor is dependent on the gene(s) responsible for tumorigenesis. Tumor induced by RasV12 ishighly heterogenous and invasive, and a fraction of the induced-tumors cells was found to exhibit properties of CSCs.
Invading cells at the tumor margin expressed high levels of CD44, which plays a role in both cell migration in extracellularmatrix and stemness of cancer cells. Furthermore, tumor cells formed cuffs around the pre-existing microvessels, andthose invading area contained numerous microglial cells. Our genetically-induced cancer systems provide ideal models forthe characterization of CSCs and the development of novel therapeutic approaches to malignant brain tumors.

- 59 -­­

Oral Presentation (0)PURPOSE: Mounting experimental evidence suggests that malignant brain tumors contain and may arise from cancer stem
cells (CSC). CSC are believed to play important roles in tumorigenesis and recurrence. CD133, a pentaspan
transmembrane glycoprotein, is a putative marker of glioma-derived CSC based on the ability of CD133-positive cells torecapitulate the tumor in animal models. Glioma tumor tissues are known to be populated by a heterogeneous mix of cellswith distinct genotypes and phenotypes, and different proliferative capacities. The cellular origin of such karyotypic
heterogeneity is unclear. Whether the observed population diversity within a tumor has mono- or polyclonal origin has
important implications for cancer progression. METHODS: To investigate the cellular origin of population diversity, weestablished 23 subclones from a single glioma CSC positive for CD133. These subclones were subsequently propagatedand analyzed. RESULTS: The self-renewal and proliferative capacities of the subclones were highly distinct. Sensitivity tochemotherapeutic agents also differed widely. FACS analysis for expression of stem and differentiation markers (e.g. CD133,
A2B5, CD44, CXCR4, and CD24) showed that each subclone was composed of distinct population of cells. Immunoblot
showed different expression levels of cell cycle regulation proteins such as Bmi-1, p53, p27, and p21. CD133-negative cells
failed to establish subclones. CONCLUSIONS: Our observations suggest that a single CD133-positive tumorigenic CSC iscapable of producing phenotypically heterogeneous self-renewing progeny in an in vitro setting. Whether such observed
diversity is regulated by genomic alteration or gene expression remains to be seen.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O004
GLIOMA STEM CELLS ARE INVOLVED IN TUMOR TISSUE REMODELING IN XENOGRAFTMODEL
Jun Dong1, Qiang Huang1, Hua Chen1, Yaodong Zhao1
Department of Neurosurgery, 2nd Affiliated Hospital of Suzhou University, Suzhou, China

1

Although tissue remodeling plays a crucial role in tumorigenesis and progression of human gliomas, its mechanisms,
however, remain largely uncertain. In the current study, we investigate the potential role of human glioma stem cells (hGSCs)
in tissue remodeling of gliomas. First of all, the GFP transgenic nude mice were obtained by crossing NC athymic nude
mice with GFP transgenic C57BL/6J mice. As a result, GFP is expressed in essentially all tissues in the offspring. Then,hGSCs were orthotopically implanted into GFP nude mice in an effort to assess the interactions between hGSCs and hostbrain , thereby elucidating the roles of tissue remodeling during tumorigenesis and progression of huaman gliomas. We
found all of the essential tissues in GFP transgenic nude mice including the brain fluoresced green under excitation light.
Therefore, the hGSCs labeled with PE-conjugated anti-HLA antibody, which manifested red color can be unambiguously
distinguished from bright green background composed of adjacent host GFP-expressing components. This techniqueenabled us to address the following concerns: (1) hGSCs were involved in the invasiveness in gliomas and adjacent stroma
degradation of the host. (2) in vivo study demonstrated that cell fusion between hGSCs and host cells were present. (3)Vasculogenic mimicry, the formation of patterned, tubular networks of vascular channels formed by trans-differentiatedhGSCs could be observed. (4) Differentiation mimicry, namely, differentiation direction of hGSCs bearing muitidifferentiation potentials seemed to be decided by local host cellular microenviroment. These results suggest that GFP
transgenic nude mouse model, with GFP expression in essentially all tissues, could be obtained by crossing nontransgenic
athymic nude mice with the transgenic GFP C57BL/6J mouse. The GFP transgenic nude mouse model should greatly
expand our knowledge of glioma &host interactions. Our data indicated that hGSCs may play a decisive role in tissue
remodeling of gliomas as well.

O005
ENDOTHELIAL CELLS AND DIFFERENTIATED TUMOR CELLS FUNCTION AS A STEMNICHE TO GLIOBLASTOMA STEM-LIKE CELLS BY PROVIDING NOTCH LIGANDS
Xing Fan1, Thant Zhu1, Angelo L. Vescovi2, Francesco DiMeco3

Oral Presentation (0)University of Michigan 2University of Milan Bicocca, Milan, Italy
Istituto Nazionale Neurologico C. Besta, Milan, Italy1
3

It has been reported recently that endothelial cells function as a stem cell niche to promote CD133-positive cancer stem
cells (CSCs) self-renewal in glioblastoma (GBM). However, the mechanism that endothelial cells function as a CSC niche islargely unknown. It has been shown that endothelial cells promote neural stem cell self-renewal by providing Notch
signaling and that Notch ligands are expressed in GBMs. To test if endothelial cells and differentiated tumor cells could
function as a CSC niche by providing Notch ligands to CSCs, first we co-cultured GBM neurospheres with primary humanendothelial cells (PHECs) which express high levels of Notch ligands Jagged/Dalta. We found the PHECs promoted GBM
neurosphere growth in vitro. Then, we found the CD133-negative population expressed a higher level of Jagged/Dalta andglial differentiation marker GFAP, compared with the CD133-positive population. When GBM neurospheres were forced
differentiation to grow as a monolayer culture, the CD133-positive population and CD133 expression were reduced,
whereas expression of GFAP (glia marker), GalC (oligodendrocyte marker), and Notch ligands were significantly induced.
Furthermore, treatment of GBM neurospheres with a Jagged peptide increases GBM neurosphere propagation in a dosage
dependent pattern, indicating that Notch ligands expressed in both differentiated tumor cells and endothelial cells canfunction as a niche to promote GBM CSC self-renewal in vitro. Finally, we found that Notch ligands were highly expressed in
the blood vessels of GBM primary tumor and intracranial xenograft, and that CSCs accumulated around the blood vessels
within the tumor. In summary, our studies demonstrate that Notch activation is driven by juxtacrine signaling between tumor
cells replicating the classical process of lateral inhibition and by stromal niche signals, suggesting that targeting both CSC
and its niche may provide a profound strategy to deplete CSCs in GBM. This may also apply to other cancers.

O006
AN ESSENTIAL ROLE OF C-MET/HGF SIGNALING IN GLIOBLASTOMA INITIATING CELLSDo-Hyun Nam1, Jeongwu Lee2, Kyeung Min Joo1, Juyoun Jin1, Bong Gu Kang1,
Doo-Sik Kong1, Jung-II Lee1, Seung-Chyul Hong1, Jong Hyun Kim1
Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute,
Sungkyunkwan University School of Medicine, Seoul, Korea
2
Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland
1

C-MET, preferentially expressed in stem/progenitor cells, plays critical roles in the regulation of cell growth and motility
during embryogenesis and throughout the life. Deregulated MET signaling has been implicated in various types of cancers
including glioblatomas (GBMs). Increasing experimental evidences support the hypothesis that a subpopulation of tumors,namely, cancer stem cell/tumor initiating cells (CSC/TICs), are responsible for tumor initiation/propagation and share many
developmental pathways with their normal counterparts. However, the precise roles of MET signaling pathway operated in
CSCs/TICs are largely unknown.Here we show evidence that some of Methigh GBM cells are indeed CSC/TICs. Methighpopulations but not Metlow/- populations are highly tumorigenic and give rise to both Methigh and Metlow/- cells, thereby
establishing tumor hierarchy. Methigh cell populations significantly overlap with cells positive for expression of CD133, aputative CSC/TIC marker, and these cells are highly resistant to radiation. Furthermore, we found that suppression of MET
pathway in these GBM CSC/TICs achieved by siRNA or shRNA mediated knockdown of c-met gene results in significantly
reduced cell survival in vitro and impaired tumorigenic potential in vivo, suggesting that C-Met activation is required tomaintain cancer stem cell phenotype in these cells. Interestingly, suppression of MET activation also significantly reduces
migration/invasion property of GBM TSC/TICs, in part by derepressing expression of E-cadherin. Taken together, our data
demonstrate that MET activation in GBM is a functional requisite for "stemness" phenotypes in CSC/TICs. In summary, we
provide experimental evidences supporting an essential role of Met signaling pathway in the survival and invasion ofglioblastoma CSC/TICs. Not only will such insights pave the way for a more thorough understanding of CSC biology, butalso they further implicate Met as a promising therapeutic target.

- 60 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO007
DEVELOPMENT AND APPLICATIONS OF STEM CELL BASED PRE-CLINICAL MODELS OF
GLIOMAS
Deepak Kamnasaran1
Department of Pediatrics, Laval University, and Pediatrics Research Unit, Laval Hospital Research Centre,
Quebec, Canada

1

Gliomas are among the most frequent tumors prevalent in the adult and pediatric populations. Unfortunately, despite
current therapies implemented for patients with high grade gliomas, the prognosis is extremely poor. There is a current
sparsity of in- vitro pre-clinical models of gliomas that recapitulate the pathological and treatment responses reminiscent in
human gliomas. Current in-vitro models such as glioma stem cells are very problematic due to having low clonality andvariable therapeutic responses. In an effort to explore alternative robust in-vitro models of gliomas, we have developed thefirst non-neural stem cell based model of gliomas from murine embryonic stem cells. Specifically, we have noted thatsynthetic astrocytes derived from murine embryonic stem cells are more representative in the origin of gliomas, even at highclonality, compared to terminally differentiated somatic astrocytes. Similar findings are also documented with synthetic
astrocytes differentiated from murine neural stem cells. With the use of molecular transcriptome fingerprinting, these stem
cell derived synthetic astrocytes are most similar (R-value = 0.8, P-value less than 0.01) to murine somatic astrocytes fromthe embryonic cortex (E13.5) and newborn hippocampus (P4). Furthermore, these synthetic astrocytes have an intrinsic
property of enhanced proliferation that may potentiate an ease towards transformation. We have noted that the genetic
alterations of these synthetic astrocytes with candidate gliomagenesis genes including MDM2, AKT and H-RAS canpotentiate intracranial high grade gliomas in Nod-Mice. Furthermore, we also undertook functional random mutagenesis
screens on these synthetic astrocytes using gene trapping. We obtained a genome wide functional map of genes that are
stringently correlated with a pathological spectrum of astrocytomas. This body of work augments the use of stem-cellbased pre-clinical models to decipher the genetic and pathological basis of gliomagenesis. Moreover, these models canalso be utilized for therapeutic targeting applications.

O008

Departments of Neurosurgery, Fudan University Huashan Hospital, National Key Laboratory for Medical Neurobiology,
Shanghai Medical College-Fudan University, Shanghai, China 200040

1

Objective: Mesenchymal stem cells (MSCs) have been shown to migrate toward tumors, but their distribution pattern inglioma is not completely portrayed. The primary purpose of the study was to assay the tropism capacity of MSCs to glioma,
to delineate the pattern of MSCs distribution in glioma after systematical injection, and to track the migration andincorporation of magnetically labeled MSCs with clinical 1.5T MRI. Methods: Fisher344 rats MSCs were co-labeled withsuperparamagnetic iron oxide nanoparticles (SPIO) and enhanced green fluorescence protein (EGFP). The tropism
capacity of MSCs was quantitatively assayed by Transwell system in vitro. To in vivo track the migration of MSCs, magnetic
resonance imaging (MRI) was performed at 7 days and 14 days after systematic administration of labeled MSCs. Afterscanned, the distribution patterns of MSCs in glioma burdened rats were examined by Prussian blue and fluorescencestaining. Results: In vitro study showed MSCs possessed significantly greater migratory capacity than fibrablast cells, andlysis of F98 glioma/cultured F98 cells showed more capacity to induce migration of cells than other stimuli. At the 7 days
after MSCs transplantation, the SPIO/EGFP co-labeled cells distributed throughout the tumor, where a well-defined dark
hypointense region represented on gradient echo (GE) sequences. While at the 14 days, most of labeled MSCs were foundat the border between tumor and normal parenchyma, which represented on GE sequence as diluted amorphous darkareas at the tumors edge. Conclusion: This result demonstrated systemically transplanted MSCs home to glioma with highspecificity with a temporal-spatial pattern, which can be tracking by MRI.

- 61 -­­

Oral Presentation (0)IN VIVO TRACKING SPIO LABELLED MESENCHYMAL STEM CELL TROPISM TOIN VIVO
TRACKING NANOPARTICLE-LABELLED STEM CELL TROPISM TO BRAIN MALIGNANT
GLIOMA AFTER SYSTEMATICAL INJECTION BY A CLINICAL 1.5T MR
Jianhong Zhu1, Xing Wu1, Liangfu Zhou1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O009
P53 INDEPENDENT ABROGATION OF G1 ARREST IN MURINE BRAIN TUMOR-DERIVED
STEM LIKE CELLS AFTER IONIZING RADIATION
Andrew B. Foy1, Hong Ye2, and Cynthia Wetmore2
Depts. of 1Neurosurgery and 2Pediatrics and Adolescent Medicine, Division of Hematology/Oncology, Mayo Clinic,
Rochester MN 55905.

Oral Presentation (0)Treatment and cure of medulloblastoma continues to be disappointing. Approximately 30% of cases recur and even when acure is achieved, the treatment is highly morbid to the developing brain results in long-term sequelae. Recent evidence
suggests that many solid tumors are sustained by a population of cells with stem cell-like properties that have extensive
capacity for self-renewal. Tumor stem cells (TSC) are also thought to have increased radio- and chemoresistance and may
be responsible for treatment failures. Mechanisms of DNA damage response have not been explored previously in neuralstem cells derived from medulloblastoma. Identifying novel therapeutic targets that spare normal neural stem cells while
eradicating the tumor-derived stem cell population is a long-term goal.
TSCs were isolated from medulloblastomas that spontaneously arose in mice haploinsufficient for Patched (Ptc), a
component of the Sonic hedgehog receptor, and cultured in serum free media as free-floating spheres. Neural stem cells
were derived from the early post-natal hippocampus and cerebellum of wild-type and Ptc+/- mice. Cultures were exposed
to 2 Gy of ionizing radiation and cell cycle progression was characterized with flow cytometery. We found that normal
neural stem cells had a similar phenotype with sustained accumulation in G1 within two hours of irradiation. In contrast, wefound that TSCs failed to arrest in G1 and showed a marked but unsustained G2/M arrest eight hours after radiation. By 48
hours after irradiation TSCs had re-entered the cell cycle. The level of apoptosis was unchanged compared to controls.
We repeated these experiments at 10 Gy of radiation and in the TSCs found a large increase in apoptosis over time.
Accumulation of TSCs in G2/M was again noted at eight hours, however the G2/M arrest was sustained at 24 and 48 hours
after irradiation. Sequencing of the open reading frame demonstrated that p53 is wild type in TSC’s, appropriately
phosphorylated on Serine15, p21 is induced and Rb phosphorylated, suggesting that the abrogated G1 arrest is not due toabrogation or mutation of p53 pathway.
We have characterized the cell-cycle and DNA damage response of murine NSCs and found that this population ofundifferentiated cells undergo cell cycle arrest in G1 after DNA damage. This is in contrast to embryonic stem cells thatlack a G1 checkpoint, do not initiate cell cycle arrest and undergo apoptosis after exposure to ionizing radiation.
Additionally, we found that TSCs have escaped the G1 checkpoint in a p53 independent manner and proceed to replicate
their DNA without adequate repair that likely contributes to genomic instability and propagation of new therapy-resistantclones through aberrant phosphorylation of Retinoblastoma gene. These data suggest that TSC and normal neural stem
cells have distinct responses to ionizing radiation and DNA damage. Studies are ongoing to determine the molecular basis
for the distinct phenotype observed in response to radiation in normal and neoplastic stem cells and to specifically increase
the sensitivity of TSCs to apoptosis after DNA damage.
Supported by NREF (AF), Sontag Foundation (CW), Waterman Foundation for Cancer Genetics (CW), Brain SPORE (CW),
Fraternal Order of Eagles (CW)O010
ANGIOGENESIS OF GLIOMAS: VASCULAR TUBE FORMATION FROM TRANSDIFFERENTIATIONOF GLIOMA STEM/PROGENITOR CELLS.
Qiang Huang1, Jun Dong1, Yaodong Zhao1, Yuntian Shen1, Qing Lan1
Department of Neurosurgery, 2nd Affiliated Hospital of Suzhou University, Suzhou, China

1

Object: Previous studies suggest that tumor cells might be the progenitor for tumor vasculature. Whether vascular tube
formation from transdifferentiation of glioma stem/progenitor cells (GSPCs) contribute to angiogenesis of gliomas remain
largely uncertain. METHODS: GSPCs were isolated from surgical specimens of gliomas and cultured in medium favoredfor stem cell growth. In viro trans-differentiation of GSPCs were performed under hypoxia. Expression of vascularendothelial cells (VECs) markers CD31, CD34 KDR, and vWF were analyzed with real-time quantitative RT-PCR and
immunofluorescence techniques. Vasculogenic mimicry of GSPCs was evaluated in xenograft model in vivo. Relationships
between content of GSPCs and expression levels of both VECs markers and proangiogenic factors in large number ofclinical specimens were further investigated in glioma tissue microarray. RESULTS: GSPCs can transdifferentiated into
VECs under hypoxia in vitro. Expressions of VECs markers including CD34, KDR, vWF and CD31 were significantly upregulated after transdifferentiation. GSPCs manifested typical flagstone pattern when cultivated in medium containing VEGF
for a few days; when cultivated on Matrigel they were capable of forming capillary-like structures. Human leukocyte antigen
positively stained vessels were observed inside the xenograft tumors after intracerebral transplantation of human GSPCs inathymic nude mice, implied part of tumor cells with human origin were involved in formation of tumor vessels. In surgical
specimens of human glioma, tumor vascular cells coexpressing the markers of early VECs (CD34) and markers of GSPCs(ABCG2 and nestin) suggest that these vascular cells stemmed from GSPCs. CONCLUSION: Our observations suggest
the functional role of GSPCs as endothelial progenitors, which have properties that give rise to vascular endothelial cells,
and have the ability to form vascular endothelial tubes.

- 62 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO011
DUAL-TARGETED ANTITUMOR EFFECTS AGAINST BRAINSTEM GLIOMA BY INTRAVENOUS
DELIVERY OF TRAIL GENE TRANSFERED STEM CELLS
Jian-Hong Zhu1, Xing Wu1, Liangfu Zhou1, Luping Chen1, Yiwen Shen1
Department of Neurosurgery, Huashan Hospital-Fudan University, Shanghai, China

1Brainstem gliomas are common in children. Despite recent attempts to optimize or combine radiotherapy andchemotherapy, the poor prognosis of these tumors has not changed in the past two decades. This poor outcome is due torelatively inoperable location and infiltration into the brain. Precisely targeting these tumor satellites may prove critical for the
success of any potential therapeutic strategy. Based on the selective killing of malignant cells by TRAIL and targeted
migration toward tumor of MSCs, it is logical to hypothesize that membrane-spanned TRAIL engineered MSCs may provide
dual-targeted antitumor effects against brainstem glioma. We have demonstrated systemically transplanted MSCs
immigrate to brainstem glioma with high specificity. MSCs can penetrate the vessels surrounding tumors, then stream as achain pattern toward gliomas, eventually circumscribe the tumor. Membrane-spanned TRAIL engineered MSCs not only
express full-length TRAIL in surface, but secrete some sTRAIL in medium. After infected with rAAV-hTRAIL, hMSCs show
no increase in apoptosis, which suggest it is feasible to engineer MSCs with TRAIL for glioma therapy. After co-cultured
hTRAIL engineered MSCs with U87MG cells, the apoptosis of U87MG cells significantly increase than sTRAIL treated
U87MG cells. Systematic delivery of hTRAIL engineered MSCs into established human brainstem glioma xenografts resultsin the potent induction of apoptosis in gliomas, but not in normal brain. This confirms that hTRAIL engineered MSCs aredramatically effective at killing glioma cells, but no toxic to normal brain tissue.

O012
ALTERED EXPRESSION OF MICRORNA CLUSTERS IS ASSOCIATED WITH THE STEMNESSPROFILE OF GLIOMASIris Lavon1,2, Daniel Zrihan1,2, Avital Granit1,2, Yoav Smith3, Ofira Einstein2, Nina Fainstein2,
Mikhal E Cohen2, Malkiel Cohen4, Bracha Zelikovitch1,2, Yigal Shoshan5, Sergai Spektor5,
Benjamin Reubinoff4, Offer Gerlitz6, Tamir Ben-Hur2, Tali Siegal1,2Gaffin Centre for Neuro-Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Department of Neurology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
3
Genomic Data Analysis Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
4
Human Embryonic Stem Cell Research Centre, Hadassah Hebrew University Medical Center, Jerusalem, Israel
5
Department of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel
6
Department of Biochemistry. Hadassah Hebrew University Medical Center, Jerusalem, Israel.
1

Background: Growing evidence suggests that the growth of brain tumours is maintained by cancer stem cells. Thus,
normal neural precursor cells (NPCs) are attractive candidates for the origin of human gliomas. Objective: To explore therelationship between gliomas and stem cell properties, by comparing the microRNA (miRNAs) expression signature of glial
tumours, embryonic stem cells (ESCs), NPCs and normal adult brain tissues of both human and mouse. Methods: We
compared the expression profiles of 186 mature microRNAs in ESCs, NPCs, gliomas and normal brains. our panel
contained RNA samples derived from glial tumours of various grades, ESCs, NPCs and normal adult brains from bothhumans and mice. The miRNA expression was quantified by RT real time PCR. Results: Human gliomas, regardless of theirgrade, displayed a miRNA expression profile that was reminiscent of that in NPCs. Of special note is the 80% identity
observed between the miRNA expression signature of human gliomas and the methylcholanthrene-induced mouse glioma,
GL-261. Interestingly, about half of the miRNAs in this shared profile were clustered in seven genomic regions susceptible togenetic/epigenetic alternations in different types of cancers. These clusters comprised the miR-17 family of miRNAclusters, mir183-182, and the stem cell-specific clusters mir367-302 and mir371-373, which are upregulated in gliomas,
ESCs and NPCs. We also identified the bipartite cluster of 7+46 miRNAs on chromosome 14q32.31, which was down
regulated; therefore, it might represent the largest tumour suppressor miRNA cluster. Conclusions: Our finding that all
gliomas displayed a NPC-like microRNA signature might imply that normal NPCs that sustain cancer-promoting mutations
are the cells of origin of gliomas. It might also suggest that cells within this differentiation window are particularly susceptible
to gliomagenesis. Alternatively, a more differentiated progeny, that acquire aberrations in specific genomic regions, could
have given rise to this characteristic "NPCs microRNA signature".

- 63 -­­

Oral Presentation (0)2The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O013
THE ROLE OF SURGERY IN THE MANAGEMENT OF PEDIATRIC BRAIN TUMORSMark M. Souweidane, M.D., F.A.C.S, F.A.A.P.
Professor and Vice-Chairman, Neurological Surgery
Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.

Oral Presentation (0)Introduction. Surgery is an integral component and typically the first line of therapy for children with central nervous
system (CNS) tumors. The outcome with regard to surgical morbidity and disease control can be greatly influenced by the
initial care that these children receive. The neurosurgeon’s role in the care of children with newly diagnosed CNS tumors isreviewed with emphasis on general surgical principles, evolving philosophies, and technical innovations.
Management of Hydrocephalus. The management of hydrocephalus is typically the most urgent issue at time ofpresentation for most children with newly diagnosed brain tumors. The percentage of children that undergo removal of aposterior fossa brain tumor and who ultimately require CSF diversion by way of shunting ranges from 10-35%. Therefore,
since the majority of children will not require postoperative treatment for hydrocephalus every effort should be made to
avoid committing the child to such preoperatively. The evolution of hydrocephalus management has been rapid in the past
couple of decades principally due to the introduction of endoscopic neurosurgery and the technique of endoscopic thirdventriculostomy (ETV). Although it has been shown to be beneficial, ETV prior to 4th ventricular tumor removal should bereserved for children that require urgent treatment of hydrocephalus when tumor removal is not imminently possible.
However, ETV for the management of hydrocephalus due to some brain tumors such as tectal gliomas and pineal reagion
tumors is state of the art.
Cytoreductive Surgery. With rare exception, the degree of tumor remvoal positively impacts the eventual outcome withrespect to disease control. Thus, whenever a total excision can be accomplished this should be the goal of theneurosurgeon. Due to the importance assigned to the degree of tumor removal, advanced strategies have been developed
to maximize this goal. Techniques that are now readily available rely on intra-operative imaging including ultrasound,computed tomography (CT), and MRI. Other important operative adjuncts include functional MRI (fMRI), MR tractography,
and stereotactic guidance. Fluorescence-guided surgery using 5-aminolevulinic acid has also been reported as a usefultechnique for differentiating neoplatic tissue from unaffected brain. With the advent of small caliber endoscopes, minimallyinvasive techniques are quickly evolving as an alternative method for some pediatric brain tumors. These lesions arecharacterized by a relatively small size (i.e. < 2 cm) and devoid of any significant intraparenchymal component. Anotherexpanding arena of minimally invasive neurosurgery has been the integration of the endoscopic-assisted transnasal
approach for tumors situated in the sella and suprasellar compartment.
Tumor Biopsy. As mentioned above, since most children’s survival is positively influenced with total tumor removal,
irrespective of tissue diagnosis, tumor sampling is rarely indicated. However, some clinical scenarios justify tumor biopsy as
an initial neurosurgical alternative, chiefly when neo-adjuvant therapy is the preferred initial treatment. Primary CNS germ
cell tumors (GCT), including both germinoma and nongerminomatous GCT (NGGCT), are renowned for being treated
without aggressive up-front tumor resection. The diagnostic yield for endoscopic tumor biopsy has been reported to be as
great as 90% with little morbidity.
Second-Look Surgery. Since total tumor removal is of such importance in many pediatric CNS tumors, a second attempt
at total tumor removal is being used on an increasing basis. There are 3 noted scenarios in which second-look surgery iscurrently being explored as a feasible alternative to adjuvant therapy: 1) incompletely resected 4th ventricular ependymoma,
2) radiographic residual disease after induction chemotherapy with nongerminomatous germ cell tumors (NGGCT), and 3)
malignant tumors of infancy.
Disease Staging. An important and unique physiologic feature of primary pediatric brain tumors is the potential for CSF
dissemination. Whether staging information can be obtained at the time of initial surgery is being actively explored in twoarenas. Preliminary data exists to support the notion that intra-operative techniques of arachnoid and CSF sampling could
play a future role in contributing toward prognostic grading for children with medulloblastoma. Equally novel is the potentialof using endoscopic inspection of the intraventricular system. Tumor dissemination observed during endoscopic surgery
has recently been highlighted in patients with GCT in which the preoperative MRI failed to exhibit metastatic disease. These
current concepts, both awaiting validation through cooperative group studies, would suggest that the pediatricneurosurgeon may play a future role in determining the degree of metastatic dissemination.
Tumor Procurement. An increasing vital role of the neurosurgeon is to submit tissue for investigative purposes. The
molecular and genetic analysis of pediatric brain tumors is an exciting and burgeoning field. As an example, prognostic
staging for medulloblastoma will soon incorporate molecular characterization to enhance outcome prediction andtherapeutic planning. Neurosurgeons are increasingly being relied upon to participate in this vital process and need to beaware of proper tissue preservation and handling.
Therapeutic Delivery. Some surgical techniques are on the forefront of therapeutic delivery of antineoplastic agents. The
limitation by the blood brain barrier (BBB) and the frequency of systemic toxicity using systemically administered agents isthe basis for exploring the alternative method of local delivery. Local delivery capitalizes on the concept of avoiding systemic
toxicity while maximizing local therapeutic concentrations. An additional appealing feature of this technology is the ability tosuccessfully deliver macromolecules such as monoclonal antibodies or virus particles that would otherwise be restricted by
the BBB. Biodegradable polymers have already been used extensively in adults with newly diagnosed and recurrent
malignant hemispheric gliomas. An alternative form of local delivery, convection enhanced delivery (CED), relies on slow
infusion of the agent directly into the brain tumor. The use of CED has gained wide popularity on the investigative preclinicaland clinical fronts. Interestingly, CED in the brain stem has been recently and extensively studied as a potential means fortreating children with diffuse pontine gliomas.
Conclusions. The neurosurgeon who is called upon to care for children with CNS tumors should be one who is
comfortably familiar with these diseases. The experience of the neurosurgeon undoubtedly can have an effect on the perioperative and long-term outcome of these children. The role of complete tumor removal with minimal morbidity has been
the genesis of newer operative techniques and technologies. The role of the pediatric neurosurgeon in the care of children
with CNS tumors is expanding to include unconventional responsibilities including disease staging, tissue procurement, anddrug delivery. It is thus anticipated that the pediatric neurosurgeon will be increasingly relied upon for oncologic therapeuticstrategies and should thus remain abreast of forthcoming information and technologies.

- 64 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO014
SURGERY OF SUPRATENTORIAL PEDIATRIC BRAIN TUMORS
Gabriele Schackert MD, PhD
Department of Neurosurgery, University of Technology, Dresden Germany
Introduction:
The treatment of malignant brain tumors comprises sugery, radiotherapy and chemotherapy. Especially in childhood,patients with malignant brain tumors are enrolled in clinical studies. This allows uniform treatment protocols, comparable
results and close follow-ups.
Patients and Results:
Children with malignant supratentorial tumors, e.g. PNETs, glioblastomas, malignant ependymomas, plexus carcinomas,
and rarely occurring tumors, e.g. chondrosarcomas and anaplastic meningiomas were admitted to our department.
Surgical resection was performed in all cases. Whenever possible, even recurrent tumors or metastases were resected. In
highly vascularized lesions, preoperative embolization was considered. Besides surgical resection, the children were allenrolled in clinical studies, being treated according to study protocols.
All children survived the surgical procedures without major neurological deficits. Particularly in tumors of the ventricle (plexus
carcinomas and a chondrosarcoma), intraoperative blood loss could be high. The surgical resection of unusually large
neoplasms is possible in children without causing major neurological deficits. Especially at very young age, the plasticity ofthe brain compensates the resection of large intraparenchymal tumor masses, not compromising the normal development of
the children. Besides well established radio- and chemotherapeutical protocols, multiple resections seem to be justified.
They are well tolerated and help to prevent neurological deficits and prolong the survival time of the young patients.
Conclusions:
Surgical resection is well tolerated by most of the infants and children, independent on age. The inclusion into clinicalstudies should be mandatory, leading to optimal radiotherapeutical and chemotherapeutical management and a close
follow-up. Re-operations should be considered, whenever possible.

O015
Department of Neurosurgery, University of California, San Francisco, USA
There is still no general consensus in the literature regarding the role of extent of glioma resection in improving patient
outcome. Although the importance of resection in obtaining tissue diagnosis and alleviating symptoms is clear, a lack ofClass I evidence prevents similar certainty in assessing the influence of extent of resection. We reviewed every majorclinical publication since 1990 on the role of extent of resection in glioma outcome. Twenty-eight high-grade glioma articles
and 10 low-grade glioma articles were examined in terms of quality of evidence, expected extent of resection, and survival
benefit. Despite persistent limitations in the quality of data, mounting evidence suggests that more extensive surgicalresection is associated with longer life expectancy for both low- and high-grade gliomas
The prognostic role of extent of resection (EOR) of low-grade gliomas (LGGs) is a major controversy. We designed a
retrospective study to assess the influence of EOR on long-term outcomes of LGGs. The study population (N = 216)
included adults undergoing initial resection of hemispheric LGG. Region-of-interest analysis was performed to measuretumor volumes based on fluid-attenuated inversion-recovery (FLAIR) imaging. Median preoperative and postoperative
tumor volumes and EOR were 36.6 cm(3) (range, 0.7 to 246.1 cm(3)), 3.7 cm(3) (range, 0 to 197.8 cm(3)) and 88.0%(range, 5% to 100%), respectively. There was no operative mortality. New postoperative deficits were noted in 36 patients(17%); however, all but four had complete recovery. There were 34 deaths (16%; median follow-up, 4.4 years). Progression
and malignant progression were identified in 95 (44%) and 44 (20%) cases, respectively. Patients with at least 90% EOR
had 5- and 8-year overall survival (OS) rates of 97% and 91%, respectively, whereas patients with less than 90% EOR had
5- and 8-year OS rates of 76% and 60%, respectively. After adjusting each measure of tumor burden for age, Karnofsky
performance score (KPS), tumor location, and tumor subtype, OS was predicted by EOR (hazard ratio [HR] = 0.972; 95%
CI, 0.960 to 0.983; P < .001), log preoperative tumor volume (HR = 4.442; 95% CI, 1.601 to 12.320; P = .004), andpostoperative tumor volume (HR = 1.010; 95% CI, 1.001 to 1.019; P = .03), progression-free survival was predicted by log
preoperative tumor volume (HR = 2.711; 95% CI, 1.590 to 4.623; P <or= .001) and postoperative tumor volume (HR = 1.007;
95% CI, 1.001 to 1.014; P = .035), and malignant progression-free survival was predicted by EOR (HR = 0.983; 95% CI,
0.972 to 0.995; P = .005) and log preoperative tumor volume (HR = 3.826; 95% CI, 1.632 to 8.969; P = .002). Improved
outcome among adult patients with hemispheric LGG is predicted by greater EOR..
Language sites in the cortex of the brain vary among patients. Language mapping while the patient is awake is an
intraoperative technique designed to minimize language deficits associated with brain-tumor resection. To study language
function after brain-tumor resection with language mapping, we examined 250 consecutive patients with gliomas. Positive
language sites (i.e., language regions in the cortex of the brain, 1 cm by 1 cm, which were temporarily inactivated by meansof a bipolar electrode) were identified and categorized into cortical language maps. The tumors were resected up to 1 cm
from the cortical areas where intraoperative stimulation produced a disturbance in language. Our resection strategy did not
require identification of the stimulation-induced language sites within the field of exposure. A total of 145 of the 250 patients(58.0%) had at least one site with an intraoperative stimulation-induced speech arrest, 82 patients had anomia, and 23
patients had alexia. Overall, 3094 of 3281 cortical sites (94.3%) were not associated with stimulation-induced language
deficits. A total of 159 patients (63.6%) had intact speech preoperatively. One week after surgery, baseline language
function remained in 194 patients (77.6%), it worsened in 21 patients (8.4%), and 35 patients (14.0%) had new speech
deficits. However, 6 months after surgery, only 4 of 243 surviving patients (1.6%) had a persistent language deficit. Corticalmaps generated with intraoperative language data also showed surprising variability in language localization within thedominant hemisphere. Craniotomies tailored to limit cortical exposure, even without localization of positive language sites,
permit most gliomas to be aggressively resected without language deficits. The composite language maps generated inour study suggest that our current models of human language organization insufficiently account for observed language
function.

- 65 -­­

Oral Presentation (0)SURGICAL RESECTION STRATEGIES FOR OPTIMIZING GLIOMA REMOVAL
Mitchel S. Berger, MD

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O016
GLIOMA SURGERY, ITS ADVANCEMENTS, PROBLEMS AND FUTURE
Takamasa Kayama, Kaori Sakruada
Department of Neurosurgery, Yamagata University Faculty of Medicine
It is well accepted that surgical management of malignant gliomas has dramatically changed by using new advanced
modalities. Preoperative precise anatomical and functional information enabled safe and sure surgical resection ofmalignant gliomas around the eloquent areas. It could be mentioned that surgery contributed to get good QOL of glioma
patients. However, improvement of survival duration has not been achieved on GBM, and more effective adjuvant therapy
should be expected. This time, I would like to show how it is possible to promote to more effective surgery, including our
new intra-operative MRI system (Surgical Suite) and review the problems with glioma surgery. Future glioma treatment,
including pathophysiology of glioma and future advancement of technology against glioma, will be addressed in my talk.

O017
AWAKE SURGERY DURING RESECTION OF INSULAR GLIOMAS
Ruben Dammers1, Daniel H. de Kruif1, Markus Klimek2, Clemens M.F. Dirven1, Arnaud J.P.E. Vincent1
Department of neurosurgery, Erasmus Medical Center, Rotterdam, the Netherlands
Department of anaesthesiology, Erasmus Medical Center, Rotterdam, the Netherlands

1
2

Oral Presentation (0)Purpose of the study. In glioma surgery, maximal cytoreduction followed by chemoradiotherapy is regarded standard ofcare for glioma treatment at present. Insular gliomas, however, are by many still considered to be inoperable. Anatomical
localisation, vascular supply, and the potential devastating complications make a complete resection highly impossible. We
present our experience with the operative treatment of patients with insular gliomas in an "awake craniotomy" setting.
Patients and methods. Sixteen consecutive patients with an insular tumor were operated awake during the period 2003
and 2008. Pre-operatively, an extensive anaesthesiologic and neuropsychologic/linquistic workup was performed. All
patients underwent MRI with neuronavigation and when possible fMRI. After cortical stimulation, de Sylvian fissure andperiinsular sulci were opened. Tumor resection was performed under speech (dominant hemisphere) and motor movement
surveillance. Results. The patients' average age was 41.6 (SD 10.2) years. Pure insular lesions were seen in two patients, a
medial temporal base-insular glioma in one, insular fronto-opercular and orbitofrontal-insular-temporal polar in five and eightpatients, respectively. Presenting symptoms included epilepsy (94%), dysphasia (19%), and cognitive problems (19%). In
eleven patients, the resection was near total (95-98%) and less than 95% in the remaining five patients. At histologicalexamination we encountered thirteen low-grade and three high-grade gliomas. The average follow-up was 1.8 (SD 1.4)
years since surgery. Perioperatively seven patients clinically deteriorated. However, all patients with a low-grade glioma
recovered to preoperative status. Two patients with a high-grade glioma have died during follow-up. Conclusion. Insularglioma surgery, facilitated by (sub)cortical stimulation in an awake setting is feasible to acquire maximal cytoreduction in asafe manner. A dedicated surgical team is required, next to neurosurgeon, anaesthesiologist, and patient interaction.

O018
AWAKE CRANIOTOMY FOR THE PRESERVATION OF THE BRAIN FUNCTIONS INCLUDINGLANGUAGE, MOTOR, AND HIGHER BRAIN FUNCTIONS
Kuniaki Saito1, Ryoji Yamada2, Yusuke Tabei2, Nobusada Shinoura2, Mizuho Yoshida3
Department of Neurosurgery, University of Tokyo, Tokyo, Japan
Department of neurosurgery, Komagome Metropolitan Hospital, Tokyo, Japan3
Department of neurology, University of Tokyo, Tokyo, Japan
1
2

OBJECTIVE: In the treatment of malignant brain tumors, maximum resection is recommended. However, aggressive
resection tends to cause neurological deteriolation such as paresis, aphasia, and many deficits of higher brain functions. For
the maximum tumor resection without any neurological deficit, we perfomed intraoperative neurological monitoring of not only
language and motor function, but also various higher brain function in awake craniotomy. METHODS: From April 2003 to
December 2008, 80 tumor resections under awake craniotomies were performed in Komagome Metropolitan Hospital. The
tumors included 28 gliomas, 39 metastatic brain tumors, 4 radiation necroses, and 9 other brain tumors. Intraoperatively, weevaluated motor function in 47 surgeries, language in 26 surgeries, and higher brain functions such as imitation, writing, motor
programming, visual memory, emotion etc. in 19 surgeries according to the location of tumors. Functional magnetic
resonance imaging (f-MRI) and fiber-trackng integrated neuronavigation was also used during tumor resection. Neurologicalexamination was performed before and after the surgery. RESULTS: The mean extent of tumor resection was not inferior tothat of our prior series of surgeries under general anesthesia. Of 47 patients harboring tumor within or adjacent to motor area,
only 4 patients experienced permanent deteriolation of paresis after surgeries. Among the 19 patients with tumors locatednearby language area, only one patients suffered worsening of aphasia after surgeries. In the evaluation of higher brain
function during the tumor resection, we found various symptoms such as imitation disorder, writing disturbance, memory loss
and so on. But the symptoms were improved after discontinuation of the resection, and no permanent disorder wasrecognized. CONCLUSIONS: Awake craniotomy contributes to the preservation of neurological functions with acceptable
extent of tumor resection and keeps high performance status of the malignant brain tumor patient after surgery.

O019
CRANIAL SURGERY AND NAVIGATION BY USING LOW-FIELD-STRENGTHINTRAOPERATIVE MAGNETIC RESONANCE IMAGING: EXPERIENCE IN 251 PATIENTSCancelled- 66 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO020
DEVELOPMENT OF THE COMPACT MAGNETIC RESONANCE IMAGING SYSTEM FOR
INTRAOPERATIVE IMAGING.
Akio Morita, MD, PhD 1), Shigeo Sora, MD 1), Toshiki Oguro 2)
1)
2)

Department of Neurosurgery, Kanto Medical Center, NTT Ec,
Yoshida MFG Co. Ltd.

Introduction: Magnetic resonance imaging (MRI) during surgery has been proven to improve surgical resection rate and to
reduce postoperative complication during brain tumor surgery. However, current commercially available intraoperative MRI
system is relatively large and requires extra room for installment. To distribute such technique in world wide, we need tobuild a small intraoperative MRI system with good imaging quality. Method: With collaboration with Yoshida MFG. Co. Ltd.,we created a new MRI system. Our concept in creating the machine is, 1) the 5 gauss line is with in the circle of 3m indiameter and 2) the system weighs less than 3 tons, which will be the limit of routine hospital elevator carriage. 3) Also, we
desired imaging time to obtain essential intraoperative imaging series should be less than 30minutes. Results: Our systemcalled “Vesalius”, fulfilled our requirements. The size of the system is half of the currently available systems and the 5 gaussline was confined within 2.2m in diameter around the center of the machine. However, to reduce outer magnetic influence,
we need limit the inter-polar gap to 35cm. With this limitation, we improved operative bed and head clamping system. Highquality images (including T1, T2, Flair) with less image distortion was obtained within 30min. We are now starting clinicalapplication. Conclusion; We have build new intraoperative small low magnetic field MRI system, with high imaging quality.
We believe this system will significantly improve future brain tumor surgery.
Key word: intraoperative magnetic resonance imaging, brain tumor surgery, low magnetic field
Disclosure:
The first and second authors has no financial relation ship with the manufacturing company. The last author is an employeeof the company involved in the development of this system.

O021

Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

1

OBJECTIVE: Information of glioma mass and involved pyramidal tracts are invaluable clinically to surgical trajectory planand therapeutic outcome. We used diffusion tensor tractography in a stereoscopic virtual reality(VR) environment toperform presurgical planning for cerebral glioma with pyramidal tracts(PT) involvement. METHODS: 45 glioma cases ofPatient-specific Digital Imaging and Communications in Medicine(Dicom) data from diffusion tensor imaging(DTI) and threedimensional magnetic resonance imaging scans were transferred to the workstation (Dextroscope; Volume Interactions Pte.
Ltd., Singapore.). The tumor and adjacent PT were segmented and reconstructed for presurgical planning andintraoperative Guidance. The number of effective pyramidal tracts(EPT) and the motor strength after operation arecompared with those before operation. RESULTS: On this VR workstation, diffusion tensor tractography and threedimensional magnetic resonance imaging scans were integrated. The brain tissue,glioma mass and PT were obviously
displayed. An individual presurgical project was meticulously planned in every case. There was no significant difference
between presurgical and postsurgical motor strength,as well as the presurgical EPT and postsurgical EPT in our study. A
positive relationship was found between presurgical EPT and follow-up motor strength. CONCLUSION: Diffusion tensor
tractography in this VR environment exhibits the information of glioma mass and the involved PT, which is invaluable indesigning a suitable presurgical trajectory. According to the presurgical tractography we can predict as well as optimize thetherapeutic outcome. KEY WORDS: virtual reality; diffusion tensor imaging; tractography;outcome; glioma

O022
ROLE OF DTI FIBER TRACKING IN PREDICTING THE EXTENT OF RESECTION IN GLIOMA SURGERY
Giorgio Carrabba1, Giulio Bertani1, Antonella Castellano2, Enrica Fava1, Alessandra Casarotti1,
Giuseppe Casaceli1, Costanza Papagno3, Sergio M Gaini1, Andrea Falini2, Lorenzo Bello1
Neurosurgery, University of Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
Neuroradiology Unit and CERMAC, Scientific Institute and University Vita-Salute San Raffaele, Milan, Italy
3
Neuropsychobiology of Language, Department of Psychology, University of Milano Bicocca, Milan, Italy
1
2

Aim: To assess the ability of pre-operative DTI-Fiber Tracking (DTI-FT) to predict the extent of resection achievable during
surgery of gliomas performed with intraoperative brain mapping. Materials and methods: 70 patients with lesions locatedin the frontal, temporal and insular lobes of the dominant hemisphere were included. All of the patients, after preoperative
neuropsychological assessment, underwent DTI-FT of the Cortico-Spinal Tract (CST) and of the Inferior Fronto-Occipital(IFO) fasciculus. Each of the tracts (CST and IFO) was scored by two independent observer as being inside or outside of
the tumor. Awake intraoperative language and motor brain mapping included EEG, ECoG, EMG and MEP monitoring.
Surgery was carried out according to the functional boundaries of the lesion. Then, for each patient preoperative andpostoperative MR images and DTI-FT were loaded into the neuronavigation software and image fusion was used in order toevaluate the extent of resection as well as the correspondence between the resection boundaries and the preoperative DTIFT. A correlation between the preoperative score (inside/outside of the lesion) of each tract (CST, IFO) and the extent ofresection was also investigated. Results: The CST was inside the lesion in 38 patients (54%) and the IFO in 23 patients(33%). In all the cases in which the CST (38 pts) or IFO (23 pts) was inside the lesion, we found only incomplete resections(subtotal 19, partial 31). When CST and IFO were both outside the lesion, complete resections was carried out (20 patients).
Conclusions: DTI-FT of the CST and IFO can help to predict the possibility of total resection. In particular, when CST andIFO are inside the tumor a radical removal is rarely possible, while when outside of lesion, an extensive resection in thedominant hemisphere with the aid of brain mapping may be possible.

- 67 -­­

Oral Presentation (0)PRESURGICAL PLANNING FOR CEREBRAL GLIOMA WITH PYRAMIDAL TRACTINVOLVEMENT IN A STEREOSCOPIC DTI-BASED VIRTUAL REALITY ENVIRONMENT
Qiu Tianming1, Wu Jinsong1, Zhang Yi1, Zhou Liangfu1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O023
OPTICAL COHERENCE TOMOGRAPHY FOR INTRAOPERATIVE ANALYSIS OF GLIOMA
TISSUE MICROSTRUCTURE AND LIGHT ATTENUATION AS A NOVEL TECHNIQUE TO
CONTROL THE EXTENT OF RESECTION
Alf Giese1, Eva Lankenau2, Sven R. Kantelhardt1, Gereon Huettmann2, Veit Rohde1
Department of Neurosurgery, Georg-August-University of Goettingen, Goettingen, Germany
Institute for Biomedical Optics, University of Luebeck, Luebeck, Germany

1
2

Objective
Optical coherence tomography (OCT) is a non-invasive imaging technique with a micrometer resolution. It operates in notissue contact and generates images based on the reflection of infrared light. We have demonstrated that OCT
discriminates tumor and normal brain in experimental preclinical settings. We have developed an OCT-integrated operating
microscope and we have performed a clinical study in 20 patients.
MethodThe optical path of an operating microscope was optimized for the near-infrared and conventional light spectrum. The OCTintegrated microscope was used to analyse brain tumor tissue and areas of the resection cavity during resection of 20
malignant gliomas. We have used post image acquisition processing to compensate for movements of the brain and to
calculate light attenuation factors for brain and brain tumor tissue.
Results
OCT imaging of cortex and white matter showed a typical light attenuation profile. Tumor tissue was identified by loss of thenormal light attenuation and appearance of a prominent microstructure. OCT analysis allowed discrimination of normal
brain tissue, invaded brain, and solid tumor tissue. In a clinical study OCT analysis of the resection cavity demonstrated
residual tumor following macroscopically complete resections, which was confirmed by histological analysis. The blindedscoring of 41 tissue samples for OCT characteristics (microstructure and light attenuation) showed a high correlation withconventional histology (r = 0.99). The OCT integrated microscope remained fully functional for microsurgery and allowed
OCT analysis of a 3 - 50 mm scan line at a zoom factor 2 - 14.3.
Conclusion
Integration of OCT into an operating microscope allows continuous tissue analysis of the resection edge during resection ofbrain tumors and identifies residual tumor prior to secondary changes such as induced by tissue contusion. OCT allows thedetection of residual tumor and extents the information provided by conventional operating microscopes today.

Oral Presentation (0)O024
SYSTEMIC INHIBITION OF TRANSFORMING GROWTH FACTOR β IN GLIOMA-BEARING
MICE IMPROVED THE THERAPEUTIC EFFICACY OF PEPTIDE VACCINATIONS TARGETINGGLIOMA-ASSOCIATED ANTIGENS
Ryo Ueda1,2, Mitsugu Fujita1,2, Xinmei Zhu1,2, Kotaro Sasaki3, Edward R. Kastenhuber2,
Gary Kohanbash2, Heather A. McDonald2, Jay Harper 4, Scott Lonning4, Hideho Okada1,2,5
Department of Neurological Surgery, University of Pittsburgh School of Medicine
Brain Tumor Program, University of Pittsburgh Cancer Institute3
Department of Dermatology and Immunology, University of Pittsburgh School of Medicine
4
Immunotherapy Research, Genzyme Corporation
5
Department of Surgery, University of Pittsburgh School of Medicine
1
2

A variety of cancers, including malignant gliomas, overexpress transforming growth factor β (TGF-β), which helps tumors
evade effective immune surveillance through inhibiting cytolytic activity of natural killer cells and CD8+ cytotoxic T
lymphocytes (CTL), and enhancing the generation of regulatory T cells (Tregs). We hypothesized that inhibition of TGF-βwould improve the efficacy of vaccines targeting glioma-associated antigen (GAA)-derived CTL epitopes by reversal of
immunosuppression. In mice bearing intracranial GL261 gliomas, intraperitoneal (i.p.) administration of the TGF-β
neutralizing monoclonal antibody (mAb), 1D11, was combined with subcutaneous vaccinations of synthetic peptides for
GAA-derived CTL epitopes, GARC-1 (77-85) and EphA2 (671-679) emulsified in Incomplete Freund's Adjuvant (IFA). Micereceiving the combination regimen exhibited significantly prolonged survival compared with mice receiving either 1D11
alone, GAA-vaccines alone or mock-treatments alone. 1D11 administration enhanced the systemic induction of antigenspecific CTLs in GL261-bearing mice. Flow cytometric analyses of brain infiltrating lymphocytes (BILs) revealed that i.p.
1D11 administration increased GAA-reactive/IFN-γ-producing CD8+ T cells and reduced CD4+/FoxP3+ Tregs in theglioma microenvironment. Systemic 1D11 administration also up-regulated plasma levels of interleukin (IL)-12, macrophageinflammatory protein (MIP)-α and interferon (IFN)-inducible protein (IP)-10, suggesting a systemic promotion of type-1
cytokine/chemokine production. Furthermore, 1D11 treatment up-regulated plasma IL-15 levels and promoted thepersistence of GAA-reactive CD8+ T cells in the GL261-bearing mice. These data suggest that systemic inhibition of
TGF-β by 1D11 can reverse the suppressive immunological environment of intracranial tumor bearing mice both
systemically and locally, thereby promoting the therapeutic efficacy of GAA-vaccines.

- 68 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O025
INTERFERON-α SIGNALING IN THE BRAIN PLAYS A MAJOR ROLE IN IMMUNESURVEILLANCE DURING GLIOMA-GENESIS IN MICE
Mitsugu Fujita1, Stacy A Decker2, Flavia Popescu2, John R Olhfest2, Heather A McDonald1,
Hideho Okada1
Department of Neurulogical Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA
The Masonic University of Minnesota Cancer Center, Minneapolis, MI

1
2

Recently, a novel spontaneous mouse glioma model has been developed, where Sleeping Beauty (SB) transposasemediated stable transfection of oncogenes in the mouse brain induces central nervous system (CNS) tumors recapitulating
human malignant glioma. This system allows us to address the mystery of early events in glioma-genesis. We havepreviously demonstrated critical roles of type-1 adaptive immunity in control of established intracranial gliomas in mice.
Although decreases in type-1 cytokine levels have been reported in glioma patients, it has not been determined whether
such changes merely reflect consequences of established glioma and/or whether pre-existing alterations play any roles inoccurrence of gliomas. We hypothesized that the interferon (IFN)-α signaling pathway might play a pivotal role in immune
surveillance protecting against glioma development. We induced gliomas in IFN-α receptor (R)1-/- or wild type neonatal
mice via intracranial injections of plasmids encoding NRas, short hairpin RNA for p53, and EGFRvIII, along with the fourth
vector encoding SB transposase. Spontaneous tumors in IFN-αR1-/- mice grew and ceased hosts more rapidly than thosein immune-competent mice. When tumor-infiltrating lymphocytes were analyzed, IFN-αR1-/- mice showed increased
accumulation of CD4+FoxP3+ regulatory T cells and CD11b+Gr-1+ myeloid-derived suppressor cells in tumors. Furthermore,
following intravenous infusions of Pmel-I mouse-derived CTLs, IFN-αR1-/- mice exhibited reduced accumulation oftransferred CTLs at the tumor site compared with wild type mice. Of great interest is that when primary tumor cells were
cultured and subsequently injected into the brain of immune-competent hosts, IFN-αR1-/- glioma cells demonstrated aremarkably lesser degree of tumorigenicity compared with those from wild type mice, suggesting a possibility that IFNαR1-/- hosts allowed growth of tumors that could be immunologically rejected or inhibited in immune-competent mice.
These results suggest a potentially pivotal role of IFN-α reactivity in CNS immunological surveillance of gliomas, andwarrant well-designed immuno-epidemiological studies in humans.

O026

Department of Neuorsurgery, Neuropsychiatric Center, China Medical University and Hospital, Taiwan

1

Background: To perform a prospective phase II clinical trial using adjuvant autologous dendritic cell-based immunotherapy
for malignant gliomas. Methods: Patients aged 14 to 70 years with malignant gliomas and initial treatment Karnosfky
Performance Scale (KPS) score of more than 50 were enrolled. Eighteen patients with newly diagnosed malignant gliomas
underwent conventional treatments (surgery, radiotherapy, and chemotherapy) and adjuvant autologous dendritic cell
immunotherapy. The control group (n=18) underwent conventional treatments only. Results: The follow-up time ranged
from 18 to 50 months (median 30 months). Fourteen of 18 patients (78%) who received immunotherapy survived, but only
17% survived in the control group (p<0.01). The median survival time for the immunotherapy group was 25.5 months andfor the control group 16.7 months (p<0.05). Four of 9 patients with glioblastoma multiforme (GBM) (44%) who received
immunotherapy survived more than 24 months compared with none in the control group (p=0.03). The survival fraction was
significantly higher in the immunotherapy group compared with the control group based on Kaplan Meier analysis (p<0.01).
The remarkable response rate in the immunotherapy group was 56% but only 6% in the control group (p<0.01). The
recurrence rate was lower in the immunotherapy group (8/18) than in the control group (17/18) (p<0.01). The KPS
maintenance rate was significantly better in the immunotherapy group (80%) than in the control group (50%) (p=0.02).
Conclusions: Adjuvant autologous dendritic cell immunotherapy may improve survival time and rate, reduce recurrence
rate, and maintain better quality of life. It seems to be a safe and effective adjuvant treatment for malignant gliomas.
Multimodality treatment for malignant gliomas is essential.

- 69 -­­

Oral Presentation (0)AUTOLOGOUS DENDRITIC CELLS-BASED IMMUNOTHERAPY FOR MALIGNANT
GLIOMAS- A PHASE II PROSPECTIVE RANDOMIZED CLINICAL TRIAL
Der-Yang Cho1, Han-Chung Lee1, Hon-Lin Lin1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O027
Phase II clinical trial of WT1 vaccination against recurrent
glioblastoma with analyses of WT1 specific cytotoxic T lymphocytes
Naoya Hashimoto1, Yasuyoshi Chiba1, Akihiro Tsuboi2, Yoshihiro Oka3, Manabu Kinoshita1,
Naoki Kagawa1, Shuichi Izumoto4, Haruo Sugiyama5, Toshiki Yoshimine1
Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan
Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan 3Department ofRespiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of
Medicine, Osaka, Japan
4
Department of Neurosurgery, Hyogo Medical University, Hyogo, Japan
5
Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan
1
2(Purpose) To investigate the safety and clinical responses of immunotherapy targeting WT1 gene product, 31 patients with
WT1/HLA-A*2402 positive recurrent glioblastoma (GB) were evaluated in a phase II clinical study. (Material and Method)
All patients were intradermally injected with an HLA-A*2402-restricted, modified 9-mer WT1 peptide every week for 12
weeks. The responses on MRI were analyzed by RECIST criteria 12 weeks after the initial vaccination. Progression-free(PFS) and overall survival (OS) after initial WT1 treatment were estimated. The percentage of numbers of WT1 specificcytotoxic T lymphocytes (CTL) among those of all lymphocytes in the patients' peripheral blood were drawn using flowcytometry, to clarify the effect of concomitantly used steroids and anti-epileptic drugs (AEDs). The same analyses weredone with peripheral blood from another group of 14 patients with WT1/HLA-A*2402 positive malignant gliomas, who has
been receiving oral administration of temozolomide, to give a rationale of the combined chemo- immunotherapy. (Results)
The protocol of phase II study was well tolerated. The clinical responses included: none with complete response (CR), 2
patients with partial response (PR), 13 with stable disease (SD), and 16 with progressive disease (PD). The overall response
rate (CR+PR) was 6.5%, and the disease control rate (CR+PR+SD) was 48.4%. The median PFS was 16.0 weeks and PFS
at 6 months was 29.0%. The median OS after initial vaccination reached to 267 days. The analyses of WT1 specific CTL
revealed that neither concomitantly used agents (steroids, AEDs) nor temozolomide does affect the percentage of WT1
specific CTL. (Conclusion) This study showed that WT1 vaccine therapy for patients with GB was safe and had a clinicalresponse as compared with any other therapeutic modalities. Analyses of WT1 specific CTL raised the possibility ofconcomitant use of considerable dose of steroids and the rationale of combined chemo-immunotherapy planning in the
future.

Oral Presentation (0)O028
PHASE I/IIA TRIAL OF AUTOLOGOUS FORMALIN FIXED TUMOR VACCINE IN
TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME.
Yoshihiro Muragaki1, Takashi Maruyama1, Hiroshi Iseki1, Kintomo Takakura1, Masahiko Tanaka1,
Chie Shinohara1, Koji Tsuboi2, Tetsuya Yamamoto3, Akira Matsumura3, Masao Matsutani4,
Katsuyuki Karasawa5, Tadao Ohno6, Tomokatsu Hori1
Department of Neurosurgery, Tokyo Women’s Medical University
Proton Medical Research Center, University of Tsukuba
3
Department of Neurosurgery, University of Tsukuba
4
Saitama Medical University International Medical Center
5
Department of Radiology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
6
Advanced Research Institute for Science and Engineering, Waseda University
1
2

Origin of Study: Tokyo and Ibaragi, Japan
Topic: J immunotherapy(Introduction) Autologous formalin-fixed tumor vaccine (AFTV) could induce killer lymphocytes in vivo and exhibited
prophylactic effect against recurrence of hepatocellular carcinoma after the surgery in a randomized clinical trial. AFTV was
combined with radiotherapy (RT) for primary glioblastoma (GBM) in a phase I/IIa trial. (Patients and Methods) Adults after
resection of GBM were treated with standard RT and AFTV. AFTV was prepared with fixed GBM fragments, PPD, and BCG
extracts suspended in saline. When the cumulative radiation dose reached 32-36 Gy, AFTV treatment was started andinjected three times weekly. Second delayed type hypersensitivity tests (DTH2) were performed two weeks after third andlast vaccination. The primary endpoint was overall survival (OS) and secondary endopoint was progression free survival(PFS). (Results) Twenty-two eligible patients from two hospitals were accrued with a median follow-up time of 18.9 months(M). Median OS and PFS were 18 M and 7.6 M, respectively. OS and PFS of RT with AFTV were not significantly different
from those of RT with Temozolomide in the same hospital. The patients whose DTH2 reaction was more than 12mm
showed significantly longer OS and PFS than those with DTH2 reaction less than 12mm (OS: 22.5M v.s. 18M, PFS: 14M v.s.
7.5M,). There was no significant adverse event whose grade was more than grade 2. (Conclusion) Concomitant use of
AFTV in the late stage of radiotherapy resulted in comparable median times of PFS and OS when compared to ourhistorical controls of RT with Temozolomide without severe adverse events.

- 70 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O029
TYPE-1 DENDRITIC CELL VACCINES IN COMBINATION WITH POLY-ICLC - ASSOCIATIONBETWEEN POSITIVE TETRAMER RESPONSE AND 6-MONTH PROGRESSION-FREE
SURVIVAL
Hideho Okada2, Frank S. Lieberman1, Ryo Ueda1, Mitsugu Fujita1, Pawel Kalinski 2, Arlan H. Mintz1,
Deric M. Park1, David L. Bartlett2, Charles K. Brown2, Herbert Zeh2, Theresa L. Whiteside3,
Lisa H. Butterfield3, Ronald L. Hamilton1, Andres M. Salazar 4, Ian F. Pollack1
Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, The United States of America
Surgical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, The United States of America
Immunological Monitoring and Cellular Products Laboratory, University of Pittsburgh Cancer Institute, Pittsburgh,
PA, The United States of America
4
Oncovir, Inc, Washington, DC, The United States of America
1
2
3

O030
INDUCIBLE ONCOLYTIC TRANSFORMATION OF REPLICATION-DEFICIENT VIRUS FOR
THE CELL-BASED VIROTHERAPY
Hiroshi Nakashima1, Yoshinaga Saeki1, E Antonio Chiocca1
Department of Neurological Surgery, The Ohio State University Medical Center, Ohio, USA

1

Replication-conditional viral mutants promise an alternative treatment modality for malignant gliomas because of theirpotential to selectively eradicate tumor cells through oncolysis and spread their progeny throughout the tumor tissues. Initial
data obtained from clinical trials have demonstrated their clinical safety, but not their effectiveness, probably because of thestill inefficient delivery, propagation and spread of such viruses in tumor tissues. Efficient delivery of oncolytic viruses totumor regions is desirable due to the diffusely invasive property of malignant gliomas as a major obstacle in their treatments.
Cell-based delivery of oncolytic viruses has become a promising strategy to target the diffused tumors. Some cell types likeneural and mesenchymal stem cells have a homing ability to pathological regions including tumors. However, oncolytic viralcarrier cells may not survive long enough to migrate to scattered tumor regions, because of viral lytic cycle.. To overcome
this limitation, we have developed a novel strategy to improve carrier cell-based virotherapy. This new method consists of
two parts: 1) transformation from replication-deficient pro-oncolytic virus to replication-competent oncolytic virus, 2)
inducible viral transformation by tumor microenvironment. Our results showed viral gene expression was suppressed in prooncolytic virus, but activated by recombinase-based inducer in the infected cells. Once pro-oncolytic viruses changed toreplication-competent viruses, these induced viruses efficiently propagated in glioma cells compared to non-induced viruses.
This strategy enables viral carrier cells to survive for a longer period of time, compared to cells carrying general oncolytic
viruses. We believe that this promising method will enhance the development of cell-based virotherapy.

- 71 -­­

Oral Presentation (0)Our previous preclinical studies have demonstrated that intramuscular (i.m.) administration of a Toll-like receptor 3 ligand
poly-ICLC remarkably enhances induction of type-1 cytotoxic T-lymphocytes (CTLs) and improves therapeutic efficacy of
vaccinations against glioma-associated antigen-derived CD8+ T cell epitopes. Based on these studies, we have developed
a phase I/II trial. Human leukocyte Antigen (HLA)-A2+ participants with recurrent malignant glioma received intra-lymphnode injections of type-1 dendritic cells (DCs) loaded with HLA-A2 binding peptides EphA2 (883-891), IL-13Ra2 (345353:1A9V), YKL-40 (202-211) and GP100 (209-217: 2M) at two-week intervals. Participants also received twice weekly i.m.
injections of 20μg/kg poly-ICLC. Participants who demonstrated positive radiological response or stable disease withoutmajor adverse events were allowed to receive booster vaccines. Primary endpoints were assessments of safety andimmunological responses. Clinical and radiological responses were also evaluated. To date, 13 participants (6 withglioblastoma multiforme [GBM], 5 with anaplastic astrocytoma [AA] and 2 anaplastic oligodendroglioma [AO]) havereceived vaccinations with no major adverse events. Increased CD8+ cells reactive to HLA-A2.1-EphA2 (883-891) or HLAA2.1-IL-13Ra2 (345-353) tetramers were detected in post-vaccine peripheral blood mononuclear cells (PBMC) in 7 of 9participants evaluated. These patients also demonstrated up-regulation of a chemokine receptor CXCR3 on CD8+ PBMC
following vaccines, indicating that the vaccine regimen induced type-1 CTL responses. One of these participants withrecurrent GBM exhibited partial radiological response, which persisted for 7 months with booster vaccines. Biopsy oftumor site after vaccination in this participant revealed intensive infiltration of CD8+ T cells and macrophages. Six patientsachieved progression free at 6 months (2 GBM, 2AA and 2 AO). Fisher’s exact test indicated an association between
positive tetramer response and 6-month progression-free survival, suggesting a possible correlation between tetramerdetected immune responses and clinical response. These interim data demonstrate preliminary safety and immunologicalactivity of poly-ICLC-assisted type-1 DC-based vaccines. Grants: 1R21-CA117152, 1P01-NS40923

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O031
ONCOLYTIC VIRUS THERAPY OF GLIOMA SENSITIZES GLIOMA CELLS TO CILENGITIDETREATMENT.
Kazuhiko Kurozumi1,2, Amy Haseley3, Christopher Alvarez-Breckenridge3,
Tomotsugu Ichikawa2, Isao Date2, E Antonio Chiocca1, Balveen Kaur1
Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State university Medical center,
Columbus, OH., 43210, USA.
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry andPharmaceutical Sciences, Okayama, Japan.
3
Integrated Biomedical Sciences Graduate Program, The Ohio State university Medical center, Columbus,
OH., 43210, USA. 4College of Medicine, The Ohio State university Medical center, Columbus, OH., 43210, USA.
Objectives: Oncolytic HSV-1 derived viruses (OVs) are being investigated as treatment modalities for many cancers. However,a clear understanding of the action of this biological therapy in human patients is currently not feasible. We have been
investigating OV therapy induced changes in the tumor extracellular matrix. Methods & Results: Transcript profiling of secreted
proteins involved in angiogenesis revealed a significant induction of Cystein-rich 61(CYR61) gene expression in tumors treatedwith OV in vivo. CYR61 is a secreted ECM protein that can bind to and activate integrins αvβ3 and αvβ5. Increased CYR61 in
the ECM of breast cancer cells has also been shown to activate an autocrine loop resulting in upregulation of its own receptor
αvβ3 resulting and increased sensitization to integrin anatgonists (Menendez JA, et al. Oncogene 2005). Consistent with this
we found that glioma cells stably over expressing CYR61 were much more sensitive to the integrin antagonist, Cilengetide, thancontrol cells. Hence we hypothesized that OV treatment, which induces secreted CYR61, would increase integrins αvβ3 onboth infected and uninfected glioma cells, and sensitize them to Cilengitide. We tested the effect of OV treatment on glioma
cells for the expression of integrin receptors αvβ3. Moreover we detected synergistic killing of glioma cells treated with OV andCilengitide compared to cells treated with either agent alone. We tested this hypothesis in immunocompromized mice withintracranial tumors (U87dEGFR). Five days after OV treatment mice were injected systemically with a single dose of cRGD
(5mg/kg) or PBS. Mice treated with OV and Cilengitide survived significantly longer than mice treated with OV alone (P < 0.01
between OV and cRGD + OV). Conclusion: These results indicate that OV therapy can sensitize glioma cells to Cilengitide andlays a rationale for designing future clinical trials combining the two agents.
1
2

O032
Oral Presentation (0)MEDULLOBLASTOMA : THE ROLE OF TOTAL TUMOR REMOVAL TO AVOID RECURRENCE
Eka JW, Jesaja J, Julius J, Harsan H, Lutfi H, Binsar N
Neuroscience Center , Siloam Hospital Lippo Village – Pelita Harapan University Medical School
Tangerang - INDONESIA
Medulloblastoma is one of the most malignant brain tumor. From 1995 to 2009 we have treated 80 cases of
medulloblastoma. There were 48 female and 32 male in our series, ranging from 2 months old to 55 years. In all cases, total
removal was attempted and achieved in 68 cases (85 %). Total removal was impossible with brainstem attachment.
Radiotherapy following surgery was routine procedure. (except in very young infants) and starting from 2005 we usedchemotherapy.
In our series, recurrent rate was 10% with total removal, in comparison with 80% in the other group. Complications
included lower cranial nerve palsy. Cerebellar dysfunction and mutism, which all recovered.
Keywords : Medulloblastoma – total tumor removal – recurrent rate

O033
OPTIMIZING THE PHYSICAL AND BIOLOGICAL PARAMETERS OF RADIOTHERAPY IN
AVERAGE-RISK MEDULLOBLASTOMA
Tejpal Gupta2, Rakesh Jalali1, Rajiv Sarin1, Anusheel Munshi1, Sabita Goswami1,
Nikhil Merchant1, Dattatreya Muzumdar2, Darshana Sanghvi2
ACTREC, Tata Memorial Centre
King Edward Memorial Hospital, Parel, Mumbai, INDIA

1
2

Purpose: To optimize physical and biological parameters of radiotherapy in average-risk medulloblastoma. Methods:
Twelve children with average-risk medulloblastoma were treated with hyperfractionated radiotherapy (HFRT). Radiotherapy
consisted of 2 fractions daily of 1 Gy each, 6 hours apart, 36 Gy/36 fractions of craniospinal irradiation (CSI), followed by
conformal tumor bed boost (32 Gy/32 fractions) for a total dose of 68 Gy/68 fractions over 6.5 weeks. Chemotherapy was
reserved for relapse. Results: The median age of the cohort was 8 years (range 5-13 years). Acute hematologic toxicity
was self-limiting, not requiring interruption of treatment, growth factor support or platelet transfusions in any patient. Grade
II neutropenia and thrombocytopenia was seen in 33% and 16% patients respectively. No one developed grade III-IV
thrombocytopenia. Five of 12 children had suboptimal mean Intelligence Quotient (IQ) scores (mean IQ less than 90) even
before initiation of radiotherapy. Two patients relapsed, at 18 and 21 months from diagnosis, both supratentorially and in the
leptomeninges, of which one died at 25 months despite salvage chemotherapy. With a median follow-up of 19 months(range 6-30 months), the 2-year event-free-survival and overall survival was 65% and 100% respectively. Mean IQ scoresfor all tested domains were preserved in all the 10 children evaluable at 1-year. Two children developed hypothyroidism
necessitating thyroxine supplementation, while no patient developed significant sensori-neural deterioration. Conclusion:
Preliminary analysis suggests that HFRT without chemotherapy for average-risk medulloblastoma is a promising option withacceptable self-limiting acute toxicity, without an unduly increased risk of relapse. Long-term results on larger number ofpatients are required to confirm its role in reducing the known late sequelae of radiotherapy.

- 72 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO034
DO MEDULLOBLASTOMAS IN ADOLESCENTS HAVE A DISTINCT MOLECULAR
SIGNATURE & DIFFERENT TUMOR BIOLOGY?
This Abstract nominated the Hoshino Award.
Please refer to P061 on page 151.

O035
Autologous hematopoetic stem cell transplantation for children withhigh risk brain tumors
Ho Joon Im1, Bock Young Jung2, Keun Wook Bae1, Jae Hee Lee3, Joon Seop Song4,
Jong Jin Seo1, Hyung Nam Moon1
Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Department of General Dentistry, Yonsei University College of Dentistry, Seoul, Korea
3
Department of Pediatrics, Chung-Ang University Hospital, Seoul, Korea
4
Department of Pediatrics, Kangdong Sacred Heart Hospital, Hallym University Medical Center, Seoul Korea
1
2

O036
Clinicopathological features of Atypical Teratoid/Rhabdoid Tumors: its
diagnosis and tumor growth factor
Hidehiro Oka1, Satoshi Utsuki1, Kiyotaka Fujii1
Depattment of Neurosurgery, Kitasato University School of Meidicine, Sagamihara, Japan

1

Introduction: The clinicopathological features of Atypical Teratoid / Rhabdoid Tumors (AT/RTs) in Japan, and theimportance of the differential diagnosis from PNET/medulloblastoma and germ cell tumor are described. Methods: Forty
one patients with AT/RT in Japan were analyzed about clinicopathological features. Results: Forty one AT/RTs (23 maleand 18 felame) were aged from 1 month to 37 years (mean 2.9 years) and tended to show increased intracranial pressure
by obstructive hydrocephalus and/or tumor volume. This tumor locations were in the posterior fossa (63%), brain
hemispheres (22%), spinal (12%), and pineal region (3%). Interestingly, younger patients (under 2 years) with AT/RT tended
to located in posterior fossa or spinal region. Leptomeningeal dissemination showed over 50% of AT/RTs. Histologically, AT/
RT is defined as a polymorphous neoplasm often featuring rhabdoid, PNET, epithelial, and mesenchymal components. AT/
RTs usually include PNET components and occur mainly in the posterior fossa, so mimic medulloblastoma. AT/RT ischaracterized by the cytogenetic finding of monosomy 22 rather than i(17q). The tumor is similarly mistaken for PNET atsupratentorial immunophenotypic diversity, particularly features indicative of epithelial and mesenchymal differentiation.
Nonetheless, the remarkable spectrum of tissues that typify teratoma is absent in AT/RT. The prognosis of this tumor is far
less favorable than that of PNET/medulloblastoma or germ cell tumor. For the diagnosis of AT/RT, Negativity of INI1 protein
is important and IGF-1 receptor tended to express in this tumor cells. Conclusions: This study describes theclinicopathological features of 41 AT/RT in Japan and we emphasizes the necessity for distinguishing this unique tumor
from other pediatric centran nervous system neoplasms. And INI1 is important for this tumor diagnosis. Moereover, IGF-1
may play a role as growth factor of AT/RT cells.

- 73 -­­

Oral Presentation (0)Purpose: Although the outcome of brain tumor in children has improved significantly over decades, the high-risk (HR) brain
tumors such as recurrent, residual or infant disease still have a poor prognosis. Autologous hematopoetic stem celltransplantation (AHSCT) has been applied to improve the outcome of HR brain tumors. We report on the outcome for HR
brain tumors receiving AHSCT at a single institution. Method: Between October 1999 and August 2008, 20 patients
received AHSCT using peripheral blood stem cells for HR brain tumor at Asan Medical Center. Their medical records
including transplant data were reviewed and the outcome was analyzed as of December 2008. Results: Of 21 patients, 8
had medulloblastoma (2 infant, 2 metastatic, 3 recurrent), 6 had supratentorial PNET (1 infant, 1 residual, 4 recurrent), 2 hadpineoblastoma (1 infant, 1 recurrent), 2 had ATRT, and 2 had recurrent GCT. At transplantation, 13 patients were in CR and
7 in PR. Nine patients (CR 5 & PR 4) received conditioning with cyclophosphamide/melphalan (CM) and 11 (CR 8 & PR 3)
with carboplatin/thiotepa/etoposide (CTE). After AHSCT, 5 patients (4 in CM, 1 in CTE) relapsed and 4 patients (3 in CM, 1
in CTE) died of causes other then disease progression. With a median follow-up of 33.7 months, 3-y EFS and OS were50.8% and 56.1%, respectively. CR at the time of AHCT tended to have better EFS compared to PR (64.5% vs 24.6%,
P=0.103). The 3-y EFS for 11 patients conditioned with CTE was better than that of 9 with CM (79.5% vs 22.2%, P=0.014).
Conclusion: AHSCT with CTE is highly successful treatment modality for HR brain tumors in children. Given the limitationof this study including small number of patients as well as heterogeneous population, further study is warranted to clarify
the role of AHSCT in pediatric brain tumors.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O037
PRE-CLINICAL TESTING OF COMBINATION RADIATION PLUS HISTONE DEACETYLASEINHIBITOR THERAPY IN TREATING ATYPICAL TERATOID RHABDOID TUMOR
Rintaro Hashizume1, Yasuyuki Aoki2, Tomoko Ozawa1, Scott R. VandenBerg1, C. David James1
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA
St. Marianna University School of Medicine, Kawasaki City Kanagawa, Japan

1
2

PURPOSE: The purpose of this study was to determine whether combination treatment involving radiation therapy (RT)and valproic acid (VA), a histone deacetylase (HDAC) inhibitor, provides superior anti-tumor effect than either therapy alone,when evaluated in the context of an intracranial xenograft model of atypical teratoid rhabdoid tumor (ATRT). METHODS:
300,000 ATRT cells, modified with luciferase for bioluminescence imaging (BLI), were injected into the supratentorialcompartment in each of 35 mice. Tumor cells were monitored by BLI until exponential growth was indicated, at which time
mice were randomized into four treatment groups: 1) Vehicle only treatment; 2) RT only (0.5 Gy/day x 5 days); 3) VA only
(150 mg/kg/BID x 7 days); or 4) RT and VA administered concurrently as indicated for monotherapy administrations. BLI
was used for continuous monitoring of tumor response to therapy, and all mice were followed until euthanasia was required
due to presentation of symptoms associated with neurological compromise from tumor burden. RESULTS: Mice receiving
concurrent RT + VA treatment experienced significant survival benefit relative to vehicle treated control group animals (p =0.0009), as well as with respect to mice receiving either treatment as a monotherapy (p = 0.0017 in comparison with VA
alone, and p = 0.0223 in comparison with RT alone). Bioluminescence imaging revealed that combination therapy reduced
the incidence of neuraxis dissemination of intracranial tumor. CONCLUSIONS: Our results indicate that combination
therapy using an HDAC inhibitor + RT has enhanced anti-tumor activity relative to either therapy used alone, and therefore
warrants consideration for use in the young pediatric patients that are affected by this highly malignant central nervous
system tumor.

O038

Oral Presentation (0)Atypical Choroid Plexus Papilloma: 2008 Interim Analysis of the CPTSIOP-2000 Study
Johannes E.A. Wolff1,2, Ove Peters6, Peter Thall2, Blanca Diez3, Martin Hasselblatt4,
Anita Mahajan5, Brigitte Wrede6
Section of Pediatric Neuro-Oncology, M.D.Anderson Cancer Center, Houston, US, 2Biostatistics, M.D.Anderson
Cancer Center, Houston US, 3Neuro-Oncology, FLENI, Buenos Aires, Argentina, 4Neuropathology, University Hospital
Muenster, Germany, 5Radiation Oncology, M.D.Anderson Cancer Center, Houston, US, 6Pediatric Oncology, Universityof Regensburg, Germany
1

Introduction: Atypical choroid plexus papilloma (APP, WHO grade II) were newly defined by the WHO in 2007 in addition to
the previously defined choroid plexus tumors (CPT), which were choroid plexus papilloma (CPP, grade I), and choroid
plexus carcinoma (CPC grade III). Methods: The CPT-SIOP-2000 study is an international observation and randomized
treatment trial for all patients with CPT. After maximal surgical resection, all patients with APP and residual tumor, withmetastases or with CPC regardless of residual tumor were treated with chemotherapy (VP16, vincristine and either
carboplatinum or cyclophosphamide). Irradiation was given to patients older than 3 years of age between the second andthird cycle. The other CPT patients were followed without further treatment. Results: Until December 2008, 23 nations
registered 152 patients with CPT. In the latest interim analysis, patients with APP (n=32) had a median age of 0.7 years andwere thus younger than patients with CPP (2.2 years; n=42) or CPC (2.2 years; n=34). Primary metastases were frequent
in CPC (20%) and APP (16%), but also occurred in CPP (5%). Complete resection was achieved in 81% of CPP, 65% of
APP, and 50% of CPC. Patients with APP had an intermediate 5-year EFS (84%±10SD) compared to CPP (91%±8SD) and
CPC (28%±20 SD; p<0.0002). Objective early response (complete remission, partial response) after two cycles ofchemotherapy among APP patients receiving further treatment was seen in 6 of 10 patients. Conclusion: The intermediate
position of APP defined by histology was confirmed by clinical data of tumor resection and frequency of metastases but notin age at diagnosis. Further molecular studies are necessary to determine if there is a further subgroup hidden with different
biology among those very young children. APP seem to respond to chemotherapy.

O039
Metastatic Choroid Plexus Tumors - Data of the CPT-SIOP-2000 Study
Johannes E.A. Wolff1, Brigitte Wrede2, Su Berrak3, Jonathan Finlay4, Ove Peters2
Depts Pdiatrics and Biostatistics, MD Anderson Cancer Center, Houston, Texas 2Dept Pediatrics, St Hedwig Hospital,
University of Regensburg, Germany3 Marmara University, Istanbul, Turkey 4Los Angeles Children s Hospital, USA

1

Introduction: Choroid plexus tumors are rare, and the pattern of dissemination has not been described in details yet.
Methods: a retrospective analysis of the CPT-SIOP-2000 database (Choroid Plexus Tumor-International Society ofPediatric Oncology - 2000) included patients randomized and treated as well as those registered only. Results: By June2008 100 patients were formally registered. In 21 of those, metastases were reported (10 of 21 male, median age 2.7 years
range 0.1 to 11.8). This includes five patients documented as metastatic but with a confirmation pending, 12 tumors
confirmed metastatic at presentation, three tumors presenting as localized but later recurring as metastatic (secondary),and 1 presenting metastatic and again recurring metastatic. Primary location was the lateral ventricle in 20 and the 4th
ventricle in 1 patent. The histology was choroid plexus papilloma 3(CPP), atypical choroid plexus papilloma 5 (APP), andchoroid plexus carcinoma 11 (CPC). Primary surgery was: gross total resection 12, partial resection 6, or biopsy 2. All
tumors were spread through cerebrospinal fluid. Eight patients received radiation and chemotherapy, 10 chemotherapy
only, and 3 neither. Those three had complete resections of either CPP (2) or APP (1), all are alive, and one recurred. Amongthe other 18, the median event free survival (EFS) was 1.33 years, and the 4 year EFS 51% (+-14 SD), 4 year overall survival
72% (+-19 SD , median not reached). In all recurrences leptomeningeal spread was documented. Conclusion:
Leptomeningeal spread is common in choroid plexus tumors, in particular when the primary location is supratentorial. The
prognosis seems to be better than other metastatic brain tumors.

- 74 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O040
Pediatric Gliosarcomas: Clinical and Epidemiological Characteristics
Michael Karremann1, Ulrike Rausche2, Torsten Pietsch3, Christof M Kramm2,
Johannes EA Wolff4
1
Department of Pediatrics, University Hospital Mannheim, Mannheim, Germany 2Department of Pediatrics andAdolescence Medicine, Martin-Luther-University Halle-Wittenberg, Halle, Germany 3Institute of Neuropathology,
University of Bonn, Bonn, Germany 4Department of Pediatrics and Biostatistcs, MD Anderson Cancer Center,
Houston, TX, USA

Purpose Gliosarcoma (GS) represents a glioblastoma with a sarcomatous component, which is presumed to be a
metaplastic differentiation of the glioma cells. We studied the clinical relevance of this histological glioblastoma subentity
within the pediatric population. Patients and Methods Patient data were obtained from the German HIT-GBM database
where clinical data of more than 600 pediatric patients with centrally reviewed high grade gliomas are accumulated. By
applying defined inclusion criteria (diagnosis of GS proven by central neuropathological review; patient age 0 to 21 years) 5
patients were identified. In addition, after review of English medical scientific literature 19 additional cases were found.
Results The relative frequency of GS in the German HIT-GBM database was only 2.4%. In the whole series of 24 pediatricGS including previously reported cases the male-to-female-ratio was 1.3:1. GS was found in all pediatric age groups with a
median age of 11 years but there was an unexpectedly high accumulation in infants (7 of 24 less than 3 year of age, 29 %).
GS showed a strong predilection of the cerebral hemispheres (23 out of 24 cases). Symptoms of increased intracranialpressure were the leading symptoms of a short clinical history with a median duration of 1 month. Interestingly, 6 patients(25 %) were reported with a history of cranial radiotherapy prior to GS diagnosis. In 62 % of GS in our series, gross total
resection was achieved. Median overall (OS) and event-free survival (EFS) of the total cohort were 13.3 and 9.8 months,
respectively but infants showed superior survival. Conclusion GS is a very rare tumor entity in children. Literature review
suggests a relatively higher incidence in infants and in patients with a previous history of radiotherapy.

O041

Department of pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan 2Department of Pediatrics, Kuang-Tien
General Hospital, Taichung, Taiwan 3Department of Pediatrics, Taipei City Hospital, Ren-Ai branch, Taipei, Taiwan
4Department of Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan 5Department of Neurosurgery,
Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan 6National Yang-Ming University, School of
Medicine, Taipei, Taiwan
1

Purpose: To assess the efficacy of temozolomide (TMZ) on diffuse brainstem glioma as concomitance with radiotherapy
and as adjuvant treatment post radiotherapy in children. Patients and Methods: Eighteen children (median age at
diagnosis, 8.3 years) with newly diagnosed brainstem tumors which were treated with TMZ at Taipei Veterans General
Hospital since Jan 2004 to Dec 2008 were eligible for the study. They were divided into two groups by the different
treatment modalities. RT+TMZ (radiotherapy alone followed by adjuvant TMZ) group received conventional radiation after
initial diagnosis. CCRT+TMZ (concomitant chemoradiotherapy followed by adjuvant TMZ) group received concurrent
chemotherapy during radiation with TMZ (75mg/M2/day). After the completion of radiotherapy, TMZ (150mg/M2) was
administered orally once daily for five consecutive days for all enrolled patients. Treatment cycles were repeated every 28
days. We evaluate the progression-free survival in both groups of patients. Results: There were 10 patients in RT+TMZ
group and 8 in CCRT+TMZ group. All patients experienced progression of disease. Twelve patients (75%) died in the study
period and all deaths were attributed to disease progression. The median progression-free survival (PFS) was 7.4 months
for the RT+TMZ group and 6.4months for CCRT+TMZ group. The 6 moths and 1year PFS in RT+TMZ group were 70% (SD,14%) and 30% (SD, 14%) respectively and in CCRT+TMZ were 50% (SD, 17%) and 0% respectively. The log-rank test in
PFS between the two groups was P=0.09. Conclusions: In this study, RT followed by TMZ or CCRT followed by TMZ did
not alter the poor prognosis of the newly diagnosed diffuse brainstem glioma in children. In addition, CCRT followed by
TMZ did not achieve a better outcome than RT followed by TMZ.

- 75 -­­

Oral Presentation (0)Role of Temozolomide for The Treatment of Newly Diagnosed Diffuse
Brainstem Glioma in Children- Experience in A Single Institution
Kuo-Liang Chiang1,2, Kai-Ping Chang1, Yi-Yen Lee3, Pin-I Huang4, Tai-Tong Wong5,6,
Ting-Rong Hsu1, Yi-Wei Chen4

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O042
Role of surgery for optic pathway/hypothalamic astrocytomas inchildren
Yutaka Sawamura1, Yuuta Kamoshima1, Junko Tsubaki2, Toshimitsu Tajima2
Departments of Neurosurgery, Hokkaido University Hospital, Sapporo, Japan
Department of Pediatrics, Hokkaido University Hospital, Sapporo, Japan

1
2

Optic pathway/hypothalamic pilocytic astrocytomas in children are usually treated with chemotherapy following a surgicalbiopsy. In this report, we retrospectively considered the role of surgical intervention. In a series of 32 patients without
neurofibromatosis type 1, the median age at initial treatment was 2.7 years (range, 0-12 years). Twenty-five cases wereverified by histology, and seven cases were diagnosed by MRI findings. Twenty-eight patients received chemotherapy. All
patients were alive at median follow-up of 65 months. Aims of surgery at the initiation of treatment were biopsy in 15 cases(1 stereotactic and 14 craniotomies) and debulking in 9 cases. The 14 open biopsies revealed pilocytic astrocytoma;
however, noticeable complications occurred in six children after the biopsies. Review of preoperative MRIs showed that all
had typical findings indicating pilocytic astrocytoma. The open biopsy offered no noteworthy benefit for the patients despite
surgical risk and delay of chemotherapy. The extent of the nine resection surgeries was 80% or less removal, andpostoperative adjuvant therapy was needed for seven of the nine patients. The remaining seven children who did notundergo surgery obtained remission with chemotherapy alone. One child underwent decompression of the optic canal thatyielded amelioration of decreasing vision. After relapse in 11 patients, 19 bulk-reduction surgeries were performed. Surgicalresection was not curative in any patient. In six patients, mostly older children, cystic expansion of tumor was partiallyresected, resulting in additional remission. In six children beyond the age of adolescent, spontaneous tumor involution wasobserved. In conclusion, considering the risk of open surgery and the effectiveness of chemotherapy, the role of surgicalintervention is restricted to bulk-reduction surgery only when it is inevitable, especially at relapse after chemotherapy.

O043
Prognositic analysis of 220 patients with intramedullary spinal cord
ependymomas
Guihuai Wang1

Oral Presentation (0)1Department of Neurosurgery, Tiantan Hospital, Capital University of Medical Sciences, Beijing, China
Objective: To assess the factors relative to the surgical prognosis of intramedullary spinal cord ependymomas. Methods:
220 patients harbored intramedullary spinal cord ependymomas were treated surgically in Beijing Tiantan Hospital from2000 to 2007. We followed them on telephone and analyzed their JOA score preoperatively and postoperatively aboutage,gender,length of tumor and spinal cord function by Spss 11.5 software. Results: Age,gender and length of tumor had
no significant influence on prognosis. Through multiple linear regression analysis and Logistic regression,we concluded thatthe postoprative JOA score highly relatived to the preoperative neurological status and other factors. Conclusion:
Determinant factors of prognosis for intramedullary spinal cord ependymomas are preoperative neurological status;extent
of removal of the lesion. KEY WORDS: intramedullary spinal ependymomas,surgery

O044
Grading system for diagnosis and treatment of intracranial
nongerminomatous malignant germ cell tumors
Xiang Huang1, Rong Zhang1, Liangfu Zhou1
Department of neurosurgery in huashan hospital, Fudan University, Shanghai, China

1

Objective To discuss the clinical feature, treatment, and prognosis of intracranial nongerminomatous malignant germ celltumors(NGMGCTs). Methods The records of 39 patients who were treated in Shanghai Huashan hospital between 1995
and 2007 were reviewed retrospectively. According to the classification of Matsutani in 1997, they were grouped into
intermediate prognosis group and poor prognosis group based on the histology of the tumor. Clinical manifestation,
diagnosis, treatment and outcome were analysis in each group. Results In these 39 cases, there were 15 mix germ celltumors, 15 immature teratomas, 7 embryonal carcinomas and 2 yolk sac tumors. All patients were treated surgically. The
tumor was totally removed in 29 cases, sub-totally in 5, and partially in 3. Biopsy was performed in the other 2 cases. 34
patients (87.2%) were followed up. The common 5-year survival rate was 36.8%. The 5-year actuarial overall survival rate
for patients in the intermediate prognosis and poor prognosis groups were 42.6% and 0%. Chemotherapy combined
radiotherapy has significant relationship with the prognosis of intermediated prognosis group (P=0.039). The 5-year survival
rate of immature teratoma patients who received gamma knife surgery after surgery was 100%. It had significant difference(P=0.0049) compared to the 5-year survival rate of patients who did not receive gamma knife surgery. Conclusions
NGMGCTs can be divided into intermediate group and poor group base on the prognosis (P= 0.0003). Embryonalcarcinoma can be classified to the intermediate prognosis group because of its similar prognosis with immature teratoma
and mixed tumors mainly composed of germinoma or teratoma. Surgery is the first choice for NGMGCTs because
treatment should be base on tumor histology. For patients in the intermediate prognosis group, combined treatment,
including surgical resection, radiotherapy, chemotherapy and gamma knife surgery was effective.

- 76 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO045
OPTIMAL TREATMENT STRATEGY FOR INTRACRANIAL GERM CELL TUMORS: SINGLEINSTITUTION ANALYSIS.
Masayuki Kanamori1, Toshihiro Kumabe1, Yukihiko Sonoda1, Teiji Tominaga1
Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan1

Purpose: To review the optimum treatment for newly diagnosed intracranial germ cell tumors. Patients and Methods: A
retrospective review of medical records at our department from April 1990 to March 2007 identified 108 patients, 86 males
and 22 females aged from 2 months to 45 years old (median 14 years), with newly diagnosed intracranial germ cell tumors.
Their diagnoses were germinoma in 83 patients, and non-germinomatous germ cell tumor in 25. Results: In the patientswith germinoma, the 10-year overall and progression free survival rates at median follow-up period of 99 months were 86%
and 74%, respectively. The recurrence occurred at 6-153 months (median 26 months) after starting the initial therapy.
Patients treated with chemotherapy alone had shorter progression-free survival rate, and patients treated withchemotherapy followed by reduced-dose radiation therapy to the whole ventricle, whole brain, or craniospinal axis had
significantly better progression-free survival rate compared to radiation alone or reduced-dose radiation therapy to focal
field. Non-germinomatous germ cell tumors were divided into good, intermediate and poor prognosis group as proposed
by Japanese Japanese Pediatric Brain Tumor Study Group. In the good and intermediate prognosis group, the 10-year
overall and progression-free survival rates were 93% and 100%, respectively. In the poor prognosis group, the 3-year
overall and progression-free survival rate were 56% and 29%, respectively. In both groups of non-germinomatous germ celltumors, all of the patients, in whom radiographic lesions have disappeared after combination therapy of surgical resection,
radiation therapy, and chemotherapy, were alive without recurrence. Conclusion: Chemotherapy followed by reduceddose radiation therapy to the field covering the whole ventricle at least was effective in the treatment of germinoma. In theinitial treatment of non-germinomatous germ cell tumor, combined treatment, including salvage surgery, is essential toachieve the complete disappearance of radiographic lesions.

O046

1
Radiotherapy Division, Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan 2Cancer Center, Taipei
Veterans General Hospital, Taipei, Taiwan 3Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General
Hospital, Taipei, Taiwan 4Radiotherapy Division, Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan
5Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan 6Division of Neurology, Department ofPediatrics, Taipei Veterans General Hospital, Taipei, Taiwan 7Division of Endocrinology, Department of Pediatrics,
Taipei Veterans General Hospital, Taipei, Taiwan 8Pediatric Neurosurgery, Neurological Institute, Taipei Veterans
General Hospital, Taipei, Taiwan

Purpose: To review the effectiveness of reduced-dose and restricted volume radiation-only therapy in treatment of
intracranial germinoma (IG), and to assess the feasibility of reducing or eliminating the use of chemotherapy.Methods andMaterials: Between January 1996 and March 2007, 51 patients with IGs underwent variable treatments at Taipei Veterans
General Hospital. A retrospective analysis was done of 38 patients with either reduced radiation alone (30 Gy for 26 patients)
or reduced radiation with chemotherapy (systemic vinblastine, bleomycin, etoposide, and cisplatin for 12 patients). All 38
patients received extended focal (including whole-ventricle) irradiation, and were followed to February 2008 withcharacterizing overall (OS) and relapse-free survival (RFS) rates. Variables associated with survival were evaluated by
univariate Cox proportional-hazards regression. Results: Median follow-up was 62.4 months (range, 10.1-142.5 months).
The total 5-year overall survival rate was 93.7%. The 5-year OS and RFS rate for patients receiving radiation only were 100%and 96.2%, respectively. For those receiving radiation plus chemotherapy were 83.3 % and 91.7% (no statisticalsignificance). There was no any predictive factor that was significantly associated with OS or RFS rates, and chemotherapy
had no significant effect on survivals but higher incidence of treatment-related toxicity. Conclusions: Further decrease ofradiation dose to 30 Gy with whole-ventricle irradiation is sufficient to treat selected intracranial germinoma. Use of wide-field
irradiation or chemotherapy should be avoided as unnecessary. We recommend exploring further radiation volume and dose
reductions to eliminate the risk of radiation-induced treatment complications. Systemic chemotherapy is only recommended
for patients at high risk of recurrence or metastasis. Reduction of radiation doses to 30 Gy may be feasible, even without
chemotherapy. Key Words: Germinoma, whole ventricle irradiation, radiotherapy, complication, craniospinal irradiation.

- 77 -­­

Oral Presentation (0)The Optimal Radiation Volume and Dose for Intracranial Germinoma
Yi-Wei Chen1, Sang-Hue Yen2, Tai-Tong Wong3, Pin-I Huang4, Donald Ming-Tak Ho5,
Kai-Ping Chang6, Dau-Ming Niu7, Muh-Lii Liang8

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O047
Germ Cell Tumors in the Basal Ganglia: Clinical Outcomes and Diagnostic
Utility of Positron Emission Tomography (PET)
Byung-Kyu Cho1, Ji Hoon Phi1, Seung-Ki Kim1, Hee-Won Jung1, Dong Gyu Kim1,
Jeong Eun Kim1, Kyu-Chang Wang1
Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea

1Introduction Germ cell tumor (GCT) in the basal ganglia is a curious neoplasm. Atypical clinical presentation and peculiar
radiological findings are common. In the present study, we analyzed the clinical outcomes of basal ganglia GCTs.
Furthermore, the diagnostic utility of positron emission tomography (PET) was analyzed. Materials and Methods The
clinical data of 21 consecutive patients from one institution were retrospectively analyzed. Nineteen patients were male andtwo were female. The median age at diagnosis was 13 years (range 7-19 years). Progressive hemiparesis was the mostcommon symptom, followed by bulbar symptoms, psychiatric problems, symptoms related to the increased intracranialpressure (IICP), and hyperkinetic movements. [F18]-fluorodeoxyglucose (FDG) PET was performed in 12 patients. [C11]methionine PET was performed in 5 patients (2 for primary tumors and 3 for recurred metastatic tumors). Results Nineteen
tumor were germinomas and two were mixed GCTs. The median period of diagnostic delay was 7 months (1-31 months).
[18F]-FDG PET showed a hypometabolic lesion in 11 patients and a hypermetabolic lesion in only one patient with a mixed
GCT. In contrast, [C11]-methionine PET showed a hypermetabolic lesion in all patients. The two patients with a mixed GCT
expired within one year from the diagnosis. The mean follow-up period of the 19 patients with a germinoma was 46 months(1-106 months): four patients (21%) had tumor progression and three patients (16%) expired at the last follow-up. The
patients with poor outcomes had a significantly prolonged period of diagnostic delay (p= 0.003). The hyperkinetic
movement disappeared after treatment in all patients. The hemiparesis slightly improved in five patients throughrehabilitation, but was unchanged or even deteriorated in 14 patients. Conclusions Timely diagnosis of basal ganglia GCTs
could affect the clinical outcomes. [11C]-methionine PET may be helpful in the early diagnosis.

O048
Late Effects of Treatment for Pediatric Brain Tumor Patients
Stephen A. Sands, Psy.D.

Oral Presentation (0)Assistant Professor of Pediatrics and Psychiatry, Columbia University Medical Center, New York, New York 10032
212-305-3649 ss2341@columbia.edu
Fortunately, survival rates for children diagnosed with malignant brain tumors have improved with advances in surgery,radiation therapy, and chemotherapy. As a result, understanding the long-term impact of therapy including theneurocognitive and psychological effects of cancer treatment are important as most children who often present withvarious deficits. Significant sequelae, including intellectual decline, as well as variable attention-concentration, slow
processing speed and motor deficits have been observed as a result of treatment, with specific risk factors including young
age at the time of treatment, higher dose and larger brain volume involved in radiotherapy, longer follow-up time since
therapy, and treatment with methotrexate. In an effort to preserve intellectual functioning and quality of life, many current
treatment studies have been utilizing reduced doses and volumes of radiotherapy, while others are employing postoperative
chemotherapy to delay or avoid radiation therapy in these children. Two prominent multi-center intervention studies in the
U.S. involve the use of Methylphenidate (Ritalin) medication and the other utilizes a Cognitive Remediation Training Programin order to address symptoms such as attention, memory and academic achievement difficulties following treatment forpediatric cancer and have demonstrated modest success.
The emotional effects of cancer upon a pediatric patient vary depending on the diagnosis, the location of the tumor and thetreatment type, and on the patient’s family dynamics and preexisting psychological conditions. The vast majority of studies
to date indicate that survivors of pediatric cancer are generally at no greater risk for long-term emotional sequelae than one
would expect to see in a healthy population. It is important to note, however, that these studies often do not include brain
tumor patients, mainly because of the physical effects that brain tumors and their treatments have on the central nervous
system (CNS) and the apparent difficulty in separating organic and psychological causes of discrepancies in patient QoL.
Of those studies that do include brain tumor patients, approximately half conclude that these patients are at no greater risk
than are the healthy controls, whereas the other half concluded that they are at greater risk. However, studies have foundthat pediatric brain tumor patients consistently score lower in the domains of psychosocial health and of physical healththan do other, non-CNS tumor patients. Thus, while information about brain tumor patients’ QoL continues to emerge,
there does appear to be an increased risk for deficit in certain domains of physical and psychosocial functioning. It will be
important to provide counseling and support before and during the transition to adulthood with experiences such as
employment, marriage, and parenthood.

O049
Caring for the Caregiver of a Brain Tumor Patient
Elana Farace
USA
I will discuss meeting the needs of the family member as a way of better caring at home for patients with brain tumors.
We will go over interventions to improve caregiving at home as well.

- 78 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O050
Late Endocrine Effects in Childhood Brain Tumors
Susumu Yokoya, MD, PhD
Director, Department of Medical Subspecialties,
National Center for Child Health and Development
Endocrine complications are the most frequent and clinically relevant among the late effects in childhood brain tumors.
Hypothalamo-pituitary hormonal axis can be impaired by the neighboring brain tumor itself or by therapeutic modalities,
especially radiation and surgical treatments. In many cases endocrinopathy can be predicted by the risk factors such assite and nature of the tumor and dosage of irradiation in the hypothalamic area. Clinicians should also be aware that it may
develop several years or even a decade after the end of oncologic treatments.
Endocrinopathy in childhood and adolescence often presents growth disturbance and/or abnormal pubertal development(i.e. precocious, delayed or absence of puberty). Therefore, statural and pubertal monitoring as well as regularmeasurements of thyrotropin, thyroxin and morning cortisol is essential during the long-term follow-up of the survivors at
risk for endocrine complications.
Treatments for endocrine disorders are usually effective and often helpful in improving quality of life (QOL). Children andadolescents, however, need induction of therapy at their pin-point timings corresponding to their specific developmental
stages in order to achieve better final results. In this context early detection of endocrine disorders through the adequate
monitoring and then involvement of pediatric endocrinologists at a suitable stage are mandatory.

O051
Pediatric Brain Tumor: Current status of Patient's Care and Problems inJapan
Yutaka Sawamura
Hokkaido University

O052
CommentaryMark W. Kieran
Dana-Faber Cancer Institute and Childen’s Hospital, Boston Associate Professor, Harvard Medical School

O053
Adult Brain Tumors
Jun A. Takahashi
Kitano HospitalPrimary brain tumors include various histological types. For most types of tumors in most locations except deep-seatedtumors such as brain stem gliomas, surgical resection is recommended. And their removal should be as complete as
possible with preservation of neurological function. Total resection of intaraaxial infiltrating tumors by surgery alone is
generally impossible. Additional options of radiation therapy and/or chemotherapy vary according to histology and degrees
of resection.
Patients with incurable or unresectable tumors are considered as candidates for clinical trials.

O054
Commentary
W.K. Alfred Yung
M.D. Anderson Cancer Center- 79 -­­

Oral Presentation (0)Survival rates of children with brain tumor have significantly improved over the years due to developments in diagnostic
techniques, neurosurgery, chemotherapy, radiotherapy, and supportive care. However, neoplasms occurring in the central
nervous system remain an important cause of cancer-related deaths in children. This lecture presents the current problem
in the medical care system for children with brain tumor in Japan and introduces some modern multi-disciplinary programsfor treatment of difficult tumors.
In our country, due to a lack of registration system, there is no exact data concerning the incidence of pediatric brain tumor.
At the time of initial diagnosis, the child is seen at a local community hospital where the knowledge of brain tumors is verysmall. Unfortunately, often the child does not get sent to the major treatment center that specializes in childhood brain
tumors and the outcome for them is not sufficient. It has been emphasized that we do need to establish specific center
hospitals and educational program to encourage young pediatric neurooncologists in our country.
Prognosis is still highly dependent on clinical characteristics, such as the age of the patient, histological type, stage, andlocalization of tumor. This uniqueness makes the treatment strategy complex in individual patient. However, increased
knowledge about the long-term functional outcome of children with brain tumor and late-effects of treatment is being
obtained and has been useful to further improve outcome for patients. The process to establish the current treatment
protocol in Japan will be introduced being focused on intracranial germ cell tumors.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O055
PEDIATRIC BRAIN TUMORS – From Research to Hope
Mike Traynor
President, Pediatric Brain Tumor Foundation, www.pbtfus.org

Oral Presentation (0)The Pediatric Brain Tumor Foundation is honored to be here today. For the past 26 years, we have supported the search forthe cause of and cure for childhood brain tumors. We want to find ways to improve those treatments, and we hope to dothat with your help.
A Mother’s Words
In the words of one mother, “We cling to hope, and hope lies in research.” That is why the PBTF is going to enormous
lengths to fund research to save the lives of these precious children.
The Numbers
I won’t burden you with too many numbers, but here are some important ones to remember about brain tumors: This year
in the United States alone, the Central Brain Tumor Registry of the U.S. tells us, 3,750 children will be diagnosed with a
primary brain tumor. That means that TODAY, while we’re at this meeting, 10 families are getting the devastating news that
their baby has a brain tumor. Even worse, 1,360 of the children diagnosed this year will die an early death. Forty percent ofkids with a brain tumor will be dead within five years of their diagnosis.
A Difficult Journey
The journey these kids face is daunting. To begin with, brain tumors are complicated to diagnose. The symptoms often
mimic that of other childhood diseases, with nausea, headaches, and hearing and vision problems.
These tumors are sometimes inoperable, and pathological diagnosis is sometimes difficult, especially with 126 different
types of tumors in existence.
And of course, once the tumor is diagnosed, the treatment options aren’t great. As you know, even if a brain tumor isbenign, its treatment is not. Surgery is invasive and can damage vital areas of the brain that control neurological functions.
Few drugs will cross the blood-brain barrier. Those that do can weaken the immune system and leave children susceptible
to a host of other infections and possible hearing loss. Radiation to a developing brain can lead to long-term cognitive
challenges and physical disabilities.
The long-term effects on children and their families are devastating. We have only yet begun to see the consequences ofcancer treatment as these children age.
There is a fine line between a healthy life and one filled with daunting medical challenges. This is the line that children
diagnosed with a brain tumor walk each day of their lives. The path followed by young brain tumor patients is filled withcountless challenges that are nearly overwhelming for them in comparison to physically healthy children.
Furthermore, if they survive the rigors of this all-consuming disease, and the devastation of their treatment, they thenembark upon a long and often immensely frustrating journey to adulthood. These children can experience an ongoing
decline in mental and physical capabilities, which impacts their self-esteem, their ability to retain learned information, andtheir ability to engage in physical activities. Often they face other cancers brought on by their treatment. The things thatcome as second nature to other children can be monumental obstacles in their daily lives.
The emotional and financial toll on the families of brain tumor patients is also devastating. Jobs and homes are lost.
Bankruptcies are not uncommon. Children require special long-term care by parents, but what happens when parents die?
Who then cares for the patient? Marriages sometimes break up under the strain. Siblings who feel ignored may have
behavioral problems. Grieving takes place during and after the illness. Even if a child’s brain tumor is not fatal, there is loss
with living.
Research Challenges
All of these children, living and dead, are MY heroes. They are the heart of the Pediatric Brain Tumor Foundation’s efforts.
Until a cure is found, we will continue our search for new non-invasive and more effective treatments. We are working toovercome considerable research challenges:• Few centers of excellence• Limited understanding of the disease• Lack of tissue samples• Widely varying response to treatment• Insufficient funding for research• Difficult to attract qualified clinicians and researchers• More oncologists need to be trained in this specialty
Funding Challenges
There are also many funding challenges. To begin with, there is a lack of funding for childhood diseases. A long-term
commitment is required for funding to have impact. And few organizations are wholly dedicated to childhood brain tumor
research and family patient issues.
• In addition, low population numbers make it unattractive to pharmaceutical companies for research funding andnew drug development. Only one new drug has been developed for the treatment of pediatric brain tumors in thepast 30 years.
• It’s also difficult to achieve research collaborations, something that we are working very hard to do.
• The PBTF is one of the largest funding sources for childhood brain tumor research, but we can’t do it alone. The
federal government’s help is needed to get pharmaceutical companies involved in research funding and drug
development, not just in the U.S., but all over the world.
Reasons for Hope
However, the work we are doing in the PBTF Institute labs is turning research into hope.
• In 1984 when we began our work long-term effects were not an issue because most children diagnosed with abrain tumor died. Today many brain tumor patients are living longer.
• We have vastly improved radiation delivery methods, meaning that fewer kids suffer the awful effects of wholebrain radiation.

- 80 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN- 81 -­­

Oral Presentation (0)• The U.S. government has made a stronger commitment to advocates in most major peer reviews over the past
few years, thereby ensuring greater care and outcomes for the children.
• Our advocacy work in Washington, D.C., and around the world has led to increased visibility for the issue ofchildhood brain tumors.
• Thanks to the efforts of the PBTF and other interested parties, there are new research programs underway atuniversities where pediatric brain tumor research was never done before—we know because we’re receiving
grant applications from more and more institutions each year.
• We have driven an increase in collaboration among researchers at the international level through our Institutes,
and we’re encouraged by the possibility of new biological treatments for brain tumors.
• The PBTF has raised more than $50 million in this fight so far. But we have a long way to go before we arefinished.
PBTF Research Funding
We fund cutting-edge medical research at dozens of the world’s leading institutions, from coast to coast in the U.S., and in
Canada, Australia, Germany and the United Kingdom.
PBTF Institute Program
We believe that research collaborations are the answer to the fast-forwarding of brain tumor research. Researchers at thePediatric Brain Tumor Foundation Institutes at Duke University, the University of California, San Francisco, and the Hospitalfor Sick Children in Canada are working together to share their findings as well as tissues and data.
In May 2008 we announced an additional $6 million grant to our research institute at Duke University.  Funding for Dukeand our two other institutes now exceeds $14 million. We are greatly encouraged by the way the doctors and researchersat these institutions are working together.
Fostering Global Collaboration
We’re already seeing the fruits of that collaboration. We held our second annual PBTFI research conference last spring, andthe excitement of discovery was uplifting. Their level of enthusiasm is the highest we’ve seen in 26 years of grant funding.
These researchers, many of whom are here for this meeting in Yokohama, will get together again this October to share theirsuccesses.
And that same month, the PBTF will sponsor the first-ever International Pediatric Basic and Translational Research
Invitational Conference. This type of scientific collaboration is a bright new source of hope for every child with a brain tumor,
from Chitose to Chicago to Chelsea and on around the world.
We also see increased interest in pediatric brain tumor research that we’ve never seen before, fostered by groups such as
the International Brain Tumor Alliance who are here today to help move the understanding of brain tumors, including
pediatrics, to all corners of the globe.
Many, many basic and clinical researchers are working on new discoveries, including: Mitch Berger and his team at UCSF
and Darell Bigner’s group at Duke, and many others, in the United States. Research is also happening in other countries,
led by Jim Rutka at Sick Kids Hospital in Toronto, Dr. Sawamura, Dr. Matsutani, Dr. Nishikawa and their colleagues here in
Japan; Stefaan van Gool in Brussels; David Ashley in Australia; David Walker in Nottingham, England; Manfred Westphal in
Germany; and many, many more. This tells us that we have much to be encouraged about regarding the future outcomesof childhood brain tumors.
Partners in HopeWe also support researchers by funding data collection and a variety of professional meetings, including:• The Central Brain Tumor Registry of the United States, for which we provided the founding grant• The World Federation of Neuro-Oncology• The Society of Neuro-Oncology, including the founding grant for the prestigious Journal of Neuro-Oncology,
which is the official neuro-oncology journal of Japan, the U.S. and Europe. We also sponsor the Society of
Neuro-Oncology Foundation, fund their Basic Research Award for Excellence, and provide grants to support theirannual meetings.
• Brain Tumor Epidemiology Consortium meetings• International Pediatric Neuro-Oncology Symposium• International Symposium on Brain Tumor Research & Therapy• Peter Steck Memorial Research Award & Lecture• Childhood Neurology Society
PBTF/Japan partnerships
Our partnership with Japan is also strong. We have sponsored medical conferences here over the years, and we also gave
the Children’s Cancer Association of Japan a grant to bring a social worker to the U.S. for cross-cultural training.
PBTF Family Support
In addition to research, the Pediatric Brain Tumor Foundation believes that it’s critical to offer emotional and educational
support to families in their time of need. Our programs include educational resources, patient services, college
scholarships, advocacy efforts, and the Ride for Kids® program.
We strongly encourage you to share information about our services. We primarily serve the United States, but our materials
are also printed in Spanish and we offer resources to people worldwide.
Online Services
Our website, www.pbtfus.org, gives families a greater number of resources and easier access to information. The site also
includes new survivor outreach information. Our family support program includes a social worker who is available to assist
patient families by phone or email.
Here in Japan, Dr. Sawamura at Hokkaido University runs a Japanese language website with information for patientfamilies. You can access that page from the link listed here. The Children’s Cancer Association of Japan is also an excellent
resource for patient families.
Advocacy in Action
The Pediatric Brain Tumor Foundation also believes that raising awareness of this disease creates hope. As an active
member of the brain tumor advocacy community, the PBTF is a:• founding member of the Alliance for Childhood Cancer• patient advocate on the National Cancer Institute’s (NCI) Specialized Program of Research Excellence (SPORE)
for brain tumors

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

Oral Presentation (0)• representative on the Patient Advocates Research Team (PART) Council for the NCI’s SPORE in cancer• patient advocate, National Institute of Neurological Disorders and Stroke (NINDS)
We also make Congressional visits to educate U.S. lawmakers on childhood cancer issues.
We invite you to join us in advocating for quality care in each of your countries for pediatric and adolescent brain tumor
patients, development of new pediatric oncology drugs, long-term follow-up care for survivors, and representation ofpatients’ needs and viewpoints when research efforts are translated into clinical trials.
Fundraising Efforts
Research is incredibly costly and requires million of dollars to fund; we hope you will join in the effort to raise the funds
needed in your respective countries for pediatric brain tumor discoveries.
One of our fundraising efforts is our Ride for Kids motorcyclists’ charity program. It is the backbone of our medical research
and family support program funding. In 1984, the first year of our work, we raised $4,000. Last year PBTF Ride for Kids
programs in 37 cities resulted in more than $5.2 million in donations to help cure the kids, and we’re on track to raise evenmore with 39 events in 2009. This program is also an important part of our family support efforts, because it brings
together the community of brain tumor survivors and their families. Our Celebration of Life program following each ride isjust that: a celebration of the lives and accomplishments of these children.
In addition to Ride for Kids, we raise awareness and funds through:• Direct mail, which helps us appeal to individuals who support similar charitable causes.
• A radiothon program, which lets us partner with radio stations to broadcast patient stories and solicit donations
from the public.
We also have thousands of people around the world who raise funds for us in many original ways. Some hold walkathons,others run marathons. We’ve even had schoolchildren send us their pennies. Every cent makes a difference in our fightagainst childhood brain tumors.
Faces of Hope
One of the most visible signs of hope is that brain tumor survivorship is increasing. For instance, when we began raisingfunds in 1984, we did not need scholarships for brain tumor survivors. Now more children are living longer, and making
plans to attend college.
However, a brain tumor places an enormous financial burden on a family. The PBTF helps make higher education possible
by offering scholarships. Here are a few of the “faces of hope” that we are helping send to college.
To date we have awarded 397 scholarships to brain tumor survivors, and the program is growing dramatically with theaddition of the Tim & Tom Gullikson Family Support Fund. How’s that for hope?
Here is a perfect example. Michelle Higa was our first scholarship recipient to graduate from college. She is now working on
her master’s degree in psychology. Like so many young adults who had a pediatric brain tumor, Michelle wants to help
children going through medical crises.
Celebrating life is what the Pediatric Brain Tumor Foundation is all about. We celebrate the lives of those children who are
no longer with us, as well as the lives of the young people who continue to suffer, by working harder each day to find a curefor this dread disease. Thank you for your time today, and for everything you are doing to help us in our fight. Please visit
our website, www.pbtfus.org, to learn more about how you can help us turn research into hope.

O056
The European brain tumour patient and caregiver community –achievements, challenges and the pursuit of hopeDenis Strangman
Chair, International Brain Tumour Alliance (IBTA), www.theibta.org
There are many challenges facing the brain tumour patient.
Brain tumours attack the very essence of who we are. Brain tumours affect the physical, emotional and cognitive
capabilities of a person, thus impacting on quality and length of life, employment and personal relationships. They strike
people of any age, from tiny babies to the elderly, male or female, in any geographic locality. Based on current knowledge,
brain tumours cannot be prevented or realistically screened for. Their causes are, as yet, largely unknown.
Beyond the patient’s own personal situation, and across Europe and beyond, there is a desperate lack of funding for
research into more effective therapies for brain tumours. Although some progress in treatment has been made, there canbe inequity in accessing promising new therapies. There are sometimes misdiagnoses and late diagnoses. There are notenough specialists and specialist centres. There is a lack of consistency in registries from country to country.
For the caregiver of someone with a brain tumour, the challenges are different but also extremely daunting. A woman
caring for a relative with a brain tumour said: “It can be hard to put someone else first all the time – to let someone go but
be there for them still. It’s like standing on the shore watching [him] out at sea. Sometimes the waves bring him backcloser to me and sometimes the tide takes him away again.”In this difficult setting, brain tumour support, awareness-raising, advocacy and fund-raising are crucial.
The European brain tumour patient and caregiver group community is rising to these challenges and achieving progress
through various activities. In some European countries – though by no means all – brain tumour foundations and groups,
where they exist, are responding to a desperate need by energetically raising money for research. They offer support andinformation and, very importantly, advocate with determination for a better, more equitable deal for patients and caregivers.
Through its two primary activities – the promotion of the International Brain Tumour Awareness Week (1-7 November 2009)
and the Walk Around the World for Brain Tumours (1 January – 7 November 2009) - the International Brain Tumour Alliance(IBTA) unites patient groups in Europe (and other parts of the world) in a global and very public effort to raise funds andawareness of this illness. More than 30 European patient organisations relevant to brain tumours supported these two
projects in 2008. Around the world, over 150 patient and professional groups and organisations were supporters.
Through the achievements of such initiatives, across Europe and beyond, the situation for brain tumour patients and theircaregivers is improving, giving hope to those whose lives are touched by this devastating disease.

- 82 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO057
The Reality of Brain Tumors: Current Status and Future Perspective in
Asian Countries
Akiko Higuchi, MSW

O058
MOLECULAR GENETIC SIGNATURES THAT DEFINES SUBTYPES OF HUMAN GLIOMASKoichi Ichimura1, Danita M. Pearson1, David T.W. Jones1, Raymond Chan1, L. Magnus Backlund2,
V. Peter Collins1
1
Department of Pathology, University of Cambridge, Cambridge, United Kingdom 2Karolinska Institute of Oncology andPathology, Karolinska Hospital, Stockholm, Sweden

We performed a comprehensive genetic profiling in a large series of astrocytic and oligodendroglial tumors to identify
specific molecular signatures that could help define biologically relevant subtypes of human gliomas. We studied 402
tumors (38 pilocytic astrocytomas (PA), 22 diffuse astrocytomas (A), 62 anaplastic astrocytomas (AA), 183 glioblastomas(173 primary GB (pGB), 10 secondary GB (sGB)), 34 oligodendrogliomas (O), 20 anaplastic oligodendrogliomas (AO), 20
oligoastrocytomas (OA), 23 anaplastic oligoastrocytomas (AOA)). All tumors were examined by 1Mb array-CGH. TP53,
CDKN2A/p14ARF, RB1, PTEN and IDH1 were investigated for mutation. Total 1p/19q loss were predominantly found among
O and AOs but rare in astrocytic tumors. TP53 mutations were common among A, AA and sGB but less common in OA,
AOA and pGB and rare among O and AO. TP53 and total 1p/19q deletions were mutually exclusive. IDH1 mutations were
frequently found among all oligodendroglial tumors, A, AA and sGBs but rare in pGBs and not found in PAs. IDH1
mutations were strongly correlated with either TP53 mutation or total 1p/19q loss. RB1 pathway alterations were exclusively
found among grade III or IV tumors, and almost always associated with p53 pathway alterations. PTEN mutations or EGFR
amplifications were exclusively found among AAs and GBs. The data suggest that IDH1 mutation is the earliest change inboth oligodendroglial tumors and adult astrocytic tumors with the exception of pGBs. IDH1 mutations followed by total
1p/19q loss may characterize oligodendrogliomas while IDH1 mutations followed by TP53 mutations may characterizeastrocytomas. RB1 pathway alterations are associated with malignant progression in all types. pGB develop throughdistinct pathways by acquiring concurrent alterations of the RB1 and p53 pathway, with or without PTEN mutations or
EGFR amplification but not IDH1. Thus, we demonstrate that sequential acquisition of particular genetic abnormalities may
define distinct subtypes of gliomas.

- 83 -­­

Oral Presentation (0)Pediatric Oncology Social Worker
Children’s Cancer Association of Japan“Why my child?” is the first reaction any parent will have when they were told of their child’s illness. In 1968, our foundation,
Children’s Cancer Association of Japan was first established in Japan to support families with children afflicted with childhood
cancer. Since then, the social workers at CCAJ have received countless phone consultations. Fears, anxieties, and uncertainties
expressed by parents are constant and have not changed since its inception. “Is the hospital we are going trustworthy?” “Aren’t
there alternative treatments?” “We are worried about our financial situation.” “What is the cure rate of this illness?” “How could
we explain the disease to our child?” “Who can look after the siblings?” “What will happen to his/her studies while in treatment?”“We have to make a decision on the child’s treatment options and we don’t know which is best.” “We want to meet others who
have the same illness.” Those are but some of the information they want.
In recent years, the number of consultation regarding childhood brain tumors has been alarmingly increasing and the contents ofquestions varied and urgent. Childhood leukemia which has been the main concern in the medical field has seen not only theremarkable improvement in the cure rate, but also due to the acceptance in the concept of total care involving professionals, it has
become possible for the leukemia patients to receive a variety of social support from the time the child is admitted to a hospital.
On the other hand, the dissemination of information and support system has not been well developed for childhood brain tumors
despite the childhood brain and spinal cancers have the second highest morbidity rate among childhood cancers. The reasons
are their numerous varieties, existence of different treatments and prognosis depending on the location and the age of patients,
poor prognosis, and complexity of communication due to treatments involving multiple fields of medicine.
Even though the methods of controlling the disease have much improved due to progress of research and treatment methods,
often patients are exposed to late-effects, have to face drastic change in their life style, and overcome huge obstacles trying tobe socially independent. In addition to above, the proliferation of conflicting information given on internet and lack of appropriate
information, and shock of diagnosis and huge problems that the families face in treatment process are the main reasons we see
the increase in the consulting cases.
Children’s Cancer Association of Japan was founded in 1968 by parents whose children died of childhood cancer. The
members of CCAJ are striving to help families and children afflicted with cancer alleviate difficulties and worries. We also help
improve their quality of life by coordinating support from medical fields and other supporting institutions and individuals. CCAJ
has now 19 associate organizations nationwide and membership of over 3,000 and will celebrate its 41st anniversary this year.
The main activities are following:
1) Funding for medical research projects for doctors, nurses, and other institutions on the subjects on treatment and/or care ofchildhood cancers.
2) Consultations by social workers, assisting different groups such as different cancer sub-groups, parents who lost their children
to cancer, cancer survivors, siblings of cancer patients, coordinating and educating volunteers and planning workshops.
3) Supporting families financially for treatments, and management of lodging facilities.
4) Dissemination of information by publishing periodicals, newsletters, informational booklets. We also hold publicity activities toadvocate the disease.
Even if the medical environment is well developed and support system established, it is important that interaction and sharing of
information among families to continue. Also vitally important is the cooperation of medical professionals and the patients’families. Groups such as Japan Brain Tumor Alliance and Japan Pediatric Brain Tumor Network involving all brain tumor patients
have been established and expanding their activities.
Our mission is to spread our activities internationally together with above mentioned groups, and not only strive for the patientsand the families to be able to receive quality treatment but work hard to improve our supporting role including enrichment of their
daily lives after the treatment.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O059
Integration of genomic alterations and expression profiling in
Glioblastoma Multiforme
Jean Mosser1,2,3, Amandine Etcheverry1,3, Stephan Saikali4, Marc Aubry 3, Abderrahmane Hamlat 5,
Veronique Quillien6, Philippe Menei7, Marie de Tayrac1,2
Medical Genomics Unit, CHU Pontchaillou, Rennes, France 2UMR6061-CNRS, IFR140, Universite de Rennes1,
Rennes, France, 3OUEST-genopole platform, Universite de Rennes1, Rennes, France 4Department of Pathology, CHU
Pontchaillou, Rennes, France 5Department of Neurosurgery, CHU Pontchaillou, Rennes, France 6CRLCC, Centre
Eugene Marquis, Rennes, France 7Department of Neurosurgery, Centre Hospitalier Universitaire d’Angers, France
1

Purpose: Glioblastomas (GBM) are highly malignant and heterogeneous gliomas with very poor prognosis. The biologicaland molecular characterization of these tumors is still challenging and impacts their therapeutic management. Previous
genomic surveys have revealed the highly rearranged nature of GBM genome and transcriptome. However, the impacts oftumor DNA aberrations on gene expression remain unclear. Methods: We investigated copy number alterations (CNA) andgene expression to identify causal genetic events in GBM. High-resolution maps of somatic chromosomal alterations wereobtained for 20 GBM. Gene expression profiling was carried out on the same tumor samples, and compared to thoseobtained on non-neoplastic brain samples. Concordance between CNA and gene expression was identified by twocomplementary approaches (correlated or targeted probes). The resulting GBM signature was validated with anindependent microarray data set of 81 GBM and 23 normal brains. Results: Loci targeted for high-priority minimalcommon regions (MCR) of recurrent CNA were defined and combined with gene expression profiles performed on thesame tumor samples. Genes with concordant changes in CNA and expression levels were defined as over- / underexpressed genes located in amplified / deleted regions, or as MCR-genes with expression correlated to the corresponding
genomic state. After validation, we found that the expression of 318 genes was significantly affected by CNA. Associatedenriched GO process annotations were related to cell cycle disorder, cellular adhesion and angiogenesis. The genesignature included well-known GBM genes such as EGFR, PDGFA, and p16INK4 but also novel candidate genes. Twotumor suppressor genes PCDH9 and STARD13, involved in tumor invasiveness and resistance to etoposide, were validated
by qPCR in an independent set of 57 glioblastoma. Conclusions: This study shows the power of combining genomic
alterations and gene expression to identify robust transcriptome signature and putative tumor biomarkers in GBM.

O060
Oral Presentation (0)GENOME-WIDE ASSOCIATION STUDY OF ADULT GLIOBLASTOMA RISK.
Jeffrey S. Chang1, Margaret Wrensch2,10, Robert B. Jenkins3, Ru-Fang Yeh1, Karla V. Ballman4,
Mitchel Berger2, Susan Chang2, Paul A. Decker4, Chandralekha Halder3, Thomas M. Kollmeyer3,
Matthew L. Kosel4, Daniel H. LaChance5, Lucie McCoy2, Brian O’Neill5, Joe Patoka2,
Alexander R. Pico6, Michael Prados2, Charles Quesenberry7, Terri Rice2, Amanda Rynearson3,
Ivan Smirnov2, Tarik Tihan8, Joe Wiemels1,10, Ping Yang9, John K. Wiencke2,10Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94143, USA
Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143, USA
Department of Experimental Pathology, Mayo Clinic, Rochester, MN 55905, USA
4
Division of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
5
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
6
Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, San Francisco, California 94143, USA
7
Division of Research, Kaiser Permanente, Oakland, California 94612, USA
8
Department of Pathology, University of California, San Francisco, San Francisco, California 94143, USA
9
Division of Epidemiology, Mayo Clinic, Rochester, MN 55905, USA
10
Institute of Human Genetics, University of California, San Francisco, San Francisco, California 94143, USA
1
2
3

Glioblastoma, the most common type of adult malignant brain tumor, has a very low survival rate. Risk factors associatedwith glioblastoma other than ionizing radiation and rare genetic syndromes are not well-established. Here we present theresults of a genome-wide association study (GWAS) with positive replications of several top single nucleotide
polymorphisms (SNPs). Initial screening for top SNPs was conducted using several data sources: 525 glioblastoma casesand 602 population-based controls from the San Francisco Adult Glioma Study, 3,390 controls from Illumina iControlDB,
and 70 glioblastoma cases from The Cancer Genome Atlas. Case-control comparisons of 306,154 autosomal SNPs
yielded several SNPs with p<10-6, including 7 SNPs in 9p21 (CDKN2B) (p-values: 6＊10-9 to 7＊10-7), 3 SNPs in 6p21 (pvalues: 6＊10-8 to 8＊10-7), 1 intronic SNP in TERT (p=6＊10-10 ), and 1 SNP in 13q34 (p=4＊10-7). Three SNPs [one linked(r 2>0.8) with SNPs in the 9p21 region, another linked (r 2>0.8) with SNPs in the 6p21 region, and one was the same SNP in
13q34] were available for replication using Mayo Clinic data for 125 glioblastoma patients and 196 hospital controls and2,937 Wellcome Trust controls. The GWAS associations in 9p21 (p=0.01) and 13q24 (p=0.004) were replicated. The
current study suggests that the regions around CDKN2B are important for the development of glioblastoma; CDKN2B islocated in a region in 9p21 that is frequently deleted in glioblastoma. The very significant result for the 1 SNP in TERT must
await replication by other studies, though a recent GWAS of lung cancer reported a significant association with the same
TERT SNP.
*Note: JS Chang, M Wrensch, RB Jenkins, and RF Yeh contributed equally to this work. P Yang and JK Wiencke are thesenior authors from the Mayo Clinic and University of California, San Francisco, respectively.

- 84 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O061
GENETIC DIVERSITY ASSOCIATED WITH SURVIVAL IN MALIGNANT GLIOMASIDENTIFIED BY LINKAGE DISEQUILIBRIUM-BASED ANALYSIS OF HAPLOTYPE BLOCKREGIONS OF DNA REPAIR GENES
Francis Ali-Osman1, Kouros Owzar2, Bartley Adams2, Eric Lipp2,James Herdon2, Dora Illyasova2,
Faith Davis3, Nicholas Vick3, Alan Friedman2, Roger McClendon2, David Reardon2,
Henry Friedman2, Michael Weale2, Darell Bigner 2
Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA 2Duke University School of
Medicine, Durham, NC27705 3University of Illinois, Chicago, Illinois, USA

1

The influence of inherited genetics on outcome of therapy in malignant brain tumors remains poorly understood. In thisstudy, using a linkage disequilibrium (LD)-based approach, we examined the relationship between genetic diversity in 45
DNA repair genes and survival in 301 adults with anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM) treatedon temozolomide and carmustine-based protocols. We genotyped a subset of 1,267 tagging SNPs within or near 45 genes
in high LD with a region of 20 kb flanking each gene, on a customized Affymetrix platform. Associations were performed
after testing for Hardy-Weinberg conformity and gender mismatches. The results identified tSNPs in and around EXO1,
DDB2, LIG1, MGMT, MSH2, MSH4, PAN3, RAD52, TDG, XRCC1, and XRCC5 to be highly associated with survival.
Although, several gene variants were associative in both AA and GBM, a subset of SNPs were associative in only one
category. The identification of highly polymorphic regions of DNA repair genes in association with outcome oftemozolomide-/carmustine therapy in malignant gliomas is consistent with the role of DNA repair in mechanisms of tumor
resistance to these agents. Resequencing is ongoing to establish the specific causative SNPs and to examine the biology
underlying their association with treatment outcome in malignant gliomas. Supported by grants RO1 CA127872, RO1 CA
112519, P50CA108786 and P30-CA14236 from the NIH, USA and the Pediatric Brain Tumor Foundation of the US.

O062
DIFFERENTIAL GENE-EXPRESSION IN RECURRENT GLIOBLASTOMA MULTIFORME
Dietmar Krex1, Katja Robel1, Christian Pilarsky2, Gabriele Schackert1
Department of Neurosurgery, University Hospital C. G. Carus, Dresden, Germany 2Department of General Surgery,
University Hospital C.G. Carus Dresden, Germany

1

O063
Multi-arm Combinatorial Study of Signal Transduction Modulators Usinga Sequential Accrual Design – A Report of NABTC 0502
Mark R. Gilbert
University of Texas, MD Anderson Cancer Center, Neuro-oncology
Background: Unlike select examples in oncology such as imatinib for CML, single- agent signal transduction modulators
have been ineffective in most cancers including glioblastoma. Combinations of agents based on established signaling
pathways may be more effective. However, performing individual phase I/II trials for each combination is inefficient. We
developed a 3-arm phase I/II trial using a sequential accrual design combining sorafenib with erlotinib, temsirolimus or
tipifarnib. Methods: The North American Brain Tumor Consortium (NABTC) conducted a phase I studies of sorafenib(VEGFR/PDGFR/Raf inhibitor) in combination with erlotinib (EGFR inhibitor), temsirolimus (mTOR inhibitor), or tipifarnib(farnesyltransferase inhibitor) in recurrent GBM. Eligibility criteria included histologically proven GBM, radiologic progression,≥ 18 yrs old, KPS ≥ 60, adequate bone marrow reserve and organ function. There was no limit on the number of priortherapies. No enzyme-inducing antiepileptic drugs were allowed. Dose-finding used a standard 3 + 3 design with the MTD
was defined as the dose with DLTs in 1/6 or fewer patients. Serum pharmacokinetic (PK) studies were performed. Accrualwas sequential, decreasing study pauses for maturation of toxicity data. Results: Overall 49 patients were enrolled. Basedon 17 patients, the MTD was sorafenib 400 mg BID and erlotinib 100 mg qD. Based on 13 patients, the MTD was
temsirolimus 25 mg qweek and sorafenib 400 mg BID. The MTD was sorafenib 200 mg BID and tipifarnib 100 mg qD x 21
days based on 19 patients, but the dose of tipifarnib is below therapeutic levels. PK studies showed no drug-druginteractions for sorafenib with tipifarnib or temsirolimus. However, there was no accumulation of erlotinib, suggesting a
drug-drug interaction with sorafenib altering erlotinib metabolism or clearance.
Conclusions: This study demonstrated that the sequential accrual design accelerates study completion and decreases
logistical problems of phase I studies in multicenter trials. Phase II doses were successfully determined for sorafenib withtemsirolimus and with erlotinib, permitting enrollment onto the phase II component. The new phase I study using analternating week schedule of tipifarnib will be performed to permit a daily dose more likely to reach therapeutic concentration.

- 85 -­­

Oral Presentation (0)Purpose: Identification of GBM subgroups might improve an aimed individualized therapeutically approach. Consequently,
in our study we looked at patients with early versus late tumor recurrences in order to identify molecular markers, whichmight be associated with those different growth patterns. These markers, in turn, could be new therapeutic aims.
Methods: Study population comprised ten pairs each of primary and recurrent tumors occurring within 180 days after initialdiagnosis (short-term recurrences, STR) and later than 300 days after initial diagnosis (long-term recurrences, LTR),
respectively. Exons 5-8 of the p53 gene and the entire coding region of PTEN were investigated by sequence analysis.
EGFR amplification was determined. Loss of heterozygosity (LOH) analysis of markers known to be involved in glioma
pathogenesis was performed. A chip-based expression analysis was performed in 6 samples (3 STR, and 3 LTR) using
Affymetrix, GeneChip Human genome U133 Plus 2.0. Two candidate genes were further evaluated by real-time PCR basedmRNA expression analysis. Results: p53 mutations are less common in STR than in LTR, while genetic variants of the
PTEN gene are more frequent in STR. In STR, p53 and PTEN variants occur in combination, while LTR harbour either p53
or PTEN variants. Clustering after Chip analysis revealed clear differentiation between STR and LTR. Construction of a
6-gene comprising predictor is possible. A set of 53 differentially expressed genes was identified. GAS6 and SNTG turned
out to be promising new candidates for determination of early recurrence. Conclusion: STR and LTR can be distinguishedby p53 and PTEN mutation status and by gene expression profile. Out of a set of 53 differentially expressed genes, GAS6
and SNTG appeared be suitable markers for early recurrence and potential therapeutic approaches. Of course, our study
sample is rather small, and data need further confirmation.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O064
Progression-free survival: an important endpoint in neuro-oncology
clinical trials
Michael Prados, MD
University of California San Francisco, San Francisco CA USA
Many endpoints have been used in the context of clinical trials in neuro-oncology including objective response, overall
survival, median time to tumor progression, progression-free survival and other landmark endpoints, such as PFS-6 months
or PFS-12 months. Endpoint determination is critical to assess the efficacy of drugs or treatment strategies in both phase-2
and phase 3 trials. There are pros and cons with each of these endpoints, and the challenge remains as to whether one or
another should be used in a given situation, and whether there is acceptance across the neuro-oncology community,
regulatory agencies or industry sponsors. Given the costs of conducting trials, and the impact of endpoints on patient
accrual and expectations, protocol design has become more and more relevant, particularly with the advent of novel agentsand strategies that may influence our interpretation of MR based imaging which is critical for endpoints that use response orprogression as major determinants of futility or success of treatment. We will present examples of the use of progressionfree survival as one potential endpoint in both newly diagnosed and recurrent disease, and the implication of landmark PFS
as a potential valid endpoint for phase-2 trials.

O065
MULTICENTER PHASE II TRIAL OF TALAMPANEL WITH STANDARD RADIATION ANDTEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: REPORT OF
TWO YEAR SURVIVAL DATA
Stuart A. Grossman1, Xiaobu Ye1, Mark Chamberlain1, Tom Mikkelsen1, Tracy Batchelor1,
Serena Desideri1, Joy Fisher1, Steven Piantadosi1, Howard Fine1
The NABTT CNS Consortium, Baltimore, MD USA

1

Oral Presentation (0)Background: Recent data suggests that the glutamatergic system is important in the proliferation and migration ofglioblastoma cells. Talampanel is a well tolerated, oral AMPA receptor blocker that could be beneficial when added toconventional glioblastoma therapy. Methods: The primary purpose of this safety and activity (phase II) trial was toestimate overall survival in adults with newly diagnosed glioblastoma treated with talampanel in addition to standard
radiation and temozolomide (RT+TMZ). A secondary purpose was to evaluate talampanel toxicity in this setting.
Talampanel was initiated with RT+TMZ and discontinued for toxicity or disease progression. Results: Survival results werecompared to historical controls. Seventy-two patients were enrolled from December 2005 to July 2006. Their median age
was 60 years (range 37-85), median KPS was 90 (70-100), and 77% had a debulking procedure. With a minimum of 18
months follow-up, 42 patients (58%) have died yielding a median survival of 18.3 months (95% CI = 14.6 to 22.5 months).
When the 60 patients who were 18-70 years old on this trial were compared with the EORTC (RT+TMZ) data, the mediansurvival (20.3 vs 14.6 months) and percent surviving at 24 months (41.7% vs 26.5%, p=0.02) appeared superior. Data on
MGMT methylation and post-progression treatment with VEGF targeted therapies for this population will be available forpresentation. Conclusion: Talampanel was well tolerated and did not appear to increase the known hematologic or nonhematologic toxicities of TMZ. Talampanel can be added to RT+TMZ without significant added toxicity. These encouraging
survival results in this study suggest that blocking AMPA receptors may be a useful strategy in glioblastoma.

- 86 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO066
ONGOING CLINICAL TRIALS AND THE FUTURE DIRECTION OF GLIOMA TREATMENT
Wolfgang Wick, M.D.

O067
The result of a clinical trial for malignant gliomas by JCOG-Brain Tumor
Study Group (JCOG 0305)
Soichiro Shibui1, Members of JCOG Brain Tumor Study Group
Neurosurgery Division, National Cancer Center Hospital, Tokyo, Japan1

Purpose: Japan Clinical Oncology Group (JCOG)-Brain Tumor Study Group conducted a multiinstitutional randomized
controlled trial on malignant gliomas entitled, a randomized controlled phase II study of chemoradiotherapy using ACNU
versus procarbazine and ACNU for astrocytoma grade 3 and 4, with the support of the Health and Labour Sciences
Research Grants of the Ministry of Health, Labour, and Welfare in order to establish a standard therapy for malignant
gliomas in Japan. Method: The patients with newly diagnosed supratentorial astrocytoma grade 3 or 4 were enrolled andrandomized into two groups. The patients in Group A were treated with ACNU (80mg/m2 iv) during the postoperative
radiotherapy (RT, 60Gy local), while those in Group B received procarbazine (80mg/m2 for 10 days per os) precedingadministration of ACNU. Each regimen was continued every 8 weeks for 2 years if it was tolerable for the patients and theirdisease did not progress. The primary endpoint was the overall survival rate and the secondary endpoints were theresponse rate on the MRI and the frequency of the adverse events. Procarbazine is expected to reduce O6-methylguanineDNA methyltransferase (MGMT) and enhance the anti-cancer activity of nitrosoureas. The protocol was activated in April
2004 and 111 patients were registered by the end of August 2006 from 19 collaborating neurosurgical institutes of JCOGBTSG. Results : The overall sur vival of the patients treated with ACNU + RT was 16.2 months and that ofprocarbazine+ACNU+RT was 18.7months, while PFS of both groups were 6 months. CTCAE grade3/4 were observed in
40-60% of the patients. Conclusion: ACNU-based chemoradiotherapy was an effective but toxic treatment.

- 87 -­­

Oral Presentation (0)Professor of Neurooncology
Department of Neurooncology, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany
Tel.: +49 (0)6221/56-7075, Fax: +49 (0)6221/56-7554 E-mail: wolfgang.wick@med.uni-heidelberg.de
Because of the proposed sensitivity to chemotherapy of oligodendroglial tumors both the RTOG and EORTC had
investigated if these tumors benefit from adjuvant PCV chemotherapy. These studies, EORTC study 26951 and RTOG
9402, both showed that the addition of PCV chemotherapy (consisting of procarbazine, CCNU and vincristine) to 59.4 Gyradiotherapy does increase progression free survival without improving overall survival in anaplastic oligodendroglioma andanaplastic oligoastrocytoma. A major finding of both studies is the large difference in prognosis of patients with and without
combined 1p/19q loss. Based on these differences in sur vival and the clear different outcome in anaplastic
oligodendroglioma with 1p/19q loss, EORTC and the collaborative groups felt that it was no longer rational to treat thesepatients according to histology without taking the genotype of these tumors into account. For studies in anaplastic gliomas
it was therefore proposed to classify into anaplastic glioma without 1p/19q loss and anaplastic oligodendroglial tumors with
1p and 19q co-deletion. Another challenge is the definition of a proper endpoint for these trials. Taken a long preservation ofneurological functions even at progression, overall survival seems to be the most relevant outcome parameter. The outline
and initiatives in grade III gliomas (EORTC 26053/22054 – CATNON plus the co- deleted trial) are presented.
Standard therapy for glioblastoma is surgical resection aimed to be as complete as possible, respecting neurological
function followed by chemoirradiation with temozolomide. TMZ given as concomitant and adjuvant therapy to RT has
shown to increase progression-free survival (PFS) (rate at 6 months: 53.9 % vs. 36.4 %) and median survival (14.6 vs. 12.1
months) compared to adjuvant treatment with RT therapy only (EORTC 26981/22981 NCIC CE.3 trial. Still, many patients
do not respond to therapy. The resistance of cells against DNA damage caused by nitrosoureas and temozolomide is atleast in part mediated by the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT). Epigenetic silencing of
the MGMT gene by promoter methylation compromises this DNA repair and has been associated with longer survival in(glioblastoma) patients who are treated with alkylating or methylating agents. An analysis of the EORTC 26981/22981 NCIC
CE.3 trial showed, that indeed patients with glioblastoma containing a hypermethylated MGMT promoter benefited from
TMZ (overall survival (OS) rate at 24 months: 46% vs. 23 %), whereas those who did not have a methylated MGMT
promoter did have a significantly worse survival and less benefit from the addition of temozolomide to RT (OS rate at 24
months: 14% vs. <2 %). This raises the question if the small benefit from chemoirradiation observed in this group outweighs
the toxicity and costs of the temozolomide treatment, and calls for the development of more effective drug regimens for thisspecific group of patients. Although there may be small numbers of patients with an unmethylated MGMT promoter that do
benefit from combined chemo-irradiation, for the entire subgroup of these molecularly defined GBM patients the overall
benefit is questionable.
Most interestingly, the phase II trial with the integrin inhibitor cilengitide also demonstrated a marked benefit mainly in thepatients with glioblastoma containing a methylated MGMT promoter. Consequently, the current Merck/EORTC phase III trial
is designated to delineate the role for cilengitide in glioblastoma with methylated MGMT. Even earlier, Eli Lilly took theapproach to examine the protein kinase C beta inhibitor, enzastaurin, together with radiotherapy but without TMZ in patientswith glioblastoma containing an unmethylated MGMT promoter.
This raises the general question whether treatment in glioblastoma trials should not only be stratified according to MGMT
but entry into those trials limited by MGMT status. This would call for different approaches of GBM patients, depending on
the MGMT promoter gene status. The primary question to address in GBM with unmethylated MGMT promoter gene is theidentification of drugs that provide more survival benefit as compared to TMZ. The current EORTC trial initiatives arepresented.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O068
Current clinical trials of glioma therapy and situations ofneurooncology practice in Korea
Yong-Kil Hong1
Department of Neurosurgery, The Catholic University of Korea, Seoul, Korea

1

There has been no qualified sponsor-investigator clinical trial program and the standard therapies have been the all we
could do for the treatment of malignant glioma patients in the Korean Brain Tumor Society. We have just started to join two
international clinical trials since 2008. Here, the past and current status of neuro-oncology field in Korea as well as EasternNorthern Asian countries will be introduced, and clinical outcome of concurrent radiotherapy and temozolomide
chemotherapy for 100 patients of four university hospitals of Korea (Advisory Board of S-P Korea) will be presented.

O069
Histogram analysis of perfusion MR imaging data for the assessment oftumor response during glioma therapy
Se-Hyuk Kim1, Ho Sung Kim2
1
Department of Neurosurgery, Ajou University School of Medicine, Suwon, Korea 2Department of Diagnostic
Radiology, Ajou University School of Medicine, Suwon, Korea

Oral Presentation (0)Purpose: A recently developed histogram analysis of relative cerebral blood volume (rCBV) from the entire tumor has beenreported to offer excellent inter-observer agreement for quantitative analysis and demonstrate the heterogenous
morphologic features of glioma vascularity. We aimed to determine whether histogram analysis can be adopted in theassessment of tumor response during glioma therapy. Methods: We retrospectively studied 51 dynamic susceptibility
contrast 3-T MR imaging data of 29 patients (mean age 50.5 years, range 18-76) with histologically confirmed gliomas (9low grade, 20 high grade). rCBV maps were created and normalized to unaffected white matter. Histogram width (HW),peak height position (PHP), and maximum value (MV) of the entire tumor were measured from normalized histogram
distribution. Results: The values (mean ± S.D.) of HW, PHP, and MV were 4.64 ± 2.03, 4.58 ± 2.63, and 6.29 ± 2.79 for the
preoperative imaging of high grade gliomas (n=8), and 3.83 ± 1.96, 2.66 ± 1.66, and 4.73 ± 1.96 for the final imaging whichshowed definite radiological tumor progression or confirmed tumor recurrence by biopsy (n=8). Thirty-two imaging dataobtained during the median imaging follow-up of 3.7 months were divided into 2 groups (progression vs. stable/radiation
necrosis) according to the follow-up result and 3 parameters were compared. All 3 parameters were positively correlatedwith tumor progression (HW, 3.05 ± 2.18 vs. 1.02 ± 0.50; PHP, 2.39 ± 1.71 vs. 0.94 ± 0.28; MV, 4.13 ± 2.83 vs. 1.56 ± 0.52)
and MV was the most predictive with multivariate analysis. Conclusion: Our results suggest that histogram analysis of
rCBV can be a more objective and useful diagnostic tool to determine tumor response during the treatment of gliomas,
compared with Region of interest method for maximum rCBV, which can be highly operator dependent.

O070
Dynamic perfusion MR images can predict the pseudoprogression
mimicking true progression in the treatment of newly diagnosed
glioblastoma
Doo-Sik Kong1, Sung Tae Kim1, Jung-Il Lee1, Kwan Park1, Jong Hyun Kim1, Do-Hyun Nam1
Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

1Introduction: Tumor progression of glioblastomas entirely depends upon the radiologically contrast-enhancement on MR
images. Disease progression can be difficult to interpret because it looks like pseudoprogression. The aim of this study was
to study the real incidence of pseudoprogression during/after concomitant chemo-radiotherapy (CCRT) for newly
diagnosed glioblastomas and the predictability of dynamic susceptibility-weighted contrast-enhanced perfusion MR scans
for the pseudoprogression/ true progression. Methods: This present study was a single arm, prospective cohort study
designed to evaluate the incidence and outcome of pseudoprogression during CCRT followed by adjuvant temozolomide(TMZ) treatment for newly diagnosed glioblastoma. Results: Between Jul. 2004 and Feb. 2008, seventy-six consecutive
patients (median age 50 years) who underwent CCRT followed by adjuvant TMZ treatment were enrolled in this study.
MGMT promoter was methylated in 26 patients (34%) and unmethylated in 50 patients (66%). Enlargement of lesions,evidenced at the MRI scan in 59 of 76 patient (77.6%), was subsequently classified as pseudoprogression in 31 patients(52.5%) and true progression in 28 patients (47.5%). Of these 31 patients, 18 patients developed pseudoprogression within
the period of CCRT (hyperacute phase) and 13 patients during the adjuvant TMZ treatment (early phase). Lower value lessthan 1.75 on the perfusion images could be predictive of pseudoprogression with the sensitivity of 91% and the specificityof 82%. Conclusions: The current study supports high incidence of pseudoprogression during the treatment for newly
diagnosed glioblastomas. Perfusion MR imaging can be used to predict the possibility of pseudoprogression in thetreatment of glioblastomas.

- 88 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO071
The anti-tumor effect of convection-enhanced delivery of micelle-Am80
with systemic administration of Temozolomide.
Michiko Yokosawa1, Yukihiko Sonoda1, Sin-ichiro Sugiyama1, Yoji Yamashita2, Ryuta Saito1,
Toshihiro Kumabe1, Masayuki Yokoyama3, Teiji Tominaga1
1
Department of Neurosurgery, Tohoku University Graduate School of Medicine, Miyagi, Japan 2Miyagi cancer center,
Miyagi, Japan 3Kanagawa Academy of Science and Technology, Kanagawa, Japan

Background. Retinoic acid derivatives exert anti-tumor efficacy by inhibiting cell proliferation, inducing cell differentiation,
apoptosis, and growth arrest. All-trans retinoic acid (ATRA), one of retinoic acid derivates, has been extensively used for thetreatment of acute promyelocytic leukemia (APL). Am80, a novel synthetic retinoic acid known to be more potent than
ATRA, is allowed to use only for ATRA resistant APL patients. Purpose. We evaluated the antitumor efficacy of CED of
micelle-Am80 against the rodent intracranial U87MG xenograft model in conjunction with systemic TMZ administration.
Methods. Cytotoxicity of Am80 for U87MG cell line were examined in vitro by MTS assay. Cells were incubated with 50,
100, 200, and 500μM of Am80 for 2, 4, and 6 days. The expression level of phospho-Akt and phospho-MAPK in the cells
treated by Am-80 were evaluated by western blotting. Toxicity of micelle-Am80 after CED was evaluated after infusion into
the rat brain striatum. The anti-tumor efficacy was also evaluated using rodent intracranial U87MG xenograft model.
Results. Am80 at 50μM revealed no cytotoxicity against U87MG cell. However, cell viability decreased as concentration
increases from 100μM to 500μM. Enhanced cytotoxicity was observed when Am80 was combined with TMZ. Western
blotting revealed decreased expression of phospho-Akt and phospho-MAPK in cells treated with Am80. When cells weretreated with combination of Am80 and TMZ, further decrease of these phosphorylated proteins were observed. In vivo
toxicity study revealed no toxicity with CED of Am80 in rodent striatum. Survival of U87MG intracranial xenografted rodents
treated with CED of micelle-Am80 combined with systemic administration of TMZ was significantly longer than thosetreated with CED of Am80 or systemic TMZ as well as control rats (P&lt65308;0.01). Conclusions. CED of micelle-Am80
synergistically enhanced the antitumor efficacy of systemic TMZ treatment.

O072

Department of Neurosurgery, University of Southern California, Los Angeles, California 2Pharmaco-kinesis, Inc. 10524
S. La Cienga Blvd Inglewood CA 90304 3California Institute of Technology 1200 E California Blvd Pasadena 91125

1

Convection enhanced delivery has been used with limited success in the treatment of malignant gliomas. Although direct
delivery of biological agents to malignant glioma patients has been performed safely with good volume of distribution,
increased survival has not been demonstrated. One reason for this lack of success is in the limitation of current convection
enhanced delivery techniques, as multiple externalized catheters are inserted into the tumor for limited time periods (ie 5-7)
days and removed; repeat infusions require another surgery for catheter placement. For the past two years, we have been
designing and performing proof of principle experiments on an implantable magnetic breather pump system for maligant
gliomas. The system has five components: 1) an intratumoral delivery catheter (for unresectable tumors) or an intracranial
pouch (for tumor cavity in resected tumors), 2) a reservoir for tapping the catheter or intracranial pouch, 3) a connecting
catheter to link the reservoir, 4) an internalized pump with canisters containing biological agents of choice, capable ofdelivering drugs at microliters/hour, 5) a lab-on-a-chip to sample tumor fluid to measure specific cytokines (ie vascularendothelial growth factor) or drug levels to monitor treatment progress. The magnetic breather pump will be implanted
much like a shunt, with the delivery pump secured at the chest wall. The canisters in the delivery pump may be accessed
via subcutaneous ports to “refill” the drugs, and can be wirelessly reprogrammed to deliver at specific time intervals anddifferent cycles using Medical Implant Communication Service (MICS) interface. We are currently developing a“pathfinder” with all five components connected to demonstrate proof of principle in-vitro. If the “pathfinder” is successful
in-vitro, it will be reduced to an implantable system, and tested in-vivo in animal models. Successful completion of animalstudies will result in human Phase I studies.

- 89 -­­

Oral Presentation (0)An implantable magnetic breather pump for metronomic convection
enhanced delivery of biological agents in malignant gliomas
Thomas C. Chen1, Josh Y. Shachar2, Leslie Farkas2, Winston H. Wu2, Kyle N. Zimmerman2,
Moran Cerf2,3, Frank Adell2

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O073
Intracerebral administration of CpG oligonucleotide for patients withrecurrent glioblastoma.A phase II study.
Renata Ursu1, Alexandre Carpentier2, Philippe Metellus3, Sarah Zohar4, Francois Lafitte5,Maryline Barrie3, Margaretha Richard7, Florence Laigle-Donatey6, Annick Tibi8, Olivier Chinot3,
Antoine F Carpentier1
Departement of Neurology, Hopital Avicenne AP-HP, Bobigny, France 2Department of Neurosurgery, Hopital de la
Lariboisiere , Paris, France. 3Department of Neurosurgery, Hopital la Timone, 264, rue Saint-Pierre, 13005 Marseillecedex 05, France. 4Department of Biostatistics, Hopital Saint-Louis, Paris, France. 5Department of Radiology,
Fondation Ophtalmologique Adolphe de Rothschild, Paris 19, France 6Department of Neurology Mazarin, Hopital PitieSalpetriere, Paris, France Assistance Publique-Hopitaux de Paris University Rene Descartes, Paris 5, France.
7
Oligovax. Paris Biotech Sante. Hopital Cochin, 24 rue Faubourg St. Jacques, 75014 Paris 8Agence generale desequipements et profuits de sante, Paris, France.
1

Background/Purpose Immunostimulating oligodeoxynucleotides with CpG motifs (CpG-ODN) have shown a promising
efficacy in cancer models. Intra-tumoural infusions of CpG-ODN in glioblastoma patients were well tolerated at doses up to
20 mg, . In a phase I clinical trial. A phase II trial was designed to study the efficacy of a local treatment by CpG-ODN inpatients with recurrent glioblastomas (GBM). Patients and Methods Patients with recurrent GBM occurring at least threemonths after radiotherapy and previously treated with chemotherapy received 20mg CpG- ODN (CpG-28) by convectionenhanced delivery. The primary endpoint was the percentage of the patient without tumour progression at 6 months after
inclusion. Secondary endpoints were tolerance, survival, and radiological response. Results Thirty-four patients wereenrolled in two centres between November 2004 and March 2006. Thirty-one patients received the treatment. The
6-months progression free survival (PFS) was 19%. One partial response and 3 minor responses were seen. The medianoverall survival was 28 weeks. Eight patients (24%) were alive after 1 year and 5 patients (15%) were alive 2 years after
inclusion. Treatment was usually well tolerated. As previously reported, the most common toxicities were lymphopenia, mild
fever , seizures, and transient neurological worsening. Conclusion Despite a few cases of radiological responses, CpG-28
showed a modest activity on the 6-months PFS in this population. However, the presence of long term survivors suggestthat this treatment might have been beneficial in some patients, whose molecular or clinical characteristics remain to be
defined.

Oral Presentation (0)O074
Biodistribution and imaging studies on transferrin targeting PEG
liposome encapsulating both BSH and iodine contrast agent by
convection enhanced delivery on rat glioma for experimental boron
neutron capture therapy
Shiro Miyata1, Shinji Kawabata1, Shin-Ichi Miyatake1, Toshihiko Kuroiwa1, Satoshi Kasaoka2
Department of Neurosurgery, Osaka Medical College 2Faculty of Pharmaceutical Sciences, Hiroshima International
University

1

Objective: To augment therapeutic efficiency of boron neutron capture therapy, we used transferrin (TF)-conjugatedpolyethylene-glycol (PEG) (TF-PEG) liposome encapsulating sodium borocaptate (BSH) and iodine contrast agent, Iomeprol
with intratumoral convection enhanced delivery (CED) in rat glioma model. Materials and Methods: Boron-10 (10B)
concentration of F98 rat glioma cells was investigated in vitro using TF-PEG liposome and PEG liposome as control. For invivo biodistribution studies, 10B concentrations in intracerebrally transplanted F98 tumor, blood and normal brain were
investigated using these boron delivery systems with CED, and computed tomography (CT) scan was carried out at the
selected time after CED. Results: 10B concentrations of F98 glioma cells 6 h after exposure to PEG liposome and TF-PEG
liposome were 16.1 and 51.9 ng 10B/106 cells respectively. 10B concentrations in F98 glioma tissue 24 h after CED was 22.5
and 82.2μg/g, by PEG liposome and TF-PEG liposome, respectively with lower 10B concentrations in the blood and normal
brain of tumor-bearing rats. The CT image showed the vivid and stable enhanced image of transplanted tumor by Iomeprol
even 48 h after CED by TF-PEG liposome. On the contrary, enhanced image had been already washed out 24 h after CED
by PEG liposome. Conclusion: The combination of TF-PEG liposome encapsulating BSH and Iomeprol and intratumoral
CED enables not only a precise and potent targeting of boron delivery on the tumor tissue but also following the trace ofboron delivery administered intratumorally by CT imaging.

O075
Intraoperative photodynamic diagnosis and therapy for malignant
glioma using second-generation photosensitizer Talaporfin sodium
Jiro Akimoto1, Jo Haraoka1
The Department of Neurosurgery, Tokyo Medical University, Tokyo, Japan1

A new photosensitizer, Talaporfin sodium, was reported to be effective for both photodynamic diagnosis(PDD) andphotodynamic therapy(PDT) of several cancers. We employed Talaporfin sodium for the intraoperative PDD and PDT for
glioblastoma patients. 22 consecutive patients, 27 times operation with glioblastoma (16 primary and 6 recurrent, aged 2382 years) received intravenous doses of Talaporfin(40mg/m2) 24 hours prior to craniotomy. Intraoperatively, tumor
fluorescence was visualized using modified operating diode laser (664nm) microscope. Fluorescence-guided resection oftumor tissue was performed, and additional PDT (150mW/cm2, 27J/cm2) was performed to 11 cases on invading tissues in
eloquent area. A clear fluorescence signal was demonstrated in the tumor bulk and peritumoral zone, and the satisfactory
resection of contrast-enhancing tumor was confirmed and achieved 19.6 months of median survival time in the primary
glioblastoma. Mild liver dysfuncion was occurred in 11.6% of cases, and skin photosensitivity was occurred in 1 case. The
clinical experience in this study indicates the efficacy and safety of Talaporfin-induced PDD and PDT for glioblastoma
patients.

- 90 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O076
Mutational profiling of high grade gliomas reveals inactivating
mutations in IDH1
This Abstract nominated the Hoshino Award.
Please refer to P057 on page 149.

O077
KCN1, A novel SMALL MOLECULE HIF inhibitor PREVENTS GLIOMA growththrough binding of Plectin-1 and inhibition of the Hsp90 pathway
Vladimir E. Belozerov1, Stefan Kaluz1, Suazette Reid2, Jiyoung Mun1, Saroja N Devi1,
Rita de Noronha3, Carlos Moreno1, Daniel L Brat1, Mark Goodman1, Kyriakos C. Nicolaou3,
Binghe Wang2 and Erwin G. Van Meir1
Department of Neurosurgery, Hematology & Medical Oncology, Radiology, and Pathology, Winship Cancer Institute,
Emory University School of Medicine, Atlanta, GA
2.
Department of Chemistry, Georgia State University, Atlanta, GA
3.
Department of Chemistry, Scripps Research Institute, La Jolla, CA
1.

O078
Direct Tyrosine Phosphorylation of GSTP1 by EGFR induces JNK activationin glioblastoma cells
TATSUNORI OKAMURA1, Francis Ali-osman1Duke Comprehensive Cancer Center, Department of Surgery and the Preston Robert Tisch Brain Tumor Center, Duke
University, Durham, NC 27710, USA.

1

In malignant gliomas, the c-jun N-terminal kinase (JNK) pathway regulates tumor growth and resistance to apoptosis, andcorrelates with histologic grade and epidermal growth factor receptor (EGFR) tyrosine kinase expression. We recently
reported that glutathione S-transferase P1 (GSTP1), a major metabolizing and stress response signaling protein that isfrequently overexpressed in brain tumors, is a downstream target of EGFR and undergoes EGFR-dependent tyrosine
phosphorylation, in vitro and in vivo, resulting in an enhancement of its enzymatic function and increased drug resistance.
Intracellularly, the dimeric GSTP1 exists in a reversible equilibrium with its monomeric form, the predominant form undermost conditions. Monomeric GSTP1 binds to JNK and acts as an endogeneous JNK inhibitor. In this study, we investigated
the impact of the EGFR-dependent tyrosine phosphorylation of GSTP1 ion the activation of JNK in glioma cells. We showedthat the EGFR-phosphorylation of GSTP1 shifts the GSTP1 dimer-monomer equilibrium toward the monomeric state.
Kinase analyses showed that the c-Jun phosphorylation by JNK was enhanced by phosphorylated-GSTP1 andsuppressed by unphosphorylated-GSTP1. EGFR activation resulted in dissociation of GSTP1 from the GSTP1-JNK1
complex in a cell-free system and in glioma cells. Mutation of the phospho-acceptor Tyr198 to phenylalanine in the GSTP1
protein and over-expression of the Tyr198Phe mutant GSTP1 protein decreased JNK activity and c-Jun phosphorylation in
EGFR-overexpressing glioma cells. Together these results indicate that in malignant glioma cells the tyrosine
phosphorylation of GSTP1 by EGFR shifts GSTP1 from the dimeric to the monomeric form leading to dissociation of GSTP1
from the GSTP1-JNK complex and reactivation of JNK, which is independent of JNK upstream signaling. This regulation of
JNK signaling function by the EGFR-GSTP1 crosstalk, defines a novel signaling network with a potential to regulate thebiology and therapeutic outcome in malignant gliomas. Supported by NIH grants RO1 CA127872, RO1 CA 112519,
P50CA108786 and P30-CA14236.

- 91 -­­

Oral Presentation (0)Micro-regional hypoxia is a well-known characteristic of glioblastoma that appears as the tumor mass outgrows the existingvascular supply. Hypoxic areas of solid tumors are resistant to traditional chemo- and radio-therapies, highlighting the needto develop new therapies for their targeting. A common property of these cells is the expression of HIF-1, a key transcription
factor that coordinates adaptive responses to hypoxia, providing cancer cells the means to survive and proliferate underhypoxic conditions. To identify specific small molecule inhibitors of HIF-1, we screened a combinatorial library of 10,000
natural product-like chemical compounds. We sh−ow that KCN1, a lead inhibitor identified in this screen, potently inhibits
HIF-1 activity in various cancer cell lines (IC50 ≈4mM), while exerting minimal effects on the levels of HIF-1b, other short-lived
proteins, or control proteins. To identify the molecular mechanism of action of this novel inhibitor, we compared the changes
in global gene expression caused by KCN1 to those caused by a variety of previously characterized drugs using theConnectivity Map database. The gene expression signature of KCN1 was found to be similar to those produced by known
inhibitors of Hsp90. Biochemical analyses confirmed that KCN1 modulates Hsp90 function by inhibiting the association of
the chaperone with a model client protein. However, in contrast to known Hsp90 inhibitors such as geldanamycin, KCN1
does not inhibit the enzymatic activity of Hsp90 via direct binding to the ATPase pocket. Rather, the small molecule
alters the availability of Hsp90 to its clients, including HIF-1a, by a novel mechanism of action. We found that KCN1
augments the interaction of Hsp90 with a cytoskeletal protein called plectin-1. This changes the bioavailability andsubcellular distribution of the chaperone. Detailed experimental evidence supporting this novel mechanism will bepresented. In an effort to translate KCN1 to the clinic we evaluated its toxicity and anti-tumor efficacy in an animal model.
Systemic administration of KCN1 in nu/nu mice harboring sc human LN229 glioblastoma xenografts evidenced strong antitumor effects in the absence of noticeable toxic effects. These data suggest that KCN1 is a promising new agent for thetreatment of malignant gliomas in a clinical trial.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O079
Quantitative expression analysis revealed significant correlation of
EGFR variant III (vIII) and Notch expression in glioblastoma
Koji Yoshimoto1, Yaulei Guan1, Xinlong Ma1, Masahiro Mizoguchi1, Tadahisa Shono1,
Tomio Sasaki1
Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan1

EGFRvIII is the exon 2-7 deletion mutant and commonly identified in glioblastoma patients. This leads to the ligandindependent tyrosine kinase activity that activates persistent downstream phosphatidylinositol 3-kinase pathway andpromotes tumor growth, which makes EGFRvIII a therapeutic target. However, functional role of EGFRvIII in the stem cellbiology, another therapeutic target, has not been evaluated.In this study, we aim to quantitate the expression level of
EGFRvIII and stem cell marker genes, and identify the stem cell marker which might have a functional association with
EGFRvIII. First, using recently development real time RT-PCR assay for detecting EGFRvIII, we evaluated EGFRvIII
expression in 105 GBM samples. We could detect and quantitate EGFRvIII expression in 22 samples (20%) with variable
expression level. Next, to evaluate the expression of stem cell marker gene, we selected 21 EGFRvIII positive samples and23 negative samples, and performed SYBR based real time RT-PCR assay. The stem cell marker gene included in thisstudy are follows; CD133, Nestin, BMI-1, MELK, Notch1, Notch2, Notch3 and Notch4. We also examined the expression
level of other growth factors such as EGFR, EGFR2, EGFR3, EGFR4, PDGFRA and PDGFRB. We evaluated the statisticallyassociation of each stem cell marker gene expression with EGFRvIII. Of the 14 genes, the result showed that EGFR
(p<0.01), Notch2 (p=0.03), Notch3 (p=0.02) and Notch4 (p=0.01).were significantly highly expressed in the EGFRvIII
positive cases. This suggests that downstream pathway of Notch 2-4 may be functionally associated with EGFRvIII
activation.

O080
EGFRvIII PREFERNTIALLY ACTIVATES STAT5 AND GAB1, CAN BE ACTIVATED BY FORCEDDIMERIZATION AND LOCATES TO THE NUCLEUS
Oliver Bogler1, Vaibhav Chumbalkar1, Anupama Gururaj1, YeoHyeon Hwang1, Khatri Latha1,
Rebecca Maywald1, Marta Rojas1, Oliver Bogler1
Departments of Neurosurgery and Neuro-Oncology, Brain Tumor Center, University of Texas MD Anderson Cancer Center

1

Oral Presentation (0)Aberrant EGFR signaling is a major contributing force to glioma progression and treatment resistance. The most prevalentmutation, EGFRvIII, promotes growth and survival of cancer cells. More recently, new point mutations in the extracellulardomain of EGFR have been identified by The Cancer Genome Atlas. We are investigating the signaling of these abnormal
receptors to identif y novel druggable targets. We have analyzed the EGFRvIII specific signal using shotgun
phosphoproteomics based on recovery of tyrosine-phosphopeptides and mass spectrometry. Glioma cell lines expressing
EGFRvIII, a kinase inactive form of EGFRvIII and wild-type EGFR (LN428 PTEN +; LNZ308 PTEN-) were compared by thisapproach. Spectral intensity and count was used in a label-free quantification, and revealed 150 and 180 phosphoproteins
respectively in the two cell lines used. Several phosphorylations showed a significantly greater level in EGFRvIII cells whencompared to wild-type EGFR. These include c-Met, Stat5 and Gab1. The signaling of EGFRvIII is ligand-independent andlow intensity. Whether it dimerizes has remained controversial. Furthermore, the low intensity signal makes it challenging tostudy. We have created a chimeric EGFRvIII that can be dimerized experimentally, using a variant FKBP12 domain andcognate small molecule, a process termed chemically induced dimerization (CID). CID increases EGFRvIII signaling several
fold in intensity, without leading to increased internalization or changes in the signaling nodes activated downstream, and isallowing us to investigate the nature of the EGFRvIII signal in greater depth than before. In itself, the observation that forced
dimerization increases the signal of EGFRvIII is strong evidence that it ordinarily does not dimerize to a significant degree.
Another possible mechanism behind EGFRvIIIs impact on glioma biology is differential cellular localization and we havefound that it localizes to the nucleus in an activity dependent manner, and requires Y1173 and Y845.

O081
Association of polymorphic variants in EGFR and LRIG2 and meningioma risk
Ghasimi S1, Andersson U1, Schwartzbaum J2,3, Sjöström S1, Ahlbom A3, Auvinen A4,5,
Collatz-Christensen H6, Feychting M3, Johansen C6, Kiuru A5, Lönn S7, Henriksson R1, Malmer B1
1
Department of Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden; 2Division of Epidemiology,
School of Public Health, Columbus, Ohio; 3Division of Epidemiology, Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden; 4Department of Epidemiology, Tampere School of Public Health, University of Tampere,
Finland; 5Department of Research and Environmental Surveillance, Radiation and Nuclear Safety Authority, STUK,Helsinki, Finland; 6Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; 7Department ofMedical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden;

BACKGROUND: Both genetic and epigenetic mechanisms contribute to meningioma development by altering gene
expression and protein function. The epidermal growth factor receptor (EGFR) is dysregulated or overexpressed in brain
tumors and its expression is directly correlated with tumor malignancy and unfavorable prognosis. The leucine-rich repeats
and immunoglobulin-like domains (LRIG) family proteins are membrane bound proteins that have been proven to inhibit
EGFR signaling through interaction with ubiquitinilation. The human LRIG2 is prominently expressed by myelinating cells andcytoplasmic expression of LRIG2 is associated with poor survival of oligodendroglioma patients. The aim of this study was totest the hypothesis that polymorphic variations in the EGFR and LRIG2 genes influences risk of meningioma. METHODS:
376 meningioma cases, and 1103 controls recruited in the Nordic Interphone study were genotyped. 89 SNPs in the EGFR
gene and 6 SNPs in the LRIG2 gene were selected to capture most of the polymorphic variants in these genes. RESULTS:
The EGFR gene SNP (rs759171) showed a higher minor allele frequency in meningioma (3%) compared with controls (1%).
The highest risk of meningioma was associated with homozygosity for the EGFR variant (OR = 3.10 CI, 95% 1.33, 7.25).
When analyzing the LRIG2 gene SNP (rs1216801), the minor allele frequency was higher in meningioma (16%) comparedwith controls (12%). A significant association between risk of meningioma and homozygosity for the LRIG2 variant (OR =1.50 CI, 1.05, 2.15) was also evident. CONCLUSIONS: As far as we know this is the first study were meningioma risk has
been analyzed in association with polymorphic variants of the EGFR and LRIG2 genes. Functional studies in this area areimportant to assess whether polymorphic variants are also associated with meningioma tumor phenotype.

- 92 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO082
A novel p53 bystander effect: paracrine induction of apoptosis in tumor
cells through the induction of Galectin-3 secretion
Fatima W. Khwaja, Sok-Hyong Lee, Abdessamad Zerrouqi, Narra S. Devi, and Erwin G. Van Meir
Departments of Neurosurgery, Hematology and Medical Oncology, and Winship Cancer Institute, Emory University
School of Medicine, Atlanta, Georgia, USA.
P53 tumor suppressor expression is lost in a variety of brain tumors. P53 is a transcription factor that regulates theexpression of a large number of proteins, some of which are critical effectors of its tumor suppressive activities. In thepresent study we demonstrate the existence of a novel mechanism whereby the tumor suppressor p53 can control thegrowth of malignant gliomas and other solid tumors. We provide evidence that activation of p53 by gamma-irradiation,
ultraviolet or chemotherapy in wtp53 cells can induce cell death specifically in bystander cancer cells (but not normal cells)
through p53-controlled release of a death-promoting factor. To identify this factor we performed proteomic analyses (2GEMS and ICAT) on supernatant of glioma cells with inducible p53 (tet-on system) and identified a number of candidate
secreted proteins. Using antibody neutralization and siRNA approaches we demonstrated that galectin-3 (Gal-3), a 31 kDa
β-galactoside-binding pro-apoptotic factor was the mediator of this bystander effect. To identify the mechanism, we first
showed that Gal-3 was not a direct target of wt-p53; rather its secretion is facilitated by p53 transcriptional activation of
TSAP6, a key mediator of the non-traditional secretory pathway. We further demonstrated the biological importance of p53
controlled Gal-3 secretion by showing that it inhibits anchorage independent tumor cell growth in vitro and can strongly
reduce malignant glioma formation in vivo. We next investigated the mechanism of death and confirmed its specificity fortumor cells. We first showed that Gal3 induces a caspase 9-dependent apoptotic pathway in over 20 different tumor celllines of different origins investigated so far, while normal cells were unaffected. Second, we demonstrated that Gal3
induced apoptosis in tumor cells could be inhibited by depletion of beta1 integrin using siRNA. Further investigations are
ongoing to unravel the mechanism underlying the tumor cell specificity. In conclusion, our data demonstrate that p53 canexert cell extrinsic control over tumor growth through a novel mechanism leading to increased secretion of galectin-3. Gal3
in turn induces apoptosis in adjacent tumor cells, suggesting that it can be directly exploited for tumor therapy. -- This work
is supported by the Goldhirsh Foundation. --O083

Dr. Senckenberg Institute for Neurooncology, University of Frankfurt, Frankfurt, Germany 2Laboratory for
Neurooncology, Department of General Neurology and Hertie-Institute for Clinical Brain Research, University of
Tuebingen, Germany 3Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, Zurich, CH-8091,
Switzerland
1

Activated epidermal growth factor receptor (EGFR) signaling is one of the most prominent molecular alterations in malignant
gliomas and sustains many of their key oncogenic capabilities. However, activation of EGFR signaling also increases energy
demands by enhancing protein synthesis and nutrient consumption. Our recent finding that EGFR inhibition confers
protection from hypoxia-induced cell death is congruent with this. Other recent work has demonstrated that p53 has animportant role in the processing of starvation signals and that the p53-dependent molecular mediators of the Warburg
effect, synthesis of cytochrome c oxidase 2 (SCO2) and TP53-induced glycolysis and apoptosis regulator (TIGAR), regulate
glucose consumption and mitochondrial function. Notably, EGFR amplification and p53 mutations are almost mutually
exclusive events in glioblastoma. We therefore hypothesized that the presence of wild-type p53 in glioma cells withactivated EGFR is necessary in order to limit metabolic demands induced by deregulated signal transduction processes in
the presence of hypoxia and nutrient depletion. We here report that shRNA-mediated gene suppression of p53 as well as
the mutant temperature-sensitive dominant-negative p53VAL135ALA increase glucose consumption and lactate production
in p53 wild-type human malignant glioma cells and enhance hypoxia-induced cell death. These findings suggest that
glioma cells may benefit from retaining p53 wild-type status by reducing their vulnerability towards tumor hypoxia and offer
an explanation for the dichotomy of EGFR amplification and p53 mutations in glioblastoma.

O084
SPONTANEOUS TRANSFORMATION OF p53 NULL SUBVENTRICULAR ZONE CELLS IN
VIVO, AND USE IN ORTHOTOPIC THERAPEUTIC TESTING
Rintaro Hashizume1, Claudia Petritsch1, Jeanette Hyer1, J. Graeme Hodgson1,
Scott R. VandenBerg1, C. David James1
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA

1

PURPOSE: To determine whether p53 deficient subventricular zone (SVZ) cells have the potential to undergo spontaneoustransformation in vivo, and whether transformed cells can be used in therapy response experiments. METHODS: Athymic
nu/nu mice were injected with either luciferase modified p53 null SVZ cells, or the same cells modified with humantelomerase reverse transcriptase (hTERT) and human papilloma virus E6/E7. Cells were monitored for proliferation bybioluminescence imaging (BLI), and resultant tumors were harvested for use in orthotopic allograft therapy response
experiments. RESULTS: BLI revealed steady cell growth in all mice receiving intracranial (IC) injection with hTERT + E6/E7
modified cells in contrast to six mice showing stable (n = 3) or lack of (n = 3) luminescence following injection of p53 nullcells. In addition to the IC injections, one mouse each received subcutaneous (SC) injection with each type of cell. p53 null +hTERT + E6/E7 cells showed progressive SC growth, producing a tumor that has been resected and whose cells have beenused for tumor propagation, both in SC and IC locations. SC injected p53 null cells showed no indication of growth for 100
days, but thereafter showed rapid growth, producing a large tumor that has been used as a source of cells for intracranial
injection in a series of 20 mice, 10 of which were treated with temozolomide. Temozolomide treatment significantly extended
the survival of mice with IC tumor (p<0.0001). CONCLUSIONS: Our study makes the following points regarding the use of
p53 null CNS cells from genetically modified mice: 1) Cells can be used to assess tumorigencity effects of transferred genes,
such as hTERT and E6/E7; 2) Cells have the ability to spontaneously transform in vivo; and 3) Spontaneously transformed
cells can be used in an orthotopic engraftment model approach for studying therapeutic response.

- 93 -­­

Oral Presentation (0)P53: AN ANTAGONIST OF EGFR-MEDIATED METABOLIC ACTIVITY IN HUMAN
MALIGNANT GLIOMA CELLS
Joachim Steinbach1, Johannes Rieger1, Daniel Brucker1, Stefan Wolking2, Michael Weller3,
Christina Nordhammer1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O085
ADP-ribosylation Factor 6 Regulates Glioma Cell Invasion through the IQdomainGTPase-activating protein 1-Rac1-mediated Pathway
Shi-Yuan Cheng1, Bo Hu1, Binhai Shi1, Michael J Jarzynka1, Jia-Jean Yiin1,
Crislyn DSouza-Schorey2
Cancer Institute and Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA 2University of Notre
Dame, Notre Dame, IN 46556-396

1

A common pathobiological feature of malignant gliomas is the insidious infiltration of single tumor cells into the brain
parenchyma, rendering these deadly tumors virtually incurable with available therapies. The ADP-ribosylation factor 6(ARF6), which belongs to ARF family of small GTP-binding proteins with multiple roles in fundamental biological processes,
has recently been shown to play an important role in tumor cell invasion. In gliomas, exogenous expression of EFA6A, aguanidine exchange factor (GEF) for ARF6 in glioma cells enhanced cell motility and invasiveness in vitro. However, whether
ARF6 exerts a direct impact on glioma cell invasion is largely unknown. In this study, we report that ARF6, a Ras
superfamily small GTPase, is abundantly expressed in invasive human glioma cells. In vitro, cellular depletion of ARF6 by
siRNA decreased Rac1 activation, impaired HGF- and serum-stimulated glioma cell migration. In vivo and ex vivo, stable
knockdown of ARF6 by siRNA markedly decreased the invasive capacity of invasive glioma in the brain. Ectopic expressionof ARF6 by glioma cells promoted cell migration through activation of Rac1. Upon stimulation, IQGAP1, a key regulator ofcell adhesion and migration was recruited to the membrane of the leading edges of migrating cells together with ARF6,
allowing forward protrusion. Cellular depletion of ARF6 by siRNA abrogated the recruitment of IQGAP1 into cell membrane
and attenuated the formation of the protrusions at the invasion fronts. Finally, using co-immunoprecipitation assays, wefound that ARF6 was associated with Rac1 and IQGAP1 in glioma cells upon HGF stimulation. Knockdown of IQGAP1 by
siRNA significantly inhibited the ARF6-promoted Rac1 activation and cell migration. In conclusion, these data suggest that
ARF6 signaling is pivotal for glioma cell invasion in the brain and IQGAP1 is required for ARF6-mediated Rac1 activation andglioma cell invasion.

O086
Oral Presentation (0)Roles of Sphingosine-1-phosphate Receptor in Glioma Cell Proliferation
and Patients Survival
Mitsutoshi Nakada1, Yuya Yoshida1, Naotoshi Sugimoto2, Yasuhiko Hayashi1, Daisuke Kita1,
Naoyuki Uchiyama1, Yutaka Hayashi1, Yoh Takuwa2, Jun-ichiro Hamada1
Department of Neurosurgery, Kanazawa University 2Department of Physiology, Kanazawa University

1

Background: Sphingosine-1-phosphate (S1P) is a bioactive lipid that signals through a family of five G protein-coupled
receptors, termed S1P1-5, and regulates cellular proliferation, migration, and survival. We investigated expression and role ofS1P receptors in glioma.
Methods: We analyzed the expression and production of S1P receptors in 58 human glioma specimens by quantitative RTPCR, Western blotting and immunohistochemistry. The relevance of S1P receptors expression levels to survival in
glioblastoma was examined by Kaplan-Meier method. We examined the mechanism of S1P receptors pertaining to glioma
cell proliferation and invasion by experiments manipulating gene expression in glioma cell lines.
Results: Expression of S1P1 receptor was significantly lower in glioblastoma than those in normal brain (P<0.01) and diffuse
astrocytoma (P<0.05). Immunoblot demonstrated that normal brain expressed more S1P1 receptor protein thanglioblastoma. S1P1 receptor was immunolocalized predominantly to the astrocytes in normal brain, but faint staining wasobserved in glioblastoma. Downregulation of S1P1 receptor expression correlated with poor survival of patients withglioblastoma (P<0.05). S1P1 receptor small interfering RNA promoted cell proliferation in high expressor glioma cell lines(T98G, G112). Cell proliferation was promoted by pertussis toxin, an inactivator of Gi/o type of G proteins, to which S1P1
receptor is coupled exclusively. Forced expression of S1P1 receptor in low expressor cell lines (U87, U251) resulted indecreased cell growth both in vitro and in vivo. In migration and invasion assays, no significant change was observed bymanipulating S1P1 receptor gene. Furthermore, we found a significant association between the expression of S1P1 receptor
and early growth response-1, a transcriptional factor which has a tumor suppressor function through PTEN in glioblastoma(P<0.05).
Conclusions: These data show that downregulation of S1P1 receptor expression enhances the malignancy of glioblastoma
by increasing cell proliferation and correlates with shorter survival of patients with glioblastoma.

- 94 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O087
EPHA3 REGULATES CANCER PROGENITOR CELL SELF-RENEWAL AND PROLIFERATIONIN GLIOMA NEUROSPHERE CULTURES
Bryan W. Day1,3, Michael J Ting1, Brent A Reynolds2, Mark D Spanevello1,3, David G Walker4,
Jason D Lickliter5, Andrew W Boyd1,3
Queensland Institute of Medical Resarch, Brisbane, Australia 2McKnight Brain Institute, University of Florida,
Gainesville, Florida, USA 3Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia
4
Department of Neurosurgery, Royal Brisbane and Womens Hospital, Queensland, Brisbane, Australia. 5Cancer
Services, Frankston Hospital, Melbourne, Victoria, Australia.
1

Purpose: Eph receptors constitute the largest sub-family of receptor tyrosine kinases and interact with membrane-boundligands termed ephrins. Eph and ephrins have many vital functions including cell adhesion, migration and axon guidance.
Eph and ephrins have been found to be aberrantly expressed in many malignancies including brain tumour. The purpose ofthis study was to investigate Eph receptor function in glioma brain tumour stem cell neurosphere cultures. Methods: Gene
expression was investigated by Q-PCR and immunoblot analysis in high grade glioma surgical specimens and cell lines.
Targeted reduction of Eph expression was performed using an inducible shRNA system. Eph receptor function was also
inhibited using soluble ephrin-Fc protein and the EphA3 mAb IIIA4. Results: In this study we investigated Eph and ephrinfamily expression in a screen of 37 high grade glioma tumour specimens. Results highlighted elevated expression of EphA3
and the high affinity ligand ephrin A5 in a significant proportion (70%) of samples. To further investigate EphA3 function thereceptor was down regulated using shRNA in an EphA3+ glioma neurosphere cell line. Inducible down regulation of the
EphA3 receptor resulted in initiation of neuronal and glial cell differentiation following activation of the ERK/MAPK pathway. A
reduction in total stem/progenitor cell proliferation was also observed when treated with EphA3 shRNA (46%) or soluble
ephrin A5-Fc (33%) to inhibit EphA3 function. Furthermore, treatment with the EphA3 mAb, IIIA4, inhibited cell proliferation(>50%) and induced rapid internalisation of the receptor, cell spreading and increased adhesion. The reduction in cellnumbers was not associated with apoptosis or cell cycle arrest. CFSE division tracking identified slower cell divisions in
populations in which EphA3 signalling was attenuated. Conclusions: We propose EphA3, in part, regulates cancer stem cell
self renewal and cell division rate in glioma and could prove a potential therapeutic target.

O088

Cancelled

O089
PRESENCE OF AN ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM AS A
FAVORABLE PROGNOSTIC MARKER IN PATIENTS WITH GLIOBLASTOMAThis Abstract nominated the Hoshino Award.
Please refer to P059 on page 150.

O090
Prognostic significance of microRNA-196 in glioblastoma
Yanlei Guan1, Masahiro Mizoguchi1, Koji Yoshimoto1, Takahisa Shono1, Tomio Sasaki1
Department of Neurosurgery, Kyushu University, Fukuoka, Japan

1

MicroRNAs (miRNA) are short non-coding RNAs associated with diverse biological processes. They are also involved intumorigenesis and function as both tumor suppressors and oncogenes. Large scale miRNA expression in glioblastomas,
however, has not been quantitatively estimated to date. Here we determined global miRNA expression profiles of 12
malignant gliomas (8 glioblasotmas (GBM) and 4 anaplastic astrocytomas (AA)) using TaqMan Human MicroRNA Array v1.0
(Applied Biosystems) by real-time PCR method. In total, the expression of 365 mature human miRNAs was examined.
Expression of the 16 miRNAs was significantly altered the two histological subtypes. Of them, the most significantly
regulated miRNA was miR-196a (p= 0.0038). In addition, miR-196b (family member of 196a) and miR-21, which waspreviously reported to be up-regulated in GBM, were also included. This result was validated in another panel of 105 gliomas(74 GBMs, 18 AAs and 13 diffused astrocytomas) with individual Taqman microRNA assay (Applied Biosystems) by real time
PCR method. Furthermore, we examined the relationship between expression levels of these miRNAs and overall survival in
39 primary GBM patients. GBM patients with high miR-196 expression level showed significantly poor survival by KaplanMieir method (p=0.0073). Multivariate analysis demonstrated that high level of miR-196 was an independent and significant
predictor of overall survival in GBM patients (p= 0.036, HR=2.81). In conclusion, our results suggest that miR-196
overexpression could be relevant for the malignant progression of glioma. Consequently, miR-196 is of significant prognostic
value for predicating survival in GBM patients.

- 95 -­­

Oral Presentation (0)THE ALTERNATIVE TRKAIII SPLICE VARIANT, EXPRESSED BY NEUROBLASTOMAS ANDGLIOBLASTOMAS, TARGETS THE CENTROSOME AND PROMOTES GENETIC
INSTABILITY

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O091
Development of a novel mouse model of glioblastoma multiforme using
lentiviral vectors
Tomotoshi Marumoto1,2, Ayumu Tashiro3, Dinorah F. Morvinski2, Miriam Scadeng4,
Yasushi Soda2, Fred H. Gage2, Iner M. Verma2
Department of Neurosurgery, National Hospital Organization, Kobe Medical Center, Kobe, Japan 2Laboratory of
Genetics, The Salk Institute for Biological Studies 32Kavli Institute for Systems Neuroscience and Center for the
Biology of Memory Norwegian University of Science and Technology, Medical Technical Research Center 4UCSD
Center for Functional MRI, University of California San Diego

1

Animal models of cancer have been very instructional in understanding the genesis of the tumors and very useful to test the
new strategy of treatment. Among the brain tumors, glioblastoma multiforme (GBM) is the most malignant, and there is stillneed to generate the animal model for this tumor that can recapitulate the abnormal molecular events causing the formationof human GBMs. We have recently developed a novel method to induce GBMs in adult immunocompetent mice byinjecting Cre-loxP controlled lentiviral vectors expressing oncogenes in a small number of cells. By injecting Cre-loxP
controlled lentiviral vectors into the specific region of the adult GFAP-Cre mice that express Cre recombinase specifically in
GFAP expressing cells, we established cell type and region specific expression of oncogenes. Activated form of H-Ras and
AKT were induced in fewer than 60 GFAP + cells in hippocampus, subventricular zone or cortex of GFAP-Cre/p53+/- mice.
Over 70% of the mice developed tumors when transduced in subventricular zone, and 100% of the mice developed tumors
when transduced in hippocampus. However, tumors were rarely found when transduced in cortex. These tumors fromhippocampus and subventricular zone showed the characteristics of human GBMs including pleomorphism,
hypervascularity, necrosis and pseudopalisading. Transplantation of less than 100 brain tumor cells into the naive recipientmouse brain lead to the formation of GBM-like tumors. When these tumor cells were cultured in the stem cell medium, they
formed neurospheres and contained CD133 + cells. Moreover these tumor cells can differentiate into neurons andastrocytes in response to the addition of fetal bovine serum to the stem cell medium. These results indicate that our novel
mouse model can be used for a wide variety of brain tumor research including the brain tumor stem cell investigation, andmight be useful for the deeper understanding of GBMs.

O092
Oral Presentation (0)Phenotypic modulation of experimental gliomas: progression fromgliomatosis cerebri-like lesions to glioblastoma
Jian Wang1, Hrvoje Miletic1, Per Oystein Sakariasseb1, Peter C Huszthy1, Hege Jacobsen1,
Narve Brekka1, Xingang Li2, Sverre Mork3, Martha Chekenya1, Rolf Bjerkivg1,4,
Per Oyvind Enger1,5
Department of Biomedicine, University of Norway, Bergen, Norway 2Qilu Hospital, Shandong University, Jinan, China
Department of Pathology, University of Bergen, Bergen, Norway 4NorLux Neuro-Oncology, Centre Recherche de
Public Sante, Luxembourg 5Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway
Glioblastoma animal models still remain a big challenge in basic and translational research as the most commonly used cellline-based models do not recapitulate the invasive growth of human glioblastomas in patients. Recently, we haveestablished a human glioblastoma xenograft model in nude rats that is highly invasive. Here, we characterize this modelwith an emphasis on neuropathological and radiological features. Immunodeficient nude rats were xenografted with biopsy
spheroids derived from 29 patients diagnosed with primary brain tumours. Amongst these, 25 were primary glioblastoma
multiforme (GBM), three were grade II gliomas and one was a grade III oligoastrocytoma. We monitored the animals with
MRI and 11 of the resulting tumours were subsequently passaged in vivo for up to 19 generations while tumour take rates
and survival data were recorded. The tumour take rate for rats xenografted with primary GBM biopsies was 77% andremained close to 100% at subsequent in vivo passages, whereas only one out of four lower grade tumours engrafted.
Average time from transplantation to the onset of symptoms was 125 days. Culture time of the spheroids correlated
inversely with tumour take rates, but not with survival. After 4-5 in vivo passages the tumours changed to a complete
glioblastoma phenotype becoming more vascular, with increased cell proliferation, less apoptosis but more necrotic areas.
By extended passages, the tumours gradually became less invasive and appeared more circumscribed (after 8-9
passages). In conclusion, the model provides reproducible high take rates and survival times if parameters related totumour burden and the operative procedure are standardized. Furthermore, passaging in vivo modulates these tumours
phenotypically, resulting in different combinations of angiogenic and invasive growth patterns. We therefore propose thatthe presented model provides a powerful tool for dissecting aspects related to brain tumour growth and progression.
1
3- 96 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO093
ISOLATION AND CHARACTERIZATION OF INTERLEUKIN 13 RECEPTOR ALPHA2SPECIFIC HEPTAPEPTIDES
Waldemar Debinski1, Shivank Garg1, Denise M. Gibo1, Steven Kridel1, Hetal Pandya1
Brain Tumor Center of Excellence, Wake Forest University, Winston Salem, NC, USA

1

Purpose. We have been developing specific delivery vectors to Glioblastoma Multiforme (GBM). Interleukin 13 receptoralpha 2 (IL-13Rα2), a cell membrane receptor, has been found to be over-expressed in more than 75 percent of GBM
patients and absent in normal brain. Recently, we have begun a search for small peptides binding specifically IL-13Rα2.
Methods. To isolate the peptides, we used the phage-display library with peptides presented on the surface of filamentous
M13 phages. We screened Ph.D-C7C (New England Biolabs)library, with a diversity of 1.2 billions. The phage library was
panned using GBM cell lines which over-express IL-13Rα2 and corresponding cell lines, which do not express the receptor.
Phages were eluted from the IL-13Rα2 positive cells and subjected to additional binding/amplification cycles. Results. We
have isolated 3 different peptide phage clones. ELISA experiments confirmed that these 3 peptide phage clones bound to
the recombinant IL-13Rα-Fc receptor chimera protein and not to an irrelevant IgG-Fc control or bovine serum albuminprotein. Moreover, ELISA experiments including the other IL-13 receptor protein, IL-13Rα1, demonstrated that one of thepeptides is truly specific for IL-13Rα2. Furthermore, a 1000 fold excess of the IL-13 ligand did not block the peptide's
binding to the IL-13Rα2. Also, cell-binding phage titer experiments were carried out on selected cell lines. We found that
200 times more peptide phages bound to the IL13Rα2 positive cell lines compared to the cell lines which do not overexpress the receptor. Conclusions. We have identified specific heptapeptides that bind to IL-13Rα2. The peptides arebinding to the receptor at the site different from that used by the natural ligand, IL-13. These peptides will be further
developed for diagnostic, imaging and molecular therapeutic interventions in GBM.

O094
Autologous SH3-domain GRB2-like 1 (SH3GL1) antibody as a novel serum
marker specific to low-grade glioma
Tomoo Matsutani1,2, Yasuo Iwadate1, Takashi Oide3, Yukio Nakatani3, Naokatsu Saeki1,
Masaki Takiguchi2, Takaki Hiwasa2
2
3

Glioma is the most common primary malignant central nervous system (CNS) tumor in adults and remains deadly disease
despite of the development of the surgical procedure, radiotherapy and chemotherapy in the last decade. We used theserological identification of antigens by recombinant cDNA expression cloning (SEREX) to determine the novel serum
markers in glioma. The phage expression library, constructed using mRNA derived from the U-87 MG glioblastoma cell-line,
was screened using sera from 48 patients with glioma and 31 independent genes were isolated. The enzyme-linked
immunosorbent assay (ELISA) using recombinant proteins indicated that the levels of serum antibodies to SH3-domain
GRB2-like 1 (SH3GL1) were significantly higher in patients with low-grade glioma than in healthy volunteers (P = 0.0045) orin patients with high-grade glioma (P = 0.0243). The independent validation test, using other sera from the patients,
presented similar results. ELISA in the purified recombinant proteins of deletion mutants of SH3GL1 showed thatapproximately 10-20 amino acids in the C-terminal were indispensable as the epitope site. In immunohistochemical
staining, overexpression of SH3GL1 proteins in cytoplasmic region of glioma cells according to its histological grade, but
not in glial cells, was observed. Consequently, the levels of anti-SH3GL1 autoantibodies can be a novel low-grade gliomaspecific serum marker.

O095
HIGH SOLUBLE P-SELECTIN AND LOW PLATELET COUNT AS THROMBOSIS RISKMARKERS IN GLIOMA PATIENTS
Rainer Vormittag1, Christine Marosi1, Cihan Ay1, Ralph Simanek1, Ilse Schwarzinger2,
Matthias Preusser1, Katarzyna Elandt1, Christoph C. Zielinski1, Ingrid Pabinger1
Department of Internal Medicine I, Medical University Vienna, Vienna, Austria 2Clinical Institute of Medical andChemical Laboratory Analysis, Medical University Vienna, Austria

1

Background Glioma patients are at high risk for venous thromboembolism (VTE). However, predictive laboratory
parameters have not been identified. High platelet count (PLC) and increased soluble P-selectin (sPsel) were reported asrisk factors in cancer patients. We investigated sPsel and PLC as risk markers in glioma patients. Methods The Cancer andThrombosis Study (CATS) is a prospective observational study, whose endpoint is the occurrence of objectively confirmed
VTE. sPsel was measured in the third week after neurosurgical intervention using a human sPsel Immunoassay (R&D
Systems, Minneapolis, USA). Multivariable Cox regression analysis was applied to calculate hazard ratios (HR) for VTE
including PLC, sPsel, age, sex and extent of surgery. Results 140 patients with newly diagnosed high grade glioma wereanalysed (52 women; median age 54.5 years [interquartile range (IQR): 42.8-5.1]) during a median observation time of 309(range: 3-1664) days. Twenty patients developed VTE (6 women, 14 men; thereof 2 events were fatal pulmonary
embolisms. The cumulative probability of VTE was 10% at six and 15% at twelve months. sPsel levels (ng/mL) were higher
in patients with VTE compared to those without (median=51.8, IQR: 36.9-66.0 versus median=38.8, IQR: 30.7-52.1,
p= 0.011). PLC (G/l) was significantly lower in patients with (median=214, IQR: 166-248) than in those without VTE(median=255, IQR: 200-327; p=0.011). In multivariable regression analysis high sPsel (75th percentile: 55.1ng/mL) and low
PLC (25th percentile: 198G/L) were significant risk markers of VTE (HR=3.4, 95% CI 1.3-9.0, and HR=3.3, 95% CI 1.2-8.8,
respectively). Conclusion Our study revealed two strong predictive risk markers for VTE in glioma patients. Elevated sPsel
is associated with a three-fold increased risk of thrombosis. In contrast to patients with other solid tumours, low PLC is
associated with increased thrombosis risk.

- 97 -­­

Oral Presentation (0)The Department of Neurological Surgery, Chiba University, Graduate School of Medicine, Chiba, Japan
Departments of Genetics and Biochemistry, Chiba University, Graduate School of Medicine, Chiba, Japan
Departments of Diagnostic Pathology, Chiba University, Graduate School of Medicine, Chiba, Japan

1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O096
Clinical Outcome and Prognostic Factors of Gliomatosis Cerebri
Jeong Hoon Kim1, Young Hyun Cho1, Jung Kyo Lee1, Chang Jin Kim1
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

1

The aim of this study was to investigate clinicoradiographic aspects together with pathologic features of an institutional
series of gliomatosis cerebri (GC) and to analyze potential prognostic factors. Between 1997 and 2004, fifty patients
underwent radiotherapy with diagnosis of GC based on radiographic feature and confirmed with biopsy. A retrospective
analysis was conducted on these patients including the entire medical records, radiographic data and pathologic features.
Survival outcome and potential prognostic factors such as the patient age, sex, performance status, the location of major
involvement, grade of contrast enhancement, performance of decompressive surgery, and pathologic subtype and gradewere analyzed. The median progression free survival and overall survival lengths were 15.7 and 25.9 months, respectively.
Poor prognostic indicators included higher pathologic grade, disease with contrast enhancement, lesions involving deepgray matter beyond the hemisphere or involving cerebellum and brainstem, and poor patient performance status. Given awide variety on clinicoradiographic feature and histopathologic characteristics in GC, the prognosis should be fairly
predicted in every individual patient to direct an optimal management.

O097
CASE-CONTROL STUDY OF LONG TERM SURVIVORS OF PRIMARY GLIOBLASTOMA
Eudocia C. Quant1, Michael Silver3, Stephen Yip2, Peter Ryg1, Kaitlyn McCormack 2,
Katelyn Provencher2, David N. Louis2, Rebecca Betensky4, Catherine Nutt2, Tracy T. Batchelor1
1
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA 2Department of Pathology,
Masschusetts General Hospital, Boston, MA, USA 3Department of Biostatistics, Masschusetts General Hospital,
Boston, MA, USA 4Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA

Oral Presentation (0)BACKGROUND: Survival of patients with glioblastoma (GBM) remains poor. However, a small percentage of primary GBM
patients live ≥ 3 years. Relatively little is known about the patterns of care and outcomes of these patients. METHODS:
Nested case-control study of long term survivors (cases) compared to standard survivors (controls) of GBM. Pathology
was confirmed by a single neuropathologist who reviewed all cases and controls included in the study. Each long term
survivor (LTS) was matched to standard survivors (SS) by age and postoperative Karnofsky Performance Status (KPS).
Clinical characteristics, treatment regimens and outcomes were reviewed. Logistic regression models were used to assess
potential associations between baseline factors and the probably of long term survival. RESULTS: Matching yielded 27
cases (LTS) with 81 controls (SS). Baseline factors were as follows: female LTS 40.1%, female SS 34.6%, male LTS 59.3%,
male SS 65.4%, LTS with hemispheric tumors 96.3%, SS with hemispheric tumors 93.8%, LTS with callosal tumors 3.7%,
SS with callosal tumors 2.5%, LTS with multifocal GBM 0, SS with multifocal GBM 3.7%, LTS with subtotal resection (STR)
51.9%, SS with STR 59.3%, LTS with gross total resection (GTR) 29.6%, SS with GTR 23.4%, LTS with biopsy 18.5%, SS
with biopsy 17.3%, percent of LTS receiving a vascular endothelial growth factor (VEGF) inhibitor 26.1%, percent of SS
receiving a VEGF inhibitor 23.4%. There were no significant associations between the baseline factors considered and longterm survival. Median overall survival for LTS was 4.76 years (range 3.15-10.54 years) and for SS was 1.30 years (range
0.54-2.99 years). CONCLUSIONS: Analysis yielded no significant associations between gender, tumor location, extent ofresection or treatment with a VEGF inhibitor and the probability of long term survival. Other factors, such as molecular or
genetic differences, may help account for differences in survival and are being assessed.

O098
Effects of pregnancy on natural history of WHO grade II gliomas. A
quantitative analysis of the tumor growth rates.
Luc Taillandier1,9,10, Johan Pallud2,9,10, Emmanuel Mandonnet3,9,10, Luc Bauchet4,9,10,
Laurent Capelle5,9,10, Denys Fontaine6,9,10, Philippe Peruzzi7,9,10, Manuel Lopez8,9,10,
Sorin Aldea9,10, Laurence Bozec-Le Moal9,10, Hugues Duffau4,9,10
Neuro-Oncology unit, Department of Neurology, Nancy Hospital, Nancy, France 2Department of Neurosurgery,
Sainte-Anne Hospital, Paris, France 3Department of Neurosurgery, Lariboisiere Hospital, Paris, France 4Department of
Neurosurgery, Gui de Chauliac Hospital, Montpellier, France 5Department of Neurosurgery, Pitie-Salpetriere Hospital,
Paris, France 6Department of Neurosurgery, Nice Hospital, Nice, France 7Department of Neurosurgery, Reims Hospital,
Reims, France 8Department of Neurosurgery, La Reunion, France 9REG, Reseau d’Etude des Gliomes, Groland, France
10
ANOCEF, Association des NeuroOncologues d’Expression Francaise, France
1

BACKGROUND WHO grade II gliomas (GIIG) are progressive tumors characterized by a continuous growth before
malignant transformation. During the initial period, their radiological mean diameter increases at an average rate of 4mm/
year and the Velocity of Diametric Expansion (VDE) has been shown to be predictive of prognosis. The recent optimizationof the therapeutic management of GIIG has allowed an improvement of their prognosis and an increase of the number ofwomen considering a pregnancy. The study goal was to determine whether pregnancy could modify the natural history ofGIIG, using a quantitative approach of the VDE.METHODS We asked the French Glioma Study Group (REG) and the
ANOCEF group to collect all cases of pregnancy in the adult female population of GIIG for whom MRI longitudinal follow-up
was available. Repeated measurements of the mean tumor diameter were performed before, during and after pregnancy.
Then, VDE were fitted by linear regression. RESULT S7 pregnancies in 7 females harboring a GIIG were reviewed (19922007). Six oligodendrogliomas and 1 mixed glioma were discovered before and during pregnancy in 4 and 3 cases,
respectively. The median VDE was at 4.7mm/year before or after pregnancy. During pregnancy, the VDE increased
markedly in 5 cases (median VDE 8.5mm/year) and remained stable in 2 cases. In one of the 5 patients negative group,
radiotherapy was performed shortly after delivery and can be responsible of the VDE decrease. CONCLUSION ANDPERSPECTIVES The present results, using a quantitative approach of VDE measurements, suggest a possible negativeinteraction of pregnancy on the natural history of GIIG. We propose to inform the patient about the possible risks. For eachenvisaged pregnancy, the benefit-to-risk ratio should be carefully weighted. If a pregnancy is decided, we advise to perform
a close neurological and MRI follow-up. Besides, cases collection continues.

- 98 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O099
WHOLE-BRAIN RADIOTHERAPY VERSUS OBSERVATION AFTER RADIOSURGERY OR SURGERY
OF 1-3 BRAIN METASTASES - RESULTS OF THE EORTC 22952-26001 PHASE III STUDY
Riccardo Soffietti1, Martin Kocher9, Sandra Colette2, Michael U. Abacioglu3, Salvador Villa4,
Francois Fauchon5, Brigitta Baumert6, Laura Fariselli7, Tali Tzuk-Shina8, Rolf P. Muller91
University of Torino, Torino, Italy 2EORTC, Brussels, Belgium 3Marmara Univ, Istanbul, Turkey 4Germans Trias i Pujol,
Barcelona, Spain 5Centre Haute Energie, Nice, France 6Academish Ziekenhuis, Maastricht, The Netherlands 7Istituto
Neurologico “Carlo Besta”, Milano, Italy 8Rambbam Medical Center, Haifa, Israel 9UniversitasKlinikum Koeln, Germany
Purpose: The EORTC designed a phase III trial to define the role of adjuvant whole brain irradiation (WBRT) after local
treatment (surgery or radiosurgery) of 1-3 brain metastases from solid tumors. Methods: Patients eligible for radiosurgery
had metastases ≤2.5-3.0 cm in diameter and in case of surgery a complete resection was mandatory. Only patients with
absent or stable systemic disease or with asymptomatic synchronous primary tumors, and with WHO PS 0-2 were allowed.
Patients were randomized to receive either adjuvant WBRT (30Gy in 10 fractions) or observation (OBS). Primary endpoint
was time to WHO PS deterioration to ≥3. Secondary endpoints were time to intracranial progression, frequency ofneurologic death and overall survival. Analysis is by intent-to-treat (Logrank, two-sidedα=0.05). Results: Since 1996 to
2007, 359 patients were recruited. Median time to WHO PS ≥3 was 9.8 months (95% CI 8.0-11.7) in the OBS arm and 9.8
months (95% CI 7.8-12.6) in the WBRT arm (p>0.5). Overall survival was 10.9 months (95% CI 9.2-14.6) in both arms(p>0.5). Cumulative incidence of intracranial progression at 6 and 24 months was 39.7% (95% CI 32.5-46.8) and 54.0%(95% CI 46.7-61.3) of the OBS pts., but only 15.2% (95% CI 9.9-20.5) and 31.4% (95% CI 24.5-38.2) of the WBRT pts(p<0.0001). Intracranial progression was a cause of the death in 77/179 pts (43%) of the OBS group and in only 45/180 pts(25%) of the WBRT group. Conclusions: After radiosurgery or surgery of a limited number of brain metastases, adjuvant
whole brain radiotherapy reduces the frequency of intracranial relapses and neurologic deaths but does not prolong thetime period of functional independence and overall survial time.

O100
The Impact of Cyst Formation and Tumor Hemorrhage on Local Recurrence inBrain Metastasis
Heon Yoo1, Eugeen Jung1, Sang Hoon Shin1, Hoshin Gwak1, Seung Hoon Lee1
Objective The purpose of this study is to examine the impact of cyst formation and tumor hemorrhage on the local
recurrence after surgery for single brain metastasis. Materials and methods Between July 2001 and February 2007, 90
patients went through surgery for single brain metastasis at our institution. 63 patients (70%) were male, and 27 (30%) werefemale. Mean age was 55 (+12) years. The primary sites were lung in 58 (64%), colon in 11 (12%), breast in 6 (7%), kidney in
5 (6%), and liver in 5 (6%). Hemorrhagic brain metastasis was noted in 11 patients. Among non-hemorrhagic 79 patients,
12 patients had large cystic brain metastasis which was determined by diameter of the tumor cyst (greater than 3 cm).
Postoperative RT was given in 4 patients (32%) in cystic group and 21 (30%) in solid group (p=0.45), and was given in 24(30%) in non-hemorrhagic group and in 4 (36%) in hemorrhagic group (p=0.73) Results Among 11 hemorrhagic brain
metastases, local recurrence was developed only in one patient. Among 79 non-hemorrhagic brain metastasis, 32 (40%)
showed local recurrence. 12 month progression free survival was 90% in hemorrhagic group, and 46% in non-hemorrhagicgroup (p=0.04). 7 patients (58%) showed local recurrence among 12 large cystic brain metastases, and 25 (37%) in theother group. 6 month progression free survival in large cystic group was 57% and 75% in the other group. 12 monthprogression free survival was 0% in large cystic group and 52% in the other group (p=0.02). Conclusion It was found fromthe results that hemorrhagic metastasis rarely recurred; however large cystic metastasis frequently recurred after surgery
regardless of adjuvant therapy. Therefore, it seems reasonable to conclude that postoperative RT and close follow-up
should be necessary in large cystic metastasis.

O101
Neoplastic meningitis - is MRI as sensitive as CSF cytology?
Peter Proemmel1, Jan Hendrik Buhk 2, Sara Pilgram2, Herwig Strik1
Department of Neurology, University Medicine Goettingen, Goettingen, Germany 2Department of Neuroradiology,
University Medicine Goettingen, Goettingen, Germany

1

Background: Although CSF cytology and MRI are standard methods for the diagnosis of neoplastic meningitis (NM), thiscomplication of neoplastic disease still remains to be difficult to detect in some cases. We therefore re-evaluated thesensitivity of gadolinium(GD)-enhanced MRI and cerebrospinal-fluid (CSF)-cytology for the diagnosis of LM differentially forsolid and haematological malignancies and for normal or elevated cell counts. Methods: we identified retrospectively 101
cases of NM diagnosed in our CSF laboratory since 1990 with complete data of both MRI and CSF-cytology. 34 had
haematological, 67 solid neoplasms. CSF-cell counts were increased in 63 and normal in 35 patients. Results: forhaematological neoplasms, MRI was positive in 53%. CSF cytology was positive in 97%. In solid tumours, we found MRIsensitivity of 0.81 and cytological sensitivity of 0.76. With normal CSF-cell-counts, MRI was positive in 63%, (0,57haematological, 0,75 solid malignancies), CSF-cytology 78%, (0,9 in haematological, 0,64 in solid neoplasms). In cases ofincreased cell-counts, MRI-sensitivity was 0.75 (0,52 for haematological, 0,87 for solid malignancies), and sensitivity of
CSF-cytology was 0.89 (1,0 for haematological and 0,82 for solid neoplasms).23 patients were treated with intrathecal MTX
or Ara-C, 16 patients with liposomal Ara-C. 62 patients were not treated intrathecally. Conclusions: we confirmed here thehigh overall sensitivity of MRI for the diagnosis of neoplastic meningitis. The best sensitivity, however, was seen in solid
tumours and elevated cell counts. In haematological malignancies, a markedly lower sensitivity of MRI was seen. Of note,
we consider the very high sensitivity of cytology in haematological malignancies to be artificial due to methodologicalreasons of this retrospective study. We conclude that MRI is a very sensitive method to detect NM especially in solid
tumours and elevated cell counts. With normal cell counts and haematological neoplasms, CSF-cytology remains to besuperior to radiological methods.

- 99 -­­

Oral Presentation (0)Neuro-Oncology Clinic, National Cancer Center, Goyang, Korea

1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O102
Immunotherapy with CpG-ODN in neoplastic meningitis( for patients withneoplastic): phase I trial.
Renata Ursu1, Sophie Taillibert2, Claire Banissi1, Dimitri Psimaras2, Irene Coman1,
Johan Le Guilloux1, Cathrine Belin1, Khe Hoang-Xuan2, Antoine F. Carpentier1
Department of Neurology, Hopital Avicenne, 93009 BOBIGNY France 2Department of Neurology Mazarin, Hopital
Pitie-Salpetriere, Paris, France Assistance Publique-Hopitaux de Paris University Rene Descartes, Paris 5, France.

1

Phosphorothioate oligodeoxynucleotides containing CpG motifs (CpG-ODNs) are immunostimulating agents with antitumor
effects in animal models. Neoplastic meningitis is a devastating disease, with no efficient therapeutic available. A phase 1
trial was conducted in patients with neoplastic meningitis to define the safety profile of subcutaneous injections, combinedor not with intrathecal administration, of a CpG ODN.Methods Cohorts of three patients were treated for 5 weeks withescalating doses of CpG-28 (level 1: 0.1mg/kg/week subcutaneously; level 2: 0.3mg/kg/week subcutaneously; level 3:0.3mg/kg subcutaneously associated with 3 mg intrathecally every other week). The diagnostic of neoplastic meningitis
was based on CSF cytology or clinical symptoms with meningeal enhancement on MRI. The primary endpoint wastolerance. Secondary endpoints were time until neurological progression and survival.ResultsNine patients (3 per level)
were treated between march 2007 and may 2008. Primary cancer was malignant glioma, breast cancer ,melanocytoma ,
ependymoma and small cell carcinoma. Median age was 51 years and median KPS was 70%. In patients who weretreated with subcutaneous injections only, no significant improvement in clinical or radiological symptoms were seen. In thethree patients who were treated with both subcutaneous and intrathecal administrations, clinical improvement wasobserved. However these patients received concomitant treatment with spinal radiotherapy or systemic chemotherapy
which might have impacted the outcome.Adverse effects possibly or probably related to the studied drug were moderateand consisted in grade 2 lymphopenia, anemia and neutropenia, local erythema at injections sites, fever, seizure and backpain.The median time until neurological progression was 9 weeks. The median survival was 17 weeks . One patient is still
alive. Conclusion CpG-28 was well tolerated at doses up to 0.3mg/kg subcutaneously and 3 mg intrathecally. Main side
effects were limited to local erythema, lymphopenia and fever. Escalating doses of CpG-28 for intra-thecal administration is
on-going.

O103
Oral Presentation (0)Establishing myeloablative chemotherapy protocols in low-resource countries:
the Pakistan experience of the Cure2Children Foundation.
Lawrence B. Faulkner, Sadaf Khalid, Naila Yaqub1, Tahira Zafar1, Kamran Rashid2, Yasir Iqbal2,
Saqib Ansari3 and Tahir Shamsi3.
Cure2Children Foundation, Florence, Italy; 1Pakistan Institute of Medical Sciences, Islamabad, Pakistan; 2Shifa
International Hospital, Islamabad, Pakistan; 3National Institute of Blood Diseases, Karachi, Pakistan.
Many children diagnosed with brain tumors in lower-income countries may not have access to appropriate neurosurgicaland/or radiotherapy standards.
The potential of high-dose chemotherapy with autologous stem cell rescue in the context of childhood brain tumors to
improve treatment efficacy while reducing long-term toxicities and costs has not been fully explored and might be usefully
applied in middle-income countries to compensate for inadequate neurosurgery and/or radiotherapy.
Since August 2008, the Cure2Children Foundation has supported both financially and professionally the development of
two centers in Pakistan for stem cell transplantation applied to the cure of thalassemia major, a very prevalent (50.000
cases in Pakistan) and curable deadly genetic disease. The methodology employed consists of matched-related allogeneic
bone marrow transplantation after administration of myeloablative chemotherapy (thiotepa 10 mg/kg, busulfan 14 mg/kg
and cyclophosphamide 200 mg/kg). Management standards for central venous access, severe pancytopenia,
immunesuppression, hospital infection control, and other relevant issues have been addressed by local training as well aswith web-based data management and videoconferencing. A total of seven transplants have been performed so far, three
in an established center (National Institute of Blood Diseases, Karachi) and four in the two newly developed services
mentioned above. No transplant-related deaths or untoward morbidities have occurred at present, detailed clinical and cost
analysis will be presented.
We believe that this experience might be relevant to the possible implementation of autologous transplantation for the cureof some brain tumors of childhood in lower-income regions.

- 100 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O104
Management of Brain Tumors in the Philippines
Julette-Marie F. Batara, M.D.
St. Luke’s Medical Center/Philippine General Hospital
The Philippines is a very diverse country because of the large socioeconomic gaps. Thus we have centers with very
advanced technology and medical expertise at par with international standards for treating brain tumors but are
inaccessible to a large majority of people because of the high cost.
For the low income groups, free medical expertise as well as minimal hospital fees are available in tertiary care government
hospitals, such that benign brain tumors can be treated. However, there are only a handful of these, hence the long waitingtime for imaging studies, elective surgeries and whole brain radiotherapy. For tumors requiring adjuvant treatment withchemotherapy and other types of radiotherapy, the high cost of medicines and lack of radiotherapy equipment ingovernment hospitals coupled with minimal insurance coverage limits care for these patients.
To standardize care, several brain tumor centers offering multi-disciplinary treatment have been set up. Regular brain
tumor board meetings are also held in various centers. A year ago, the Philippine Society for Neuro-oncology was started toenhance brain tumor education and management .
Each doctor seeing brain tumor patients tries to help by doing surgeries or chemotherapy in government hospitals where
they can be done for free or at one-third of the cost, by referring patients for assistance to receive medicines at a reduced
cost from either government agencies or other funding agencies. Despite this, the majority of low income patients will not
get the care they need, not because of a lack of medicines nor a lack of medical expertise but mainly because of the lack ofmoney to pay for diagnostic tools, chemotherapy or radiotherapy.
Long term solutions are needed such as increasing imaging and radiotherapy facilities in government hospitals, lowering
the cost of chemotherapeutic drugs or improving accessibility through various foundations. We can continue to improve
the quality of care by continuing education programs and by involvement in clinical trials to increase patient options.

O105

St. Jude Children’s Research Hospital
262 Danny Thomas Place, Memphis, TN 38138, USA
BACKGROUND
Establishing a pediatric neuro-oncology service can be challenging given the complexity of brain tumors in children.
Creating such a service requires the involvement of different disciplines such as neurosurgery, neuropathology, andradiation oncology. These challenges are tougher and more multifaceted in a developing country than a developed one.
STEPS NEEDED TO BUILD AND SUSTAIN A NEURO-ONCOLOGY SERVICE
The basic factors required to build and sustain a successful pediatric neuro-oncology service are common to developed
and developing countries. These include establishing a dedicated multidisciplinary team, empowering nursing, providing
palliative care, and adhering to approved disease-specific protocols and guidelines.
For developing countries, twinning initiatives with developed countries have been shown to enhance and speed theprogress of newly established services in leukemia and lymphoma, but their contribution remains to be tapped for brain
tumors. Integrating telemedicine into a twinning program can improve the quality of care of patients, especially if
implemented in a prospective fashion.
OBSTACLES ALONG THE WAY
It is a major challenge to coordinate different disciplines to work in conjunction and approve standard therapeutic
approaches in developing countries. Another major obstacle is the inherent attitude toward nursing in many developing
countries. Although twinning and telemedicine can positively influence a newly developed neuro-oncology service, it still
can provoke sensitive issues to local teams in developing countries. To avoid unconstructive impact of telemedicine andtwinning the mentoring team should be perceptive of such issues. This can be achieved though frank and continuous
communication.
CONCLUSION
There is an urgent need to improve the care for children with brain tumors in developing countries. Immediate steps need tobe taken at the local and international levels and individual plans developed for each program and country.

- 101 -­­

Oral Presentation (0)THE CHALLENGES OF BUILDING AND SUSTAINING A PEDIATRIC NEURO-ONCOLOGYPROGRAM IN A DEVELOPING COUNTRY
Ibrahim Qaddoumi, MD MS

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O106
CHILDHOOD BRAIN TUMORS INCIDENCE AND CARE IN THE KYRGYZ REPUBLIC
E. Makimbetov, Z. Kamarli
Kyrgyz-Russian Slavic University
BACKGROUND
There were some important obstacles regards pediatric brain tumors registrations and cares in the Kyrgyz republic.
STATEMENT ON THE PURPOSE OF THE STUDY: study childhood brain cancer incidence, age, sex, and ethnic
differences.
METHODS USED. Childhood cancer registration in Kyrgyzstan is carried out by network of population-based regional
registries, National Center of Statistic since 1983. Collected date from forms submitted along morphological findings anddeath certificates. The population figures and cancer incidence rates were provided in for age (0-4, 5-9, 10-14), ethnic
groups, for each sex and calendar years. Counted crude, age-standardized rates (ASR) per 1 000 000. Estimatedpopulation relative risk in the urban and rural areas.
SUMMARY OF RESULTS AND STATISTICAL ASSESSMENTS. There were 270 registered with new diagnoses of brain
cancer in children (1983-2007): 150 (ASR 7.5) boys, and 120 (ASR 6.9) girls. Male/female proportion is 1.25. Total ASR
annual childhood cancer incidence was 74.8. The most frequent diagnostic groups were leukaemia's (30.3%, ASR 20.8),
non-Hodgkin lymphomas (9.9%, ASR 7.3). Non-registered patients – 17%.
Analyses of geographical variations showed highest incidence of brain tumours in urban (Bishkek, Chui) than rural
mountains regions (Osh, Naryn, Issyk-kul), (RR=2.2, CI 95% 1.57-8.99). Incidence rate was significantly higher in Russians(ASR 10.8), compared with native Kyrgyz’s (5.7) and Uzbeks (8.5).
Only one pediatric oncology department (30 hospital beds) is in Bishkek (capital) on whole republic. Surgical treatment
performed at the National (adult) hospital without radiation or chemotherapy. About 60% of childhood population (Southpart - Osh, Djalalabat, and Batken areas) haven’t any possibility to receive any treatment, even chemotherapy or adequate
initial brain surgery.
CONCLUSIONS. Childhood brain cancer incidence in Kyrgyzstan is low and similar to those reported from some Asiandeveloping countries. The setting (radiotherapy) at the National cancer center is unsatisfactory both with regard to trained
physicians, medical supplies and supportive care. Too many patients are seen in an inadequately staffed and equipped
department. High risk patients with brain tumors are at a definite loss, especially since supportive care is basically absent.
There is an urgent need to improve the care for children with brain tumors.

Oral Presentation (0)O107Management of Cancer Pain in Developing Countries
Stuart A. Grossman, MD*
Professor of Oncology, Medicine & Neurosurgery
The Johns Hopkins University School of Medicine, Baltimore, MD 21231
Cancer pain is often undertreated even in developed countries with abundant resources and easy access to oral,
parenteral, and transdermal opioids. In developing countries, where opioids are generally not available, the challenges toproviding adequate analgesia to patients with cancer are often insurmountable. In spite of concerted efforts by the World
Health Organization and other organizations to make oral opioids available and to educate physicians and government
officials, little progress has been made in relieving pain in cancer patients in this important area. Major obstacles include: 1)
a limited budget for pharmaceutical agents, 2) preference for agents that prevent (ie vaccines) or cure (ie antibiotics)
disease, 3) a focus on children and young adults who have many years to live, and 4) concerns about compliance (asimmediate release opioids must be taken every three to four hours), storage (especially in poor households), and drug
diversion. The documented association between drug diversion, addiction, violence, and AIDS in the West is worrisome topublic health officials in developing nations who face many other important health issues.
Nevertheless, the management of cancer pain is of high priority given the rapidly increasing incidence of cancer in thedeveloping world and the fact that approximately 70% of patients with cancer experience severe pain during the course of
their illness. As a result, novel approaches that address fundamental concerns regarding opioid availability in thesecountries are needed. One such approach employs an inexpensive, non-biodegradable, polymeric implant designed toprovide continuous hydromorphone to the subcutaneous tissue for one to three months. This subcutaneous implant isconstructed of materials that are all approved by the FDA, can be implanted by a physician extender, and releases at acontinuous rate without an initial “burst”. The materials and manufacturing are designed to provide an inexpensive productsuitable for use in developing nations. It has the potential to reduce concerns about patient compliance, drug storage, andopioid diversion while making opioids available to patients in rural areas and reducing the number of follow-up visits
necessary for medication refills,.

References:
Lesser G.J., Grossman, S.A., Lo H., Leong, K., Eller, S. In vitro and in vivo studies of subcutaneous hydromorphone
implants designed for the treatment of cancer pain. Pain, 65:265-72, 1996.
Koshy RC, Rhodes D, Devi S, Grossman SA. Cancer pain management in developing countries: A mosaic of complex
issues resulting in inadequate analgesia. Support Care Cancer, 6:430-437, 1998.
*Disclosure: Dr. Grossman holds several patents on the implantable hydromorphone polymer and is a principal in
Axxia Pharmaceuticals- 102 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO108
Descriptive Epidemiology of Cerebral Gliomas in Albania; Comparative
Analysis during the period of 1993-2004
Gentian Kaloshi1, Eduard Haxhihyseni2, Artur Xhumari1, Ramazan Doka1, Mentor Petrela1
Department of Neurosurgery 2Department of Pathology

1

Purpose:Descriptive epidemiology of cerebral gliomas has recently been the subject of several studies, reporting an increase in brain
tumor rates (both incidence and mortality). Epidemiological data from low and middle income (LAMI) countries, andespecially Albanian data, have not been reported. The purpose of this study is to make a descriptive analysis of cerebral
gliomas in Albania between 1993 and 2004.
Methods:
The cancer database of information on pathologically proven intracerebral gliomas identified in our department between
1993 and 2004 was reviewed. The incidence rates by histological subtype, age and gender were calculated and comparedin three time intervals divided by two &quotmilestones&quot, the introduction of CT scan in 1997 and of MRI in 2001.
Variation of the incidence between 1993 and 2004 was also analyzed.
Results:
The highest cumulated incidence was observed in the high grade astrocytoma group (1.1/100/000/year) followed by the low
grade glioma group (astrocytoma and oligodendroglioma and mixed tumors) (0.9/100.000/year). A significant increasing
trend of 75% per year and per time interval was observed in the incidence of astrocytic tumors in all age groups
demonstrating the important impact of radiological improvement. The incidence rates of high grade astrocytoma and low
grade glioma displayed a Gaussian distribution with mean age at 50-60 years and 31-40 years respectively.
Conclusions:This study represents an interesting analysis of data belonging to three different periods: a) 1993-1997, which represents
the early post-communist period when CT and MRI were lacking, b) 1997-2000, when the CT scan was used, and c) 20012004 when the MRI was also used. As a result of these two important radiological developments, our data show a relative
and absolute (as stated in observations made in other countries) increase in the incidence rate of cerebral glioma.

O109

Department of Neurosurgery, Kanazawa University, Kanazawa, Japan 2International Agency for Research on Cancer,
Lyon, France 3Departments of Radiation Oncology, University Hospital Zurich 4Departments of Pathology, University
Hospital Zurich1

We have evaluated 715 glioblastoma patients who were diagnosed in the Canton of Zurich, Switzerland between 1980 and
1994, to provide information on how patients were treated at the population level. Despite a general policy during the study
period of treatment by surgical intervention aimed at maximum tumour removal followed by radiotherapy, there was amarked tendency toward limited intervention and lack of treatment with advancing patient age. Of those younger than 65
years, 82% were treated either with surgery followed by radiotherapy, surgery alone or radiotherapy alone, versus 47% of
patients 65 years or older. Only 25% of patients older than 75 years underwent surgery and/or radiotherapy, while theremaining patients were given best supportive care (BSC). The mean age of patients was 54.5 years for those treated withsurgery and radiotherapy, 58.3 years for surgery alone, 62.2 years for radiotherapy alone and 69.2 years for BSC. Among
patients who were treated with surgery plus radiotherapy and those treated with radiotherapy alone, younger patients (<60years) had a significantly higher survival rate than older patients (≥60 years). In contrast, no significant difference in survival
was observed between younger and older patients treated with surgery alone or receiving BSC, suggesting that lower
survival rates in elderly patients with glioblastoma may be at least in part due to a lesser response to radiotherapy.

- 103 -­­

Oral Presentation (0)Age as predictive factor in glioblastomas: population-based study
Daisuke Kita1,2, Hiroko Ohgaki2, Ilja F Ciernik 2, Salvatore Vaccarella2, Silvia Franceschi2,
Paul Kleihues3, Urs M Lutolf1, Mitsutoshi Nakada1, Yutaka Hayashi1, Jun-ichiro Hamada1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O110
TUMOR TISSUE IDENTIFICATION IN THE PSEUDOCAPSULE OF PITUITARY ADENOMA:SHOULD THE PSEUDOCAPSULE BE REMOVED FOR TOTAL RESECTION OF PITUITARYADENOMA?
Sun Ho Kim1, Jung Yong Ahn1, Eun Jig Lee2, Se Hun Kim3, Tai Seung Kim3
Department of Neurosurgery, Yonsei Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea
Division of Endocrinology, Pituitary Tumor Clinic, Yonsei University College of Medicine, Seoul,Korea
Department of Pathology, Yonsei University College of Medicine, Seoul, Korea

1
2
3

OBJECTIVE: The pseudocapsule can be found in the transition zone between the adenoma and surrounding normal
pituitary tissue. We investigated the precise histology of the pseudocapsule and evaluated the remission rate, pituitary
function and recurrence rate after intensive resection of the pseudocapsule. METHODS: In 616 patients with pituitaryadenomas (Hardy type I to III) over a period of 14 years, we have introduced intensive resection of the pseudocapsule toachieve complete tumor removal. A combined pituitary function test and radiological study were performed before surgery,one year after surgery and at subsequent 1.5 year intervals. RESULTS: Pseudocapsules were identified in 343 (55.7%)
patients and the distinct pseudocapsules were observed in 180 (52.5%) patients. In the remaining 163 patients, thepseudocapsules were incompletely developed. Tumor infiltration was present in the pseudocapsule in 71 (43.6%) patients.
The presence of a pseudocapsule was more frequent in prolactin (PRL)-secreting tumors (70.9%) than in growth hormone(GH)-secreting (55.0%) and adrenocorticotropin (ACTH)-secreting (40.0%) tumors. In the 243 patients of the total resectiongroup, surgical remission rate was 99.1% in clinically non-functional tumors (CNPTs), 88% in GH-secreting, 70.6% in PRLsecreting, and 100% in ACTH-secreting tumors. The surgical remission rate was 86.2% in the presence of apseudocapsule and 94.3% in the absence of a pseudocapsule. Preoperative hypopituitarism improved in 140 patients(57.6%), persisted in 47 patients (19.3%), and was aggravated in 33 patients (13.6%). The tumor recurrence rate was 0.8%
in the total resection group and was 42.1% in the subtotal resection group. CONCLUSION: We have shown that tumor
tissue is a frequently present within the pseudocapsule, suggesting that any tumor remnant in the pseudocapsule could bea source of recurrence and an obstacle to achieving complete remission. These results indicate that intensive resection of
the pseudocapsule could result in higher remission rate without deteriorating pituitary function.

O111
Oral Presentation (0)Management of pituitary adenoma with stereotactic radiotherapy at
Princess Margaret Hospital.
This Abstract nominated the Hoshino Award.
Please refer to P067 on page 153.

O112
Long Term Follow Up of Patient with Acromegaly after LINAC Radiosurgery
This Abstract nominated the Hoshino Award.
Please refer to P060 on page 151.

- 104 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO113
Several tips to avoid complications of intracystic chemotherapy withbleomycin for craniopharyngioma in children
Akira Gomi1), Hiroshi Takahashi3), Toshihiro Mashiko2), Eiju Watanabe2)
Department of Pediatric Neurosurgery, Jichi Children’s Medical Center Tochigi, Jichi Medical University, Tochigi, Japan
Department of Neurosurgery, Jichi Medical University, Tochigi, Japan3)
Department of Neurosurgery , Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan
1)

2)

Objectives: We have reported the effectiveness of intracystic chemotherapy with bleomycin for cystic craniopharyngiomas.
This result has been confirmed by the following reports. However, relevant complications, including cerebral ischemia,
visual and hypothalamic damages, associated with local bleomycin therapy have been also reported. We have, so far,experienced no such significant complications with our methods. Here we report the way to avoid such complications.
Methods and results: Intracystic belomycin administration was performed on 14 children since 1988 in our institutes.
When radiological examinations indicated cystic craniopharyngiomas, we removed the cyst wall partially to confirm thepathological diagnosis and then placed the Ommaya reservoir tube into the tumor cavity. It is important to place all the side
holes of tube within the cyst cavity and to tighten its entrance so as to avoid leakage of infused bleomycin. Bleomycin was
administrated 2 weeks postoperatively via the Ommaya reservoir connected to the tube. Cystography should be performed
prior to bleomycin administration. A smaller dose (5 mg or less) per injection or infrequent (every other day) injections would
lessen the complications. In addition, the concentration of bleomycin in the cyst is most important. If the dilution of
bleomycin is not enough, the drug may leak through the wall of the cyst. We suggest an appropriate concentration of
bleomycin solution is 1 mg/ml or less and the timing of injection is immediately after the aspiration of cystic fluid. In 9
children the cysts have almost disappeared and the children have achieved a good school life. Four children are alsoachieving a good life condition after additional stereotactic radiosurgery. No severe complications were obeserved.
Conclusion: We recommend several tips for appropriate usage of bleomycin to avoid complications and to achieve a goodresult.
Keywords: craniopharyngioma, bleomycin, complication

O114
Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China. 2Department of
Neurosurgery, Neurological Institute, Taipei Veterans General Hospital 3National Yang-Ming University, School of
Medicine, Taipei, Taiwan, Republic of China.
1

BACKGROUND: Craniopharyngioma is a histologically benign tumor that originates from epithelial nests or from areas ofsquamous metaplasia. The incidence of craniopharyngioma is 2-10% in pediatric primary brain tumors. Surgical removal
and radiation therapy are associated with significant risk for morbidity in the pediatric population with craniopharyngioma.
Intracystic bleomycin therapy (IB) has been proposed as a treatment for predominantly cystic craniopharyngioma. The aimof the study was to review the effectiveness of intracystic bleomycin therapy in our craniopharygioma children. METHODS.
Pediatric craniopharyngioma patients treated with IB at Taipei Veteran General Hospital had been enrolled to participate theretrospective review from 1999 to 2008. Brain MRI or CT was performed every 3 months to evaluate the objective responseof intracystic bleomycin injection. RESULTS. There are 7 boys and 2 girls received the intracystic bleomycin therapy. The
median age is 7.8 years (range from 3.3 to 11.8 years). The median follow-up duration was 44 months (range from 9 to 79
months). For the total 9 patients, 8 achieved good response to IB therapy, and 1 achieved progression. The patient with
progression showed no response to IBT and tumor relapsed quickly after 2 months of treatment. The median progressionfree-survival was 29 months ( range from 2 to 79 months.). CONCLUSIONS. Our preliminary results showed intracystic
administration of bleomycin is a valid and effective therapy for certain children with craniopharyngioma. IBT may delay theneed for aggressive surgery or radiation therapy for several years. However, further prospective randomized studies areneeded to evaluate the feasibility and effectiveness of this treatment.

O115
Intratumoral bleomycin injection as a primary therapy for cystic
craniopharyngioma
Seung-Ho Yang1, Il Sup Kim1, Jae Taek Hong1, Jae Hoon Sung1, Byung Chul Son1, Sang Won Lee1
Department of Neurosurgery, St. Vincent’s Hospital, The Catholic University of Korea

1

While total resection is a desirable goal for the treatment of craniopharyngioma, it is not always accomplished, and isassociated with permanent endocrinological and visual deficits. This knowledge has led us to perform intratumoral
bleomycin injection as a primary therapy for cystic craniopharyngioma. Five patients (4 adult and 1 child) in whom cystic
craniopharyngioma was recently diagnosed were treated primarily with a schedule of 3 mg of intracystic bleomycin threetimes a week for 5 weeks. One patient was excluded due to bleomycin leakage in reservoir permeability test. Remainders
didn't require subsequent resection and radiotherapy. Median follow-up period was 36 months.There was a reduction in
cyst size greater than 90% with the preservation of visual and endocrinologic function.Intracystic bleomycin administration
could be a feasible option for the treatment of predominantly cystic craniopharyngioma in terms of tumor control andtolerability.

- 105 -­­

Oral Presentation (0)Intracystic Bleomycin Therapy for Craniopharyngioma in Children.
Ting-Rong Hsu1,3, Kai-Ping Chang1,3, Tai-Tong Wong2,3

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O116
Differential Imaging Characters of the Tumors Involving the Cavernous
Sinus
Liang Chen1, Zhiguang Pan1, Wei Zhu1, Ying Mao1, Liangfu Zhou1
The Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

1

Purpose: Preoperation diagnosis of 10-20% cavernous sinus tumors remains unclear. Tumor rarity is one factor, butcommon lesions with atypical manifestations maybe another. This review aims at illustrating these untypical manifestations,so as to improve the accuracy of imaging diagnosis of common tumors within the cavernous sinus. Methods: From 20002008, a total of 445 cavernous sinus tumors were surgically resected in a single neurosurgical center. Meningioma (38.7%),
schwannoma (17.8%), bone derived tumor (13.0%), cavernoma (11.2%), dermoid or epidermoid tumor (6.7%), pituitaryadenoma (4.7%), metastatic tumor (3.6%) accounted for the most common types of cavernous sinus tumors. We
retrospectively reviewed 56 patients who were either indefinitely diagnosed or misdiagnosed before operation. Their
imaging characters were carefully reviewed, including the tumor location, brightness and contrast properties of CT and MRI
results, enhancement patterns, presence of tumor compression or incorporation of the ICA, the positional relationship of
the tumor to the dural layers of the cavernous sinus walls, the extra-sinus invasion or derivation, manifestions on MRS,SPECT and PET. The operation records were also closely examined, regarding blood supply, hardness, and mostimportantly, the positional relationship of the tumor and neurovascular structures within the cavernous sinus. Both intraoperative and pathological findings were also thoroughly compared with preoperational imaging characteristics. Results:
The size of these tumors was usually extremely large or small in comparison with their typical counterparts. Growth
patterns of the tumor were of potential value in indicating the tumor properties in larger tumors while location was indicativein smaller ones. Intra-lesional patterns on MR imaging were suggestive of certain pathological changes under certain
circumstances. Conclusion: Detailed insight of the imaging characteristics may add more knowledge to the differential
diagnosis of tumors within the cavernous sinus.

O117

Oral Presentation (0)Results of the Queen Square Meningioma Study: Epidemiology, epileptic
characterization, presenting symptoms, treatment, clinical outcome
and recurrence.
Say Ayala1, Andrew Tarnaris1, Jesus LaFuente1, Neil Kitchen1, David Thomas1, Laurence Watkins1
National Hospital Neurology &Neurosurgery,UK.

1Introduction: Despite meningiomas being the most common benign intracranial tumour little is known about theirassociation with epilepsy and outcome. The aim of this study was to define their epidemiology, identify their relation withepilepsy, and the factors predisposing to recurrence as well as prediction of outcome. Material and methods: The casenotes of 1101 patients treated in the National Hospital for Neurology and Neurosurgery, London, UK 1975 to 2000 wereanalyzed. Data collected included age, sex, clinical symptoms, GCS, tumour location, type of pre and postoperative
epilepsy, Simpson grade, treatment, recurrence and outcome using Karnofsky score. Results: Mean follow up: 36months.
Females: 65%, males: 35%. Age at presentation ranged from seven to 97 (mean 56) years. Meningiomas were more likely
to present with visual symptoms (25.28%), headaches (21.19%), seizures (17.20%) and paresthesia (10.97%). Presenting
symptoms and tumour location were statistically linked (p&lt:0.0001). Symptoms and recurrence were not strongly related(p&lt:0.475) as opposite to symptoms and postoperative Karnofsky score (P&lt:0.0001).Simpson resection grade (I &II areless likely to recur), and pre and postoperative epilepsy are related to tumour recurrence. Preoperative epilepsy is linked totumour location (p&lt:0.013) and postoperative epilepsy, age andhistopathology results were linked to recurrence(p&lt:0.0001)as well as tumour location (p&lt:0.006)and laterality (left tumours recur more than right-sided) (p&lt:0.006) .
The presence of psammoma bodies was related to a benign histological diagnosis (p&lt:0.004). Postoperative radiotherapy
reduced recurrence rate (p&lt:0.0001). Recurrence peaks on the 24 months and 10th year from the first treatment date.
Conclusions: Assessment of the identified factors may aid in outcome prediction and preoperative counselling anddecisions related to patients treatment.

O118
Ki67 PROLIFERATION INDEX DOES NOT PREDICT SURVIVAL IN PATIENTS WITH NONBENIGN MENINGIOMAS: ANALYSIS OF 86 CASES
Andrej Vranic1, Mara Popovic2, Joze Pizem2, Andrej Coer3, Borut Prestor1
Department of Neurosurgery, University Medical Centre Ljubljana 2Institute of Pathology, Faculty of Medicine, Universityof Ljubljana, Slovenia 3Institute of Histology, Faculty of Medicine, University of Ljubljana, Slovenia

1

Background: Non–benign (atypical and malignant) meningiomas are rare tumors and only few studies on larger series
have been preformed so far. Because of their tendency to recur and thus poorer prognosis, they constitute a separate
biological and clinical entity compared to benign meningiomas. Methods: 92 patients with non–benign meningiomas
operated on in years 1990–2002 at the University Medical Centre Ljubljana were analyzed in our retrospective study.
Adopting the newest (2007) WHO classification criteria, 86 tumors were microscopically reclassified as primary atypical or
malignant meningiomas. A histological, immunohistochemical and statistical analysis was undertaken to determine thecorrelation of several clinical, radiological, histological, and immunohistochemical factors with survival. Results: Mean andmedian overall survival times were 6.9 and 6.3 years, respectively. Overall 5– and 10–year survival rates were 74.7% and54.3%, respectively. Univariate analysis of 86 non–benign meningioma patients confirmed female sex (p=0.035) and age
under 56 years (p=0.004) were significantly related to prolonged survival. Among histological factors, microinvasion into
brain parenchyma (p=0.011), dense cellularity (p= 0.030), prominent nucleoli (p=0.020), and sarcomatous appearance(p=0.019) all correlated with decreased survival. There was no difference in survival between patients with low (equal orless than 5%) or high (greater than 5%) proliferation index (p=0.329). Conclusion: In patients with totally excised atypicaland malignant meningiomas, presence or absence of microinvasion into brain parenchyma is a better predictor of survival
than Ki67 proliferation index.

- 106 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O119
Analysis of 56 meningioma cases classified as WHO grade III
Ye Gong1, QING XIE1, YING MAO1, YU ZHOU1, XIANCHENG CHEN1, LIANGFU ZHOU1
Department of Neurosurgery, Huashan Hospital of Fudan University, Shanghai, China

1

Background: According to the WHO classification 2007, there are three subtypes of WHO grade III as anaplastic(malignant), rhabdoid and papillary meningiomas. Here we analyze 56 meningioma cases classified as WHO grade III in our
hospital from 2004 to 2007, when 2,310 meningioma cases were operated (male 697, female 1610). Methods: 47 cases
are anaplastic meningiomas, 3 cases are rhabdoid meningiomas and 6 are papillary meningiomas. 21 patients of them arerecurrent cases who had operations before. Follow up period is at least one year. Results: The patient age ranges from10yrs to 79yrs with mean age 51.1yrs, with a male to female ratio of about 3:2. The distribution position of these tumors are
as follows: 21 at convex of brain hemisphere, 15 into sagittal sinus, 11 at skull base, 4 at tentorium, 3 in lateral ventricles, 1
at spinal cord and 1 at sellar region. Resection extent of Simpson grade is I 34, II 16, III 5, and IV 1. Rhabdoid meningiomas
had rather worse prognosis than papillary meningiomas. Mean survival time of anaplastic meningiomas is 52.9months(range from 13months to 8years) in 25 patients, 12 patients died at follow-up time with mean survival time 54.3months(range from 1 month to 10 years) and 9 patients lost contacts. Half of patients underwent radiotherapy after operation, andhalf of them had not shown recurrence. Only 6 patients had chemotherapy without much effect. Conclusions: Quick
progression, high rate of recurrence and mortality are characters of malignant meningiomas, though each subtype has alittle different prognosis. Treatment for malignant meningiomas is still relied on the extent of resection and very difficult.
Radiotherapy has poor outcome and risk for malignant transformation. So it is very urgent to look for appropriate combined
treatment for this type of meningiomas.

O120
Chordoma and Chondrosarcoma of the Skull Base: Comparative Analysisof Outcomes in 30 patients
Jeong Hoon Kim1, Young Hyun Cho1, Jung Kyo Lee1, Chang Jin Kim1
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

1

O121
TREATMENT WITH HIGH MARGINAL DOSE IS MANDATORY TO ACHIEVE LONG-TERM
CONTROL OF SKULL BASE CHORDOMAS AND CHONDROSARCOMAS BY MEANS OF
STEREOTACTIC RADIOSURGERY
Tomoyuki Koga1, Masahiro Shin1, Nobuhito Saito1
Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan

1

PURPOSE: The purpose of this study was to evaluate the effect of stereotactic radiosurgery (SRS) for chordomas andchondrosarcomas of the skull base and to determine the optimal marginal dose to control these tumors. METHODS:
Fourteen patients with histologically confirmed chordomas or chondrosarcomas underwent 16 sessions of SRS using
gamma knife. The mean tumor volume was 12 cm3 and the marginal doses ranged from 10 to 20 Gy (mean, 15 Gy). Lower
marginal doses of 12 Gy on average (range, 10-12.5 Gy) was applied for 4 patients since they underwent prior fractionatedradiotherapy, and partial treatment for which parts of tumors were excluded from planned target volume (PTV) because of
their proximity to critical normal structures such as the optic pathway and the brainstem was applied for 5 patients. The
whole tumor volume was covered with higher marginal doses of 18 Gy on average (range, 16-20 Gy) for 6 patients. The
mean follow-up period after SRS was 55 months. RESULTS: Progression free survival (PFS) rates at 1, 2, and 5 years after
SRS were 93%, 51%, and 34%, respectively. Five-year PFS rate for patients whose tumors were completely covered by
PTV was 53 months and tended to be higher than that of 17 months for partially treated patients (p = 0.11). Five-year PFS
rates for patients underwent SRS with higher and lower marginal doses were 60% and 14%, respectively, which weresignificantly different (p = 0.023). Tumor progression after partial irradiation mainly occurred from sites where delivered
doses were reduced. CONCLUSIONS: Sufficient marginal dose at least 18 Gy appears crucial to obtain tumor control incase of chordomas. Proper combination with surgical resection to detach tumors from critical structures and to reducetumor volume is necessary to completely deliver sufficient marginal doses to lesions at the time of SRS.

- 107 -­­

Oral Presentation (0)To review the skull base chordomas and chondrosarcomas and analyze comparative outcomes between these tumors.
Between 1991 and 2005, thirty consecutive patients with pathological diagnosis of chordoma (n=19) or chondrosarcoma(n=11) of the skull base were managed by multimodal treatment combining one or more surgical approaches withconventional radiotherapy and/or GKRS. A retrospective analysis was conducted on these patients. Follow-up data werecomplemented by a most recent telephone interview with the patients or their family members. Age of the patients ranged
from 3 to 69 years (median, 36 years). Seventeen patients were female and 13 male. Average length of follow-up was 56
months (range, 2-172 months). A total of 43 surgical approaches (31 for chordoma vs. 12 for chondrosarcoma) were
performed at the initial or recurrent setting. Adjuvant radiotherapy and GKRS were performed on 21 and 6 patients,
respectively. Four deaths occurred during the follow-up, two of which resulted from progression or recurrence of
chordoma, one from pulmonary embolism, and another one from the sepsis unrelated primarily to the tumor. Recurrence of
chordoma was observed in 5 patients out of 13 (38%) and 6 out of 10 (60%), each within 3 and 5 years after the initial
treatment, whereas only 1 recurrence of the chondrosarcoma was observed in 2 years after the surgery with no radiation.
Among 15 survivors with the chordoma, 4 patients were suffering from severe disability with progressive disease. In
contrast, most patients with the chondrosarcoma harbored stable disease and less disabling symptoms except one
instance of recurrence.Outcomes in the functional status as well as survival were much worse in chordomas than those inchondrosarcomas. The authors recommend a maximum safe resection, possibly to the extent of total resection at the initial
setting, combined with complementary treatment, especially GKRS for the management of the skull base chordomas.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O122
Results of proton beam therapy for chordoma and chondrosarcoma of
the skull base: Shizuoka Cancer Centre experience
Yoko Nakasu1, Hiroshi Fuji2, Satoshi Horiguchi1, Koichi Mitsuya1, Yuji Ishida3
Division of Neurosurgery, Shizuoka Cancer Centre 2Division of Proton Beam Therapy, Shizuoka Cancer Centre
Division of Paediatrics, Shizuoka Cancer Centre

1
3

Purpose : To assess the results of proton beam therapy ( PBT) in the treatment of skull base chordomas andchondrosarcomas..Methods: Between April 2004 and August 2008, 11 patients (median age, 40years) with chordomas(n=6) and chondrosarcomas (n=5) underwent proton therapy at Shizuoka Cancer Centre. The median tumour dose was 67
GyE. Late toxicity was assessed using the NCI-CTCAE grading system. The median follow-up time was 29.1 months (range,
3-55.8 months). Results: Actuarial 2-year local control rates were 80% for chordoma and 100% for chondrosarcoma. No
regional failure or distant metastasis was observed, except for one patient with dedifferentiated chordoma. Four patients
had pharyngitis, otitis media, and skin trouble of grade 1 to 2 as acute adverse events. No patients presented with posttherapeutic brainstem or optic pathways necrosis or dysfunction. Conclusion: The results compare favorably to otherirradiation series. Observed toxicity was acceptable. These preliminary results are encouraging, but should be confirmedwith a long-term follow-up.

O123
Cdk inhibitor blocks DNA repair following G2 checkpoint activation inhuman glioma cells treated with temozolomide
Yuichi Hirose1, Hirotoshi Sano1
Department of Neurosurgery, Fujita Health University, Toyoake, Japan

1

Oral Presentation (0)Temozolomide (TMZ) induces prolonged G2-M arrest of glioma cells, and then non-apoptotic cell death associated withsenescence-like phenomenon (in p53-wild type cells) or mitotic catastrophe (in p53-non-functional cells). To clarify themechanism of TMZ resistance and to develop more effective TMZ-based regimen, we established U87MG-derived TMZresistant (TR) clones by serial treatment with TMZ. We found that TR clones underwent only transient or minimal G2 arrest
following TMZ treatment even though G2 checkpoint was clearly activated as in their parental cells and that G2 checkpoint
inhibitor re-sensitized these clones to TMZ. Since it has been suggested that G2 checkpoint system might suppress thelinkage between DNA damage and cell death, we tested the effect of a cdk inhibitor flavopiridol which could target cdc2
(cdk1), a key protein in G2 checkpoint pathway, on TMZ-treated cells. Flavopiridol (< 10 nM ) potentiated the cytotoxicity of
TMZ, and suppressed the expression of key proteins at G2-M transition including polo-like kinase 1, aurora kinases andPin1. FACS analysis revealed flavopiridol induced accumulation of TMZ-treated cells, but not untreated cells, exclusively at
G2 (4N DNA content). This "complete" G2 arrest was associated not only with increased expression of γ-H2AX, a DNA
double strand break marker, but also with increased release of cytochrome C in cytoplasm, which suggests that flavopiridol
promoted apoptotic cell death signal in TMZ-treated glioma cells. Flavopiridol also enhanced cytotoxity of TMZ to the cellswith over-activated Akt which has been previously shown to promote TMZ resistance, and re-sensitized TR clones to TMZ.
Our results suggest that TMZ resistance could be promoted by enhanced DNA repair activity in G2-M transition following
G2 checkpoint activation, and that cdk inhibitor enhanced TMZ cytotoxicity by suppression of this activity. We conclude
that cdk1-targeted compound might be useful as chemosensitization agent for gliomas

O124
Temozolomide-Induced Differential Expression of DNA Repair Genes in
Malignant Glioma Cells
Congju Zhu1, Siaw Wei Teng1, Shi Yuan Cheng1, Meng Cheong Wong1
Division of Medical Sciences, National Cancer Centre of Singapore

1Temozolomide (TMZ), an active alkylating agent in treating malignant gliomas, kills tumor cells with ill-defined molecularmechanism. To understand TMZ genotoxicity, we analyzed temporal regulation of DNA repair genes with levels of DNA
damage, checkpoint activation and cellular status of O6-methylguanine-DNA methyltransferase (MGMT). During the firstpost-drug treatment cell cycle (PTC), rapid DNA double strand breaks (DSBs) were detected (1h) in MGMT-deficient cells,followed by ATM phosphorylation, p53 accumulation, transient G1/S arrest and significantly reduction of S-phaseprogression. Concurrently, global transcription repression was discerned, followed by 2 to 5-fold up-regulation of 9
nucleotide/base excision repair (BER/NER) and 5 DSB repair genes. During the second PTC, prominent G2/M arrest was
accompanied by more than 5-fold up-regulation of 29 genes, which were members of multiple DNA repair pathways. In
MGMT-proficient cells, significantly lower levels of DSBs (less than 30% of MGMT-deficient cells) and lack of NER gene upregulation were identified in the first 6h when substantial level of MGMT was observed. Association of NER and rapid DSB
formation was further demonstrated by overlapping nuclear staining of the major NER endonuclease, XPG and the DSB
marker, g-H2AX proteins. In conclusion, our data suggest that distinct transcriptional regulation of DNA repair genes
contributes to the different TMZ genotoxicity at the first two PTCs. To our knowledge, this is the first study analyzing
temporal regulation of global DNA repair and corresponding genotoxicity in different MGMT context for SN1-type alkylating
agent. Our findings will also have significant implications for improving O6-alkylguanine based cancer chemotherapy.

- 108 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO125
MGMT promoter gene methylation as determined with Multiplex Ligationdependant Probe Amplification (MLPA) is prognostic for survival afterradiotherapy but not predictive for outcome to chemotherapy inoligodendroglial tumors
M.J. van den Bent1, H.J. Dubbink1, C.R. van der Lee-Haarloo1, W.N.M. Dinjens1, M. Hegi2,
J.W.M. Jeuken2, M. Sanson3, A. Ibdaih3, A.A. Brandes4, D. Lacombe5, T. Gorlia5, J.M. Kros1
Dept Neuro-Oncology and Pathology, Daniel den Hoed Cancer Center and Erasmus University Hospital Rotterdam,
the Netherlands; 2Department of Pathology, Nijmegen Center for Molecular Life Sciences, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands; 3Department of Neurology, Centre Hospitalier Universitaire
Pitié-Salpêtrière, Paris, France; 4Medical Oncology Department, Bellaria-Maggiore Hospital, Bologna, Italy; ; 5 EORTCHeadQuarters, Brussels, Belgium
1

O126
A PHASE I, OPEN LABEL, MULTI-CENTER STUDY TO ASSESS THE SAFETY AND
TOLERABILITY OF CEDIRANIB [RECENTINTM ] IN COMBINATION WITH LOMUSTINECHEMOTHERAPY FOR PATIENTS WITH RECURRENT GLIOBLASTOMA
T.T. Batchelor1, J.S. de Bono1,2, P.Y. Wen3, J. Drappatz3, S.R. Plotkin1, F.H. Hochberg1, A.S. Chi1,
D. Harris2, J. Barriuso2, S. Frentzas2, J. Robertson4, Q. Xu4, Q. Liu4
Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School,
Boston, USA 2Institute of Cancer Research, Royal Marsden Hospital, UK 3Center for Neuro-Oncology, Dana-Farber/
Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA 4AstraZeneca

1

Purpose: The objective of this study was to assess the safety and tolerability of cediranib (RecentinTM ), an oral, pan-VEGF
receptor tyrosine kinase inhibitor, in combination with oral lomustine and to determine a dose for further studies with thiscombination in recurrent glioblastoma patients.
Methods: Patients at least 18 years old with pathological confirmation of recurrent glioblastoma were eligible. Patients
could not have received previous anti-VEGF therapy and could have had no more than 2 prior chemotherapy regimens.
Patients completing the first cycle (6 weeks) or having a dose limiting toxicity (DLT) before 6 weeks were evaluable. A totalof 12 patients were enrolled into the study. Six patients were enrolled in the first cohort at a dose of cediranib 30mg incombination with lomustine 130 mg/m2. Another 6 patients were enrolled in the second cohort at a dose of cediranib 30mg
in combination with lomustine 110 mg/m2.
Results: There were 2/6 DLTs reported in the first cohort (one grade 3 fatigue, one hypertensive crisis due to untreatedhypertension). Five of 6 patients developed grade 3 or 4 hematological toxicities attributed to lomustine. The lomustine
dose was reduced to 110 mg/m2 for the second cohort. There was 1/6 DLT (grade 3 fatigue) in the second cohort.
Conclusions: The results of this phase I study demonstrate that the combination of cediranib 30mg with lomustine 110
mg/m2 is safe and tolerable. An international, multicenter, randomized phase III trial has been initiated.

- 109 -­­

Oral Presentation (0)Introduction. Anaplastic oligodendroglial tumors (AOD) are chemosensitive tumors. Two large randomized trials not see
improved survival in patients treated with adjuvant pivotal trial on chemo-irradiation with temozolomide suggested that
benefit from the addition of temozolomide to radiotherapy was basically confined to patients with a methylated MGMT genepromoter and thus no alkyltransferase expression. . In the present study we assessed the impact of MGMT promoter
methylation on progression free survival (PFS) and overall survival (OS) using MLPA in the prospective randomized EORTC
study 26951 on adjuvant PCV on 368 patients with AOD. The control arm received only radiotherapy (RT), the experimentalarm RT plus PCV.
Material and methods. MGMT methylation was assessed using a methylation-specific MLPA (MRC-Holland) based on
methylation sensitive restriction analysis. To estimate the fraction of methylated MGMT promoter DNA, normalized values
obtained with each MGMT probe of digested DNA samples (in which only methylated DNA will remain undigested andproduce a PCR product) were divided by normalized values of corresponding undigested DNAs. For the MGMT genepromoter CpG methylation in three regions was assessed, from which an average score was calculated; a ratio above 0.25
is considered indicative of methylation. Statistical analysis was done using this cut-off and with the MGMT average scoreexpressed as a continuous variable, both for PFS and OS.
Results. In 152 of the 165 patients with sufficient material available for MGMT promoter analysis a result was obtained.
Thirty-nine of these tumors showed 1p/19q co-deletion. In 121 of the 152 cases (80%) an MLPA average consistent withmethylation was observed, which included 38 of the 39 1p/19q co-deleted samples (97%, p < 0.001). MGMT promoter
methylation was found to be equally prognostic in both the RT and the RT/PCV treated patients, for both PFS and OS. In
multivariate analysis using MLPA average as a continuous variable, MGMT promoter methylation and 1p/19q wereindependent prognostic factors. The PFS hazard ratio reduction of MGMT promoter methylation was 0.303 [95%confidence interval (CI) 0.135-0.677], for 1p/19q co-deletion 0.423 [95% CI: 0.232-0.768]. The cut-off as proposed for MSMPLA was not optimal to separate patients in two groups of different prognosis.
Conclusion. 1p/19q co-deletion was strongly associated with MGMT gene promoter methylation. In this homogeneously
treated group of AOD patients, the independent prognostic favourable effect of MGMT promoter methylation on both PFS
and OS was equally strong in the RT group as compared to the RT/PCV group. There is currently no mechanistic
explanation for the improved PFS in MGMT gene promoter methylated tumors after RT only, and other possible
explanations need to be investigated.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)O127
MULTIARM COMBINATORIAL STUDY OF SIGNAL TRANSDUCTION MODULATORS USINGA SEQUENTIAL ACCRUAL DESIGN: A REPORT OF THE NORTH AMERICAN BRAIN
TUMOR CONSORTIUM (NABTC) 0502
Mark R. Gilbert1, Patrick Y. Wen2, John Kuhn3, Michael Prados4, Timothy Cloughesy5
1
Department of Neuro-Oncology, M. D. Anderson Cancer Center, Houston, Texas, USA 2Dana Farber Cancer Institute,
Boston, Massacheusetts, USA 3University of Texas, San Antonio, San Antonio, Texas, USA 4University of California,
San Francisco, San Francisco, California, USA 5University of California, Los Angeles, Los Angeles, California, USA

Background: Single agent signal transduction modulators generally have been ineffective in most cancers including
glioblastoma. Therefore, inhibiting multiple signaling pathways may be a more effective. However, performing individual
phase I/II trials for each combination is inefficient. This study used a sequential accrual design to test three combinationsof sorafenib, with erlotinib, temsirolimus or tipifarnib. Methods: The NABTC conducted phase I studies of sorafenib(VEGFR/PDGFR/Raf inhibitor) in combination with erlotinib (EGFR inhibitor), temsirolimus (mTOR inhibitor), or tipifarnib(farnesyltransferase inhibitor) in recurrent GBM. Accrual was sequential, decreasing study pauses for maturation of toxicity
data. Eligibility: histologically proven GBM, radiologic progression, >18 yrs old, KPS >60, adequate bone marrow and organfunction. No limit on the number of prior therapies. No enzyme-inducing antiepileptic drugs were allowed. Dose-findingused a standard 3 + 3 design. MTD was defined as the dose with DLTs in 1/6 or fewer patients. Serum pharmacokinetic(PK) studies were performed. Results: Overall 49 patients were enrolled onto phase I. The MTD was sorafenib 400mg
BID and erlotinib 100mg qD. The MTD was temsirolimus 25mg qweek and sorafenib 400mg BID. The MTD was sorafenib
200mg BID and tipifarnib 100mg qD x 21 days, but the tipifarnib is below therapeutic levels. PK studies showed no drugdrug interactions for sorafenib with tipifarnib or temsirolimus. However, there was no accumulation of erlotinib, suggestingthat sorafenib alters erlotinib metabolism or clearance. Conclusions: This study demonstrated that sorafenib can be
combined with other targeted agents in and a sequential accrual design decreases logistical problems of phase I studies in
multicenter trials. Phase II doses were successfully determined for sorafenib with temsirolimus and with erlotinib,
permitting enrollment onto the phase II component. The new phase I study using an alternating week schedule of tipifarnib
will be performed to permit a dose more likely to reach therapeutic concentrations.

O128
Oral Presentation (0)PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT
MALIGNANT GLIOMA PATIENTS: FINAL STUDY RESULTSDavid A. Reardon1, Annick Desjardins1, James J. Vredenburgh1, Sridharan Gururangan1,
Katherine B. Peters1, Julie A. Norfleet1, Allan H. Friedman1, Henry S. Friedman1
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA

1

Background: Recurrent malignant glioma (MG) patients treated with bevacizumab (BV), a neutralizing monoclonal
antibody to vascular endothelial growth factor (VEGF) with or without chemotherapy, have noted significant therapeutic
benefit. In this study, we evaluate the efficacy of BV plus etoposide (E), a topoisomerase inhibitor, among recurrent MG
patients. Methods: Recurrent patients with no more than three prior episodes of recurrence are eligible, while those withprior BV treatment or prior intracranial hemorrhage are excluded. The primary outcome measure is 6 month progressionfree survival (6-PFS). BV is dosed at 10 mg/kg intravenously every other week. Etoposide is orally administered daily (50
mg/m2) for days 1-21 of each 28-day cycle. Results: Fifty-nine patients (GBM, n=27; grade 3 MG, n=32) with a median of
2 prior progressions have enrolled. With a median follow-up of 45 weeks, median overall survival (OS) for GBM and grade 3
MG patients were 46 and 47 weeks, while the 6-PFS is 44% and 40.6%, respectively. The most common toxicities were
neutropenia (41%), fatigue (22%), and infection (20%) and were grade 2 in most cases. One patient developed grade 1
intracranial hemorrhage and 1 patient had a grade 4 GI perforation. Conclusions: Combination of bevacizumab andetoposide is well tolerated in recurrent MG patients and is associated with encouraging anti-tumor benefit. Accrual iscomplete and an update of further treatment and follow-up will be presented.

O129
BEVACIZUMAB AND NITROSOUREA IN PATIENTS WITH RECURRENT MALIGNANT
GLIOMA: A PHASE II MULTICENTER ITALIAN STUDY
Roberta Ruda’1, Elisa Trevisan1, Elisabetta Picco1, Daniele Guarneri1, Manuela Caroli2,
Maria G. Fabrini3, Valerio Scotti3, Riccardo Soffietti1
University of Torino, Torino, Italy 2University of Milano, Italy 3University of Pisa, Italy

1

Purpose of study: Bevacizumab (BV) has shown a promising activity in recurrent malignant gliomas (MG) in combination
with irinotecan. Few data are available on the combination of bevacizumab and nitrosoureas. Methods: In this ongoingphase II study patients with MG recurrent after surgery, radiation therapy and temozolomide are eligible. The treatment
consists of an induction phase with BV at 10 mg/kg intravenously on day 1 and 15 and fotemustine (FTM) (a nitrosourea
with elevated lipophilic properties) at 75 mg/m2 intravenously on day 1 and 8, followed after a 3-week interval by amaintenance phase with BV at 10 mg/kg i.v and FTM 75 mg/m2 i.v every 3 weeks until tumor progression or unacceptabletoxicity. Patients undergo clinical and MRI assessment. The co-primary endpoints are objective response rate (ORR) andprogression-free survival at 6 months (PFS6), with secondary endpoints of safety time to tumor progression (TTP) andoverall survival. Results: From April 2008 to December 2008, 34 patients were enrolled, and 31 (22 glioblastomas and 9
anaplastic gliomas) are evaluable for response. Overall response rate (2 CR and 9 PR) was 35% (glioblastomas 33%,
anaplastic gliomas 41.5%). Steroids were reduced in 50% of patients. Sixteen of 31 patients progressed with a TTP of 2.6
months (1-8.5). Progression was local in 10/16, local + leptomeningeal spread in 3/16 and gliomatosis in 3/16. Fifteen
patients are free of tumor progression (from 2 to 8 months). Toxicities included grade III-IV neutropenia in 3 patients, grade
III-IV piastrinopenia in 5 and grade III thrombosis in 2. Seventeen patients developed mild to moderate fatigue, 6 arterial
hypertension and 3 grade I intratumoral haemorrhage. Conclusions: Combination of bevacizumab and fotemustine inrecurrent malignant gliomas is safe and promising. Updated results, monitoring of CBV with perfusion MRI and correlations
between MGMT promoter methylation and response/outcome will be presented.

- 110 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO130
BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II
TRIALThis Abstract nominated the Hoshino Award.
Please refer to P052 on page 147.

O131
Phenotypic and physiologic effects of bevacizumab in a highly
infiltrative and angiogenic human glioblastoma model
Simone P. Niclou1, Mikael Johansson1, Olivier Keunen1, Jian Wang2, Frits Thorsen2,
Rolf Bjerkvig1,2
Norlux Neuro-Oncology Laboratory, CRP-Sante, Luxembourg 2Norlux Neuro-Oncology, Department of Biomedicine,
University of Bergen, Norway

1

O132
Response assessment in neuro-oncology
David R. Macdonald1, Susan M. Chang2, Martin J. van den Bent3, Michael A. Vogelbaum4,
Patrick Y. Wen5
Department of Oncology, London Regional Cancer Program, London, Ontario, Canada 2Department of Neurosurgery,
University of California San Francisco, San Francisco, California, USA 3Department of Neuro-Oncology, Rotterdam
Cancer Center, Rotterdam, The Netherlands 4Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland,Ohio, USA 5Center for Neuro-Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA1

Accurate determination of response and progression is crucial in the evaluation of new treatments for brain tumor and in thecare of individual patients. Macdonald,s criteria (Macdonald DR, et al. J Clin Oncol 1990; 8: 1277-80) are based on
measurement of cross-sectional area of enhancing tumor, taking into account changes in steroid dose and neurologicalstatus. These criteria have been widely used in clinical trials of brain tumor therapy. Limitations include difficulty inmeasuring tumors with complex shapes and components (i.e., cystic or post-operative tumors) or indistinct borders, nontumor factors that can produce imaging changes (i.e., enhancement due to post-operative inflammation, infarction,
hemorrhage, infection, epilepsy), reaction to local therapies (convection-enhanced delivery, chemotherapy wafers,
radiosurgery, etc.), post-treatment changes that may mimic tumor (i.e., pseudoprogression, radiation necrosis), and lack ofapplicability to non-enhancing tumors (i.e., low-grade gliomas). Anti-angiogenic therapies, which may reduce MRI
enhancement by restoring the blood-brain barrier, while non-enhancing T2/FLAIR hyperintense tumor may continue toenlarge, highlight the difficulty of assessing response to novel treatments. The RECIST criteria (Therasse P, et al. J NatlCancer Inst 2000; 92: 205-16) use uni-dimensional tumor measurements and have all the limitations of Macdonald,scriteria.
The Response Assessment in Neuro-Oncology (RANO) group is an ongoing unofficial international multi-disciplinaryconsensus-building effort to develop new response criteria to address these issues. Three working committees (high-grade
glioma, low-grade glioma, surgical therapies) are outlining strengths and limitations of current response criteria, evaluating
new imaging modalities, exploring clinical, neuro-cognitive and quality of life endpoints, and will propose standardized
response guidelines. The input of clinicians, investigators, industry, regulatory agencies, and funding bodies will beobtained. Preliminary guidelines will be presented at ASCO 2009 in Orlando. This WFNO presentation will summarize thecurrent status of the RANO effort.

- 111 -­­

Oral Presentation (0)We have established highly invasive non-angiogenic and less invasive highly angiogenic GBM xenografts by passaging
human glioblastoma biopsies in nude rats. The animal model shows that GBM progression is characterized by two distinct
tumor phenotypes; one stem-like phenotype that relies on pro-invasive programmes and one less infiltrative angiogenesis
dependent phenotype that shows loss of stem cell markers. Recent clinical information indicates that bevacizumab
treatment has a dramatic effect on the contrast enhancing tumor compartment whereas the invasive part of the tumour isaffected to a lesser extent. At present it is unclear if the remaining tumour cells represent a particular stem cell like
subpopulation within the GBM.To address this question we assessed the treatment response of GBM xenografts tobevacizumab. In particular we asked the following: 1. To what extent does anti-angiogenic treatment effectively reducetumor volume by decreasing proliferation and/or inducing tumor cell death, as opposed to simply inducing a normalizationof blood vessels. 2. To what extent does it induce the survival and proliferation of the cancer stem-like cell leading toincreased tumor invasiveness and the development of secondary tumor foci. 3. Alternatively, does it trigger a conversion of
the tumor cell metabolism? Finally we address whether the phenotypic changes induced by anti-angiogenic treatment are
sustained after re-implantation into the nude rat brain. Animals were treated with bevacizumab 10 mg/kg i.v. once weekly.
Before sacrifice tumours were evaluated by T1 and T2 weighted MRI, and dynamic contrast enhancement MRI (DCE-MRI).
Magnetic resonance spectroscopy ( MRS) was applied to assess the metabolic tumor profile after treatment.
Immunohistochemical analysis showed a normalization of vascular elements after treatment, these observations werecorrelated with the MRI observations and with the histological phenotype. In addition, tumor cell proliferation and apoptosis,
and the behavior of the invasive, cancer stem-like cell population was quantified.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)O133
CREATION OF A CHEMOTHERAPY SIMULATOR TO PREDICT THE CONCENTRATIONS OFSYSTEMICALLY ADMINISTERED CHEMOTHERAPY WITHIN BRAIN TUMOR TISSUE
Stuart A. Grossman1, Arati Desai1, Marshall Pitz3, Jaishri Blakeley1, Jana Portnow4,
Martin Brady5, Raghu Raghavan5
1
The Johns Hopkins University Comprehensive Cancer Center, Baltimore, MD USA 2Johns Hopkins University,
Baltimore 3University of Winnepig, Canada 4City of Hope Cancer Center, Los Angeles 5Therataxis, Inc, Baltimore

Backgound: While neurosurgeons and radiation oncologists caring for patients with brain tumors carefully pre-planinterventions using image based guidance systems and simulators, oncologists choose systemic administration with noquantitative estimates of drug distribution. Clinicians generally assume that small lipid soluble agents penetrate an intact
blood brain barrier and water soluble agents enter brain tumors in a manner similar to available radiographic contrast
agents. Important drug related factors governing drug entry into brain and brain tumors include molecular weight, charge,
protein binding, serum pharmacokinetics, and whether the agent is a substrate for efflux pumps. The integrity of the blood
brain barrier varies in different regions of the tumor and may be influenced by external factors such as radiation,
glucocorticoids, and anti-VEGF targeted therapies. Other tumor related variables may include necrosis, cyst, hemorrhage,
and local edema, mass effect and pressure. Results: We have created (patent pending) a Drug Entry Simulator whichdisplays a contrast enhanced MRI of the patient, a serum concentrations of drug over time, and an overlay of drugconcentrations over time superimposed on the MRI. The area under the concentration time curve can be assessed for any
region of interest. The accuracy of the model is continually refined using results from clinical trials employing microdialysis
or surgical biopsies which measure concentrations of systemically administered agents within brain tumors. Examples will
be presented to illustrate the information this simulator can provide using water soluble (methotrexate), more lipid soluble(temozolomide) chemotherapy, and targeted agents (imatinib). Conclusions: Pretreatment estimates of drug entry,
maximal concentration, time over effective concentration, and area under the concentration time curve should result in
more informed choices regarding the use of systemically administered agents in patients with primary and metastatic brain
tumors and the best timing of radiation therapy.

O134
Oral Presentation (0)TARGETING OF THE TYROSINE KINASE RECEPTORS EGFRVIII AND C-MET IN GBM
Terrance G Johns1, Andrew M Scott2, Vinochani Pillay2
Monash Institute of Medical Research, Clayton, Australia 2LICR, Heidelberg, Australia

1

The most common mutation of the epidermal growth factor receptor (EGFR) in GBM is EGFRvIII. HGF/SF is the ligand forthe receptor tyrosine kinase c-Met, both of which are often co-expressed in GBM. The presence of the HGF/c-Met axis or
expression of EGFRvIII each independently enhances GBM growth and invasiveness. Using tyrosine kinase array
technology, we show that expression of EGFRvIII in U87MG GBM cells (U87MG.de2-7 cells) leads to co-activation of several
receptor tyrosine kinases, including PDGFRbeta; and c-Met. A fully human neutralizing antibody directed to HGF (AMG
102) did not inhibit this EGFRvIII mediated activation of c-Met, demonstrating that it is ligand independent. Treatment of
parental U87MG xenografts with low doses of AMG 102 resulted in significant inhibition of tumor growth, while U87MG.de27 xenografts were profoundly resistant to AMG 102 treatment. Treatment with Panitumumab, a fully human antibody
directed to the EGFR and EGFRvIII, was able to inhibit the EGFRvIII mediated activation of c-Met and significantly reversed
the resistance to AMG 102. Indeed, combination therapy with Panitumumab and AMG 102 resulted in a marked increase intumor cell apoptosis. An EGFRvIII molecule with an active kinase but incapable of autophosphorylation at the five major
autophosphorylation sites involved in signal transduction was also able to mediate resistance to AMG 102, suggesting thatthe activation of c-Met by EGFRvIII occurs via a direct interaction rather than through these docking sites. Thus, expressionof EGFRvIII leads to the promiscuous activation of several kinases, causing resistance to ligand inhibitory based strategies.
Since Panitumumab can reverse this process, the combination of this antibody with AMG 102 may be an effective
treatment for GBM patients.

O135
ASSESSMENT OF THE EFFICACY OF ETOPOSIDE AND TEMSIROLIMUS IN AN
INTRACRANIAL RODENT MODEL WITH SPECIAL ATTENTION TO THE RELATIONSHIP OF
TUMOR AND WHITE CELL P70S6 KINASE ACTIVITY DURING THERAPY
Jeffrey J. Olson1, Zhaobin Zhang1
Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia

1

PURPOSE: Clinical experience in malignant glomas suggests that agents targeting single molecular abnormalities do notcontrol tumor growth . This investigation attempts to improve this situation by testing the efficacy the cytotoxic agent
etoposide added to the mTOR inhibitor temsirolims in an intracranial tumor model. Additionally it evaluates peripheral blood
monocyte (PBMC) p70S6 Kinase production and activity as a surrogate for brain tumor changes after mTOR inhibitor
treatment. METHODS AND RESULTS: Nude mice with intracranial U87 tumors treated with etoposide or etoposide plus
temisirolimus therapy survived significantly longer than a control vehicle group. The addition of temsirolimus to etoposideincreased survival over etoposide alone. A substantial in vitro decline in U87 cell phosho-p70S6 Kinase protein expression
occurred in a dose related manner to temsirolimus. U87 cell 70S6 Kinase activity as measured by a P32 based p70s6
Kinase assay declined to 22% of baseline after 30 minutes in 1 nM temsirolimus and 5% of baseline after 30 minutes in 10
nM temsirolimus. P70S6 Kinase activity in PBMCs, and concurrent intracranial and flank U87 tumors after temsirolimus (10mg/kg) treatment was 29%, 39% and 34%, respectively, after 24 hours. These declined to 20%, 28% and 27%,
respectively, after 72 hours. CONCLUSIONS: In the U87 model used, temsirolimus slightly improves the survival
advantage provided by etopside. Temsirolimus decreases phospho-p70S6 Kinase protein and its activity in a dose
dependent manner in vitro. P70S6 Kinase activity impairment in U87 intracranial and flank subcutaneous U87 tumors isparalleled by that in those same animals PBMCs. Thus this assay can be used to monitor biologic effect of this drug in thismodel. These results warrant (1) assessment of the combination of etoposide and temsirolimus clinically, and (2) correlative
confirmation of the use of PBMCs as a surrogate monitor of the management of these patients.

- 112 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO136
CDK4/6 SMALL MOLECULE INHIBITOR PD-0332991 DEMONSTRATES ANTI-TUMORACTIVITY AGAINST AN INTRACRANIAL GLIOBLASTOMA XENOGRAFT LACKING p16
FUCNTION
This Abstract nominated the Hoshino Award.
Please refer to P064 on page 152.

O137
Results of a Phase IIb Study with trabedersen (AP 12009) in Recurrent orRefractory High-Grade Glioma Patients
Ulrich Bogdahn1, Z. H. Rappaport2, V. Olyusin3, V. Parfenov4, A. K. Mahapatra5,
A. Balasubramaniam6, N. K. Vankataramana7, G. Stockhammer8, H. Heinrichs9,
K.-H. Schlingensiepen91University of Regensburg, Department of Neurology, Regensburg, Germany 2Rabin Medical Center (Beilinson),
Neurosurgery Dept., 49100 Petach-Tikva, Israel 3Polenov Neurosurgery Research Institute, 12, Majakovskogo Str.,
191104 St. Petersburg, Russia 4Military Medical Academy, Neurosurgery Department, 6, Lebedeva Str., 194175 St.
Petersburg, Russia 5All India Institute of Medical Sciences, Department of Neurosurgery, Ansari Nagar, 110029 New
Delhi, India 6National Institute of Mental Health and Neurosciences, Department of Neurosurgery, Hosur Road, 560029
Bangalore, India 7Manipal Hospital, Manipal Institute for Neurological Disorders, Airport Road, 560017 Bangalore, India
8
University of Innsbruck, Department of Neurology, Anichstr. 35, 6020 Innsbruck, Austria 9Antisense Pharma GmbH,
Josef-Engert-Strasse 9, 93053 Regensburg, Germany

O138
PHASE I STUDY OF TERAMEPROCOL IN PATIENTS WITH RECURRENT HIGH GRADE
GLIOMAS: A NABTT CNS CONSORTIUM TRIAL
Stuart A. Grossman1, Xiaobu Ye1, David Peereboom2, Myrna Rosenfeld3, Tom Mikkelsen4,
Serena Desideri1
Department of Oncology, The Johns Hopkins University School of Medicine 2Cleveland Clinic 3University ofPennsylvania 4Henry Ford Hospital

1

Background: Terameprocol is a global transcription inhibitor that affects cell division (Cdc2, G2/M), apoptosis (survivin
pathway), drug resistance (MDR1 and PGp), radiation resistance in hypoxia (HIF-1a), and hypoxia responsive genes (VEGF).
Methods: A dose escalation study was conducted in heavily pretreated, recurrent, measurable, high grade gliomas.
Terameprocol was administered intravenously for 5 consecutive days each month and discontinued for toxicity or
progression. Patients taking and not taking enzyme inducing anticonvulsants (EIAC) were escalated independently.
Results: 35 patients were accrued with a median age of 46 (29-71), KPS of 80 (60-100), number of prior chemotherapy
regimens of 2 (1-6). 43% had glioblastoma and 57% had anaplastic gliomas. Pharmacology revealed no differences withcoadministration of EIAC. Treatment related grade 3 or 4 toxicities began at 1700mg with one low phosphorus. In 8
patients treated at 2200mg, there was one metabolic acidosis (secondary to PEG formulation) and one ileus. The drug wasreformulated to avoid acidosis and was well tolerated at 1700mg, but hypoxia and interstitial nephritis were seen at
2200mg. Thus, the recommended daily dose for future studies is 1700mg. No radiologic responses were seen but stabledisease was noted in 9 of 32 (28%) evaluable pts. 5 patients (13%) remained on treatment for more than 6 months (6+, 8,
10, 10, and 21+ months). The median survival of this patient population was 5.9 months. Conclusion: This study
established the toxicity profile of terameprocol, determined that EIASD do not affect its pharmacology, and identified thedose to be used in future studies. Encouraging long term stability was noted in this Phase I trial of heavily pretreatedrecurrent high grade gliomas. The toxicity profile and observed disease stability suggest that terameprocol could be safely
combined with temozolomide and radiation and has the potential to impact survival in newly diagnosed glioblastoma.

- 113 -­­

Oral Presentation (0)Objective: High-grade gliomas (HGG) show an overexpression of TGF-beta 2. AP 12009 was developed for targeted
suppression of TGF-beta 2. Aim of the Phase IIb study was to evaluate the efficacy and safety of AP 12009 compared tostandard chemotherapy in recurrent or refractory HGG patients.
Methods: The Phase IIb study G004 was an international, open-label, randomized and active-controlled dose-finding
study. Main objective was to compare 2 doses of AP 12009 (10 μM or 80 μM) and standard chemotherapy (TMZ or PCV)with regard to response rate, survival, and safety. Patients with recurrent or refractory HGG (AA WHO grade III and GBM
WHO grade IV, N=145) were randomized into the 3 treatment groups. AP 12009 was administered intratumorally by
convection-enhanced delivery with up to 11 treatment cycles (7-d-on, 7-d-off / cycle).
Results: In both AP 12009 treatment groups, long-lasting tumor responses were observed in AA as well as in GBM
patients. For 10 μM AP 12009-treated AA patients, a significantly better overall response rate (CR+PR) at 14 months
compared to control was observed (p=0.034). Also the tumor control rate (CR+PR+SD) differed significantly compared tocontrol (p=0.003). The observed tumor responses correlate with superior overall survival. A median overall survival benefitof 17.4 months was noted for AP 12009-treated AA patients compared to the chemotherapy control. In the GBM subgroup,
AP 12009 was as efficacious as standard chemotherapy regarding short-term survival and superior in terms of long-term
survival.
Conclusion: The Phase IIb study revealed the superior long-term survival of recurrent or refractory HGG patients treatedwith AP 12009. A pivotal Phase III study in AA patients has started and a pivotal study in GBM patients is being planned.
Clinical studies with AP 12009 are also ongoing in pancreatic and colorectal carcinoma and malignant melanoma.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O139
THE COMBINATION OF TEMOZOLOMIDE AND RTA203, A SELECTIVE H + -ATPASEINHIBITOR, AUGMENT THE CYTOTOXIC EFFECT ON MALIGNANT GLIOMAS THROUGHBLOCKADE OF AUTOPHAGY
Hiroshi Aoki1, Naoki Shinojima2, Yasuko Kondo2, Seiji Kondo2, Yukihiko Fujii1
1
The Department of Neurosurgery, Brain Research Institute, University of Niigata, Niigata, Japan 2MD Anderson
Cancer Center

Autophagy is organelles and proteins degradation system through the lysosomal machinery in eukaryotic cells.
Accumulating evidences show that irradiation or some chemotherapy-agents cause autophagy in various types of tumor
cells. However the autophagy may have opposite effects, that is, cell-kiling or cell-protective effect on tumor depending ontype of tumor, of anticancer therapies. Therefore appropriate modification of autophagy, i.e., inhibition of cell-protective
autophagy or promotion of cell-kiling autophagy could augment cytotoxicity caused by anticancer therapy in tumor cells.
We previously reported Temozolomide (TMZ) caused not apoptosis but autophagy in malignant glioma cells. The purposeof this study is to clarify which type of autophagy is induced by TMZ in glioma cells and to determine the appropriate
modification of TMZ-induced autophagy. Autophagy assays showed that TMZ induced cell-protective autophagy in glioma
cells. When glioma cells were treated with combination of TMZ and RTA203 (RTA), a specific inhibitor of vacuolar type H +ATPase, TMZ-induced autophagy was blocked at the late stage by abrogating function of lysosome, resulting inaugmentation of cytotoxicity. The combination of TMZ and RTA represented more than additive effect in cell viability assay.
Apoptosis assays showed RTA alone induces a few apoptosis, while combination of TMZ and RTA significantly increased
apoptosis. In animal study, the combination treatment shows significantly longer survival time compared with each single
treatment. In conclusion, TMZ induce cell-protective autophagy in malignant glioma cells and inhibition of TMZ-induced
autophagy by RTA enhanced cytotoxicity through increase of apoptosis.

O140

Oral Presentation (0)INTERIM ANALYSIS OF COMBINATION CHEMORADIOTHERAPY BY MEANS OFTEMOZOLOMIDE (TMZ) AND INTERFERON (IFN) BETA FOR MALIGNANT GLIOMA:
MULTICENTER CLINICAL TRIAL (INTEGRA STUDY)
Toshihiko Wakabayashi1, Atsushi Natsume1, Masazumi Fujii1, Jun Yoshida1, Takamasa Kayama2,
Ryo Nishikawa3, Masao Matsutani3, Hiroshi Takahashi4, Nobuo Hashimoto5, Toshiki Yoshimine6,
Kazuhiko Sugiyama7, Kaoru Kurisu7, Tomokazu Aoki8
1
Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan 2Department of
Neurosurgery, Yamagata University Graduate School of Medicine, Yamagata, Yamagata, Japan 3Department of
Neurosurgery, Saitama Medical University, School of Medicine, Saitama, Saitama, Japan 4Department of
Neurosurgery, Nihon Medical University, School of Medicine, Bunkyo, Tokyo, Japan 5Department of Neurosurgery,
Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan 6Department of Neurosurgery, Osaka University
Graduate School of Medicine, Osaka, Osaka, Japan 7Department of Neurosurgery, Hiroshima University Graduate
School of Medicine, Hiroshima, Hiroshima, Japan 8Department of Neurosurgery, Kitano Hospital, Osaka, Japan

Backgound: Previously, we demonstrated that Interferon (IFN) beta markedly enhanced chemosensitivity to Temozolomide(TMZ) in an in vitro study (Natsume, Cancer Res, 2005); this suggested that one of its major mechanisms is thedownregulation of MGMT transcription via p53 induction. This effect was also observed in an experimental animal model(Natsume, Cancer Chemother Pharmacol, 2007). Following those preclinical studies, we conducted the Integrated
Japanese Multicenter Clinical Trial of IFN beta and TMZ for Glioma in Combination with Radiotherapy (INTEGRA Study).
Study design and Results: Twenty two patients with malignant gliomas (newly diagnosed and recurrent) were enrolled inthis study. All the newly diagnosed patients received radiotherapy (fractionated focal irradiation in daily fractions of 2 Gy
administered 5 days per week for 6 weeks, i.e., a total of 60 Gy) plus TMZ (75 mg/m2/day, daily from the first to the last dayof radiotherapy); and IFN beta (3 MIU/body, administered IV on alternate days during radiotherapy), followed by 6 cycles ofadjuvant TMZ (200 mg/m2/day, on days 1 to 5, administered every 28 days) and IFN beta (3 MIU/body, administered once
every 28 days). Recurrent tumors were treated with TMZ (200 mg/m2/day, on days 1 to 5, administered every 28 days) andIFN beta (3 MIU/body, administered once every 28 days). The preliminary results reveal that this combination therapy
causes minimal toxicity. The most frequent toxic effect is the inhibition of hematopoiesis (leukopenia and neutropenia) that,in most cases, recovered within a month after the cessation of drug administration. In 15 patients with measurable
malignant tumors, 3 had complete response, 3 had partial response, 5 had stable disease, and 4 had progressive disease.
Conclusions: A combination of IFN beta and TMZ tolerated well, and has great potential of enhancing the efficacy of TMZ.
Further clinical trials will be warranted.

- 114 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO141
The Korean experiences of concurrent chemoradiotherapy withtemozolomide for the newly diagnosed glioblastoma: metaanalysis ofprospective study of four centers
Yong-Kil Hong1, Chae-Yong Kim2, Jong Hee Chang3, Jeong Hoon Kim4
1
Department of Neurosurgery, The Catholic University of Korea, Seoul, Korea 2Department of Neurosurgery, Seoul
National University College of Medicine 3Department of Neurosurgery, Yonsei University College of Medicine
4
Department of Neurosurgery, Ulsan University College of Medicine

Concurrent chemoradiotherapy using temozolomide (TMZ)demonstrated a clinical efficacy as primary therapy for thepatients with newly diagnosed glioblastoma (GBL), and its effect was influenced by the molecular genetic factors such as
MGMT status. The authors postulated a possible racial difference in the response to this therapy and performed a metaanalysis of 103 Korean patients with primary GBL treated from June 2004 to November 2007 in four major institutions(Yonsei University, Ulsan University, Seoul National University, The Catholic University of Korea). The patients received
radiotherapy for a total 60 Gy plus continuous daily TMZ (75 mg/m2/day), followed by six cycles of adjuvant TMZ (150 to
200 mg/m2/day). The median age was 57 yr, and 77% of the patients underwent debulking surgery (more than subtotal
resection). At a median follow up of 12 months, the progression free survival (PFS) was 9 months and 6-month PFS rate
was 66.3%. The median OS was 19 months. The 12-month OS rate was 78.7% and 24-month OS rate was 48.9%. The
response rate was 73% (21 CR and 32 PR of 73 evaluable patients). Median OS (19 months vs 14 months) as well as
6-month PFS (71% vs 47%) was significantly improved in the debulking surgery group. No grade 3 or 4 hematologic toxicity
was noticed and grade I or 2 toxicity developed in only 8.3% of the patients. Concomitant chemoradiotherapy with TMZ
appeared to prolong the survival of Korean patients with newly diagnosed GBL and was safe in terms of toxicities andtolerability. However, further investigations are mandatory in larger number of patients, longer term follow-up, and molecular
genetic analysis, which have already been undertaken.

O142

Children’s Memorial Hospital, Chicago, Illinois, U.S.A. 2Children's Memorial Research Center, Chicago, Illinois, U.S.A.

1

Purpose: Few studies have compared the effects of low dose frequent administration of chemotherapeutic agents,
metronomic therapy, versus bolus chemotherapies on tumor bed vasculature and other tumor characteristics. In this study,
we evaluated tumor control, anti-angiogenic effects, and tumor cell characteristics in a rodent glioma model in response tothese two methods of drug administration.
Methods: Rat 9L gliosarcoma cells were stably transduced with the luciferase gene, allowing cells to be monitored using
Bioluminescent Imaging (BLI). BLI admits tumor response to treatment to be observed in animals both immediately andrepeatedly imaged over time. Fifty thousands tumor cells were inoculated into the right striatums of 15 Fisher 344 rats. 10days after inoculation, animals were randomly divided into 3 groups. Group 1 received no treatment. Group 2 received 10
mg of carboplatin via bolus intraperitoneal (i.p.) administration every 2 weeks. Group 3 received 2mg of carboplatin i.p 5
times per week. Tumor growth was measured every 2 to 3 days. To observe tumor vascularity and reaction to hypoxia,
immunohistochemical assessments were carried out on brain specimens excised from rats 4 weeks after initialchemotherapeutic treatment.
Results: Metronomic and bolus administration of carboplatin both controlled tumor growth and vascularity. However, levelsof hypoxic reaction and malignant mutation were significantly lower in tumors treated with metronomic therapy; represented
by hypoxia inducible factor-1 alpha (HIF-1α) and cMet protein, respectively.
Conclusion: Recent evidence has shown that tumor cells in a hypoxic condition may survive with malignant changes
which appear to be triggered by cMet protein activation. Our results suggest bolus administration of drug is more likely toresult in cells becoming hypoxic, and acquiring malignant mutations. Metronomic therapy may provide a better alternative
for treatment, as it appears to produce lower levels of hypoxia and malignant mutations.

O143
Phase II trial of low-dose continuous (metronomic) treatment oftemozolomide for recurrent glioblastoma
Jong Hyun Kim1, Doo-Sik Kong1, Jung-Il Lee1, Do-Hyun Nam1
Department of Neurosurgery, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan
University School of Medicine, Seoul, Korea

1

PURPOSE: We performed a phase II trial of low-dose continuous (metronomic) treatment using temozolomide for recurrent
GBMs. PATIENTS AND METHODS: Temozolomide-refractory patients with GBM who experienced disease recurrence orprogression during or after cyclic treatment schedule of temozolomide after surgery and standard radiotherapy were
eligible. This phase II trial included two cohorts of patients. The initial cohort, comprising 10 patients, received
temozolomide at 40 mg/m2 everyday. After this regimen seemed safe and effective, the metronomic schedule was changed
to 50 mg/m2 everyday. The second cohort, comprising 28 patients, received temozolomide at 50 mg/m2 everyday.
RESULTS: The 6-month progression-free survival in all 38 patients was 32.5% (95% CI: 29.3-35.8%) and the 6-monthoverall survival was 56.0% (95% CI: 36.2-75.8%). One patient developed a grade 3 neutropenia, grade 2 thrombocytopenia
in three patients, and grade 2 increase of liver enzyme (GOT/ GPT) in three patients. Of all patients included in this study,
four patients were withdrawn from this study because of side effects including sustained hematological disorders,
cryptococcal infection, and cellulitis. In a response group, quality of life measured with SF-36 was well preserved, as
compared with the pre-treatment status. CONCLUSION: Metronomic treatment of temozolomide is an effective treatment
for recurrent GBM which is even refractory to conventional treatment of temozolomide and has acceptable toxicity.

- 115 -­­

Oral Presentation (0)COMPARISON OF BOLUS AND METRONOMIC CHEMOTHERAPY ON TUMOR
CHARACTERISTICS
Akihide Kondo1, Stewart Goldman1, Veena Rajaram1, Marcelo B Soares2, Tadanori Tomita1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O144
A continuous schedule of TMZ for GBM at first relapse may overcome thetherapeutic disadvantage of non-methylated MGMT: results from thephase II RESCUE trial
J. Perry, W. Mason, K. Belanger, P. Kavan, D. Fulton, J. Easaw, S. Kirby, D. Macdonald, C.
Shields, and J.-F. Pouliot
Rescue Study Group, Canadian Brain Tumour Consortium Investigators, Toronto, Canada

Oral Presentation (0)Background: Most pts with newly diagnosed GBM progress after standard RT with concomitant and adjuvanttemozolomide (TMZ) and there is no standard second-line regimen. Continuous dosing and dose intensification of TMZ arethought to reduce levels of O-6-methylguanine-DNA methyltransferase (MGMT), which has been associated with TMZ
resistance. Altering the schedule of TMZ may be one strategy to re-induce response. A prospective phase II study was
conducted to investigate this approach; we report the survival analysis and MGMT data.
Methods: Patients with GBM (n=90) and anaplastic glioma (n=30) who failed standard TMZ (5/28d adjuvant regimen)
received continuous dose-intense TMZ 50 mg/m2 for 28/28 days for up to one year. The primary endpoint was 6-mo
progression-free survival (PFS).
Results: 120 pts were enrolled at 11 centres. Pts were divided into four cohorts: recurrence during the first 6 mo of
adjuvant therapy (early group); after 6 mos of therapy (extended group); after stopping adjuvant TMZ (completed group);
and anaplastic glioma. No enrollment was permitted in the first 3 mos after RT in order to minimize the influence ofpseudoprogression. Six-mo PFS was 28% (early), 13% (extended), 29% (completed), and 33% (anaplastic). Non
hematological toxicity was mild and easily managed. Progressive lymphopenia was seen in 40% but no serious
opportunistic infection was observed.
MGMT promoter methylation was tested in 71/120 pts of which 51 could be evaluated. 22 (43%) and 29 (57%) had amethylated and unmethylated promoter, respectively. These 2 groups were similar in age and surgical resection but more
non-methylated patients were ECOG 0 (45% vs 32%). They received a median of 6 cycles of continuous TMZ with a
median TTP of 4.6 (meth) vs 5.4 (non-meth) months and median time to death on study of 8.8 (meth) vs 9.4 (non-meth)
months. 5/17 (29%) MGMT promoter methylated GBM pts reached >6mo PFS compared to 7/22 (32%) non-methylated.
Conclusions: Continuous dose-intense TMZ 50 mg/m2 administered on a 28/28 day schedule is active and well tolerated
after failure of the conventional 5/28 day regimen. Efficacy compares favorably to other commonly used second-line
agents. This analysis revealed similar on-treatment time, 6 mo PFS, TTP, and survival for GBM patients regardless of MGMT
promoter methylation. Continuous TMZ given at first recurrence of GBM may overcome the disadvantage of high MGMT
expression. Further studies of this extended TMZ schedule are warranted.

O145
THE MIR-17/92 POLYCISTRON IS AMPLIFIED AND UP-REGULATED IN SONICHEDGEHOG-DRIVEN MEDULLOBLASTOMAS AND INDUCED BY N-MYC IN SONICHEDGEHOG-TREATED CEREBELLAR NEURAL PRECURSORSThis Abstract nominated the Hoshino Award.
Please refer to P043 on page 143.

O146
EPIGENETIC SILENCING OF KRUPPEL-LIKE FACTOR 4 (KLF4) IN MEDULLOBLASTOMA
Yukiko Nakahara1, Paul A. Northcott1, Paul N. Kongkham1, Young Shin Ra1, Christian A. Smith1,
James T. Rutka1, Michael D. Taylor1
The Hospital for Sick Children, University of Toronto, Toronto, Canada

1

The genetic and epigenetic events involved in the initiation and progression ofmedulloblastoma (MB) are poorly described.
To gain a better understanding ofMB pathogenesis, we have analyzed 201 primary MBs and 11 MB cell lines using a highdensity single nucleotide polymorphism (SNP) array platform. We identified a discrete area of homozygous deletion on
9q31 in a primary MB sample containing 9 known genes. As loss of heterozygosity (LOH) at this locus is relatively frequentin MBs, we focused on one of the genes, Kruppel-like factor 4 (KLF4) as a possible tumour suppressor gene in MB. KLF4
is a zinc-finger transcription factor that regulates the expression of genes involved in differentiation and cell-cycle arrest andhas recently been shown to undergo promoter methylation and LOH in gastrointestinal cancer. To determine if KLF4 issimilarly inactivated by epigenetic mechanisms in MB, we profiled its epigenetic status using multiple complementary
techniques. KLF4 expression was restored in MB cell lines after treatment with 5-aza-deoxycytididine, as shown by semiquantitative RT-PCR. Bisulfite sequencing analysis showed methylation of the promoter region of KLF4 in MB cell lines andnot in normal cerebellum. We examined the DNA methylation status of KLF4 in 45 primary MBs by methylation-specific
PCR and determined that 18% of the tumours showed methylation of the KLF4 promoter region. We re-expressed KLF4 in
KLF4-negative human MB cell lines and observed a decreased growth rate of MB cells in vitro, and extended survival ofmice harboring intracranial xenotransplanted human MB cells in vivo. Our results suggest that KLF4, which appears to beinactivated frequently in MBs through genetic and/or epigenetic mechanisms, may be a novel factor in MB carcinogenesis.

- 116 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

O147“Ependymoma Treatment: An Update”
Zacharoulis S
Royal Marsden Hospital, UK
PURPOSE: To review state of art and relevant advances in the management of ependymomas. RECENT FINDINGS:
Ependymomas are uncommon neoplasms of the central nervous system, and may occur either in the brain or the spinal
cord. Compared with intracranial ependymomas, spinal ependymomas are less common. Studies performed on genetic
changes in ependymoma provide some insight into the pathogenesis and prognostic markers and yield new therapeutictargets. Almost all clinical studies have shown a major impact of extent of resection; thus, a complete resection must be
attempted, whenever possible, at first surgery or at reoperation. Involved field radiotherapy is the recommended adjuvant
therapy. The lowest limit age than radiotherapy can be used safely, and, the need for radiotherapy for completely resectedsupratentorial non-anaplastic ependymomas are controversial issues that are examined in clinical trials. Craniospinal
irradiation is used occasionally for metastatic disease. Chemotherapy is reserved for young infants in order to avoid or delay
the use of radiotherapy or in an attempt to facilitate second look surgery. Data from relevant studies will be presented.
Patients with relapsed disease have very prognosis with variable occasionally chronic course with multiple relapses. Reoperation can provide improvement in progression free survival. Small series without long term toxicity data have shownthat re-irradiation following relapse can occasionally result in long term survival in relapsed patients. Chemotherapy
regimens have been used in relapsed ependymoma with only occasional responses without providing benefit in overall
survival. New agents are desperately needed for this rare disease. Molecular biology studies suggest some potential new
therapeutic targets.

O148
Medulloblastoma in infants
Susan N Chi, MD
Pediatric Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

O149
RECURRENT MEDULLOBLASTOMA- RECENT ADVANCES IN TREATMENT
Sri Gururangan
MRCP (UK), The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710
Medulloblastoma is the commonest malignant brain tumor in childhood with an annual incidence of around 400 cases per
year in the United States. In recent years significant strides have been made in the treatment of this tumor with long-term
survival of 85% in children with average risk disease and up to 70% in those with disseminated tumor. However, theoutcomes in infants and those with recurrent disease remains poor. While high-dose chemotherapy with stem cell rescue
has been the main stay of salvage therapy at recurrence with or without radiation therapy, it is far from clear if this approach
can be successfully employed in all children at recurrence. A profusion of studies have focused on the pathology andmolecular characteristics of this tumor. Identification of histologic subtypes, alterations in the Sonic Hedgehog (SHH) andWNT signaling pathways, over-expression of ERBB2, OTX-2 gene amplification, and the recent efforts to identify theputative tumor initiating cell in medulloblastoma have helped in the understanding the biologic basis of this disease,assessing prognosis, and to begin devising a more biology-based therapy of children with this tumor. A significant
proportion of children suffer from leptomeningeal disease (LMD) at relapse. Therapeutic options are currently limited for thisgroup and more effective strategies are needed. This discussion will focus on the recent advances in the treatment ofchildren with recurrent medulloblastoma with specific emphasis on HDC with stem cell rescue, treatment of LMD,
molecular targeted therapies, immunotherapy, and other innovative strategies that are already being tested in the clinic or
actively being explored in the laboratory.

- 117 -­­

Oral Presentation (0)Infants with malignant embryonal brain tumors have poorer survival compared with older children. Surveillance,
Epidemiology and End Results (SEER) Program data on the survival of all children with medulloblastoma/ primitive
neuroectodermal tumor (PNET) confirms this pattern of poor survival rates in the youngest group of patients, less than three
years of age, with an overall survival rate of 39% at five years and median survival of 1.8 years. Previous studies in large
cooperative study groups consistently report this same trend, with collective survival rates ranging from 22% to 47%.
There have been divergent strategies across international cooperative groups, strategies such as prolonged post-operative
chemotherapy; intraventricular administration of chemotherapy; intensive frontline chemotherapy with further intensification
with stem cell rescue; and adjuvant focal conformal radiation. Metastatic disease at diagnosis remains problematic but
there is evidence to suggest that intensive therapy with stem cell rescue is encouraging. The incidence of the histologic
subtype, desmoplastic medulloblastoma, among the infant population is notable and their potential improved outcome ascompared to the classic variety is of great interest. The ability to identify infants with medulloblastoma from those withatypical teratoid rhabdoid tumor must be considered a confounding factor. Recent molecular profiling data on
medulloblastoma will guide therapy in the future, thus impacting the approach to treating young infants.
The predominant issue that surrounds therapy for infants is the well established risks of radiation therapy in terms ofneurocognitive development, far outweighing the benefits of therapeutic response. Focused developmental assessments
should be a required aspect in determining the “success” of any future therapy.
An international collaborative effort investigating the varying treatment strategies in concert with measuring long-term
neurocognitive outcomes is currently underway.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O150
Measuring Performance Status in Pediatric Brain Tumor Studies Experience of the HIT-GBM-C Protocol
Kamran Mohiuddin1, Peggy Nagel1, Rachel Bingham1, Pourmina Navalkele1, Johannes E A Wolff1
MD Anderson Cancer Center

1

Introduction: Measuring children has proven to be a challenge. We have previously described the FMH, a questionnaire forpediatric brain tumor protocols. Here we report the experience in the treatment protocol HIT-GBM-C which included
intensive simultaneous radiochemotherapy followed by further chemotherapy for high grade glioma and diffuse intrinsic
pontine glioma Method: The FMH ("Fertigkeitenskala Muenster/Heidelberg (FMH)") is a quantitative measure of healthstatus, which includes 56 simple questions between 2 and 15 words to be answered with yes or no. The number of positive
answers is translated in age dependent percentiles (FMH%). Physicians were also asked to rank the handicap in a 5 point
scale: normal, mild handicap, age normal activity severely reduced but not in bed, in bed but not in ICU, and ICU. No
financial compensation was offered. RESULTS: Questionnaires were available from 50 of 97 eligible patients. 5 Patientsscored initially over 40 on FMH%, four of which survived. 16 Patients scored less than initially 39%, and 15 of them died.
The physicians judged the patients as normal in 20.4% initially, which decreases to 16.3% in the middle of the protocol. In
reverse only 16.3% had activity severely reduced, which increased to 30.6% after receiving the half of the treatment. The
FMH% correlated well with the physicians judgments (p less than 0.005). Conclusion: The FMH scale is valid as itcorrelated with the physician assessment. Patients with poor performance at treatment start had a poor prognosis. The
number of questionnaires sent back was insufficient for answering a treatment related question. If a treatment comparison
is to be answered, an incentive needs to be provided.

O151
Development of the Japanese version of Pediatric Quality of Life
Inventory TM Brain Tumor Module
Iori Sato1, Akiko Higuchi2, Takaaki Yanagisawa3, Akitake Mukasa4, Kohmei Ida5,
Yutaka Sawamura6, Kazuhiko Sugiyama7, Nobuhito Saito4, Toshihiro Kumabe8,
Mizuhiko Terasaki9, Ryo Nishikawa3, Yasushi Ishida10, Kiyoko Kamibeppu1

Oral Presentation (0)Department of Family Nursing, Graduate School of Health Sciences and Nursing, Faculty of Medicine, The Universityof Tokyo 2Children’s Cancer Association of Japan 3Department of Neuro-Oncology, International Medical Center,
Saitama Medical University 4Department of Neurosurgery, Faculty of Medicine, The University of Tokyo 5Department ofPediatrics, Faculty of Medicine, The University of Tokyo 6Department of Neurosurgery, Hokkaido University Hospital
7
Department of Neurosurgery, Graduate School of Biomedical Sciences Hiroshima University 8Departments of
Neurosurgery, Tohoku University Graduate School of Medicine 9Department of Neurosurgery, Kurume University
School of Medicine 10Department of Pediatrics, St.Luke’s International Hospital
1

The Pediatric Quality of Life InventoryTM, PedsQLTM, is a widely-used modular instrument for measuring health-related qualityof life in children aged 2 to 18. The PedsQLTM Brain Tumor Module is comprised of six subscales: cognitive problems, CP,
pain and hurt, PH, movement and balance, MB, procedural anxiety, PA, nausea, NA, and worry, WO. Here, we developed
the Japanese version of the PedsQLTM Brain Tumor Module. [METHODS] Translation equivalence was confirmed using thestandard back-translation method, and content validity was assured by cognitive debriefing tests of both children andparents separately. Self-reported or interviewer-administered questionnaires including both the PedsQLTM Generic Core
Scales and the State-Trait Anxiety Inventory for Children, STAIC, were completed by 137 children with brain tumors, 90 selfreported, 47 interviewer-administered, and 166 parents (all self reported). Average child age was 9.8 years. Forty-sevenchildren had embryonal tumors (29.0%), 36 had germ cell tumors (22.2%), 25 had high-grade glioma (15.4%) and 39 had
low-grade glioma (24.1%). Sixty-five children (39.2%) were under treatment. [RESULTS] High internal consistency(Cronbach’s α= 0.75-0.84 for children, 0.80-0.96 for parents) and sufficient test-retest reliability (Intraclass Correlation
Coefficient [ICC] = 0.67-0.77 for children, 0.74-0.95 for parents) were demonstrated for all subscales except child-reported
PH (α=0.50, ICC=0.45). Factorial validity was supported through exploratory factor analysis (factor-item correlation = 0.330.96 for children, 0.55-1.00 for parents). Known-groups validity confirmed that CP was sensitive for developmental
disorders, MB for paresis, and NA for currently undergoing chemotherapy. Convergent and discriminant validity with thePedsQLTM Generic Core Scales and STAIC were acceptable. Child-parent correlation was 0.41-0.65 for five of the six
subscales and 0.18 for WO. [CONCLUSION] The Japanese version of the PedsQLTM Brain Tumor Module is suitable for themeasurement of health-related quality of life of children with brain tumors in clinical trials and research.

- 118 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO152
A NEW ASSESSMENT TOOL FOR MEASURING NEUROLOGICAL AND BEHAVIORALFUNCTION ACROSS LIFESPAN: THE NIH TOOLBOX
Jin-Shei Lai1,2, Richard Gershon1,2, David Blitz1, Susan Magasi1,2, Cindy Nowinski1,2,David Reuben4, William Rymer3, Sandra Weintraub2, Molly Wagster5
Center on Outcomes, Research and Education, NorthShore University HealthSystem, Evanston, IL 2Northwestern
University, Chicago, IL 3Rehabilitation Institute of Chicago 4UCLA, Los Angeles, CA, USA 5National Institute of Health,Bethesda, MD

1

AIMS: The NIH Toolbox, part of the NIH Blueprint for Neuroscience Research, seeks to develop brief, comprehensive
assessment tools measuring motor, cognitive, sensory and emotional health. The ultimate goals of the Toolbox include theprovision of: 1) uniformity among measures across disease groups, and 2) measures that demonstrate stable psychometricproperties across the lifespan. Upon completion, the Toolbox will be available for use in longitudinal epidemiologic studies
and clinical trials for people ages 3-85. In this paper, we describe the Toolbox developing process using motor andcognitive function as examples. METHODS: We first conducted both on-line surveys and in-depth interviews with clinicalresearch experts in each domain. Specifically, experts were asked to nominate essential constructs to be assessed for
motor and cognitive function and rank them based on conceptual and clinical relevance. A follow-up consensus meeting
was held to finalize the constructs to be included in the Toolbox. RESULTS: 147 responded to an on-line survey; additional
12 and 8, respectively, completed in-depth interviews for motor and cognition. The results were reviewed by the NIH project
team and external advisory group. The follow-up consensus meeting led to the inclusion of locomotion, balance, dexterity,
strength, and endurance for the motor domain, and attention, episodic memory, executive function, language, processing
speed and working memory for the cognition domain. CONCLUSIONS: We are currently revising existing instruments anddeveloping additional instruments to assess the selected constructs, which will be completed by spring 2009. Normative
data from the US general population will be completed in 2010, and with the final Toolbox to be available in 2011. The final
Toolbox will be a valuable research resource, improving the ability to compares results from different studies. Use ofToolbox assessments holds the promise of improving our understanding of the overall health of neuro-oncology patients.

O153

This Abstract nominated the Hoshino Award.
Please refer to P054 on page 148.

O154
MANGING CHALLENGING BEHAVIOURS AFTER BRAIN CANCER: A RESOURCE FOR
PATIENTS, CARERS AND HEALTH PROVIDERS
Teresa Simpson1,4, Kylie M Wright2,4, Diane Whiting3, Grahame Simpson3,5,
Eng Siew Koh1,4, Rochelle Firth6, Kathryn Younan3
1.Cancer Therapy Centre - Liverpool Hospital , Sydney South West Area Health Service, Sydney, Australia .
Department of NeuroSurgery - Liverpool Hospital, Sydney South West Area Health Service, Sydney, Australia 3Brain
Injury Rehabilitation Unit - Liverpool Hospital 4NSW Oncology Group - NeruoOncology, NSW Cancer Institute, Sydney,
Australia 5Rehabilitation Studies Unit , University of Sydney, Sydney, Australia 6Royal North Shore Hospital, Northern
Sydney and Central Coast Area Health Service, Sydney, Australia.
1
2

Purpose: Between 17-50% of people with brain tumour (BT) display some degree of challenging behaviour (CB) including
executive impairment, behavioural disturbance, or social/emotional dysfunction. However, little information on management
strategies is available for patients and/or their carers to assist in coping with these problems. A web-based review identified
17 key English language information resources (web-based or hard copy) on BT from across Australasia, North America,
and the United Kingdom. Although 47% contained lists of cognitive/behavioural impairments, 71% provided either no or
minimal information (1-2 sentences) on management strategies. This project aimed to develop patient/carer oriented Fact
sheets to address this information gap. Methods: A literature review regarding behavioural / cognitive impairments after BT
was conducted. Resources developed for other neurologic groups were reviewed. Combining data from these sources
with the clinical experience of the project team, draft fact sheets were devised and presented to a focus group of patientsand carers for feedback. Drafts were also circulated to a state multidisciplinary health provider BT network convened by the
New South Wales Cancer Institute. Readability statistics were also calculated to ensure that the resources met public healthstandards for comprehension. Results: Sixteen Fact sheets (web-based and hard copy) were developed addressing
apathy, anger, stress/anxiety, fatigue, high level thinking problems (executive impairment), inappropriate social/sexual
behaviour, lability, perseveration, disorientation/confusion, egocentricity, impulsiveness, depression, neglecting personalcare, memory difficulties, attention/concentration and communication. Each sheet contains a definition of the problem,
prevalence statistics, symptom list, de-identified case-study, management strategies for the person with BT and carer(s),key questions to ask health professionals and web-links to further information. After only three months of release,substantive requests for these resources from across Australia have been received. Conclusion: Results suggest thatthese Fact sheets fill an important information gap, providing an important resource for patients, carers and healthproviders.

- 119 -­­

Oral Presentation (0)Detailed prospective neuropsychological, activity of daily living andendocrine function assessment in children with craniopharyngioma
treated with stereotactic conformal radiotherapy

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)O155
PATIENT FUNCTIONAL STATUS IS STRONGEST CORRELATE OF CHALLENGINGBEHAVIOUR AFTER BRAIN TUMOUR
This Abstract nominated the Hoshino Award.
Please refer to P053 on page 148.

O156
Mouse models of CNS embryonal tumors
Hiroyuki Momota1, Eric C. Holland2,3
1
Neurosurgery Division, National Cancer Center Hospital, Tokyo, Japan 2Department of Cancer Biology and Genetics,
Memorial Sloan-Kettering Cancer Center, New York, USA 3Department of Neurosurgery and Neurology, Memorial
Sloan-Kettering Cancer Center, New York, USA

Oral Presentation (0)Background: CNS embryonal tumors are devastating cancers in children, consisting of medulloblastomas, supratentorial
primitive neuroectodermal tumors (sPNETs), and atypical teratoid/rhabdoid tumors. Based on the genetic alterations foundin human, multiple models of human CNS embryonal tumors have been developed in genetically engineered mice. The
objectives of this study were to create novel mouse models for discovering efficient therapy and to understand brain tumor
biology. Methods: The RCAS/tv-a system was used for modeling brain tumors in p53 null mice. The experimental
retrovirus RCAS that has an inserted oncogene c-Myc or β-catenin was injected into neonatal mouse brains. Transgenic
mice expressing RCAS receptor tv-a under the control of the GFAP promoter (Gtv-a mice) allow cell type-specific RCAS
infection and gene transfer in vivo. Symptomatic mice were sacrificed and examined histologically. We also reviewed
published reports of the molecular and cytogenetic abnormalities in human CNS embryonal tumors. Results: sPNETs weregenerated in Gtv-a p53-/- mice by forced c-Myc expression with 34% incidence. Combined β-catenin activation with
c-Myc promoted tumor progression and induced divergent differentiation. This sPNET was histologically similar to humanlarge cell /anaplastic variant of medulloblastomas and when injected into cerebellum, large cell /anaplastic
medulloblastomas formed at higher incidence. By reviewing published reports, we found that human sPNETs seemed toshare the several genetic abnormalities with other CNS embryonal tumors. The strongest similarity of the molecular/
cytogenetic profile was observed between sPNETs and large cell/anaplastic medulloblastomas in terms of chromosome 1q
gain, c-Myc and N-Myc amplification, β-catenin stabilization, and p53 inactivation.Conclusions: These findings indicate that
common genetic abnormalities are seen in variants of human CNS embryonal tumors, and multiple histologic variants ofthese tumors can be generated from a single set of genetic abnormalities in mice. These data provide insight into the
biology and classification of CNS embryonal tumors.

O157
MULTIPLE RECURRENT GENETIC EVENTS CONVERGE ON CONTROL OF HISTONE
LYSINE METHYLATION IN MEDULLOBLASTOMAThis Abstract nominated the Hoshino Award.
Please refer to P044 on page 144.

- 120 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO158
Clonal selection and parallel evolution define the hierarchicalstructure of metastatic medulloblastoma
Xiaochong Wu1, Lara Collier2, Jessica McLeod1, Paul Northcott1, Sid Croul3, Adam Dupuy4,
Junjun Zhang3, Steve Scherer3, David Largaespada5
Arthur and Sonia Labatt Brain Tumour Research Centre , Hospital For Sick Children, Toronto, Canada 2University of
Wisconsin, USA 3University Health Network 4University of Iowa 5University of Minnesota

1

We modified the Sleeping Beauty (SB) system so that SB is mobilized in the EGL under the influence of the Math1enhancer. Nearly 100% of Math1-SB11, SB transposon donor, ptch +/- mice develop medulloblastoma withleptomeningeal metastases by 3 months, where-as 10-20% of Ptch +/- mice develop localized medulloblastoma by 8months. Mice carring Math1-SB11, or transposon donor, or both do not develop cancer. We sequenced over one million
insertions mapping to over 158,000 sites from over 140 SB-induced primary medulloblastomas and leptomeningeal metsusing 454 technology. Statistical analysis identified 29 common insertion sites (CISs) in primaries and 44 CISs in
metastases including well-known medulloblastoma genes such as CREBBP, and PTEN, as well as other cancer genes
such as FHIT, CACNA2D1, and ERAS. CISs also frequently targeted genes involved in neural stem cell biology such as
NFIA and NFIB.All primary/met pairs arose from a common ancestor as they share common clonal insertions. Someclonal events present in the mets are present in only a small subclone of the primary, supporting the clonal selection theoryof metastasis and suggesting that some of these events affect metastasis virulence genes. Similarly, some highly clonal
events seen in the primary tumor are not seen in the metastases. These likely represent events that have arisen postmetastatic dispersion, demonstrating that paralell evolution also occurs. Most importantly, comparison of insertions fromprimary tumors, and matched spinal and frontal lobe leptomeningeal metastases reveals that in some cases the mets sharea clonal insertion that is only present in a very minor subclone of the primary tumor. This highly suggests that
leptomeningeal dissemination only occurs once. Our results suggest reasons for the failure of medulloblastoma therapies
developed against targets discovered in the primary tumor. Further understanding of the clonal hierarchy of
medulloblastoma metastases will help design future effective therapies.

O159

Division of Hematology-Oncology, Hospital for Sick Children, Toronto, Canada 2John Hopkins University Medical
School 3University of Cambridge 4Medical College of Virginia 5Taipei Veterans General Hospital 6Instituto Nazionale perlo Studio La Cura dei Tumori 7Boston Children’s Hospital 8St. Judes' Childrens Research Hospital1

Primitive neuroectodermal tumors (PNET) represent one of the largest groups of malignant pediatric brain tumors andinclude medulloblastoma as well as CNS-PNET arising in the cerebral hemispheres. Despite histologic similarities, CNSPNET exhibit worse outcomes than medulloblastoma. In contrasts to medulloblastoma, CNS-PNET remain poorly
characterized with limited studies of less than 10 cases reported to date. Prior studies indicate CNS-PNET differ geneticallyfrom medulloblastoma, however, specific biological features of CNS-PNET remain to be defined. In this study, we
performed high resolution gene expression and copy number analyses on 40 primary CNS-PNET using the Illumina
Human-6 V2 BeadChip expression and the Affymetrix 500K GeneChip Mapping arrays. Data analysis revealed absence ofisochromosome 17q and MYCC amplification, and only 1 case of MYCN amplification in 40 CNS-PNET. 1/5 of CNS-PNET
had chr22q loss that did not involve the rhabdoid tumor IN1/SMARCB1 locus. These data support the distinct identity of
CNS-PNET. Copy number analysis respectively identified 28 and 13 regions of focal deletions and amplification in CNSPNET involving known and novel tumor suppressor and oncogenic loci. Remarkably although CNS-PNET exhibitedheterogeneity in copy number profiles, integrated gene expression and DNA copy number analysis demonstrated
segregation of CNS-PNET into 2 major subgroups with specific molecular and clinicopathologic characteristics. Notably, adistinct subgroup, characterized by recurrent copy number alterations of chr 2, 3 and 19 was associated with younger age
at diagnosis (less than 4yrs, p=0.026) and significantly poorer survival (mean of 4+/-1.3 vs 44+/-12.8 months; p=0.0001).
Interestingly, gene expression profiles of these aggressive CNS-PNET indicated significant enrichment (p=0.00001) ofgenes associated with pluripotentcy and downregulation of pro-apoptotic loci. In summary, through integrated genomic
analysis we have identified genetic features that define sub-groups of CNS-PNET. Our data leads us to propose that
aggressive CNS-PNET are characterized by early developmental lineages and pro-survival phenotypes.

O160
Genomic Profiling of Intracranial Germ Cell Tumors with Single
Nucleotide Polymorphism Array
This Abstract nominated the Hoshino Award.
Please refer to P058 on page 150.

- 121 -­­

Oral Presentation (0)Integrated gene expression and copy-number analyses identify
aggressive pediatric central nervous system primitive neuroectodermal tumors
Annie Huang1, Meihua Li1, Kyle F Lee1, Yuntao Lu1, Charles Eberhart2, V Peter Collins3,
Timothy Van Meter4, Muh-Lii Liang5, David Shih1, Eric Bouffet1, Piergiorgio Modena6,
Scott Pomeroy7, Amar Gajjar8, Cynthia Hawkins1, Annie Huang1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O161
Pathways and genes associated with ependymoma location, grade andsubgroups.
Catherine Godfraind1, Thomas Palm2, Francoise Chapon3, Dominique Figarella-Branger4,
Miikka Vikkula2
Laboratory of Pathology, University of Louvain, Brussels, Belgium 2Laboratory of Human Molecular Genetics, de Duve
Institute, University of Louvain, Brussels, Belgium 3Laboratory of Pathology, CHU-Caen, Caen, France 4Department of
Pathology and Neuropathology, La Timone’s Hospital, AP-HM, Marseille, France

1

Purpose of the study: Unravelling specific signatures of ependymoma sub-groups and understanding molecularalterations involved in their tumorigenesis. Materials and Methods: A series of 34 frozen ependymomas were analysedusing Affymetrix HG-U133 Plus 2.0 arrays. Obtained data were compared with histological features. Results: Spinal cord
ependymomas demonstrated a HOX gene signature, whereas intra-cranial tumors had Notch, Hedghog and BMP
pathways upregulation. High expression levels of the oncogenes SOX2, HDAC1, NPM1, YAP1 and JAG1 were observed in
PF ependymomas when compared to normal brain. Grade II ependymomas were associated with up-regulation of dyneins,and grade III with activation of the Wnt and E2F1 pathway, cell cycle, adherens junction dysfunction, apoptosis andangiogenesis. Hierarchical clustering and Correspendance analysis established the presence of three molecular subgroups of posterior fossa (PF) ependymomas, while WHO only recognizes two. One of them regrouped tumors withspecific histology characterized by biphasic and cerebriform appearance, which is either WHO grade II or III. They also
demonstrated activation of genes implicated in glycogene metabolism and central nervous system development. We
suggest to name this newly identified sub-group of children PF ependymomas: biphasic-cerebriform ependymoma.
Conclusion: These data illustrated heterogeneity of ependymomas and assigned gene signatures to tumor locations andgrades. They reinforced the notion of these tumors to derive from cancer stem cells bearing radial glial cell phenotype. In
this context, Hox, Notch and Hedghog pathways play a role in maintenance and renewal of cancer stem cells, and BMP in
their differentiation. This, together with the genes up-regulated in posterior fossa ependymomas, pinpoints Notch pathway
as a major player of ependymoma tumorigenesis, and Wnt of high grade oncogenesis. Identification of three molecularsubgroups in PF ependymomas, among which, the newly identified biphasic-cerebriform pattern, may partly account fordiscordance in histological ependymoma grading.

O162
Oral Presentation (0)Genetic profiling of pediatric non-ependymal gliomas associated withtemozolomide resistance
Taketo Ezaki1, Tomoru Miwa1, Hikaru Sasaki1, Yuichi Hirose2, Kazunari Yoshida1, Takeshi Kawase1
Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan 2Department of Neurosurgery, Fujita
Health University School of Medicine, Aichi, Japan

1

Background: Temozolomide is now widely used as the first line chemotherapy for gliomas. However, efficacy oftemozolomide is virtually based on reports on adult gliomas, and recent results for pediatric gliomas have not necessarily
demonstrated similar efficacy of temozolomide shown in adult gliomas. Pediatric gliomas are characterized by distinct
chromosomal abnormality from adult gliomas, and it is of interest whether any genetic or epigenetic characteristics ofpediatric gliomas cause distict sensitivity to temozolomide. Methods: We examined several factors that affect sensitivity totemozolomide in pediatric gliomas with comparison to adult gliomas. We studied expression of MGMT (O6-methylguanine
methyltransferase) and DNA mismatch repair gene MSH 6 (mutS homolog 6) by immunohistochemistry, presence orabsence of promoter methylation of the MGMT gene by methylation-specific PCR, and genetic aberrations by comparative
genomic hybridization. Results: Expression of MGMT in pediatric astrocytic tumors was significantly higher than those of
adult tumors by immunohistochemistry. Moreover promoter region of MGMT gene was unmethylated in almost all pediatricastrocytic tumors by methylation-specific PCR. However, there was no significant difference in expression of MSH6
between pediatric and adult tumors. Codeletion of 1p and 19q was not observed in pediatric gliomas, and the mostfrequent aberration in those tumors was gain on 1q, with 10 of 23 cases showing the chromosomal abnormality. Gain on 1q
showed tendency towards poor survival and aggressive behavior of the tumors regardless of grade. Conclusions:
Pediatric gliomas appear to have distinct genetic profiling associated with temozolomide resistance. Higher expression of
MGMT, absence of codeletion of 1p and 19q, and frequent gain on 1q in pediatric gliomas might be related to differential
sensitivity to temozolomide from their adult counterparts.

- 122 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO163
The MAPK pathway is altered in the majority of pilocytic astrocytomas
David T.W. Jones1, Sylvia Kocialkowski1, Lu Liu1, Danita M. Pearson1, L. Magnus Backlund2,
V. Peter Collins1, Koichi Ichimura1
Department of Pathology, University of Cambridge, Cambridge, United Kingdom 2Karolinska Institute of Oncology andPathology, Karolinska Hospital, Stockholm, Sweden

1

Pilocytic astrocytomas (PAs) are the most frequently occurring brain tumor in 5-19 year-olds. Little is known about thegenetic alterations underlying their development. We carried out a genome-wide genetic analysis in 44 PAs to elucidate themolecular mechanisms underlying the development of these tumors. Array-CGH analyses using a combination of a 1Mb
and a chromosome 7 tile path BAC-array as well as a custom-designed oligonucleotide array identified two types oftandem duplication, one being very common and the other rare. The former spanned approximately 2Mb at 7q34 and wasfound in 29 out of 44 (66%) PAs. This rearrangement was not observed in any of 244 higher-grade astrocytic tumors. PCR
confirmed that the duplication resulted in a novel fusion gene between KIAA1549 and BRAF. The fusion gene encodes anovel, in-frame fusion protein that lacks the BRaf regulatory domain, has constitutive kinase activity, and confers anchorage
independent growth on transfected NIH3T3 cells. The other tandem duplication was found at 3p25 in a single tumor
without the BRAF fusion gene. This resulted in an in-frame oncogenic fusion between SRGAP3 and RAF1, which lacks theRaf1 autoregulatory amino-terminus but retains the kinase domain. It shows elevated kinase activity when compared withwild-type Raf1 and transforms NIH3T3 cells. Among the remaining 14 PAs without the BRAF or RAF1 fusion genes, threetumors had BRAF mutations, including one with a novel 3bp insertion. Three other patients without RAF gene alteration had
clinical features of NF1. Mutations of the NF1 gene in this syndrome lead to hyperactive Ras signaling and Raf activation.
Our results thus show that the great majority of PAs (36 out of 44, 82%) have alterations of the MAPK pathway. Thishighlights the central importance of this pathway in PA tumorigenesis and underlines its potential as a therapeutic target.

O164
PATIENT-SPECIFIC VIRTUAL CONTROLS CAN BE USED TO SIMULATE AND PREDICTRESPONSE TO RADIATION THERAPY IN INDIVIDUAL GLIOBLASTOMA PATIENTS

Please refer to P065 on page 152.

O165
CAN WHOLE BRAIN IRRADIATION (WBI) REALLY IMPROVE NEUROLOGICAL STATUS ANDQUALITY OF LIFE OF PATIENTS WITH BRAIN METASTASES (BM)? A PROSPECTIVE
MULTICENTER ANALYSIS OF THE BARCELONA GLIOMA GROUP. FINAL RESULTS
Salvador Villa1, Jordi Bruna2, Eugenia Verger3, Francesc Graus3, Rafael Fuentes4, Anna Lucas5,
Miquel Gil5, Nuria Vinolas3, Avelina Tortosa6, Valenti Navarro5
Catalan Institute of Oncology. HU Germans Trias. Badalona. Barcelona 2HU Bellvitge. Hospitalet. Barcelona 3Hospital
Clinic. Barcelona 4Catalan Institute of Oncology. H J Trueta. Girona 5Catalan Institute of Oncology. H Duran i Reynals.
Hospitalet. Barcelona 6University of Barcelona. Campus Bellvitge. Hospitalet. Barcelona
1

Purpose: to prospectively analyze neurological status (NS) and quality of life (QL) of patients affected with BM treated with
WBI. Method: Patients with prognostic RPA classes I, II, IIIa-b (Lutterbach, 02), any age, KPS 50-100, no chemotherapy
during WBI, and informed consent were included. Exclusion criteria were class IIIc, poor medical or psico-social conditions,or leptomeningeal dissemination.NS was based on modified cerebral stroke scale with the following items: headache,seizures, speech, visual, motor, brainstem, sensitive, gaiting disorders, and MMSE. EORTC QLQ C-30 and BN-20 wereused for each patient. WBI consisted on total dose of 30 Gy/ 10d.Changes of NS were defined as follows: Clinicalimprovement was the reduction of 25% of scoring and equal or less dose of DXM; clinical progression was the increase of
25% of scoring or more dose of DXM or both, and clinical stability was defined as other situations Results: 278 patientswere registered; 103 (37%) accomplished inclusion criteria. Most patients had lung (57%) or breast cancers (23%). 98/103
patients finalized WBI. At the first month, 80.6% of intention-to-analyze cases (79 patients) fulfilled neurological evaluation.
NS improvement or stabilization at the first month was 64%. Maintained good MMSE (29-30) influenced NS (p=.04); noneof the following variables did not: age, gender, histology, number of BM, BM location, RPA class, radiological response,
dose of DXM, or baseline NS. Median progression to NS deterioration was 2.3 m. QL improved in emotional (significant)and cognitive fields (trend), and worsened in physical and fatigue fields (both significant). Conclusions: 1- 63% of the entire
cohort were not able for the study. 2- Only 80.6 % were able to be scored at the first month. 3- NS improvement or
stabilization at the first month was 64%. 4- Neuro-cognitive function could determine NS. 5- QL did not decrease after
WBI.

- 123 -­­

Oral Presentation (0)This Abstract nominated the Hoshino Award.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)O166
INTENSITY MODULATED RADIATION THERAPY FOR CRANIOSPINAL IRRADIATIONUSING HELICAL TOMOTHERAPY: FROM PLANNING TO DELIVERY
Tejpal Gupta1, Bhooshan Zade1, Rakesh Jalali1, Zubin Master1, Reena Phurailatpam1,
Anusheel Munshi1, Rajiv Sarin1
Department of Radiation Oncology, ACTREC, Tata Memorial Centre, Mumbai, INDIA

1

Purpose: To establish feasibility of doing Intensity Modulated Radiation Therapy (IMRT) for craniospinal irradiation (CSI)
using Helical TomoTherapy (IMRT_Tomo) and report challenges in clinical implementation. A dosimetric comparison withconventional IMRT (IMRT_LA) and three-dimensional conformal radiotherapy (3DCRT) is also reported. Methods: Initially,
computed tomography (CT) datasets of 4 previously treated patients of medulloblastoma were used to generate 3DCRT;IMRT_LA; and IMRT_Tomo plans for CSI. Standard CSI dose of 35 Gy/21 fractions was prescribed to planning target
volume (PTV). Subsequently, 5 patients were treated on an ongoing prospective protocol of IMRT for CSI using Helical
TomoTherapy. Results: The mean volume of PTV receiving at least 95% of prescribed dose (V95%) was more than 98%
in all techniques. All techniques resulted in comparable dose homogeneity index (DHI) for PTV_brain. For PTV_spine, IMRT_
Tomo achieved highest mean DHI of 0.96 as compared to 0.91 for IMRT_LA and 0.84 for 3DCRT. The best dose conformity
index was achieved by IMRT_Tomo for PTV_brain (0.96) and IMRT_LA for PTV_spine (0.83). IMRT_Tomo was superior interms of reduction of maximum and mean doses to almost all OARs. The average beam-on time was significantly longer in
IMRT_Tomo. Issues in implementation included whole-body immobilization, areas to be imaged daily, co-registration
efficiency, intrafraction motion, and impact of differential shifts, which were handled using appropriate methodology.
Conclusion: Helical TomoTherapy seems to be ideally suited for CSI avoiding junctions, field-matching and abutment
dosimetry. It is favorable in terms of target coverage, dose homogeneity, conformity, and OAR sparing. Challenges insuccessful implementation of IMRT_Tomo for CSI can be circumvented provided they are preempted during the planningphase. The longer beam-on time in IMRT_Tomo raises concerns about intrafraction motion and secondary carcinogenesis.

O167

Oral Presentation (0)AGE AND RADIOTHERAPY DOSES TO LEFT TEMPORAL LOBE PREDICTNEUROCOGNITIVE OUTCOMES IN YOUNG PATIENTS WITH BENIGN AND LOW GRADEBRAIN TUMOURS: DATA FROM A PROSPECTIVE TRIAL OF STEREOTACTIC CONFORMAL
RADIOTHERAPY
Rakesh Jalali1, Debnarayan Dutta1, Indraneel Mullick1, Tejpal Gupta1, Anusheel Munshi1,
Savita Goswami1, Rajiv Sarin1
Tata Memorial Hospital

1

Background: To report the effect of age and RT doses to volumes of different normal structures on neurocognitive
outcomes in young patients with benign and low grade brain tumours treated prospectively with stereotactic conformal
radiation therapy (SCRT). Materials and methods: Twenty eight patients (median age 13 years; 23 male and 5 female)with low grade and benign residual/progressive brain tumours (10 craniopharyngioma, 8 cerebellar astrocytoma, 8 cerebral
low grade glioma) were treated with SCRT to a dose of 54Gy/30Fr/6weeks with at least 2-years follow up were analyzed.
Prospective neuropsychological assessment were done at baseline pre-radiotherapy (RT) and at subsequent follow up withan age-appropriate neuropsychological battery of tests. The change in intelligent quotient (IQ) scores was correlated withthe age and dose-volumes to normal structures using logistic regression analysis. Results: While the overall mean full-scale
IQ (FSIQ) at baseline pre-RT was 80 and remained unchanged at 2-year follow up, a third of patients had &gt10% drop in
FSIQ over baseline. Patients &lt15 years of age had a significantly higher chance of developing &gt10% drop in FSIQ [53%vs. 10%, p=0.03]. Comparison of dosimetric data in patients showing a significant drop in IQ with patients with maintained
IQ revealed that patients receiving &gt42.5 Gy (80% of the prescribed dose) to &gt13% of volume (p=0.048) and &gt27 Gy(50% of the prescribed dose) to &gt50% of the volume of left temporal lobe were the ones to show significant drop in FSIQ
(p=0.06). Calculation of the RT doses to other normal structures including supratentorial brain and right temporal lobe did
not reveal any significant correlation. Conclusion: Our detailed dosimetric data shows younger age and radiotherapy doses
to left temporal lobe to be predictors of neurocognitive decline, and could be used as possible dose constraints for highprecision RT planning.

- 124 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO168
CARBON ION RADIATION THERAPY FOR PAEDIATIC PATIENTS AND YOUNG ADULTS
TREATED FOR TUMORS OF THE SKULL BASE
Stephanie E Combs1,2,3, Anna Nikoghosyan1, Oliver Jaekel2,3, Christian P. Karger2,
Thomas Haberer3, Marc Muenter1, Peter E Huber2, Juergen Debus1,3, Daniela Schulz-Ertner1
1
University Hospital of Heidelberg, Department of Radiation Oncology 2German Cancer Research Center (DKFZ),
Department of Medical Physics in Radiation Oncology and Clinical Cooperation Unit Radiation Oncology, Im
Neuenheimer Feld 280, 69120 Heidelberg, Germany 3Heidelberger Ionenstrahl Therapiezentrum (HIT), Im Neuenheimer
Feld 450, 69120 Heidelberg, Germany

Purpose To evaluate the outcome of carbon ion radiotherapy (RT) in children and young adults with skull base chordomas
and chondrosarcomas. Patients and Methods We treated 394 patients with carbon ion RT at GSI in Darmstadt, of which
17 were younger than 21 years and were treated for chordoma or low-grade chondrosarcomas of the skull base. Irradiation
was performed with a median total dose of 60 Gy E in a fractionation of 7x3 Gy E per week. Results The median follow-up
time was 49 months. Acute side effects were only minor. Alopecia occurred in the periauricular region in a patient with alarge chondrosarcoma with the tumor extending to the lateral skull base. Skin erythema was observed at the left cheek in a
6 years old boy with a chondrosarcoma of the left nasal cavity and maxillary sinus together with CTC grade 1 conjunctivitis
in the left eye. Two patients developed mucositis of the soft palate(CTC grade 1 and 2). One patient developed temporary
middle ear effusion. All symptoms resolved completely. No patient developed new neurological deficits or temporal lobe
damage.In a 6 year old boy with a chondrosarcoma of the left nasal cavity and maxillary sinus a slight facial asymmetry
could be observed. No other growth abnormalities or secondary malignancies developed.Prior to RT, 10 out of 17 patients
presented with neurological deficits. None of these symptoms worsened after carbon ion RT. In one patient, paresis of the
facial nerve resolved after carbon ion RT. Only one patient with chordoma developed tumor progression 60 months after
RT. Conclusion Further evaluation of carbon ion RT is required in this patient population. Randomized studies comparing
the outcome after carbon ion RT with proton RT are needed to evaluate the role of particle beams in the treatment of skull
base tumors.

O169
PSEUDOPROGRESSION IN BORON NEUTRON CAPTURE THERAPY
Shin-Ichi Miyatake2, Shinji Kawabata1, Naosuke Nonoguchi1, Toshihiko Kuroiwa1, Koji Ono2
Pseudoprogression has been recognized and widely accepted in the treatments for malignant gliomas, as transient
increase in volume of enhanced area just after the chemo-radiotherapy, especially using temozolomide. We experienced
the similar phenomenon in the treatments of malignant gliomas and meningiomas using boron neutron capture therapy(BNCT). BNCT is high linear energy transfer, cell-selective particle radiation. Here we introduce the representative cases
and analyze this pathogenesis. Fifty two cases of malignant glioma and 13 cases of malignant meningioma who weretreated by BNCT were reviewed retrospectively mainly in MRI. Twelve out of 52 malignant gliomas and 3 out of 13
malignant meningiomas showed transient increase of enhanced volume in MRI within 3 months after BNCT, without any
chemotherapy. For these cases peak tumor doses were given by BNCT between 234.7 to 1774.2 Gy-Equivalent as given indaily 2-Gy by fractionated XRT. In these cases, 6 glioma cases underwent operation for the suspicion of relapse. In
histology, most part of the specimen showed necrosis with small amount of tumor cell residual. Ki-67 labeling index
showed decreased positivit y in comparison with previous samples of the individuals. Fluororide-labeledboronophenylalanine positron emission tomography (PET) was applied in 5 and 2 cases of malignant gliomas andmeningiomas, respectively at the time of transient increase of lesions. These PETs showed decreased lesion/normal brain
ratio in all cases in comparison with those obtained prior to BNCT. With surgery or without surgery, all lesions weredecreased or stable in size during observation. Transient increase in enhanced volume in malignant gliomas andmeningiomas immediately after BNCT seemed to be pesudoprogression. This pathogenesis was considered as treatmentrelated intra-tumoral necrosis in subacute phase after BNCT. Pseudoprogression has been recognized as good prognosis
landmark with intensive treatments. Therefore pseudoprogression in BNCT suggested potential therapeutic effects of thisparticle radiation methodology.

O170
DIAGNOSIS AND TREATMENT OF RADIATION NECROSIS IN THE BRAIN
Shin-Ichi Miyatake2, Shinji Kawabata1, Minoru Miyashita1, Toshihiko Kuroiwa1, Koji Ono2
Depaertment of Neurosurgery, Osaka Medical College 2Kyoto University Research Reactor Institute1

Recently, new radiation therapies, such as IMRT, BNCT and other particle radiation modalities using high absorbed doses
to tumor tissue have been developed for patients with malignant gliomas, mainly glioblastomas (GB), with good clinicalresults. While, clinically, the differential diagnosis of the tumor progression (TP) of GB and radiation necrosis (RN) has
become important, as has the assessment of tumor activity after adjuvant therapy. We determined how to evaluate tumor
activity before and/or after radiation therapy using positron emission tomography (PET) with boronophenylalanine (BPA) asa tracer. F-BPA-PET images were obtained from histologically verified 38 GB, 8 RN, and 5 RN cases with partial residual
tumors. The lesion/normal (L/N) ratios for these groups were 4.2±1.4, 1.5±0.3, and 2.0 ±0.3, respectively. Also Repeat-PET
imaging was found to be useful for evaluating changes in GB-associated tumor activity with respect to the treatment
received. For the treatment, we experienced 20 RN cases in these 3 years. Anticoagulants and vitamine E alone improved
or stabilized RN in one third of the RN cases, especially for relatively small lesions in Gd-enhancement. Also this treatment
was effective for prevention of RN. In 11 RN cases, lesionectomy was applied with 5-ALA-guided microsurgery. Four out of
11 cases showed improved KPS one month after surgery, while 2 cases showed aggravation and the remaining 5 were
unchanged and stable in KPS. Steroids could be decreased in amount in all 11 cases. 5-ALA guided resection showed aclear boundary between the necrotic tissue and surrounding normal brain in surgery. Recently we experienced thetreatment of 3 medically-refractory RN in eloquent area using humanized anti-VEGF antibody, bevacisumab. This treatment
showed rapid shrinkage of perilesional edema and enhanced lesion in all cases only by single intravenous administration of
bevacisumab at 5mg/kg. Let me show the representative cases in my talk.

- 125 -­­

Oral Presentation (0)1Department of Neurosurgery, Osaka Medical College, Takatsuki. Osaka, Japan 2Kyoto University Research Reactor
InstituteThe 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O171
BRIEF REPORT: ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ACGH) CONFIRMSFLUORESCENT IN SITU HYBRIDIZATION (FISH) 6Q DELETION IN POOR-PROGNOSISDIFFUSE LARGE B-CELL, CD20 POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA (PCNSL).
Brian Patrick O'Neill1, Esteban Braggio1, Ellen D. Remstein1, Caterina Giannini1, Paul A. Decker1,
David M. Kurtz1, Ahmet Dogan1, Rafael Fonseca1
Department of Neurology, Mayo Clinic, Rochester, MN USA

1

Our data suggested that deletion of chromosome locus 6q22-23 was a characteristic of poor prognosis PCNSL patients. In
this report we describe a pilot study of aCGH in combination with FISH to confirm deletion status and assess copy member
changes. Frozen tumor samples were retrieved from Mayo Tumor Registry (IRB 08-001933). All cases were reconfirmed as
PCNSL; as having diagnostic tissue without hemorrhage or necrosis; and as EBV-encoded RNA (EBER) negative. Eachcase was interrogated using well validated and published protocols for FISH, aCGH; and immunohistochemistry (IHC) for
protein tyrosine phosphatase kappa (PTPRK), the gene product of 6q22-23. The cohort comprised two male and threefemale immunocompetent patients. Two of the four patients with sufficient frozen tumor samples had 6q deletion by aCGH,
one complete and one partial. The patient with complete deletion had homozygous deletion by FISH. The patient withpartial 6q deletion by array CGH had no FISH abnormalities. Other recurrent abnormalities included partial 1p and partial 1q
loss, partial 6p loss, and partial or complete gains on chromosomes 7, 12, 13, 18 and 19q; as well as deletions affecting
well characterized tumor suppressor genes p16 and Rb1. This combination of complimentary techniques was chosen on
the premise that it would better ascertain whole genome chromosomal imbalances, ploidy, and chromosome integrity. This
combination strategy is the most logical next step in the determination of genomic signatures consistent with chromosomal
instability mechanisms in PCNSL. This approach may provide important insights concerning the mechanisms responsible
for generating complex genomes. The resulting phenotypic diversity can generate tumors with a propensity for an
aggressive disease course. A better understanding of the underlying mechanisms leading to PCNSL development could
result in the identification of prognostic markers and therapeutic targets.

O172
Oral Presentation (0)PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS DERIVE FROM B-CELL IN
TRANSITION STAGE FROM GERMINAL CENTER B-CELL TO POST GERMINAL CENTER
B-CELL.
Manabu Kinoshita1, Yoshiko Okita1, Yasuyoshi Chiba1, Fukuko Yamamoto1, Naoki Kagawa1,
Naoya Hashimoto1, Toshiki Yoshimine1
Department of Neurosurgery, Osaka University Medical School, Osaka, Japan

1

Although most primary central nervous system lymphomas (PCNSL) are diffuse large B-cell lymphomas (DLBCL),
biological characteristics of PCNSL are not fully understood. We have attempted to investigate the origin of PCNSL withrespect to the stage of B-cell differentiation and challenged the hypothesis that the tumor's stage of differentiation could
impact the patient's prognosis. Clinical data of 33 patients treated under the diagnosis of DLBCL of the CNS wereretrospectively collected. In 32 patients, immunohistochemical study for the following antigen was performed for classifying
B-cell differentiation: CD10, BCL-6, MUM1 and CD138. The median PFS of all 33 patients was 17.2 months and median OS
was 63.3 months. 40% of the cases showed CD10-/BCL-6+/MUM1+ indicating that the tumor was originating from thetransition stage from germinal center B-cell (GCB) to post-GCB. 25% cases were CD10-/BCL-6-/MUM1+, suggesting postGCB origin. 25% cases were CD10+ or CD10-/BCL-6+/MUM1-, suggesting GCB origin. When B-cell stages of the tumor
were compared to clinical outcomes, late B-cell origins (post-GCB) showed a statistically significant better prognosis thanearly B-cell origins (pure GCB type and transition stage from GCB to post-GCB type) with a median PFS of 42.4 and 9.6
months respectively. We suggest that PCNSL often derive from B-cell in a differentiation stage from GCB to post-GCB andthat classifying PCNSL as above could be beneficial for predicting the patient's outcome and provide more insights into the
biology of PCNSL.

- 126 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANO173
NEUROLYMPHOMATOSIS (NL)IN HEMATOLOGIC MALIGNANCIES:AN INTERNATIONALPRIMARY CNS LYMPHOMA COLLABORATIVE GROUP REPORT.
Sigal Grisariu1, Batia Avni1, Martin J. van den Bent2, Felix Bokstein3, David Schiff4, Outi Kuittinen5,
Marc C. Chamberlain6, Patrick Roth7, Anatoli Nemets8, Edna Shalom9, Tali Siegal91Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 2Neuro-Oncology Unit,
Daniel den Hoed Cancer Center, Rotterdam, The Netherland 3Department of Oncology, Sourasky Medical Center, TelAviv, Israel 4Neuro-Oncology Center, University of Virginia, Charlottesville, USA 5Department of Oncology, Oulu
University Hospital, Oulu, Finland 6Department of Neurology, University of Washington, Seattle, USA 7Department of
Neurology, University Hospital Zurich, Switzerland 8Department of Hematology, Barzilai Medical Center, Ashkelon,
Israel. 9Gaffin Center for Neuro-Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

Background: Neurolymphomatosis (NL) is defined as a clinical neuropathy induced by infiltration of peripheral nerves,
nerve roots, plexus, or cranial nerves by any hematologic malignancies. Given the rarity of this condition, a retrospective
review with collaboration across many centers is underway. Objective: to describe the demographics, diagnostic details,
management, and outcome of NL. Methods: 40 patients (diagnosed 1993 to 2008) were retrospectively assembled from
10 centers in 5 countries. Results: Median age was 55.5 years and 60% were males. NL was related to systemic
lymphoma in 80%, to acute lymphoblastic lymphoma in 12.5% and to primary CNS lymphoma in 7.5%. It occurred as theinitial manifestation of the malignancy in 30% of cases. The most common manifestations were related to peripheral nerves
involvement observed in 55%, followed by spinal nerve roots (42.5%), cranial nerves (37.5%) and plexus (35%) with multiplesite symptomatology in 50% and painful neuropathy in 78%. Diagnostic evaluations included imaging, CSF studies (36 pts)
and biopsies (19 pts). Imaging studies suggested the diagnosis in 78% of cases with 70% (26/37) of MRI and, 82% (14/17)
of CT-PET being positive. CSF cytology was positive in 36% and nerve biopsy confirmed the diagnosis in 16/19 (84%).
Therapeutic approaches in 39 patients included high-dose methotrexate and/or Ara-c in 61.5%, intra-CSF chemotherapy in
50% and radiotherapy in 36%. Response to treatment by MRI in 21/39 cases revealed 13(62%) CR, 3(14%) PR, 1(5%) SD
and, 4(19%) PD. Response by neurological score in 36/39 (92%) patients showed improvement/stabilization in 27(75%).
Median survival was 15 months with 31% alive at 56 months. Conclusions: NL is a challenging diagnosis associated withan overall dismal prognosis. Contemporary imaging techniques frequently detect the relevant neural invasion. An
aggressive multimodality therapy can prevent neurological deterioration and is associated with a prolonged survival in 30%of the affected patients.

SALVAGE CHEMOTHERAPY WITH TEMOZOLOMIDE IN REFRACTORY OR RELAPSEDPRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Keishi Makino1,Hideo Nakamura1,Takuichiro Hide1,Jun-ichi Kuratsu1
Department of Neurosurgery, Kumamoto University Graduate School, Kumamoto, Japan1

Purposes: High-dose methotrexate (HD-MTX) has been considered as the most effective agent in the initial treatment ofprimary central nervous system lymphoma (PCNSL). However, some patients have refractory lymphoma to initial treatment
and another patients relapse easily. Since treatment options for patients with progressive or recurrent PCNSL are limited,their prognoses are very poor. Temozolomide is well-tolerated oral alkylating agent and easy to permeate the blood brain
barrier. The effectiveness of temozolomide is reported on not only malignant glioma, but also recurrent PCNSL. In thisstudy, we evaluated the results of treatment with temozolomide for the patients with refractory or relapsed PCNSL.
Methods: Immunocompetent patients with refractory or relapsed PCNSL were eligible after the initial treatment with HDMTX (3.5 g/m2) with or without irradiation. All of the patients were treated with temozolomide 150 to 200 mg/m2, for 5 daysin 28 days. This treatment was continued until disease progression. Results: Seventeen patients with a median age of 68
years (ranged from 49 to 88 years) were included in this study. Four patients were used as second line treatment, ten as
third and three as fourth. Five complete remissions (median treatment 12 times; ranged from 4 to 35 times), five partial
response and stable disease and seven progressions were observed. No major toxicities were observed, apart from grade
3 thrombocytopenia in one patient. Conclusions: Although some patients were elderly and had been heavily pre-treated,temozolomide yielded 29% objective responses and was well tolerated without any major toxicity.

- 127 -­­

Oral Presentation (0)O174The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

O175
THE ARGENTINE PEDIATRIC ONCOLOGY REGISTRY AS A TOOL TO EVALUATE THE
SITUATION OF CHILDREN WITH CNS TUMORS IN ARGENTINA.
Florencia Moreno1, Marcelo Scopinaro2, Enrique Schvartzman2, Mercedes Garcia Lombardi3,
Maria Teresa G De Davila2, Daniel Alderete2, Dora Loria4, Blanca Diez5
Argentine Pediatric Oncology Registry - KALEIDOS Foundation. Buenos Aires, Argentina.
Hemato-Oncology Department, Hosp. Prof. Dr. JP Garrahan. Buenos Aires, Argentina
3
Oncology Service. Hosp. Child R. Gutierrez. Buenos Aires, Argentina
4Area Research Institute of Oncology Angel H. Roffo. Buenos Aires, Argentina
5
Program NeuroOncologia FLENI. Buenos Aires, Argentina
12Oral Presentation (0)Objectives
The Argentine Pediatric Oncology Registry - KALEIDOS Foundation (ROHA) has recorded since 2000, cancer cases inchildren less than 15 years of age in Argentina. Our aim is to highlight the usefulness of a population-based cancer registry(with significant participation of hospital-based cancer registries) and its ability to evaluate the situation of children with CNS
tumors at a national level.
Methods
ROHA has developed numerous children's hospital cancer registries. ROHA includes not only cases from hospital cancer
registries (its major source of data) but also from: all-ages population-based regional cancer registries, some cooperative
groups for the treatment of specific tumors, the National Mortality Database, the National Bank of Antineoplastic Drugs andfrom private physicians’ practices. We evaluated the early mortality in meduloblastoma and low-grade glioma as indirect
markers of the care of children with CNS tumors.
Results
Between 2000 and 2006, the average number of cancer cases annually was 8,741 with a crude incidence rate of 128.2 per
million, with estimated coverage of 93%, total CNS tumor cases of 1,634, with a crude incidence rate of 23.7 per million. On
average, 86% of the children were cared for in public institutions. The percentage of children who sought specialized
centers at some stage during treatment, varied according to their province of residence (6% to 100%) and to the tumor
type (49% cases of CNS tumors and 29% of leukemia). For a total of 294 evaluable medulloblastoma cases, 140 are deadand 63 (21.4%) died during the first 6 months following diagnosis. For a total of 136 evaluable low-grade glioma cases, 46
are dead and 21 (15.5%) died during the first 6 months following diagnosis.
After evaluating the situation of cancer patients in the northwestern area of the country, government entities (national andprovincial), with support from non-governmental entities, have developed a collaborative program between the nationalreferral hospital (Hospital Prof. Garrahan, HPG, Buenos Aires) and the pediatric hospital in the Tucumán province, to
optimize oncology services and develop then as a model reference in the region. ROHA has developed, as a tool for thisprogram, a booklet "When to suspect cancer in children”, accompanied by an audio-visual (both published by theFundación Garrahan and of free distribution). In addition, ROHA will participate in a multi-center study on the mortality ofpediatric oncology patients in public hospitals. The origin of this study, (HPG coordinated), was the observation of lower
cancer survival rates in Argentine children, especially those with CNS tumors, compared with that expected frominternational publications.
Conclusions
The preponderance of hospitals as source of data and the population-based coverage, make ROHA particularly valuable.
The diagnostic data from each institution provide useful information to improve hospital activities. The early mortality inmedulloblastoma and low -grade glioma is very high, and is representative of the rest of childhood CNS tumors. We haveobserved: delayed diagnoses; delayed time to surgery and deficits with neuro-surgical experience; difficulties in defining
pathological anatomy in patients and in interdisciplinary communication The analysis of national data has provided tools forthe design of health policies for children with cancer in Argentina. The booklet "When to suspect cancer in children”, will
facilitate improvements in earlier diagnosis and allow the implementation of less intense and expensive treatments. The
study on hospital mortality will support enactment of measures to increase survival. National cancer registries, as
exemplified in Argentina by ROHA, can be of great value if their data can be used to optimize the quality of childhood
cancer patient management.

O176
TREATMENT OF OPERABLE HIGH-GRADE GLIOMA WITH SITIMAGENE CERADENOVEC
GENE THEREAPY AND GANCICLOVIR: RESULTS OF A RANDOMIZED PHASE III TRIAL
Zvi Ram1, Manfred Westphal2, Peter C Warnke3, Philippe Menei4, Seppo Yla-Herttuala5
Department of Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel
Department of Neurosurgery, University Hospital, Hamburg, Germany
3
Dept of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, USA
4
Centre Hospitalo-Universitaire, Angers, France
5
Department of Biotechnology and Molecular Medicine, AI Virtanen Institute, University of Kuopio, Finland
1
2

Background: High-grade glioma (HGG) continues to have a dismal prognosis with limited survival despite multimodal
therapy. This study assesses the impact of the delivery of the HSV-tk gene into the healthy tumour bed of resected HGG
using a serotype 5 adenoviral vector (sitimagene ceradenovec). This gene induces the expression of thymidine kinase, which
phosphorylates the systemically administered ganciclovir to be effective locally against malignant cells. Methods: 250
patients with operable HGG were recruited from 38 centres in Europe and Israel between November 2005 and April 2007.
Patients were randomized to receive standard therapy, with or without sitimagene ceradenovec injections. On Days 5-19
post-operatively, the active group received ganciclovir (5 mg/kg i.v. twice-daily). Adjuvant treatment with temozolomide waspermitted, but not obligatory, depending on local treatment practice. Patients are currently being followed for reinterventionfree survival, overall survival (OS) and MRI progression, as well as standard safety monitoring. The primary outcome measure
is time from surgery until reintervention or death. The principal secondary outcome was time to all-cause mortality - OS.
Results: The study completed in May 2008. Updated final results from the OS outcome will be available in early Q1 2009
and will be presented at the meeting, along with demographics of the study population, efficacy of the therapy (as KaplanMeier survival plots and statistical analyses) and the overall time-based safety profile. Conclusions: Conclusions will bederived from the results to provide an overall risk and benefit assessment of this form of gene therapy in operable HGG.

- 128 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P001
CD133 : STILL A MARKER OF BRAIN TUMOR STEM CELLS?
Xuqun Tang
China

The brain tumor stem cells (BTSCs) hypothesis presumes that BTSCs are responsible for the initiation, progression andrecurrence of several typies of malignant brain tumors, such as glioblastoma multigorme(GBM), medullblastoma(MB). They
can proliferate, self-renew infinitely and differentiate into diverse populations such as neuronal, astrocytic andoligodendroglial cells. Treating the differentiated brain tumor cells will not cure the tumor so the therapeutic strategy should
target on the stem cells.
Till now, the most popular reported and applied cell marker of BTSCs is CD133. Several brain tumor researchers
demonstrate that CD133 positive cells can produce tumors in nude mice that recapitulate the original tumor and possess
the capacities for resistence to chemotherapy and radiotherapy. In our previous studies, we also found CD133 positive cells
have a higher proliferation index when compared to CD133 negative cells. But the CD133 expression can not always be
detected in malignant brain tumors which, on the contrary, include a proportion of cells with significant capacities forneurosphere forming, clonegenecity and tumorgenecity. Here we discuss the relationship between the cell surface antigen
CD133 and BTSCs in GBM, MB and pituitary adenomas. We hope to explore a better approach to study BTSCs in both
CD133 positive and negative brain tumors and finally to make an individual therapeutic strategy that target on BTSCs.
Introduction

P002
CD133 NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE
MARKERS DISPLAY TUMORGENICITY IN VIVOPer Oyvind Enger1
Oncomatrix Research Lab, Institute of Biomedicine, University of Bergen, Norway

1

Lars Prestegarden, Agnete Svendsen, Jian Wang, Lasse Askland, Andreas Persson,
Per Sakariassen, Kai Ove Skaftnesmo, Randi Hovland and Per Oyvind Enger.
Purpose: The cancer stem cell hypothesis implies that intratumor heterogeneity is created by rare cancer stem cells. Thesecells have the capacity to differentiate into various tumor cell types as well as to self renew. In brain tumors, CD133 hasbeen proposed as a marker for cancer stem cells, although this has been challenged by a series of studies demonstratingtumor formation from CD133 negative glioma cells as well. Methods: To further elucidate the heterogeneity seen in
Glioblastoma Multiforme (GBM), we created lineage specific lentiviral reporter constructs that expressed GFP under the
Nestin, glial fibrillary acidic protein (GFAP) or neuron specific enolase (NSE) promoter. The U373 and U87GBM cell lines
were infected with these constructs, and separated with simultaneous removal of CD133 positive cells using fluorescenceactivated cell sorting (FACS). Results: This way, we obtained glioma subpopulations expressing different cell type markers,
and subsequently implanted these cells in NOD-SCID mice. Finally, we repeated the experiments using two primary GBM
biopsies instead of cell lines. In the cell lines, all glioma cell populations gave rise to tumors at similar rates. For the biopsies,
both nestin + and nestin- cells grew tumors, while none of the lineage specific cells (GFAP and NSE) produced tumors.
Conclusions: We conclude that different glioma subpopulations exhibit tumor initiating ability, although glioma cells
expressing mature markers may be relatively less tumorogenic than other glioma cell populations.

NOVEL TECHNIQUE FOR ESTABLISHMENT OF GLIOBLASTOMA STEM CELL LINE AND
PATHOLOGICAL VERIFICATION OF DISTRIBUTION AND DIFFERENTIATION STAGE OF
TUMOR CELLS ON ITS XENOGRAFT.
Koichi Yoshikawa1, Michiyasu Suzuki1,Ian Clarke2, Peter Dirks2
Department of Neurosurgery, Yamaguchi University School of Medicine
Arthur and Sonia Labatt Brain Tumor Research Center, Program in Developmental and Stem Cell Biology,
The Hospital for Sick Children, University of Toronto, Canada

1
2

We successfully apply the monolayer culture method to establish glioma stem cell line from surgical sample (paper insubmission). We present our novel technique for establishment of GBM stem cell line and some particular feature of its
xenografts. Methods We used 3 glioblastoma surgical samples. We cultured cells from each sample on monolayer methods
with EGF/FGF without serum. After conformation every cell lines fulfill the criteria of glioma stem cell, we inject cells into NOD/SCID mouse brain and observed the pattern of invasion and differentiation of tumor cells pathologically on its xenograft.
Results We established 3 GBM stem cell lines from 3 samples successfully. Every lines fulfill the criteria of glioma stem cell.
They express stem cell markers such as Sox2, Nestin and have ability of multilineage differentiation. All lines have tumor
initiating ability in vivo. Although ratio of CD44 expression is almost 100% in all lines, interestingly ratio of CD133 expression
varied as follows; 96.5%, 1.4%, 43.6%. Xenograft have gliobalstoma specific feature such as necrosis/pseudopallisading.
The undifferentiated GFAP(-)Nestin(+) tumor cell showed strong invasive capacity, invaded contralaterally even in the earlystage. Undifferentiated GFAP(-)Nestin(+) tumor cell favored invasion to subventricular zone (stem cell niche). In all xenogarft,
invasive front is formed by undifferentiated GFAP(-)Nestin(+) tumor cell. The higher CD133 expressed line has the stronger
invasive capacity. Lower CD133 line formed somewhat well margined mass. Differentiated GFAP(+) tumor cell remained
injection site and expanded and formed tumor bulk. Conclusions The novel monolayer culture method is useful to establish
glioma stem cell line and provides enough chances to study glioma stem cell from surgical sample. The xenografts of GBM
stem cell lines recaptured the pathological feature of original sample patient. Undifferentiated stem-like tumor cell have strong
invasion ability and formed invasive front of tumor.

- 129 -­­

Poster Presentation (P)P003

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P004
THERAPEUTIC EFFECT OF GENETICALLY ENGINEERED MESENCHYMAL STEM CELLS IN
RAT EXPERIMENTAL LEPTOMENINGEAL GLIOMA MODEL
Chunyu Gu1,2, Shaoyi Li2, Naoki Yokota1, Hiroki Namba1
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, China

1
2

Purpose: Disseminating disease of high grade gliomas is difficult to treat. We examined, in this study, the therapeutic effectof intrathecal administration of mesenchymal stem cells transduced with herpes simplex virus-thymidine kinase gene
(MSCtk) in experimental leptomeningeal glioma model.
Methods: Leptomeningeal glioma model was produced by injecting C6 glioma cells into the cisterna magna in SpragueDawley rats. Mesenchymal stem cells were isolated from 6-week-old rats and MSCtk cells were established using retrovirustransduction system. First, to examine in vivo bystander effect, rats were intrathecally co-injected with a mixture of MSCtk
and C6 cells and then, intraperitoneally administered with gancicloir (GCV) or saline for 10 days (co-injection model). Next,
to examine the therapeutic effect of MSCtk/GCV therapy, MSCtk cells were intrathecally administered one day after C6
injection and then, GCV or saline was administered (treatment model). Tumor volume was measured on day 14 in one
group and survival time was measured in the other group for each model.
Results: GCV administration significantly reduced tumor sizes both in the co-in jection model (0.41 ±0.22 vs 3.10 ±0.97mm2, p p<0.01) and in the treatment model (0.73 ± 0.29 vs 2.84 ± 0.82 mm2 , p p<0.01). Survival was also significantly
prolonged in GCV group both in the co-injection model (29.17 ± 3.27 vs 18.83 ± 0.79 days, p p<0.01) and in the treatment
model (21.50 ± 1.48 vs 17.17 ± 0.48 days, p<0.01).
Conclusions: This study provided a novel treatment strategy for leptomeningeal glioma dissemination using intrathecal
MSCtk injection followed by systemic GCV administration.

P005
CHLOROQUINE SUPPRESSES GLIOMA CELL VIABILITY AND SENSITIZES
RADIORESISTANT STEM-LIKE GLIOMA CELLS TO IONIZING RADIATION AND
CHEMOTHERAPYElla L. Kim1, Walter Schulz-Schaeffer 2, Wolfgang Deppert 3, Agatha A. Pilzak 1,
Christoph Richter 1, Christoph Schmitz-Salue 1 , Margret Rave-Fraenk 4, Veit Rohde 1, Alf Giese 1
Department of Neurosurgery, Georg-August-University of Goettingen, Goettingen, Germany
Department of Neuropathology, Georg-August-University of Goettingen, Goettingen, Germany
3
Department of Tumor Virology, Heinrich-Pette-Institute, Hamburg, Germany
4
Department of Radiotherapy and Radiation Oncology, Georg-August-University of Goettingen, Goettingen, Germany
1
2

Poster Presentation (P)Study purpose
The purpose of this study was to evaluate the effects of chloroquine on glioma cell viability in vitro and in vivo, and to
explore the therapeutic potential of chloroquine as an adjunct to glioma therapy.
Methods
Human glioma cell lines with known p53 status or primary cultures derived from surgical specimens of humanglioblastomas were propagated in the presence of serum or under serum-free conditions as neurospheres. Radioresistantpopulations were selected from neurosphere cultures of glioma stem-like cells by repetitive exposures to clinically relevant
doses of radiation. The tumorigenic potential was evaluated inan orthotopic glioma mouse model. Assessment of cell death
was performed by trypan blue exclusion, by immunofluorescence detection of cells positive for activated caspase-3 or
TUNEL (TdT-mediated dUTP-nick end labeling). The transcriptional activity of p53 was assessed by western blot.
Results
ClQ potently induces death response in glioma cells in vitro and inhibits growth of experimental gliomas in an orthotopic
glioma mouse model. We demonstrate that accumulation of the p53 protein, activation of p53 transcriptional response andinduction of p53-dependent apoptosis are the mechanisms underlying induction of cell death by ClQ in cells with wild typep53. Unlike DNA damage, chloroquine does not induce p53 posttranslational modifications contributing to p53 stabilization
through phosphorylation. In addition to its p53-activating effects, chloroquine is also able to suppress glioma cell growth via
p53-independent mechanisms. We found that chloroquine inhibits growth of glioma cells that express mutant p53, possess
stem-like properties and are capable of establishing highly invasive tumours. Furthermore, chloroquine treatment renders
radioresistant cell populations selected from glioma stem-like cultures susceptible to radiation, and chemotherapy withBCNU or temozolomide.
Conclusions
Chloroquine possesses therapeutic potential and can be envisaged as an adjunct for glioma therapy.

- 130 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P006
Establishment and characterization of an experimental model ofinvasive glioma with highly radioresistant phenotype.
Ella L. Kim1, Christoph Richter1, Agatha A. Pilzak1, Walter Schulz-Schaeffer2, Bastian Gunawan3,
Christoph Schmitz-Salue1, Margret Rave-Fraenk4, Veit Rohde1, Alf Giese1
Department of Neurosurgery, Georg-August-University of Goettingen, Goettingen, Germany
Department of Neuropathology, Georg-August-University of Goettingen, Germany
3
Department of Gastroenteropathology, Georg-August-University of Goettingen, Germany
4
Department of Radiotherapy and Radiation Oncology, Georg-August-University of Goettingen, Germany
1
2

Study purpose
A distinct sub-population of tumorigenic cells exhibiting properties of neural stem cells, generally termed as brain tumour
initiating cells (BTICs), has recently emerged as the major cellular component determining the invasive and radioresistantphenotype of malignant brain tumours. There is an urgent need for experimental models that would recapitulate thehallmark features of human glioblastoma multiforme (GBM) such as histological heterogeneity and a highly invasive,
radioresistant phenotype. The purpose of this study was to develop an invasive orthotopic GBM mouse model using humanglioma cells with defined genetic background and the hallmark features of stem-like BTICs.
Methods
Stem-like BTICs were selected from the human glioma cell line G112 and propagated in the presence of serum or underserum-free conditions as floating neurospheres. Cell viability was assessed by using a neurosphere assay and trypan blue
exclusion. The BTICs stem-like phenotype was assessed in vitro by immunofluorescence staining of cultured cells and invivo by immunohistochemical examinations.
Results
The human glioma cell line G112 shows a stem-like BTIC phenotype under serum-free culture conditions. Genetic analyses
indicate that G112-BTIC derive from a single genotype. The G112-BTIC neurosphere cultures are capable of long-term selfrenewal, show immunoreactivity for neural stem cell markers nestin and CD133 and display a radioresistant phenotype invitro and in vivo. Tumours formed by G112-BTIC cells show an extremely aggressive growth pattern, exhibit the hallmark
features of human GBM and show an impaired radio-response. In contrast, non-BTIC tumours show significant reduction
upon treatment with identical radiation doses.
Conclusion
The G112-BTIC glioma model provides an adequate experimental platform for the testing of potential therapeutic efficacy of
existing treatments and developing new strategies to target radio- and chemoresistant glioma cell populations.

P007
FUNCTIONAL RESULTS AFTER RESECTION OF GLIOMA INVOLVING THE SUPPLEMENTARY
MOTOR AREA
Takeo Uzuka1, Manabu Natsumeda1, Hiroshi Aoki1, Makoto Oishi1, Masafumi Fukuda1,
Akihiko Saito1, Yukihiko Fujii1
Department of Neurosurgery, Brain Research Institute, University of Niigata, Niigata, Japan1- 131 -­­

Poster Presentation (P)[OBJECTIVE] Surgically induced supplementary motor area (SMA) deficiency syndrome has been reported, andreversibility of the SMA deficiency syndrome has been emphasized. In this report, we aimed to confirm functional results
after the resection of gliomas involving the SMA. [METHODS] Twelve patients with gliomas of the SMA treated by surgery
between 2002 and 2007 were studied. The nondominant side was affected in 7 cases and the dominant side in 5. Degreeand duration of postoperative deficits were evaluated and correlated with the extent of tumor resection on the postoperative
magnetic resonance imaging and intraoperative neuromonitoring findings. [RESULTS] Postoperatively, motor deficits were
evident in 11 of 12 patients and speech deficits in 4 of 5. Recovery of motor function began between a few hours and 7
days after the surgery, and significantly improved within 2 months. Five patients in whom the posterior resection margin
was at a distance of less than 0.4mm from the precentral sulcus experienced a persistent drop in skilled motor function.
Two patients who complained of cognitive dysfunction subjectively after the surgery were assessed with WAIS-III, and adiminishing in processing speed was recognized in both patients. [CONCLUSIONS] Preserved muscle tone and recovery
from the distal part of the limbs were characteristic of SMA deficiency syndrome compared with damage to the pyramidal
tract. A good correlation existed between the severity and duration of postoperative motor deficits and the distance of theresection margin from the precentral sulcus. The follow-up of cognitive dysfunction, characterized a diminishing inprocessing speed, is necessary.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P008
THE DIAGNOSTIC IMPACT OF RADICAL RESECTION IN THE MANAGEMENT OF LOW-GRADE
GLIOMA
Yoshiki Arakawa1,2, Yo Kishi1, Mitsuaki Shirahara1, Nobuhiro Mikuni1, Jun A. Takahashi3,
Yasuaki Nakashima2, Nobuo Hashimoto4
Department of Neurosurgery, Kyoto University Graduate School of Medicine
Department of Diagnostic Pathology, Kyoto University Graduate School of Medicine
Department of Neurosurgery, Kitano Hospital 4National Cardiovascular Center

1
2
3

OBJECTIVE: The extent of resection in low-grade glioma (LGG) still remains controversial to be concerned with patient
outcome. A part of LGGs behave progressive growth and malignant transformation, however, there are no diagnostic tool
to distinguish their clinical natures. In this study, we assess the diagnostic role of radical resection in the management of
LGG. METHODS: A series of 40 patients has been diagnosed as LGG, World Health Organization (WHO) grade II, bymodern diagnostic imaging since we introduced awake surgery into LGG resection in 2004. The high intensity area in
FLAIR images was defined as LGG. The tumor was radically resected within the limits avoiding neurological deficits. The
widespread histopathological analyses were performed at the various loci of resected LGGs. RESULTS: 2 patients werediagnosed with stereotactic biopsy because of difficulties of tumor resection. Although the diagnostic images show
characteristic features of LGG, the widespread histopathological studies demonstrated local malignancy in a part of LGGs.
In the series of 40 LGGs, there are 9 diffuse astrocytomas, 10 diffuse astrocytomas with mitosis, 5 anaplastic
astrocytomas, 4 dysembryoplastic neuroepithelial tumors, 5 oligodendrogliomas, 2 oligoastrocytomas, and 1 corticaldysplasia. CONCULSION: The widespread histopathological study with radical resection of LGGs helps us to detect local
malignancy. This finding suggests that extensive surgical resection and widespread histopathological study in large
specimen are recommended to decide the management of LGG.

P009
EXPERIENCE WITH SPECTROSCOPY-SUPPORTED STEREOTACTIC BRAIN BIOPSY
Mikhail Chernov1, Yoshihiro Muragaki2, Taku Ochiai2, Yuko Ono3, Takaomi Taira2,
Hiroshi Iseki4, Osami Kubo2, Tomokatsu Hori2, Kintomo Takakura4
International Research and Educational Institute for Integrated Medical Sciences (IREIIMS); Tokyo Women`s Medical
University, Tokyo, Japan2
Department of Neurosurgery; Tokyo Women`s Medical University, Japan3
Department of Neuroradiology; Tokyo Women`s Medical University, Japan
4
Faculty of Advanced Techno-Surgery; Tokyo Women`s Medical University, Japan
1

Poster Presentation (P)OBJECTIVE Comparative evaluation of the diagnostic efficacy of stereotactic brain biopsy performed with and without
additional use of spectroscopic imaging (SCI) for target selection was done. METHODS From 2002 to 2006, 39 patientswith parenchymal brain lesions underwent frame-based image-guided stereotactic biopsy based on structural
neuroimaging, whereas in 30 others SCI-supported procedures were performed. Comparison of the diagnostic yield of theprocedure in these subgroups was done. Additionally, the diagnostic accuracy was evaluated in 37 lesions, which were
surgically resected within 1 month after initial tissue sampling. RESULTS Definitive histopathological diagnosis wasestablished in 57 cases, diagnosis of low-grade glioma without specific tumor typing in 8 cases, and in 4 cases the biopsy
findings were non-specific. In 5 out of 8 cases with incomplete histopathological diagnosis and in all non-diagnostic cases
target selection was done without use of SCI (P=0.2073). The diagnostic yield of stereotactic biopsy was 90±5% in cases
based on structural neuroimaging compared to 100% in SCI-supported procedures (P=0.1268). Among lesions surgicallyresected thereafter 10 cases of major diagnostic disagreement in histopathological diagnosis were met. The diagnostic
accuracy was 79±9% in cases based on structural neuroimaging compared to 67±11% in SCI-supported procedures(P=0.4756). Conclusion It seems, that use of SCI-detected metabolic information during stereotactic brain biopsy may
increase the diagnostic yield of the procedure, but optimal selection of the metabolic target for improvement of its
diagnostic accuracy remains unclear.

P010
USEFULNESS OF FDG-PET-CT-GUIDED STEREOTACTIC BIOPSY FOR BRAIN TUMORS
Satoshi Horiguchi1, Koichi Mitsuya1, Yoko Nakasu1
Division of Neurosurgery, Shizuoka Cancer Center, Shizuoka, Japan

1

Objectives: PET image is useful for detecting biologically active lesions. Sometimes it is difficult to distinguish neoplasms
from inflammatory changes by MR-guided biopsy. We report the usefulness of FDG-PET-CT-guided stereotactic biopsy.
Materials and Methods: We performed FDG-PET-CT-guided stereotactic biopsy for seven patients (age 47-78 years,
M:F=5:2). Komai-type head ring was applied to patients. CT and FDG-PET images were obtained sequentially after
injection of FDG. A biopsy target was set on a lesion of the highest FDG accumulation using spatial coordinates calculated
from CT scan data. Single biopsy tract was designed not to pass the ventricles and eloquent areas. Results: In two cases,
the targets that we planned on MR images had little FDG accumulation, so we changed the target. All seven biopsies got
histological diagnoses. Small bleeding was observed at the target in two cases on postoperative CT: one had
noSymptoms, the other showed transient hemiparesis. Measurement of radioactivity revealed our specimens equal to thebackground of the operating room. Conclusions: With FDG-PET-CT images, a biological active lesion can be accurately
obtained leading to a correct diagnosis. Careful management of radioactive materials is mandatory with multidisciplinary
cooperation for this method.

- 132 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP011
NEURONAVIGATION AND BRAIN BIOPSY. SURGICAL TECHNIQUE AND COMPARISONWITH TRADITIONAL ESTEREOTAXIC METHOD.
Jesus Merino1, Antonio Belenguer1, Ramon de las Penyas2, Antonio Conde2, Vicente Joanes1
Department of Neurosurgery, General Hospital of Castellon, Castellon de la Plana, Spain
Hospital Provincial of Castellon

1
2

Since the introduction and generalization of Neuronavigation, brain biopys had to be performed with stereotactic
procedures such Leksell frame. Classic technique had inconvenients like having to perform a CT scan the day ofprocedure, placing the frame and carry the patient to make the CT. In the last eigthteen months we have performed brain
biopsys with the Navigus system by Medtronic (optical mode) in thirteen pacients, all of them with intracerebral tumors (lowgrade astrocitoma and glioblastoma).We have analyzed the surgical procedure, problems and results of these surgerys andcompared with the results of the last twenty brain biopsys with Leksell frame.We have concluded that, in our experience,
Neuronavigation provides visual assited guide and accuracy and the possibility of variation of target if desired.

P012
THE ROLE OF DIFFUSION TENSOR IMAGE OF THE TUMOR RESECTION
Chi-tun Tang1, Juming Sun1, Ming-Ying Liu1
The Department of Neurosurgery, National Defense Medical Center, Taipei, Taiwan

1

Introduction Diffusion tensor image plays a role based on the anisotopy of the hydrogen ions in the interesting area; In thecurrent state, the DTI tractography can predict intracranial structure especially corticospinal tract, optic radiation, ...et.al.thepreoperative recognition of the tarctcan avoid iatrogenic damage to the eloguent area. Methods From year 2002-2008, We
applied 15 cases of brain tumors who obtained well-studied data and benefit from the DTI analysis;there were 6
meningiomas with compression on the motor strip; 5 gliomas with presentral gyrus involved; the others were matastatic
tumor feasible for surgical resection.The preoperative tractography were analyzed and incoporated into navigation
system(Brain Lab). Result There is no major motor deficit after the DTI-assisted resection for 24-month follow up except
trasient edema by manipulation on 2 glioma cases; there is one mortality carried out by the underlying lung malignancy
after 5 months. Conclusion The DTI is poved to be the good example of neuroradiology incoporation with clinicalapplication;it provides a exact guidance of surgical margins and avoids hazadous sequalae. Familiarity with the newtechnology and well practice make a promising chapter on neuro-oncology.

P013
USEFULNESS OF FIBER TRACT NAVIGATION IN TUMOR SURGERY ADJACENT TOELOQUENT AREA
Seung Hwan Lee1, Bong Jin Park1, Tae Sung Kim1, Bong Arm Rhee1, Young Jin Lim1
Department of Neurosurgery University of Kyunghee, Seoul, Korea

1- 133 -­­

Poster Presentation (P)PURPOSE: There is a significant risk of neurological deficits after tumor surgery near the eloquent areas. The purpose ofthis study was to minimize the postoperative injuries by means of the magnetic resonance based intraoperative
neuronavigation with fusion of the preoperative diffusion tensor imaging, which was used for tracking of the white matter
fibers, such as the motor cortex, the pyramidal tract and the optic radiation. METHODS: From September 2007 to
December 2008, there were 15 patients who underwent surgery for brain tumor adjacent to the eloquent area. In eachcase, the DTI combined neuronavigation was performed preoperatively. RESULTS: There were 10 female patients and 5
male patient. Their mean age was 43.6 years old. The location of the tumor was adjacent to the motor cortex in 11 patients,
the pyramidal tract in three patients, and the optic radiation area in one patient. The pathologic diagnosis was glioblastoma
in 8 cases, anaplastic astrocytoma in 3 cases, diffuse astrocytoma in 3 cases, and atypical choroid plexus papilloma in one
case. Gross total removal was performed in 10 patients and subtotal resection was done in 5 patients. There were threecases of patients whose hemiparesis aggravated after surgery in which one of them was permanent and the others
recovered within 4 weeks. CONCLUSION: It is considered very safe and useful for the surgery of tumors located near theeloquent area when functional neuronavigation is utilized. However, limitations of the neuronavigation such as brain shifting
during the operation. Moreover, development of imaging techniques for the visualization of surgical field is demanded.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P014
PREOPERATIVE FUNCTIONAL IMAGING AND INTRAOPERATIVE MONITORING FOR
IMPROVING RESECTION RATE OF GLIOMAS AND FUNCTIONAL OUTCOME OF THEIRPATIENTS
Katsushi Taomoto1, Hideyuki Ohnishi1, Yoshihiro Kuga1, Kazuya Nakashima1,
Tsugumichi Ichioka1, Yuuji Kodama1, Hisashi Kubota1, Takashi Tominaga1, Tomofumi Hirose1,
Masato Hayashi1
Department of Neurosurgery, Ohnishi Neurological Center, Akashi, Japan1

Purpose To examine how the preoperative functional imaging of the MRI and intraoperative physiological monitoring
contribute to the improvement of the resection rate of the tumor and postoperative functional outcome in the glioma
surgery. Cases and Methods Resection rate of the glioma and functional outcome of the patients were compared with theearly cases (12 cases) (group A) between 2001-2005.11 with later cases (26 cases) (group B) after December, 2005. We
used MRI, CT, DSA and SPECT as preoperative neuro-radiological images, functional MRI, tractography and SPGR as
functional images, VEP, ABR and ECHO as intraoperative physiological monitoring and 5-ALA, ICG as fluorescent markers.
We compared the functional outcome of group A with group B by neurological symptoms and KPS at discharge. Results
The glioma in eloquent area was 3 cases in Group A (30%), 11 cases in Group B (42.3%). SEP, MEP and Echo were done
as intra-operative monitors in 3 cases of group A, and in15 cases of group B. Grossly total and subtotal removal of thetumor were done in each 3 cases (50%) of group A, while those removal of the tumor were performed in 19 cases (73%) ofgroupB. Histologically, 6 GBMs, 4 AAs and 2 benign gliomas in group A, while 19 GBMs, 5 AAs and 2 benign gliomas ingroup B. Functional outcome at discharge was 3 improved(25%) and 4 deteriorated(33.3%) in group A, while 14 improved(54%) and 6 deteriorated (23%) in group B. Conclusion Our results demonstrated that preoperative evaluation on thetumor characteristics by functional images and intraoperative physiological monitoring as well as fluorescent tumor labelingmade it possible to remove gliomas as much as possible without serious neurological deficit, followed by better functional
outcome.

P015
AWAKE CRANIOTOMY AND ELECTROPHYSIOLOGICAL MAPPING IN A HIGH FIELDINTRA-OPERATIVE MRIIan F. Parney1, Stephen Goerss1, Kiaran McGee1, John Huston1, Frederic B. Meyer1
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, U.S.A.

1

Poster Presentation (P)Objective and importance: Awake craniotomy and electrophysiological mapping (EPM) are established techniques tofacilitate resection in or adjacent to eloquent cortex. Intraoperative MRI (iMRI) is increasingly used to aid resection of
intracranial lesions. Awake craniotomy and EPM with low-field iMRI has been reported but awake craniotomy and EPM
with high-field iMRI has not. Here, we describe a simple technique for awake craniotomy, EPM, and high-field iMRI.
Clinical presentation: A 57 year-old right-handed man presented with new onset generalized seizures and one episode ofspeech arrest. MRI demonstrated a large left temporal intra-axial mass with a small area of contrast enhancement. A
biopsy at an outside hospital showed anaplastic astrocytoma. Technique: The patient underwent an awake, left
frontotemporal craniotomy in the supine position. EPM demonstrated a single critical area for speech in his inferior frontal
gyrus. After an initial anterior temporal lobectomy and tumor debulking, the scalp flap was loosely approximated, theoperative field was covered with a sticky Steri-Drape, and the excess drapes were trimmed. The patient was kept inposition and transferred to an adjacent 1.5 Tesla GE scanner. An intraoperative MRI was obtained. The image-guidancesystem was re-registered and the patient was re-draped. Further resection of residual tumor was performed, allowing an
extensive removal. The patient tolerated this well without any new neurological deficits. Conclusion: Prior protocols for
positioning and draping in high-field iMRI units made awake craniotomies problematic. This technique for combined awake
EMD and iMRI is simple and can facilitate safe removal of large lesions in eloquent cortex.

P016
NEW INTRAOPERATIVE MRI SYSTEM IN BRAIN TUMOR SURGERY
Kaori Sakurada1, Atushi Sato1, Atushi Kuge1, Sunao Takemura1, Daisuke Tsuchiya1,
Takamasa Kayama1
Department of Neurosurgery, Yamagata University Faculty of Medicine

1

Background of Study: Extensive surgical removal will contributes to longer life expectancy for brain tumors. As dynamicchanges occurred during surgical procedures, intraoperative MRI system is important tool for safe and maximum resectionof tumors. In July 2008, new operation room with intraoperative high-field MRI (1.5 T) system, neruonavigation, andfluorescence diagnosis system (Surgical Suite) opened at the Yamagata University Hospital. This new suite is also
compatible for intraoperative angiography. Methods: Preoperatively, the 3T MR studies including morphological study,
multivoxel MR spectroscopy, tractography and functional MRI was performed. If the tumor located in or near eloquent area,
we performed MEP (motor evoked potential) / SEP (sensory evoked potential) monitoring and/or awake surgery using
cortical and subcortical stimulation. Intraoperative MRI is performed after total resection or to up-dated data (to get
information of brain shift) during removal of the deep sheeted tumors. Results: Using this new suite, we treated safely brain
tumors including gliomas, metastatic brain tumors, menigniomas and pituitary adenomas. Intraoperative MR images
contribute to improvement of the tumor resection rate. Conclusion: In this paper, we present our first 10 months ofexperience using this suite, and discuss its advantages and limitations. We also present the relation of the results ofpreoperative chemical shift, intraoperative photodynamic diagnosis and pathological findings.

- 134 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP017
NOVEL SURGICAL TECHNIQUE OF RADICAL REMOVAL FOR GLIOMAS
Kyung Gi Cho1
Department of neurosurgery, Ajou University School of Medicine

1

Despite the improvement in surgical technique, more powerful sources of radiation and development of new
chemotherapeutic agents, the prognosis for patients with malignant gliomas remains very poor. One of the most importantfactors which limits our ability to successfully treat these patients is the diffuse and infiltrative nature of glioma growth.
Although extensive radical resection fails to cure the malignant gliomas, it does both improve the quality of life for thesepatients and increase the duration of survival for selected patients. In my series of 125 patients with malignant gliomas, theextent of surgical excision as judged by postoperative enhancement on MRI was one of the strongest factor for survival.
The median survival with patients with glioblastoma was 36.3months in extensive removal, 15.4 months in subtotal removal
and 12.5months in biopsy group. Many retrospective studies have reported that there is an improvement in both mediansurvival and long-term survival with extensive surgical resection for malignant gliomas. Because the reduction of tumor
mass provides space for postoperative brain swelling, the extensive resection can be less risky than open biopsy or limited
resection. To enable safe and radical resection of malignant gliomas, especially those adjacent to eloquent brain areas, I
used the tiny special markers which were inserted into the tumor margin using navigation systems. And awaken surgery
with intraoperative brain mapping can remove tumor safely and adequately without postoperative cerebral edema andneurological deficits. In summary, Extensive radical surgery is one of the most prognostic factors for the patients withmalignant gliomas. I will discuss the detail surgical techniques.

P018
DISSECTION AND SEPARATION OF HIGH GRADE GLIAL TUMORS FROM BRAIN TISSUE BY
USING METHALIC DISSECTOR WITH THE CAPABILITY OF PRODUCING VIBRATION
Cengiz Cokluk1
Ondokuzmayis University, Medical Faculty, Department of Neurosurgery

1

Purpose: Previously, some different techniques had been presented in terms of precise dissection and separation oftumors from surrounding brain. Purpose of this study was to describe the effect of vibration in the surgical dissection andseparation of malignant brain tumors. Method: We recently developed an instrument for micro-dissection and separationof brain lesions from brain tissue. This instrument was produced in a medical instrument producing factory in Samsun. This
instrument has the capability of producing mechanical vibration. The holding and using of this instrument was described.
Results: In this study, we used this instrument in five high grade glial tumors for dissection and separation of these lesions
from surrounding brain tissue. Dissection and separation were graded as poor, moderate and good. Vibrato-dissection
technique was superior to those of conventional technique in the aspect of dissection and separation of brain tissue.
Conclusion: The capability of dissection and separation with this instrument during surgical treatment of brain tumors may
enhance dissection and separation of lesions. Key Words: Micro-vibration, glial tumors, dissection, separation.

P019

Ondokuzmayis University, Medical Faculty, Department of Neurosurgery

1

Purpose: The primary treatment of malignant glial tumors is surgical intervention for maximally reducing and/or total
removing of tumors. The purpose was to describe pial sinangiosis for diversion of blood brain barrier for enhancing ofsystemic blood-brain tissue penetration and the effect of chemotherapy. Method: We developed a new surgical techniquein the surgical treatment of malignant glial tumors for enhancing of systemic blood-brain tissue penetration. Preoperativeand postoperative magnetic resonance images were obtained to evaluate peri-lesional edema and complications. Results:
This technique was used in three cases of malignant glial tumors. There were no operative mortality and morbidity related
to this technique. Conclusion: This technique may be used in the surgical treatment of malignant glial tumors to enhance
penetration of chemotherapeutic agents into the brain tissue. Key Words: Pial synangiosis, malignant glial tumors, surgicaltreatment.

- 135 -­­

Poster Presentation (P)THE OPERATION OF PIAL SYNANGIOSIS IN THE SURGICAL TREATMENT OF MALIGNANT
GLIAL TUMORS
Cengiz Cokluk1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P020
THE CLINICAL RESULTS OF FIVE CASES OF INSULAR TUMOR RESECTION
Chun Kee Chung1, Chi Heon Kim1
Department of Neurosurgery, Seoul National University, Seoul, Korea

1

PURPOSE: Because of its complex and critical neurological function, the insular lobe has been considered to be difficult toapproach. However, insular glioma could be controlled and complication could be prevented with exact anatomical
knowledge. The purpose of this study is to introduce our clinical results of five cases of insular tumor and to present
anatomical consideration. MATERIALS AND METHODS: Five patients who had intraaxial tumors in insular lobe wereselected. Three were men and two were female. Chief complaint was seizure and there was no neurologic deficit. Tumor
located entirely in insular lobe in 2, with frontal extension in 1, with temporal extension without medial temporal invasion in 1
and with medial temporal invasion in 1. Follow up period was 15 months. RESULTS: Tumor resection was performed underG/A in four patients and there was one awake anesthesia case. Subtotal resection was possible in four and tumor waspartially removed in one. Four cases were WHO Grade III or IV glioma and one was WHO grade II glioma. None had
postoperative neurological deficit. There was no progression of tumor during follow up period. Seizure was disappeared in
3 and worthwhile improved in 2. CONCLUSIONS: Both tumor control and seizure control are possible with detailed
understandings of anatomy and dissection plane. Insular glioma is no more difficult tumor, if surgeon follows anatomical
caution.

P021
KEYHOLE SURGERY IN THE TREATMENT OF GLIOMAS
Toshihiko Iuchi1, Tsukasa Sakaida1, Seiichiro Hirono1
Division of Neurological Surgery, Chiba Cancer Center, Chiba, Japan

1

Backgrounds: Recent innovation of diagnostic and therapeutic modalities such as tractography and neuronavigation
system (NNS) have contributed the progression in glioma surgery, and sufficient resection of tumor has been achieved.
Therefore, we initiated keyhole surgery as less invasive treatment of gliomas in 2005. The aim of this analysis is to evaluate
the clinical significance of this treatment. Methods: Under the guide of NNS, the outlines of the tumor and risk organs werevisualized in the microscope through scalp before surgery, and the minimum craniotomy area, 3 to 5 cm in majority ofcases, was designed on the scalp. These small craniotomies required only linear scalp incision. 103 gliomas were resectedwith this method (Group K). The surgical results were compared with 36 gliomas removed by standard navigation surgery(Group S). Tractography was evaluated before surgery and SEP/MEP was performed if necessary in both of the groups.
Results: The median extent of resection was 95.2% in Group S and 98.0% in Group K (p=0.212). Among the independent
pts, 3% (2/67) deteriorated function and became dependent after surgery in Group K, while 14% (3/22) in Group S(p=0.095). In the dependent pts, 32%(12/38) improved function and became independent after surgery in Group K, while
21% (3/14) in Group S (p=0.731). Indeed the statistical significance was not proved, the overall survival time of glioblastoma
in Group K (median: 37months) was superior to that in Group S (median: 13 months, p=0.153). On the other hand, boththe operation time (median: 215 min. Group K and 265 min. in Group S) and hospitalized period (12 days in Group K and 24days in Group S) were significantly decreased by our keyhole manner (p=0.022 and 0.005). Conclusions: Keyhole surgery
was time-effective and less invasive for brain and scalp, while keeping the sufficient extent of resection.

Poster Presentation (P)

P022
SIGNIFICANCE OF PORPHYRINS IN BLOOD AND URINE OF BRAIN TUMOR PATIENTSTHAT UNDERWENT 5-ALA ADMINISTRATION
Satoshi Utsuki1, Hidehiro Oka1, Sachio Suzuki1, Sumito Sato1, Ikki Mabuchi1, Chihiro Kijima1,
Kiyotaka Fujii1
Department of Neurosurgery, Kitasato University, School of Medicine, Kanagawa, Japan

1

Protoporphyrin IX is known to accumulate in tumors when 5-ALA is administered to brain tumor patients followed by thetumor resection using protoporphyrin IX fluorescence. However, there is no report on measured blood and urinary
porphyrins during 5-ALA administration in humans. This study reviewed the significance of such measurement.Fifteen
brain tumor patients and 8 adult volunteers were given 5-ALA orally. Blood and urinary porphyrins were measured before
and at 4 hr after 5-ALA was administered. Urinary levels of coproporphyrin and blood levels of uroporphyrin weresignificantly high in the brain tumor patients compared with the volunteers.A high urinary coproporphyrin level or blood
uroporphyrin level after 5-ALA administration suggests the possibility that urine coproporphyrin level or blood uroporphyrinlevel could become a tumor marker. These high levels indicated 5-ALA hypermetabolism of the lesions in the patients.

- 136 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP023
ELECTROLOADED DENDRITIC CELLS WITH WHOLE TUMOR LYSATE ELICIT ENHANCEDINDUCTION OF TUMOR-SPECIFIC IFNγ PRODUCING CELLS IN PATIENTS WITHGLIOBLASTOMA
Shusuke Moriuchi1, Masashi Takahara2, Mie Nieda2, Kiyoshi Yokokawa3, Yonehiro Kanemura1,4
Department of Neurosurgery, National Hospital Organization Osaka National Hospital, Osaka, Japan
Medinet Medical Institute, Tokyo, Japan
Medinet Co, Ltd., Tokyo, Japan
4
Department of Regenerative Medicine, Institute for Clinical Research, Osaka National Hospital, National Hospital
Organization, Japan1
2
3

We demonstrate in vitro using peripheral blood (PB) and tumor lysates derived from patients with glioblastoma that tumor
lysate-loaded dendritic cells (DCs) by electroporation (Lysate-EP DCs) can elicit better induction of IFN g producing cells,
which may be associated with anti-tumor immunity than tumor lysate co-cultured DCs (Lysate-Coculture DCs). Further thishigher induction of IFN g producing cells by Lysate-EP DCs could be enhanced by co-incubations of Lysate-EP DCs withZoledronate. The number of IFN g-producing cells in lymphocytes following stimulation with autologous Lysate-EP DCs
determined by ELISPOT assay significantly increased in the all patients so far tested in comparison with using LysateCoculute DCs. This enhancing effect of Zoledronate was observed also in all the patients, in which expansion of N g δ Tcells may be partly contributed to the enhancement of IFN g producing cells. Tumors expressing higher HLA class I
molecules seemed to be associated with higher induction of IFN g producing cells, in which HLA class I-restricted CD8+
CTLs might be major components. These data suggest that Lysate-EP DCs may be extensively useful to induce more
effective immune responses in immunotherapy, including DC therapy.

P024
Cytotoxic T lymphocytes induction with HLA-A2402-restricted glioma
specific peptides
Hidemitsu Sato1, Hiroyuki Sasaki2, Hiroaki Ichikawa2, Daisuke Ishiwata2, Masahiro Yoshinari2,
Akimune Hayashi1, Mutsuhiko Minami2
Department of Neurosurgery, Kanagawa Cancer Center, Yokohama, Japan
Department of Immunology, Yokohama City University,Yokohama, Japan

1
2

P025
Characterization of a novel tumor-associated antigen for targeted
toxin therapy in gliomas.
Oscar Persson1, Johan Fransson2, Bengt Widegren1,3, Carl AK Borrebaeck 2, Bo Holmqvist 4,
Leif G Salford1
Deptartment of Neurosurgery and The Rausing Laboratory, Lund University, Lund, Sweden
Deptartment of Immunotechnology, Lund University, Lund, Sweden
3
Division of Tumor Immunology, Lund University, Lund, Sweden
4
Deptartment Oncology and LBIC optical unit, Lund University, Lund, Sweden
1
2

Therapies targeting specific tumor-associated antigen have shown promising initial results in the treatment of glioma
patients. A desirable target antigen should be unique for tumor cells, abundantly expressed and readily available for
antibody binding. One of the main obstacles is the identification and characterization of such specific targets, especiallysince most antigens in gliomas exhibit quantitative rather than qualitative alterations. The genetic heterogeneity and large
capacity for immune escape in gliomas also makes identification of several distinct targets an important task for the
successful development of targeted therapies. We describe the identification and characterization of the Ku70/80 protein
complex as a novel target in gliomas. The Ku70/80 protein has previously been reported to be abundantly expressed in thecell nuclei of normal cells, but localize to the plasma membrane specifically in some transformed cell types. We show thatthe antigen localizes to the cell surface of glioma tumor cells, and that it is prominently expressed in human glioma tissue,
while no expression could be found in normal human brain tissue. We further demonstrate that upon antibody binding theantigen-antibody complex undergoes endosomal internalization, and that this internalization can be efficiently used fordelivery of toxins in cultured glioma cells. These results pinpoints Ku70/80 as one important novel glioma-associatedantigen for antibody based therapy.

- 137 -­­

Poster Presentation (P)[Purpose] Glioma is a malignant brain tumor with poor prognosis. Recently, basic and clinical study showed that
immunotherapy using cytotoxic T lymphocytes (CTLs) against tumors is expected to be effective for the treatment.
Successful immunotherapy against tumors needs identification of HLA-restricted tumor-specific antigenic peptide.
Unfortunately, a few glioma-specific antigenic peptides bound to HLA-A2402, major haplotype in Japanese population,
have been identified. Therefore, we searched glioma specific antigen-derived and HLA-A2402-restricted peptides which are
effective for induction of tumor-specific CTLs. [Methods] We analyzed HLA-A2402-restricted glioma specific peptides
using the combination of two computer algorithms. CD8+ T cells and DCs were prepared from HLA-A2402 positive PBMCs
from healthy donors. Glioma antigenic peptide-specific CTLs were induced by culturing CD8 T cells with DCs pulsed withthese four peptides. Effective tumor antigenic peptides were screened for their ability of CTLs by 51Cr release assay andintracellular IFN--&gamma staining. [Results and Discussion] We selected glioma antigenic peptides, which showed highaffinity to HLA-A2402 molecules. CTLs induced by the stimulation with DCs pulsed with both peptides showed strong
cytotoxicity against tumor cell lines and also produced IFN-&gamma. Additionally, the peptides specific CTLs killed glioma
cell line, YKG1 (an HLA-A2402 positive glioma cell line) . Therefore, these peptides could be ideal candidates for DCs- or
CTLs- based immunotherapy against glioma.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P026
Tumoricidal bystander effect-mediated suicide gene therapy of glioma using
genetically engineered bone marrow-derived mesenchymal stem cells
Shinji Amano1, Hiroki Namba1
Department of Neurosurgery, Hamamatsu University school od Medicine, Shizuoka, Japan1

In our previous study, we successful treated an established C6 brain tumor using neural stem cells transduced with theherpes simplex virus-thymidine kinase gene (HSVtk) and ganciclovir in the rat. In the present study, we investigated the useof mesenchymal stem cells transducerd with HSVtk (MSCtk) instead of neural stem cells because mesenchymal stem cells
are much easier to obtain from the adult subjects. In vitro co-culture experiment revealed a sufficient bystander tumoricidal
effect between MSC and tumor cells and only 1/32 MSCtk cells were needed for complete tumor eradication. In vitro
bystander effect was also observed in a real-time fashion using a culture microscope and it was shown that only tumor cells
that had contact with MSCtk cells died. In vivo treatment of an established C6 brain tumor with an intratumoral injection of
MSCtk cells followed by systemic ganciclovir administration resulted in a significant reduction of the tumor size and asignificant survival prolongation. The treatment strategy using MSCtk and ganciclovir ("MSCtk therapy") is more feasible forclinical application that the method using neural stem cells.

P027
An efficient targeted gene therapy using brain tumor-specific promoter
Toshio Yawata1, Eri Ishida1, Yu Kawanishi1, Masakazu Tamura1, Keiji Shimizu1
Department of Neurosurgery, Kochi Medical School, Nankoku, Japan

1

Despite many efforts to develop effective therapy, the outcome of malignant glioma remains poor. Gene therapy for thisdisease using retroviral vector is attractive, because the virus can infect only mitotic cells. Previously, we reported theeradication of mouse glioma by retroviral-mediated gene therapy. In this study, a tumor-specific targeting system wasstudied to develop the effective and safe gene therapy. We searched for genes expressing at high frequency in brain
tumors but not in normal human astrocyte (NHA) among cancer testis antigen (CTA) genes. MAGEA3 and brain tumorspecific gene 2 (BTSG2) were identified as tumor-specific genes. The promoter of both genes was cloned into luciferase
reporter vector and the activity was measured in glioma, telomerase-immortalized fibroblast and normal human astrocyte
cells. The BTSG2 promoter but not MAGEA3 showed the tumor-specific activity. The minimal promoter of BTSG2 were
defined as a 256 bp fragment upstream of transcriptional start site. In order to define a useful tumor-specific promoter fortargeting in context of retroviral-mediated gene therapy, the BTSG2 promoter were used to restrict the expression of suicide
gene HSVtk in retroviral vector. The glioma cell lines transduced with the retroviral vector were killed efficiently by addition of
ganciclovir (GCV), but telomerase-immortalized fibroblast BJ-5ta cells were not. Mouse glioma RSV-M cells transducedwith the retroviral vector were transplanted into S.C. of syngeneic mouse. The administration of GCV suppressed the tumor
growth completely. These results suggest that the promoter of BTSG2 is useful for tumor-specific gene therapy, andpromising the safe and effective retroviral-mediated gene therapy.

P028
Poster Presentation (P)LONG-TERM OUTCOME OF 23 CONSECUTIVE CHILDREN WITH PRIMARY INTRADURALSPINAL TUMORS TREATED AT THE MEDICAL UNIVERSITY OF VIENNA (1997-2008)
Thomas Czech1, Andreas Peyrl2, Amedeo Azizi2, Christine Haberler3, Karin Dieckmann4,Daniela Prayer 5, Irene Slavc 2
Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
Department of Pediatrics, Medical University of Vienna, Vienna, Austria
3Institute of Neurology, Medical University of Vienna, Vienna, Austria
4
Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
5Department of Radiology, Medical University of Vienna, Vienna, Austria
12

Primary intradural spinal tumors are rare in childhood and there is little information on therapy and outcome in this location.
We report on the histology, management and outcome of 23 consecutive patient with intradural spinal tumors treated at our
institution over the past 11 years.
Patients: From 1997 to 2008, 23 patients (10 m, 13 f) aged between 2 and 17 years (median 10) were treated for intradural
spinal tumors. 18/23 tumors were intramedullary (gangliocytoma, n=2, pilocytic astrocytoma, n=5, diffuse astrocytoma
WHO grade II, n=1, anaplastic astrocytoma WHO grade III, n=2, glioblastoma WHO grade IV, n=1, ependymoma WHO
grade II, n=5, atypical teratoid rhabdoid tumor, n=2) and 5 were extramedullary (myxopapillary ependymoma, n=2,
neurofibroma, n=3). Total or subtotal resection was performed in 16 patients, partial resection in three and biopsy only infour. Surgery was the only treatment in 14 patients. The three patients with high-grade gliomas received chemo-andradiotherapy as did the patient with progressive diffuse glioma. Two patients with ependymoma WHO grade II, who were
irradiated postoperatively received additional radio- and chemotherapy for secondary metastases. One patient withmyxopapillary ependymoma was irradiated for secondary leptomeningeal dissemination. The two patients with atypicalteratoid rhabdoid tumor received chemo- and radiotherapy.
Results: In January 2009, 20/23 patients are alive with a median survival time of 5.5 years (range 8 months to 11 years).
The two patients with atypical teratoid rhabdoid tumor and the patient with glioblastoma died of their disease. In all patients
preexisting neurological deficits improved after treatment and no permanent postoperative worsening occurred in any of thepatients.
Conclusion: Surgery only may suffice for ependymoma and low-grade glioma when gross total removal is confirmed by
immediate postoperative MRI and long-term survival may be achieved with combined chemo-radiotherapy in patients with
disseminated ependymoma and nonpilocytic astrocytoma.

- 138 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P029
Effectiveness of multi-staged operations with combined chemotherapies
for huge malignant infantile brain tumors in the first year of life
Naoki Kagawa1, Naoya Hashimoto1, Yasuyoshi Chiba1, Manabu Kinoshita1, Yoshiko Okita1,
Fukuko Yamamoto1, Noriyuki Kijima1, Mami Yamasaki2, Toshiki Yoshimine1
Department of Neurosurgery, Osaka Univeristy Graduate School of Medicine, Osaka, Japan
Department of Neurosurgery, Osaka National Hospital, Osaka, Japan

1
2

Purposes: Infantile brain tumors are extremely rare and mostly malignant, and difficult to be treated because they arealmost huge and easy to bleed. We performed multi-staged operations with combined chemotherapies for malignant infantcases which were massive and hypervascular. We estimated effectiveness and limitation of this procedure. Materials andMethods: Out of pediatric cases treated in the past seven years at our related institutions, six cases with infantile brain
tumors in the first year of life were picked up. Out of six, three cases were neonate cases. All cases showed hydrocephalus
and symptom of increased intracranial pressure. In five cases, intraventricular hemorrhages or intratumoral hemorrhages
were observed at the first examination. All tumors were huge, irregular and heterogeneous on MRI imaging. Results: We atfirst performed biopsy intentionally for histopathological diagnosis. Histopathological diagnosis included three central
PNETs, one immature teratoma, and one choroid plexus carcinoma, one desmoplastic infantile astrocytoma. After biopsies,
following adjuvant chemotherapies were done in four cases. In all, Volume of tumors were reduced, and decrease in MIB-1
index and intratumoral vessels were seen as histopathological changes after chemotherapies. During chemotherapies,
multi-staged removals were performed. Two cases needed removal at two times. In huge immature teratomas, operationfrom two directional approach were needed. Intraoperative blood loss was less and hemostasis was safer than the first
operation. In all cases, gross total removal or complete remission (CR) was obtained. After CR, postoperative adjuvant
chemotherapies were added without radiation therapy. Treatment for hydrocephalus was done in five. As complication, Onemeningitis and a subdural abscess was seen. Two malignant cases suffered from relapse at brain stem, additional
chemotherapy and radiation was needed. Conclusion: Multi-staged operations with combined chemotherapies formalignant infantile brain tumors is safer and more effective especially in huge and hypervascular cases.

P030
WHICH THERAPY WORKS BETTER IN METASTATIC CHOROID PLEXUS CARCINOMAS?
Su G Berrak 1, Brigitte Wrede 2, Diane Liu 3, Jonathan Finlay 4, Johannes E Wolff 2,5Pediatric Hematology-Oncology, Marmara University Medical Center, Altunizade, Istanbul, Turkey
Pediatric Oncology, St. Hedwig Hospital, University of Regensburg, Germany
Biostatistics, MD Anderson Cancer Center, USA
4
Pediatric Hematology-Oncology, Children’s Hospital Los Angeles, USA 5Pediatrics, MD Anderson Cancer Center,
USA
1
2
3

P031
99 Tc Sestamibi scan differentiates tumor from other contrast
enhancing tissue in choroid plexus tumors - Case report and Revi+ew of
Literature
Vivek Subbiah1, Rudolfo Nunez1, Leena Ketonen1, Rachael Bingham1, Johannes Wolff1
University of Texas MD Anderson Cancer Center
Background: Choroid plexus tumors (CPT) are rare brain tumors which account for 0.4-0.6 % among brain tumors. Tumor
resection is known to be of large prognostic impact, and re-resection of residual tumors is a part of standard care.
However, after multiple resections it can become difficult to differentiate what is tumor, what is reactive tissue. 99 m TC
Sestamibi scans show normal choroid plexus tissue, and may assist in differentiating neoplastic (sestamibi +) from nonneoplastic tissue (sestamibi -). Case Report: 6 month old girl presented with signs of poor feeding, weight loss andexcessive crying. MRI showed a left parietal mass. Gross total resection revealed atypical choroid plexus papilloma (WHOII). The tumor recurred and she was enrolled into CPT SIOP 2000 protocol, re-resected, treated with chemotherapy, proton
beam radiation, further chemotherapy, re-resected again, and finally completed the treatment protocol. On MRI, thelocation of the primary tumor still contained contrast enhancing tissue. Various imaging techniques were attempted to solve
the problem but never completely resolved it. On Sestamibi scans normal choroid plexus enhanced on the right, and noenhancement on the left choroid plexus suggesting no active CPP but post-operative and post-RT reactive tissue. We
decided against further resection. Further follow up showed the patient asymptomatic, on MRI the contrast enhancing
tissue shrinking and the sestamibi scan remained negative. Conclusions: Previous literature showed sestamibi to be
helpful detecting residual choroid plexus tumors resulting in further resection (Med Pediatr Oncol 36:323-5, J Nucl Med
43:1438-43) this is the first reported case to show that sestamibi scans can also help with the opposite decision.
Sestamibi-scans should be included in the decision process for choroid plexus tumor treatments.
1- 139 -­­

Poster Presentation (P)Background: Metastatic choroid plexus carcinomas (CPCs) have a dismal prognosis. Besides, the role of surgery is notaddressed yet. Material and Methods: The database registering all cases of CPTs recorded in the National Library ofMedicine (PubMed) until 2008 March was created using the method previously described. Results: Of 906 documented
CPTs patients, 361 were choroid plexus carcinoma (CPCs). There were 46/361patients that were found to be metastatic at
diagnosis. In order to find the best therapeutic option in metastatic CPCs, patients that had surgery for certain, and thosethat did not have it for certain are compared using Kaplan Meier curves and log rank test. Patients with gross total resection
after surgery were found to have a significantly better Kaplan Meier curves and log rank tests (p=0.021). However, an effectof radiotherapy or chemotherapy on survival could not be demonstrated using Kaplan Meier curves and log rank test
(p&lt0.05). With a further Cox regression analysis, we have demonstrated that gross total resection has a positive effect ofon metastatic CPCs, regardless of other prognostic factors namely, the patients age, sex, location of the tumor or if thepatients’ were given or not given radiation or chemotherapy. Discussion: This literature database analysis confirms thatmaximal efforts to resect even metastatic CPCs are well supported.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P032
Adjuvant chemoradiation for mixed germ cell tumors
Yuji Uematsu1, Junya Fukai2, Ryuji Okita2, Yoshihiro Owai2, Kohji Fujita2, Yoshiyuki Tanaka2,
Tohru Itakura2
School of Health and Nursing Science, Wakayama Medical University, Wakayama, Japan
Department of Neurological Surgery, School of Medicine, Wakayama Medical University, Japan

1
2

Purpose: The aim is to demonstrate the efficacy of adjuvant chemoradiation for mixed germ cell tumors and the histology
after this particular treatment.Methods & Results: There were six cases. Main regimens of chemotherapy (chemo.) was
CBDCA and VP-16(CARE) or CARE and IFM. Histologically, they were examined by H&E and immunohistochemistry for
AFP, β-hCG, p53, p21, and MIB-1. Case 1: 9 years-old girl presenting a HCG and AFP producing pineal tumor. After GKs
and chemo., complete remission was achieved. However, she died 2 years later due to repeated recurrence. The autopsy
revealed the histology of choriocarcinoma(Ch) and embryonal carcinoma(Ec). Case 2: 22 years-old man presenting an
AFP producing pineal and thalamic tumor. The histology of the surgery was germinoma(G) with york sac tumor(Ys). During
the chemoradiation, he was complicated by sepsis, and then died. The autopsy revealed no tumor cells. Case 3: 17 yearsold man presenting an AFP producing tumor on the left basal ganglia. Although chemoradiation(8Gy) was tried, hedeteriorated resulting in an emergent removal. The histology was Ys showing pleomorphism and huge necrosis. Case 4: 44
years-old man presenting a pineal immature teratoma(T) with G. After chemoradiation, the histology on the salvage surgery
was mature T. Thereafter, he died 2 years later due to spinal metastasis. Case 5: 7 years-old girl presenting an AFP and
HCG producing suprasellar tumor. After chemoradiation, the histology on the salvage surgery was partly immature T. Case
6: 8 years-old girl presenting an AFP and HCG producing suprasellar tumor. Although 2 courses of chemotherapy weretried, her hydrocephalus was deteriorated resulting in a removal. The histology was partly immature T. Conclusion: The
results suggest that the efficacy of adjuvant chemoradiation for mixed germ cell tumors was better in G and Ys than in Ec,
Ch, and immature T.

P033
OVER A 10-YEAR SURVIVAL AND COMPLETE RESPONSE OF A PATIENT WITH DIFFUSE
INTRINSIC BRAINSTEM GLIOMA (DBSG) TREATED WITH ANTINEOPLASTONS (ANP)
Robert A. Weaver1, Barbara Szymkowski1, Stanislaw R. Burzynski1
Burzynski Clinic

1

Poster Presentation (P)Our purpose is to report a case of a long-term complete response (CR) in a DBSG treated at our center and to discuss thefactors contributing to the success. The patient received intravenous injections of ANP every 4 hours through a subclavian
central venous catheter via a double channel infusion pump followed by PO ANP only. Response was assessed bygadolinium-enhanced MRIs of the brain. The patient is currently a 101/2 year-old Caucasian female who, as a 6-week-old
infant, was diagnosed with a DBSG on August 12, 1998. The tumor was inoperable and the pediatric oncology service feltthat chemotherapy as well as radiation therapy would not be an option considering the potential toxicity and the age of thepatient. On October 14, 1998, she began IV ANP under the FDA’s special exception to phase II protocol BC-BT-11, wasconverted to PO ANP on June 8, 2000 and permanently discontinued ANP on July 8, 2004. She achieved CR in late
February 1999 after discontinuation of dexamethasone and MRI of the brain showed resolution of the enhancing tumor.
She developed only one episode of grade 3 vomiting which resolved within 3 days. Her most recent MRI of the brain on
April 2, 2008, did not show any sign of recurrence. In November 2008, her father stated that clinically she was doing very
well. ANP is a multi-gene-targeted therapy that is well tolerated with minimal and reversible adverse events and has
multiple different mechanisms of action by affecting the AKT, RAS, TP53, p21 and PTEN pathways. This patient with DSBG
achieved CR and over a 10-year survival after treatment with ANP. These promising results have already been confirmed ina larger group of children in phase II studies.

P034
Improved response of pontine glioma with simultaneousradiochemotherapy: results of a retrospective image analysis
Liunan Li1, Peggy Nagel1, Leena Ketonen2, Anita Mahajan3, Johannes Wolff1
Department of Pediatrics, The University of Texas M. D. Anderson Cancer Center
Department of Radiology, The University of Texas M. D. Anderson Cancer Center3
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center
1
2

Background: Magnetic resonance imaging (MRI) is the standard method of diagnosis for diffuse intrinsic pontine glioma(DIPG). Conventional fractionated radiation improves survival time of these patients; the benefit of adding of chemotherapy
is frequently debated.
Methods: We conducted a retrospective analysis of DIPG from 2001-2008. The mediolateral diameter of the pons wasmeasured horizontal in T2/Flair axial images. We calculated the differences of the pontine diameters before and afterconventional fractionated radiation, and then compared the changes between patients with and without simultaneous
chemotherapy. The hypothesis that the addition of chemotherapy improved tumor shrinkage was tested and p<0.05 (ttests) was considered statistically significant.
Results: From 2001 to 2008, 20 patients (10 males, 10 females), age 7.7 years (± 3.7 SD) with pontine gliomas wereavailable. The mean time interval between the images was 70.2 ± 16.4 days. The average change of pontine diameter was
5.9 ± 4.9 mm (n = 20) for all patients. The shrinkage was larger when radiation was given with chemotherapy (8.3 ± 4.4mm, n = 12) as compared to without chemotherapy (2.4 ± 3.4 mm, n = 8). This difference was statistically significant(p=0.0028).
Discussion: Tumor shrinkage was more prominent with chemotherapy. This might translate into improved quality of life,
while overall survival improvement might depend on the velocity of the still inevitable tumor recurrence.
Conclusion: This provides evidence that irradiation with simultaneous chemotherapy resulted in tumor shrinkage
advantages.

- 140 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P035
Tactics For Diagnosis and Surgical Treatment of Brain Stem Tumors
Qianxue Chen1
1Dept of Neurosurgery, Renmin Hospital of Wuhan University, China
Objective To explore the diagnosis and microsurgery indication,approaches and curative effective of brain stem tumor.
Methods The cases of 32 patients with brain stem tumor were retrospectively reviewed, during 2002.1 to 2007.12. Results
All patients were underwent microsurgrical treatment, attenuation of craninal nerves was obviously improved in 22 cases,
no change in 7 cases, deterioration in 2 cases, respiration and circulation dysfunction in 1 case. Conclusion Preoperation
MRI examination is the frist choice. The correct choice of microsurgery indications and approaches, precise operation,
active precaution, management of postoperative complications are the key points to increase the curative effect.

P036
Profile of Patients with Medulloblastoma at the Philippine General
Hospital: a Six-Year Review
Jessie T. Colacion1, Roland Dominic G. Jamora1, Mayvelyn D. Gose1
Department of Neurosciences, University of the Philippines Manila, Manila, Philippines

1

Background: Medulloblastoma is a primitive neuroectodermal tumor of the posterior fossa, and the most common
malignant brain tumor in childhood. Local data on medulloblastoma are limited to epidemiologic studies of primary pediatricintracranial tumors. Objectives: To determine the local incidence of histologically confirmed medulloblastoma at thePhilippine General Hospital (PGH), and to review the demographic, clinical features and patient outcome on discharge.
Material and Methods: The incidence of medulloblastoma between 2000 and 2005 was determined from the databaseof the neurosurgical and surgical pathology sections of the PGH. Clinical charts of patients were reviewed, anddemographic, and clinical features and outcome on discharge of the patients were summarized in a unified database.
Results: In this 6-year review, the prevalence of medulloblastoma is 4.85% (n= 62) of the total 1,279 primary CNS
malignancy seen. Of these, 90.32% were children, and 9.68% were adults. The mean age at diagnosis was 9.82 (SD 8.06)
years (median of 8 years). The male-female ratio was 1.21:1. The most frequent presenting clinical manifestations were
headache and papilledema. The mean symptom duration prior to diagnosis was 3.39 months (median of 2 months).
Majority of the tumors were midline (77.42%). Hydrocephalus was seen in 87.10% of patients, majority (92.59%) of which
underwent CSF diversion. Total and subtotal resection was done in 51.61% and 48.39% of the patients, respectively.
Seizure, CNS infection, and hemorrhage were the most common postoperative complications. Twenty-four (77.42%) of thepatients were alive on discharge. Conclusion: This study determined the local prevalence of medulloblastoma at the PGH.
A great majority of which were children, with slight male predominance. The most common clinical manifestations were
headache and papilledema. Most patients had midline tumors and developed hydrocephalus. Total and subtotal
resections were done with a 77.42% survival rate on discharge.

P037
Department of Neurosurgery, Gifu University Graduate School of medicine, Gifu, Japan

1

Objective : The result of treatment for medulloblastoma is improving by the novel therapy. We evaluated the curative effects
for the medullobalastoma patients with three different protocols in Gifu University. Materials : Between 1976 and 2008, 16
medulloblastoma patients (8 boys and 8 girls ) with median age of 8.5 years ( range 4-16 years ) received initial treatment
with surgery followed by chemotherapy and craniospinal radiotherapy in our institute. The early 7 cases (group A) were
underwent chemotherapy with nimustine (ACNU) and vincristine (VCR) and the total 39 Gy of fractionated external beam
radiation therapy (EBRT) to the posterior fossa with craniospinal radiation. The middle 7 cases (group B ) were with cisplatin(CDDP) and etoposide (VP-16) and total 52-56Gy of EBRT to the posterior fossa with craniospinal radiation. The recent 2
cases (group C) were not high risk group, treated with cyclophosphamide (CPM), VP-16 and carboplatin (CBDCA) and total
50Gy of EBRT to the posterior fossa with craniospinal radiation. Results : Median progression-free survival (PFS) was 36
months and median overall survival (OS) was 81 months. 5- and 10-year OS rate was 71 and 50%. The significant
difference was not recognized between group A and group B in PFS (p=0.903 ) and OS (p=0.893). All patients, who
passed from a first operation in 81 months, were alive. There were 3 patients with the long-term survival for more than 25
years. Conclusion : The treatment results for the medulloblastoma are improved, and some patients were considered to be
cured during a long-term follow-up. In addition, it was considered that the appropriate therapies might contribute to a goodfunctional prognosis.

- 141 -­­

Poster Presentation (P)Results of treatment for medulloblastoma in our instituteNaoyuki Ohe1, Hirohito Yano1, Noriyuki Nakayama1, Toru Iwama1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P038
Can absolute lymphocyte count really be a prognostic indicator for
overall survival in patients with Medulolblastoma?
Digvijaya D. Navalkele1, Tribhawan S Vats1, Margaret Nagel1, Anita Mahajan2,
Johannes E. Wolff1
Division of Pediatrics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Radiation Oncology, MDAnderson Cancer Center

1
2

Background: Recently, in a number of studies a link between absolute lymphocyte count and survival rate was shown. The
purpose of this study is to determine if absolute lymphocyte recovery is an independent prognostic indicator in an overall
survival in patients with medulloblastoma. Methods: After institutional review board approval, a retrospective chart review isbeing conducted for patients diagnosed with medulloblastoma treated at MD Anderson Cancer Center between years
1988-2008. The clinical data collection includes the absolute lymphocyte count (ALC), hemoglobin, platelet count, whiteblood cell count and absolute neutrophil count (ANC). Result: Data was available on 33 patients for analysis. Median age 9
years (14month-32 yrs), Males n=20, Females n=13, median survival 2.05 years. After analyzing the data using log rank teston the various blood parameters in different combinations no significant relationship could be established between the
blood count and the survival rate. The only significant finding was in the sub-group of males who had ANC at day 15 of thetreatment more than 1.5K/UL. Total n=19, ANC less than 1.5 = 4, ANC15 more than 1.5 = 15(median overall survival 1.81
years versus 3.52 years, p=0.001). No finding was significant for females with ANC15 over 1.5. Conclusion: No correlation
could be found between ALC and survival rates in patients with medulloblastoma. This is different from almost all othermalignancies examined so far and could be due to the use of steroids in patients with medulloblastoma decreasing the ALC
count which is not the case in ALL, AML and Ewing sarcoma.

P039
Integrating Complexity, Therapeutic Recreation, and Radiotherapy in
Multidisciplinary Medical Team on Reducing Anesthesia/Sedation
Requirement for Toddlers and Young Children with Brain Tumor
I-Tsun Chiang1, Sang-Hue Yen2, Tai-Tong Wong2, Yi-Wei Chen2, Ya-Chun Chu2
National Changhua University of Education
Taipei Veterans General Hospital1
2

Poster Presentation (P)BACKGROUND: Complexity theory has been pervasively applied in medical education to adapt multiple environmental
changes and multidisciplinary collaboration in recently research. More than forty percent of children with brain tumor
require radiotherapy to have better disease control and prognosis. Painless radiotherapy procedures always create
tremendous psychological fear for young children, especially aged 3 to 5. General anesthetic (GA) or conscious sedation(CS) procedures were generally necessary for young children with malignant brain tumor undergoing radiotherapy.
PURPOSE: Recent studies have called for humanizing GA/CS procedure and other better preparation to reduce the needof repeat GA or CS in 30- to 40-day radiation therapy to reduce related medical costs and to avoid potential physical or
psychological side effects on children with brain tumor. The purpose of the study is to employ complexity theory as atheoretical framework, to develop therapeutic recreation interventions to assist communication among medical team,patients and family members, to create flow experience for children with brain tumor in radiotherapy process, and tohumanize GA/CS protocol to reduce the need of repeat GA or CS. METHOD: Fifteen Children with Brain Tumor wereselected and had individualized therapeutic recreation interventions, which included video viewing, art and crafts, story
telling, and drama playing. RESULTS: After interventions, all of children were able to complete multiple radiotherapy
sessions without GA or CS. CONCLUSIONS: Evolving from chaos theory, complexity theory not only keeps theunpredictability and nonlinearity but also develops mutual-adaptation, co-evolution, dynamic interaction and selforganization. SUGGESTIONS: According to the interviews from primary caregivers and related medical service
professionals, positive recognition and feedback recommend that complexity theory are viable and valuable to offer further
development of standard operating procedure, executive professional team training, and quantitative evaluation to ensure
the quality of life for toddlers and young children with brain tumor.

P040
Implications of Complexity: Leisure Participation on Primary Caregivers
and Hospitalized Children with Brain Tumor
I-Tsun Chiang1
National Changhua University of Education

1

This purpose of the study is to explore benefits of leisure participation on improvement of life quality for primary caregivers
who have hospitalized children with brain tumor under the theoretical framework of complexity theory. Complexity theory
has been pervasively applied in medical services to adapt multiple environmental changes and multidisciplinary
collaboration to enhance the quality of life for clients. Primary caregivers of 3 children aged 3-7 with brain tumor wererecruited and provided 4-week leisure activity interventions. After interventions, participants and children completed indepth interviews. According to the results, the primary caregivers stated that they emphasized and cared their children too
much to keep participating past leisure activities and expressed that leisure interventions during the hospitalization
alleviated their life stress and empowered them to face their routine daily life enthusiastically. Complexity theory implicatedthat providing leisure activities for primary caregivers and their children with brain tumor not only conform to the challenges
of unpredictability and nonlinearity in medical service system but also develops mutual-adaptation, co-evolution, dynamic
interaction and self-organization to provide a better quality of medical services for primary caregivers and their children withbrain tumor.

- 142 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P041
Endothelial Cell Transdifferentiation of Human Glioma Stem/ Progenitor
Cells In vitro
Yaodong Zhao1, Jun Dong1,2, Qiang Huang1,2, Aidong Wang1,2, Qin Lan1,2
Deparment of Neurosurgery, the 2nd Affiliated Hospital of Suzhou University
The Laboratory of Aging and Neuro-disease of Suzhou University

1
2

Objective: The transdifferentiation of normal stem cells in many kinds of tissues or organs has been studied. However,whether tumor stem cells can transdifferentiate is seldom reported. Meanwhile, the mechanism of angiogenesis in tumors isin disputations, and it is still unknown that whether glioma stem/ progenitor cells (GSPCs) participate into angiogenesis inglioma. In this study, we tried to prove that GSPCs could transdifferentiate into endothelial cell-like cells, and participate into
the angiogenesis of glioma. Methods: GSPCs were cultivated in endothelial differentiation medium, as well as on Matrigel,for 10 days, their morphological changes were observed. Meanwhile, a transmission electron microscope was used todetect the ultrastructural characteristics of GSPCs cultivated on Matrigel for 10 days. Furthermore, GSPCs were also
cultured in hypoxia or oxygen-glucose deprivation (OGD) for 4 hours, then the transcriptions and expressions of endothelial
cells markers, including CD31 and CD34, were detected by RT-PCR and immunocytochemical stain. Results: After culture
for 10 days in endothelial differentiation medium, GSPCs presented to be the typical "flagstone" appearance of vascularendothelial cell (VEC); when cultivated on Matrigel, GSPCs gradually formed tubular-like structures in vitro; and cells
composing of the tubular-like structures showed typical ultrastructural characteristics of VEC, and expressed CD31.
Furthermore, when cultured in hypoxia or OGD, GSPCs transcribed and expressed CD31 and CD34. Conclusion: GSPCs
could participate into angiogenesis of glioma by transdifferentiating into VEC-like cells.

P042
The New Diagnosis and Treament of Pituitary Apoplexy
Shou Xuefei1, Wang Yongfei1, Li Shiqi1,Wu Jingsong1, Zhao Yao1
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, P. R. China

1

Objects: To explore the pathogenesis of typical and atypical pituitary apoplexy for the sake of helping to formulate thetreatment program reasonably and to select operation occasio correctly. Methods: 28 cases of pituitary apoplexy werediagnosed by the clinical manifestation and findings from operation or pathology. 24 presented typical manifestation, andthe other 4 without clinical manifestation fit pathologic diagnosis. We analyzed the relationships between the course of
disease and clinical manifestation, image study, operation and pathology, and the characters of them during all periods ofcourse. Results: Based on the analysis between the course of disease and clinical manifestation, image study, operationand pathology, we suggested that the typical pituitary apoplexy should be divided into two stage: the early stage ofhemorrhagic necrosis and the late stage of complete necrosis. The atypical pituitary apoplexy was proved the obsolete
hemorrhage inside the tumor by image study, operation and pathology. The total removal rate was 75%;. Conclusions: thetypical pituitary apoplexy was mainly caused by infarcted necrosis and subsequent hemorrhage of the tumor. The purposeof emergency operation is the remission of severe acute headache onset, visual acuity disorder, and consciousness
disorder. The operation effect of the late stage of complete necrosis was obviously better than the early stage ofhemorrhagic necrosis. The patients with no significant symptoms can be treated by hormone substitution conservative
therapy. Most atypical pituitary apoplexy cases are characterized by the chronic bleeding and have no index of emergency
operation. The typing and staging of the pituitary apoplexy are considerably important to its treatment strategy.

THE MIR-17/92 POLYCISTRON IS AMPLIFIED AND UP-REGULATED IN SONICHEDGEHOG-DRIVEN MEDULLOBLASTOMAS AND INDUCED BY N-MYC IN SONICHEDGEHOG-TREATED CEREBELLAR NEURAL PRECURSORSPaul A. Northcott1, Africa Fernandez-L2, John P. Hagan3, David W. Ellison4, James T. Rutka1,3,
Carlo M. Croce3, Anna M. Kenney2, Michael D. Taylor1
The Hospital for Sick Children, University of Toronto, Toronto, Canada 2Memorial Sloan-Kettering Cancer Center, New
York, NY 3The Ohio State University Medical Center, Columbus, OH 4St Jude Childrens Research Hospital, Memphis, TN

1Medulloblastoma is the most common malignant pediatric brain tumour and mechanisms underlying its development arepoorly understood. We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatricmedulloblastomas by high-resolution SNP genotyping arrays and subsequent interphase FISH on a human medulloblastoma
tissue microarray. Profiling the expression of 548 mature microRNAs in a series of 90 primary human medulloblastomas
revealed that components of the miR-17/92 polycistron are the most highly up-regulated microRNAs in medulloblastoma.
Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the Sonic
Hedgehog (Shh) signaling pathway as compared to other subgroups of medulloblastoma. Medulloblastomas in which miR17/92 was up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its regulation by Shh, weobserved that Shh treatment of primary cerebellar granule neuron precursors (CGNPs), proposed cells-of-origin for the Shhassociated medulloblastomas, resulted in increased miR-17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1,
induced miR-17/92 expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh and enabled themto proliferate in the absence Shh. We conclude that Hedgehog signaling promotes the transformation of cerebellar neuralprecursor cells, driven at least in part by over-expression of the miR-17/92 polycistron. Moreover, in a subset of
medulloblastomas, excessive Sonic Hedgehog signaling drives oncogene addiction to miR-17/92, and selects for
subsequent genomic amplification of the miR-17/92 polycistron.

- 143 -­­

Poster Presentation (P)P043

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P044
MULTIPLE RECURRENT GENETIC EVENTS CONVERGE ON CONTROL OF HISTONE
LYSINE METHYLATION IN MEDULLOBLASTOMAPaul A. Northcott1, Yukiko Nakahara1, Xiaochong Wu1, Lars Feuk1, David W. Ellison2, Sid Croul3,
Stephen Mack1, Paul N. Kongkham1, John Peacock1, Adrian Dubuc1, James T. Rutka1,
Michael D. Taylor1
1
The Hospital for Sick Children, University of Toronto, Toronto, Canada 2St Jude Childrens Research Hospital,
Memphis, TN 3University Health Network, Toronto, ON

Genotyping of 212 medulloblastomas (MBs) using high-resolution SNP arrays identified novel amplifications and homozygous
deletions, including recurrent, mutually exclusive, highly focal genetic events in genes targeting histone lysine methylation,
particularly histone 3, lysine 9 (H3K9). Proper control of histone lysine methylation is critical for transcriptional regulation andplays an essential role in the differentiation of stem and progenitor cell populations. We identified two tumors with focal
homozygous deletions of EHMT1 on 9q34, whose protein product is an H3K9 methyltransferase. Similarly, we found focal
deletion of SMYD4 on 17p13, another histone lysine methyltransferase (3 tumors). Conversely, we found amplification of
JMJD2C (7 tumors) and JMJD2B (5 tumors) through the combined analysis of our SNP array data and FISH probing of a MBtissue microarray. The JMJD2 family genes encode H3K9 demethylases, whose effect is opposite to that of EHMT1 on H3K9.
The ability of EHMT1 to methylate H3K9 is blocked by acetylation. We found amplification of MYST3 (4 tumors), a histone 3
lysine acetyltransferase. We also found deletions in polycomb genes that interpret the state of H3K9 methylation including
L3MBTL3 (1 tumor), L3MBTL2 (4 tumors), and SCML2 (3 tumors). Re-expression of L3MBTL3 in a MB cell line where it ishomozygously deleted resulted in decreased growth, and cell cycle redistribution. Re-expression of L3MBTL3 also increased
H3K9 dimethylation of E2F6 target gene promoters as demonstrated by chromatin immunoprecipitation. Additionally,
retroviral-mediated over-expression of JMJD2C in cerebellar granule cell progenitors caused a reduction in the levels of H3K9
dimethylation. Copy number aberrations of genes with critical roles in writing, reading, removing, and blocking the state ofhistone lysine methylation, particularly H3K9, suggest that defective control of the histone code contributes to thepathogenesis of medulloblastoma.

P045
MEDIP-CHIP AND MEDIP-SEQ IDENTIFY NOVEL EPENDYMOMA TUMOUR SUPPRESSOR
GENES THROUGH DELINEATION OF THE EPENDYMOMA EPIMETHYLGENOME
Stephen Mack1, Adrian Dubuc1, Paul N. Kongkham1, Paul A. Northcott1, Michael D. Taylor1
The Hospital for Sick Children, University of Toronto, Toronto, Canada

1

Poster Presentation (P)Ependymoma is the third most common pediatric brain tumor and little is known about its genetic underpinning. At thegenetic level, many pediatric posterior fossa ependymomas have a balanced karyotype, suggesting that they are initiatedand maintained by very small copy number aberrations, small sequence changes, or epigenetic events such as DNA
promotor methylation or histone modifications. We fragmented genomic DNA from 27 primary pediatric posterior fossa
ependymomas, 10 normal brain samples, and 4 ependymoma xenograft cell lines and subjected them to MeDIP(methylation dependant immunoprecipitation). The IP fraction (enriched for methylated DNA) was then compared to thewash fraction (impoverished for methylated DNA) by differential labeling and hybridization to Nimblegen Promotor tilingarrays (MeDIP-ChIP). Regions of the genome in which the ratio of IP/Wash DNA was >2 in one or more tumor samples, but
not in normal brain samples were identified as methylated. We identified methylation of numerous genes involved intranscriptional regulation (HOXD5, FOXD4, RASSF2), apoptosis (BMF, TNF, TRADD, BCL2L2) in addition to several othergene families. We subsequently analyzed 4/27 of the primary ependymoma samples by MeDIP-Seq using a next
generation sequencing strategy. Tumor DNA was subjected to MeDIP, and then subsequently analyzed by generating >30
million short (35 bp) reads for IP and wash fractions, followed by mapping and alignment to the genome on the UCSC
genome browser. Genomic regions showing significantly more reads in the IP fraction versus the wash fraction wereidentified. There was a significant overlap between genes identified as methylated by MeDIP-ChIP and MeDIP-Seq.
MeDIP-Seq also identified a number of regions of intragenic and intergenic tumor specific methylation that are currently of
uncertain significance. Our data demonstrate that MeDIP-ChIP and MeDIP-Seq are useful tools to delineate theependymoma epimethylgenome.

P046
Clinical Diagnosis of Optic Nerve Hemangioblastoma
Xuhui Bao1, Kang Zheng1, Gang Wu1, Xiang Zhou1, Fengping Huang1
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

1

Objective To study the clinical diagnosis and treatment of optic nerve hemangioblastoma. Methods A 38-year-old man
with solitary hemangioblastoma in intracranial segment of optic nerve who was the initial case in our country was treated in
Huashan Hospital, and analyzed based on the reviews on 17 reported cases of optic nerve hemangioblastoma in the world.
Results Optic nerve hemangioblastoma might occur in any segment of the optic nerve. The initial symptoms were
progressive visual loss and visual field defect. The preoperative differential diagnosis from optic nerve gliomas ormeningiomas was quite difficult. Magnetic resonance imaging could provide more information than other radiologicalexaminations. The hemangioblastoma at the peripheral optic nerve could be removed totally with the preservation of optic
nerve and vision. Conclusion Solitary optic nerve hemangioblastoma is extremely rare, and preoperative diagnosis isdifficult. The majority of the patients with optic nerve hemangioblastoma are complicated by Von Hippel-Lindou`s disease.
The only way to cure optic nerve hemangioblastoma is surgical treatment.

- 144 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P047
Gene expression meta-analysis identifies grading and survival markers in
anaplastic glioma
Marie de Tayrac1,2, Marc Aubry3, Stephan Saikali4, Cyrille Surbled1, Rachel Boniface1,
Amandine Etcheverry1,3,Philippe Menei5, Jean Mosser1,2,3
Medical Genomics Unit, CHU Pontchaillou, Rennes, France 2UMR6061-CNRS, IFR140, Universite de Rennes1,
Rennes, France, 3OUEST-genopole platform, Universite de Rennes1, Rennes, France 4Department of Pathology, CHU
Pontchaillou, Rennes, France 5Department of Neurosurgery, Centre Hospitalier Universitaire d'Angers, France
1

Purpose: Although molecular analyses have been shown to be useful for classifying tumors and formulating a prognosis forpatients, current methods applied to glioma are mostly based on histopathology. To search for robust diagnostic andprognostic markers of high-grade gliomas (HGGs), we applied a meta-analysis that extracts the most reliable informationfrom the available gene expression data. Methods: We obtained data sets from three studies in HGGs. We selected aconsensus set of 267 patients. Differential analyses were performed separately for each study and we applied a metaanalysis approach base on non-parametric rank products to evaluate the combined data. The genes selected in bothanalyses were used to construct a gene classifier by logistic regression modeling. We performed survival analyses on 144
patients by fitting Cox proportional hazard model. Genes identified as both differentially expressed and correlated tosurvival were used to build an optimal survival model. Performances were evaluated on an independent data set
comprising 54 patients. Several genes were validated using RT, Q-PCR and immunohistochemistry on a local cohort of 130
patients. Results: This inter-study cross-validation approach generated a set of 65 genes consistently and specificallydifferentially expressed in GBM. Functional annotation revealed a clear association with the nervous system development
and the cell communication. The genes significantly associated with grading were mostly related to the extracellular matrix.
The optimal survival model was built on a four genes signature. Kaplan-Meier curves and the log rank test (training: p = 2e11, testing: p = 1e-4) indicated the high survival prognostic potential for this classifier. Finally, applied only to GBM it clearly
outperformed previous reports, by grouping GBM in two subtypes with significant different prognosis (p = 3e-4).
Conclusions: Meta-analysis allows the identification and validation of HGGs biomarkers that might represent goodcandidates for novel diagnostic and prognostic approaches in HGGs.

P048
Multiparameteric MR approach for tissue characterization of patientswith GBM
Moran Artzi1,2, Haim Ben-Ami1, Orna Aizenstein3, Deborah Blumenthal4, Felix Bokstein4,
Rinat Abramovitch5, Yifat Edrei5, Ben Corn6, Dafna Ben Bashat1
Functional Brain Imaging Center, Tel Aviv sourasky Medical Center, Tel Aviv, Israel 2Tel-Aviv University - Sackler
Faculty of Medicine, Tel Aviv, Israel 3Radiology Department, Tel Aviv sourasky Medical Center, Tel Aviv, Israel
4
Neuro-Oncology, Tel Aviv sourasky Medical Center, Tel Aviv, Israel 5Goldyne Savad Institute of Gene Therapy,
Hadassah University Medical Center, Jerusalem, Israel 6Institute of Radiotherapy, Tel Aviv Sourasky Medical Center,
Tel Aviv, Israel1- 145 -­­

Poster Presentation (P)Aim: To use a combination of conventional and advanced MR methods, in order to improve diagnosis and definition oflesion boundaries. Methods: Study-groups: five patients with GBM and five healthy volunteers were scanned using
3T-GE scanner. MRI protocol: included conventional imaging: T1/T2 weighted images(WI), FLAIR, GE and T1WI postcontrast. In addition advanced MR methods included: diffusion tensor imaging(DTI), dynamic susceptibility contrast(DSC)
and calculated T1-maps. Data analysis: Data from all sequences and calculated maps were realigned and co-registeredinto the same space. In the healthy controls, several white and gray matter volumes of interest (VOIs) were defined in theoccipital lobe and the mean value of each parameter was calculated separately. In the patients, VOIs were defined fromenhanced lesion and pure and infiltrative edema. Normalized ratios relative to mean values of the contra-lateral hemisphere
were calculated for all images having arbitrary units (such as T1/T2WI). Each VOI was defined by a multi-parameters
pattern. Results: Healthy-controls: different multiparametric patterns differentiated between the white and gray matter.
Patients-group: different multiparameters patterns distinguished between enhanced lesion, pure and infiltrative edema. In
addition, within the peritumoral edema, different compartments were obtained characterized by varying multiparametricpatterns. The main differences were in their 3DT1W post contrast intensity (although both areas presented as nonenhancing tissues); in the perfusion parameters and in its T1 values. Conventional imaging failed to detect any differences
between these compartments. Conclusion: Those finding present specific finger-prints for normal and pathologic tissues
using conventional and advanced MR methods. Such an approach may provide more accurate definition of tumor
boundaries regarding the extent of infiltration. If so this tool will impact differential diagnosis, planning of not only biopsy but
also radiotherapy, and the follow-up of these patients.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P049
NG2 EXPRESSION ESTABLISHES A LINK BETWEEN NEURAL PRECURSORS AND
CANCER STEM CELLS IN GLIOBLASTOMA
Talal M. Fael Al-Mayhami1, Richard Grenfell3, Lawrance Petalidis2, Emma Kenney-Herbert1,
Koichi Ichimura2, Peter Collins2, Colin Watts1
Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
Department of Pathology, University of Cambridge, Cambridge, UK
3
MRC Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
12Introduction
NG2 expressing cells (NG2+ cells) are the largest group of neural cycling precursors in the adult brain and exhibit wide
anatomical distribution and proliferative activity. Based on these characteristics, we hypothesised that NG2+ve cells arepotential candidates as cancer stem cells (CSCs) that maintain the glioblastoma (GBM) growth.
Methods
GBM tumour-initiating cell (TIC) lines were derived from fresh clinical samples under serum-free (SF) conditions according
to our Cambridge Protocol (Fael Al-Mayhani et al.; 2009). Cells were analysed and sorted using FACS. Comparative studies
on NG2+ and NG2- cells were conducted in vitro and in vivo. Molecular studies were performed using microarray andcomparative genomic hybridization (CGH).
Results
Microarray data showed that genes associated with neural precursors (NG2, Olig2, PDGFRa and NKX2.2) were expressedby all GBM TIC lines and the majority (90%) of GBM tumours tested (n=147). In vitro data show that NG2+ cells isolated
from TIC lines exhibit high level of growth, proliferation and clonogenic potentiality compared to NG2- cells. Only NG2+ cells
were able to form tumours in vivo. Array CGH demonstrate that both NG2 populations have typical GBM cytogenetic profile(e.g. Ch7 gain and Ch10 loss), however, NG2+ cells exhibit significant additional abnormalities.
Conclusion
Genes associated with neural precursors are widely expressed by GBM tumours and GBM TIC lines. NG2+ cells isolated
from TIC lines appear to conserve the precursor status of their normal counterparts and have tumourigenic characteristics
in vivo. In addition, NG2+ cells exhibit significant structural chromosomal abnormalities that differ from NG2- cells andamong different samples reflecting GBM heterogeneity. These data indicate that NG2 can be used as CSCs marker in GBM
and draw attention to possible clinical implications (for more details see abstract by Watts C. et al.)

P050
UNUSUAL CASE OF RADIATION-INDUCED GROWING TERATOMA SYNDROME
Aliasgar Moiyadi1, Rakesh Jalali 2, S V Kane3
1
Neurosurgical Services, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India 2Department ofRadiation Oncology, tata Memorial Hospital 3Department of Surgical Pathology, tata Memorial Hospital

Poster Presentation (P)Introduction
Intracranial Germ cell tumors (GCT) are rare. The mixed varieties require a multimodality therapy including chemotherapy.
While on chemotherapy, radiologically progressing masses with decreasing tumor markers have been found to be
teratomas . Such an occurrence while on radiotherapy is unusual and never reported before.Case
A 5-year-old boy diagnosed with a posterior third-ventricular mass underwent endoscopic biopsy and ventriculostomy. Witha diagnosis of a pineal parenchymal tumor he was commenced on radiotherapy. After the first ten fractions (18Gy) he had
progressive neurological deterioration. Repeat CT and MR were highly suggestive of a teratoma and he underwent
emergency surgical excision .histology revealed features of a mature teratoma. He had a stormy postoperative course
succumbing to deep venous infarction.Discussion
Intracranial mixed GCTs usually require multimodality therapy inclusive of chemotherapy which is usually effective for themalignant elements. The mature teratomatous components however being resistant, may persist and occasionally growrather rapidly , a phenomenon described as Growing Teratoma Syndrome (GTS). 7 such cases have been reported. Noneof these however had this whilst on radiotherapy. Our patient had an erroneous diagnosis (a known limitation withsterotactic/endoscopic biopsy methods) for which radiotherapy was given leading to this occurrence. Whether this was a
result of the radiotherapy or part of the natural history of this tumor remains conjectural. absence of any immature/malignant transformation on histology coupled with the known indolent history of mature teratomas, most probably
suggests a case of radiotherapy-induced GTS, much like the chemotherapy-induced GTS. This report also reiterates thefact that mature teratomas are best treated surgically, with favourable outcomes provided lesions are small and detected
early before neurological compromise.

- 146 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P051
Causes and correlates of distress and major depression in high-grade
gliomaAlasdair G. Rooney1, Shanne McNamara1, Mairi MacKinnon2, Roy Rampling2, Robert Grant1
1
Edinburgh Centre for Neuro-oncology, Western General Hospital, Edinburgh, Scotland (UK) 2Beatson West of
Scotland Cancer Centre, Glasgow, Scotland (UK)

Purpose To study causes of distress and how it relates to depression in malignant glioma, to help optimise future
supportive and psychological care.
Methods We studied 50 adults with histologically proven high-grade glioma
attending two tertiary referral centres at the start of their radiotherapy. All patients completed the NCCN distressthermometer and received a clinical interview to diagnose DSM-IV Major Depressive Disorder (MDD). The frequency andcauses of distress and its associated clinical characteristics were surveyed. Data were analysed with respect to clinicalvariables, including MDD, using Fishers exact test. Results Distress was high in 23 subjects (46%) and severe in 8 (16%).
Mean distress score was 3.5 (SD 2.7; 95% CI 2.7-4.3). The commonest problems were physical: getting around (30%),
fatigue (26%) and sleep (24%); and emotional: worry (22%), anger (20%) and sadness (12%). Distress scores were higher inpatients with MDD (p=0.001). However, depressed glioma patients tended not to complain specifically of depression.
Emotional sources of distress were more common in patients with MDD (82% vs 38%; p=0.02), and in women (74% vs32%; p=0.008). There were no other statistically significant differences in distress score or source in respect of MDD, age,sex, physical function, cognitive status or presence of epilepsy. Discussion Distress scores vary widely in patients withhigh-grade glioma at the start of radiotherapy. Perhaps surprisingly, most patients (54%) report low distress. Women anddepressed patients report more emotional problems, but the broad causes of distress otherwise seem similar acrossdifferent groups. Anger is surprisingly prominent and may easily be missed unless enquired about.Overall distress score,
and the presence of emotional sources of distress, may aid in deciding which patients to screen for MDD. Assessing only
those patients who complain of depression risks missing cases. A larger sample size may clarify these findings.

P052
BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II
TRIAL
Sith Sathornsumetee1, Annick Desjardins1, James J. Vredenburgh1, Jeremy N. Rich1,
Sridharan Gururangan1, DE Janney1, Allan H. Friedman1, Henry S. Friedman1, David A. Reardon1
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA

1- 147 -­­

Poster Presentation (P)Background: Bevacizumab (B), a neutralizing VEGF monoclonal antibody, has anti-glioma activity as single agent and incombination with cytotoxic therapy. Erlotinib (E), an EGFR tyrosine kinase inhibitor, may exhibit anti-tumor activity in somehigh-grade glioma (HGG) patients. B plus E was associated with clinical benefit in several cancers. We performed a singlearm, phase II trial to assess the efficacy and safety of B and E in patients with recurrent HGG. Methods: The primary
endpoint was 6-month progression-free survival (PFS-6). Radiographic response, pharmacokinetics and correlative
biomarkers were secondary endpoints. E was orally administered daily at 200 mg/day for patients not on enzyme-inducing
anticonvulsants (EIAC) and 500 mg/day for patients on EIAC. All patients received 10 mg/kg of B intravenously every two
weeks. Results: Fifty-six patients with recurrent HGG (n=24 for glioblastoma multiforme [GBM] and n=32 for anaplastic
gliomas [AGs]) were assessable for outcome. The PFS-6 rates were 25% for GBM and 50% for AGs. There was no survival
difference between EIAC and non-EIAC groups. Rash (54% grade 1-2 and 38% grade 3) was the most common side
effect. Fatigue, nausea and diarrhea were also common but mostly grade 1-2. Serious side effects were rare and included
two patients with pulmonary embolism, single patients with either intestinal perforation, ischemic stroke, gastric bleeding or
nasal septal perforation. Pharmacokinetic and tissue biomarker profiles are in preparation. Conclusions: Combination of
bevacizumab and erlotinib is tolerated and associated with anti-tumor benefit among heavily pretreated recurrent highgrade glioma patients.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P053
PATIENT FUNCTIONAL STATUS IS STRONGEST CORRELATE OF CHALLENGINGBEHAVIOUR AFTER BRAIN TUMOUR
Eng-Siew Koh1,7, Grahame Simpson2, Diane Whiting3, Kylie M. Wright4,7, Teresa Simpson5,7,Rochelle Firth6, Kathyrn Younan3
1
Liverpool Cancer Therapy Centre, Liverpool Hospital, University New South Wales, Sydney, Australia. 2Brain Injury
Rehabilitation Unit, Liverpool Hospital and Rehabilitation Studies Unit, University of Sydney, Sydney, Australia. 3Brain
Injury Rehabilitation Unit, Liverpool Hospital and Rehabilitation Studies Unit, Sydney, Australia. 4Department of
Neurosurgery, Liverpool Hospital, Sydney, Australia. 5Liverpool Cancer Therapy Centre, Liverpool Hospital, Sydney
South West Area Health Service, Sydney, Australia. 6Department of Neurosurgery, Royal North Shore Hospital,
Northern Sydney Central Coast Area Health Service, Sydney, Australia. 7New South Wales Oncology Group , Neurooncology, New South Wales Cancer Institute, Sydney, Australia.

Purpose: Few studies have documented behavioural disturbance, impairments in executive functioning as well as
emotional/social dysfunction (as distinct from mood disturbance) associated with brain tumour (BT). This study investigated(i) the prevalence of such challenging behaviours (CBs) and (ii) potential correlates among patient, tumour, treatment
variables and functional status. Methods: A consecutive series of 54 patients with BT recruited from two Sydney-based
hospitals completed a series of self-report surveys documenting patient impairment. Thirty seven carers derived from thisseries also participated. Measures of CBs included the Frontal Systems Behaviour Rating Scale (FRSBE), Overt Behaviour
Scale (OBS), and Emotional/Social Dysfunction Questionnaire (ESDQ). Functional measures included the Sydney
Psychosocial Reintegration Scale (SPRS; self-report scale documenting function in occupational, relationship, andindependent living domains) and clinician-rated Karnofsky performance scores (KPS; 31% at 90-100; 34% at 80; 35% at
50-70). Results: Median patient age was 51 years (range 18-91) and time since diagnosis was 4 months (range 1-82).
Patients had high grade (39%), low grade (22%) or benign tumours (39%) and 60% underwent radiotherapy. Patient selfreport found prevalence rates of CBs ranging from 17% - 50% across various domains including verbal aggression,
physical aggression, lack of initiation, disinhibition, apathy and executive impairments. No consistent pattern of correlates
was found between CBs (patient or carer report) and patient demographics, tumour features (benign versus malignant
diagnosis, grade, location), treatment timing or modality (surgery, radiotherapy or chemotherapy). However, functional
status (Karnosfsky and SPRS scores) demonstrated significant correlations (.30-.50 range) with various carer-rated CB
variables including FRSBE apathy and executive impairment sub-scales; ESDQ emotional dysfunction, fatigue,
inappropriate behaviour, and poor insight sub-scales, and OBS total score. Conclusions: Patients functional status may be
the most useful indicator of challenging behaviours after brain tumour. Karnofsky scores could be linked to further
screening questions to help identify and subsequently manage challenging behaviours in brain tumour patients.

P054
Detailed prospective neuropsychological, activity of daily living andendocrine function assessment in children with craniopharyngioma
treated with stereotactic conformal radiotherapy
Debnarayan Dutta1, Tejpal Gupta1, Anusheel Munshi1, Savita Goswami3, Nalini Shah2,
Rajiv sarin1, Rakesh Jalali1
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India 2Department of Endocrinology, KEM
Hospital, Mumbai, India 3Clinical Psychology, Tata Memorial Hospital, Mumbai, India

1

Poster Presentation (P)Purpose: We report prospective neuropsychological and neuroendocrine function in young patients with residual/recurrent
craniopharyngioma treated with stereotactic conformal radiotherapy (SCRT). Material and method: Eighteen patients(median age 14 years) treated with SCRT underwent prospective detailed serial evaluation of neurocognitive, Barthel index(BI), LOTCA and neuroendocrine function. Result: Among eighteen patients (14 males, 4 females; mean follow up 28.4
months), 16 (89%) were controlled and two (11%) patients died with disease progression. At pre-RT, 16 (89%) patients had
full scale IQ (FSIQ) below normal. Pre-RT mean verbal IQ (VQ), performance IQ (PQ) and FSIQ were 74.12, 82.42 and 76.53
respectively. Mean FSIQ at 6 month and 2 year were 80.5 and 77.7; PQ score 87.5 and 86.6; VQ score 86.33 and 82.88
respectively. Mean trait anxiety (C2) score was poor at baseline (29.67) and improved to 21.83 at 2 year follow-up. Mean BIscore at baseline, 6 month and 2 year were 95.64, 99.81 and 100 respectively. LOTCA scores were maintained at 2 year inorientation, spatial-perception, thinking and attention concentration domain. At baseline, 83.3% (15) patients had hormone
deficiency in at least one axis. Growth hormone, corticosteroid, thyroid and sex hormone axis impairment were in 67% (12),61% (11) 33.3% (6) and 5% (1) patients respectively. Pre-RT BI score was significantly lower in visually handicapped(p= 0.007), low KPS score (0.004), poor neurological function status (NPS) (p= 0.014) and in patients with severehydrocephalus (p=0.031). FSIQ score was significantly lower in patients with thyroid replacement (p=0.05). LOTCA scores
were lower in visually impaired (p= 0.071) and in patients with poor neurological function (p= 0.021). Conclusion:
Craniopharyngioma patients have poor neuropsychological and endocrinal function even before starting RT. However, there
is no further decline upto 2 years follow-up. Factors other than RT such as tumor, patient-related factors and surgery may
influence baseline neurocognitive function.

- 148 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP055
Human neural stem cells can target and deliver therapeutic genes tobreast cancer brain metastases
Kyeung Min Joo1, Jeongwu Lee2, Juyoun Jin1, Bong Gu Kang1, Doo-Sik Kong1, Jung-II Lee1,
Seung-Chyul Hong1, Jong Hyun Kim1, Do-Hyun Nam1
Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan
University School of Medicine, Seoul, Korea 2Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland

1

The tumor-tropic properties of neural stem cells (NSCs) led to the development of a novelstrategy for delivering therapeutic
genes to tumors in the brain. To apply this strategy to thetreatment of brain metastases, we made a human NSC line
expressing cytosine deaminase(F3.CD), which converts 5-fluorocytosine (5-FC) into 5-fluorouracil, an anti-cancer agent. In
vitro,the F3.CD cells significantly inhibited the growth of tumor cell lines in the presence of the prodrug5-FC. In vivo, MDAMB-435 human breast cancer cells were implanted into the brain ofimmune deficient mouse stereotactically, and F3.CD
cells were injected into the contralateralhemisphere followed by systemic 5-FC administration. The F3.CD cells migrated
selectively intothe brain metastases located in the opposite hemisphere and resulted in significantly reducedvolumes. The
F3.CD and 5-FC treatment also decreased both tumor volume and number oftumor mass significantly, when immune
deficient mouse had MDA-MB-435 cells injected into theinternal carotid artery and F3.CD cells were transplanted into thecontralateral brain hemispheresterotactically. Taken together, brain transplantation of human NSCs, encoding thesuicideenzyme CD, combined with systemic administration of the pro-drug 5-FC, is an effectivetreatment regimen for brain
metastases of tumors.

P056
Steroid Requirements during Radiotherapy for Malignant Gliomas
Athina Marantidou1,2, Christine Levy2, Irene Coman1, Johan Le Guilloux1, Catherine Belin1,
Antoine F. Carpentier1
Department of Neurology, Avicenne Hospital, AP-HP, Paris, France 2IRHE Avicenne Hospital, AP-HP, Paris, France

1

P057
Mutational profiling of high grade gliomas reveals inactivating
mutations in IDH1
Fonnet E Bleeker1,2, Simona Lamba2, Carlo Zanon2, Angela A van Tilborg3, Nadia Atai4,
Theo Hulsebos5, Dirk Troost6, Sieger Leenstra7, W. Peter Vandertop1, Cornelis J van Noorden4,
Alberto Bardelli1
Neurosurgical Center Amsterdam, Location Academic Medical Center, University of Amsterdam, Amsterdam,
The Netherlands 2Laboratory of Molecular Genetics, The Onco Genomics Center, Institute for Cancer Research andTreatment, University of Torino, Medical School, Candiolo, Italy 3Department of Pathology, Erasmus Medical Center,
Rotterdam, The Netherlands 4Department of Cell Biology and Histology, University of Amsterdam, Academic Medical
Center, Amsterdam, The Netherlands 5Department of Neurogenetics, University of Amsterdam, Academic Medical
Center, Amsterdam, The Netherlands 6Department of Neuropathology, University of Amsterdam, Academic Medical
Center, Amsterdam, The Netherlands 7Department of Neurosurgery, Erasmus Medical Center, Rotterdam,
The Netherlands
1High grade gliomas (HGG) are malignant brain tumors for which no cure is available. To identify new therapeutic targets weperformed an extensive mutation analysis. We sequenced 39 genes in 113 HGG (including 109 glioblastoma) tumor samples
and 16 HGG cell lines. We analysed 200 exons belonging to 35 kinases, isocitrate dehydrogenase 1 (IDH1), NRAS, PTEN andTP53 genes. At least one somatic mutation was found in 90 out of 129 HGG samples (70%). Most mutations were observedin genes belonging to the PI3K-AKT pathway; in more than 45% of HGGs we detected a mutational activation of the pathway,
indicating that the PI3K-AKT axis represents a relevant therapeutic target for HGG. In addition, five different types of somatic
mutations affecting the IDH1R132 residue were detected in 20% (23 of 113) HGG tumor samples. IDH1 mutations werepredominantly observed in secondary glioblastoma (11 of 94 vs. 11 of 15, p-value =0.0000016). It has been established that
IDH1 mutations occur early in gliomagenesis and that the overall survival in both primary and secondary glioblastoma is betterin patients with IDH1 mutations. However, it remains to be determined whether the mutations functionally activate or inactivate
the IDH1 enzymatic activity. To address this issue we performed metabolic mapping (enzyme histochemistry) on wild-type
and mutated HGG samples. Our initial results suggest that IDH1 mutations are inactivating. These data have relevant
implications to exploit IDH1 mutations for diagnostic, prognostic and therapeutic purposes.

- 149 -­­

Poster Presentation (P)Objective: To assess the steroid requirements during Radiation Therapy (RT) in patients with malignant gliomas.
Introduction: Radiotherapy is the mainstay of treatment for high-grade gliomas. However, even with optimal RT regimen,
toxicity may develop, such as brain oedema and worsening of neurological symptoms. Steroids are currently used for the
management of these complications. Steroid requirement has been mainly described in patients with brain metastasis, but
not in adult patients with malignant gliomas.
Design/Methods: We evaluated prospectively all patients with malignant gliomas addressed for RT to Avicenne Hospitalfrom January 2007 to September 2008. Age, sex, initial Karnofsky performance status, tumor localization and histology,
type of surgical resection, clinical target volume, total dose and duration of RT, concomitant treatment with temozolomide
and steroid dosage during RT and at 1 and 3 months after RT, were recorded in all patients.
Results: Out of 49 patients, 27 (55%) required instauration or increase of steroids during RT because of headache,vomiting, seizures, neurological decline or intracranial hypertension. The median time to steroid increase was 5 days. 31%
of patients were free of steroids at the beginning of RT, 14% by the end of RT and 33% at 3 months after RT. The mediandosage of prednisone was 40 mg during RT and 20mg 3 months after RT. Poor performance status, biopsy, concomitant
TMZ and young age, but not clinical target volume, total dose and duration of RT, were associated with higher dosage ofsteroids.
Conclusions/Relevance: In our series, half of the patients required instauration or increase of steroids during RT. Poor
performance status, young age, biopsy and combination of temozolomide to RT seem to be factors that require more
steroids.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P058
Genomic Profiling of Intracranial Germ Cell Tumors with Single
Nucleotide Polymorphism Array
Keita Terashima1, Jim Hsu1,2, Thomas W. Chow1,2, Ryo Nishikawa3, Masao Matsutani3, Hideo
Nakamura4,Ho-keung Ng5, Kenneth Aldape6, Jack M. Su1,2, Adesina Adekunle1, Jefferey Allen7,
Kwong-kwok Wong6, Hon-chiu E. Leung1,2, Tsz-Kwong Man1, 2, Ching C. Lau1,2
Baylor College of Medicine, Houston, USA 2Texas Children's Cancer Center 3Saitama Medical University 4Kumamoto
University 5Chinese University of Hong Kong 6M.D. Anderson Cancer Center 7New York University
Intracranial germ cell tumors (GCTs) are relatively rare brain tumors affecting primarily adolescents. Although the survival
rate of pure germinoma is excellent (>90%), optimal volume and dose of radiation or the role of chemotherapy is not clear,and the risk factors of relapse is unknown. In contrast, the outcome of nongerminomatous germ cell tumors (NGGCTs) ispoor (30-40% survival) and the standard treatment for NGGCTs remains controversial. The lack of progress in improving
the outcome of these patients is due to our poor understanding of the biology of intracranial GCTs. To better characterize
underlying genetic alteration of intracranial GCTs, copy number aberration (CNA) analysis using genome-wide genotyping
microarray was performed.
We have analyzed the DNA samples of 55 intracranial GCTs by GeneChip Human Mapping 100K Array. After applying
stringent quality control criteria, 30 cases with both tumor and matched blood samples (18 pure germinomas and 12
NGGCTs) were selected for further analysis using. the Copy Number Analyzer for GeneChip (CNAG).
Overall, copy number gains are observed more frequently than losses. The most frequently observed CNAs include gain ofchromosomes 1q, 2, 7, 8, 12p, 21, and X as well as loss of chromosomes 11q and 13. Validation of these results are
ongoing using real time quantitative PCR method. The CNAs which are specific to histologic subtypes were also identified.
Loss of choromosomes11q and 13 were specific to germinomas. Gain of chromosome 2 was observed more frequently ingerminomas, whereas gain of chromosomes 1q and 12p were more frequently observed in NGGCTs.
We identified multiple frequently altered loci of intracranial GCTs genome. Similar CNAs have been observed in intracranial
GCTs as well as extracranial counterparts. These findings will serve as the focus of further search for the genes involved intumorigenesis of intracranial GCTs.

1

P059
PRESENCE OF AN ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM AS A
FAVORABLE PROGNOSTIC MARKER IN PATIENTS WITH GLIOBLASTOMA
Kerrie L McDonald1, Julie McDonnell2, Jeremy Henson3, Alessandra Muntoni3, Helen R Wheeler5,
Bruce G Robinson1,6, Roger R Reddel3,6, Janice Royds4
1
Hormones and Cancer Group, Kolling Institute of Medical Research 2Millenium Institute, Westmead, Australia 3Cancer
Research Unit, Childrens Medical Research Institute, Austalia 4Dunedin School of Medicine, University of Otago, New
Zealand 5Department of Oncology, Royal North Shore Hospital, Australia 6Faculty of Medicine, University of Sydney

Poster Presentation (P)Objectives: During proliferation of normal human somatic cells, telomeres progressively shorten, leading eventually tosenescence. However, the majority of cancers evade this by activating either telomerase or the alternative lengthening oftelomeres mechanism (ALT) to prevent telomere shortening. Why ALT, rather than telomerase, is switched on in certain
tumors is unknown and its presence has been associated with good and bad prognosis, depending on tumor type. Our
goal in this study was to examine whether the presence of ALT in GBM tumors has prognostic significance. Methods: We
performed a retrospective review and analysis of 432 cases of GBM diagnosed from 1998-2007 at Royal North Shore andNorth Shore Private Hospitals, Australia and Auckland Hospital, New Zealand. To assess ALT, ALT-associatedpromyelocytic leukemia ( PML) bodies (which are a known hallmark of ALT) were detected by combined PML
immunofluorescence and telomere fluorescence in situ hybridization. Results: Of the 432 cases, 61 patients received
surgery only, 110 patients were postoperatively treated with radiotherapy (RT), while 261 patients were postoperatively
treated with RT plus chemotherapy administered either concurrently with RT or post RT. ALT was detected in tumors from
61 patients (14.1%). In all treatment arms, ALT positive patients displayed longer median survival when compared topatients without ALT: No treatment: 3.8 months compared to 2.2 months, p=0.696; RT only: 10.1 months compared to 7.3
months, p=0.026; RT + Chemotherapy: 17.8 months compared to 13.9 months, p=0.051. Approximately 33% of ALT
positive patients survived more than 2 years post diagnosis as opposed to 12% of all ALT negative patients treated with RT
and chemotherapy. Conclusion: The presence of ALT in GBM tumors correlates with patient survival. ALT positivity in
GBMs not only predicts better outcome for these patients but also identifies a subgroup that will not benefit fromtelomerase inhibitors.

- 150 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P060
Long Term Follow Up of Patient with Acromegaly after LINAC Radiosurgery
Jiun-lin Yan1,2,3, Pen-Wei Hsu1, Chuang-Chi Chen1, Der-Jen Lin3, Kuo-Jen Wei1,
Jen-Kan Tseng2, Shi-Tseng Lee1, Chen-Nen Chang1
Department of Neurosurgery, Chang Gung Memorial Hospital, Taipei, Taiwan 2Department of Radiation Oncology,
Chang Gung Memorial Hospital and Chang Gung University. Taipei, Taiwan 3Department of Endocrinology andMetabolism, Chang Gung Memorial Hospital and Chang Gung University. Taipei, Taiwan

1

Purpose The authors retrospectively reviewed the long term outcome of linear accelerator radiosurgery for patients withacromegaly in our hospital in the view of biochemical remission and further analyzed the associated factors. Materials andMethods We reviewed patients who received LINAC radiosurgery between 1994 and 2004 due to residual or recurrent
growth hormone (GH)-secreting functional pituitary tumor in our hospital. All patients were followed &gt 3 years. The
residual or recurrent of the tumor were defined persisted high level of growth hormone or insulin-like growth factor-1 (IGF-1).
The biochemical remission was defined as basal growth hormone &lt 5ng/ml with a normal sex-and-age adjusted IGF-1.
Results Total 22 patients were included in our reviewed. The mean follow up after radiosurgery was 94.68 months.The
overall mean biochemical remission time was 49.2 months (median 42 months). Nineteen patients (86.4%) achieved thebiochemical remission throughout the follow up period. The 3, 5, 8 years biochemical remission rate were 36.4%, 54.5%
and 72.7% respectively. The inital GH at diagnosis and the pre-SRS GH correlated with biochemical remission (p=0.005,
p&lt 0.0001). Overall post SRS hormone deficit was in 5 patients (22.7%). ConclusionIn comparison to other radiosurgery
facilities, LINAC radiosurgery also provided a competent outcome. SRS has maximun effect in the first two years.
Moreover, SRS showed long term biochemical effects and needs longer follow up for better biochemical remission.

P061
DO MEDULLOBLASTOMAS IN ADOLESCENTS HAVE A DISTINCT MOLECULAR
SIGNATURE & DIFFERENT TUMOR BIOLOGY?
Wan-Yee Teo1, Alexander Yu1, Jian Wang1, Jianhe Shen1, Tsz-Kwong Man1, Ching Lau1
Department of Pediatric Hematology-Oncology, Texas Children s Cancer Center, Baylor College of Medicine

1

P062
Aberrant expression of GDF-15 contributes to proliferation and immune
escape of malignant gliomas
Patrick Roth1, Isabel Tritschler2, Michael Weller1, Joerg Wischhusen2,3
Department of Neurology, University Hospital Zurich, Zurich, Switzerland 2Department of General Neurology,
University of Tuebingen, Tuebingen, Germany 3Interdisciplinary Center for Clinical Research, University of Wuerzburg,
Wuerzburg, Germany
1Growth and differentiation factor (GDF)-15 is a member of the transforming growth factor (TGF)-beta family. Its biological
function has been linked to neuronal survival and tumor cell apoptosis. Here we demonstrate that glioma patients display
elevated serum levels of GDF-15 compared to healthy controls. GDF-15 mRNA and protein are also expressed in humanglioma cells in vitro. Suppression of GDF-15 expression by RNA interference reduces the proliferation of malignant glioma
cells. Intriguingly, GDF-15-depleted glioma cells are more susceptible towards NK and T cell-mediated cytotoxicity.
Moreover, GDF-15-deficient glioma cells are less tumorigenic than control cells in syngeneic mice in vivo. GDF-15 is thus anovel aberrantly expressed molecule which contributes to proliferation and immune privilege of human malignant gliomas.

- 151 -­­

Poster Presentation (P)Purpose
Incidence of invasive cancer rises from adolescence (SEER Data). Brain tumor types change with age; embryonal brain
tumors become less common in adolescence (CBTRUS data). Our hypothesis is that medulloblastomas (MB), an
embryonal tumor, is biologically different in adolescence due to differences in host biology. Adolescence is defined as >/=9,</=15years in this study.
MethodsmRNA expression profiles of 71 MB and 6 normal brain specimens were characterised using Affymetrix HG-U133plus2.0
Gene-Chips. Unsupervised hierarchical clustering identified 4 clusters. Cluster C comprised of 6 normal brain tissues and 1
tumor (non-adolescent). Class comparison was performed between adolescents and non-adolescents, between clusters
to establish significant differences in gene expression (using FDR=0.001, CI=95%). Differentially expressed genes werecategorized in GeneOntology groups using the DAVID Tool.
Results
Adolescents accounted for 44.1% (15/34) of Cluster D, Cluster A (6/27), Cluster B (0/9), p=0.019 (Fisher,s Exact Test).
There were 21 adolescents; 71.4% of adolescents have Cluster D signature. Cluster D has 3 subgroups; majority ofadolescents occurred in Subgroup D1 (11/20), D2 (1/11), D3 (3/3).
No significant difference in gene expression of adolescent MB compared to non-adolescents across clusters.
Tumor Clusters A, B, D compared among each other; Cluster A significantly overexpressed genes involved in brain
development, organ, cellular, neurite morphogenesis, neurogenesis and axon guidance, compared to Cluster D(p=0.0000007-0.04).
Class comparison between Subgroup D1 and D2 revealed 153 significantly differentially expressed genes. D1 significantly
underexpressed genes of light perception (p=0.0008), pathways (p=0.0004-0.001) involved in T-cell receptor (TCR) locus.
Conclusions
Adolescent MB have different molecular signatures, majority showing the D1 signature, underexpressing genes of lightperception and TCR as compared to D2. The presence of T-cells and its potential significance in the prognosis of MB is
being explored.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P063
Personalized chemotherapy based on O6-methylguanineDNAmethyltransferase (MGMT) expression pattern for glioma patients:
experience of 57 cases
Junping Zhang1,2, Zhongping Chen1
1
Neuro-oncology, Cancer Center, SUn Yat-sen University, Guangzhou, China 2Neuro-oncology, Beijing Sanbo Brain
Hospital, Beijing

There were 57 malignant glioma patients (anaplastic oligodendroglioma, AO 3 cases, anaplastic astrocytoma, AA 36 cases,
glioblastoma multiforme, GBM 18 cases) received chemotherapy in Cancer Center of Sun Yat-sen University, based on
expression of O6-methylguanine-DNAmethyltransferase (MGMT) and response as well as survival time were evaluated. In
which 36 were recurent cases, and 21 were initial chemotherapy. Twenty patients had received previous chemotherapy and37 cases without previous chemotherapy. All the pateients had received radiotherapy before. Thirty-five patients with
MGMT positive tumors received no-alklating agents chemotherapy regimen, which consisted of teniposide (VM-26),
cisplatin (DDP), carboplatin(CBP), isophosphamide(IFO), etoposide(VP16), or cisplatin plus TMZ regimen. While 22 patientswith MGMT negative tumors, there was no restriction on chemotherapy regimen. That was eigther nitrourea or TMZ had
been used in the regimen, and the most commonly used regimen were PCV;TMZ+VM26; MeCCNU+VM26. There was no
significant difference on objective response (OR) or response rate (RR)between MGMT positive and negative patients(p>0.05). By following up 0.7-53.4 months(mean 11.7 months), progressive-free survival (PFS) in MGMT negative andpositive patients were 8.5 months(95% CI 4.8-19.3) and 6.7 months(95% CI 3.7-9.3), and overall survival(OS) were 20.3
months (95% CI 14.3-) and 16.1 months (95% CI 11.1-26.2, respectively. (p>0.05). Our results indicated that personizedchemotherapy for glioma patients based on MGMT expression can obtain satisfactory results espercially for patients with
MGMT positive gliomas.Key words: chemotherapy, glioma, O6-methylguanine-DNAmethyltransferase

P064
CDK4/6 SMALL MOLECULE INHIBITOR PD-0332991 DEMONSTRATES ANTI-TUMORACTIVITY AGAINST AN INTRACRANIAL GLIOBLASTOMA XENOGRAFT LACKING p16
FUCNTION
Karine Michaud1, Tomoko Ozawa1,J anina De La Torre1, Michael D. Prados1, Mitchel S. Berger1,
Scott R. VandenBerg1,C. David James1
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA

1

Poster Presentation (P)PURPOSE: The purpose of this study was to achieve a preliminary assessment of whether glioblastomas (GBMs) with p16
homozygous gene deletions (approximately two-thirds of all GBM) are responsive to cyclin dependent kinase (CDK) 4 andCDK-6 small molecule inhibition, in the context of an orthotopic GBM xenograft therapy response model. METHODS:
Luciferase-modified U87 GBM cells, which lack p16 function, were injected into the brains of athymic nu/nu mice that wererandomized to CDK4/6 inhibitor PD-0332991 vs. vehicle only treatment groups, with oral administration of inhibitor 1x daily(150 mg/kg) for four consecutive weeks, beginning at day 13 subsequent to tumor cell injection. All animals were monitored
1-2x weekly using bioluminescence imaging (BLI) to assess tumor response to therapy, and each animal was followed until
presentation of neurological symptoms indicative of excessive tumor burden that requires euthanasia. RESULTS: BLI
monitoring revealed sustained anti-tumor activity for the entire period of therapy administration, which was followed by rapid
tumor growth after completing the 4 week CDK4/6 inhibitor administration regimen. CDK4 inhibitor extended median survival
by 18 days (60%) relative to vehicle treatment, with mean survival extended by greater than 19 days. One CDK4/6 inhibitor
treatment group mouse showed no evidence of intracranial tumor following completion of treatment, and was euthanized atday 100 following tumor cell injection. Comparison of MIB-1 staining in tumor from the brain of one mouse that was
sacrificed while on therapy vs. the MIB-1 staining in tumor from a control (untreated) group mouse revealed a greater than
8-fold reduction in tumor MIB-1 positivity resulting from CDK4/6 inhibitor treatment. CONCLUSIONS: Our results indicatethat oral administration of CDK4/6 inhibitor PD-0332991 results in substantial anti-proliferative activity against an orthotopic
GBM xenograft lacking p16 function, and support further investigation of this therapeutic for treating patients with GBM.

P065
PATIENT-SPECIFIC VIRTUAL CONTROLS CAN BE USED TO SIMULATE AND PREDICTRESPONSE TO RADIATION THERAPY IN INDIVIDUAL GLIOBLASTOMA PATIENTS
Kristin R Swanson1, Russ Rockne1, Jason K. Rockhill2, Maciej Mrugala3, Ellsworth C. Alvord, Jr1
Department of Pathology, University of Washington School of Medicine, Seattle, WA 2Department of Radiation
Oncology, University of Washington School of Medicine, Seattle, WA 3Department of Neurology, University ofWashington School of Medicine, Seattle, WA
1Patient-specific virtual controls (VCs) are created for 26 patients with histologically diagnosed glioblastoma multiforme
allowing testing and validation of a biomathematical model for glioma response to radiation therapy (RT). Individualized
glioma growth kinetics, described by the mathematical model parameters quantifying net rates of invasion and proliferationof glioma cells, are determined from serial magnetic resonance imaging prior to treatment for each patient[1]. Knowledge ofthese patient-specific growth kinetics allows for simulation of untreated VCs for each patient against which therapeutic
response can be assessed. Serial post-treatment imaging is used to assess response to RT. The net proliferation rate isstrongly correlated (r = 0.84, p &lt 0.01) with the radiation efficacy (&alpha from the classical linear-quadratic radiobiology
model). This correlation was tested as a means of predicting radiation efficacy from the pre-treatment proliferation rateusing a leave-one-out-cross-validation analysis yielding a mean error between simulated and actual post-RT tumor radiusof 3 mm. In a survival analysis, pre-treatment growth kinetics and radiation response metrics was a significant predictor ofsurvival even when controlling for the prognostic value of recursive partitioning (RPA) class established by the radiation
therapy oncology group (RTOG). The fundamental result from the investigation is the ability to predict response to therapy
prior to treatment using a variety of clinically established and novel biomathematical model-based metrics. Ultimately,
directing treatment with knowledge of VCs allows for improvement in the design of individualized patient therapies, such as
RT, as well as a novel technique to assess response for any therapies since an untreated VC provides comparison for theactual tumor behavior. [1] HLP Harpold, EC Alvord, Jr, KR Swanson: The Evolution of Mathematical Modeling of Glioma
Growth and Invasion. Journal of Neuropathology and Experimental Neurology, 66(1):1-9, 2007

- 152 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P066
Autophagy Induced by Valproic Acid is Associated with Oxidative Stress in
Glioma Cell Lines
Jun Fu1, Zhong Ping Chen1
1
State Key Laboratory for Cancer Research in Southern China and Department of Neurosurgery/Neuro-oncology,
Cancer Center, Sun Yat-Sen University, Guangzhou, China

Autophagy represents an alternative tumor-suppressing mechanism to overcome the dramatic resistance of malignant
gliomas to radiotherapy and proapoptotic related chemotherapy. In this study, we reported that valproic acid (VPA), a widelyused anti-epilepsy drug, induces autophagy in glioma cells. Autophagy, crucial for VPA-induced cell death, is independentof apoptosis, even though apoptotic machinery is proficient. Oxidative stress induced by VPA occurs upstream of
autophagy. Oxidative stress also activates the ERK1/2 pathway, whereas blocking ERK1/2 pathway inhibites autophagy andinduces apoptosis. VPA-induced autophagy can not be alleviated by inositol, suggesting a different mechanism fromlithium. Moreover, VPA potentiates autophagic cell death, but not apoptosis, when combined with other autophagy inducers
such as rapamycin, Ly294002 and temozolomide in glioma cells, which may warrant further investigation toward possible
clinical application in patients with malignant glioma.

P067
Management of pituitary adenoma with stereotactic radiotherapy at
Princess Margaret Hospital.
Nikhilesh Patil*, James Brierley*, Monique van Prooijen +, Mostafa Heydarian +, Sharon
Mckinnon #, Shenaz Ladak #, Sharon Fung § , Richard Tsang*.
Departments of *Radiation Oncology, ++Radiation Physics, # Radiation Therapy and § Biostatistics
Princess Margaret Hospital, University of Toronto, Toronto, Canada.

P068
Genomewide Analysis of Loss of Heterozygosity in Glioblastoma using
the SNP mapping array and the PCR with multiple microsatellite markers
Masahiro Mizoguchi1, Daisuke Kuga1, Yanlei Guan1, Nobuhiro Hata1, Koji Yoshimoto1,
Tadahisa Shono1, Tomio Sasaki1
Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan1[PURPOUSE] Loss of heterozygosity (LOH) analysis is an effective approach to classify the malignant gliomas. Recent
development of genomewide analysis revealed that the LOH extent could have different consequences for clinical courses.
Thus, LOH analyses with limited numbers of markers cannot evaluate LOH status accurately. [MATERIALS andMETHODS] We analyzed LOH status of 92 malignat gliomas (61 glioblastoma (GBM), 16 anaplastic astrocytoma (AA), 15
anaplastic oligodendroglioma (AO)) using the PCR with multiple microsatellite markers. Furthermore, we applied 50K SNP
mapping array for comprehensive analysis of LOH status in 14 glioblastomas. For the conventional PCR analysis, we set six
markers for 1p region, ten for chromosome 10 (ch10) and four for 19q region, respectively. We distinguished between
partial and total LOH for 1p and ch10 region. [RESULTS] Total loss of ch10 was observed in 38 GBMs (66%) and 4 AAs(25%). All AO cases except two cases showed 1p total loss combined with 19q loss. In contrast, only seven GBM cases
showed 1p total loss. Moreover, ten GBM cases showed 1p partial loss. Only GBM with 1p total/ 19q loss showedfavorable overall survival compared with the others. SNP array analysis can detect both copy number and allelic imbalance
simultaneously. In total, we identified 254 LOH loci in 14 GBM cases. Interestingly, 143 out of 254 loci (56.3%) showed
copy number neutral LOH (cnLOH). Thus copy number analyses such as FISH and CGH may underestimate LOH locicompared with SNP array analysis. The PCR analysis with multiple mirosatellite markers is accurately detected LOH lociidentified by SNP array analysis. [CONCLUSIONS] The PCR with multiple microsatellite markers is practically usefulapproach to evaluate LOH status. LOH pattern and cnLOH should be considered for accurate LOH analysis.

- 153 -­­

Poster Presentation (P)Purpose: To evaluate local control and toxicity for pituitary adenomas treated with stereotactic radiotherapy (SRT).
Methods: Patients with pituitary adenomas referred and treated 1997-2007 were retrospectively reviewed (n=83). Medianage was 47 years (range: 14-73), with 46 males and 37 females. Twenty patients had functional and 63 had non-functional
tumors. Median follow up was 42 months (range: 1-137). Two patients received SRT as their primary treatment, 38 received it
postoperatively and 9 for raised hormones. Thirty-four patients received SRT for radiological progression despite priorsurgery with median time to progression following surgery being 12 months (range 1-275). Before SRT, hormone
replacement therapy was observed in 37% (thyroid), 35% (cortisol), and 30% (testosterone, males only). SRT dose was
50Gy in 25 daily fractions using the GTC frame, and CT-MR fusion for planning (RadionicTM ). The GTV and sella contents
were treated, with no expansion from CTV for PTV margin. The prescription guideline was > 95% coverage of the CTV by aminimum dose of 47.5 Gy, and maximum dose < 52.5 Gy.
Results: The 3-year progression free survival for functional and non-functional adenomas was 94% and 92% respectively(p=0.90). Four patients had progression (3 nonfunctional and 1 functional); among these, 2 had metastatic spread. One
patient had salvage excision, 1 had radiosurgery, 1 patient required temozolamide for lepto-meningial disease and 1 required
palliative radiation to treat lumbar bony metastases. Post SRT 43 patients (52%) had hypothyroidism, 35 (42%) required
cortisol and 20 (24%) required testosterone. 1 patient had severe optic neuropathy. To date there were no second cancers.
Conclusion: Though with a relatively short follow up, this study suggests fractionated stereotactic radiotherapy with anarrow margin is safe and effective for the treatment of pituitary adenomas.
Reference and Updating Password: doctor

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P069
Molecular allelokaryotyping of malignant glioma by high-resolution
single nucleotide polymorphism (SNP) oligonucleotide genomic
microarray
Hideo Nakamura1, Takaaki Goto2, Keishi Makino1, Takuichiro Hide1 ,Motohiro Kato3, Seishi
Ogawa3, Hideyuki Saya2, Jun-ichi Kuratsu1
Dept. of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, 2Division of Gene Regulation,
Institute for Advanced Medical Research, Keio University School of Medicine 3Regeneration Medicine of
Hematopoiesis, University of Tokyo, School of Medicine
1

Purpose: Glioma is a CNS tumor resulting from accumulation of genetic alterations. Whole genome analysis clarifying thecorrelations between genetic abnormalities and clinical features in gliomas may provide a new strategy for determining
prognosis and treatment of glioma patients. Patients and Methods: A robust technology, single nucleotide microarray(SNP-chip) was used for the whole genome analysis in all grade gliomas. We examined 73 samples with GBM, 58 withgrade III glioma, 18 with low grade glioma and their matched blood samples at 50000/250000 SNP sites using an SNPchip platform. Correlations between genetic alterations and prognosis in malignant gliomas were also analyzed. In thisanalysis we focused on several genetic alterations such as loss of heterozygosity (LOH) of chromosome 10, 1p, 19q,
amplifications sites of PI3KC2B, PDGFRA, EGFR and LOH of CDKN2B locus on chromosome 9p21, p53 locus on 17p13,
RB locus on 13q14. Results: Frequent changes detected in GBM were LOH of Chromosome 10 (49/73, 67%) and LOH of
CDK2B locus (41/73, 56%). On the other hand LOH of 1p or 19q was frequently found in anaplastic oligodendroglioma(20/21, 95%) or oligo-astrocytoma (11/22, 50%). Amplification of EGFR or PDGFRA was found in approximately 30~40% of
GBM cases but none in pure oligodendroglioma (grade II & grade III). LOH in 17p13 (p53) locus was equally found in grade
III glioma and GBM (15/58, 26% in grade III, 18/73 25% in GBM). LOH in 13q14 (RB) locus was found in 22% (16/73) of
GBM. Multiple chromosome alterations (at least 5 ) were dismal prognosis factor in GBM and 1p and 19q LOH was good
prognosis factor in grade III glioma. No Genetic alteration was found in low grade gliomas. Conclusion: Although there arevarious genetic alterations, common genetic alterations were observed in all grade gliomas.

P070
An ANOCEF genomic and transcriptomic microarray study of the
response to radiotherapy or to alkylating first-line chemotherapy inglioblastoma patients.
Francois Ducray1,4,10, Aurelien De Reynies2, Olivier Chinot 3,10, Ahmed Idbaih4,10,
Dominique Figarella-Branger5,10, Lucie Karayan-Tapon6, Herve Chneiweiss7, Michel Wager6,10,
Francois Vallette7, Yannick Marie4,10, Jean-Yves Delattre4,10, Jerome Honnorat1,10, Marc
Sanson4,10, Francois Berger 9
INSERM U842, Lyon, France 2CIT, Ligue Nationale Contre le Cancer, Paris, France 3Universite de la Mediterranee,
Faculte de Medecine de Marseille, Assistance Publique-Hopitaux de Marseille 4INSERM U711 and Universite P&M
Curie, Paris, France 5Faculte Medecine Timone, Universite de la Mediterrannee UMR911 CRO2, Service d’Anatomie
Pathologique et de Neuropathologie 6Universite de Poitiers, EA3805, CHU de Poitiers, 86022 Poitiers cedex 7UMR 894
INSERM, Faculte de Medecine Universite Paris Descartes, Paris, France 8Centre de Recherche en Cancerologie
Nantes Angers, Centre INSERM U892, Universite de Nantes 9Inserm U836, Grenoble Institut de Neurosciences, Unite
Joseph Fourier, 38042 Grenoble Cedex 9 10ANOCEF (French NeuroOncologist Association)
1

Poster Presentation (P)Context: The molecular characteristics associated with the response to treatment in glioblastomas remain largely
unknown. Methods: Here, we compare the gene expression (n=56) and genomic profiles (n=67) of responders and nonresponders to either first-line chemotherapy or radiation therapy alone. Results: We show that the characteristics
associated with treatment response are different according to the type of treatment received. In patients treated withradiation therapy alone, the response was associated with the differential expression of microenvironment-associatedgenes, where the expression of immune genes was associated with prolonged progression-free survival, whereas theexpression of hypoxia-related genes was associated with early relapse. In patients treated with first-line chemotherapy, we
found a significant association between the treatment response and p16 locus deletions, in particular in patients without
MGMT promoter methylation. This association was further validated in an independent data set. Our results demonstrate
that, according to the tumor genomic characteristics, some patients benefit more from chemotherapy and others morefrom radiotherapy. Conclusion: These results encourage the combination of both treatment strategies to increase thelikelihood of glioblastoma response and suggest that further work could identify specific markers to predict chemo- orradiotherapy efficacy.

- 154 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P071
Selective Expression of a Subset of Neuronal Genes in
Oligodendrogliomawith Chromosome 1p Loss
Akitake Mukasa1,4, Keisuke Ueki2, Saito Nobuhito1, Takaaki Kirino3, Hiroyuki Aburatani4
Department of Neurosurgery, University of Tokyo, Tokyo, Japan 2Department of Neurosurgery, Dokkyo University
School of Medicine 3International Medical Center of Japan 4Genome Science Division, Research Center for Advanced
Science and Technology, University of Tokyo

1

Gliomas are classified based mainly on microscopic resemblance to their presumed glial origin such as astrocyte andoligodendrocyte. However, more objective diagnostic criteria are indispensable for the precise treatment of patients. For
instance, loss of the short arm of chromosome 1 (1p) in oligodendrogliomas is recognized as an important marker for better
response to chemotherapy and longer survival of the patients. To gain insight into their molecular biological backgroundand to identify genes characterizing each subgroup, we investigated gene expression profile of the 4 glioma subsets,oligodendroglioma with and without 1p loss, diffuse astrocytoma and glioblastoma using DNA microarray. Remarkably,most of the genes showing distinctive expression in oligodendroglioma with 1p loss were also highly expressed in normal
brain tissues and had neuron-related function, which included MYT1L, INA, RIMS2, SNAP91 and SNCB. Histologicalanalysis also demonstrated that MYT1L, which were abundantly expressed in normal neuron, were certainly present intumor cells. These results suggest that oligodendroglioma, especially with 1p loss, has more or less neuronalcharacteristics although oligodendroglioma is thought to originate form glial lineage cell. With further pathological studies,those neuron-related genes might be good diagnostic markers for oligodendroglioma of better prognosis as well.

P072
LOSS OF HETEROZIGOSITY AT 1p-19q INDUCES A GLOBAL CHANGE IN
OLIGODENDROGLIAL TUMOR GENE EXPRESSION.
Horacio Martinetto1, Ruben Ferrer-Luna2, Manuel Mata2, Lina Nunez1, Eugenia Arias1,
Jorge Calvar 4, Ana L. Taratuto1, Bernardo Celda2,3, Gustavo Sevlever1
1Department of Neuropatholgy, FLENI, Buenos Aires, Argentina 2Universitat de Valencia (UVEG), Valencia, Spain
3
CIBER Bioengineering , Biomaterials and Nanomedicine, ISC-III, Valencia, Spain 4Department of Neuroimaging,
FLENI, Buenos Aires, Argentina

P073
Functional analysis of the proteome related to the chemotherapy
sensitivity in anaplastic oligodendroglioma and anaplastic
oligoastorocytoma
Nobuyuki Tsubota1,2, Takashi Morikawa2, Uichi Midorikawa2, Daiki Kobayashi2, Hideo Nakamura1,
Junichi Kuratsu1, Norie Araki2
Dept. Nuerosurg, Grad. Sch. Med., Kumamoto Univ. 2Dept. Tumor Genet. and Biol., Grad. Sch. Med., Kumamoto Univ.

1

Malignant gliomas are generally resistant to all standard therapies. However, patients with anaplastic oligodendroglioma(AOG)/anaplastic oligoastorocytoma (AOA) with loss of heterozygosity on chromosome 1p and 19q (LOH+) frequently
respond to chemotherapies. To date, the responsible molecular factors for this chemosensitivity have not been clarified indetail. In this study, we analyzed the specific proteins related to this chemosensitivity by using newly established proteomic
strategies such as 2D-DIGE combined with phospho-specific staining and iTRAQ LC-shotgun methods. As a result, we
identified 105 specific proteins differentially expressed in LOH- AOG/AOA, and 34 phosphorylated proteins highly modified
in LOH- vs LOH+ tumors, including EGFR-MAPK, vascular PIFs, adhesion molecules, cell cycle regulator, CDK families, andcytoskeletal organizing factors. Among them, we focused on vimentins that were highly phosphorylated in LOH- samples(at least 15 vimentin modified spots were identified in the 2D). The specific increase of vimentin expression in LOH- tissues
was confirmed by immunohistochemistry and wetern blotting. By 2D-Western blotting and MS analysis, we found that the
specific phosphorylated vimentins had some cleavage forms and these short vimentins were statistically increased in 30
LOH-AOGs. Interestingly, the responsible enzymes for vimentin modifications, such as PAC, CaMK2, caspases, calpains,
identified as up-regulated proteins in LOH- AOG in our proteomic study, were found on the ch1p, 19q or 10pq. We discuss
the structure and function of vimentin and responsible enzymes related to AOG/AOA chemotherapy sensitivity in detail. The
idea for cellular activity regulation of vimentin and its modification enzymes may hold some potentialities for a new strategy
against AOG/AOA.

- 155 -­­

Poster Presentation (P)PURPOSE: Oligodendroglial tumors presenting loss of heterozigosity (LOH) at 1p and 19q have been shown to be sensitive
to chemotherapy, thus making of 1p-19q status testing a key aspect in oligodendroglioma diagnosis and prognosis. Our
aim was to develop a molecular signature identifying tumors bearing 1p-19q LOH. METHODS: Twenty-nine tumor samples(19 oligodendrogliomas, 10 oligoastrocytomas) were analyzed by microarrays in order to obtain the expression profile.
Other genomic anomalies usually present in gliomas such as EGFR amplification, CDKN2A/ARF deletion, 10q LOH andTP53 mutation were also studied. RESULTS: Tumors with 1p-19q LOH over-expressed genes related to neurogenesis.
Genes linked to immune response, proliferation and inflammation were over-expressed in the group with intact 1p-19q; thisgroup could in turn be further divided in two subgroups: one over-expressing genes involved in immune response andinflammation which did not show major genetic aberrations other than TP53 mutation and EGFR trisomy in few cases, andanother over-expressing genes related to immune response and proliferation which concentrated samples carrying several
anomalies and presenting worse outcomes. This molecular signature was validated by analyzing a set of 10 tumor samples(3 oligodendrogliomas, 7 oligoastrocytomas); all 10 samples were correctly assigned. CONCLUSION: LOH at 1p-19q
produces a global change in gene expression inducing a pro-neural status that results in restrictions to cell migration andproliferation. Tumors without LOH at 1p-19q exhibit opposite characteristics, explaining their more aggressive behavior.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P074
Establish the overall proteins reference database of human normal
pituitary using 2D-HPLC combined with LTQ-Orbitrap MS
Rong Xie1, Wei Ming Bao1, Hang Liu1, Bo Jie Yang1, Xiao Yun Cao1
1Department of Neurosurgery, Huashan Hospital, Fudan, Shanghai,China
Objective: To establish the quantitative reference database of overall proteins expression of human normal pituitary.
Methods: Three samples of human normal pituitary tissues were collected during the transphenoidal approach operationsof pituitary microadenoma for enlarging resection, which was consented by the patients and approved by the Ethics
Committee of Huashan Hospital, Fudan University. Total proteins were extracted and analyzed using 2D-HPLC combinedwith LTQ-Orbitrap MS proteomics technology to establish the quantitative overall proteins reference database of humannormal pituitary. Results: The quantitative database containing 406 total proteins of human normal pituitary has been
established successfully. The proteins by turns according to the amounts are type VI collagen 1.30%, fibrinogen 0.99%,
vimentin 0.73%, prolactin 0.69%, ATP synthase and H+ transporting mitochondrial F1 complex 0.52%. The types ofproteins by turns are the combining proteins 40.1%, the catalysis proteins 28.3% and the signal transducer proteins 9.8%.
Conclusion: The quantitative overall proteins reference database of human normal pituitary has been precisely andefficiently established by the proteomics technology, which could settle the foundation for the studies of pituitary adenoma
and other diseases related to the pituitary. The discoverable proteins such as cytoskeletal proteins, CA I and HSP 90 may
provide suitable targets for the progressive research.

P075
CD52 protein may be a potential tumor marker of hemangioblastoma incentral nerval systerm with cDNA microarray filtration of the gene
expression profiles
Xing-hua Ding1, Xiao-luo Zhang1, Ying Mao1, Yao Zhao1, Jia-lei Gong2, Liang-fu Zhou1
Department of Neurosurgery, Huashan Hospital, Shanghai medical college, Fudan University, Shanghai, China;
Institute of biochemistry and cell biology, Chinese academy of sciences, Shanghai,China

12[Abstract] Objective To analyze the gene expression profiles of central nerval systerm hemangioblastoma by using cDNA
microarray and detect target genes for further study. Methods Two mixed samples from 5 cases of hemangioblastomas
and 3 cases of normal cerebellum tissue were studied by means of cDNA microarray consisting of 14000 genes. Results
There were 61 expressed genes which difference were more than 3 times between two samples including 10 up regulated
and 51 down regulated genes. The results of cDNA microarray were repeated by RT-PCR and immunohistochemistry.
Tumor suppressor genes, growth factor, cell signal conduction genes and so on were identified. Analysis with cDNA
microarray, expression level of CD52 between HBs and normal cerebellar tissues were up-regulated for 3 times. With
Western-Blot, expression level of CD52 in 4 HBs are obviously higher than normal cerebellar tissue. By CD52
immunohistochemistry stain, only stromal cells in 40 HBs showed positive reactions. By CD52 immunofluorescence stain in
cultured cells of HBs , membrane and cytoplasm of stromal cells showed positive reaction. Conclusion The results ofcDNA microarray in hemangioblastoma were reliable.Many genes would be involved in the pathogenesis ofhemangioblastoma besides VHL gene. CD52 protein may be a tumor marker of HB. [Keywords] hemangioblastoma, gene
expression, cDNA microarray

Poster Presentation (P)P076
Genome-wide analysis of gene expression during brain metastasis
formation
Norihiko Saito1, Kazuya Aoki1, Tsutomu Hatori2, Keisuke Itou1, Morito Hayashi1, Yoko Hirata1,
Kenichiro Sato1, Haruo Nakayama1, Junichi Harashina1, Masaki Akahata1, Satoshi Iwabuchi1
Department of Neurosurgery, Toho University Ohashi Medical Center 2Department of Surgical Pathology, Toho
University School of Medicine

1

The brain is frequently affected by the spread of lung cancer, and hematogenous metastasis is a common route to brain
metastasis. In the present study, we attempted to characterize genetically the dynamic changes occurring during brain
metastasis formation by DNA microarray, and attempted to compare these findings with histological observations.
In histological observation, tumor cells were observed in capillary vessels at day 1 after injection. At day 3, the tumor cells
had begun to proliferate, forming metastatic foci. At day 6, the metastatic foci showed an angiocentric pattern, and were
designated perivascular proliferations.
Next, we performed a pairwise comparison of gene expression microarray data from day 1 to day 9 after injection. The firstmajor change occurred between Phase Two and Phase Three. However, there were no distinct morphological changes atthe point the second major change occurred. When hierarchical clustering was performed between different samples using
the 867 genes that had been extracted, they could be classified into identical clusters for days 1 and 2, identical clusters forday 3 to day 5, and identical clusters for day 6 to day 9. For time course analysis of individual genes, we extracted 623
genes from the 5157 genes obtained by the pairwise comparison. By using the QT nonhierarchical clustering method, we
identified 37 expression patterns. These 37 expression patterns can be separated into 8 clusters by using the k-means
method.
The microarray results reported here strongly suggest that a large number of genes exhibit a spike pattern, which istantamount to phase-specific expression.

- 156 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P077
Hypoxia promotes expansion of the CD133-positive glioma stem cells
through activation of HIF-1α
Akio Soeda1
Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Hypoxia contributes to the progression of a variety of cancers by activating adaptive transcriptional programs that promote
cell survival, motility, and tumor angiogenesis. Although the importance of hypoxia and subsequent HIF-1α activation intumor angiogenesis is well known, their role in the regulation of glioma-derived stem cells is unclear. Here we show thathypoxia promotes the self-renewal capacity of CD133-positive human glioma-derived stem cells. Propagation of theglioma-derived cancer stem cells (CSC) in a hypoxic environment also led to the expansion of cells bearing CXCR4(CD184), CD44-low and A2B5 surface markers. The enhanced self-renewal activity of the CD133-positive CSC in hypoxia
was preceded by upregulation of HIF-1α. Hypoxia also promotes vascular endothelial growth factor production in CSCs.
Knockdown of HIF-1α abrogated the hypoxia-mediated CD133-positive CSC expansion. HIF-1α protein expression andtransactivity are due to the phosphorylation of Akt, extracellular signal-reglated kinase 1/2 (ERK1/2), p70S6 kinase, as
indicated by application of the these inhibitors, LY294002, PD98059 and rapamycin, suggesting that thephosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and ERK pathways, in a potentiallyindependent and co-operative fashion, can modulate HIF-1α activation by hypoxia. Lastly, CSC propagated at hypoxia
robustly retained the undifferentiated phenotype, while CSC cultured at normoxia did not. These results suggest that
response to hypoxia by CSC involves activation of HIF-1α to enhance the self-renewal activity of the CD133-positive cells
and inhibit induction of CSC differentiation. This study illustrates the importance of the tumor microenvironment indetermining cellular behavior.

1

P078
Effects of hypoxia on expression of a panel of stem cell andchemosensitivity markers in glioblastoma cell line-derived spheroids
Jesper Kolenda1, Stine Skov Jensen1, Charlotte Aaberg-Jessen1, Karina Christensen1,
Bjarne Winther Kristensen1
Department of Clinical Pathology, Odense University Hospital, Odense, Denmark1

P079
Cell motility features are identified in the CD133-positive glioma andendothelial progenitor cells
Ping-Pin Zheng1, Johan M Kros1
Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands

1

Cell motility is required for gliomagenesis during invasion of glioma cells, migration of endothelial progenitor cells (EPCs) fromthe blood stream into tumor cell populations to form new blood vessels (vasculogenesis) and for navigation of local
endothelial tip cells during sprouting angiogenesis. CD133-positive tumor stem cells are capable of tumor initiation andCD133-positive EPCs are a major determinant of nascent tumor neovascularization in experimental animals. Obviously,
therapeutic interference with motility of both vascular cells as well as tumor cells within the CD133-positive population would
be an important strategy in future anti-tumor therapy. These migrating cells usually escape from all conventional anti-tumor
or anti-angiogenesis therapies. So far, no studies on the identification of motility-related cellular features in tumor cells andEPCs present in human tumor specimens have been undertaken. Glial tumor cells are notoriously invasive and also, in
gliomas prominent neovascularization takes place. In the present study we sought motility-related cell features as describedin cell cultures in glial tumor tissue obtained from surgery. To this aim, a cohort of samples of glioma were investigated byusing confocal microscopy to double- and triple immunostained tissue specimens. Several functional stem cell and EPC
surface markers were used for the investigation of the cell populations. We discovered a variety of plasma membrane
protrusions which are known to be involved in cell motility in CD133-positive glioma cells and endothelial progenitor cells in
the tumor samples. We conclude that the features which are characteristic for cell motility as observed in vitro are identifiablein native human glioma specimens. Subsequent studies are necessary to discover the trigger for the formation of thesefeatures and their protein composition, in order to develop strategies for therapeutic elimination of the migrating cells.

- 157 -­­

Poster Presentation (P)Glioblastomas are the most frequent and malignant primary brain tumor. Tumor stem cells in these tumors have recently beensuggested to possess innate resistance mechanisms against radiation and chemotherapy possibly explaining their high level oftherapeutic resistance. Moreover, tumor hypoxia with oxygen tensions below 1-5% O2 has been attributed to play a crucial rolein tumorigenesis and therapeutic resistance in glioblastoma. In this study the influence of hypoxia on the expression of a panelof stem cell and chemosensitivity markers was therefore investigated using glioma spheroids derived from the conventional
glioblastoma cell line U87. The glioma spheroids were derived at normoxic (21% O2) and hypoxic (1% O2) culturing conditions
in serum-free medium with EGF and bFGF. The entire immunohistochemical panel included hypoxia (HIF-1&alpha, HIF2&alpha), proliferation (Ki-67) and stem cell (CD133, nestin, podoplanin, Bmi-1, Sox-2) markers as well as markers related tochemosensitivity (MGMT, MDR-1, TIMP-1, Lamp-1). Since spheroids derived in hypoxia were smaller than in normoxia, a set ofexperiments was included, in which the culturing time of hypoxic spheroids was extended to obtain equally sized spheroids.
HIF-1&alpha was significantly increased in hypoxia, whereas the Ki-67 positive fraction of proliferative cells was significantly
reduced. The expression of stem cell markers CD133, nestin, podoplanin and Bmi-1 was significantly increased in hypoxia
similar to what was found for TIMP-1 and Lamp-1. Similar differences in the expression pattern was observed in equally sizednormoxic and hypoxic spheroids, although more pronounced differences were found for podoplanin, nestin and TIMP-1 as well
as for Ki-67. Hif-2&alpha, Sox-2, MGMT and MDR-1 were not detectable in U87 spheroids. In conclusion, the expression oftumor stem cell and chemosensitivity markers seems to depend on the oxygen tension suggesting that future development oftherapeutic strategies targeting tumors stem cells should take this experimental design into account.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P080
GLIOBLASTOMA TUMOUR INITIATING CELLS DEMONSTRATE VEGF BUT NOT PDGF
AUTOCRINE SIGNALLING

Cancelled

P081
Establishment of artificial Glioblastoma initiating cells in mouse
Takuichiro Hide1,2, Tatsuya Takezaki1,2, Hideo Nakamura1, Keishi Makino1, Jun-ichi Kuratsu1,
Toru Kondo2
1
Department of Neurosurgery, Kumamoto University Graduate School, Kumamoto, JAPAN 2Laboratory for Cell Lineage
Modulation, RIKEN Kobe Institute, CDB

Cancer initiating cells (CICs) in brain tumors, such as GBM, medulloblastoma, ependymoma and anaplastic
oligoastrocytoma have been reported. CSCs are small fraction of cancer cells and CD133 is one of the markers of CICs inbrain tumors. However even collecting CD133 expressing cells, bona fide CICs are still minor in this population. To progress
the study of CICs on GBM, we tried to establish GBM initiating cells using mouse cells. Neurosphere cells (NSCs) wereprepared from embryonic mouse brain at 14.5 dpc. Astrocytes (ASTs) and oligodendrocyte precursor cells (OPCs) were
induced from the NSCs in suitable culture conditions and then purified them. NSCs, ASTs and OPCs were transfected with
vector plasmid expressing oncogene X with GFP by electroporation. After passaging, GFP positive cells were collected withcell sorter to establish oncogene X expressing cell lines (NSCX, ASTX and OPCX). To characterize these cell lines,
proliferation assays and soft agar assays were performed. The ability of proliferation was up-regulated in all three cell lines
compared to individual control cell lines. Colonies were seen in soft agar culturing NSCX and OPCX, but not ASTX. Next toanalyze tumor forming ability, these three cell lines were injected into nude mouse brain. In 1,000 cell injection, NSCX andOPCX could form GBMs and all mice died in a month but ASTX did not form tumor in the mouse brain. Moreover GBMs
were detected in the mouse brain, even 10 cells injection of NSCX and OPCX, respectively. Three of eight mice injected
10.000 ASTX could initiate anaplastic astrocytomas more after one month. The cells in different lineages and/or stages ofdifferentiation possess distinct transforming potential. NSCs and OPCs maintain the potential transforming to GBM initiating
cells compared to ASTs in this model.

P082
CD133 ON STEM CELLS IS REQUIRED FOR APOPTOTIC INDUCTION IN GLIOMASJasti S. Rao1, Christopher S. Gondi1, Bharathi Gorantla1, Lavanya Talluri1, Meena Gujrati1,
Dzung H. Dinh1, Jasti S. Rao1
University of Illinois College of Medicine at Peoria, Peoria, IL, USA

1

Poster Presentation (P)CD44 and CD133 enriched human umbilical cord blood stem cells (hUSC) were used for these studies, and a modified
Boyden-s chamber for the co-culture experiments. Human glioma cells (SNB19 or U87) or xenografts (4910 or 5310) were
cultured with hUSC, with or without CD133 (siRNA/CD133 antibodies), or with hUSC-conditioned media or serum-free
media. 48h later the glioma cell layer was subjected to TUNEL assay and apoptotic induction observed in glioma hUSC
cultures (70&plusmn3%) when compared to hUSC-conditioned media (3&plusmn1%) or with serum-free media(2&plusmn1%). Glioma cells cultured with CD133 siRNA/antibody pretreated with hUSC showed 42&plusmn5% (siRNA)
36 & plusmn5% (antibody) apoptotic events. FACS analysis showed an increase in subG0/1 phase in SNB19(83&plusmn3%) and U87 (87&plusmn4%) glioma cells and in 4910 (76&plusmn2%) and 5310 (73&plusmn5%) xenograft
cells when cultured with hUSC indicative of DNA damage. Glioma cells cultured with CD133-siRNA pretreated with hUSC
showed an increase of 23&plusmn5% (SNB19), 15&plusmn3% (U87), 22&plusmn2% (4910) and 26&plusmn4% (5310) in
the sub G0/1 phase when compared to untreated cells. Similar results were observed when cultured with CD133 antibody
pretreated with hUSC. Cleavage of caspase 8 was observed in glioma cells cultured with hUSC when compared to controls
indicative of extrinsic apoptotic pathway. In vivo studies were done with nude mice implanted with 1x106 SNB19 glioma cells
followed by hUSC (&plusmnRNAi/antibody pretreatment) and showed the least tumor development in hUSC implanted
mice (1.8&plusmn0.2mm3) when compared to controls (15.2&plusmn0.5mm 3). Pretreatment of hUSC with CD133 siRNA/
antibody showed a slight decrease in tumor development (8&plusmn2mm3) when compared to controls. To determine therole of glioma CD133, we downregulated CD133 (siRNA/antibody) in gliomas, co-cultured with hUSC, and observed for
apoptosis molecules. From western-blot analysis of caspase 8 and PARP, no contribution of CD133 to apoptosis wasobserved. Our results suggest that hUSC require CD133 for apoptotic induction in gliomas.

- 158 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P083
Tumor stem-like associated antigens and their irradiations improve theeffect of dendritic cell-based vaccination against human glioma
Wei Hua1, Ying Mao1, Yiwei Chu2, Baoguo Xiao3, Liangfu Zhou1
Department of Neurosurgery, HuaShan hospital , FuDan University, Shanghai , China 2Department of immunology,
Fudan University 3Institute of Neurology, Huashan Hospital, Fudan University

1

Tumor stem-like cells (TSC) are becoming a novel target in cancer therapy,we compared the different effects of DC
targeting of TSCs and of non-TSCs in immunogenecity and cytotoxicity in vitro.Two primary malignant glioma cell lines,
SHG62 and SHG66 , as well as U87 cells were cultured in the DMEM contained serum (SCM) and in DMEM/F12
supplemented with EGF/bFGF but no serum (SFM). Immunocytochemistry showed that the two groups of glioma cells
have different molecular and biological characteristics, and cells in SFM expressed higher levels of CD133 and manifested
TSC features. Cells in SFM demonstrated a comparably higher potential for clone formation of 50.3±2.63%, while cells in
SCM exhibited only 0.42±0.22% . Stem-like cells in SFM also expressed higher levels of HLA-A than differentiated cells.
Autologous DCs from PBMCs were then used for immunotherapy on the tumor cells in vitro. Flowcytometric analysis
determined that corresponding HLA-A, HLA-DR, CD80 and CD86 on DCs were up regulated after stimulated by different
antigens. T cells were significantly multiplied by autologous DCs. DCs loaded with non stem-like associated antigens(nonSAAs) killed 26% of differentiated glioma cells (GCs) and 9% of stem-like cells (SCs) respectively (p<0.001), whereas DCs
loaded with SAAs eliminated 55% of GCs and 38% of SCs (p<0.001). Strikingly, antigens obtained by irradiating SCs(6Gray) raised the cytotoxicity significantly to 75% (to GCs) and 59% (to SCs) (p<0.05). No difference of CTL killing ability was
detected between targeted glioma cells before and after irradiation (2 Gray)(p>0.05).These findings suggest that SAAs
provide a higher protection against glioma and the irradiations seemed to improve the effect, and radiotherapy had no
positive effect on immunotherapy, meanwhile SCs have a better ability of immune escape. These data offer a new design ofclinical trials based on DC vaccination.

P084
Immunosuppressive B7-H1 Protein is Expressed by Differentiated Glioma
Cells but not Glioma Stem Cells
Ian F. Parney1, Lei Zhang1, Guido Gonzalez1, John J. Kelly2, Samuel Weiss2
1
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, U.S.A. 2Hotchkiss Brain Institute, Universityof Calgary, Calgary, Canada

P085
B7-H1 is correlated with the malignancy grade of human astrocytic
tumors but it is not the privilege of brain tumor stem-like cells
Yu Yao1, Ying Mao1, Liangfu Zhou1
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China

1

Human glioblastoma is notorious for its capacity to interfere with effective anti-tumor immune responses. B7-H1 is the third
member of the B7 family that plays important roles in tumor immune evasion. Recent studies showed that brain tumor
stem-like cells (TSCs) contributed to tumorigenesis and radioresistance. However, the relationship between B7-H1 and theclinical behavior of brain TSCs remain unclear. In the present study, we reported that B7-H1 was correlated with themalignancy grade of astrocytic tumors. There was significant up-regulation of B7-H1 at the growing edge of the tumors.
Immunostaining indicated that B7-H1 was primarily expressed by Ki67 negative tumor cells. In vitro, tumors cultured under
medium favoring the growth of neural stem cells were able to form spheres, along with expression of neural stem/
progenitor cell markers. These cells were able to differentiate into different neural lineages when cultured in differentiation
medium, indicating that these cells have TSCs characteristics. We also found that B7-H1 was expressed, but not exclusively
on CD133+ stem cells. Interestingly, we found CD133- tumor cells also had the capacity to form brain tumor. Our data
establish a correlation between the expression of negative costimulatory molecule B7-H1 and the malignancy grade ofhuman gliomas, suggesting B7-H1 can be a novel tumor marker & target for therapy although it is not the privilege of brain
tumor stem-like cells.

- 159 -­­

Poster Presentation (P)Background: Transcript for the immunosuppressive T cell costimulatory molecule B7-H1 is constitutively expressed inmany nucleated cells but protein expression is tightly regulated. B7-H1 protein expression can be increased in response tointerferon-gamma. In glioblastomas, B7-H1 protein is constitutively expressed in tumors with PTEN deletion/mutation.
Here, we explore B7-H1 expression in glioma stem cells and differentiated glioma cells. Method: Human glioma stem celllines (BT12, BT25, BT30) were derived from fresh glioblastoma specimens by culturing single cell suspensions in minimally
hormonally supplemented media in the presence of EGF and FGF. From these, differentiated glioma cells were created byculturing in the presence of 10% fetal calf serum. B7-H1 expression was determined in the presence or absence ofinterferon-gamma. PTEN, Akt, and phospho-Akt expression were also determined. Naive allogeneic T cells were cocultured with glioma stem cells or differentiated cells and proliferation in the presence or absence of anti-B7-H1 antibodies
was determined. Results: B7-H1 transcript was present in both glioma stem cell and differentiated cells but constitutive
protein expression was only present in stem cells. Interferon-gamma minimally increased B7-H1 protein expression in stem
cells but markedly increased it in differentiated cells. PTEN protein was detectable in all cells but phospho-Akt wasincreased compared to controls, suggesting PTEN function was impaired. More T cell proliferation was seen after coculture with stem cells than differentiated cells but this could be reversed by blocking B7-H1. Conclusions :Immunosuppressive B7-H1 protein expression is limited in glioma stem cells but is upregulated in differentiated cells. This
does not reflect differences in phospho-Akt and the mechanism regulating B7-H1 protein expression in these cells remains
unknown. Glioma stem cells that do not express B7-H1 protein are an attractive target for immunotherapy.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P086
EXPRESSION LEVEL OF STEM CELL MARKERS IS ASSOCIATED WITH THE SOURCE OF
NEUROSPHERE MEDIA USED FOR GLIOBLASTOMA STEM CELL CULTURE.
Tony AVRIL1, Elodie Vauleon1, Stephan Saikali2, Abderahmane Hamlat3, Sylma Diabira3,
Veronique Quillien1,4
CRLCC Centre Eugene Marquis, Rennes, France 2Department of Pathology, CHU Pontchaillou, Rennes, France
Department of Neurosurgery, CHU Pontchaillou, Rennes, France 4UMR6061, University of Rennes1, Rennes, France

1
3

Glioblastoma multiforme (GBM) is a brain tumor with a very poor prognosis due to inevitable recurrence. A contingent ofcells within the tumor, so-called stem-like tumor cells (STC), has been recently characterized in GBM. These cells have
similar properties to neural stem cells and can, with a limited number of cells injected in vivo in animals, recapitulate an
entire initial tumor. STC are considered to play a major role in the recurrence observed in GBM patients and are appealing
targets for new therapeutic approaches. Most of STC studies are dependent of an in vitro step in which tumor cells areamplified in a serum-free medium in order to expand STC. In this work, we have amplified 5 tumor samples from GBM
patients in two different neurosphere media containing EGF et bFGF: a serum-free medium (NS) previously described by
Reynolds (Science, 1992) and a medium containing the commercially available B27 and N2 supplements (BN). Cell growth
was faster in BN compared to NS culture and higher cell number was obtained with the BN medium. Phenotypic analyses
show that cells derived from the BN cultures express higher levels of CD133 and to a lesser extent nestin, two neural stem
cell markers. In contrast, A2B5 a progenitor marker, is expressed in a higher level on cells derived from NS cultures.
Concerning the immunological characterization, cells derived from BN cultures express higher levels of HLA class I
molecules, essential for specific recognition of tumor cells by cytotoxic T lymphocytes. Experiments of differentiation andinjections in mice are currently in progress to test eventual functional differences between the neurosphere media. In
conclusion, one should be aware of the use of specific media for generating STC from GBM samples due to their influenceat least on the level of expression of the stem cell markers.

P087
AN EVALUATION OF THE NEURAL STEM CELL MARKER NG2 AS A BIOMARKER OFDISEASE IN PATIENTS WITH GLIOBLASTOMAColin Watts1, Talal F. al-Mayhani1, Hani Marcus1, Koichi Ichimura1, Peter Collins1
Department of Clinical Neurosciences, Cambridge University, Cambridge

1

Poster Presentation (P)IntroductionThe identification of cancer stem cells, including Glioblastoma (GBM), often utilises expression of CD133.
However, an increasing body of evidence suggests that this is neither sensitive nor specific and alternative markers areurgently needed. We have investigated the expression and clinical relevance of markers expressed during neuraldevelopment in GBM.MethodsUsing GBM as a model system we have derived tumour initiating stem-like cells (TICs) using
our Cambridge Protocol1. TICs were sorted into NG2+/Olig2+ and NG2-/Olig2+ populations using FACS. Patterns of gene
expression were examined in 39 GBM samples using Affymerix platforms and validated on independent data sets. Clinicaldata was obtained retrospectively from 8 GBM patients from whom TICs had been derived.ResultsNG2+/Olig2+ TICs canbe derived from GBM under serum-free conditions and expression of both markers is common in GBM tumours (for moredetails see abstract by al Mayhani et al). Some TIC lines contain large numbers of NG2+ cells and some TIC lines containlow numbers of NG2+ cells. This pattern is representative of the parent tumour.The self-renewal rate varies between
different tumour TIC lines from different patients.TIC lines containing lots of NG2+ cells (NG2hi) expand slowly. TIC lines
containing low numbers of NG2+ cells (NG2lo) expand rapidly.NG2hi patients had reduced progression free survival
compared to NG2lo patientsConclusionsTumour forming cancer stem-like cells are common in GBM. Cancer stem cells
from different GBM patients behave differently.NG2 expression has potential as a biomarker of disease in GBM but a larger
cohort of patients is needed to validate this hypothesis.

P088
Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood-Derived
Mesenchymal Stem Cells against Intracranial Glioma
Sin-Soo Jeun1, Wan-Soo Yoon1, Yong-Kil Hong1
The Department of Neurosurgery, Catholic University, Seoul, Korea

1

Adenovirus-mediated gene therapies against brain tumors have been limited by the difficulty in tracking glioma cells
infiltrating the brain parenchyma. Human umbilical cord blood-derived mesenchymal stem cells (UCB-MSC) are particularly
attractive cells for clinical use in cell-basedtherapies. In the present study, we evaluated the tumor targeting properties andantitumor effects of UCB-MSCs as gene delivery vehicles for glioma therapy. We efficiently engineered UCB-MSCs todeliver a secretable trimeric form of tumor necrosis factor-related apoptosis-inducing ligand(stTRAIL) via adenoviraltransduction mediated by cell-permeable peptides. We then confirmed the migratory capacity of engineered UCB-MSCs
toward tumor cells by an in vitro migration assay and by in vivo injection of UCB-MSCs into the tumor mass or the opposite
hemisphere of established human glioma in nude mice. Moreover, in vitro coculture, experiments on Transwell plates, and invivo survival experiments showed that MSC-based stTRAIL gene delivery has more therapeutic efficacy compared withdirect injection of adenovirus encoding the stTRAIL gene into a tumor mass. In vivo efficacy experiments showed that
intratumoral injection of engineered UCB-MSCs (MSCs-stTRAIL) significantly inhibited tumor growth and prolonged thesurvival of glioma-bearing mice compared with controls. These results suggest that human UCB-MSCs have potential use
as effective delivery vehicles for therapeutic genes in the treatment of intracranial glioma.

- 160 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P089
Brain Easy Analysis Tool For 201Tl SPECT in Brain Tumors
Yasushi Shibata1, Akira Matsushita1, Manabu Akimoto1, Tetsuya Yamamoto1, Shingo Takano1,
Akira Matsumura1
Department of Neurosurgery, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences,
University of Tsukuba, Tsukuba, Japan1

Purpose: 201Thallium SPECT is a useful functional imaging modality for the diagnosis of malignancy and activity of brain
tumors. The coregistration of functional SPECT images and high resolution anatomical MRI is considered to be areasonable method to improve the low spatial resolution of SPECT. We used a newly developed software Brain Easy
Analysis Tool for Tl-SPECT (BEAT-Tl) for the coregistration of Tl-SPECT and MRI in patients with brain tumors. Methods:
MRI was performed using the 1.5 Tesla clinical MRI scanner. Tl-SPECT images were acquired 15 minutes (early) and 3
hours (delayed image) after the intravenous injection of 74 MBq of Thallium Chloride using multi-detector SPECT machine.
Both the MRI and SPECT data of analyze format were transferred to the BEAT-Tl program and then coregistered images
were created. Results: The coregistered images were easily and promptly created. The image quality was sufficient. There
were no large displacements of the MRI and SPECT images and no major artifacts. Small hot uptake in Tl SPECT always
coregistered with an enhanced tumor in MRI. Conclusion: BEAT-Tl is a useful coregistration software program to evaluate
brain tumors. It improve the spatial resolution of SPECT images and such coregistration images demonstrate a metabolic
heterogeneity in tumors.

P090
123I-IMP SPECT in Brain Tumor: Anatomical Standardized Statistical
Mapping
Yasushi Shibata1, Manabu Akimoto1, Akira Matsushita1, Tetsuya Yamamoto1, Shingo Takano1,
Akira Matsumura1
Department of Neurosurgery, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences,
University of Tsukuba, Tsukuba, Japan

1

Introduction: 123I-iodoamphetamine Single Photon Emission Computed Tomography (IMP SPECT) is used to evaluate thecerebral blood flow. However, its application for patients with brain tumors has so far been rarely reported. Primary central
nervous system lymphoma (PCNSL) is a rare tumor that shows a delayed IMP uptake. The relatively low spatial resolution of
SPECT is a clinical problem to diagnose brain tumors. We examined anatomical standardized statistical mapping of 49 IMP
SPECT in patients with brain tumor. Method: After the intravenous injection of 222MBq of I-IMP, early and delayed images
were acquired using a multi-detector SPECT machine. Results: Sixteen patients showed a high uptake in the delayed IMP
SPECT images. Other tumor or diseases did not show a high uptake of delayed IMP SPECT, so there was no false positive.
Four patients with pathologically proven PCNSL showed no uptake in IMP SPECT. These tumors were too small to detect in
IMP SPECT or IMP SPECT was taken after the steroid administration. However, statistical mapping revealed the IMP uptake
in 2 of 4 patients. Conclusion: IMP SPECT is the sensitive examination for the diagnosis of PCNSL, although there is somefalse negative. Anatomical Standardized Statistical Mapping is useful to improve the diagnostic sensitivity, spatial resolution
and accuracy of IMP SPECT.

The application of Susceptibility Weighted magnetic resonance Imaging(SWI) to diagnosis and treatment of meningiomas.
Kanji Mori1, Reiichi Ishikura2, Shigekazu Fujita1, Yusuke Tomogane1, Norio Arita1
Department of Neurosurgery, Hyogo College of Medicine 2Department of Radiology

1[Purpose] To evaluate usefulness of Susceptibility magnetic resonance Imaging (SWI) for management of meningiomas.
[Methods] Pathologically confirmed meninsiomas, 7 WHO grade 1, 2 atypical and 2 anaplastic, were included. Patientswere evaluated by MRI preoperatively. SWI was compared with T2 and diffusion weighted images, and angiography andhistological findings. [Results] Signal intensity of the tumor in SWI was similar with that in T2WI. But heterogeneity in thetumor was more clearly observed in SWI. Vascular structures in and around the tumor were displayed as no signal spots or
curved-linear lines in SWI. Density and distribution of tumor vessels in SWI were well correlated with results of angiography.
Signal intensity of atypical and anaplastic meingiomas in SWI were lower than that of grade 1 tumors. Meningiomas withhigher MIB-1 staining indices showed lower signal intensity than those with lower MIB-1 indices. [Conclusion] SWI canprovide more useful information for management of meningiomas such as vascularity and proliferation potential.

- 161 -­­

Poster Presentation (P)P091

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P092
Choline-enhanced proton MRS of brain tumors
Mikhail Chernov1, Yoshihiro Muragaki2, Yuko Ono3, Osami Kubo2, Hiroshi Iseki4,
Tomokatsu Hori2, Kintomo Takakura4
International Research and Educational Institute for Integrated Medical Sciences (IREIIMS), Tokyo Women’s Medical
University, Tokyo, Japan 2Department of Neurosurgery, Tokyo Women`s Medical University, Tokyo, Japan 3Departmentof Neuroradiology, Tokyo Women`s Medical University, Tokyo, Japan 4Faculty of Advanced Techno-Surgery, Tokyo
Women`s Medical University, Tokyo, Japan
1

OBJECTIVE The present study was done for evaluation of the possible influence of the oral administration of choline on
metabolic characteristics of gliomas detected with proton magnetic resonance spectroscopy (MRS). METHODS Thirtypatients (22 men and 8 women; mean age 38±15 years) with suspicious intracranial gliomas underwent single-voxel longecho (TR: 2000 ms, TE: 136 ms, 128-256 acquisitions) MRS of the tumor, peritumoral brain tissue and distant normalappearing white matter before and several hours (median, 3 hours; range, from 1.2 to 3.7 hours) after ingestion of choline
with prescribed dose 50 mg/kg (median actual dose, 52 mg/kg; range, from 48 to 78 mg/kg). Investigations were doneusing 1.5 Tesla clinical MR imager. The volume of the rectangular MRS voxel was either 3.4 cc or 8 cc. At the time of both
spectroscopic examinations similar voxels` positioning and size, and technical parameters of MRS were used. Surgery wasdone in 27 patients within 1 to 68 days thereafter. In all cases more, than 80% resection of the neoplasm was attained.
RESULTS There were 12 low-grade gliomas and 15 high-grade gliomas. MIB-1 index varied from 0 to 51.7% (median,
13.8%). Statistical analysis did not disclose significant differences of any investigated metabolic parameter of the tumor,
peritumoral brain tissue and distant normal-appearing white matter between two spectroscopic examinations.
CONCLUSION Single-voxel MRS at 1.5 Tesla could not detect significant changes of the metabolic characteristics ofgliomas, peritumoral brain tissue and distant normal-appearing white matter after oral administration of choline.
Nevertheless, further search for possible modifiers of the metabolites` resonance intensity seems important, because theiridentification can potentially increase the diagnostic efficacy of the spectroscopic imaging.

P093
Preoperative evaluation by proton magnetic resonance spectroscopy in
the grading of gliomas
Shinya Oshiro1, Hitoshi Tsugu1, Fuminari Komatsu1, Takeo Fukushima1, Tooru Inoue1
Department of Neurosurgery, Fukuoka University, Faculty of Medicine, Fukuoka, Japan

1

Poster Presentation (P)Background: Advanced magnetic resonance (MR) techniques provide physiological and metabolic information thatcomplements the anatomical information available from conventional MR imaging. The purpose of this study was toevaluate the clinical usefulness of proton MR spectroscopy (1H-MRS) in preoperative quantitative assessment of gliomas.
Materials and Methods: Sixteen patients with histologically verified gliomas, comprising 7 cases with high-grade glioma(HGG) ((4 glioblastoma multiforme (GBM), 2 anaplastic oligodendroglioma (AO), 1 anaplastic astrocytoma (AA)) and 9cases with low-grade glioma (LGG) ((8 fibrillary astrocytoma (FA) and 1 oligoastrocytoma (OA)) were evaluated using the
1H-MRS protocol following conventional MR imaging, diffusion-weighted imaging (DWI), and perfusion-weighted imaging(PWI) preoperatively. Results: HGG tended to demonstrate signal hyperintensity by DWI and higher relative cerebral blood
volume (rCBV) by PWI. Increased ratios of choline (Cho) to N-acetylaspartate (NAA) (Cho/NAA) and Cho to creatine (Cr)(Cho/Cr) correlated highly with tumor malignancy. The presence of lipid was predominately detected in patients with HGG,
though lactate was confirmed even by half of LGG. Conclusion: The combination of multiple MR parameters, based on
DWI, PWI and 1H-MRS, appears valuable for preoperatively predicting the degree of malignancy in glioma.

P094
Modified 11C-Methionine PET imaging to distinguish radiation necrosis
from recurrent glioma
Shunsuke Takenaka1, Jun Shinoda1, Yoshitaka Asano1, Kazuhiro Miwa1, Takeshi Ito1,
Takashi Maruyama2, Yoshihiro Muragaki2, Yoko Nakasu3, Hirohito Yano4, Toru Iwama4
1
Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, Department of ClinicalBrain Scienses, Gifu University Graduate School of Medicine Institution, Gifu, Japan 2Neurological Institute, Tokyo
Women’s Medical University, Tokyo, Japan 3Division of Neurosurgery, Shizuoka Cancer Center, Shizuoka Japan
4
Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan
11
C–Methionine (MET) –PET is useful for evaluating radiation necrosis (RN) and glioma recurrence. However, it is sometimes
difficult to distinguish these lesions because the accumulation of MET is affected not only by tissue proliferative activity but
also by vascular factors, such as the vascular bed volume or the disruption of BBB. MET accumulation in RN is mostly
affected by the latter factors. To exclude the vascular factors, we made modified MET (mod–MET) PET images. We report
the usefulness of these images for more precisely distinguishing RN from recurrence compared to MET–PET.
MET–PET and 11C–Choline (CHO) –PET were examined simultaneously for each patient. Based on our previous studies,accumulation of CHO is thought to be mostly affected by the vascular factors. In the choroid plexuses of 30 normal adults,
in which both MET and CHO were prominently accumulated only by vascular factors, there was a significant positive linear
regression between MET–SUVmax and CHO–SUVmax. The vascular MET–SUV, which reflected only the vascular factors,
could be obtained from the CHO–SUV using linear regression for the choroid plexuses. The mod–MET–PET, which is
obtained by eliminating the vascular MET–SUV from the original MET–SUV, is thought to mostly reflect tissue proliferation.
We studied histologically verified 13 RNs, 16 recurrent grade-3 gliomas (Gr.3) and 10 recurrent glioblastomas (Gr.4).
Mod–MET L/N ratio for RN, Gr.3 and Gr.4 were 3.33±1.37, 9.18±7.78 and 10.07±5.66, respectively. The mod–MET L/N ratiofor RN was significantly lower than those for Gr.3 and Gr.4 (,P <.005). Even for cases in which RN is barely distinguishable
from recurrence on the original MET–PET, the mod–MET–PET made it easier to visually distinguish these lesions. The mod–
MET–PET image is useful for distinguishing RN from recurrent gliomas.

- 162 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P095
Matching analysis of PET and chemical shift imaging on proton MRS inpatients with supratentorial glioma
Hirohito yano1, Noriyuki Nakayama1, Naoyuki Ohe1, Kazuhiro Miwa2, Jun Shinoda2,
Toru Iwama1
Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan 2Chubu Medical Center for
Prolonged Traumatic Brain Dysfunction, Department of Neurosurgery, Kizawa Memorial Hospital, Minokamo, Japan

1<Objective> The goal of this study is to collate the results of positron emission tomography (PET) and chemical shift
imaging (CSI) on proton magnetic resonance spectroscopy in glioma patients. <Materials and Methods> Total 48 times ofmethionine (met) PET, fluorodeoxy glucose (FDG) PET and CSI (choline: cho, lactate: lac) were performed on the same day
in 35 cases of supratentorial gliomas including 3 of astrocytomas (A), 4 of oligodendrogliomas (O), 3 of anaplastic
astrocytomas (AA), 5 of anaplastic oligodendrogliomas (AO) and 15 of glioblastomas (GBM). PET results were qualitatively
evaluated in 5 grades (0-4) and CSI results were in 2 grades (high signal: HS, low signal and below: LS). <Results> HS incho was observed in A (2/4 cases), AA (2/3) and GBM (13/16). All cases of O and AO showed HS in cho. Cases showing
HS in cho and high uptake (3,4) in met were in A (0/4 cases), AA (1/3) and GBM (12/16). They were much in the cases withhigh grade gliomas. In totality, 27 cases of them were significantly much than the 4 cases showing LS in cho and highuptake in met. Secondly, HS in lac was observed in A (0/4 cases), AA (2/3) and GBM (14/16). They were much in the caseswith high grade gliomas In totality, 25 cases of them were significantly much than the 3 cases showing LS in lac and highuptake in met. Accordingly, it was demonstrated that the lesion showing high uptake of met tended to show HS in cho andlac. The concordance rate in met-cho and met-lac was approximately half, respectively. In contrast with met, FDG uptake
did not correlate with HS of cho and lac. <Conclusion> CSI was secondarily useful for evaluating the degree of malignancy
from the aspect of amino acid metabolism in tumors.

P096
Augmenting Intraoperative MRI with Preoperative DTI and fMRI by
Simulation of Brain Deformation Using Mathematical Model Based onThin-Plate Splines:A Preliminary Research
Cheng-Jun Yao1, Liang-Fu Zhou1, Ying Mao1, Jin-Song Wu1
1Shanghai Neurosurgical Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical School, Fudan
University, Shanghai, China

P097
The Value of rCBV Ratio in Perfusion MR for Differentiating Radiation
Necrosis from Tumor Recurrence in High Grade Glioma; comparison with
18F-FDG and 11C-Methionine PETYong Hwy Kim1, Jung Ho Han1, Chul-Kee Park1, Hee-Won Jung1
1Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea
Object: The authors analyzed the characteristics of perfusion magnetic resonance images (MRI), 18F-fluorodeoxyglucose(FDG) positron emission tomography (PET) and 11C-Methinonine (MET) PET in order to evaluate the efficacy of the imaging
modalities used to differentiate radiation necrosis from recurrence of high- grade glioma. Materials and Methods: Tenpatients were evaluated with perfusion MRI, 11C-MET PET and /or 18F-FDG PET simultaneously for gadolinium- enhanced
lesion on T1-weighted MRI during the follow-up period after radiation. Six cases of radiation necrosis and four cases ofrecurrence were confirmed by clinical course (n=7) or pathological examination (n=3). On perfusion MR images, the four
regions of interest (ROIs), which measured 6＊6mm, was drawn, and then the average values were calculated. A reference
ROI of the same size was defined in the white matter of the contralateral hemisphere to obtain the lesion-to-normal brain
ratio of rCBV (L/R ratio). After the coregistration of 18F-FDG and 11C-MET PET with MRI, and the maximum standard
uptake values (SUVmax) of the lesion and contralateral cerebral hemisphere white matter were measured as a reference
area for the Lmax/Rmax ratio. Result: Only the L/R ratio of rCBV was higher in the recurrence than necrosis group.
(p=0.010) There was no difference in Lmax/Rmax ratio of 18F-FDG and 11C-MET PET between the groups. Conclusion: A
quantitative ratio of rCBV ratio on perfusion MR is superior to the Lmax/Rmax ratio of 18F-FDG and 11C-MET PET in
distinguishing recurrence of high-grade glioma from radiation necrosis.

- 163 -­­

Poster Presentation (P)OBJECTIVE: Intraoperative magnetic resonance imaging(iMRI) integrated with diffusion tensor imaging(DTI) or blood
oxygen level dependent(BOLD) proved to be effective in neurosurgical operations, but DTI or BOLD images was still
provided before the surgery. Brain shift will certainly cause navigative errors. We used a mathematical model to adjust thethis errors. METHODS: Pre-operative iMRI and intra-operative iMRI were used respectively for data fields, and a non-rigid
calculation was applied for predicting the tendency of brain shift. When this calculated tendency was integrated into DTI or
BOLD images, predictive DTI or BOLD images after brain shift were acquired. Then we integrated these compensated DTI
or BOLD images into iMRI images to learn the relationships of the tumor and white matter fiber tracts or functional cortex
after brain shift. RESULTS: The predictions of DTI and BOLD images shift were successfully computed. The real-measured
brain shifts by iMRI were 0.5~9.8mm, the predicted brain shifts were 0.4~9.0mm. The slight extent of most of the predicted
shift points was less than those in the real-measured points, however, the averages of predicted and real-measured points
were statistically insignificant CONCLUSIONS: The mathematical model was effective and reliable in predicting the shift of
DTI or BOLD images during neurosurgical operations.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P098
Evaluation of glioma grading on MR imaging: Diagnostic value of minimum
apparent diffusion coefficient compared with positron-emission
tomography
Yoshitaka Asano1, Syunsuke Takenaka1, Takayuki Kato1, Kazuhiro Miwa1, Takeshi Ito1,
Jun Shinoda1, Takashi Maruyama2, Yoshihiro Muragaki2
1
Chubu Medical Center, Kizawa Memorial Hospital, Department of Clinical Brain Scienses, Gifu University Graduate
School of Medicine 2Department of Neurosurgery, Neurological Institute, Tokyo Women's Medical University, Tokyo, Japan

Purpose: Apparent diffusion coefficient (ADC) calculations improve the diagnostic efficacy and the evaluation of glioma
grading. Positron-emission tomography (PET) is another useful tool that provides valuable metabolic informations forgliomas. The aim of this study was to evaluate the advantages of ADC on MR imaging compared with PET for diagnoses ofgliomas. Materials and methods: We performed MR imaging and 11C-methionine (MET) PET for 71 newly diagnosed
gliomas (35 grade II, 29 grade III and 7 grade IV). ADC maps were calculated from isotropic DWI, and images wereobtained with a b-value of 0 s/mm2. The minimum ADC for each tumor was determined by placing regions of interest (ROIs)
using an Advantage Workstation. The ROI with the lowest ADC value was chosen from these ROIs as the minimum ADC for
the tumor. PET examinations were performed to measure tumor / normal brain uptake ratios (T/N ratios). Each resected
tumor was classified according to its histological diagnosis using the WHO classification and calculated Mib-1 labelingindex by immunohistochemical examination. We investigated the correlations between the minimum ADCs, T/N ratios,
tumor grades, and tumor proliferation activities. Results: The minimum ADCs of gliomas showed a significant inverse
correlation with tumor proliferation activities (r=-0.66, p<0.001) and the MET T/N ratio showed a positive correlation withactivities (r= 0.64, p<0.001). The mean minimum ADCs (×10-3mm2/s) for the WHO grade II, grade III and grade IV gliomas
were 1.058 ±0.203, 0.830 ±0.143 and 0.693 ±0.087, respectively. Significant differences were found between each glioma
grade (grade II/grade III: p<0.001; grade III/grade IV: p<0.001). For MET T/N ratios, however, no significant differences wereseen between the grade II and grade III gliomas. Conclusion: The minimum ADC can provide more valuable diagnostic
information for the preoperative grading of WHO grade II and grade III gliomas than MET PET.

P099
Glioblastoma treated with postoperative radio-chemotherapy:
Prognostic value of apparent diffusion coefficient at MR imaging
Fumiyuki Yamasaki1, Kazuhiko Sugiyama1, Yoshinori Kajiwara1, Taiichi Saito1,
Toshikazu Hidaka1, Takeshi Nishimoto1, Yosuke Watanabe1, Kaoru Kurisu1
Department of Neurosurgery, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan

1

Poster Presentation (P)Purpose: To retrospectively evaluate whether the mean-, minimum-, and maximum apparent diffusion coefficient (ADC) ofglioblastomas obtained from pretreatment MR images is of prognostic value in patients with glioblastoma. Materials andMethods: The the institutional review board approved our study and waived the requirement for informed patient consent.
Between February 1998 and January 2006, 33 patients (24 males, 9 females; age range 10 - 76 years) with supratentorial
glioblastoma underwent pretreatment magnetic resonance (MR) imaging. The values of the mean-, minimum-, andmaximum ADC (ADC-mean, ADC-MIN, and ADC-MAX, respectively) of each tumor were preoperatively determined fromseveral regions of interest defined in the tumors. After surgical intervention, all patients underwent irradiation andchemotherapy performed according to our hospital protocol. The patient age, symptom duration, Karnofsky performancescale score, extent of surgery, and ADC were assessed using factor analysis of overall survival. Prognostic factors were
evaluated using Kaplan-Meier survival curves, the log-rank test, and multiple regression analysis with the Cox proportional
hazards model. Results: Likelihood tests confirmed that ADC-MIN was the strongest among the 3 prognostic factors. Total
surgical removal was the most important predictive factor for overall survival (P < 0.01). ADC-MIN was also statisticallycorrelated with overall survival (P < 0.05) and could be used to classify patients into different prognostic groups.
Interestingly, ADC-MIN was also the strongest prognostic factor (P < 0.01) in the group of patients in whom total tumor
removal was not possible. Conclusion: The ADC-MIN value obtained from pretreatment MR images is a useful clinicalprognostic biomarker in patients with glioblastoma.

- 164 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP100
DIFFUSION-WEIGHTED IMAGING IN PATIENTS WITH GLIOBLASTOMA MULTIFORMETREATED WITH BEVACIZUMAB
Kevin P. Becker1, Joachim Baehring2, Jill Lacy3, Tina Mayer3
Department of Neurology, Yale University School of Medicine, New Haven, CT. USA 2Department of Neurology and
Neurosurgery, Yale University School of Medicine, New Haven, CT. USA 3Yale Cancer Center, Yale University School of
Medicine, New Haven, CT. USA
1

Purpose: Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, has shown
effectiveness in relapsed glioblastoma multiforme. Conventional outcome measures (MacDonald criteria) have proved
problematic in patients treated with antiangiogenic agents. Diffusion-weighted MRI (DW-MRI) has been shown to be useful inassessing tumor cellularity, grade, and early treatment response in a variety of brain tumors. This spurred our interest in
studying DW-MRI in bevacizumab recipients. Methods: We performed a retrospective analysis of patients with relapsed
malignant glioma treated with bevacizumab. Comprehensive MRI studies including diffusion-weighted imaging (DWI) andapparent diffusion coefficient maps (ADC) obtained at the time of disease progression, after initiation of bevacizumab
treatment, and at the time of treatment failure were reviewed. Presence or absence of restricted water diffusion withinenhancing and non-enhancing tumor areas were assessed at the time of best tumor response based on conventional criteria
and thereafter until tumor progression. Kaplan-Meier survival curves were calculated. Results: 36 individuals with relapsed
malignant glioma treated with bevacizumab between 12/05 and 12/07 were identified. In 34 patients who received more than 4cycles, median time to treatment failure (TTF) and overall survival (OS) were 16 and 32 weeks, respectively. Seven patients were
excluded due to insufficient clinical data. 29 patients met eligibility criteria. DW-MRI revealed areas of restricted water diffusion
in non-enhancing tumor areas in 11 individuals. The analysis is ongoing. We will further assess the median time interval
between initial occurrence of DWI/ADC abnormalities and TTF and correlate presence of diffusion abnormalities with TTF and
OS. Conclusion: DW-MRI may be a sensitive tool to detect early tumor progression in patients treated with bevacizumab.
Whether it may serve as a more accurate outcome measure than post-gadolinium T1-weighted sequences in this patient
population will require prospective evaluation correlating DWI and ADC findings with performance status and survival.

P101
Evaluation of anti-angiogenic therapy response in patients with GBM; a
Homodynamic Response Imaging study
Dafna Ben Bashat1, Moran Artzi1,2, Haim Ben-Ami1,Orna Aizenstein3, Deborah Blumenthal4,
Felix Bokstein4, Yifat Edrei5, Ben Corn6, Rinat Abramovitch5
1
Functional Brain Imaging Center, Tel Aviv sourasky Medical Center, Tel Aviv, Israel 2Tel-Aviv University - Sackler Facultyof Medicine,Tel Aviv, Israel 3Radiology Department, Tel Aviv sourasky Medical Center,Tel Aviv, Israel 4Neuro-Oncology,
Tel Aviv sourasky Medical Center, Tel Aviv, Israel 5Goldyne Savad Institute of Gene Therapy, Hadassah University
Medical Center, Jerusalem, Israel 6Institute of Radiotherapy, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel- 165 -­­

Poster Presentation (P)Aim: The aim of this study was to evaluate the sensitivity of a novel fMRI method, hemodynamic response imaging - HRI, toassess therapy response of patients with GBM who received antiangiogenic therapy. We have previously presented thismethod using hyperoxia and hypercapnia for the detection of vascular functionality and maturation. This method has beenshown to facilitate detection of mature vessels resistant to anti-angiogenic therapy in animal models, and to differentiate
between various tissue types with high sensitivity in humans1, 2. Methods: Three patients with recurrent GBM treated witha combination of anti VEGF and cytotoxic chemotherapy were scanned on a 3T GE magnet several times before and during
the course of therapy with conventional MRI methods and the proposed HRI method, at intervals of 2-8 weeks (total of 10
MR examinations). For the HRI method, gradient-echo EPI sequence was used and two separated scans were performed,
each using a block design paradigm with inhalation of either 95%O2+5%CO2 or 95%air+5%CO2 and 100% air. Statisticalmaps of the signal intensity changes were analyzed and realigned to the contrast enhanced 3D images using Matlab
package SPM5. Results: At baseline scan (before the initiation of therapy), HRI maps demonstrate areas that response toO2 within the enhanced lesion and show no response to CO2. After two week along the antiangiogenic therapy, responses
to CO2 become visible within the enhanced tumor area. This vascular response to CO2 might demonstrate a process of“vessel normalization” as a response to the antiangiogenic therapy.
Conclusion: HRI is a novel non-invasive method for
vascular assessment which provides additional information regarding vessel permeability and maturation. This method
shows high sensitivity for evaluating therapy response and might have added value in clinical management.
References: 1.Abramovitch R, Neoplasia 6:480-489 2004; 2.13th meeting of the ISMRM, 2005,Abramovitch R

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P102
PROGNOSTIC SIGNIFICANCE OF GROWTH KINETICS IN NEWLY DIAGNOSEDGLIOBLASTOMA: A ROLE FOR PATIENT-SPECIFIC VIRTUAL CONTROLS
Kristin R. Swanson1, Christina Wang1, Russ Rockne1, Jason K Rockhill2, Maciej Mrugala3,
Ellsworth C. Alvord, Jr1
Department of Pathology, University of Washington School of Medicine, Seattle, WA 2Department of Radiation
Oncology, University of Washington School of Medicine, Seattle, WA 3Department of Neurology, University ofWashington School of Medicine, Seattle, WA
1

A number of factors have been found to allow stratification of glioma patients according to probable survival times: 1) as tothe tumor: type and grade, size and site, and 2) as to the patient: age and neurological functioning, and history of previous
treatment (extent of surgery, x-irradiation, chemotherapy). None of these factors concerns the in vivo kinetics of the tumor
itself. It is the purpose of this presentation to demonstrate statistically that two such factors, the net rates of proliferation anddispersal, offer independent additional prognostic information, more accurately predicting the duration of survival of theuntreated glioblastoma. Our predictive bio-mathematical model for glioma growth and invasion (reviewed in [1]) allowed
creation of virtual controls (VCs) for 32 newly diagnosed GBM patients by translating changes seen on serial pre-treatment
magnetic resonance imaging (MRIs) into quantitative rates of net proliferation and invasion rates for each glioma. Univariate
and multivariate analyses revealed that even when controlling for standard clinical parameters (e.g., age, RTOG RPA
classification) the bio-mathematical model parameters quantifying net proliferation rate (&rho) of the glioma cells and theratio of the net proliferation to the net invasion rate (&rho/D) were significantly associated with prognosis. To our knowledge,
this is the first time in which routine clinical MRIs pre-treatment have been translated to prognostically significant measuresof glioblastoma net cell proliferation and invasion rate. Such a novel tool for quantifying glioma kinetics has numerous
potential applications focusing on the creation of VCs for each glioma against which treatment effects can be measured
and in which novel treatment approaches can be optimized. 1. HLP Harpold, EC Alvord, Jr., KR Swanson: Visualizing
Beyond the Tip of the Iceberg: The Evolution of Mathematical Modeling of Glioma Growth and Invasion. J Neuropath Exp
Neurol, 66(1):1-9, 2007

P103
Effectiveness of Gorei-San ( Wuling San ) for eliminating brain edema due
to malignant brain tumors
Akimune Hayashi1, Hdemitu Sato1
Department of Neurosurgery, Kanagawa Cancer Center, Yokohama, Japan

1

Poster Presentation (P)Objectives: Glyceol, isosorbide and steroids, which are covered by Japanese health insurance system, are widely used toeliminate brain edema produced by malignant brain tumors and to relieve headache and several focal neurological deficits.
Their side effects, however, sometimes prevent them from long-term use. The authors have tried to reduce brain edemawith one of the traditional oriental medical prescription, Gorei-San ( Wuling San ) , which promotes diuresis and eliminates
dampness. This prescription is constituted of five kinds of herbs, such as Polyporus 3 g, Rhizoma Alismatis 4 g, Rhizoma
Atractylodis 3 g, Poria 3 g, and Ramulus Cinnamomi 1.5 g. And it is known to suppress pathologically increased Aquaporin
4 which increases in various pathological conditions such as malignant brain tumor, trauma, cerebrovascular disease, andso on. Methods: Between October 2006, and December, 2008, Gorei-San were prescribed to 41 patients ( 49 courses )with malignant brain tumors ( male 24, female 17, ages ranges between 24 to 83 years-old, mean 57.7). Headaches werecomplained of in 18 cases, and focal neurological deficits were complained of in another 33 cases. The efficacy were
evaluated with improvement rate of symptoms and neurological deficits: excellent ( Improvement rate more than 50 %),good ( Improvement rate less than 50 %);, no effect, and deterioration. Results: excellent 13 (26.5%), good 23 (47.0%), no
effect 13(26.5%). There were no deteriorated cases. No significant complications were recognized. Conclusion: Gorei-San( Wuling San ) can be used as a substitute for glycerol, isosorbide and steroids to reduce mild brain edema.

P104
Image guided Convection-enhanced delivery of nimustine hydrochloride(ACNU) in recurrent glioma patients
Ryuta Saito1, Yukihiko Sonoda1, Shin-ichiro Sugiyama1, Yoji Yamashita1, Ken-ichi Nagamatsu1,
Masayuki Kanamori1, Toshihiro Kumabe1, Teiji Tominaga1
Department of Neurosurgery, Tohoku University Graduate School of Medicine

1

Object. Although Temozolomide improved the survival of patients suffering high-grade gliomas, efficacy of systemic
chemotherapy is still not satisfactory. In this study, we investigated the safety of intra- or peri-tumoral convection-enhanced
delivery of nimustine hydrochloride (ACNU) and feasibility of image guidance methods in patients with histologicallyconfirmed recurrent malignant gliomas. Methods. Eight patients received a total of ten times infusion of intra- or peritumoral infusion of ACNU. In seven patients, nine times infusion was aided by image guidance using MRI. After determining
the target with MRI, one to three infusion catheters were inserted stereotactically. After confirming the position of thecatheters, ACNU solution (0.5-1.0 mg/ml) was infused via CED methods. For image guidance, 1uM meglumine gadoterate(Gd-DOTA) was co-infused with ACNU solution. MR image was acquired subsequently during the infusion to evaluate the
distribution of infused drug. Results. Catheters were successfully inserted in all patients without any morbidity. No severe
neurological deterioration or systemic toxicity was noted in any patients during and after infusion. MR image successfully
detected the distribution of infused solution during infusion, though several problems including rapid clearance of Gd-DOTA
were found. Four patients demonstrated stable disease and one patient partial response after the treatment. Conclusion.
Intra- or peri-tumoral convection-enhanced delivery of nimustine hydrochloride (ACNU) can be performed safely with MR
image guidance. Image guidance using co-infused Gd-DOTA visualized the infusion. Although there still are problems to beresolved, this strategy may improve the efficacy of chemotherapy against high-grade gliomas.

- 166 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP105
Convection enhanced delivery of nimustine hydrochloride (ACNU) withsystemic administration of temozolomide in recurrent glioma patients
Yukihiko Sonoda1, Shin-ichiro Sugiyama1, Ryuta Saito1, Yoji Yamashita1, Masayuki Kanamori1,
Ken-ichi Nagamatsu1, Toshihiro Kumabe1, Teiji Tominaga1
Department of neurosurgery, Tohoku University School of Medicine, Sendai, Japan

1

Object. Despite aggressive multimodal therapy, the prognosis of patients with high-grade glioma remains dismal.
Temozolomide improves the survival of patients with high-grade glioma, median survival is still less than 15 months, andfurther exploration is needed in order to increase the efficacy of temozolomide-based regimens in the treatment of highgrade glioma. O6-methylguanine-DNA methyltransferase (MGMT) causes the chemoresistance of tumor cells totemozolomide. Co-systemic administration of temozolomide and other alkylating agents such as nimustine hydrodhloride(ACNU) might result in depletion of O6-methylguanine-DNA methyltransferase (MGMT), however enhance systemic side
effect. Convection-enhanced delivery (CED) is a local infusion technique that delivers chemotherapeutic agents directly tothe central nervous system, circumventing the blood-brain barrier and reducing systemic side effects. The abundant O6alkylguanine produced by continuous infusion of ACNU using CED might deplete MGMT and enhance the efficacy oftemozolomide. This study evaluated the safety and efficacy of combined-modality treatments using CED of ACNU withsystemic administration of temozolomide. Methods. Three patients with progressive recurrent gliomas (two withglioblastoma, and one with diffuse astrocytoma) were treated with CED of ACNU (0.5mg/ml, day 1) with systemic
administration of temozolomide (150-200mg/m2, day 1-5). MR imaging was used to confirm accurate cannula placement
and monitor drug distribution. Results and conclusion. Neither patients had clinical or imaging evidence of short- andlong-term infusate-related toxicity. ACNU can be delivered safely and effectively to the human gliomas at therapeutic
concentration and over clinically relevant volumes using convection enhanced delivery. All patients are still alive 1-5 months
after CED treatment. While the efficacy of direct infusion of ACNU with oral administration of temozolomide in recurrent
glioma cannot be determined until more patients are treated, all patients tolerated convective infusion of brain without
irreversible toxicity. Patients with recurrent gliomas may benefit from this treatment paradigm.

P106
SURVIVAL OF PATIENTS WITH GLIOBLASTOMA MULTIFORME AT HARTFORD HOSPITAL
Alexandra Flowers1
Department of Neurology, Hartford Hospital, Hartford, CT, USA

1

P107
SINGLE CENTER SURVIVAL OUTCOMES OF 167 GLIOBLASTOMA PATIENTS: BEFORE
AND AFTER TEMOZOLOMIDEUfuk Abacioglu1, Aysegul Kefeli1, Zuleyha Akgun1, Hale Caglar1, Beste Atasoy1, Fulden
Yumuk 2,Turker Kilic3
1
Radiation Oncology Department, Marmara University Hospital, Istanbul, Turkey 2Medical Oncology Division, Marmara
University Hospital, Istanbul, Turkey 3Neurosurgery Department, Marmara University Hospital, Istanbul, Turkey

Purpose: Evidence based standard treatment of glioblastoma (GBM) is radiotherapy (RT)+concomitant and adjuvanttemozolomide (TMZ), currently. In this study, we aimed to assess the value of addition of TMZ in a cohort of 167 GBM
patients, treated in a single center consecutively.
Patients and Methods: Patients were treated between 1997 and 2008. Median age was 59 years (range 18-82) and male/
female ratio 106/61. KPS score ranged between 30 and 100 (median 80). Median duration of symptoms was 1 month (1-84months) and 19% had a history of convulsions. Multicentricity was present in 9% and the median tumor diameter was 4 cm
(1.5-8 cm). Type of surgery was gross total resection in 49%, subtotal resection in 25% and stereotactic biopsy in 26%. All
patients received median dose of 60 Gy RT (range 6-72 Gy). Concomitant and adjuvant TMZ was given in 76 patients(45%), after 2004. Overall survival (OS) curves were plotted by Kaplan-Meier method, and differences were calculated bylog-rank test. Multivariate analysis of prognostic factors was performed by Cox regression analysis.
Results: Median OS was 12 months (%95 CI 10.18-13.82), and 2 year OS rate was 15% for entire cohort. In multivariate
analysis, younger age (p= 0.001), higher KPS score (p= 0.006), longer history of symptoms (p= 0.05), single lesion(p=0.029), type of surgery (p=0.005) and addition of TMZ (p<0.001) were observed to be predictive factors for higher OS
rates. Patients treated with RT+TMZ had a median OS time of 16 months (%95 CI 13.94-18.06) compared to 9 months(%95 CI 6.61-11.39) with RT only (p<0.001). Two-year actuarial survival rates were 28% and 5%, respectively.
Conclusions: In the TMZ era, classical prognostic factors continue to be significant for survival. Out of clinical studies, TMZ
addition to RT has increased the overall survival of GBM patients in this series very significantly.

- 167 -­­

Poster Presentation (P)Objective: Prognosis for patients (pts) with glioblastoma multiforme (GBM) remains poor, even with treatment with radiation(RT) and chemotherapy (CTX). This retrospective study evaluates survival for pts with GBM treated at Hartford Hospitalover a ten years period. The purpose is to determine whether evolving treatment modalities influenced survival.Design/
Methods: From 1997 to 2007 181 pts with GBM were treated at Hartford Hospital. Median age was 59 years (24-87 years).
There were 105 males and 76 females. All pts had surgery (32 biopsy, 123 subtotal resection, 26 gross total resection). 19
had second and 6 had third resection. 176 pts had RT, 24 pts had combination RT and temozolomide (TMZ). 83 pts had
adjuvant CTX with BCNU, PCV, and starting in 1999 with TMZ. 42 pts were treated at recurrence with CPT-11 or
Carboplatin and Etoposide, more recently CPT-11 and Bevacizumab. Survival data was analyzed by age and treatment
modalities and compared with national SEER reported data and with 10 years survival reports in the literature. Results:
Median survival for the whole group was 70 weeks (4- 719 weeks). 1 year, 2 years, 3 years, 4 years, 5 years and 10 years
survival was 30%, 10%, 6%, 5%, 5% and 3.6% respectively, similar to SEER data. Survival was significantly better for pts
younger than 45 years of age (40% at 1 year, 30% at 2 years, 23% at 3 years, 15% at 5 years and 10 years). Mediansurvival was 70 weeks for pts who received adjuvant CTX (76 weeks with TMZ) vs. 40 w eeks with RT alone). CTX atrecurrence further prolonged survival (150 weeks with CPT-11 or combination TMZ and 6 thioguanine). Conclusions: Oursurvival data compares favorably with the national SEER data and reports from other institutions. Multimodality therapy
helps prolong survival for patients with GBM.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P108
Clinical outcomes of adult supratentorial grade 3 malignant gliomas ina single institution
Yoshitaka Narita1, Yuko Matsushita1, Kaori Suzuki1, Yasuji Miyakita1, Hiroyuki Momota1,
Aya Shinomiya1, Soichiro Shibui1
Neurosurgery Division, National Cancer Center, Tokyo, Japan

1

Objectives: We analyzed the clinical outcomes of adult supratentorial grade 3 malignant gliomas including anaplastic
oligodendrgoglioma (AO), anaplastic oligoastrocytoma (AOA) and anaplastic astrocytoma (AA) and the relationship between
their prognoses and 1p/19q LOH and MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation status.
Methods: Ninety newly diagnosed grade 3 malignant glioma patients were treated with in National Cancer Center Hospitalin Japan from 1996 to 2008. Results: The average age of AO (n=10), AOA (n=18) and AA (n=62) were 47.8, 44.9 and 51.3
years old. RT plus ACNU (nitrosourea) or RT plus ACNU and VCR (vincristine) were used for AA or AO/AOA until 2007 as
an initial therapy. Then ACNU or PAV (Procarbazine, ACNU, VCR) were used for AA or AO/AOA as a maintenance therapy
for 2 years. RT plus TMZ (temozolomide) have been used for all grade 3 gliomas from 2007. Median survival time (MST) in
AO, AOA and AA were NR (not reached), 54.5 months and 28.6 months, respectively. Progression free survival (PFS) of
each patients are NR, 44.9 months and 15.0 months, respectively (p=0.08). Discussion: Malignant gliomas including
oligodendroglial component have better prognoses than AA as reported so far. We are examining the geneticalbackgrounds of each tumor specimens and their influence for sensitivity of radiation therapy and chemotherapeutic agents.

P109
Glucocorticoid-induced bone fracture in progressive glioma patientsAya Shinomiya1, Yoshitaka Narita1, Yasuji Miyakita1, Hiroyuki Momota1, Soichiro Shibui1
Neurosurgery Division, National Cancer Center Hospital ,Japan

1[Objective] Glucocorticoid is necessary for progressive glioma patients with cerebral edema to improve their neurologicalsymptoms and to keep performance status (PS). However, one of side effects of glucocorticoid is osteoporosis and bone
fracture that worsen PS of glioma patients. Therefore, we examined the frequency of a bone fracture and its problems inglioma patients. [Methods] One hundred ninety five consecutive adult glioma patients (109 men and 86 women, mean
age: 51.1 years old) were treated in Neurosurgery Division, National Cancer Center Hospital, Japan from 2002 till 2007. We
reviewed their clinical records and picked up the patients with a bone fracture. Then, we examined the cause of fractureand duration and total dose of glucocorticoid in those patients. [Results] One hundred seventeen among 195 patients(60%) received glucocorticoid after they showed such neurological symptoms as hemiparesis because of a tumor
progression or a cerebral edema. Eight (total 6.8%; 3 men (4.6%) and 5 women (9.8%)) among 195 patients had a fracture.
Seven patients had a lumbar compression fracture and 3 patients (2.6%) had a femoral neck fracture. Two patients had
fractures in both locations. Only one woman among 78 patients without use of glucocorticoid had a femoral neck fracture.
Mean duration from use of glucocorticoids until fracture was 11.5 months (1-27 months). Average dose of oral
glucocorticoid administered for the patients with fractures was 17.5mg (as prednisolone equivalent) at a fracture andaverage dose was 180 mg x months. All patients became disable to walk after a fracture. [Conclusions] Long-term
application of glucocorticoid increased the risk of bone fracture in glioma patients. To increase quality of life in progressive
glioma patients, we analyzed the relationship between glucocorticoid and fracture and discuss the prevention of fracture inglioma patients.

Poster Presentation (P)P110
NEWLY DIAGNOSED PREGNACY AND GLIOBLASTOMA MULTIFORME (GBM): AN
ETHICAL COLLISION COURSEGlen H.J. Stevens1, Kathy Lupica1, Sam Chao1, Mike A. Vogelbaum1
Brain Tumor and Neuro-Oncology Center, Taussig Cancer Center, Cleveland Clinic Foundation

1

35 year old right handed female presented with an unprovoked seizure April 08. She was started on lamotrigine. Imaging
studies at outside facility showed a right frontal lesion concerning for a stroke. Repeat MRI with perfusion studies at our
institution 5 8 08 showed a lesion most consistent with a tumor. Routine pre-op pregnancy test was positive. Patientelected to maintain the pregnancy and proceed with the surgery. She underwent a craniotomy 5 12 08 and gross total
resection of her lesion. Pathology revealed a glioblastoma multiforme, 1p19q intact and EGFR amplified. Her post-op beta
human chorionic gonadotrophin was 800 mU/ml. Prognosis and treatment options were discussed. The patient wished tomaintain her pregnancy and hence our recommendation was for radiation therapy with shielding without concomitantchemotherapy. Patient and husband refused any form of adjuvant treatment at that time. She was followed clinically withhigh risk obstetrics (OB). Mid July she presented with progressive headaches and left hemiplegia. MRI revealed a large
cystic recurrence. She underwent a second craniotomy July 23 2008. Pathology again showed GBM. Seen by high risk OB
and fetus was stable. Post operative she consented to radiation therapy with shielding and completed 60 Gy. She
completed radiation therapy without specific complications and underwent a non contrasted MRI that showed minimalchange from her preop MRI. She developed progressive headache and HELLP syndrome at 37 1/7th weeks andunderwent a primary low transverse cesarean section. A healthy baby girl was delivered 12 5 08 with APGAR scores of 9
and 9 at one and five minutes. This presentation will explore the various ethical dilemmas faced during the care of thepatient and fetus including surgery, radiation (shielding) and the role of chemotherapy.

- 168 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP111
Vntricular and Leptomeningeal Seeding in a Patient with Medullary
Anaplastic Oligodendroglioma
Young-Cho Koh1, Dong-Cheon Kim1, So-Duck Lim1, Hong-gee Roh1
Department of Neurosurgery, Konkuk University, Seoul, Korea

1

Intracranial metastasis originating from the glial tumors is rare. In a review of 116 cases of metastatic gliomas, thecommonest metastasizing tumor was glioblastoma (41.4%) and oligodendrogliomas(ODGs) accounted for the lowest
metastasizing rate(5.25%). We have treated a very unusual metastatic intraventricular and parenchymal metastases from a
medullary anaplastic ODG(AODG). A 38-year-old woman was presented with the left facial pain and hemiparesis. She has
been treated with steroids under the diagnosis of idiopathic pulmonary fibrosis for the past several years . She had facial
hypesthesia on the left side with motor weakness of grade IV and hyperreflexia and pathologic reflex in the left extremities.
Brain and Cervical MRI showed a discrete mass with a little enhancement in the left medulla oblongata extending down to
C2 level. A midline suboccipital craniectomy with C1 laminectomy was done to excise the tumor partially. The pathology
was turned out to be AODG. She was given conformal RT of 5,600 cGy to the medullary tumor followed by 12 cycles ofTemozolomide(TMZ) to result in partial remission for 30 months. A routine follow up MRI revealed a well defined enhancing
intraventricular mass with stable medullary tumor. Right frontal interhemispheric approach was done to remove the septal
and intraventricular tumor totally. On the second postoperative day she had another emergency surgery to decompress
venous infarct complicated by draining vein injury. Three months later she developed communicating hydrocephalus, forwhich she underwent a VP shunt. Six months after the ventricular tumor removal she developed generalized seizure
showing bilateral medial temporal enhancing tumors. The medullary tumor remained stable. Postoperative WBRT of
6000cGy/6weeks was added. Even with active rehabilitation, her neurologic condition deteriorated gradually to be bedridden 38 months after the initial medullary surgery. We report this unusual upward intracranial metastases from a
medullary AODG, even the original tumor remained stable.

P112
Long-term outcome of low-grade gliomas treated with radiotherapydeferring therapeutic policy
Yasuo Iwadate1, Tomoo Matsutani1, Yuzo Hasegawa1, Natsuki Shinozaki1, Yoshinori Higuchi1,
Naokatsu Saeki1
Neurological Surgery, Chiba University Graduate School of Medicine

1

P113
Considerations for diagnosis and treatment of classical gliomatosis
cerebriKazuya Aoki2, Norihiko Saito1, Morito Hayashi1, Kei Takahashi2, Satoshi Iwabuchi1
The second Department of Neurosuegery, Toho University Ohashi Medical Center, Tokyo, Japan 2The Department of
Pathology, Toho University Ohashi Medical Center, Tokyo, Japan

1

Gliomatosis cerebri (GC) was included in the new WHO classification (4th edition) in the group of asrocytic tumors and the
diagnostic criteria was also varied slightly. Because GC is a rare tumor, there were no large-sized studies and histologicalvariation, such as astrocytoma, oligodendroglioma even glioblastoma, existed in the previous reports. For these reasons,
we still could not establish an appropriate treatment. This time, we discuss the issue of making diagnosis and treatment of
GC by means of clinical course and radiological findings of one case of classical GC we experienced. We present a
15-years-old man who had a classical GC. He complained neck pain and tinnitus of more than 1.5 year's duration, andblurred vision for a half year. These symptoms were getting worse but nobody could make the diagnosis of GC with a CT
scan at the local hospital. MR imaging revealed a diffuse lesion spreading at each side of whole brain, especially brain stem
and cerebellum, and no tumor mass could be detected on contrast enhanced MRI. Although ICP was elevated, lateral andthird ventricles were enlarged and acquired Chiari malformation was shown. VP shunting improved his symptoms andhistological examination of biopsy specimens revealed diffuse glioma. He received 60Gy irradiation to the whole brain andthe lesion responses completely. Seven months after radiotherapy, he complained gait disturbance and sensory
disturbance in his chest and MRI of the spine revealed a tumor spreading at entire spine. A spinal coed lesion responded
partially with 35Gy irradiation, and then we started treatment with temozolomide administration.

- 169 -­­

Poster Presentation (P)Purpose: The therapeutic strategy for low-grade gliomas is still controversial especially for the use of radiotherapy. The
purpose of this study is to know the long-term outcome of low-grade gliomas treated with a radiotherapy-deferring
therapeutic policy. Methods: We have treated all low-grade gliomas with radiotherapy-deferring therapeutic policy, andanalyzed 60 consecutive adult patients having diffuse astrocytoma (25 cases) or oligodendroglial tumors (35 cases). The
treatment protocol was as follows: i) simple observation even after incomplete resection of tumors showing no evidences ofprogression, ii) salvage resection for the surgically-accessible recurrent tumors, iii) nitrosourea-based chemotherapy for
progressive oligodendroglial tumors, and vi) radiotherapy for progressive astrocytoma. Results: The median follow-up
period was 7.0 years and no patient was lost during the follow-up periods. All the patients with oligodendroglial tumorssurvived without receiving radiotherapy (10-year survival rate: 100 %), and the 5-year and 10-year progression free survival
rates were 89.6% and 65.1 %, respectively. The patients in their sixties had a significantly higher recurrence rate, and two ofthem (29%) suffered from leukoencephalopathy following the chemotherapy alone. Among the patients with diffuse
astrocytoma, 9 (36 %) subsequently received radiotherapy, and 7 of the 9 irradiated patients died. The 10-year survival rateof diffuse astrocytoma patients was 60.0 %. MIB-1 labeling index has predictive value for malignant transformation andsubsequent shorter survival in diffuse astrocytoma. Conclusions: Our data suggest that low-grade oligodendroglial tumors
can be successfully treated by the nitrosourea-based chemotherapy alone without applying radiotherapy.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P114
Growth rates of metastatic brain tumors in non-small cell lung cancer;
estimation from micro-metastasis
Heon Yoo1, Eugene Jung1, Sang Hoon Shin1, Ho Shin Gwak1, Jae Ill Zo2, Seung Hoon Lee1
Neuro-Oncology Clinic, National Cancer Center, Goyang, Korea 2Center for Lung Cancer, National Cancer Center,
Goyang, Korea

1Among 1,372 lung cancer patients without brain metastasis who underwent resection of the lung cancer at our institutefrom 2001 to 2007, brain metastases developed in 72 patients (5.2%) during their hospital course. We hypothesized that
there were micro-metastases in the brain at the time of lung surgery in these patients, even though there was no detectablebrain metastases in the MRI. The purpose of this study was to evaluate the growth rates of metastatic brain tumors in thisunique subset of patients, and to compare it with our previous report that calculated growth rate during chemotherapy.
Among 72 patients, 22 patients with cystic or hemorrhagic metastases were excluded. 77 metastatic brain tumors in 50
patients were reviewed. 25 patients underwent adjuvant or neoadjuvant chemotherapy, however, for the rest of the patients,
chemotherapy was not added after lung cancer surgery. Tumor volume was determined by using V-works software (v. 4.0)
(Cybermed, Seoul, Korea) and T1 gadolinium enhanced MR images.The median tumor growth rate was 12.5 mm3/day(interquartile range, 5.7-32.6). There were no statistically significant differences between lung cancer stages, and thegrowth rates were similar regardless of chemotherapy. The growth rate reported here corresponded to that of our previous
report (12.1 mm3/day). These findings may help optimize patient management during follow up.

P115
Prognostic factors in 57 patients with metastastic brain tumors frombreast cancer.
Tomohiko Ozaki1, Jyun Yamamura2, Norikazu Masuda2, Masahiro Nonaka1, Kazunori Yamanaka1,
Mami Yamasaki1, Youhei Banba1, Daisuke Eino1, Shusuke Moriuchi1
The Department of Neurosurgery, Osaka National Hospital, Osaka, Japan 2The department of surgery,
Osaka National Hospital

1

Introduction: For neurosurgeon, it is difficult to analyze whole metastatic brain tumor patients from breast cancer who had
neurosurgical therapy or medical therapy or radiation therapy. In this manuscript, 57 metastatic brain tumor patients frombreast cancer who had not only neurosurgical treatment, but also medical treatment or radiation therapy, were reviewed
and prognostic factors were analyzed by both univariate and multivariate analysis. Patients: 57 metastatic brain tumor
patients from breast cancer were treated in our single hospital between January 2003 and October 2008. Median age is
56 years old. Treatments: 21 patients were undergone both surgery and whole brain radiotherapy. 5 patients were
undergone surgery alone. 24 patients received radiotherapy alone. 7 patients received medical supports alone.Results:
Median survival was 7.4 months. 1 year survival rate was 37%. Under univariate analysis, metastic status for other organs,positive rate of hormone receptors ( ER, PR, HER2) were not significant as prognostic factors. Single brain
metastasis(p=0.031), resection(p=0.013) and triple negative for hormone receptors(p<0.001) were significant prognostic
factors. Under multivariate analysis, resection(p=0.019) and triple negative for hormone receptors(p=0.005) were significant
prognostic factors. Conclusions: Single brain metastasis, resection and HER2 positive were good prognostic factors.
Triple negative for hormone receptors was poor prognostic factor.

Poster Presentation (P)P116Intramedullary spinal cord metastasis in breast carcinoma, casereport.
Lumir Hrabalek1, Ondrej Kalita1, Hana Studentova2, Jana Jankova3, Jiri Ehrmann Jr.3,
Radek Trojanec4, Marian Hajduc4
Department of Neurosurgery, Palacky University Olomouc, University Hospital Olomouc, Olomouc, Czech republic
Department of Oncology, Palacky University Olomouc, University Hospital Olomouc 3Department of Pathology,
Laboratory of Molecular Pathology, Faculty of Medicine, Palacky University Olomouc, University Hospital Olomouc
4
Laboratory of Experimental Medicine, Department of Pediatrics, Palacky University Olomouc, University Hospital
Olomouc
1
2

Case report: 41-year-old premenopausal woman was presented with a locally advanced tumour of the left breast in 2001.
Histopathological examination revealed an infiltrating ductal carcinoma. She underwent oncotherapy and surgicalovarectomy. She achieved complete remision. In August 2007, reccurency of the tumour was diagnosed in the left breast
and a right axillary lymph nodes. She started hormonal therapy and underwent left breast ablation and bilateral axillary
lymph nodes dissection followed by oncotherapy. This woman felt severe weakness of lower extremities in August 2008. A
whole body PET/CT showed only tumour of the spine or spinal canal at level L1. MRI showed leptomeningeal infiltration of
the spinal cord at L1 (medullary conus) and cauda equina. Laminectomy L1 was performed and partial resection of theintramedullary and cauda equina tumour was achieved. Histology revealed breast carcinoma metastasis. Postoperatively
she underwent local radiotherapy. Her clinical status, especially right leg weakness and sensory loss in the lower
extremities, immediately improved, but she still was not able to walk. The case report is documented by MRI, histological,
immunohistochemical and cytogenetic examinations. Discussion: patients who have no evidence of widespread organ
metastases or multiple intramedullary lesions and who have a life expectancy of at least a few months with tumours of
nonlymphomas histology should be considered for tumour resection. Intramedullary spinal cord metastases are
infrenquently observed. According to all cases previously published in the English literature, they clinically affects only 0.10.4% of all cancer patients. Lung cancer (54%) with breast carcinoma (11%)accounted for a majority of cases. We foundonly 7 cases of surgical resection (including 2 cases with localisation in medullary conus) of breast spinal cord metastasesin the literature. To our knowledge, we report the first case of a succesful surgical treatment of metastatic leptomeningeal
infiltration in medullary conus and cauda equina.

- 170 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP117
Spinal cord metastasis of adenocarcinoma, case Report
Ondrej Kalita1, Lumir Hrabalek1, Jiri Ehrmann Jr. 2, Marian Hajduch3, Jiri Srovnal3
Department of Neurosurgery, Palacky University Olomouc, University Hospital Olomouc, Olomouc, Czech republic
Department of Pathology, Laboratory of Molecular Pathology, Faculty of Medicine, Palacky University Olomouc,
University Hospital Olomouc 3Laboratory of Experimental Medicine, Department of Pediatrics, Faculty of Medicine,
Palacky University Olomouc, University Hospital Olomouc
12

Introduction: Metastasis of adenocarcinoma to the spinal cord is a rare condition, that accounts in approximately 1-3% ofspinal tumours. Case report: The authors present the case of a 74-year-old man who suddenly developed quadriparesis
and was subsequently diagnosed with a tumour of the cervical spinal cord at level C4. The spinal tumour was removed
surgically and a metastasis of an adenocarcinoma was shown histologically to originate from the colon. Discussion: Early
diagnosis of spinal metastases by means of magnetic resonance imaging (MRI) and microsurgical resection can improve
prognosis and neurological deficit of patients to certain extent. The available literature presents all together 71 cases ofsurgery, which is recommended in indicated patients, particularly in those with a potentially radio-resistant metastasis. The
aim of surgery is the decompression of functional nerve tissue and histological verification of the tumour origin. Survival
time of surgically treated patients is approximately twice longer that in those without surgery.The case report is well
documented by preoperative and postoperative MRI, histological, immunohistochemical and genetic examination of thetumour.

P118
Complete response of a large recurrent metastatic brain tumor
treated by CyberKnife: a case report and review of literature
Da-Tong Ju1, Cheng-Fu Chang1, Cheng-Ta Hsieh1
Department of Neurological Surgery, Tri-Service General Hospital, Taipei, Taiwan, Republic of China

1

The CyberKnife(Accuray Incorporated, Sunnyvale, California, USA) is a frameless stereotactic radiosurgery system withreal-time image-guidance to provide high-dose radiation with more accurate target localization and dose delivery. The
CyberKnife has proven to play an important role in management of metastatic brain tumors, especially those that recurredfollowing whole brain radiotherapy. Most metastatic brain tumors smaller than 1 cm3 have shown complete response after
CyberKnife radiosurgery. However, a dramatic change in size of large metastatic brain tumors is rarely discussed in theliterature. Here, we report a case of adenocarcinoma of the lung with brain metastases. Because the metastatic brain tumor
initially measured about 3 cm in diameter, the patient had previously undergone two craniotomies followed by externalbeam radiation to the resection cavity. The tumor subsequently recurred and was treated with CyberKnife radiosurgery.
Complete disappearance of the recurrent tumor by magnetic resonance imaging three months after radiosurgery wasobserved. The relevant literature is also reviewed.

P119

Department of Neurosurgery, Komagome Metropolitan Hospital, Tokyo,Japan 2Department of Neurosurgery,
University of Tokyo, Tokyo, Japan

1

Recently, sustained-release cytosine arabinoside : DepoCyt, has been reported to be useful for the treatment of
leptomeningeal dissemination of malignant tumors. But it is still off-label pharmaceutical in Japan. We succeeded atcontinuous intrathecal administration of arbitrary antineoplastic agents via "Ventricular port" . "Ventricular port"is asubcutaneous port (P-U Celsite port brachial ,Toray Medical Industries,Tokyo, Japan) connected to a ventricular catheter.
The goal of the present study is to determine the effect and the safety of continuous intrathecal treatment(CIT) withmethotrexate(MTX). Twenty patients with leptomeningeal dissemination (primary disease 10 cancers;6 gliomas and 4
lymphomas) were given 2 to 7 cycles of CIT with MTX 10 mg administered into the lateral ventricle for 5 consecutive days
biweekly. The concentration of MTX in the lateral ventricle was 7 to 10 x 10-6 M from Day 1 to 4. Response to this therapy
included 6 patients with complete remission, 7 with progressive disease, and 7 with stable disease. Kaplan-Meier analysis
revealed a median overall survival of 8 months while the overall survival rate for leptomeningeal-specific death 13
months,and that for metastasis from cancer was 5 months,respectively. Complications of CIT with MTX were relatively
low(<0.5%), and nausea and vomiting did not occur in any of the patients. In conclusion, CIT with 10 mg MTX via"Ventricular port" for 5 days improved the therapeutic effect and reduced the complications associated with treatment of
leptomeningeal dissemination from malignant tumors.

- 171 -­­

Poster Presentation (P)Continuous intrathecal treatment with methotrexate via "Ventricularport" for leptomeningeal dissemination of malignant tumors
YUSUKE TABEI1, Nobusada Shinoura1, Tomoyuki Koizumi1, Ryozi Yamada1, Kuniaki Saito2

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P120
Population Based Epidemioly of Central Nervous System (CNS)
malignancies in the Girona province (Spain). Results of an 11 years survey(1994-2004).
Rafel Fuentes1, Rafael Marcos-Gragera3, Loreto Vilardell3, Salvador Villa-Freixa1,
Ferran Perez Bueno4
Institut Catala d'Oncologia. Girona 2Institut d’Investigacio Biomedica de Girona 3Unitat d’Epidemioloiga i Registre delCancer Girona 4Hospital Josep Trueta de Girona

1

Background Epidemiological data incidence regarding survival of CNS malignancies are infrequently reported. We present
an updated assessement of survival rates obtained from the Girona population-based cancer registry. Patients andMethods Analyses included all cases of primary CNS malignancies registered between 1994-2004. Meningeal and soft
tissues tumours were not included. Pathological diagnoses were reviewed and grouped according to the last WHO
classification of of CNS tumours (2007). Cases notified only by the death certificate [n= 27 (5.5%)] were excluded from thesurvival analysis. Overall survival was calculated from the date at diagnosis to the date of death or the end of the study(December 31st, 2005). Probability of survival was calculated according to Kaplan-Meier method. Results A total of 493
patients were registered during the 11 years survey study. Distribution by histology was: astrocytic tumours = 243 (49.3%);
oligodendroglial and oligoastrocytic tumours = 17 (3.4%); ependimal tumours =13 (2.6%); embryonal tumours= 18 (3.7%)
and CNS primary malignancies without histological confirmation = 202 (41.0%) The mean ages for embryonal tumours and
CNS primaries without histological confirmation were respectively 18.2 yrs (±SD) and 66.3 yrs (±SD). A predominance ofelderly patients was demonstrated. An increasing incidence of glioblastoma was also observed along the study period.
Five-years overall survival rates were: astrocytic tumours=14.6%; oligodendroglial and oligoastrocitic tumours =35.7%;
ependymal tumours=41.0%; embryonal tumours=32.4% and CNS malignancies without histological confirmation=7.5%.
Discussion Our data showed a clear increased incidence of astrocytic tumours by age. Survival figures showed that
ependymal and oligodendroglial tumours were the histological groups with a better survival rate. This is consistent withpreviously published data. The group of patients with CNS malignancies without histological confirmation had the worst
survival figures. This finding is due to a more conservative attitude in the diagnosis and treatment of older patients.

P121
THE FIRST FINGERPRINTS OF NEUROONCOLOGY IN PREHISTORIC ERA; PREHISTORIC
TRAPENATED SKULLS MAY BE THE FIRST ATTACT TO TREAT TUMORS IN
NEUROONCOLOGY
Cengiz Cokluk1
Ondokuzmayis University, Medical Faculty, Department of Neurosurgery

1Prehistorical skull trepanations were discovered in some areas of the world. In this study we reported the operated skulls
discovered in Samsun-Ikiztepe. These skulls were evaluated in the aspect of the possibility of the first effort to treat tumorsin neurooncology. Four prehistoric skull skeletons were found in Samsun-Ikiztepe area. The craniectomy sites were locatedon the right parietal bone in two subjects. One of them had occipital craniectomy defect. In remaining one of themcraniectomy was located on the superior sagittal suture line. In this study we described general charactheristics ofprehistoric skull trepanation in the aspect of first fingerprints in neurooncology. Key words. Prehistoric skull skeletons,
history of neurooncology.

Poster Presentation (P)P122
Expanded Endonasal Resection of Supra- and Extra-Sellar Lesions
Doo-Sik Kong1, Do-Hyun Nam1, Kwan Park1, Jong Hyun Kim1
Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

1Introduction: The aim of this study was to report the results of a consecutive series of patients undergoing pituitary andnon-pituitary surgery using a fully endoscopic endonasal approach and to evaluate the efficacy and safety of thisprocedure. Methods: For last14 months, we performed a fully endoscopic endonasal resection for 51 patients with pituitaryand non-pituitary lesions in a single institute. Among them, we reviewed patients who underwent expanded endonasal
resection for supra- and extra-sellar lesions. Results: Among 51 patients, a total of 21 patients had supra- and extra-sellar
lesions including anterior cranial base meningiomas, giant pituitary adenomas, and craniopharyngiomas, etc. Their mean
age was 51.5 years with a range of 27 to 84 years. There were 13 men and 8 women. Gross total resection was performed
in 12 patients and subtotal resection in 9 patients. Postoperatively, CSF leakage requiring second revision operation
developed in only one patient, vasospasm in one patient, and rebleeding requiring transcranial approach in one case. For
even giant pituitary tumors, optic nerve and chiasm was not necessary to be intentionally visualized, because large pituitary
tumors could be removed without interrupting the arachnoid membrane. Conclusions: Expanded endonasal resection foranterior cranial base lesions is still challengeable. Our series is too small to determine the clinical outcome and to compare
its superiority to the conventional microscopic approaches. However, we believe that to share the preliminary experienceswith each other institutes can be helpful to achieve the optimal surgical results in the treatment of anterior cranial basetumors.

- 172 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP123
Extended endoscopic endonasal transsphenoidal approach for skull
base lesion - Availability of multilayered reconstruction method Shigetoshi Yano1, Takayuki Kawano1, Mareina Kudo1, Hideo Nakamura1, Keishi Makino1,
Jun-ichi Kuratsu1
Department of Neurosurgery, Kumamoto University Graduate School

1

Background: Endoscopic surgery is suitable for transsphenoidal approach in the point which can be performed by brightvision and by minimum invasiveness. Using bilateral nostril approach, extended transsphenoidal surgery (E-ETSS) is able tobe applicated easily. We examined the availability and issue of E-ETSS based on our experience. Materials and methods:
Between 2004 and 2008, total 15 procedures of E-ETSS were performed in our institute. They included 8 meningiomas, 2
pituitary adenomas, 2 Rathke's cleft cysts, 2 chordomas and 1 craniopharyngioma. Operation was performed throughbilateral nostrils using rigid endoscope with preparing wide mucosal flap from one septal mucosa Bone window wasenlarged anteriorly to planum sphenoidale, laterally to expose the cavernous sinus and inferiorly to expose basilar arterydepend on the lesion. Reconstruction of skull base after removal of the tumors were performed by multilayered methodwith PGA sheet and mucosal flap. Results: Gross total removal was achieved in all meningiomas, pituitary adenomas, andcraniopharyngioma in the 11 frontal base lesion. Intracavernous extension of meningiomas and chordomas were partiallyremoved. No cranial nerve injuries and visual disturbance was observed after surgery. CSF leakage was observed in one
patient who was required surgical repair. Spinal drainage was performed in 10 of 11 frontal base lesion and continued for
average 5.2 days. Excellent mucosal adhesion was observed within 3 months after the operation when we examinedendoscopically. Conclusion: Extended endoscopic approach thorough bilateral nostrils and multilayered reconstruction ofskull base with mucosal flap and PGA-sheet are safe and effective procedure.

P124
Results of Extended TSA to anterior skull base
Seong M Kim1, Han K Kim1
Department of Neurosurgery, Eulji University, Daejeon, Korea

1

P125
Two-Surgeons Technique for infratemporal fossa tumor; Simultaneous
lateral transzygomatic and endoscopic endonasal approaches withtechnical note
Shin Jung1, Kyung-Sub Moon1, Sang-Chul Lim1, Tae-Young Jung1, In-Young Kim1
Department of Neurosurgery, Department of Otolaryngology-Head and Neck Surgery, Chonnam National University
Hwasun Hospital & Medical School, Gwangju, Republic of Korea

1

Although the advent and widespread development of endoscopic techniques have combined with transcranial microscopic
surgery for skull base, its clinical adaptation for lesions around middle skull base has not been published to date.
Endoscopic approach may have several advantages for the lesion in the infratemporal fossa (ITF), compared to traditional
lateral approaches. However, the limitation of endoscopy is the inability to safely access to the rostral part of the ITF,
especially in a case with extension into the middle skull base. To overcome this limitation, we used combined endoscopy
and transcranial approaches for recurred carcinomas on the ITF.Two recurred carcinomas (adenoid cyst carcinoma,
nasopharyngeal carcinoma) were mainly located on ITF with extension into middle skull base. Initially, endoscopic
endonasal approach was used for debulking and peripheral demarcation of tumor. After deskeletalization of middle skull
base via lateral transzygomatic approach, two surgeons could simultaneously access to the rostral part of the ITF andperform the gross total resection with preservation of the trigeminal nerve (V2 and V3). Despite the uncertain local control
due to small number of cases and short follow-up duration, this combined approach may prove to be safe and effective
under multidirectional visualization to the ITF and middle skull base.

- 173 -­­

Poster Presentation (P)With development of navigation system and endoscopic surgery, the extension of TSA(transsphenoidal approach) was
surprisingly increased with safety. We present the surgical results of extended TSA to anterior skull base including sellar,parasellar and clival lesion. We introduce several tactics of extended TSA for exposure and hemostasisand discuss aboutcomplications.From 2001 to 2007, we have done extended TSA on 24 patients. We analyzed extent of tumor removal andpostoperative complications retrospectively. Patients were diagnosed pituitary adenoma(5), craniopharyngioma(2),meningioma(1), chordoma(9), chondrosarcoma(1), squamous cell carcinoma(1) and others(6). Cases of pituitary adenoma
which showed large suprasella extension or cavernous sinus(CS) extension were included. Transseptal approaches weredone only 2 cases in early period and the others were approached via endonasal paraseptal route. Trans-ethmoidal
approach was combined in one pituitary adenoma extended to CS. Operations were done in microscopic view assisted
endoscopic system. Total or radical removal rate was 88%(15/17). The group of subtotal removal were pituitary adenoma(1),meningioma(1), chordoma(1) patients. These three patients had previous operation on other institution. Squamous cell
carcinoma was excluded analysis of removal rate because operation was scheduled biopsy. Others excluded in analysis ofremoval rate were non-tumorous condition which were CSK leakage(3), arachnoid cyst and rheumatoid arthritis(2) and theirproblems were resolved successfully after extended TSA. Complication rate was 17%(4/24). There were three CSF leakand one aggravation of visual compromise. One of CSF leak patients undergone reoperation and others were treatedconservatively via lumbar drain. There were not ant complication related ICA.Extended TSA was useful and minimallyinvasive surgery on sellar and parasellar lesions. For safe and successful operation, precise acknowledges of surgicalanatomy and technique of hemostasis and reconstruction were necessary. And addition of endoscopic surgical techniqueand equipment was needed. Navigation system was also useful.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P126
Application of Endoscopes in minimally invasive neurosurgery
Chiung-Chyi Shen1, Wen-Yu Cheng1, Shiuh-Dung Lee1, Meng-Yin Yang1
Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.

1

Objective: The use of endoscopes in neurosurgery has made an unexpected progress during recent years. Advanced
endoscopes have simultaneously stimulated the development and application of minimally invasive treatment concepts inmany neurosurgical fields. Now they are considered as a well-established operative technique in skull base surgery. We will
present our experiences of the application of endoscope in the skull base surgery. Materials and Methods: Various rigid
and/or flexible endoscopes were used according to the indication and the planned operative approach. Neuroendoscopic
interventions were applied for therapeutic interventions for more than 1000 skull base surgeries. Special monitor,
instruments and Navigator were applied in some situations. Results: From 1997 to 2008, we have successfully performed
more than 1000 endoscopic or endoscopy assisted microneurosurgical interventions, including 850 pituitary tumors, 30
skull base lesions, 30 acoustic neuromas, 20 intracranial aneurysms, 20 intracranial arachnoid cysts, 40 neurovascularcompression syndromes, 50 hydrocephalus. No mortality was found. The morbidity rate is below 1% Conclusion:
Neuroscopy has become an essential part of minimally invasive neurosurgery in skull base surgery. We feel that thistechnique will be more acceptable to treat a vast majority of skull base lesions with low morbidity and short hospital stay.

P127
Clinical correlation between peritumoral edema and various factors inmeningioma.
Jeong-Taik Kwon1, Kyoung-Tae Kim1
Department of Neurosurgery, Chung-Ang University, Seoul, Korea

1Introduction: Peritumoral edema in meningioma is important for clinical progress. The purpose of this study was toanalysis the relationship between the clinical characteristics and the formation of peritumoral edema in meningiomas.
Methods: From February 2005 to March 2008, we removed the meningioma from thirty patients whose mean age was
53.9 years old (29 - 73) and 1 : 1.5 (Male : Female). We checked edema index (peritumoral edema volume/tumor volume,
EI=1; no peritumoral edema) in all patients. The patients were evaluated by MRI, MRS and pathology. We analyzed
peritumoral edema according to patient sex, age, tumor size, peritumoral rim, pial blood supply, MR spectroscopy (NAA,
tCho, tCr, Lip and Alanine) and pathology. Results: We evaluated various clinical factors with multivariate regression
analysis. Pial blood supply was statistically significant (P = 0.035). However, sex, age, tumor size, peritumoral rim, MR
spectroscopy and pathology were not significant. Especially, we analyzed between MR spectroscopic and peritumoral
edema using various methods, but we could not find the correlation of that. Conclusions: Pial blood supply was
associated with peritumoral edema, but sex, age, tumor size, peritumoral rim, MR spectroscopy and pathology were notassociated. However, this result needs further study, because the number of patient was only thirty.

P128
Poster Presentation (P)Meningioma operations in the elderly patients: efficient way to internal
decompression
Sun-Chul Hwang1, Kwan-Woong Park1, Bum-Tae Kim1, Soo-Bin Im1, Won-Han Shin1
Department of Neurosurgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

1

Objectives: Great care must be taken in the operations for the elderly because of their premorbid conditions. Blood loss
and operation time should be minimized to get satisfactory results. We present the our surgical experiences for themeningioma in the elderly patients
Materials and Methods: The medical records of 10 patients older than 65 years old were reviewed retrospectively. All
patients had neurological deficits and incidental meningiomas were excluded. In the large mass, two operators took
participated in the internal decompression. One operator usually used ultrasonic aspirator to remove the mass and theother got the hemostasis. And then one of operators performed tumor-arachnoid dissection meticulously.
Results: The mean age was 68 (65-73) years old. Only 2 patients had not medical illness. The meningiomas are located in
the convexity (4 cases), falx (4 cases), parasagittal (1 case), and lateral ventricle (1 case). The size of tumor was 47 ± 17 (2572) mm. Only one case had the preoperative embolization. The operation time was about 5 hours. Four patients weretransfused during the operation. The neurological deficits were completely recovered without any postoperative events.
Conclusions: Minimal blood loss and operation time is necessary for minimizing the operative morbidity. Two-operatorsinternal decompression in the large meningioma may be helpful to get successful outcome.

- 174 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP129
A 57-patient experience on the surgical strategies of petroclival
meningiomas
Peiliang Li1
Department of Neurosurgery, HuaShan Hospital, Shanghai Medical College, FuDan University

1

OBJECTIVE: To distinguish the possible risk factors in the surgical treatment of petroclival meningioma and define optimal
surgical strategies concerning about the balance between postoperative quality of life and tumor progression/recurrence
rate.
METHODS: We recruited 57 patients with petroclival meningioma who received operations in our hospital during
2002~2006. There were 14 male and 43 female patients with a mean age of 50.5 years, of which 53 patients (93%) wereprimary cases. The primary outcomes including postoperative neurological deficits, modified Rankin scale (MRS) score andrecurrence rate were evaluated and the possible risk factors were examined. The mean follow-up time was 34 months(range, 10-67 months).
RESULTS: Gross total resection was achieved in 58% of patients. One patient died in the peroperative period because of
intracranial hemorrhage. 67% patients experienced new postoperative neurological deficits and 26% patients had a higher
MRS score when assessed at follow-up. Postoperative complications were observed in 24 patients. Postoperative radiationor γ-knife therapy was adapted to 19 of the 24 patients who had residual tumors and no progression was found.
Radiographic recurrence occurred in 12.3% of patients at a mean follow-up of 42 months. Tumor adhesion,
hypervascularity and engulfment of neurovascular structures were three risk factors to increased MRS score (p=0.0002;
p=0.0051; 0.0009) and furthermore adhesion to adjacent structures obviously affected the extent of resection (p=0.0029).
The risk of postoperative cranial nerve deficit increased with tumor engulfment of neurovascular structures (p=0.0004) andfibrous tumor consistency showed a tendency (p=0.0622).
CONCLUSION: Intraoperatively defined tumor characteristics played a critical role in identifying the subset of patients withan increased risk of postoperative morbidity and an unfavorable postoperative MRS score. Despite of a conservative
attitude in the operation, an individual strategy of treatment based on the careful preoperative evaluation could help toimprove the quality of life.

P130
Retrospective analysis of the post-operative outcome of petroclival
meningiomas
Matthias Kirsch1, Gabriele Schackert1
Neurosurgery, Carl Gustav Carus University Hospital, Technical University Dresden

1

P131
Advantages of the Pterional approach for Olfactory groove andTuberculum Sellae Meningiomas
Chul-gu Jung5, Ho-gyun Ha2, Hyun-woo Kim3, Tae-gi Yang4, Ji-hoon Kim5
Nueurosurgery Department, Konyang university hospital, Daejeon, South Korea 2Same as above 3Same as above
Same as above 5Same as above

1
4

Objective There is much controversy regarding the surgical approach for olfactory groove and tuberculum sellae
meningiomas. There is a need for a retrospective review concerning the approach for such tumors in reducing thesymptoms, morbidity and mortality.The author is reporting on the advantages of the pterional approach for suchcases(5cases of Tuberculum sellae meningiomas, 3cases of Olfactory groove meningiomas and one case of planum
sphenoidale meningioma). Methods During a period of 5 years(2003 to 2008) there were 9 cases approached by thepterional approach with microsurgical tumor resection(5cases of Tuberculum sellae meningiomas, 3cases of Olfactory
groove meningiomas and one case of planum sphenoidale meningioma)The diameter of the tumor ranged from 3.0 to
7.3cm presenting with visual disturbance, anosmia, headache, mental dysfunctions and seizures. Results Total
removal(Simpson Grade I-II) was possible in all cases with intact parenchyma on postoperative MRIs. There was one death
unrelated to surgery(sepsis secondary to pseudomembranous enterocolitis). In all, except for anosmia, the symptoms were
improved Conclusion The main advantages of the pterional approach is that the main tumor feeders(ethmoidal arteries)
can be devascularized early in the dissection, with the dissection of the sylvian fissure a very good orientation of the sellar
area can be realized, tumor excision can be done with minimal retraction, contralateral olfactory nerve can be preserved incases of minimal invasion, and the frontal ascending veins can be preserved to prevent venous infarction postoperativelySo
we are of the opinion that the pterional approach is a superior approach compared to other approaches to olfactory groove
meningiomas or tuberculum sellae meningiomas- 175 -­­

Poster Presentation (P)Introduction: The purpose of this retrospective study was to analyze the outcome and recurrence of petroclival
meningiomas. Methods: A total of 571 meningiomas were operated upon between Jan.1994 and Dec.2002. Of these, 35
were true petroclival meningiomas that were amendable for follow-up including regular ambulatory visits and aquestionnaire. Results: The median age of the 27 women and 8 men was 55.4 years. The patients most commonly
presented with headaches, trigeminal neuralgiform pain, dizziness, ataxia, unsteadiness, and hearing loss. The mediantumor volume was 62 cm3. Histology was mostly meningothelial (16) and transitional (9). Intraoperative radicality according
to Simpson was 14 grade 2, 6 grade 3, and 12 grade 4. Four pts. underwent two-staged operations. There was no
perioperative death. Six pts. suffered from liquorrhea treated with lumbar drainage or open revision. One post-operative VPshunt placement, one tracheostomy , one facial nerve reconstruction were necessary. Four patients received radiation
therapy for recurrence/progression. Post-OP morbiditiy was improved with regards to hearing loss, trigeminal-type pain,
eye movement tempotrarily worsened. Operative radicality was associated with location, medial structure involvement, andsize. Conclusion: Petroclival meningiomas represent an entity that has a higher than usual treatment related morbidity thanmeningiomas in other tumor locations.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P132
Meningioma arising from the lateral recess of 4th ventricle
Seong M Kim1
Department of Neurosurgery, Eulji University, Daejeon, Korea

1

Seung-Min Kim, Ki-Seok ParkDepartment of Neurosurgery, Eulji University College of Medicine, Daejon, KoreaThe primaryoccurrences of meningiomas without attachment of the dura are rare. Clinical considerations and pathophysiologic
mechanisms about theses tumors have not been sufficiently explored, and a complete classification has not beenaccomplished. A 59-year-old female presented with headache and dizziness for 1 year. Neurologic deficits were not foundon admission. Magnetic resonance imaging revealed a 52x28 mm mass lesion without dural attachment located in the Lt.
lateral recess of the 4th ventricle. The tumor was dumbbell-shape, iso-intense on T1-weighted and heterogenous on T2weighted images, and became homogenously well enhanced with gadolinium. We removed the tumor via Lt. far-lateraltranscondylar approach. Care was taken not to injure the lower cranial nerves and the tumor was totally removed except fora tiny piece which invaded the brain stem. Histologic examination indicated that the lesion was a mixed pattern meningiomaof meningothelial and fibroblastic type.We present case of meningioma on lateral recess which should be considered as
one type of meningiomas without attachment of the dura

P133
Surgical management for trigeminal schwannoma
Chao Zhang1, Ying Mao1, Wei Zhu1
The Department of Neurosurgery, Huashan hospital, Fudan University, Shanghai, China

1

Surgery has historically been the mainstay of treatment of trigeminal schwannoma. With gross total resection, cure can beachieved. However, before the era of microsurgery, gross total resection was achieved in only 50% of patients, and oftenwith high morbidity and mortality. The advance of microsurgical techniques and skull-base approaches has greatly
enhanced the surgical management of these tumors, and outcomes have improved markedly. This report documents 57
cases of histologically verified schwannomas that arose from the trigeminal nerve and were treated surgically in our clinic
between December 2002 and May 2008. The patients were 36 women and 21 men of age 45.8 years (range, 17~81 years).
The tumor was located mainly in the middle fossa (type A) in six cases, in the middle and posterior fossa (type C) in 36
cases, mainly in the posterior fossa (type B) in 15 cases. Total excision was achieved in 35 cases, subtotal excision was
achived in 21 cases, partial cytoreductive excision was achived in 1 case, and there was no mortality in the series. In thelatter two groups, all 22 patients underwent planned stereotactic radiosurgery for residual tumor. Outcome after surgery
was gratifying. The mean follow-up time for this study was 42 months (range 7~72 months). 52 of the 57 patients who had
their tumors surgically excised have no aggravation of clinical symptoms and showed no MR imaging evidence of recurrent
disease during follow-up. 38 of them have obvious amelioration of clinical symptoms. Our results indicate that surgicalresection to the best of the operator’s ability via skull-base approaches, combined with stereotactic radiosurgery forresidual tumor, was the secure and efficient treatment for trigeminal schwannoma.

P134
Poster Presentation (P)Lateral or anterolateral approach for large dumbbell-shaped
cervical neurinoma
Mingguang Zhang1
1
The Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P.R.China. Xu, qiwu The Dpt of
Neurosurgery, Huashan Hospital, Fudan University,Shanghai,P.R.China. 12 Wulumuqizhong Rd, Shanghai. Zip
Code,200040. 86+21+52889999*8112[Abstract] Objective: Generally, the two-stage operation (combined posterior and anterior approach) for the large
dumbbell-shaped cervical neurinoma is widely accepted by the most of neurosurgeons. The purpose of the research iswhether the tumors can be resected with one-stage operation without corpectomy and fusion of the vertebral bodies.
Methodes: Datas from seven cases of patients (female 3, male 4) with large dumbbell-shaped cervical neurinoma fromFebruary 2006 to November 2008 were analyzed retrospectively. There was tumor in the enlarged cervical intervertebral
foramen on MRI of the patients. The tumors of the patients were resected through the enlarged cervical intervertebral
foramen by the lateral or anterolateral approach. The partial removal of the intracanal tumor of two patients was carried out
using posterior approach some time ago in other hospitals. Results: Three patients were treated with the lateral approachfor the tumor locating above C3 level. The tumors of the other patients were resected by the anterolateral approach without
corpectomy and fusion of the vertebral bodies. Total removal of the tumor was obtained with one-stage operation in allseven patients. Six of the seven patients showed excellent neurological improvement. One patient had slightly muscle
weakness of the left shoulder remained up to six months after surgery. Conclusion: Total removal of the large dumbbellshaped cervical neurinoma can be obtained with one-stage operation by the lateral or anterolateral approach. The
approaches can expose tumors through the enlarged cervical intervertebral foramen and require no laminectomy,
discectomy or interbody fusion, which may frequently produce spinal deformity. [key words]: Lateral approach,Anterolateral approach
Dumbbell-shaped neurinoma, Intervertebral foramen- 176 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP135
Clinical Course of Piuitary Adenoma after Apoplexy
Yong Hwy Kim1, Jung Ho Han1, Chul-Kee Park1, Hee-Won Jung1
Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea

1

Object: To elucidate the characteristics of pituitary apoplexy, the authors retrospectively reviewed the clinical course of
pituitary adenomas after apoplexy, which were remnant after surgical resection or managed conservatively in a single
institution.Material and method: We collected the clinical and radiological data of twenty-eight patients (15 males and 13
females) who were managed for pituitary apoplexy from January1997 to May 2007. Nineteen of 28 patients were operated
and 9 tumors were resected subtotally. And 9 patients were managed conservatively in the absence of altered mentality
and progressive visual deterioration. Totally, the authors reviewed clinical and radiological characteristics of these 18
tumors. On radiological and pathological examination, the cause of apoplexy was the intratumoral hemorrhage in all cases.
Result: Seven (39%) of eighteen tumors disappeared completely during the follow-up period and 8 tumors (44%) weredecreased in size spontaneously. Two residual tumors regrew increased in size at 55 and 66 months after surgery. One
tumor managed conservatively was increased in size due to the resolution of hemorrhagic content without clinicaldeterioration. Twelve patients were suffered with visual disturbance and vision was recovered in 10 patients. On last clinicalfollow-up, 9 (50%) patients needed the hormone replace therapy due to the panhypopituitarism. Eight patients complained
the diplopia or ptosis and these symptoms resolved spontaneously. Conclusion: We showed the spontaneous shrinkageof pituitary adenoma after apoplexy and improved vision and 3rd nerve palsy during the follow-up period. Considering
radiologic, visual and endocrinological outcomes, complete surgical resection of apoplexic pituitary adenoma is notmandatory. And conservative management should be considered in the absence of rapid clinical deterioration.

P136
Efficacy and Safety of Cabergoline as a First Line Treatment for Invasive
Giant Male Prolactinoma
Jeong Hoon Kim1, Chang Jin Kim1, Eun Hee Cho2, Min-Seon Kim2
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan
College of Medicine, Seoul, Korea
1
2

P137
Comparison of lateral and superior walls of the pituitary fossa withclinical emphasis on pituitary adenoma extention: cadaveric-anatomic
study
Kaya Aksoy1, SUAT BOYACI1ACIBADEM UNIVERSTY BURSA HOSPITAL, NEUROSURGERY DEPARTMENT BURSA, TURKEY

1

Pituitary adenomas extend to the suprasellar region via diaphragmal passage and extend to the cavernous sinus via themedial wall. Better understanding of the dynamics of suprasellar and parasellar extension of sellar region pathologies
requires microanatomical comparison of diaphragma sellae and the medial wall of the cavernous sinus. This study provides
the first detailed quantitative assessment between diaphragma sellae and medial wall of the cavernous sinus.
Microanatomical details and histopathological examinations of the diaphragma sellae and medial wall"s of the cavernous
sinus were studied in sphenoid block samples obtained from adult cadavers, and the thicknesses of the diaphragma sellae
and the medial wall of the cavernous sinus were measured. Mean thickness of the diaphragma sellae was 216.73 ± 51.26 μm in the center and 367.33 ± 133.66 μm in the periphery. Mean thickness of the lower third of the medial wall was 161.53 ±53.86 μm and that of the upper third was 278.46 ± 162.79 μm. Difference between the thicknesses of the upper and lower
thirds was significant (P<0.001). When the central thickness of the diaphragma sellae and lower third of the medial wall
were compared, a significant difference was found (P<0.01). Our measurements suggest that when the diaphragma sellae
is thick and the stalk opening is complete, the thickness of the lower third of the medial wall could be the major determinantof parasellar extention.

- 177 -­­

Poster Presentation (P)Cabergoline is known to be effective in the treatment of micro- and macro-prolactinoma. We investigated the efficacy andsafety of cabergoline in the treatment of invasive giant prolactinoma. Ten male patients with invasive giant prolactinomas
participated in this study and their average age was 37.2 years. Before treatment, mean serum prolactin level was 11,426
ng/ml (range: 1,450-33,200 ng/ml) and mean maximum tumor diameter was 50 mm (range: 40-77 mm). They received
cabergoline treatment (0.5-3 mg/week) without surgery and radiotherapy. More than 97.7 % decrease in serum prolactin
levels was achieved in all patents except one at 3 months after initiation of cabergoline treatment. At the last follow-up(average treatment duration: 19 mo), they showed average 99 % decrease in serum prolactin levels, five of them having
normal serum prolactin levels. In all patients, cabergoline treatment caused a significant reduction in tumor size (85&plusmn 13 %; range: 57-99 %) at first MRI follow-up conducted between 3 to 12 months of cabergoline treatment. A
greater reduction in tumor size was achieved by cabergolin treatment of more than 12 months, compared to that of lessthan 12 months (97 &plusmn 2 % vs. 85 &plusmn 13 %, p< 0.05). An excellent and rapid reduction in both serum prolactin
levels and tumor sizes was induced by a low dose of cabergoline in the most of patients with giant prolactinoma. Therefore,cabergoline represents an effective and well-tolerated first-line therapy for invasive giant prolactinoma in male patients.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)P138
METASTATIC ACTH PRODUCING PITUITARY CARCINOMA (PCA) TREATED WITHTEMOZOLOMIDE(T): CASE REPORT AND REVIEW OF THE LITERATURE
Sarah Taylor1
Division of Hematology/Oncology, University of Kansas, Westwood, Kansas 66205

1

PCa is a rare tumor defined by the presence of metastatic disease. It is poorly responsive to treatment. The majority arefunctionning and frequently produce ACTH. This is the first reported case of an ACTH producing tumor treated with T. It isalso unusual in that the patient experienced a flare response either to treatment or treatment induced hemorrhage with atransient but symptomatic increase in ACTH production immediately after treatment with T. A 59yo WF underwent STR of apituitary adenoma followed by post op XRT in 1997. In 2005 she presented with back pain and Cushings disease. Total freeurinary cortisol, serum cortisol and ACTH were elevated and accompanied by severe hypokalemia. An extramedullary
intradural tumor at L2-3 was resected. Pathology was identical to the pituitary tumor. IHC was strongly positive for ACTH.
Post op XRT was given. The Cushings resolved. In 2008 she presented with diplopia and right third nerve palsy caused bya right parasellar mass encasing the carotid artery. MGMT immunoexpression in the spinal tumor was low. T was
administered at 150mg/ m2 days 1-5 and was complicated by severe myelosuppression and hemorrhage into the mass.
Hypokalemia and elevated ACTH followed but resolved after her second cycle. After 8 cycles, her diplopia and palsy haveresolved. Six other pt(5M/1F)with PCa treated with T have been reported. 4 produced prolactin, 1 luteinizing hormone and
1 was silent. Two had MGMT testing which correlated with response. 5/6 responded to T.Responses were often
prolonged. None had a flare in hormone production. Hemorrhage/necrosis were documented in one.This pt lends support
for the use of T in this rare group of pts.

P139
Isolated Ocular Paresis in the Pituitary Adenoma: Review of 4 cases
Sun-Chul Hwang1, Kwan-Woong Park1, Bum-Tae Kim1, Soo-Bin Im1, Won-Han Shin1
Department of Neurosurgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

1

Poster Presentation (P)Objectives: Neuro-ophthalmological consequences of the pituitary apoplexy are included in loss of visual acuity, defect ofvisual fields, and ocular paresis. Isolated ocular paresis, the clinical symptom of ophthalmoplegia without visual symptoms,
is rare. We are to present the characteristics of the pituitary apoplexy with the isolated ocular paresis.
Materials and Methods: We reviewed retrospectively 32 cases of the pituitary adenomas with surgical resection. Fourcases (2 male and 2 female) were presented with isolated ocular paresis. The neuro-ophthalomogical, radiological andhormonal characteristics were investigated.
Results: In the clinical symptoms, all the cases had headaches 1-3 day(s) before onset of ophthalmoplegia. One had theleft oculomotor nerve palsy, one was the right abducens nerve palsy, and the others were the right total ophthalmoplegia.
The involvements of the oculomotor nerve were shown pupil-sparing ophthalmoplegia. In the hormonal studies, one was
Cushing's disease, one acromegaly, and the others non-functioning adenomas. In the radiological findings, intrasellar
hemorrhages and invasion or compression into the cavernous sinus of the affected side were shown. No suprasellar
extensions enough to compress the optic nerve were found. The tumors were removed totally (2 cases) or subtotally (2cases) by the trans-sphenoidal approach in elective surgeries(mean intervals from ocular paresis to operation: 9.3 days)
and the only one case(acromegaly) was explored for the cavernous sinus. The symptoms were gradually improved few
days after operation and the abducens palsy was the last to recover. The coagulative necrosis and hemorrhage was foundin the pathology of all the cases.
Conclusions: Isolated ocular paresis is one of presenting symptoms of pituitary apoplexy. The outcome of ocular paresis
seems to be good with the fashion of elective surgery.

P140
The effective treatment of craniopharyngioma using highly conformal
hypofractionated stereotactic irradiation
Moon-Jun Sohn1, Dong Joon Lee1, Sang Won Yoon1, Chae Hyuck Lee1, C. Jin Whang1
Neurosurgery, Novalis Radiosurgery Center, Inje University Ilsan Paik Hospital, Goyang, Korea

1

Objective: The development of an effective dose protocol for the treatment of craniopharygioma through planned dose
escalation and follow-up analysis. Methods : A total of 15 patients with recurrent or post-operative residual
craniopharyngioma were treated with Novalis shaped beam radiation. Three fractionated stereotactic radiation protocols
were used with effective biological effective doses ranging from 50Gy to 140Gy. Group A comprised three patients who
were treated with aproximately 50Gy of BED (range 39.9~53.2). Group B was made up of seven patients and were
irradiated with about 66.5Gy of BED(range 61.2~66.5). The third group, group C was made up of 5 patients and were
irradiated with more than 80Gy of BED(range 80~140). The equivalent single doses being 10.7 Gy for group A and 12.6 Gy
and 15.3 Gy for groups B and C respectively. MRI and ophthalmological evaluation was conducted during follow-up.
Results: Local tumor control was achieved for all members of group C and for the majority of patients in group B(71%).
However all patients in group A showed increased tumor volumes with a median period of 20 months for regrowth. No
further visual impairment was recorded for any of the groups while three patients in group C demonstrated improvements intheir visual field. Conclusion : Effective local control of craniopharygioma was achieved using highly targeted
hypofractionated irradiation with a dynamic conformal beam and intensity modulation. No reduction in visual function wasrecorded in any of the patients despite the relatively high BEDs used (3 to 4Gy daily fraction sizes). Additional long term
follow-up is necessary to ascertain the optimal minimum dose and the ultimate efficacy of this approach.

- 178 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP141
Lymphocytic hypophysitis with reference to MR imaging
Jeong-Hyun Hwang1, Sung-Kyoo Hwang1, Yeun-Mook Park1
Department of Neurosurgery, School of Medicine, Kyungpook National University, Daegu, Korea

1

Purpose: Lymphocytic hypophysitis (LH) is a very rare disease but now being recognized more frequently as a cause of
pituitary mass or pituitary insufficiency. LH occurs almost exclusively in women during pregnancy or postpartum, but may
occur unrelated to pregnancy. The authors report the clinical experience and unique imaging characteristics of LH.
Methods: Seven cases (M/F=4/3, mean age=42.3 (rage 27-61) years) were included this study. Two out of three female
patients were related to pregnancy. Common presenting symptoms were visual disturbances by pituitary mass andpolyuria/polydipsia in three patients respectively. None of the patients were related to autoimmune disorders. Results: Sixpatients were pathologically confirmed with trans-sphenoidal route. Biopsy was performed in four patients and mass
decompression was performed in two patients with significant visual disturbances. The three patients with diabetes
insipidus showed no improvement with steroids therapy. The other two patients with mass decompression showed
hypopituitarism and required hormone replacement. All cases showed a thickening of pituitary stalk/infundibulum and astrong enhancement of basal hypothalamus on MR with Gd-DTPA. Five cases revealed a symmetrical triangular shaped
diffuse enlargement of pituitary gland and an enhancement of diaphragma sellae of adjacent dura mater. Conclusions: LH
showed heterogeneity in presenting symptoms and treatment outcome. It was difficult to differentiate LH from otherpituitary diseases before tissue diagnosis. Preoperative presumption should be attempted with characteristic MR findings
and endocrinological work-up.

P142
Central Neurocytoma Presenting with Intraventricular Hemorrhage
Min-Su Kim1, Seong-Ho Kim1, Byung-Yon Choi1, Oh-Lyong Kim1
Department of Neurosurgery, Yeungnam University College of Medicine, Daegu, Korea

1

P143
Clinical Treatment of Intracranial Malignant Nerve Sheath Tumors
Kang Zheng1, Xuhui Bao1, Gang Wu1, Qing Xie1, Fengping Huang1
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

1

Objective To understand more about intracranial malignant nerve sheath tumors (MNST) by analyzing the clinical data of agroup of patients with this kind of rare tumor, in order to improve treatment effects. Methods From January 1994 toNovember 2006, 11 cases of intracranial MNST were diagnosed pathologically and treated at our department. Their clinicaldata were retrospectively analyzed. Results There were 7 male and 4 female patients ranging in age from 3 to 51 years.
Most of them had cranial neurological disorder, and main clinical manifestations included local swell and their previous
symptom recurrence. Three subgroups were categorized by their origins: one was from cranial nerve root, the other wasfrom unspecified central nerve root, and the last one had malignant transformation after recurrence. 5 cases had total
removal of tumors, 3 cases subtotal removal, and 3 partial removal. Short-term effects were good. 3 cases underwent
radiotherapy. Though these patients recovered quickly after operations, 3 cases survived longer than 5 years, and thelongest life span was more than 10 years. Conclusion Such a tumor often occurs in children or middle-aged people. The
illness course is short in most patients. Clinical manifestations are mainly neurological disorders of the site where the tumor
is located on. The short-term curative effects are satisfied. The complete resection and radiotherapy can promote the5-year survival rate.

- 179 -­­

Poster Presentation (P)Introduction: Central neurocytomas are rare neoplasms that usually occur in young adults and the most commonly arise in
the lateral ventricles near the foramen of Monro. Although intracranial hemorrhage is a well-recognized complication inseveral types of neuroepithelial tumors, intratumoral hemorrhage in central neurocytoma is not generally acknowledged. We
report a case of central neurocytoma with sudden-onset of symptoms due to intratumoral hemorrhage. Method andresult: A 47-year-old male patient was transferred to our hospital from a nearby local clinic due to sudden onset of severe
headache and vomitting. On admission, he had progressive disturbance of consciousness, but there were no focal
neurological deficits. The computed tomography scan showed hydrocephalus and a huge mass with heterogeneousdensity involving left lateral ventricles near the foramen of Monro. On magnetic resonance imaging (MRI), the mass
appeared grossly isointense on the T1-weighted image and hypointense on the T2-weighted image. A well-demarcatedcentral hypointensity was noted on T2-weighted image. After contrast medium injection, the MRI showed no enhancementof the lesion. The tumor was subtotally resected by a frontal transcortical approach. Pathological examinations confirmed aneurocytoma. Discussion : Spontaneous hemorrhage occurs very rare in primary brain tumors. As tumors ofneuroepithelial origin, glioblastoma, astrocytoma, oligodendroglioma, and medulloblastoma are more susceptible toproducing intratumoral hemorrhage. There are few cases of central neurocytomas presented by intraventricularhemorrhage in the literature. Hemorrhagic neurocytomas may present with an acute onset of symptoms such as is
generally observed in stroke patients. The cause of bleeding in neurocytomas is unclear. Numerous thin-walled tumor
vessels may be responsible for the bleeding. Conclusion: Central neurocytoma have a favorable prognosis and for thisreason it is important to consider neurocytoma in the differential diagnosis of neoplasms in the lateral ventricles near theforamen of Monro that present with intraventricular hemorrhage.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P144
A rare tumor-like lesion of peripheral nerve sheath in an unusual site.
Neuromuscular choristoma of intraorbital retrobulbar conus. A casereport and literature review.
SUAT BOYACI1, KAYA AKSOY1ACIBADEM UNIVERSTY BURSA HOSPITAL, NEUROSURGERY DEPARTMENT BURSA, TURKEY

1

OBJECTIVE: Neuromuscular choristoma (NMC), are rare benign tumors of the peripheral nerves. Histopathologicalcharacteristics of this unusual lesion well described, but neuroimaging findings have not been well descriped. We report
first intraconally located NMC that affecting the oculomotor nerve, with histopathologic and radiological characteristics.
CLINICAL PRESENTATION: A 10 years old girl presented with sudden onset left temporal and retro-orbital pain.
Magnetic resonance imaging scans demonstrated a small, retro-orbital, intraconal solid lesion that have capsule formation.
Our first provisional diagnosis was dermoid cyst in an atypical site. INTERVENTION: The tumor could be resected
subtotally. Post-operatively, the patient became pain-free but she had ipsilateral ptosis and upward movement failure.
Histologically, the lesion consisted of well differentiated striated muscle fibers intermingled with mature nerve elements
consistent with the NMC. CONCLUSION: NMC may need histological confirmation for diagnosis if they occur in theintracranial space. Pre-operative diagnosis with neuroimaging would be changed management strategy of treatment. Thislesion is the fist NMC lesion which intraconally located. It is very rare, but should be considered in the differential diagnosis
of intraorbital tumors.

P145
Clinical Experiences Of Intracranial Hemangioblastoma
Seung Heon Cha1, Jun Kyeung Ko1, Won Ho Cho1, Byung Kwan Choi1, Chang Hwa Choi1
Department of Neurosurgery, Pusan National University Hospital, Busan, South Korea

1

Poster Presentation (P)Introduction: Intracranial hemangioblastoma is benign vascular tumors arising either sporadically or as a manifestation ofvon Hippel-Lindau (VHL) disease, a hereditary cancer syndrome. We analysed a series of patients with intracranialhemangioblastoma to review our strategy of treatment. Materials and Methods: Consecutive patients with intracranialhemangioblastoma who underwent surgery and then adjuvant therapy if needs, at our institute were enrolled. Eighteenpatients (14 female and 4 male patients) underwent 22 operations for removal of 20 intracranial hemangioblastoma (age atsurgery 45 years, follow-up duration 37 months). Serial clinical characteristics, radiologic studies and medical records wereanalyzed. Results: Twelve patients (66%) were sporadic hemangioblastoma and six patients (34%) were von Hippel-Lindau
disease. Symptoms and signs included headache (60%), ataxia (66%), gait disturbance (20%), and hydrocephalus (47%).
Total resection was achieved in 16 cases(73%). 16 patients underwent total removal of tumor were more likely to havegood clinical outcome than 6 patients whose tumor were partially removed. Adjuvant radiosurgery was performed to 6
patients whose tumor partially removed. 4 patients of them showed good tumor control afrer radiosurgery. 2 cystic
hemangioblastomas were aggravated in the size of cystic portion, so revision were performed. Preoperative tumor
embolization was performed in two patients. Preoperative hydrocephalus resolved after tumor removal in 6 cases (100%)
without cerebrospinal fluid diversion One VHL patient was expired due to pheochromocytoma. Conclusion: Symptoms
and signs caused by intracranial hemangioblastoma can be treated safely and effectively with surgical resection.
Cerebrospinal fluid diversion is rarely necessary after complete tumor removal in patients with preoperative hydrocephalus.
Tumor recurrence is avoided by meticulous extracapsular resection. Radiosurgery may be adequate adjuvant therapy forremnant or recurrence intracranial hemangioblastoma except cystic hemangioblastomas.

P146
Surgical management of CNS hemangioblastomas in von Hippel-Lindau
diseaseHiroshi Kanno1, Hidetoshi Murata1, Nobutaka Kawahara1
Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan

1

Central nervous system (CNS) hemangioblastoma (HB) is the most frequent tumor in von Hippel-Lindau disease (VHL). The
tumor occurs in cerebellum, brain stem, and spinal cord. However, management of CNS HBs in VHL has been
controversial. Here, we discuss the management of CNS HBs in VHL. Surgically treated 59 CNS HBs (cerebellar 42, spinal17) in 33 VHL patients from 1992 to 2008 were retrospectively examined in diagnosis and surgical treatment. Diagnosis of
CNS HBs depended on symptoms, neurological examination, laboratory data, CT, MRI, and gene diagnosis. Symptoms in
cerebellar HB were faintness, gait disturbance, nausea, and headache while those in spinal ones were pain, numbness,
and weakness in extremities. Neurological examination revealed cerebellar dysfunction for cerebellar HB and regional
hypesthesia or muscular weakness for spinal one. Laboratory data often reveal polycythemia due to secretion oferythropoietin from the tumor. Gene diagnosis for VHL gene mostly revealed germline mutation in VHL gene. Treatment for
CNS HBs in cerebellum as well as spinal cord after symptomatic was surgical resection in the first choice. Surgicaloutcomes was mostly excellent or good except for large tumors (cerebellar HB above 4cm, spinal HB above 2 cm ). In thesecond choice, stereotactic irradiation did not always control the tumor. VHL patients bearing CNS hemangioblastoma
mostly developed other CNS ones in a different site. In conclusion, surgical resection is the first-choice treatment for CNS
HB in VHL, and it should be done at appropriate timing without neurological deterioration.

- 180 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP147
Clinical Diagnosis and Treatment of Hypothalamic Hamartoma inChildrenFengping Huang1, Kang Zheng1, Xuhui Bao1, Gang Wu1, Xiang Zhou1
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

1

Objective To discuss the clinical features, diagnosis and treatment of hypothalamic hamartoma. Methods The clinicaldata of 4 patients treated in our department from January 1998 to December 2007 was retrospectively analyzed. Results
There were 2 male and 2 female patients ranging in age from 6 to 14 years. 2 of them had initial symptom of precocious
puberty, while the other two had clinical manifestation of hypoevolutism and visual disorder. But none of them presented
with gelastic seizures. Good results were achieved with surgical resection in all the patients. Neuronal structure and gliosis
were found by pathology. Conclusion Hypothalamic hamartoma can be treaed by surgical resection. Drug therapy may
be useful for precocious puberty.

P148
Clinical Diagnosis and Treatment of Third Ventricle Cavernous Angioma
Gang Wu1, Kang Zheng1, Xuhui Bao1, Dongxiao Zhuang1, Fengping Huang1
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

1

Objective To explore more about third ventricle cavernous angioma by analyzing the clinical data of 4 patients in order toimprove treatment effects of this rare disease. Methods From 2001 to 2007, 4 cases of third ventricle cavernous angioma
were diagnosed pathologically and treated at our department. Their clinical data were retrospectively analyzed. Results
There were 3 male and 1 female patients ranging in age from 21 to 44 years. The initial symptom of all of them washeadache and dizziness. None of them presented with polydipsia and polyuria. The physical examination of them was
negative. All of them accepted CT scan and MR imaging. Among them, 4 cases had total removal of tumors, 1 casepartial removal. Short-term effects were good. Conclusion Cavernous angioma rarely occurs in third ventricle. Clinicalmanifestations are not specific, only headache or dizziness. CT scan and MR imaging are the key methods to diagnose
this disease. Surgical resection can achieve good curative effect.

P149
MULTIFOCAL, PROTEINACEOUS CNS DEPOSITS MIMICKING NEOPLASIA: REPORT OF
AN UNUSUAL CEREBRAL AND CEREBELLAR AMYLOIDOMA WITH LONG LASTING
CLINICAL HISTORYPeter Molnar1, Gyorgy Pfliegler2, Gabor Mehes1, Ervin Berenyi3
Department of Pathology, Medical and Health Sci. Ctr., University of Debrecen 22nd Department of Internal Medicine
Department of Medical Laboratory and Diagnostic Imaging

1
3- 181 -­­

Poster Presentation (P)Aim: A rare, multifocal pathological tissue alteration is presented because it may represent diagnostic challenges. Detailed
imaging features are compared to histomorphological and immunohistochemical (IHC) characteristics. Methods: State-ofthe-art neuroimaging (MR, MRS, PET/CT) is not pathognomonic, biopsy material is necessary for establishing the proper
diagnosis. The latter is based upon traditional and immunomorphology, histochemical stains for amyloid (Congo red, CR)
and polarized light microscopy. Case report: 32-y-old female patient with headaches dating back to her early childhood
had had her first MR in 2003, which showed several intracerebral abnormalities with variable calcification. She had no
epileptic seizures, only mild perioral hypaesthesia. Eventually increasingly marked tremor developed. Repeated MR studies
prior to biopsy showed increasing number of foci in both hemispheres; low T1W and variable T2W signal intensity wasseen, only one deposit showed intensive contrast enhancement. Tissue obtained by craniotomy was paucicellular, almost
avascular; the amorphous, often concretion-filled masses induced low intensity inflammation with scattered foreign body
type giant cells. Flocculent or laminated, frequently partially calcified deposits displayed characteristic birefringence proving
beta-pleated sheath structure. The congophilic structures were often concentric with a central, lamellated and calcified
core. Deposition of the von Kossa +, intensely PAS+ (digestion resistant) material induced marked macrophage
accumulation (CD68, vimentin +). Mib-1 LI was less than 1%. Only a few, thin walled blood vessels were seen (CD34). The
neuropil around the affected foci was rich in reactive, densely arborized astrocytes. The multinucleated giant cells were also
CD68 +. The process is independent from congophilic angiopathy and/or plasma cell neoplasia. Conclusions: Differential
diagnoses of irregular, multifocal lesions, mimicking tumor, particularly in women, include proteinaceous deposits with orwithout calcification. Our case had no relationship with systemic or dural lymphoma or plasma cell dyscrasia. Currently noactive treatment is possible, systemic amyloidosis must be excluded.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P150
Primary Burkitt lymphoma of CNS in an immunocompetent old woman: arare case report and review literatures
Jui-Ming Sun1,4, Da-Tong Ju1, Ching-Liang Ho2, Ming-Fang Cheng3, Cheng-Ta Hsieh1
Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan,
Republic of China 2Division of Oncology and Hematology, Department of Internal Medicine, Tri-Service General
Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China 3Department of Pathology, Tri-Service
General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China 4Department of Surgery,
Songshan Armed Forces General Hospital, Taipei, Taiwan, Republic of China.
1

Primary CNS Burkitt lymphoma is rare and often occurs in patients with immune deficient state, especially in acquired
immunodeficiency syndrome (AIDS). Herein, we presented an immunocompetent 77-year-old female, who was health in thepast, complained of general malaise and dizziness 3 days prior to admission. Computed tomographic scan revealed abutter-flied shape mass located in the pericallosal white matter, extending to the left basal ganglion and peduncle. The
mass appeared as homogenous-enhancement after contrast injection. Magnetic resonance images exhibited a huge,enhancing and infiltrative tumor involving the genu to splenium of corpus callosum, bilateral radiata, bilateral corticospinal
tract, hippocampi, posterior limb of internal capsule and left cerebral peduncle and ventrolateral pons, causing prominent
vasogenic edema of bilateral parietal, left frontal and temporal lobes. She underwent stereotactic biopsy of the brain lesion
and the pathology confirmed the diagnosis of Burkitt lymphoma. Postoperatviely, intrathecal chemotherapy and palliative
radiotherapy were administrated and the patients expired half a year later because of systemic sepsis. The relevant literatureis also reviewed.

P151
Primary leptomeningeal melanomatosis in a 31-year-old woman
Young-Cho Koh1, Dong-Cheon Kim1, So-Duck Lim1, Won-Jin Moon1
Department of Neurosurgery, Konkuk University, Seoul, Korea

1

Poster Presentation (P)The majority of the central nervous system melanomas are metastatic in origin, and primary cerebral melanoma or
melanomatosis is rare. We have treated a very unusual primary cerebral melanomatosis, which presented with repeatedbouts of intracerebral hemorrhages. A 31-year-old woman was presented with parietal ICH. she had been healthy till twodays prior to admission, when she complained right hemiplegia. At admission, she was alert with grade 3 motor deficits on
the right side. Brain CT showed a left parietal ICH. Brain MRI showed an acute left parietal hematoma with two small roundenhancing nodules and well enhancing meninges. Surgery was undergone to find black leptomeninges overlying thehematoma. After drainage of the hematoma partial removal of the fragile and vascular tumor was done. Postoperatively,
her motor function improved. Pathologic diagnosis was melanoma. After surgery, she underwent conformal radiation
therapy(RT) to the enhancing leptomeninges and the tumor followed by 6 cycles of DVC(Dacarbazine, Vinblastine, Cisplatin)
chemotherapy. Her neurologic status remained normal with no tumor recurrence on MRI follow up until 10 months after
surgery, when she revisited with sudden right hemiplegia and facial palsy. Brain CT & MRI showed another left parietal ICH
with new leptomeningeal tumor. Second surgery was undergone to remove the ICH and the tumor to result in neurologic
improvement. On routine follow up two new tumors occurred in the falx cerebri, for which surgery was done followed by
gamma knife radiosurgery(GKRS). Two months after the GKRS, she presented again with stuporous mentality. Brain MRI
showed diffuse basal meningeal seedings and ventricular seedings and. She died of tumor progression 18 months after the
first clinical presentation. Here, we present a rare case of primary leptomeningeal melanomatosis showing characteristic
MR findings and clinical courses with pertinent literature review.

P152
Primary Intracerebral Malignant Fibrous Histiocytoma, Case report
Young-Cho Koh1, Dong-Cheon Kim1, So-Duck Lim1, Johan Cho1, Hong-gee Rho1
Department of Neurosurgery, Konkuk University, Seoul, Korea

1

Malignant fibrous histiocytoma (MFH) is a soft tissue sarcoma arising from the extremities and retroperitoneum in older
adults. Primary intracranial MFH is extremely rare. A 29-year-old woman presented with headache showing three large
masses in the right frontal lobe, left parietal and right occipital lobe on brain MRI scan. She had undergone extended total
gastrectomy with splenectomy followed by 6 cycles of chemotherapy(5-FU, Pirubicin, Cisplatin) because of advanced
gastric cancer three years previously. PET scan revealed no hot spot elsewhere. Under the impression of the multiple
metastases the three masses were totally removed at a single session. Postoperative MRI scans confirmed complete
removal of the masses. Pathology was confirmed to be typical MFH, for which 5000 cGy/5weeks WBRT was done followedby chemotherapy.Two months later, she presented with tonsilar exophytic mass and underwent tonsillectomy to get thesame pathologic diagnosis of the brain. Then, another 6 cycles of chemotherapy with vincristine, ifosfamide andetoposide(VIP) was followed. Ten months after the brain surgery she presented again with severe headache with left
hemiparesis showing huge recurrent tumor at the right frontal lobe with massive peritumoral edema. Two months after thesecond surgery gamma knife radiosurgery was undergone to the marginal enhancing nodule on routine follow up scan.
Three months later, another metastasis was discovered at the mediastinum and anterior chest region to be treated by local
radiotherapy. Under the basis of PET-CT scan pre- and postoperatively of the intracranial MFH, we concluded this case to
be primary cerebral MFH metastasized to the tonsil and the mediastinum. We report this rare primary MFH with pertinent
literature review.

- 182 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP153
Incidentally discovered Clival Pseudomeningocele : A Case Report
Seong M Kim1
Department of Neurosurgery, Eulji University, Daejeon, Korea

1

Clival pseudomeningocele is an extremly rare lesion. Commonly, pseudomeningocele may result after trauma, brain
surgery, spine surgery, or brachial plexus avulsion injury. A 21-year-old man with headache was found to have a clival
pseudomeningocele. He had not specific past medical history, for instance, trauma or surgery. At first, this lesion was
misunderstood to clival chordoma or chondrosarcoma, due to Magnetic resonance(MR), 3-dimensional computerized
tomography(CT) finding. At operation, by a extended transsphenoidal approach, clival pseudomeningocele was diagnosed
grossly, and confirmed by pathologic finding. This is the first case of clival pseudomeningocele in an adult, incidentally.
Clival pseudomeningocele should be taken into consideration in patient with clival chordoma or chondrosarcoma.

P154
Malignant brain tumor in a patient with AIDS
Bong Jin Park1, Seok Keun Choi1, Sung Bum Kim1, Tae Sung Kim1, Bong Arm Rhee1,
Young Jin Lim1
Department of Neurosurgery University of Kyunghee,Seoul,Korea

1

Purpose: Toxoplasmosis and lymphoma are frequently occurring intracranial mass lesions in AIDS patients. The authors
would like to report 2 cases of malignant brain tumors developed in AIDS patients, our experiences in their treatment inconsideration of related articles. Method: A female patient of 31 year old presented with headache and right side
weakness.Another male patient of 58 years old presented with left side weakness. Their HIV antibody quantification atadmission showed positive and a more specific examination proved them AIDS. Brain MRI revealed a 22x18x20mm sized
mass at left frontal lobe with peripheral rim enhancement pattern and peritumoral edema. The other MRI showed multiple
rim enhanced masses at right frontal and temporal lobes and left cerebellum and pons. Results: Navigationguided biopsy
was performed to make the diagnosis and GMB and primary CNS lymphoma was confirmed through pathologic report.
CCRT for the case 1 patient and temozolomide chemotherapy following radiation of 30 Gy for the case 2 patient wereapplied respectively. Conclusion: It is difficult in terms of treatment in AIDS patients because active management of thetumor is necessary as well as the AIDS itself. Recently developed medications for AIDS allowed positive treatment
measures. Temozolomide is recommended for limited cases of CNS lymphomas.

P155
Glioblastoma developed in a cured pediatric CNS leukemia
Bong Jin Park1, Seok Keun Choi1, Sung Bum Kim1, Tae Sung Kim1, Bong Arm Rhee1,
Young Jin Lim1
Department of Neurosurgery University of Kyunghee,Seoul,Korea

1- 183 -­­

Poster Presentation (P)Purpose: It have been known that CNS invasion of ALL is less than 10%. The authors would like to report a cured ALL with
CNS leukemia patient through chemotherapy and WBRT, who developed glioblastoma at 6 years after RT. Method: A 17
year old female patient presented with 3 weeks of progressive headache and right hemiparesis Gr. III. Brain MRI showed a
58x56x52mm sized cystic mass at left frontal lobe which enhanced peripherally. She had started chemotherapy forALL(type L1) 10 years ago, undergone concomitant chemotherapy and 20 Gy of RT for CNS leukemia 6 years ago and was
decided cured 5 years ago. Result: The mass was removed under functional neuronavigation technique and globlastoma
was confirmed through pathologic report. After surgery, right hemiparesis was gained to Gr. IV and adjuvant CCRT wasapplied. Conclusion: The authors experienced a globlastoma suspected its origin as previous radiation, developed in 6
years after cured pediatric CNS leukemia.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)P156
A PATIENT WITH GLIOBLASTOMA MULTIFORME AND A LEFT CERVICAL MASS- A CASEREPORT
Jarungchai Vatanagul1, Julette Batara1
INTERNATIONAL INSTITUTE FOR NEUROSCIENCES- ADULT Neurology- St. Luke’s Medical Center. Quezon City,
Manila, Philippines

1

A Patient with Glioblastoma Multiforme and a Left Cervical Mass- A CASE REPORT ABSTRACTGlioblastoma multiforme(GBM) is a highly malignant primary brain tumor in which the reported frequency of extracranial metastasis is only 0.44%.
We report a patient with lymph node metastasis from a left parieto-occipital GBM 30 months from diagnosis. This is thefirst documented report of extracranial metastasis from a GBM in the Philippines. The patient is a 51 year-old, Male with
GBM, left parieto-occipital area post gross total excision followed by concomitant radiotherapy and Temozolomide andadjuvant Temozolomide for 6 months. 11 months after diagnosis, he was enrolled in a Clinical Trial of Immunotherapy
Peptide Vaccine and received a total of 3 doses of the said vaccine but went off study because of a presumed recurrence.
Another craniotomy was performed and excision of the mass was done, and patient continued to receive Temozolomide on
a metronomic schedule. He remained well with a KPS of 100 until 20 months post diagnosis when he developed anotherrecurrence and again had a craniotomy followed by Tarceeva and carboplatin chemotherapy. He again remained well for 10
months until 30 months postdiagnosis when a left cervical mass was noted. No other extracranial lesion was seen on PET
CT Scan. A biopsy of the mass showed sheets and nodules of neoplastic cells with pleomorphic hyperchromatic nuclei
and clear cytoplasm separated by dense to fibrous stroma. Areas of necrosis were seen with neoplastic cells palisading
around them. Immuno-histochemical staining showed positive immunoreactivity for glial fibrillary acid protein (GFAP), CK,CK 7, S100 and Vimentin. Shortly thereafter, a recurrence of the intracranial mass was noted on routine follow-up MRI.
Prolonged survival and multiple craniotomies may increase the risk of occurrences of extracranial GBMKeywords:
Glioblastoma Multiforme, Extracranial metastasis

P157
GLIOBLASTOMA MULTIFORME IN FASCIA LATA
Ahmet Kahraman1, Ahmet Bekar2, Ramazan Kahveci1, Turgut Kuytu2, Sahsene Tolunay3
Department of Plastic and Reconstructive Surgery, University of Uludag, School of Medicine, Bursa, Turkey
Department of Neurosurgery, University of Uludag, School of Medicine, Bursa, Turkey 3Department of Pathology,
University of Uludag, School of Medicine, Bursa, Turkey
1
2

Glioblastoma multiforme (GBM) is a malign and highly aggressive entity that rarely shows extracranial and extraneuralinvasion. In the literature approximately 250 extracranial metastases that of 8 cases with cutaneous-subcutaneus
metastases were published during the last 70 years. The dura defect can be occurred after primary tumor surgery. A 51
year-old man with a metastatic mass developed in the graft donor area of tensor fascia lata tendon due to thereconstruction of dura is presented in this report. According to the excisional biopsy result; the developed mass is defined
as gliosarcoma showing the exact characteristics of the primary tumor. The authors report that the contaminated surgery
tools and instruments can bring on the fact of distant spread of tumoral cells. Depending on this fact, the renewal of thesurgery tools and instruments and the irrigation of the surgery area after primary tumor resection is emphasized.Key words:
glioblastoma multiforme, subcutaneous metastases, metastases in the donor area, fascia lata metastases

Poster Presentation (P)P158Intraparenchymal germinoma
Bong Jin Park1, Seok Keun Choi1, Sung Bum Kim1, Tae Sung Kim1, Bong Arm Rhee1,
Young Jin Lim1
Department of Neurosurgery University of Kyunghee, Seoul, Korea

1

Purpose: Germinomas are known to occur at pineal gland or suprasellar region. We would like to report a case of a patient
who underwent operation with an impression of PNET which turned out to be intraparenchymal germinoma. Method: A 10
year old male patient presented with 2 weeks of headache, vomiting and left side weakness. On brain MRI, a 56x48x42mm
sized mass at right basal ganglia, accompanying multiple cysts which enhanced peripherally was shown. Results: A
transcortical approach through superior temporal gyrus was performed and the soft mass which bled at multiple stages
was removed. Pathologic examination confirmed the tumor as germinoma and adjuvant chemotherapy was applied. Lefthemiparesis was improved after surgery and no further neurologic deterioration was noted. Conclusion : We experienced agood treatment results in management of a very rare case of pure intraparenchymal germinama which occurred in pediatricpatients through surgery, chemotherapy and radiotherapy.

- 184 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P159
Early detection of the venous thromboembolism in glioma patient
Tomohiro Kawaguchi1, Toshihiro Kumabe1, Yukihiko Sonoda1, Yoji Yamashita1,
Masayuki Kanamori1, Mika Watanabe2, Teiji Tominaga1
1
Department of Neurosurgery, Tohoku University, Sendai, Japan 2Department of pathology, Tohoku University, Sendai,Japan
Purpose: The purposes of this study are to clarify the incidence of venous thromboembolism (VTE) in patient with glioma
and to investigate the efficacy of quantitative d-dimer test and venous echogram with Doppler ultrasonography (USG) forearly detection of deep vein thrombosis to prevent the pulmonary embolism (PE). Clinical Materials and Methods: During
the period from June 2007 to December 2008, 90 patients were treated for glioma in our institution. Histologically, 42 cases
were diagnosed as WHO grade IV, 23 cases were grade III, 18 cases were grade II and 7 cases were grade I. In all patients,
d-dimer was measured once a week and USG was followed every two weeks since admission.Results: Of these patients,
12 patients were diagnosed as VTE (13.3%) and among them, 3 cases presented PE so that anticoagulant was started(3.3%). The maximum d-dimer value in patient with VTE was significantly higher than those without VTE (mean 14.6μg/l vs
4.19μg/l). USG showed thrombus in soleus vein to popliteal vein in all VTE cases. Histologically, high grade tumor was asignificant risk for VTE occurrence (Grade I and II : Grade III and IV=0% : 21.4%). Patients with hemiparesis or low
performance status after operation were prone to VTE occurrence. Conclusions: Our prospectively collected data showedthat VTE incidence in glioma patient is much higher than we have expected. Continuous quantitative d-dimer measurement
is useful for early detection of VTE for appropriate therapy.

P160
2 CASES OF EXTRADURAL GLIOBLASTOMA MULTIFORME PRESENTING AS
TRIGEMINAL NEURALGIA; PATTERNS OF MOLECULAR TARGETS OF INVASIVENESS.
Lawrence Cher1, Simone Steel1, Carmel Murone2, Renata Kalnins3, Eliza Hawkes1
1
Medical Oncology Department, Austin Hospital, Melbourne, Australia 2Ludwig Institute , Austin Hospital, Melbourne,
Australia 3Anatomical Pathology Department, Austin Hospital, Melbourne, Australia

P161
Pontine Cryptococal granuloma in a healthy, non-immunocompromised
patient-Case reportKyung Gi Cho1
Department of Neurosurgery, Ajou University School of Medicine

1

We report a very rare case of the brain stem cryptococcoma in a previously healthy, non-immunocompromised adultwithout previous evidences of CNS infection. The patient is a 47-year-old man with no significant medical history presented
with a month history of progressively worsening headaches and nausea. He had several episodes of vomiting without fever
for several days until the day of admission. He had no predisposing factor of immunocompromised condition such as
diabetes mellitus, organ transplantation, HIV infection and chemotherapy. The patient showed an alert mentality with noneurologic deficits. There were no evidences of infection on physical examination. An Gd-enhanced MRI scan of the brain
demonstrated a homogeneous enhancing mass with central necrosis in the left pons with adjacent edema. MRI images
demonstrated a heterogenously low or iso-signal intensity on diffusion-weighted images and a increased cerebral blood
perfusion. PET scans of the whole body including a brain demonstrated a hot uptake of FDG on brain stem and didn't show
any evidences of systemic metastasis.. We thought this lesion the tumorous conditions such as high grade glioma than
nontumorous condition including granuloma and performed the excision of mass. The mass was removed totally via thelateral suboccipital craniotomy using neuronavigation system and SSEP monitoring. The final report of pathology revealed
the Cryptococcus neoformans. The CSF study and HIV test via lumbar tap were negative. The patient recovered without
any neurologic deficits. The patient had been treated initially with two antifungal agent such as Amphotericine B andflucytosine for 4 weeks .The clinical course of CNS cryptococcosis is highly variable, relating in part to underlying medical
conditions. If untreated, it is invariably fatal. Early diagnosis and initiation of treatment such as the surgical strategy andantifungal therapy is essential.

- 185 -­­

Poster Presentation (P)Background: Glioblastoma Multiforme, a highly invasive tumour, is the most common primary brain tumour. Despite theaggressive local growth pattern, extradural extension and metastasis is rare, usually occurring in patients with prolonged
survival. The molecular characteristics and mechanism of dissemination in a GBM that spreads beyond the central nervous
system is not fully understood.
Method: We describe two cases of extradural Glioblastoma Multiforme (GBM) presenting as trigeminal neuralgia. Bothfollowed aggressive disease courses. One case metastasised to liver and bone. The second case was refractory to multiplelines of therapy. We have compared the histopathology of these 2 cases with controls. Morphology andimmunohistochemistry panels were examined. The immunohistochemistry panel included stains previously explored in theliterature as possible molecular targets for invasiveness of GBM. The controls consisted of tissue from temporal lobe GBMs
demonstrating typical pathological features of WHO grade 4 astrocytoma. The panel included pEGFR, pAkt, pMAPK, p53,
c-MET, PTEN, Tenascin C, E-cadherin, N-cadherin, MMP2, and MMP9.
Results: The initial radiological diagnosis in both patients was thought to be a benign process due to the extradural
extension along the trigeminal nerve. From time of pathological diagnosis, the patients had survivals of 10 months and 15
months. Both underwent debulking surgery, local radiotherapy and at least 2 lines of chemotherapy. The 2 tumours weremorphologically similar. The results from the panel of immunohistochemistry staining are pending, but will be included in the
final discussion.
Conclusion: We report two cases of extradural GBM presenting unusually as trigeminal neuralgia. Both patients had
refractory disease, resulting in a decreased survival. Morphologically these tumours were similar. Assessing these tumours
for molecular targets of invasiveness, may assist in identifying those at risk of extradural extension and a more aggressive
clinical course.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P162
Surgery for intramedullary spinal tumors
Guihuai Wang, M.D.
Department of Neurosurgery, Tiantan Hospital, Capital University of Medical Sciences, Beijing, China
Prognositic analysis of 220 patients with intramedullary spinal cord ependymomas
Objective: To assess the factors relative to the surgical prognosis of intramedullary spinal cord ependymomas. Methods:
220 patients harbored intramedullary spinal cord ependymomas were treated surgically in Beijing Tiantan Hospital from2000 to 2007. We followed them on telephone and analyzed their JOA score preoperatively and postoperatively about age,gender, length of tumor and spinal cord function by Spss 11.5 software. Results: Age, gender and length of tumor had no
significant influence on prognosis. Through multiple linear regression analysis and Logistic regression, we concluded thatthe postoprative JOA score highly relatived to the preoperative neurological status and other factors. Conclusion:
Determinant factors of prognosis for intramedullary spinal cord ependymomas are preoperative neurological status, extent
of removal of the lesion. KEY WORDS: intramedullary spinal ependymomas, surgery

P163
The Rational Neurosurgical Treatment of pineal region tumors
Chen Jin-cao1, Lei Ting1
Department of Neurosurgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science andTechnology , Wuhan 430030 , China

1

Poster Presentation (P)h pineal region tumors were treated by microsurgery from June, 1993 to July, 2008. Infratentorial supracerbellar approach(Krause approcach) was adopted in 63 cases, and occipital transtentorial approach (Poppen approcah) in 13 cases;
Parieto-occipital transtentorial approach (Brunner-Dandy approach) in 10 cases respectively. The Krause approach was
performed when tumor is under moderate size and mainly inferior to the tentorial incisure; the Brunner-Dandy approach
was selected when tumor is large or mainly superior to tentorial notch or invaded to the corpus callosum or growth laterally;
the Brunner-Dandy approach was elected when tumor is mainly within the third ventricle. The tumors were resected totallyin 82% cases and no mortality concerned with surgery occur in the study. No-Germinoma Germ cell Tumor recurred in 8
cased and tumor metastasized localy in 1 cases, among these, 7 cased died within 1 year , whether the shunt forhydrocephalus seconday to the pineal region tumors were needed, the time of shunt, the choice of shunt style werediscussed. We think contimuous CSF external drainage, before and after tumor remove, was suital for exposing tumor,
reducing the operative complication and unnecessary CSF shunt. The ICP mornitor care have a significant value in judge ofthe patency of CSF circulation postoperatively. The ventriculoper itoneal shunt is superior to the ventriculoatrial shunt. It isvery importance to measure the tumor marker such as HCG in serum routintly. The functional tumor for positive tumor
marker is differ to differ to other ones in poor effect of radiotherapy and recurrence of metastasis. Prophylactic spinal
radiation must be performed for the functional germ-cell tumors(GCT). The tumor tissue must be examed carefully in
different site of tumor sample to prevent ignorance of combined malignant GCT. When the tumor marker was positive ingerminoma diagnosed initially. Comparison between the tumor remove followed by radiation and CSF shunt followed byradiation, no significant difference were made in survive rate of short term follow-up. In the view of operative morbidity, theshunt followed by radiation is superior to the tumor remove followed by radiation in pure germinoma. According to thecharacter of patient clinical course, neuroradiological image and tumor marker measure in serum. The malignant GCT,
which is 10-20 year-older, male and prediagnosis course within 1 month, is differ to the benign tumor, which is 30-40 year
older , no difference in sex and prediagnosis within 2 months to 6 months. Considering of the safity of tumor remove. The
patients whose tumor feature is uncertain and unimproved after the control of increasing ICP, and serum tumor marker
positive should be performed direat tumor removal. Malignant tumor should be undergone radiotherapy or/and
chemotherapy deponding on the tumor pathological diagnosis. Key word: Pineal region tumors; Operative approach;Shunt HCG; Radiotherapy

P164
Conservative Management of Pseudomeningoceal Formation after
Posterior Fossa Tumor Surgery in Children
Sang-Dae Kim1, Yong-Gu Chung1, Se-Hoon Kim1, Dong-Jun Lim1, Jung-Yul Park1
Department of Neurosurgery, Korea University Ansan Hospital, Ansan, Korea

1Introduction This is the report of two cases of children, who had complication of pseudomeningocele after resection ofposterior fossa tumor, medulloblastoma, and had cured with conservative management not with exploration and reclosure.
Case Report Case 1 6 years old, male, who had symptoms of headache and vomiting, had findings which suspecting
medulloblastoma at brain magnetic resonance imaging(MRI). Near total resection with craniotomy had performed. After 14days from operation(OP), the wound site bulging and increasing fluid collection were identified and pseudomenigocele wasconfirmed with computed tomography (CT) scan and MRI. But with a week after removal of LD, only with compression
bandage, the bulging of wound was improved progressively. Case 2 13 months old, male, had hydrocephalus and findingsof which suspecting medulloblastoma at brain magnetic resonance imaging(bMRI). Total resection with cranietomy andexternal ventricular catheter(EVD) insertion had performed. Several days after EVD removal, wound bulging was identified
and pseudomenigocele with progressed hydrocephalus was confirmed with CT scan. Ventriculo-peritoneal shunt OP had
taken with compression bandage application. Now, 14th day after V-P shunt OP, wound bulging was disappeared.
Conclusion The rate of pseudomeningoceles after posterior fossa tumor surgery in this study was consistent with thatreport, with an incidence of 23% when clinically diagnosed and 30% if the radiologically diagnosed cases only are included.
So, many maneuvers and techniques was suggested, but in adults and children who kept of pseudominigocele and CSF
leakage were concerned revision OP. But, revision OP may have anesthesia and OP complication rather than conservative
management, revision OP should not be considered impatiently at children cases.

- 186 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP165
Posterior Fossa Tumors with Hydrocephalus: Outcome of Surgery
without CSF Diversion
Gerardo D. Legaspi1, Kay M. Pioquinto1
Section of Neurosurgery, Department of Neurosciences, University of the Philippines, Philippine General Hospital

1

ABSTRACT The authors reviewed 72 patients with posterior fossa tumors and hydrocephalus, treated at a large tertiary
hospital between 2006 and 2007, to determine clinical outcome and factors that predispose to subsequent need for postoperative CSF shunting, after surgery without CSF diversion. A retrospective review of prospectively collected clinical,
radiologic and operative data was conducted for all patients treated surgically with suboccipital craniectomy/craniotomy
and tumor excision without pre- or intra-operative external ventricular drainage and ventriculoperitoneal shunting. The
factors evaluated included age, tumor location, extent of tumor resection, and tumor type. The low postoperative shunt
insertion rate (5%) and good clinical outcome in our series led us to believe that routine pre- or intra-operative CSF
diversion is not entirely justified. Factors such as age, tumor type, tumor location and extent of excision, which showed astatistically significant association with the postoperative shunt requirement in our study, should be considered when thedecision regarding CSF diversion is made.

P166
Atypical miningioma in French West Indies
Keyvan Mostofi*, Norbert Manzo*, Didier smadja**, Daniel Memia Zolo* ,Mohamed Rabhi*, Catherine Lorinet **** Department of Neurosurgery, CHU de Fort de France, Martinique** Department of Neurologie, CHU de Fort de France, Martinique

P167
Atypical Rathke’s cleft cyst with calcification
1
Lu-Ting Kuo, 2Kuang-Ting Kuo, 3Yong-Kwang Tu
Division of Neurosurgery, Department of Surgery, National Taiwan University Hospital, Yun-Lin branch, Yun-Lin
county, Taiwan
Department of Pathology, and 3Division of Neurosurgery, National Taiwan University Hospital, Taipei, Taiwan

1
2

Rathke’s cleft cysts should be differentiated from craniopharyngiomas because of different treatments. We report a rarecase of Rathke’s cleft cyst in a 14-year-old boy, presenting with headache, hormonal imbalance and conscious change.
Computed tomographic scans showed round calcification on the wall of the cyst. Magnetic resonance images revealed alarge cystic intra- and supra-sellar lesion with a relatively large solid part extending to the roof of the third ventricle. He
underwent placement of an external ventricular drain emergently for acute hydrocephalus and then the tumor was excised
via the subfrontal approach. Following surgery, the boy had a good recovery except diabetes insipidus. This case illustrates
that calcification of the intra- and supra-sellar cyst with large solid portion does not always suggest craniopharyngioma.

- 187 -­­

Poster Presentation (P)Introduction
Meningiomas are the most common intracranial primary neoplasm in adults. Annual incidence of meningiomas isapproximately 6 for 100 000habitants in the medical literature. We noticed a rate abnormally increased especially atypicalmeningiomas in Martinique( French west Indies), we analysed retrospectively the patients admitted and operated for ameningioma in our department during a period of 6 years from 2003 till 2008 .
Material and Method
The study was performed in department of neurosurgery at General hospital of Fort de France in Martinique(French west
Indies). This regional unit provides neurosurgical service for a population of 600 000(400 000 in Martinique and 200 000 in
French Guyana)
369 Patients have been admitted in our department for a meningiomas during a period of 6 years: January 2003 till
December 2008 .The incidence of meningioma is 10.25 per year.11 patients were not operated for diverse reasons and they
were excluded of study.358 patients underwent surgery.
Results
We found 62 atypical meningioma (Grade II according to the WHO classification) among 358 patients(17.3%).We had 38
female and 24 male with an average of 54.6 year.47 of patients had at first side an atypical meningioma and 15 had an
atypical tumour at the time of the recurrence. 41 patients underwent two interventions and 13 three interventions .8 patientsdied after their exit of the service for diverse reasons. When surgery was macroscopically complete( Simpson grade 1-3),
for the atypical miningiomas the recurrence arose within 4 in 48 months with a average period of 40 months. In the patients
who underwent a radiotherapy after one or several operations, the recurrence arose on average after 7,63 years. We foundno previous history of radiotherapy for atypical miningioma.
Discussion
More detailed studies are necessary to clarify causes and possible genetic and environmental factors of this highfrequency of miningioma especially atypical miningioma in Martinique.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P168
The correlation and prognostic significance of MGMT promoter
methylation and the MGMT protein in glioblastomas
Tae-Young Jung1,3, Van Thang Cao3, Shin Jung1,3, Shu-Guang Jin3, Kyung-Sub Moon1,3,
In-Young Kim1, 3, Sam-Suk Kang1, Chang-Soo Park 2, Kyung-Hwa Lee2
Department of Neurosurgery, Chonnam National University Hwasun Hospital & Medical school, Gwangju, Republic ofKorea 2Department of Pathology 3Brain tumor research laboratory and Chonnam national university research instituteof medical sciences
1

Objective: The aim of this study was to evaluate the correlation and prognostic significance of MGMT promoter
methylation and protein expression in patients with glioblastoma.Methods: Eighty-three patients with glioblastoma
underwent surgery followed by radiotherapy and temodal chemotherapy between October 2000 and June 2008. To
investigate the correlation between MGMT methylation and MGMT expression, methylation-specific PCR (MSP) andimmunohistochemical staining (IHC) was performed. To analyze the correlation between MGMT methylation and MGMT
expression according to location, biopsies were obtained from 37 different sites within the tumors in 12 patients. Age,
gender, KPS, extent of removal, chemotherapeutic methods, MGMT promoter methylation and protein expression wereanalyzed as prognostic factors. Results: The total median survival was 15.8 months (min 12.6, max 19.1). The results of
MSP were the same at various sites in 12 patients. A correlation between MSP and IHC was observed in 50 percent of thepatients. Out of 73 patients, negative MGMT expression was detected in 70.5 percent of 44 patients with MGMT promoter
methylation, and positive expression was observed in 55.2 percent of the 29 patients with unmethylated promoters.
Multivariate analysis revealed that the extent of removal (P<0.001) and the combination of MGMT promoter methylation andnegative MGMT expression (median survival: 20.06 months, P<0.006) were significantly associated with longer survival.
Conclusions: We suggested the feasibility of using MSP combined with IHC as a prognostic factor. The results of thepresent study suggest that MGMT promoter methylation in combination with negative MGMT expression might be a good
prognostic factor in patients with glioblastoma.

P169
Relevance of MSP assay for the detection of MGMT promoter
hypermethylation in glioblastomas
Kazunari Yachi1, Takashi Ohta1, Akiyoshi Ogino1, Takao Fukushima ,Takao Watanabe1,
Atsuo Yoshino1, Yoichi Katayama1
1Department of Neurosurgery, Nihon University, Tokyo, Japan

Poster Presentation (P)O 6-Methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation has recently emerged as a powerfuldeterminant of chemotherapy sensitivity in glioblastomas. To adapt such an important epigenetic biomarker to routine
application in the clinical setting, we validated the conventionally used methylation-specific polymerase chain reaction(MSP) assay for its relevance in the determination of MGMT methylation status. MGMT promoter hypermethylation analysis
employing MSP was performed on 25 primary glioblastoma samples and 7 cell lines, and compared with the more robust
direct promoter sequencing that profiled the methylation status of 27 CpG sites within the MGMT promoter. In addition, the
MGMT expression at the protein level was evaluated in the primary tumor samples using immunohistochemistry and in thecell lines using Western blotting analysis. Our MSP analyses yielded reproducible results, which were identical to thebisulfite sequencing data in all except one primary tumor that was negative on MSP. A poor correlation existed between
the immunohistochemical staining results and the methylation status of the MGMT promoter in primary glioblastoma
samples. In all of the cell lines with loss of MGMT expression, signals of methylated DNA were detected by MSP. Our data
support the feasibility and reliability of MSP analysis, which could be routinely implemented in the diagnostic setting.

P170
Clinical significance of polymorphism of DNA repair gene MGMT in
Glioblastomas
Takao Fukushima1, Kazunari Yachi1, Akiyoshi Ogino1, Takashi Ohta1, Takao Watanabe1,
Atsuo Yoshino1, Yoichi Katayama1
Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan

1(Purpose) Inactivation of O6-methylguanine DNA methyl-transferase (MGMT) gene by promoter hypermethylation is amajor determinant of sensitivity to alkylating agents in chemotherapy of malignant glioma, and is correlated with survival.
Since single nucleotide polymorphisms (SNPs) may influence the methylation status of gene promoters, here we evaluatedfive MGMT SNPs in relation to promoter methylation and expression of the MGMT gene in patients with glioblastomas. We
also examined the influence of the SNPs on prognosis.(Materials and methods) In 25 patients with glioblastomas,
admitted between 2002 and 2007, MGMT promoter methylation status was assessed by methylation-specific polymerase
chain reaction (MSP) and direct promoter sequencing. Gene expression was determined by immunohistochemistry. MGMT
SNPs were evaluated by real-time PCR. (Results) Leu53Leu (CTC/CTT) and Leu84Phe (CTT/TTT) were found in 9 of 25
patients (36%) with glioblastomas, and were linked in all those patients. The minor allelic frequency of each SNP in patientswith glioblastomas was higher than that of a control population. Leu84Phe was detected in 4 of 8 patients (50%) with
MGMT promoter hypermethylation and in 5 of 17 patients (23.5%) without hypermethylation, but the difference was notstatistically significant (p=0.394). The presence of MGMT SNPs was not associated with MGMT expression. These SNPs
did not appear to be related to prognosis. (Conclusion) Our data suggest that MGMT SNPs might not affect MGMT
promoter methylation and expression in patients with glioblastomas, although the sample number was small.

- 188 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP171
IMMUNOHISTOCHEMICAL ASSESSMENT OF O6-METHYLGUANINE DNA
METHYLTRANFERASE FOR GLIOBLASTOMAS: A REAPPRAISAL
Manabu Natsumeda1, Akiyoshi Kakita2, Takeo Uzuka1, Yukihiko Fujii1, Hitoshi Takahashi2
1
Department of Neurosurgery, Brain Research Institute, University of Niigata, Niigata, Japan 2Department of
Pathology, Brain Research Institute, Niigata, Japan

Background: Preusser and Stupp et al. reported the unreliability of O6- methylguanine DNA methyltransferase (MGMT)
immunostaining as a clinical biomarker for glioblastomas (GBM). Purpose: To demonstrate the prognostic significance of
MGMT immunohistochemisty for GBM, we retrospectively stained 15 surgical specimen of newly diagnosed GBM takenfrom patients who went on to receive at least 3 courses of maintenance therapy with temozolomide (TMZ) after induction
therapy. Method: Paraffin embedded surgical tissue of GBM was stained with MGMT using the ABC method.
Endogeneous peroxidase was blocked with 0.3% hydrogen peroxide in methanol and sodium azide. Antigen retrieval wasachieved with autoclave processing. MGMT positivity was assessed at the site of greatest MGMT positivity, and subdivided
into three groups: MGMT positivity of 0-10% ((-) group), 11-50% ((+) group), and 51-100% ((++) group). Only MGMT positive
tumor cells were counted; MGMT positive vascular endothelial cells, oligodendrocytes, and lymphocytes were discarded.
Results: The mean follow up period was 16 months (6 to 16 months). 2 cases were MGMT (-), 9 cases were (+), and 4cases (++). 6 month progression free survival was 100%, 67%, and 0% in the 3 groups, respectively. Kaplan-Meier curves
also showed the 3 groups to have different outcomes. Conclusion: With careful staining and interpretation of MGMT
positivity in GBM specimen, we were able to successfully divide patients into 3 groups with different outcomes. MGMT
immunostaining should be reconsidered as a useful biomarker in GBM patients.

P172
MGMT methylation status may predict survival in elderly patients with
newly diagnosed glioblastoma (GBM)
Elizabeth R. Gerstner1, Stephen Yip1, Daphne L. Wang1, David N. Louis1, A. John Iafrate1,
Tracy T. Batchelor1
Massachusetts General Hospital, Boston, MA, USA

1

Purpose: In patients with GBM <70 years old, methylation of the MGMT gene promoter is associated with prolonged
survival and response to temozolomide. We evaluated if this held true for patients >=70. Methods: We reviewed MGMT
promoter methylation status in patients >=70 years with newly diagnosed GBM seen at our institution from 1998-2008.
Patients were included if tumor tissue was available for MGMT testing. MGMT analysis was performed by extracting tumor
genomic DNA for bisulfite conversion. MGMT methylation specific PCR (MSP) was then performed using PCR primer sets
specific for methylated and unmethylated MGMT promoter sequence (EZ DNA Methylation Gold-Kit, Zymo Research).
Results: Thirty-five patients were included in the analysis. Twenty-one patients (60%) were ME while 14 (40%) were UN.
The table below summarizes the characteristics of the study population. Patients were treated with multimodality treatment(radiation + chemotherapy), radiation alone, or chemotherapy alone. Conclusions: MGMT methylation is associated withprolonged PFS and OS in elderly patients with GBM. Knowledge of MGMT status may help improve prognostication in thispatient population.
ME
21

UN
14

22
13
80 (50-100)
74 (70-83)
28 (19-30)
22
10.6

13
8
90 (60-100)
74 (70-78)
28 (25-30)
11
14.5

mPFS (months)

7.7

11.7

9
5
60 (50-80)
74 (70-83)
28 (19-30)
116.9(logrank p=.0042)
3.5(logrank p=.0127)

First Line Therapy:
Multimodality therapy
Chemotherapy or RT alone
Unknown/none

17
12
6

12
5
4

5
7
2

P173
Methylation-sensitive high resolution melting analysis :a newquantitative assessment of MGMT promoter methylation in gliomas
Jun-ichi Adachi1, Kyouko Totake1, Kazuhiko Mishima1, Kenji Wakiya1, Tomonari Suzuki1,
Takaaki Yanagisawa1, Masao Matsutani1, Ryo Nishikawa1
Department of Neuro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan

1<Objectives> The methylation status of the MGMT (O6-methylguanine-DNA methyltransferase) gene has been shown to
be a predictive marker in malignant gliomas treated with temozolomide. Methylation-specific PCR (MSP) is widely usedmethod for the detection of the MGMT methylation. Despite its widespread use, MSP has several disadvantage. False
positives can arise if primers are badly designed or used at too low a temperature. MSP is very sensitive but is notquantitative. Here, we show that high resolution melting analysis (HRM) can detect MGMT methylation with high sensitivity
and moreover estimate quantitatively the extent of methylation in tumors. <Materials & Methods> We used genomic DNA
derived from high-grade glioma samples and univeral methylated/unmethylated DNA standards. After bisulfite treatment,
PCR was carried out in the presence of dye to fluoresce when intercalated with double-stranded DNA. Methylated andunmethylated DNA acquire different sequences resulting in PCR products with markedly different melting profiles. By
comparing the melting profiles of unknown samples with the profiles of methylated and unmethylated template ratio, wewere able to estimate quantitatively the MGMT methylation levels of glioma samples. <Results and Conclusions> It took
us only about 90 minutes to get the data from PCR. MGMT methylation could be detected at levels as low as 1 %.
Methylation level measured by this assay was inversely correlated to the MGMT mRNA expression level quantified by realtime RT-PCR. Gliomas with MGMT methylation less than 45 % showed significantly short progression-free survival.
Methylation-sensitive HRM is the rapid and useful method for predicting the effect of Temozolomide in glioma therapy.

- 189 -­­

Poster Presentation (P)All
35

Number of patients
Extent of surgery:
STR
GTR
KPS
Age
MMSE
Gender (men)mOS (months)

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P174
MGMT testings for temozolomide efficacy on glioblastoma
Motoo Nagane1, Keiichi Kobayashi1, Saki Shimizu1, Andreas Waha2, Yoshiaki Shiokawa1
Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan 2Department of Neuropathology,
University of Bonn, Bonn, Germany

1

Background: O6 -methylguanine-DNA methyltransferase (MGMT) is implicated in resistance to temozolomide (TMZ), a
standard chemotherapeutic agent against glioblastoma (GBM). MGMT status has been shown to correlate with survival ofpatients with GBM. We evaluated the relationship between promoter methylation status and protein expression of the
MGMT gene in patients with GBM who were treated with TMZ, and also analyzed their prognostic value regarding response
to TMZ and survival. Methods: Among the TMZ-treated patients with GBM from September 2003 to January 2008, frozen
tumor tissues were available for analysis in 33 cases. Among them, 22 patients who were treated with TMZ only at tumor
progression were subjected to survival analysis. TMZ was given daily orally 75mg/m2 during radiotherapy, or administered150-200mg/m2 on days 1 to 5, repeated every 28 days. MGMT protein expression was examined by Western blotting, andpromoter methylation status by the methylation-specific PCR (MSP) and pyrosequencing. Results: MGMT promoter
methylation was detected in 14/33 cases (42.4%), and significantly correlated with low MGMT protein expression (p<0.001).
Upon TMZ treatment for recurrent GBM, patients with low MGMT protein expression as well as those with methylated
MGMT promoter had a significantly improved progression-free survival (PFS) and overall survival (OS) compared to thosewith either high expression or unmethylated promoter, respectively. Both low MGMT expression (p = 0.02) and promoter
methylation (p = 0.04) persisted as significant independent favorable prognostic factors for PFS, while low MGMT
expression remained significant for OS (p = 0.004). Conclusions: The two MGMT assays showed close association toeach other, and were suggested to be important prognostic factors for patients treated with TMZ. Further quantitative
analysis of MGMT promoter methylation is underway using pyrosequencing.

P175
A NOVEL AND SPECIFIC INHIBITOR OF MGMT TRANSCRIPTION INCREASES THE
SENSITIVITY OF GLIOMA CELL LINES TO TEMOZOLOMIDE TREATMENT.
Iris Lavon1, Ariel Bier1, Miri Refael1, Tali Siegal11Gaffin Centre for Neuro-Oncology and Department of Neurology, Hadassah Hebrew University Medical Center,
Jerusalem, Israel.

Poster Presentation (P)Introduction: Alkylating agents are the mainstay of chemotherapy for gliomas. An important mechanism of resistance toalkylating agents is mediated by the DNA repair enzyme O6-methylguanine methyltransferase (MGMT), the only gene
known to be critical to direct reversal repair of the effects of alkylating agents on DNA. We previously demonstrated (Lavon
I. et al. Cancer Res;67(18):8952, 2007) that MGMT transcription is dependent on binding of NF-kappaB to specific kappaB
sites within MGMT promoter. Objective: To reduce MGMT expression and sensitize resistant gliomas to alkylating therapy
by a conditioning regimen that use decoy oligonucleotides that distinctively interfere with NF-kappaB binding to MGMT
promoter. Methods: The specific interference with the binding of NF-kappaB to MGMT promoter was accomplished byprototypes of locked nucleic acid (LNA) modified-oligonucleotides (LMO) corresponding to the sequence of the active NFkappaB site within MGMT promoter. Specific and nonspecific LMO were liposomaly introduced (Lipofectamine 2000,
Invitrogen) to various glioma cell lines. Twenty four hours later the cells were subjected to increasing doses oftemozolomide, and then followed by cell viability tests. Results: We demonstrated that conditioning treatment with 2nm of
specific LMO sensitized the cells to temozolomide and enhanced cell mortality by approximately 300% (from 60% live cells
following temozolomide treatment to only 22% of live cells after temozolomide that was anteceded by LMO conditioning).
Furthermore, we showed that LMO by itself was not toxic to the cells as treatment with a nonspecific LMO did not induce
cell death. Thus, the observed cytotoxic effect was related to the targeted activity of the specific LMO. Conclusions: We
demonstrated that, in-vitro, specific MGMT transcription inhibitors effectively overcome glioma cell chemoresistance. Thesefindings may lead to a novel therapeutic approach that utilizes a conditioning regimen of modified oligonucleotides given to
chemoresistant glioma in order to sensitize the tumor to alkylating agents.

P176
Mechanism of Thalidomide to enhance the cytotoxicity of Temozolomide
in U251-MG glioma cells in vitro
Xuejun Yang1, Song Gao1, Qiang Pan1, Yanwei Ji1, Wengao Zhang1
Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, PR China

1

Background: Chemotherapy is the key part of the treatment for gliomas. Temozolomide, a novel oral cytotoxin inducing
autophagy, has been used with Thalidomide, the anti-angiogenic agent. Although a promising result is shown, but thesynergistic mechanism is poorly documented. To provide an optimal strategy for combined treatment of the two drugs, weinvestigated the synergistic mechanism of Thalidomide possibly to enhance the cytotoxicity of Temozolomide in vitro.
Methods: Human malignant glioma cells U251-MG were cultured and divided in four groups with different treatment for 3
days: Temozolomide group (100uM), Thalidomide group (100ug/L), Temozolomide plus Thalidomide group (100uM
Temozolomide with Thalidomide 100ug/L) and control group. MTT assay was used to evaluate the cell viability. Cell cycle
was analyzed with flow cytometry. Acridine orange and monodansylcadaverine were adopted to label autophagosomes
and flow cytometry was applied for quantification of autophagosomes. The expression of autophagy-associated protein
was detected by Western Blotting. Results: Proliferation of tumor cell was obviously suppressed by Temozolomide with
Thalidomide treatment than either drug used alone (P=0.000 for each day). The combination treatment induced cell cycle
arrest at G0/G1 phase. Thalidomide promoted the autophagy induced by Temozolomide. The autophagy-associatedproteins --- Microtubule Associated Protein 1 Light Chain 3 (MAP1LC3) and Belin1 were more significantly up-regulated byTemozolomide with Thalidomide treatment than Temozolomide used alone (MAP1LC3 P=0.000; Beclin1 P=0.004). The
expression level of phosphatase and tensin homolog deleted on chromosome ten (PTEN), which promoted autophagy, waselevated by in Temozolomide with Thalidomide group (P =0.002), while the expression level of phosphorylated-AKT in thesame group was decreased significantly (P=0.000). Conclusions: Thalidomide enhances the cytotoxicity of Temozolomide
by promoting the autophagy induced by Temozolomide. The mechanism might be related to the blockake of PI3K/AKT/mTOR signalling pathway which antagonized autophagy, contributing to the up-regulation of PTEN by Thalidomide.

- 190 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP177
Neural differentiation markers expression in human glioblastomas may
predict their response to chemotherapy
Igor J. Sulla1, Marek Sarissky2, Vladimir Balik3, Igor Sulla4
Department of Neurosurgery, AD Centre, Safarik University School of Medicine, Kosice, Slovakia 2Department ofPharmacology, Safarik University School of Medicine, Kosice, Slovakia 3Department of Neurosurgery, Safarik
University School of Medicine, Kosice, Slovakia 4Department of Anatomy, Histology and Physiology, UVM, Kosice,Slovakia
1

Introduction: Glioblastoma multiforme (GBM) often represents a chemoresistant tumour. Authors decided to analyse theimmunophenotype of GBM cells and correlated their immunophenotypic characteristics with sensitivity to chemotherapy.
Materials and methods: The expression of selected differentiation markers including A2B5, CD34, CD45, CD56, CD117,
CD133, EGFR, GFAP, Her-2/neu, LIFR, nestin, NGFR, Pgp and vimentin was analysed by flow cytometry in eleven GBM
patients. The sensitivity of tumour cells to a panel of chemotherapeutic agents was tested by the MTT assay. Results: Alltumours were positive for A2B5, CD56, nestin and vimentin. CD133, EGFR, LIFR, NGFR and Pgp were expressed only byminor tumour cell subpopulations. CD34, CD45, CD117, GFAP and Her-2/neu were constantly negative. Direct correlations
were found between the immunophenotypic markers and chemosensitivity: A2B5 vs. lomustine (r2=0.642, p=0.033), CD56
vs. cisplatin (r2=0.745, p=0.013), %Pgp+ vs. vincristine (r2=0.846, p=0.008), and %NGFR+ vs. daunorubicine (r2=0.672,
p=0.047) and topotecan (r2=0.792, p=0.011). In contrast, inverse correlations were observed between: EGFR vs. paclitaxel(r 2=-8722;0.676, p = 0.046), CD133 vs. dacarbazine (r 2=-8722;0.636, p = 0.048) and LIFR vs. daunorubicine (r 2=8722;0.878, p=0.004). Significant associations were also found between sensitivity to different chemotherapeutic agentsand some immunophenotypic markers. Conclusions: Histopathologically identical GBM tumours displayed a marked
immunophenotypic heterogeneity. The expression of A2B5, CD56, NGFR and Pgp appeared to be associated withchemoresistance whereas CD133, EGFR and LIFR expression was characteristic of chemosensitive tumours. The
flowcytometric analyses of GBMs may predict chemoresponsiveness and help to identify patients who could benefit fromchemotherapy.Acknowledgement: This work was supported by the Slovak Research and Development Agency under thecontract No. APVT-20-032504, APVV-20-052005 and VEGA grant 1/3361/06.

P178
Extended use of temozolomide based on O6-methylguanineDNAmethyltransferase (MGMT) expression pattern for glioma patients:
experience of 17 cases
Zhongping Chen1, Gang Li1Cancer Center, SunYat-sen University, Guangzhou, China

1

P179
Pysosequencing: a good option for MGMT analysis.
Veronique Quillien1, Lucie Karayan-Tapon2, Catherine Gratas-Rabbia-Re3
CRLCC Eugene Marquis, Rennes, France 2EA3805, Universite de Poitiers, CHU de Poitiers/France 3INSERM U601,
Nantes, CHU de Nantes/France

1

MGMT is currently recognized as a major mechanism of resistance to alkylating agents in glioblastoma (GBM) patients, but
so far there is no consensus about the best technique for MGMT analysis. In a previous study, we compared fivetechniques (qualitative and semi-quantitative MS-PCR, pyrosequencing, MGMT RNA level and immunohistochemistry) on aretrospective series of 81 newly diagnosed GBM patients treated with a standard therapeutic schedule involving TMZ. The
best predictive value for overall survival was obtained by pyrosequencing (PyroMarkTM MGMT kit - Biotage) with a cut-off
of 8% (median of the population). We analyse here the analytical performance of this technique, a critical point if such atechnique is to be used in a clinical setting. To assess repeatability and reproducibility, 2 primary cell lines (obtained in thelaboratory), the U251 cell line and a universal methylated DNA (100% methylated) were tested at least 5 times in single orseparate runs. For linearity, sequential mixing of the 100% and 0% samples were tested 5 times in a single run. The limit ofquantification was defined as the lower concentration detected with a coefficient variation (CV) over 15%. Mean levels of
methylation were 9, 73, 90 and 97% for GB3, GBM2, U251 and universal methylated DNA, respectively, with repeatabilities
and reproducibilities below 10%, 9%, 5% and 3%. A good linearity was observed for each CpG site tested, as well as forthe mean of methylation. A CV below 15% was obtained for the lowest sample tested (5% for a theoretical result of 2.5%),
indicating a limit of quantification between 0 and 5%. Pyrosequencing appears as a very robust technique for analysing
MGMT status. It is currently compared to other promising approaches such as MethyLight and MS-HRM in a French
multicentre study.

- 191 -­­

Poster Presentation (P)The 6-cycle of temozolomide (TMZ) have being used as a standard chemotherapy. We have treated 17 patients with highgrade gliomas (HGGs) or unfavorable low-grade gliomas (LGGs) with TMZ for more than 6 cycles. The regimen of TMZ
was selected based on MGMT expression of the tumor. Patients with MGMT-negative tumors had received the standard
dosing regimen (200 mg/m2 for 5 days every 28 days). While patients with MGMT-positive tumors were treated with
3-weeks-on/1-week-off schedule, or cisplatin plus TMZ (cisplatin 75 mg/m2 on Day 1 and 2, TMZ 200 mg/m2 on Day 2 to6, every 28 days). About 174 cycles of TMZ were administered to the 17 patients. The TMZ cycles administered per patient
ranged from 7 to 24 (median = 8 cycles). Myelosuppression including lymphopenia and leukopenia were the most common
high grade toxicities (grade 3), both occurring in 11.8 % (2 / 17) of patients. The most frequent toxicities were fatigue (76.5%), lymphopenia (58.8 %), alopecia (58.8 %), constipation (41.2 %), leukopenia, nausea, depression and vomiting (all with35.3 %). The median progress free survival (PFS) was 29.9 months. Six month PFS and 12 month PFS were 100% and
73% respectively. Two patients received gross total tumor resection are still no evidence of disease now. One patient (5.9 %) demonstrated a complete response (CR), 12 patients (70.6 %) a minor response (MR), and 2 patients (11.8 %) stabledisease (SD). The overall response rate was 76.5 % ( 95% CI, 50-90 %) and the disease control rate was 88.2% ( 95% CI,
64-98 %). Extended use of TMZ based on MGMT expression pattern is safe to glioma patients. Extended use may improve
response rates and PFSs compared to conventional regimen.Key words: chemotherapy, glioma, temozolomideThe 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)P180
ANGIOGENIC POTENTIAL OF LOW GRADE OLIGODENDROGLIOMAS IS AN IMPORTANT
DETERMINANT OF PROGNOSISTurker Kilic1, Mustafa Guduk1, Abdulkadir Ozkan1, Necmettin Pamir1
Institute of Neurological Sciences, Marmara University, Istanbul, Turkey

1Angiogenic potentials of oligodendroglioma WHO grade 2 tumors were studied by rat cornea angiogenesis model andcompared the relationships between MRI contrast enhancement, 1p/19q loss of heterozygosity (LOH) and time to tumor
recurrence.Twenty oligodendroglioma WHO grade-2 cases had been randomly chosen, 10 of those were enhancing with
contrast in preoperative MRI, while 10 were not. All of those had total excision verified by postoperative 24 hour MRI andnone had an adjuvant treatment unless a recurrence was noted. The tumor samples were inoculated into rat corneas andobserved and graded. 1p/19q LOH study was performed by fluorescent in-situ hybridization.The time to tumor recurrenceof those cases were correlated with contrast enhancement and angiogenic grades, but 1p/19q LOH. The angiogenic
potentials of tumors were significantly different between those having a time to recurrence >60 months and those having=60 months. 1p/19q LOH was not a determinant of angiogenesis.Though all tumors were oligodendroglioma WHO grade 2
their angiogenic potentials were heterogenous and angiogenic potentials seemed to have an important role on time torecurrence and thus survival. This study, for the first time, tests the angiogenic activity of low grade oligodendrogliomas andexamines its possible role in prognosis.

P181
Identification of a novel small molecule HIF-1α translation inhibitor
Takuhito Narita1, Shaoman Yin1, Christine F. Gelin2, K.C. Nicolaou2, Erwin G. Van Meir1
Laboratory of Molecular Neuro-Oncology, Departments of Neurosurgery, Hematology/Oncology, Winship Cancer
Institute, Emory University, Atlanta, U.S.A. 2Department of Chemistry and The Skaggs Institute for Chemical Biology,
The Scripps Research Institute and Department of Chemistry and Biochemistry, University of California, San Diego1

Poster Presentation (P)Purpose: Hypoxia inducible factor-1 (HIF-1) is the central mediator of the cellular response to low oxygen and functions as
a transcription factor for a broad range of genes that provide adaptive responses to oxygen deprivation. HIF-1 is overexpressed in cancer and has become an important therapeutic target in solid tumors. In this study, a novel HIF-1α inhibitor
was identifiedand its molecular mechanism was investigated. Methods: Using a HIF-responsive reporter cell-based assay,
a 10,000-membered natural product-like chemical compound library was screened to identify novel HIF-1 inhibitors. This
led us to discover KC7F2, a lead compound with a central structure of cystamine. The effects of KC7F2 on HIF-1
transcription, translation and protein degradation processes were analyzed. Results: KC7F2 markedly inhibited HIFmediated transcription in cells derived from different tumor types, including glioma, breast and prostate cancers. KC7F2
prevented the activation of HIF-target genes such as Carbonic Anhydrase IX, Matrix Metalloproteinase 2 (MMP2),
Endothelin 1 and Enolase 1. Investigation of the mechanism of action of KC7F2 showed that it worked through the downregulation of HIF-1α protein synthesis, an effect accompanied by the suppression of the phosphorylation of eukaryotic
translation initiation factor 4E binding protein 1 (4EBP1) and p70 S6 kinase (S6K), key regulators of HIF-1α protein
synthesis. Conclusion: These results show that KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer
therapy agent warrants further study.

P182
PHASE I STUDY OF VANDETANIB, IMATINIB MESYLATE AND HYDROXYUREA FOR
RECURRENT MALIGNANT GLIOMADavid A. Reardon1, James J. Vredenburgh1, Annick Desjardins1, Sridharan Gururangan1,
Katherine B. Peters1, Susan T. Boulton1
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA

1

Background: Malignant glioma (MG) is characterized by frequent aberrant activation of EGFR, VEGFR and PDGFR. We
determined the MTD and DLT of vandetanib (V), a once-daily, oral selective inhibitor of VEGFR and EGFR when combinedwith imatinib mesylate (IM), a multi-kinase inhibitor including PDGFR, and hydroxyurea (H). Methods: Adult recurrent MG
patients with ≤ 3 prior recurrences, KPS ≥ 60% and adequate organ function were stratified based on concurrent enzymeinducing anticonvulsant use (EIAC). Both strata were independently escalated using a "3+3" design. V was increased by
100 mg in successive cohorts beginning at 100 mg and 200 mg for patients not on and on EIAC, respectively, withestablished dose levels of IM and H. Evaluations were after every other 28-day cycle. Pharmacokinetics of V and IM wereobtained on days 1 and 28 of cycle 1. Results: Twenty-six patients (grade 4 MG, n=20; grade 3 MG, n=6) enrolled. Only 1
DLT (reversible grade 4 transaminase elevation; dose level 1) occurred among 22 non-EIAC patients. The MTD of V for
patients on EIAC is 200 mg/day due to 2 of 3 patients developing grade 3 thrombocytopenia at the 300 mg/day dose level.
Evidence of therapeutic benefit to date includes 1 partial response and 15 patients (58%) with stable disease for at least 4
weeks, including 4 patients for ≥ 4 months. Conclusions: V, IM and H is well tolerated in recurrent MG patients. An updateof outcome, toxicity and pharmacokinetic analyses will be presented.

- 192 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP183
A PHASE I STUDY OF SUNITINIB PLUS IRINOTECAN IN THE TREATMENT OF PATIENTSWITH RECURRENT MALIGNANT GLIOMADavid A. Reardon1, James J. Vredenburgh1, Annick Desjardins1, Dorothea E. Janney1,
Katherine B. Peters1, Allan H. Friedman1, Sridharan Gururangan1, Henry S. Friedman1
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA

1

Background: Malignant glioma (MG) are highly angiogenic due to overexpression of VEGF/VEGFR. The current study was
designed to determine the MTD and DLT of sunitinib (S), a once-daily, oral selective inhibitor of VEGFR when combined withirinotecan (I), a topoisomerase-1 inhibitor among recurrent MG patients. Methods: We employed a "3+3" dose escalation
design to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of S, administered once daily forthe first 28 days of each 42 day cycle, with I, administered every 2 weeks. The initial S and I doses were 25 mg/day and 75
mg/m2. Key eligibility criteria included KPS ≥ 70%, adequate organ function and no concurrent CYP3A-inducing antiepileptics. Pharmacokinetic studies for S are obtained during cycle 1 among 6 additional patients treated at the MTD.
Results: Eleven patients (grade 4 MG, n=6; grade 3 MG, n=5) have enrolled. No DLTs were observed in cohort 1, but 2
patients experienced hematologic DLT (grade 3 thrombocytopenia, n=2; grade 4 neutropenia, n=1) in cohort 2. Therefore
the MTD for this regimen is 25 mg of S plus 75 mg/m2 of I. Evidence of therapeutic benefit to date includes 8 patients (73%)
with stable disease including 3 who continue on therapy. Conclusions: Combination of sunitinib plus irinotecan is welltolerated in recurrent MG patients at the defined MTD dose level. Accrual to the PK dose expansion cohort continues.

P184
A PHASE IB TRIAL OF CEDIRANIB IN ADDITION TO STANDARD TEMOZOLOMIDE AND
RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Andrew S. Chi1, Elisabeth R. Gerstner1, April F. Eichler1, Houng K. Chea1, Nancy Shearer1,
Jan Drappatz2, Patrick Y. Wen2, S. Percy Ivy3, Jay S. Loeffler4, A. Gregory Sorensen5,
Rakesh K. Jain4, Tracy T. Batchelor1
Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School,
Boston, USA 2Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical
School, Boston, USA 3Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA 4Department ofRadiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA 5Department ofRadiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA

1- 193 -­­

Poster Presentation (P)Background: Pre-clinical evidence suggests the effects of radiation therapy (RT) and chemotherapy may be potentiated byinhibitors of angiogenesis. This is a phase Ib study to evaluate the safety and toxicity of the combination of cediranib, apotent pan-VEGF receptor tyrosine kinase inhibitor, standard RT and temozolomide (TMZ) in patients with newly diagnosed
GBM who were not taking enzyme-inducing anti-epileptic drugs (EIAED).
Methods: 14-21 days after undergoing tumor biopsy or resection 6 patients with histologically confirmed GBM weretreated with concurrent TMZ (75mg/m2/day), RT (60 Gy) and cediranib (dose level 1 = 20mg/day; dose level 2 = 30mg/day)followed by post-radiation TMZ (150-200 mg/m2 on days 1-5 of each 28 day cycle) and cediranib (45mg/day) for up to 6
monthly cycles.
Results: Six patients were treated (cediranib 20mg = 3 patients; cediranib 30mg = 3 patients). No patients experienced a
DLT, establishing the maximum tolerated dose (MTD) for cediranib in combination with RT and TMZ as 30mg/day in thispatient population. Expected toxicities of hypertension, fatigue, and palmar/plantar erythema were observed. During
combined cediranib and TMZ therapy in the post-radiation setting, 1 patient discontinued cediranib because of toxicity(grade 3 transaminase elevation) and 1 patient required dose reduction to 15mg/day due to grade 3 proteinuria. During thecourse of cediranib treatment, no intratumoral or intracerebral hemorrhages were detected and no cases of wound
infection or wound dehiscence were observed. All patients are alive with a median follow-up of 156 days.
Conclusions: The MTD for cediranib given in combination with standard RT and TMZ for newly diagnosed GBM patients
not on EIAEDs is 30mg/day, and the therapy is well tolerated. The phase II component of this trial will include correlative
biomarker and MRI studies and is underway.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P185
THE POTENTIAL BENEFIT OF NEOADJUVANT AND EXTENDED-ADJUVANTTEMOZOLAMIDE WITH THE STUPP-REGIMEN IN THE TREATMENT OF GLIOBLASTOMA
Ian Brown1, Ian T. Edwards1
Neurosciences - Arden Cancer Centre, UHCW-Walsgrave, Coventry, United Kingdom

1

In adults, glioblastoma (GBM) is the most common primary cerebral neoplasm and is associated with a poor prognosis.
However encouragingly, post–operative concomitant temozolamide (TMZ) – radiotherapy (RT) has led to improved 2, 3 and4–year survival rates of approximately 37, 25 and 12 % respectively.
Purpose – Evaluation of the potential benefit of combined neoadjuvant TMZ/concomitant TMZ–RT / extended–adjuvant
TMZ in the treatment of good performance status patients with GBM.
Methods – Thirty two consecutive patients with supra–tentorial GBM (WHO Grade 4) and KPS of 90 – 100% received the
combined regimen. Craniotomy and maximal tumour debulking had been performed in 27, the remainder underwent
biopsy only. The median age was 53 (18 – 69) years. Patients were predominantly male (28). All received 1 cycle
neoadjuvant TMZ (150 mg /m2 po daily × 5d) prior to commencing standard Stupp–regimen concomitant TMZ–RT (60 Gy 6
MV X–rays TD/ 30 fractions / 42 d; TMZ 75 mg/ m2 po daily). Extended–adjuvant TMZ (vide supra) was given at 28 day
intervals subject to satisfactory blood count, 4 weeks following completion of RT. On average, patients received 18 cycles
extended–adjuvant TMZ (7 – 31), which was well tolerated with negligible haematological toxicity or deterioration in QOL.
Survival data was analysed using the Kaplan–Meier lifetable method in order to estimate the survival probability over a 36
month period.
Results – For all patients, the estimated survival rate at 12, 18, 24 and 36 months was 87.5, 78.1, 68.8 and 68.8 %respectively. Of the majority subgroup that underwent craniotomy/debulking, survival was not significantly better (70.4 % at
36 months).
Conclusion – The addition of neoadjuvant TMZ and extended–adjuvant TMZ to standard concomitant TMZ–RT proved welltolerated and has appeared to confer a significant survival benefit, with an estimated 3–year survival rate in the order of 70 %.

P186
Dose dense one week on/ one week off temozolomide in recurrent
glioma.
Walter Taal1, J.M.W. Segers-van Rijn1, J. M. Kros2, C.D.D. van der Rijt3, J.E. Bromberg1,
P.A.E. Sillevis Smitt1, M.J. van den Bent1
Department of neuro-oncology/neurology, ErasmusMC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Department of Pathology, ErasmusMC, Rotterdam, The Netherlands 3Department of Medical Oncology, ErasmusMC/
Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
1
2

Poster Presentation (P)Background.
Only few studies examined the effect of dose dense temozolomide (TMZ) in recurrent glioma. We investigated the efficacy
and tolerability of one week on/one week off TMZ (ddTMZ) regimen in patients with a recurrent glioblastoma or otherheavily pretreated recurrent glioma.
Material and methods.
In a retrospective study we evaluated a cohort of patients treated with ddTMZ in our center between 2005 and 2008 forprogression of a glioblastoma during or after chemo-irradiation with TMZ or a recurrence of another type of glioma afterradiotherapy and at least one line of chemotherapy. All evaluated patients received TMZ at 150 mg/m2/d (days 1 through 7
and 15 through 21 on a 28-day basis) with individual dose adjustments according to hematologic toxicity. Response wasassessed with MRI using Macdonalds criteria, complete and partial responses were considered objective responses.
Primary endpoint was progression free survival (PFS). Totoxicity was evaluated according to the Common Terminology
Criteria for Adverse Events (CTCAE; version 3.0).
Results.
Thirty-seven patients were included. 16 patients had a progressive glioblastoma after or during chemo-irradiation with TMZ.
Twenty-one patients had a recurrence of an originally low-grade or anaplastic glioma after radiation. All these 21 patients
received one line or two lines of prior chemotherapy before the start of ddTMZ. The median number of cycles of ddTMZ
was 4 (range 1-12). Six patients had to stop chemotherapy because of toxicity; two because of grade 4 thrombocytopenia,
1 because of persistent grade 2 thrombocytopenia, 1 because of elevated transaminases and 2 because of fatigue. The 6
months PFS was 37%, the median overall survival was 9 months. An objective response was obtained in 6 of the 35
patients (17%) evaluable for response. Two of the 16 patients with a progressive glioblastoma had a complete or partial
responseand the 6 months PFS was 29%.
Conclusion.
This study indicates that ddTMZ is safe and effective in recurrent glioma, despite previous TMZ and/or nitrosurea
chemotherapy.

- 194 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP187
CLINICAL TRIAL WITH TEMOZOLOMIDE IN AN ALTERNATING WEEKLY REGIMENAGAINST RECURRENT MALIGNANT GLIOMAS-A PRELIMINARY REPORT
Akio Asai1, Hideyuki Oshige1, Hirokazu Takami1, Tatsuro Uesaka1, Jun-ichi Takeda1,
Kunikazu Yoshimura1, Keiji Kawamoto2
1
Department of Neurosurgery, Kansai Medical University Hirakata Hospital 2Department of Neurosurgery, Kansai
Medical University Takii Hospital

Wick et al. reported therapeutic data of temozolomide in an alternating weekly regimen against recurrent gliomas. They
used temozolomide at 150mg/m2 Days 1 through 7 and 15 through 21 every 4 week. Although progression free survival
rate at 6 months was 43.8%, grade 4 lymphopenia still developed in 12% of patients. Also, their dose is beyond thelimitation set by the Ministry of Health, Labour and Welfare of Japan. Therefore, we reduced the dose to the half. Five
patients with recurrent malignant gliomas (4 glioblastomas and 1 anaplastic astrocytoma) initially treated with surgicalresection and radio-chemotherapy (60Gy (2Gy x 30 fr.) to extended local field plus concomitant temozolomide (75mg/m2 x
42 days)) were treated with temozolomide in alternating weekly regimen (at 75mg/m2 Days 1 through 7 and 15 through 21
every 4 weeks). One patient (20%) has responded to the regimen although the mean and longest follow up period is 2
months and 4 months, respectively, so far. Grade 4 lymphopenia or myelosuppression developed in none of patients. We
will discuss a response rate and toxicity of this regimen.

P188
Safety and efficacy of near-continuous dose-dense temozolomide(Tegwondo) for recurrent gliomas
Herwig Strik1, Jan-H Buhk1, Christoph-H Bock1, Arne Wrede1, Christine Marosi2,
Ulrich Kaiser3, Markus Christmann4, Bernd Kaina4
Departments of Neurology, Neuroradiology, Neurosurgery and Neuropathology, University Medicine Goettingen,
Goettingen, Germany 2General Hospital, Univ. of Vienna, Austria 3St. Bernward Hospital Hildesheim, Germany
Department of Toxicology, University of Mainz, Germany

1
4- 195 -­­

Poster Presentation (P)Background: We report on safety and efficacy of a rechallenge of recurrent gliomas with dose-dense 21/28-day or nearcontinuous 5/7-day ("Tegwondo") temozolomide (TMZ). Methods: 56 recurrent glioma patients received over 300 cycles of
TMZ, initially at 100mg/m2 with individual dose adaptation: 21 pts. received 148 cycles day 1-21/28 (18 WHO IV [GBM], 3
WHO III). 35 patients with recurrent or progressive glioma received 186 cycles of near-continous TMZ day 1-5/7, initially at
100mg/m2 (17 GBM, 8 WHO 8, 6 low-grade). All malignant gliomas were pretreated with temozolomide. Results: Toxicity
was: hematotoxicity grade 3/4 (asymptomatic): 2/21 pts. (21/28-day, 10%) and 6/35 pts. (5/7-day, 17%); nonhematological
3/4: 4/21 Pts. (21/28, 19%), 0/19 (5/7, 0%). Only in 2/56 patients (one 21/28, one 5/7), haematological toxicity required
treatment (platelet transfusion, G-CSF). GBM-pts. (n=35) had a mean age of 55y, median KPS was 65%. Efficacy was: 4
CR (11%), 2 PR (6%), 11 SD (31%) and 18 PD (51%) at >3 months. Progression-free survival at 6 months was 37%, at 12
months 9% and at 24 months 6% (2 pat.). Survival after relapse was 30.6 weeks. First exemplary tests during the 5/7-day
regimen indicate that MGMT in the peripheral blood is permanently depleted despite the 2-day pause of TMZ application.
Conclusions: In line with our previous reports, we demonstrate that rechallenge of recurrent gliomas with dose-dense
temozolomide starting at 100 mg/m2 and individual dose adaptation is feasible and active also in patients with critical bloodcounts and unfavourable prognosis. Near-continuous application day 1-5/7 allows best for an individual dose adaptationand seems to permanently deplete the alkylation-resistance factor MGMT. These updated results support our previous
experience that near-continous TMZ ("Tegwondo") (TEmozolomide Glioma WOrkiNgday DOse-dense regimen) has activity
and may overcome MGMT-mediated resistance to chemotherapy.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P189
Pharmaceutical control of temozolomide chemotherapy with original
leaflets and administration history database
Sanae Miyano1,Tomomi Kataoka1,Satoshi Motokawa1,Michihiro Shino1,Yoko Nakasu2
1Division of Pharmacy, Shizuoka Cancer Center,Shizuoka, Japan 2Department of Neurosurgery, Shizuoka Cancer
Center,Shizuoka, Japan
BackgroundTemozolomide (TMZ) is a new oral cytotoxic chemotherapeutic agent for gliomas. The usage and dosage are different
between standard induction course combined with radiotherapy and maintenance course of five days every 28 days.
Therefore, monitoring and assessment of prescription contents are important to keep validity in dosage and schedule. On
the other hand, TMZ has many hematologic and non-hematologic adverse effects. Several reports showed lethal
Pneumocystis carinii infection in patients with severe lymphocytopenia caused by TMZ. The observance of treatment
schedules including TMZ, 5-HT3 antagonist, and antibacterial medicine regimens are of importance to achieve maximum
therapeutic effects and also to reduce side effects.
Purpose and methods
We constructed an administration history database using a commercial software (Microsoft Office Access) and routinely
checked each dosage and treatment schedule. We also made leaflets of TMZ for patients to support their start andmaintenance of the treatment. Adverse events were analyzed in 53 patients ( twenty-two patients treated with induction
course and thirty-one patients treated with maintenance course ) according to CTCAE grading system.
Results
Prescriptions were monitored and assessed in 81 patients. Administration deviations were reported to prescribing doctors
and regulated in 2 patients by our database monitoring. Support with our original leaflets were performed for 23 patients inward; it helped especially children with safe administration of TMZ. Grade 3 or 4 lymphocytopenia were observed in 12
patients without noticeable decrease in white blood count or clinical manifestations. No patients suffered from pneumonia
during investigation.
Conclusion
Our new administration history database was simple and useful to monitor treatment schedules and doses. Our
pharmaceutical service with original leaflets helped patients and families to understand drugs and treatment schedule.
Lymphocyte count must be followed up in patients during treatment with TMZ.

P190
Safety and efficacy of temozolomide treatment with newly diagnosed
glioblastoma in Japan. A multicenter phase II clinical study
Kazuhiko Sugiyama1, Ryo Nishikawa2, Hideo Takeshima3, Hideo Nakamura3, Tomokazu Aoki4,
Jun Takahashi5, Hideaki Takahash6, Akihiko Saito6, Yutaka Sawamura7, Kaoru Kurisu1,
Masao Matsutani2
Department of Neurosurgery, Hiroshima University Hospital 2 Department of Cerebral-Spinal Cord Tumors,International Medical Center, Saitama Medical University 3Department of Neurosurgery, Kumamoto University Hospital
4
Department of Neurosurgery, Kitano Hospital 5Department of Neurosurgery, Kyoto University Hospital 6Department of
Neurosurgery, Niigata University Hospital 7Department of Neurosurgery, Hokkaido University Hospital
1

Poster Presentation (P)Objective: An open-labled phase II study was conducted to evaluate the safety and efficacy of temozolomide (TMZ) in
Japanese patients with newly-diagnosed glioblastoma. Methods: Thirty patients with supratentorial glioblastoma (26-69
years old, median: 55.5) were enrolled post-operatively from Oct. 2005 to Nov. 2006. They were fourteen males, andsixteen females. Tumors were resected totally in 7, partially in 21, and biopsied in 2. According to the therapeutic regimenof Stupp et al. (EORTC study, N Engl J Med 2005), the patients received daily administration of TMZ concomitantly withradiotherapy (RT) followed by TMZ monotherapy (5 on/23 off) up to 12 months after the beginning of RT. For prophylaxis ofpneumocystis pneumonia (PCP), oral administration of 1g trimethoprim-sulfamethoxazole 3 times a week or anotheralternative was required during the RT period. Results: Seven patients did not progress to the TMZ monotherapy phase, 4
due to disease progression and 3 due to grade 3-4 adverse events. Of the remaining 23 patients, 9 completed thistreatment and 14 discontinued treatment, 11 due to disease progression, 2 due to other malignancies, and 1 due topulmonary embolism. The tumor reduction effect in 19 patients with measurable lesion was CR in 3, PR in 6, NC in 6, and
PD in 4, and the response rate was 47%, with a median response period of 10.5 months. The main adverse events with
Grade 3&4 were neutropenia(17%), lymphocytepenia(7%), and constipation(7%). No PCP was observed. Medianprogression-free survival was 8.3 months, and median overall survival was 18.1 months. Conclusions: Concomitanttherapy with TMZ and RT followed by TMZ monotherapy was also effective in Japanese patients with newly-diagnosed
glioblastoma. The safety profile in this trial was similar to that observed in the EORTC Phase III study.

- 196 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP191
RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA (GBM) PATIENTS TREATED WITHTEMOZOLOMIDE (TMZ)-RADIOTHERAPY FOLLOWED BY TMZ FOR 2 YEARS OR UNTIL
PROGRESSION: SURVIVAL ANALYSIS
Alejandro D Muggeri1, Juan Pablo Alderuccio1, Horacio Martinetto1, Blanca D Diez1
Neuro-oncology Department, Institute for Neurological Research Dr Raul Carrea (FLENI), Buenos Aires, Argentina

1

The standard treatment of newly diagnosed GBM is TMZ followed by adjuvant TMZ for six months. The optimal duration ofmaintenance therapy with TMZ is controversial.We evaluated in a retrospective analysis the 12 and 24 month overall survival
and progression free survival in GBM patients treated with resection or biopsy followed by chemo-radiotherapy followed by
TMZ (150 to 200 mg/m2/day for 5 days each 28) for two years or until disease progression or unacceptable toxicity.We also
evaluated if age (< 40 vs. > 40), gender, KPS (< 70 vs. > 70), and type of resection (partial -PR, complete -CR and biopsy)
impacted survival. Fifty-six patients with primary GBM treated in our institution between May 2005 and September 2008
were included and stratified according the study parameters.The median age was 59 years, range (35-75), 62% weremales. Ninety two percent had undergone debulking surgery. MGMT promoter gen metilathion status was done in 25/56(15/25 were metilathed), and EGFR amplification in 39 of 56. (26/39 were amplified).The median follow-up was 11 month,range (5-44). PFS was 32% at 12 months; the two-years survival rate was 30%. Interruptions due to toxicity occurred in 7%
of patients during induction and 95% completed both radiation and TMZ therapy as planned. Nine (16%) patients could notstart maintenance because progression of disease or severe toxicity.Concomitant treatment with radiotherapy plus
temozolomide resulted in grade 3/4 hematological toxic effects in 10,7% of patients. During the maintenance phase with
TMZ 6,4% of patients experienced hematological toxicity (grade 3/4).These results suggest that long-term treatment with
TMZ is feasible and well tolerated. The KPS >70 and age < 40 was related significantly to survival (p=0.004 and p=0.05
respectively). Update results will be presented at the meeting.

P192
Pseudprogression or tumor progression in gliomas: what kinds ofdiagnostic tools are more reliable?
Kyung Gi Cho1
Department of Neurosurgery, Ajou University School of Medicine

1

P193
Hypofractionated high-dose irradiation by IMRT concurrent withprophylactic intrathecal chemotherapy for the treatment ofglioblastoma
Toshihiko Iuchi1, Kazuo Hatano2, Takashi Kodama2, Seiichiro Hirono1, Tsukasa Sakaida1
Division of Neurological Surgery, Chiba Cancer Center, Chiba, Japan 2Division of Radiation Oncology, Chiba Cancer
Center, Chiba, Japan

1

Backgrounds: For the better survival of pts with glioblastoma (GBM), we initiated hypofractionated high-dose irradiation(HdI; 68Gy/8F) by IMRT to control regional tumor, and prophylactic intrathecal administration of thiotepa (piT) to prevent
cerebrospinal fluid dissemination (CSFd). The aim of this analysis is to evaluate the clinical significance of these treatments.
Methods: Histologically confirmed GBMs without CSFd at diagnosis were enrolled. Pts were classified into three groups
owing to the post-surgical treatment as follows: Group A pts (n=62) were treated by conventional radiotherapy (60Gy/30F)
alone, Group B pts (n=28) were by HdI alone and Group C pts (n=30) were by HdI concurrent with piT. The patterns ofrecurrence and overall survival (OS) were compared in these three groups. Results: The dominant pattern of recurrence
was local in all groups. HdI decreased the local failure from 71 to 41% (p=0.003), but increased the CSFd from 8 to 37%,
resulted in the similar total recurrence rates (Group A: 79%, Group B: 78%). However, in Group C, CSFd was decreased to
13% while keeping the low ratio of local failure (30%), and total recurrence rate was decreased to 43% (p=0.029 vs. GroupB). The median OS was 12.4 months in Group A, 17.3 months in Group B and 37.4 months in Group C. There was no
significant difference of OS between Group A and B (p=0.409), but Group C showed significantly longer OS than Group A(p=0.005) and B (p=0.010). Radiation injury was the cause of deterioration in 50% of the pts who lived more than 2 years,
although in only 5% of pts died within 2 years. Conclusions: HdI concurrent with piT showed significant effect on both thelocal control and prevention of CSFd, resulted in good survival of pts with GBM. However, radiation injury was a problem inlong survivor.

- 197 -­­

Poster Presentation (P)Differentiation of peudoprogression from tumor progression remains a challenging diagnostic problem. Conventional MR
imaging findings are considered to be inadequate for reliably distinguishing peudoprogression from tumor progression inpatients with glioma.. This study was undertaken to determine diagnostic value for peudoprogression in 15 patients withpeudoprogression who were underwent surgery for glioma during last 10 years. All patients had previously undergone tumor
resection followed by radiotherapy. The most histological type was glioblastoma in 12 patients (63%). There were 10 males
and 5 females (ratio female: male 2:1) ranging in age from 31 to 85 years(mean 47.8. years). The clinical symptoms of thepatients with peudoprogression was motor weakness in 8. headache in 5, mental change in 3, generalized seizure in 2
patients. 18-FDG PET was done in 9 patients who have high uptake in only 5 patients. The sensitivity of a combination of
MR spectroscopy with perfusion imaging for peudoprogression was better than conventional contrast-enhanced imaging
and /or 18-FDG-PET. Three patients were treated conservatively with steroid medication and other 12 patients were treatedby decompressive removal of necrotic mass after confirmed diagnosis by stereotaxic biopsy. Follow-up examination showed
12 patients alive with median survival of 56.3months. Three patents were died of severe brain swelling and systemic
complications. The survival following stereotactic biopsy was markedly increased in patients suffering from radiation effectcompared with those harboring recurrent malignant glioma. In patients with previously irradiated gliomas in whom wereclinically or radiographically suspected, MR spectroscope and perfusion MRI might be more reliable diagnostic tool todifferentiate peudoprogression from tumor recurrence. In addition, the decompressive removal of necrotic mass could
improve survival rates.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P194
A Pilot Safety Trial of Hypofractionated Radiation Therapy plus
Concomitant and Adjuvant Temozolomide for Adults with Glioblastoma
Multiforme
Mizuhiko Terasaki1, Minoru Shigemori1
The Department of Neurosurgery, Kurume University, Fukuoka, Japan1

Purpose To prospectively evaluate the impact of hypofractionated radiotherapy (RT), confirmed by randomized clinical trial
with no differences in survival compared with standard radiotherapy and meaningful neurocognitive toxicity profile in older
patients with glioblastoma multiforme (GBM), in adults with newly-diagnosed GBM when given concurrently withtemozolomide (TMZ). Patients and Methods Twenty adults with newly-diagnosed GBM received shorter-courses RT (45Gy in 15 fractions over 3 weeks) concurrently with TMZ given for 3 weeks followed by a 28 days rest period and continued
TMZ at 150-200 mg/m2/d on days 1-5 until tumor progression or unacceptable toxicity. Primary objectives were to
determine progression-free survival (PFS) at 6 months for abbreviated RT plus TMZ treatment. Secondary objectives wereto assess health-related quality of life (HRQOL), early progression, and seizure control. HRQOL was assessed using
Karnofsky performance status (KPS) and Functional Assessment of Cancer Therapy-Brain (FACT-Br) Subscale. Results.
Twenty patients were enrolled, of all were treated and evaluable for both PFS and HRQOL. The 6-month PFS measured
from start of treatment was 70%. KPS score and FACT-Br Subscale have a good correlation but there were not statisticallysignificant between the pre- and post-treatment. Early progression occurred in 5 patients (25%), and seizure relapse wasobserved in two (10%) patients. Conclusions. Hypofractionated RT concurrently with TMZ has superior impacts on PFS
compared with a historical control. Decreased in seizure frequency, same impacts on early progression, and reduced
treatment time offers advantage for adults with GBM.

P195
Upfront chemotherapy for gliomas deleting 1p and 19q followed bysecond-look removal and/or radiotherapy at maximum response
Hikaru Sasaki1, Yuichi Hirose2, Takahito Yazaki3, Kazunari Yoshida1, Takeshi Kawase1
Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan 2Department of Neurosurgery, Fujita Health
University, Nagoya, Japan 3Department of Neurosurgery, International University of Health and Welfare, Tokyo, Japan

1

Background: Oligodendroglial tumors losing 1p and 19q are associated with increased response to chemotherapy andsurvival. In low-grade gliomas, presence of the codeletion correlates with those favorable clinical parameters regardless ofhistology (Neurology 68:1831-6, 2007; J Clin Oncol 24:4758-63, 2006). Methods: Gliomas with 1p and 19q codeletion
have been treated by upfront chemotherapy regardless of histology (Keio protocol Feb/08). At maximum response, patientsare re-evaluated to see if effective removal is possible, and second look-removal is recommended if near total removal
seems amenable. Grade 3 tumors are irradiated after max. response or after second look-removal if performed. Results:
Eighteen gliomas with the codeletion have been treated (8 PR/MR, 8SD, 2NE). Two tumors recurred after partial response(AO at 12 months; OD at 17 months). However, tumor recurrence occurred within the area that was to be resected if
second look-removal were planned. Near total removal was performed in two tumors after tumor shrinkage by upfront
chemotherapy for which effective removal was not initially possible. In an AO, radiotherapy was given after max. response.
Conclusion: Upfront chemotherapy for gliomas deleting 1p and 19q followed by second-look removal and/or radiotherapy
seems beneficial to improve survival times of patients with those tumors.

Poster Presentation (P)P196
Benefit of Chemotherpy in Anaplastic Astrocytomas
Jung Ho Han1, Yong Hwy Kim1, Chul-Kee Park1, Hee-Won Jung1
Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea

1

Object: To evaluate the role of chemotherapy in the management of anaplastic astrocytomas (AAs), the authors
retrospectively reviewed the survival outcome according to the treatment regimens in a single institution.Patients andMethods: Eighty six patients (39 men and 47 women) with newly diagnosed AAs between 1990 and 2004 were enrolled inthis study. All lesions were proven pathologically and 47 lesions were resected surgically. The mean age was 40.9 years(range: 18 ~70). Thirty one (36.0%, median age; 42 years) of all patients were treated with only conventional radiotherapy(CRT) post-operatively (CRT Group) and 25 patients (29.1%, median age; 37 years) with the CRT followed by adjuvant
chemotherapy with PCV (procarbazine, lomustine and vincristine) regimen (PCV group) Thirty patients (34.9%, median age;
40.5 years) were managed postoperatively with nimustine-cisplatin followed by CRT (ACNU-CDDP group). The survival timeas analyzed according to the performance status, degree of surgical resection and post-operative management strategy
with log rank test. Toxicity associated with treatments was also analyzed. Results: The median survival was 72.0, 30.0, and14.0 months in PCV, ACNU-CDDP and CRT group, respectively. (95% CI= 52.0-91.9; 21.4-38.6; 7.8-20.2) The PCV group
showed the longer survival time than both ACNU-CDDP and CRT group. (p=0.045; p=0.002) And neoadjuvant nimustinecisplatin was beneficial than only CRT(p=0.039) In the multivariate analysis, good performance status, large degree ofsurgical resection (than biopsy only), adjuvant or neo-adjuvant chemotherapy (ACNU/CDDP-CRT or CRT-PCB than CRTonly) were positive prognostic factors. In terms of complications related to treatments, PCV group showed the low
incidence than ACNU-CDDP group, also. Conclusion: Adjuvant or neo-adjuvant application of chemotherapy to radiation
therapy showed benefit compared with RT in prolonging the survival in anaplastic astrocytomas patients. PCV after CRT
seems to be better than other strategies, considering the survival benefit and low toxicity profile.

- 198 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP197
Therapy-related myelodysplastic syndrome following treatment for
malignant glioma
Keiichi Sakai1, Tsuyoshi Tada1, Kazuhiro Hongo1
Department of Neurosurgery, Shinshu University School of Medicine, Matsumoto, Japan

1

Objective: Therapy-related myelodysplastic syndrome (t-MDS) is a rare complication of cancer treatment. The prognosis isvery poor. We present three cases of myelodysplastic syndrome (MDS) following treatment for malignant glioma. Clinicalpresentation: Case 1: A 2-year-old boy was diagnosed with anaplastic astrocytoma after gross total removal of the tumor.
The cumulative doses of chemotherapy were 1100 mg MCNU and 590 x 106 IU interferon-beta. Gamma knife therapy wasdone for the recurrent tumor. T-MDS was diagnosed 12 years after the initial treatment. The patient is alive without recurrent
tumor. Case 2: A 10-year-old girl was diagnosed with anaplastic astrocytoma after biopsy. Craniospinal radiation andchemotherapy were performed. The cumulative doses of chemotherapy were 1495 mg MCNU, 915 x 106 IU interferonbeta, 200 mg cisplatin and 100 mg etoposide. Gamma knife therapy was done for the recurrent tumor. t-MDS was
diagnosed 15 years after the initial treatment. The patient is alive without recurrent tumor. Case 3: A 45-year-old man was
diagnosed with anaplastic oligoastrocytoma after partial removal of the tumor. He received chemotherapy and irradiation.
For the recurrent tumor, partial removal was performed. The cumulative doses of chemotherapy were 2400 mg MCNU, 562
mg ACNU, 16 mg vincristine, and 5600 mg procarbazine. t-MDS was diagnosed 7 years after the initial treatment. He diedalthough he received bone marrow transplantation. Conclusions: t-MDS may be a complication of chemotherapy forpatients with brain tumor. Therefore, they should be carefully followed up by regular physical examination and complete
blood counts.

P198
Teniposide and Nimustine Regimen for Malignant Gliomas with O6methylguanine-DNA methyltransferase (MGMT) Negative Expression:Experience of 18 cases
Gang Li1, Zhongping Chen1Department of Neuro-oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China

1- 199 -­­

Poster Presentation (P)[ABSTRACT] BACKGROUND and OBJECTIVE: The present study was to elucidate the efficiency and side effects ofteniposide (VM-26) and nimustine (ACNU) regimen for high grade gliomas ( HGGs) with O6-methylguanine-DNA
methyltransferase(MGMT) negative expression. METHODS: Eighteen HGG patients received previous radiotherapy wereenrolled in this study. The expression of MGMT protein was detected by immunohistochemistry. The regimen consisted of
ACNU 2-3 mg/kg administered once and VM-26 300mg/m2, which was divided for 1-3 days intravenous administration
with every 6~8 weeks a cyc1e. RESULTS: Seventy cycles were admitted and included for evaluation, with the cycle rangeof 2-6(median 3.9) for each patients. No complete response (CR) was achieved, while partial response (PR) in 1 patient(5.6%), minor response(MR) in 13 patients(72.2 %), stable disease (SD) in 3 patients(16.7%), and progressive disease (PD)in 1 patient, respectively. Objective response rate (CR+PR), overall response rate (CR+ PR+MR) and disease control rate
(CR+PR+MR+SD) were 5.6 %, 88.9 %, and 94.4 %, respectively. Median progression free survival (PFS) was 2.6 months(95% CI:2.49-2.90), 6 month PFS was 36%, and median overall survival (OS) was 6.7 months (95% CI: 3.35-11.1).
Myelosuppression including leukopenia and plateletpenia were the most common high grade toxicities (grade 3 and 4). The
incidences of grade III and IV leukopenia were 51.4%(36/70) and 25.7 % (18 / 70), and those of grade III and IV plateletpenia
were 24.3%(17/70)and 12.9 % (9/70), respectively. The incidences of high grade leukopenias and plateletpenias were notrelated to prior chemotherapy(p>0.05). CONCLUSION: VM-26 and ACNU regimen for MGMT negative glioma patients is
acceptable, and may improve overall response rate, disease control rate and 6 month PFS.KEY WORDS:Glioma,
Chemotherapy,Teniposide, NimustineThe 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P199
Safety profile of carmustine wafer treatment in first line treatment ofmalignant glioma with carmustine implants followed by concomitantradiochemotherapy
Alf Giese1, Hans-Christoph Bock1, Veit Rohde1
Department of Neurosurgery, Georg-August-University of Goettingen, Goettingen, Germany

1

Objective
Randomized trials have shown improvement of survival for patients with newly diagnosed malignant gliomas for resection
and implantation of BCNU-wafers followed by radiation and also for postoperative concomitant radiochemotherapy with
TMZ. This has resulted in protocols combining BCNU-wafer and concomitant radiochemotherapy. We have compiled thetreatment experience of 7 neurosurgical centers using implantation of carmustine wafers at primary surgery followed by six
weeks of radiation therapy (59-60 Gy) and 75mg/m2/d TMZ in patients with newly diagnosed glioblastoma.
Patients and methods
We have retrospectively analyzed the postoperative clinical course, occurrence and severity of adverse events, progression
free interval, and survival in 44 patients who received tumor resection, BCNU-wafer implantation and concomitantradiochemotherapy.
Results
Of 44 patients who received gliadel wafer 25 patients (57%) had died and 3 patients (7 %) had progressed at time of data
analysis (mean PFS 7.7 &plusmn 6.3 months). Mean overall survival was 11.3 &plusmn 6.7 months at the time of data
closure with 19 patients alive (median follow up 11.6 &plusmn 8.2 months). Adverse events of any kind were reported for 23
patients (52%) and resulted in therapy delays for concomitant radiochemotherapy (18%) or a deferred start oftemozolomide monochemotherapy (9%). Surgical complications such as wound healing abnormalities (16%), CSF-leakage(11%), meningitis (7%), intracranial abscess formation (5%), cerebral edema ( 25%) and hydrocephalus (7%) were observed.
Unscheduled readmission was required for 19 patients and surgical intervention was necessary in seven. Medical
complications included thrombembolic events and hematotoxicity. Adverse events in 57% occurred during
radiochemotherapy and later during TMZ monochemotherapy (39%).
Conclusion
Our data demonstrate that combination of local chemotherapy and concomitant radiochemotherapy is promising, but
carries a significant risk of toxicity that currently appears underestimated. A modified follow up is required to account for thefrequent occurrence of late adverse events.

P200
THE GROWTH PATTERN OF RECURRENT GLIOBLASTOMA AFTER GLIADEL(TM) WAFER
IMPLANTATION IN FIRST RECURRENCIES
Dietmar Krex1, Patrick Weigel1, Dino Podlesek1, Gabriele Schackert1
Department of Neurosurgery, University Hospital C. G. Carus, Dresden, Germany

1

Poster Presentation (P)Purpose: Although in recent years several approaches for local therapies in the treatment of glioblastoma multiforme havebeen tested in clinical trials, carmustine polymeres (Gliadel(TM) wafer) is the only evaluated local therapy to date. Becauseof the predominance of temozolomide, Gliadel(TM) is frequently used in recurrent gliomas only. However, data about
effectiveness and the pattern of re-recurrences are rare. Therefore, we initiated the present MRI-based retrospective study.
Methods: 37 patients had surgery for first recurrence of glioblastoma, where Gliadel(TM) wafers (n=1-8) were implanted.
Early post-op MRI was performed documenting the extent of resection, tumor remnants and wafer placements. Follow-up
MRI was performed every two months looking particularly for tumor growth in relation to the wafer placements.
Progression-free and overall survivals were recorded. Results: 27 patients were available for evaluation, while 10 patients
had incomplete data. In 24 (88%) patients an early tumor growth was recorded in the first MRI follow-up, 2 months post-op
in areas where the wafers were not implanted. If the wafers had been placed in areas with suspicious tumor according to
the early post-op MRI, tumor progression was recorded in the follow-up in 10 (67%) of 15 patients. If the wafers wereplaced in areas without suspicious tumor remnants (12 patients), regrowth in those areas was recorded only in 4 (33%)
patients, meaning 67% of the patients had no early tumor progression when Gliadel(TM) was placed in tumor-free areas.
However, tumor pseudo-progression has to be taken into account for all cases. Survival data will be determined.
Conclusions: The use of Gliadel(TM) wafer in recurrent glioblastoma is most effective in areas with no tumor remnants,
underlining the meaning of surgical resection of recurrent tumors, also.

- 200 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP201
Pre-radiation chemotherapy with ACNU-CDDP in patients with newly
diagnosed glioblastoma: a retrospective analysis
Jung Ho Han1, Chul-Kee Park1, Chae-Yong Kim1, Sun Ha Paek1, Dong Gyu Kim1, Hee-Won Jung1
Department of Neurosurgery, Seoul National University College of Medicine

1

OBJECTIVE We evaluated the benefit of pre-radiation chemotherapy with ACNU (nimustine) and CDDP (cisplatin) inpatients with newly diagnosed glioblastoma by retrospective analysis. METHODS A total of 151 patients were newly
confirmed to have glioblastoma between January 2000 and December 2004. All patients underwent surgical resection: 38(25.2%) patients underwent complete resection, 73 (48.3%) underwent incomplete resection, and 40 (26.5%) underwent
biopsy. Pre-radiation chemotherapy using ACNU-CDDP was administered as an initial adjuvant therapy for 87 (57.6%)
patients (ACNU-CDDP group), radiation therapy was performed in 31 (20.5%) patients (RT group), and the remaining 33(21.9%) patients were treated with other regimens or refused to undergo further treatment. RESULTS The median survival
time was 13 months (95% CI, 11.29-14.71), and the overall survival rate was 54.0% at 1 year and 21.3% at 2 years. The
differences in median survival time between the complete resection group and biopsy group and between the ACNUCDDP group and RT group were significant (15.0 months vs 10 months, p=0.028; 16.0 months vs 12.0 months, p=0.036)
in the univariate analyses. Even in the multivariate analysis, pre-radiation chemotherapy using ACNU-CDDP had asignificant effect on survival prolongation (HR=0.628, p=0.042). The usage of temozolomide for adjuvant or salvage
therapy also had an independent and significantly positive effect on survival (HR= 0.511, p= 0.006). Grade 3 and 4
hematologic toxicities occurred in 28 (32.1%) patients in the ACNU-CDDP group, but there were no treatment-related
deaths. CONCLUSION Pre-radiation chemotherapy with ACNU-CDDP as an initial therapy has independently beneficial
effects on survival prolongation, with tolerable treatment-related toxicities in patients with newly diagnosed glioblastoma.

P202
A concurrent association radiation therapy fotemustine for newly
diagnosed malignant gliomas, a phase II.
Patrick D Beauchesne1, Luc Taillandier1, Valerie Bernier2, Charlotte Carnin1
Neuro-Oncology/Neurology, CHU de Nancy, Nancy,France 2Radiotherapy, Centre Alexis Vautrin,
Vandoeuvre-les-Nancy, France

1

P203
TOXICITY PROFILE OF VALPROATE AND ETOPOSIDE METRONOMIC CHEMOTHERAPY
Pournima Navalkele1, Margeret Nagel1, David S Hong2, Razelle Kurzrock 2, Johannes E Wolff1,3
1
Dept of Pediatrics, MDAnderson Cancere Center, University of Texas 2Dept. Experimental Therapeutics,
MDAnderson Cancer Center, Univeristy of Texas, USA 3Dept Biostatistics, MDAnderson Cancer Center,
Univeristy of Texas, USA

Introduction: Valproate, an antiepileptic drug, also inhibits histone deacetylase. When given with etoposide the drugs
synergistically induce apoptosis and cell differentiation in vitro (Das J Neurooncol 85:159-70). Here, we describe the toxicity
profile of the valproate and etoposide given as combined oral metronomic dose. Methods: A Retrospective chart review
was conducted for patients treated with both valproate and etoposide. Dose limiting toxicities were categorized according
to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Results: Eight patientswith relapsed CNS malignancies were included (4 males, 4 females; 6 children, 2 adults). The median of individual
maximum blood valproate level was 129 microg/ml (range: 39-221). The most common dose-related side effect was
mucosal thickening seen on MRI (6/7). An episode of grade III hand-foot syndrome with redness, pain and swelling of theskin resulted in discontinuation of etoposide. Other dose limiting toxicities were fatigue (n=2), grade III leukocytopenia(n=5) and grade III mucositis (n=2) in children and thrombocytopenia in adults (n=2), resulting in scheduled dose
reductions. The median of individual Maximum Tolerated Dose (iMTD) for Valproate was 10 mg/kg/day (range 5-37) when
given simultaneously with etoposide (median iMTD 32 mg/m2/day, range 22-54). Discussion: The toxicity profile of thiscombination chemotherapy appears to be age-dependent. Fatigue, mucositis and leukocytopenia were observed as
chronic toxicities. All dose related toxicities were reversible. Conclusion: Bone marrow, skin and mucosal toxicities limit thedose of this combination chemotherapy. The inter-person variability in toxicity was large, requiring further studies.

- 201 -­­

Poster Presentation (P)Purpose: Fotemustine, a nitrosourea compound, is used for the treatment of malignant gliomas, especially in France.
Recently, EORTC NCI Canada have been showed that a concomitant combination radiation therapy temozolomide (oralcytotoxic drug) improve survival in glioblastomas. We are testing a concurrent combination of fotemustine and radiotherapy
for newly malignant gliomas. Methods: A prospective phase II study has opened for accrual in September 2004. Patientsover 18 years of ages who are able to give informed consent and have histological proven, newly diagnosed supratentorial
malignant gliomas are eligible. All patients were treated by a standard cranial irradiation (conformal irradiation, tumor bulk
plus a margin of 2.5 cm) and concomitant daily administration of 10 mg/m2 of fotemustine (5 days per week, 6 weeks, 1hour 30 before radiation therapy). Adjuvant chemotherapy, fotemustine, was administered at tumor progression as standard
and classic regimen. Results: 22 patients have been enrolled in this study, 16 men and 6 women, median age 56 years-old(range 32 to 74), median Karnofsky performance status 70 (range from 60 to 90). Histology included 16 glioblastomas, 3anaplastic astrocytomas, 2 anaplastic oligodendrogliomas and 1 mixed glioma, Surgery (3 total resections) was performedfor 5 patients and stereotactic biopsy for 14 patients. This concurrent association radiation therapy fotemustine has been
well tolerated, the toxicity was mild; three hematologic toxicities as grade III-IV has been observed. Median survival frominitial diagnosis was 9.9 months, two patients currently remain alive. Median survival was 11 months for surgery and 9months for stereotactic biopsy. Conclusions: Concomitant combination fotemustine radiation therapy is safe and welltolerated. Overall survival of over 10 months for all population compares favorably with other reports.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P204
Combination therapy with carboplatin and etoposide for recurrent
malignant gliomas
Keiichi Kobayashi1, Motoo Nagane1, Shigeomi Yokoya1, Yoshiaki Shiokawa1
Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan

1

Background. The current standard care for newly diagnosed glioblastoma (GBM) includes chemotherapy withtemozolomide (TMZ), but no standard regimens have been established for recurrent GBM. We investigated efficacy andtoxicity of combined chemotherapy with carboplatin (CBDCA) and etoposide (VP16) (CBET) for recurrent GBM. Methods.
Forteen patients with recurrent high grade glioma treated with CBET from December 2001 to April 2008 at Kyorin University
Hospital (median age of 52 yo, 19-65; median KPS 70) were included. Since March 2003, the intensified dose regimen(CBDCA 360mg/m2, day 1; VP16 120mg/m2, day 1-3) was applied to 11 cases (anaplastic astrocytomas 2, GBM 9).
Results. Among the 11 patients, three received the treatment as the second line, eight as the third line, and ten (91%) had
undergone previous TMZ therapy. Six patients received only one cycle, while other five did three or more cycles. Stabledisease (SD) was achieved in five patients (45%), but there were no complete or partial responses. The median PFS fromthe start of CBET was 1.7 months, PFS at 6 months was 14%, the median survival from the start of CBET was 5.6 months.
CBET as the second line (p = 0.03) and no history of previous TMZ (p= 0.02) were associated with longer time toprogression in a log-rank analysis. The best response of SD had a statistical impact on overall survival (p=0.02) comparedwith progressive disease. Grade 3 or 4 neutropenia was observed in 100% of patients, thrombocytopenia in 55%, andanemia in 27%. Conclusions. CBET induced a stabilization of disease in a half of recurrent GBMs, but caused a notable
hematotoxicity. TMZ-pretreated GBM tended to fail to respond CBET. Dose modification needs to be considered forfurther application.

P205
Phase II Study of Ifosfamide, Carboplatin and Etoposide for Patients with
Glioblastoma at first relapse
Tomokazu Aoki1, Tomohiko Mizutani2, Kuniharu Nojima3, Takehisa Takagi4, Ryosuke Okumura4,
Yoshiaki Yuba5,6, Tetsuya Ueba1,6, Jun A Takahashi1, Shin-Ichi Miyatake7, Kazuhiko Nozaki8,
Waro Taki9, Masao Matsutani10
Department of Neurosurgery, Kitano Hospital Medical Research Institute 2Department of Neurosurgery, Hyogo Prefectural
Amagasaki Hospital, Hyogo, Japan 3Department of Neurosurgery, Ako City Hospital, Hyogo, Japan 4Department ofRadiation Oncology, Kitano Hospital Medical Research Institute 5Department of Pathology, Kitano Hospital Medical
Research Institute 6Department of Neurosurgery, Kishiwada City Hospital, Osaka, Japan 7Department of Neurosurgery,
Osaka Medical College, Osaka, Japan 8Department of Neurosurgery, Shiga University of Medical Science, Shiga, Japan
9
Department of Neurosurgery, Faculty of Medicine, Mie University, Mie, Japan. 10Department of Neurosurgery, Saitama
Medical University International Medical Center, Saitama
1

Poster Presentation (P)Purpose The prognosis of patients with recurrent glioblastoma is remains unsatisfactory. We conducted a phase II study of
ifosfamide, carboplatin and etoposide ( ICE ) for patients with glioblastoma at first relapse to prolong the useful life. Patientsand methods This was an open-label, single-center phase II study. Forty-two patients with first glioblastoma at first
relapse after surgery followed by standard radiotherapy ( 60 Gy ) with a first-line temozolomide-based or ACNU-based
chemotherapy, were enrolled. The primary endpoint was progression-free survival at 6 months ( PFS-6 ), and secondary
endpoints were response rate, toxicity, and overall survival. Chemotherapy consisted of ifosfamide ( 1000 mg / m2 on day 1,
2 and 3 ), carboplatin ( 110 mg / m2 on day 1 ), etoposide ( 100 mg / m2 on day 1, 2, and 3 ), every 6 weeks. PFS-6 was 35% ( 95%CI, 22 % to 50 % ). The median PFS was 17 weeks ( 95% CI; 10 to 24 weeks ). Response rate was 25 % ( 95% CI,
9 % to 34% ). Adverse events were generally mild and consisted mainly of alopecia. Conclusion This regimen is welltolerated and has some activity and could be one of the options for patients with recurrent glioblastoma.

P206
PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH BRAINSTEM
GLIOMA. PROTOCOL BC-BT-11
Stanislaw R. Burzynski1, Tomasz J. Janicki1, Robert A. Weaver1, Barbara Szymkowski1,
Gregory S. Burzynski1
Burzynski Clinic

1

The aim of this study is to evaluate the outcome of the treatment of brainstem gliomas with ANP. A total of 40 patients wereenrolled, but twelve were not evaluable due to too short a duration of treatment and lack of follow-up MRIs. Among 28
evaluable patients (ST), there were 23 children and five young adults. Twelve patients were newly diagnosed, and sixteen
were previously treated. The additional group of 52 evaluable patients (40 children and 12 young adults) were treated under
special exception (SE), and eighteen of these patients were newly diagnosed. In both ST and SE groups, 92% of patients
suffered from diffuse intrinsic brainstem gliomas (DBSG). ANP was administered daily through a subclavian venous
catheter via a double channel infusion pump. The median duration of treatment was 5.4 (ST) and 5.6 months (SE). The
median of average dosages of A10 was 9.0 g/kg/d (ST) and 9.4 g/kg/d (SE), and AS2-1 0.3 g/kg/d in both groups. ANP
was well tolerated with serious toxicities occurring in less than 10% of patients in both groups including fatigue,somnolence, hypernatremia, hypokalemia, skin rash, polyuria, anemia, vomiting, elevated transaminases, dyspnea, andsubcutaneous extravasation with no chronic toxicities. The responses in both groups were as follows: complete response
18% (ST), 10% (SE), partial response 14% (ST), 4% (SE), stable disease 43% (ST), 54% (SE), progressive disease 25%(ST), 32% (SE). The overall survival (OS) at two years was 36% (ST), 42% (SE), and at 5 years was 25% (ST), 19% (SE).
ANP resulted in marked responses and survival rates in patients with uniformly fatal, inoperable brainstem gliomas. These
results compare favorably to radiation therapy and chemotherapy (Mandell et al 1999, 7% OS at two years and 0% at five
years), but should be confirmed in Phase III trials scheduled to begin in 2009.

- 202 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP207
Treatment of primary malignant gliomas and meningiomas with ruta/calc
phos
Prasanta Banerji1, Pratip Banerji1, Barbara Sarter2
PBH Research Foundation 2University of San Diego, Hahn School of Nursing

1

Purpose: In India, the vast majority of people with brain tumors have no access to conventional therapy. At our community
clinic in Kolkata, India, we use the ultra-dilute medicines Ruta 6 and Calc Phos 3X, prepared according to government
regulated standard pharmacopeias commonly used in homeopathic practice, to treat all brain neoplasms, including thecommonly occurring malignant gliomas and meningiomas. . Previous in vitro studies suggest that Ruta/Calc Phos
selectively induces cell death in brain cancer cells but promotes proliferation in normal peripheral blood lymphocytes. The
purpose of this study was to document our outcomes using this novel non-surgical approach to treatment of primarymalignant gliomas. Methods: A retrospective chart review of 90 gliomas, 58 astrocytomas and 144 meningiomas withtreatment initiated in 2000 and extending into 2007 was conducted. All available clinical, histological and radiologicalrecords for diagnosis and follow-ups were analyzed. Patient reported outcomes (PRO) as well as disease status outcomeswhen available in the clinical records and reports were tallied. We only report on patients who returned for at least one
follow-up visit. Results: : Overall survival rates for gliomas were 74%, 53%, 43%, 39% and 32% at 1,2,3,4 and 5 years
respectively. For the astrocytomas grades 2-4, survival rates were 81%, 66%, 48%, 38% and 35%. Meningioma survival
rates were 99%, 83%, 54%, 39%, and 33%. Of special note is that 21% of the astrocytomas, 22% of gliomas, and 20% of
meningiomas went into complete remission without any surgery, chemotherapy or radiation therapy. The majority ofpatients reported their status as better than before initiating treatment with Ruta/Calc Phos. Conclusions: Treatment with
Ruta/Calc Phos achieved survival rates comparable to conventional aggressive treatment at a fraction of the cost and withno adverse impact on quality of life. Further prospective trials are needed.

P208
Leptomeningeal gliomatosis in patients treated with bevacizumab
Maciej M Mrugala1, Jason K Rockhill1
Departments of Neurology, Neurosurgery and Radiation-Oncology, University of Washington Medical School, Seattle,
WA, USA

1

P209
Response to intrathecal infusions of Depocyte in secondary diffuse
leptomeningeal gliomatosis. A case report.
Patrick D Beauchesne1, marie Blonski1, helene Brissart1
Neuro-Oncology/Neurology, CHU de Nancy, Nancy, France

1

Purpose: Secondary diffuse leptomeningeal gliomatosis, in which a glioma of the brain or spinal cord infiltrates theleptomeninges, is a clinical uncommon metastatic complication of malignant gliomas, for which there is no consensus
regarding treatment. In an ante mortem series in which the diagnosis of leptomeningeal gliomatosis was based onneuroradiological results, an incidence of 2% was reported. The appearance of leptomeningeal gliomatsosis is a preterminal event. Case Report: A 44 year-old woman rapidly developed an intracranial pressure and impairment of cognitive
function. A huge right temporal tumor was diagnosed, and an incomplete resection was performed. Histology was
glioblastoma, a concomitant radiation therapy temozolomide was administered. Her clinical status was sub normal. The firstcourse of adjuvant temozolomide was administered, and in days after, her neurological status suddenly impairment. An
alteration of cognitive function status was noted, she was unable to walk, and aphasia was reported. The neurologicalexamination revealed a confusion, aphasia and walk disabilities. The CSF showed an elevated protein content of 2 g/l, andglucose concentration was low. Cytology of CSF showed no malignant cells. Systemic nitrosourea chemotherapy,
fotemustine, was administered. Intrathecal sustained release cytarabine, Depocyt, was performed (an induction cycle
followed by a consolidation), the patient received 7 intrathecal infusions. Her clinical status dramatically improved, and she
was discharged to medical unit. Conclusions: Intrathecal infusions of Depocyt, sustained release cytarabine,
recommended for treatment of lymphoma neoplastic meningitis, seems to be effective in secondary diffuse leptomeningeal
gliomatosis, temporary remission could be obtain.

- 203 -­­

Poster Presentation (P)Anti-angiogenic therapy is utilized in therapy of malignant gliomas with increasing frequency. While dramatic radiographic
responses and improved survival can be seen in many patients receiving VEGF inhibitors, rapid progression of the diseasehas been observed. We describe our experience with two patients who developed leptomeningeal gliomatosis (LG) during
therapy with bevacizumab.A twenty-eight year old man was diagnosed with pleomorphic xanthoastrocytoma withanaplastic features, WHO grade III, 22 months prior to presentation with LG. At the time of recurrence tissue diagnosis
identified high grade glioma with features of glioblastoma. The patient received therapy with radiation and temozolomide (6adjuvant cycles). He was then found to have a subependymal nodule in the left frontal lobe and received stereotactic
radiosurgery. Bevacizumab and irinotecan were started. After 2 cycles patient worsened clinically and his MRI identified
extensive FLAIR changes involving both hemispheres and ventral brainstem with leptomeningeal enhancement. A twentyeight year old man was diagnosed with ganglioglioma WHO grade I, 35 months prior to presentation with LG. Initial therapy
included resection with subsequent radiotherapy. Patient progressed 23 months later and tissue diagnosis confirmed highgrade glioma with features of glioblastoma. Temozolomide was introduced for 6 cycles. At the time of second progression
patient was treated with bevacizumab and carboplatin. After receiving 1 cycle of therapy he was found to have extensive
intracranial disease with leptomeningeal involvement. Leptomeningeal gliomatosis is a rare complication of malignant
glioma. It is of great importance to identify which patients are at risk for this complication and as our report indicates age
and secondary vs. primary glioblastoma might play an important role. Since it was recently recognized that bevacizumab
can alter patterns of recurrence in malignant gliomas, this report is very timely and implicates possible deleterious effects ofanti-angiogenic therapies in this malignancy.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P210
New therapeutic approach for brain tumors: intranasal administrationof Ras inhibitor monoterpene perillyl alcohol.
Clovis Fonseca1, Thereza Qurico-Santos1
Universidade Federal Fluminense 2Universidade Federal Fluminense
Perillyl alcohol (POH) is a monoterpene with preclinical antitumor activity which proposed mechanism of action involves
inhibition of post-translational isoprenylation of small G proteins, including p21-Ras, thereby blocking signal transduction.
Deregulated p21-Ras function, as a result of mutation, overexpression or growth factor-induced overactivation, contributes
to growth of malignant gliomas. Intranasal administration is a practical and non-invasive approach that allows therapeutic
agents which do not cross the blood-brain barrier to enter the Central Nervous System, reducing unwanted systemic side
effects. Applying this method we performed a phase I / II study of POH in patients with relapsed malignant gliomas after
standard treatment. POH was administrated in concentration (55mg) 4 times daily. The objective of this study was toevaluate the toxicity and progression-free survival after 6 months of treatment. The cohort consisted of a total of 68 patientswere investigated, 52 (76.4%) with glioblastoma (GBM), 10 (14.7%) with anaplastic astrocytoma (AA) and 6 (8.8%) withanaplastic oligodendroglioma (AO). Neurological examination and suitable image analysis established disease progression.
After 6 months of treatment it was observed the following: Partial Response: 4% (n=2) with GBM and 33% (n=2) with AO;
Stable Disease: 44% (n=23) with GBM, 60% (n=6) with AA and 33.3% (n=2) with AO; Progressive Course: 52 % (n= 27)
with GBM, 40% (n=4) with AA and 33% (n=2) AO. The progression free survival (sum of partial responses and stabledisease) was 48.2% for patients with GBM, 60% for AA patients and 66.6% for AO patients. The present work indicate forthe first time, that intranasal administration of the signal transduction inhibitor, perillyl alcohol, is a safe, non invasive, lowcost and regression of tumor size in some patients is suggestive of antitumor activity.

1

P211
Cetuximab does not influence Serum Magnesium Homeostasis in Patientswith Glioblastoma Multiforme treated with concomitant Radiotherapy
and Temozolomide
Stefan Rieken1, Angela Mohr1, Thomas Welzel1, Juergen Debus1, Stefanie Milker-Zabel1,
Michael Platten2, Wolfgang Wick 2, Stephanie E. Combs1
Department of Radiooncology, University of Heidelberg, Heidelberg, Germany 2Department of Neurooncology,
University of Heidelberg, Heidelberg, Germany

1

Poster Presentation (P)Purpose: In 2008, 5 years after introducing epidermal growth factor receptor (EGFR) targeting antibodies into cancer
therapy, several authors demonstrated that in colorectal cancer patients early serum magnesium (Mg2+) reduction caused
by weekly infusions of irinotecan and cetuximab, a monoclonal antibody to EGFR, may serve as a positive predictor oftherapy response and outcome. Gradual decrease of serum Mg2+ was attributed to insufficient activation of renal epithelial
EGF dependent Mg2+ channels.
Whether EGFR-inhibition influences Mg2+ homeostasis and treatment response in patients with glioblastoma (GB) has notbeen addressed to date. Following the GERT phase I/II protocol, patients with primary GB are treated with radiation andconcomitant temozolomide as well as weekly infusions with cetuximab. We analysed serum Mg2+ concentrations inpatients and studied possible associations with efficacy and outcome.
Methods: Thirty-nine patients have until now entered the protocol and were included in this analysis. Cetuximab wasgiven at a loading dose of 400 mg/m2 one week prior to radiochemotherapy, followed by a total of six weekly infusions of
250 mg/m2. Chemotherapy consisted of concomitant and adjuvant temozolomide according to the EORTC 22981/26981
protocol. Serum Mg2+ levels were measured prior to study enclosure and weekly afterwards. Statistical analysis was
performed via Students t test.
Results: No significant decrease in serum Mg2+ levels was detected, neither during EGFR inhibition nor during the first two
hundred days after initial cetuximab exposure. Even though two patients displayed early Mg2+ reductions of > 20% within
the first 21 days after the loading dose of cetuximab, average Mg2+ levels remained stable (p < 0,05).
Conclusion: In contrast to reported data on colorectal cancer patients, addition of cumulative doses of 1,900 mg/m2
cetuximab to standard radiochemotherapy does not cause significant reduction in serum Mg2+ levels in patients withglioblastoma.

- 204 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP212
A retrospective single institutional analysis of cilengitide (CGT) andchemotherapy for heavily pre-treated recurrent glioblastoma
multiforme (GBM).
Mustafa Khasraw1, Nick Pavlakis1, Helen Wheeler1
Royal North Shore Hospital 2Royal North Shore Hospital, RNSH, Pacific HWY, St Leonards NSW 2065 Australia

1

Background: CGT, an integrin inhibitor, has been shown to have activity in the treatment of recurrent glioblastoma in
combination with chemotherapy in Phase II trials. Methods: We conducted a retrospective analysis of all patients treated at
our institution for recurrent GBM with CGT containing regimens. Results: Between 1/2008 and 12/2008 15 patients withrelapsed GBM received CGT 2000mg given by intravenous infusion 2 times per week. The median age was 51. The ECOG
performance status was 1-2. Multi-focal GBM was present in 7 patients. All patients had previous postoperative
radiotherapy (60Gy in 42 # over 6 weeks) as part of the initial management. 10 patients had multiple craniotomies. 10
patients had primary GBM and 5 were initially grade III with transformation to GBM on subsequent biopsy. 8 patients hadprior concurrent chemo-radiotherapy with temozolomide (T). 11 patients had previous bevacizumab (B) in combination withchemotherapy, 6 with good response. All 15 patients had chemotherapy prior to CGT: T (n = 3), T with procarbazine (P) (n =3), carboplatin (C) and etoposide(E) (n = 3), PT followed by CE (n = 5) or E alone (n = 1).CGT was administered with thefollowing: PT (n = 12), E (n = 3), B with CGT (n = 5). The median number of CGT doses given was 22. Stable disease (SD)was achieved in 10 and progressive disease (PD) in 4 patients. Partial response (PR) was seen in one case. The median
duration of response was 10 wks (range 3-21 weeks). Toxicity was minimal and most likely attributable to the concomitantchemotherapy. There was one grade II thrombocytopenia and one grade I neutropenia. There were no infusion reactions,no nausea and vomiting, no acute haemorrhage or thrombotic problems and no wound dehiscence. 4 patients were still on
treatment at time of writing this abstract. 1 discontinued because of exhaustion and 10 because of progressive disease.
Conclusions: In this uncontrolled series CGT was observed to be extremely safe given with chemotherapy and/ or B, withsome activity observed. Prospective evaluation of CGT in combination with other treatments is warranted.

P213
Cilengitide modulates attachment and viability of human glioma cells,
but not sensitivity to irradiation or temozolomide in vitro
Gabriele Maurer1, Isabel Tritschler1, Barbara Adams1, Ghazaleh Tabatabai1, Wolfgang Wick 2,
Roger Stupp3, Michael Weller4
1
Hertie-Institute of Clinical Brain Research, Tuebingen, Germany 2Department of Neurooncology, German Cancer
Research Center, Heidelberg, Germany 3Centre Hospitalier Universitaire Vaudois and University of Lausanne,
Lausanne, Switzerland 4Department of Neurology, Laboratory of Molecular Neuro-Oncology, University Hospital
Zurich, Zurich, Switzerland

P214
METABOLIC FACTORS GOVERN THE CYTOTOXIC POTENTIAL OF EGFR INHIBITION IN
HUMAN MALIGNANT GLIOMA CELLS
Johannes Rieger1, Christina Nordhammer1, Ulrike Naumann2, Michael Weller3,
Joachim Steinbach1, Stefan Wolking2
Dr. Senckenberg Institute for Neurooncology, University of Frankfurt, Frankfurt, Germany 2Laboratory for
Neurooncology, Department of General Neurology and Hertie-Institute for Clinical Brain Research, University of
Tuebingen, Germany 3Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, Zurich, CH-8091,
Switzerland
1

Inhibition of epidermal growth factor receptor (EGFR) signaling efficiently sensitizes human malignant glioma cells towards
apoptosis induced by death ligands, radiotherapy and chemotherapy in vitro. In clinical trials, however, EGFR inhibition has
generated disappointing results in glioblastoma patients. We have recently found that EGFR inhibition confers protection
from hypoxia-induced cell death by decreasing energy demand. Here, we have characterized in detail the importance ofoxygen and glucose availability for the modulation of cell death by EGFR inhibition. The EGFR inhibitors PD153035 anderlotinib profoundly inhibited cell death under starvation conditions (0.1% O2 and 2 mM glucose). With increasing O2 andglucose concentrations, EGFR inhibition progressively induced cytotoxicity. Whereas cell death under starvation conditions
was necrotic, cytotoxic conditions induced caspase activation and a sub-G1 peak, indicating apoptosis. EGFR inhibition
also resulted in a decrease in mitochondrial membrane potential preceding cell death under cytotoxic conditions,suggesting mitochondrial injury. We further examined whether cell death was mediated by reactive oxygen species (ROS).
ROS were not induced by EGFR inhibition, and antioxidants did not inhibit its toxicity. The protective effects of EGFR
inhibition towards hypoxia-induced cell death, but not the cytotoxic effects, were mimicked by inhibition of PKB/Akt.
Notably, protection from hypoxia was also conferred by EGFR inhibition in HCT116 cells. These data demonstrate thatmetabolic conditions govern the effects of EGFR inhibitors on glioma and colon carcinoma cell viability and suggest that the
microenvironment of solid tumors may be responsible for the low clinical activity of these promising therapeutics.

- 205 -­­

Poster Presentation (P)Cilengitide is a cyclic peptide antagonist of integrins &alpha&nu&beta3 and &alpha&nu&beta5 which is currently evaluated as anovel therapeutic agent for recurrent and newly diagnosed glioblastoma. Its mode of action is thought to be mainly
antiangiogenic, but may include direct effects on tumor cells, notably on attachment, migration, invasion and viability. Here weshow that cilengitide induces detachment in some glioma cell lines, while the effect on cell viability is modest. Detachment
induced by cilengitide could not be predicted by the level of expression of the cilengitide target molecules at the cell surface.
Glioma cell death induced by cilengitide was associated with the generation of caspase activity, but caspase activity wasdispensable for cell death since ectopic expression of cytokine response modifier (crm)-A or the broad spectrum caspase
inhibitor, zVAD-fmk, were not protective. Moreover, forced expression of Bcl-XL or altering the p53 status did not modulatecilengitide-induced cell death. No consistent effects of cilengitide on glioma cell migration or invasiveness were observed in vitro.
Neither ectopic expression of MGMT in MGMT-negative cells nor silencing the MGMT gene in MGMT-positive cells altered their
response to cilengitide alone or cilengitide in combination with temozolomide. These data suggest that the beneficial clinicaleffects derived from cilengitide in vivo may arise from altered perfusion which promotes temozolomide delivery to glioma cells.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P215
AN EPIGENETIC GENOME-WIDE SCREEN IDENTIFIES THE SFRP FAMILY OF WNTSIGNALING INHIBITORS AS NOVEL TUMOR SUPPRESSOR GENES IN
MEDULLOBLASTOMAPaul N. Kongkham1, Paul A. Northcott1, Michael D. Taylor1, James T. Rutka1
The Hospital for Sick Children, Division of Neurosurgery, University of Toronto, Toronto, Canada

1Medulloblastomas (MB) are the most common pediatric nervous system malignancy. Despite treatment, mortality rates
remain 30%. Known mutations account for only a subset of MB cases. We hypothesize that screening for tumor
suppressor genes (TSGs) silenced by promoter CpG island methylation may uncover TSGs not previously described in MB.
We performed an epigenome-wide screen of 9 MB cell lines treated with decitabine using Affymetrix HG U133 plus 2.0
expression arrays, identifying genes with increased expression following treatment. We identified 3 members of the SFRP
family of Wnt signaling inhibitors as putative TSGs silenced by promoter methylation in MB. The SFRP gene family consistsof 5 members: SFRP1, SFRP2, SFRP3, SFRP4, and SFRP5. Of these, only SFRP1, SFRP2, and SFRP3 were appreciably
expressed in normal cerebellum, and demonstrated increased expression in a subset of MB cell lines following treatment.
We confirmed methylation of the SFRP1, SFRP2, and SFRP3 promoter regions using bisulfite sequencing, and foundaberrant methylation in 12/51, 2/51, and 8/51 primary MB tumors by methylation specific PCR, respectively. TSG function
was assessed through stable reexpression of SFRP1, SFRP2, and SFRP3 in the D283 and ONS76 MB cell lines.
Reexpression of each gene reduced MB cell proliferation by MTS assay. SFRP1, SFRP2, and SFRP3 reexpression in D283
cells reduced its ability to form colonies in soft agar. Reexpression of these Wnt signaling inhibitors also limited Wnt
signaling axis activity, as evidenced by reduced phosphorylated DVL2 levels by western blotting. Aberrant Wnt signaling is
known to play a role in the pathogenesis of a subset of MB cases. We have identified for the first time a novel mechanism(loss of normal pathway inhibition) that contributes to upregulated Wnt signaling in this disease.

P216
SILENCING OF NEURONAL DIFFERENTIATION GENES REVEALED BY PROFILING THE
MEDULLOBLASTOMA EPIMETHYLGENOME
Adrian Dubuc1, Stephen Mack1, Yukiko Nakahara1, Paul A. Northcott1, Paul N. Kongkham1,
Steve Baylin2, Neil D. Watkins2, Michael D. Taylor1
The Hospital for Sick Children, University of Toronto, Toronto, Canada 2Cancer Biology Division, The Sidney Kimmel
Comprehensive Cancer Center at John Hopkins, Baltimore, MD

1

Poster Presentation (P)In order to identify novel genes and pathways deregulated in medulloblastoma, we carried out a genome-wide screen forgenes silenced through methylation of promoter CpG islands. We screened seven medulloblastoma cell lines by treatment
with either 5-aza-deoxycytidine (DAC), or Trichostatin A (TSA), followed by hybridization of RNA to expression
microarrays. We identified 1102 genes that exhibit increased expression (>2-fold) upon treatment with DAC, but which did
not increase in expression after TSA treatment alone (<1.4-fold). We then performed
Methylated DNA ImmunoPrecipitation (MeDIP) on eight cell lines as well as normal adult and fetal cerebella. Methylation enriched DNA was thencompared to methylation impoverished DNA (wash fraction) by hybridization to a genome-wide CpG island promoter
array (MeDIP-ChIP). Of the 1102 genes that increased in expression with DAC, 333 were specifically methylated at theproximal CpG island in MB cell lines versus normal adult cerebellum in one or more cell lines (P<0.01). To determine if
genes targeted by promoter methylation in cell lines were also silenced in human primary tumors, we subsequently
integrated gene expression data derived from 112 primary medulloblastomas and 14 normal fetal and adult cerebella. Of
the 333 methylated candidate genes identified above, 99 showed greater than two-fold down regulation in >10% of primarytumors as compared to normal controls. Strikingly, 20/99 (20%) genes have known roles in neuronal differentiation andsynaptogenesis such as LRRC4, BHLHB5 and CYP26B1, suggesting that avoidance of terminal neuronal differentiation isa critical event in medulloblastoma pathogenesis. Additionally, negative regulators of the Wnt pathway (5/99) and the
CXCR4-CXCL12 chemokine axis (5/99) were also frequently targeted. Poorly characterized genes made up a large
fraction of silenced, methylated genes (15/99). These data demonstrate the utility of combining DAC screening with
MeDIP-ChIP, and suggest that differentiation agents should be considered in the treatment of medulloblastoma.

- 206 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP217
Pediatric intracranial germ cell tumors of different prognosis
outcomes and ethnic background inherit characteristic embryonic stem
cell traits and microRNAome profiles
Hsei-Wei Wang1, Allen YH Wu1, Tai-Tong Wong2
Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan 2Department of
Neurosurgery, Neurological Institute, Veterans General Hospital Taipei, Taipei, Taiwan

1Intracranial pediatric germ cell tumors (PGCTs) are rare and heterogeneous neoplasms with different clinical behaviors.
About 40 to 50% of intracranial PGCTs are germinomas, which are classified in the good prognostic group with mature
teratoma. In contrast, PGCTs of other types, including yolk sac tumor (YST), embryoncal carcinoma (EC), immature
teratoma and mixed PGCTs of these subtypes, are recognized as poor prognostic ones which are resistant to drug or
irradiation treatment. The underlying mechanisms are not clear yet. We applied genomics approaches to unmask thetranscriptome compositions of Asian intracranial PGCTs and then compared them to those of Caucasian cases. Clear
microRNAome and mRNA profiles associated with tumor prognosis were identified. Differentially expressed microRNAs
were confirmed by real-time PCR. Genes responsible for self-renewing pluripotent and apoptosis phenotypes wereabundant in germinoma and mature teratoma, while genes associated with differentiation, tumor invasiveness andepithelial-mesenchymal transition (EMT) in PGCTs of poor prognosis. We also observed complex microRNA and gene
networks functioning in different PGCTs, in which Wnt pathway genes such as beta-catenin acted as hubs to maintain thestability and connectivity of the whole genetic network in poor prognostic PGCTs. MicroRNAs inhibiting angiogenesis genes
in the same genetic network were also down in poor prognostic PGCTs. We further compared these findings withpublished Caucasian PGCT data, and found clear segregation between Asian and Caucasian cases, with Asian malignant
PGCTs being the closest ones to embryonic stem cells. We conclude that the observed clinical differences between PGCTs
of different prognosis types and ethnic background are mirrored by significant differences in global microRNA and mRNA
expression, and that unique stem cell traits are associated with clinical outcomes of PGCTs and reflect the origins ofdifferent PGCTs. Genes and microRNAs identified hold the potential of being novel therapeutic targets in further
differentiation therapy.

P218
The frequent expression of ARF-BP1 in primary intracranial germ celltumorsKazuo Washiyama1, Hiroshi Usui1, Yukihiko Fujii2, Ryuichi Tanaka2, Toshiro Kumanishi3
Department of Molecular Neuropathology, Brain Research Institute, Niigata University, Niigata, Japan 2Deapartmentof Neurosurgery, Brain Research Institute, Niigata University 3Niigata Longevity Research Institute1

P219
Frequent single nucleotide polymorphism (SNP) of BCL10 and association
with poor prognosis in primary intracranial germ cell tumors
Yutaka Hayashi1, Takuya Watanabe1, Daisuke Kita1, Mitsutoshi Nakada1, Junkoh Yamashita1,
Jun-ichiro Hamada1
Department of Neurosurgery, Kanazawa University Hospital, Kanazawa, Japan

1

Intracranial germ cell tumors (ICGTs) are uncommon neoplasms, but they occur more frequently in the Japanese
population than the West. Little is known about the mechanisms of ICGTs development and the reasons for its Japanesepropensity. Recently, the BCL10 gene, which is a proapoptotic signaling molecule involved in the Apaf-1/caspase-9 cell
death pathway, may act as tumor suppressor gene in multiple types of tumors including testicular germ cell tumors. To
evaluate whether genetic alterations of the BCL10 gene occur in the genesis of ICGTs, we analyzed the BCL10 gene in 20
ICGTs ; 10 pure germinomas (PG) and 10 nongerminomatous germ cell tumors (NGGCT). While no inactivating mutations
were found, five of 10 cases (50%) of PGs and one case of 10 NGGCTs had specific single nucleotide polymorphism (SNP)
that carried an amino acid substitution at codon 5 in exon 1 or codon 162 in exon 3. This specific SNP is also known tooccur at higher frequency than in healthy individuals. In addition, four of 6 cases (66%) with SNP suffered from CSF
dissemination (p = 0.037). These data suggested that this specific SNP in the BCL10 gene may be partly responsible for thetumorigenesis of pure germinoma in Japanese individuals, and may associated with aggressive nature of the tumor.

- 207 -­­

Poster Presentation (P)Background and Purpose; The ARF binding protein 1 (ARF-BP1) directly binds and ubiquitinates p53, and this activity is
inhibited by ARF. The alterations of p53 gene are rare in intracranial germ cell tumors (GCTs). The ARF gene is frequently
deleted in intracranial GCTs. To analyze the role of ARF-BP1, the immunohistochemical study was performed for primary
intracranial GCTs. Materials and Method; A total of 33 formalin fixed, paraffin embedded intracranial GCT specimens wereused and previously diagnosed by H.E., CK, HCG, AFP, PLAP staining. 27 pure GCTs (20 germinomas, 3 yolk sac tumors,
2 choriocarcinomas, and 2 teratomas), and 6 mixed GCTs (including 5 foci of germinomas, 2 embryonal carcinomas, 2 yolksac tumors, 4 teratomas) were prepared for the immunohistochemical study of ARF-BP1 protein. Result; ARF-BP1 waspositive in 18 of 20 germinomas, in 2 of 3 yolk sac tumors, in 2 of 2 choriocarcinomas, in 0 of 2 teratomas, and in 6 of 6
mixed GCTs. ARF-BP1 showed relative over-expression in germinoma compared with the other types of GCT. The
frequency of nuclear and/or cytoplasmic expression of ARF-BP1 was various in each case. Conclusion; The highfrequency of the positivity of ARF-BP1 suggests that the ARF-BP1 is a key molecule in the pathogenesis of primary
intracranial GCTs.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P220
EXPRESSION PROFILES OF MICRORNA IN PEDIATRIC MALIGNANT GLIOMAS
Muh-Lii Liang1, Hsei-Wei Wang1, Meng-En Chao1, Tai-Tong Wong1
Department of Neurosurgery, Neurological Institute, Veterans General Hospital Taipei, Taipei, Taiwan 2Institute ofMicrobiology and Immunology, Institute of Clinical Medicine, National Yang-Ming University 3Department of
Neurosurgery, Neurological Institute, Veterans General Hospital Taipei, Taipei, Taiwan 4Department of Neurosurgery,
Neurological Institute, Veterans General Hospital Taipei, Taipei, Taiwan

1

Purpose: Pediatric malignant gliomas occur rarely as compared to the counterparts of adult patients. The concept of
distinct tumorigenesis between pediatric and adult patients leading to the common phenotype of malignant gliomas havegained general acceptance in the decade. In recent years, the studies of microRNA(miRNA) demonstrated that miRNAs
could target mRNAs which oncogene and tumor suppressor gene transcribed. Through this way, they will also act theeffect of tumor suppression or oncogenesis. Methods and materials: In order to elucidate the key contribution of miRNAin glioma tumorigenesis and the related pathways, we carried out expression profiling of miRNA in pediatric malignant
gliomas, neural stem cells (NSC) and mesenchymal stem cells (MSCs) by miRNA microarray. Results: Our data showedbulk tumor become more stem cell-like during grade 2, 3 & 4 tumors. Many down-regulated miRNAs are also down in stem
cells. One of which is miR-296, which can target Nanog and relate to the property of stemness and malignancy. Oncogenic
miRNAs, such as miR-122, are also up-regulated in our pediatric glioblastomas samples. Conclusion: By targeting thegenes and microRNAs we identified, it will hold the potential of discovering novel tumorigenesis mechanism and developing
further differentiation therapy for pediatric gliomas.

P221
STRESS LEVELS AMONG PARENTS OF CHILDHOOD BRAIN TUMOR SURVIVORSJin-Shei Lai1, Zeeshan Butt1, Stewart Goldman2
1
Center on Outcomes, Research and Education, Northwestern University and NorthShore University HealthSystem,
Evanston, IL, USA 2Children’s Memorial Hospital at Chicago, Chicago, IL, USA

AIM. Few studies of childhood brain tumor survivors have focused on the stress of survivors' parents, which can play animportant role in survivor well-being. The purpose of this study was to better understand the range of stress experienced byparents of brain tumor survivors. METHODS. 72 parents of childhood brain tumor survivors who were at least one year
past treatment were recruited. For survivors, mean age = 10.7 years, mean time since last treatment = 2.6 years, 36.6%
had low grade astrocytoma and 15.5% had ependymoma. Parents (79% mothers) mean age=41.2 years, 88.9% were
married, 82% had at least college degree. Most parents reported survivors having good (19.1%), very good (33.3%), or
excellent (33.3%) quality of life in general. Parents were asked to complete the 15-item Impact of Events Scale (IES), which
was designed to evaluate specific life event stress (i.e., their child's brain tumor). In addition to a total subjective stressscore, the IES can also produce two subscale scores: intrusion and avoidance. Cut-off scores are available to determine
range of stress (subclinical, mild, moderate and severe) for ease of intepretation. RESULTS. Only 28.2% of the parents
exhibited subclinical stress. 46.1% parents showed mild range of stress, 21.1% moderate and 5.6% severe. There was no
significant difference between fathers and mothers on total subjective stress (p=0.09), avoidance (p=0.06) or intrusion(p=0.22). No significant correlation between years since the last treatment and stress, avoidance and intrusion (p&gt0.05
for all three comparisons) were identified. CONCLUSIONS. Most parents of childhood brain tumor survivors reported
clinically significant levels of stress even considering that they rate their children's quality of life as being good more than
one year after treatment. Further research is necessary to determine predictors of paternal stress in this population.

Poster Presentation (P)P222
MULTI-TIERED INTERVENTION STUDY FOR PATIENTS, CARERS AND HEALTHPROVIDERS TO ADDRESS CHALLENGING BEHAVIOURS AFTER BRAIN TUMOUR
Eng-Siew Koh1,7, Diane Whiting2, Grahame Simpson3,7, Teresa Simpson4,7, Kylie M. Wright5,7,Rochelle Firth6, Kathryn Younan2
1
Liverpool Cancer Therapy Centre, Liverpool Hospital, University New South Wales, Sydney, Australia. 2Brain Injury
Rehabilitation Studies Unit, University of Sydney, Sydney, Australia. 3Brain Injury Rehabilitation Unit, Liverpool Hospitaland Rehabilitation Studies Unit, University of Sydney, Sydney, Australia. 4Liverpool Cancer Therapy Centre, Liverpool
Hospital, University New South Wales, Sydney, Australia. 5Department of Neurosurgery, Liverpool Hospital, Sydney,
Australia. 6Department of Neurosurgery, Royal North Shore Hospital, Northern Sydney Central Coast Area HealthService, Sydney, Australia. 7New South Wales Oncology Group , Neuro-oncology, New South Wales Cancer Institute,
Sydney, Australia.

Purpose: Untreated cognitive/behavioural impairments (challenging behaviours, CBs) associated with brain tumour (BT)adversely affect functional status and quality of life. A "Behavioural Consultancy" approach is a psychosocial intervention to
manage the person with CBs within their naturalistic environment. Compensatory strategies are introduced that can be
adopted by the person with BT themselves, or utilised by family members (carers) and staff to structure the environment tominimise the impact of CBs. This study piloted a multi-tiered intervention (individual, carers, staff) to treat CBs after BT
utilizing the Behavioural Consultancy model. Methods: Participants for the individual and family interventions wererecruited from a broader prevalence study of CBs after BT. For the individual case, a single case experimental design was
employed to evaluate the efficacy of skill-based training and environmental changes in managing excessive talking in awoman with a benign BT. For the carer intervention, a half-day workshop to train seven carers in the use of compensatory
strategies to manage CBs was trialled. Finally, 43 allied health staff from neurosurgical and cancer services attended a oneday training workshop in the Consultancy approach. A pre-post impact evaluation was employed for both workshops,
employing a purpose-designed Strategies Use Measure. Results: All three interventions demonstrated positive results.
The single case (n=1) showed a 71% decrease in time in excessive talking after the Consultancy intervention. Three monthfollow-up found the subject maintaining a 38% decrease from baseline, emphasising the need for ongoing environmental
supports. Participants attending the carer workshop demonstrated significant post-intervention increases in perceived
knowledge of Strategy Use (t = 3.33, p<.05). Similarly, staff attending the full-day workshop recorded significant posttraining gains in knowledge of Strategy Use (t = -10.76, p<.001). Conclusions: The potential efficacy of a Consultancy
approach can be demonstrated at the level of individual patients, carers and health providers alike.

- 208 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP223
Knowledge and Attitudes On The Diagnosis, Treatment And Prognosis
Among Patients With Brain Tumor And Their Caregivers in a Tertiary
Hospital
Natasha L. Fabiana1, Jessie T. Colacion1, Julette Marie F. Batara1
Department of Neurosciences, Section of Adult Neurology, University of the Philippines, Philippine General Hospital

1

Background: Quality of life (QOL) studies show that brain tumors and treatment have physical, cognitive, and emotional
effects on patients and caregivers. It is prudent to study first how the subjects understand the disease. This may correct
misconceptions, enhance effective treatment and lead to better QOL study results. Objectives: This study aims todetermine the knowledge and attitudes on diagnosis, treatment and prognosis among the subjects in a tertiary hospital.
Methods: A 14-item questionnaire was drawn from a previous qualitative study on brain tumors. Descriptive analysis wasused. Results: During the one month study period, 30 patients and 20 caregivers were tested. Majority were females,
unemployed, with mean age of 44.75. Forty-three percent of patients finished secondary education; 40% of caregivers
graduated college. Memory has been mainly affected by the illness. Most participants said that brain cancer is different
from systemic cancers. Majority assumed that brain tumors can be cured and are not infectious. A few thought it equates
to death (26% patients; 45% caregivers). Sixty-six percent of patients and 60% of caregivers said that brain tumors arehereditary. Frequent head trauma was the most commonly cited cause of brain tumors (66% patients; 70% caregivers).
Majority (93.3%) did not choose between quality rather than prolongation of life. Family was most influential in treatment
choices. Spiritual beliefs greatly helped them cope with their infirmity. Thirty-three percent of patients and 25% ofcaregivers believed in mercy killing. Conclusion: There is lack of knowledge on brain tumors among patients and theircaregivers. Most subjects did not understand the concept of quality vs. quantity of life. Hope and spiritual belief are their
key strengths. Majority avoided active decision making in treatment options. Therefore, it is essentially important tounderstand the mindset of brain tumor patients and their caregivers in order to provide comprehensive care.

P224
Management of Primary Malignant Brain Tumors During Pregnancy
Julette F. Batara1, Stuart A. Grossman1
1
Dept. of Neurosciences, St. Luke’s Medical Center, Quezon City, Philippines 2Sidney Kimmel Comprehensive Cancer
Center, Johns Hopkins MedicalInstitutions, Baltimore, Maryland, USA

P225
Cancer Stem Cells from Glioblastoma Multiforme Patients
Wen-Yu Cheng1, Chiung-Chyi Shen1, Shiuh-Dung Lee1, Meng-Yin Yang1, Yuang-Seng Tsuei1
Department of Neurosurgery, Taichung Veterans General Hospital, Taiwan, ROC

1

Glioblastoma multiforme (GBM) in current clinic diagnosis was highly malignancy because of the survival rate of patientswas approximately only 15% at two years even those patients have offered to standard-of-care therapy includes surgicalresection radiotherapy, and temozolomide, administered both during and after radiotherapy. However, again recurrence
revealed that small subset of cells and drugs resistance population sufficient to form a new tumor according to current
cancer stem cell hypothesis. In our progress reports, we present data showed that isolated tumor stem cells from GBM
patient have seemed to establish a standard protocol including self-renewal in vitro and tumor-initiated in nude mice. In
addition, used to identified cancer stem cell marker: CD133 and Nestin was present positive in our tumor spheres. Tumor
spheres of differentiation ability of both neurons and astrocytes lineage existed at serum condition. We have also foundsome properties in tumor spheres including aggregation of tumor spheres, rich in alkaline phosphatase : embryonic stem
cell enzymic activity, altered nuclear morphologies at differentiation condition, and to stand seized ability of highly migrationand invasion. CD44 surface molecular relating to vessel was high expression at cancer stem cells derived cancer cell atserum condition, but absent at tumor spheres.In summary, we indeed established a method for isolation of cancer stem
cells from GBM patients no matter how present data in vitro or in vivo. In further, we hope that these cancer stem cells
could help us to understand how the ability of cancer stem cells to against chemotherapy and finally find out several
methods for absolute eliminating cancer.

- 209 -­­

Poster Presentation (P)The incidence of brain tumors is reduced by about 64% in the pregnant population compared to nonpregnant women ofsimilar age. Although rare, they are worthy of consideration in that, of all the diferent cancers seen arising during pregnancy,
brain tumors carry perhaps the greatest potential for maternal and fetal death. Moreover, there is almost always a conflict ofinterest between optimal maternal therapy and fetal well-being that emotionally taxes both patient and physician alike. The
maternal interest may require an immediate treatment of the recently diagnosed tumor, however, the optimal therapy may
impose great risks to the fetus.This is is an extensive literature review leading to a suggested algorithm for the treatment ofbrain tumors in pregnancy.An extensive literature review revealed several case reports and a few small retrospective caseseries. Clearly, randomized studies are not possible in this situation and decisions hence have to be made on a case tocase basis. This study is a review dealing with the dilemmas in the diagnosis and treatment of primary malignant brain
tumors in pregnancy, the use of diagnostic modalities and its effect on the developing fetus.It provides guidelines for
optimum treatment of these tumors, delineating first the present standard of care for the various tumor types as it relates topregnancy and subsequently the attendant risks of neurosurgery, radiation, chemotherapy and ancillary medications suchas corticosteroids and anticonvulsants, in a pregnant patient.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P226
Characterization of Cancer Stem-like Cells Derived from Human
Glioblastomas
Masamichi Takahashi1, Yasushi Ino2, Junji Shibahara3, Nobuhito Saito1, Tomoki Todo2
1
Department of Neurosurgery, the University of Tokyo, Tokyo, Japan 2Translational Research Advancement Center,the University of Tokyo, Tokyo, Japan 3Department of Pathology, the University of Tokyo, Tokyo, Japan

It has been recognized that cancer stem-like cells play an important role in progression in brain tumors. We aimed to study
the characteristics of cancer stem-like cells derived from human brain tumors. Thirteen surgically obtained brain tumor
specimens were used that included 9 glioblastomas, 1 medulloblastoma, 1 pleomorphic xanthoastrocytoma (PXA) withanaplastic features, 1 anaplastic astrocytoma and 1 oligodendroglioma. Tumor-derived cells were cultured in serum-free
media, containing EGF and bFGF, under the floating culture condition for neural stem cells. The percentage of CD133
positive cells among cancer stem-like cells was measured by flow cytometry. Tumorigenicity of cancer stem-like cells fromsurgical specimens was evaluated in athymic mice. Cancer stem-like sphere cells or anchored cells cultured under anadherent condition were injected into the right cerebral hemisphere, and the mice were observed for the number of days
survived (n=10/group). Stem cell cultures from 2 glioblastomas, PXA with anaplastic features, anaplastic astrocytoma, andoligodendroglioma failed to form spheres, whereas 7 stem cell cultures from glioblastoma specimens and 1 frommedulloblastoma developed spheres. Three sphere series from glioblastomas, named TGS01, TGS02 and TGS04, werepositive for CD133 at the percentage of 85.0%, 13.7% and 16.3%, and median survival time of mice injected with 5.0x104
cells were 42days, 90days and 66days, respectively. TGS01 cells showed decrease in CD133-positive cells from 85.0% to28.9% through several passages supplemented with growth factor once a week, and we called them as TGS01-CD133low.
Median survival time of mice injected with 5.0x104 TGS01-CD133low cells were 56days. Brain tumors of these mice weresimilar to original tumors pathologically except for less invasiveness. These results indicated that CD133-positive rate might
correlated with their propagation ability in vivo, even though these rates were unstable under in vitro condition.

P227
Characterization of cancer stem cells in human glioblastomas
Akihiro Inoue1, Hironobu Harada1, Shohei Kohno1, Shiro Ohue1, Toshimoto Seno1, Takanori
Ohnishi1, Hisaaki Takahashi2, Hajime Yano2, Jyunya Tanaka2
Department of Neurosurgery, Ehime University School of Medicine, Tokyo, Japan 2Department of Molecular andCellular biology, Ehime University School of Medicine, Tokyo, Japan

1

Poster Presentation (P)There is a growing body of evidence showing the exsistence of cancer stem cells (CSCs) in malignant brain tumors, andthese CSCs are supposed to play pivotal roles in tumor initiation, growth and recurrence. In this study, we isolated putative
CSCs from a human glioblastoma cell line U251 and partially characterized the isolated cells. Methods: Cells forming
spheroid aggregates (sphere cells) and those attaching to plastic dishes (adherent cells) were separately isolated from U251
cells by culturing cells in the presence of growth factor mixture. Proliferation, migration and invasion activities of the original
U251 cells, sphere-forming cells and adherent cells were investigated using Alamar blue assay and boyden chamber assay.
Protease activity was examined by gelatin zymography. Results: When cultured in serum-free medium with the growth
factor mixture, some U251 cells formed spheres. Such sphere cells had abilities of self-renewal, forming secondary spheres
derived from single cells in spheres and differentiating into neuron-like cells. Sphere cells continued to proliferate for months
and formed solid tumors when grafted subcutaneously to nude mice. By contrast, adherent cells did not have theseproperties. Sphere cells possessed much higher migration and invasion activities than adherent cells. However, there wasno correlation between the invasive activity and the enzymatic activity of matrix metalloproteinase. Conclusion: U251 cellline contained a sub-population of cells characterized as CSCs. The currently characterized properties of sphere cells may
be responsible for the resistance to treatment for glioblastoma.

P228
Characterization of tumor stem cells isolated form humanglioblastoma multiforme
Kiminobu Sugaya1, Melvin Field2, Sergey Bushnev2
College of Medicine, University of Central Florida, Orlando, Florida, USA 2Florida Hospital, Orlando, Florida, USA

1

Glioblastoma multiforme tumors contain a sub-population of cancer stem cells that contribute to malignancy and resistanceto therapy. Previous studies have characterized these cells based on their similarity to adult neural stem cells and theirexpression of CD133. In this study, we separated cancer stem cells from non-pluripotent cells comprising the bulk of thetumor based on their physical growth properties using both serum and serum-free cell culture media. We successfully
generated cancer stem cells from multiple tumor masses as well as from the surgical flush. Cancer stem cells were able toproliferate as non-adherent spheroids and differentiated along neuronal and glial lineages following culture in serumsupplemented media. Compared to adherent cancer cells and human fetal neural stem cells, tumor spheroids showed
increased rates of proliferation, as measured by BrdU incorporation, and greater resistance to differentiation, respectively.
Further characterization of these cells were carried out using immunohistochemistry and real-time PCR to reveal molecularmarkers enriched in cancer stem cells that are absent in both cells comprising the bulk of the tumor as well as in normal
neural stem cells. These markers are down-regulated following differentiation and may serve as important diagnostic andprognostic factors. Moreover, the presence of unique markers offers exciting new therapeutic targets.

- 210 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP229
STAT3 SERINE727 ACTIVATION IN GLIOMA CANCER STEM CELLS
Akio Soeda1, Myung-Jin Park1, Dae-Hee Lee2, Arlan Mintz2, Johnathan Engh2, Amin B. Kassam1,2,
Ian F. Pollack1,2, Toru Iwama3, Takahiro Kunisada4, Andreas Androutsellis-Theotokis5,
Ronald D. McKay5, Deric M. Park1,2
Brain Tumor Program, University of Pittsburgh Cancer Institute 2Department of Neurological Surgery, University ofPittsbugh 3Department of Neurosurgery, Gifu University School of Medicine, Gifu, Japan 4Department of Tissue andOrgan Development Regeneration and Advanced Medical Science, Giful University 5Laboratory of Molecular Biology,
National Institutes of Health, Bethesda, MD

1

PURPOSE: Persistent activation of the signal transducer and activator of transcription 3 (STAT3) has been observed inmany cancers. Various cytokines and growth factors such as the epidermal growth factor (EGF) are capable of leading to
STAT3 phosphorylation at the tyrosine-705 position via recruitment of JAK2. Recent studies showed that neural stem cells
are characterized by activation of STAT3 at the serine-727 position by the Akt-mTOR pathway in the absence oftyrosine-705 phosphorylation. Differentiation into terminal lineages was associated with loss of serine activation and gain oftyrosine phosphorylation. Because cancer stem cells (CSC) represent a population of malignant cells with stem-like
properties, we investigated the presence and significance of STAT3-S727 activation in glioma-derived CSC. METHODS:
CSC isolated from acutely resected tumor specimens that are capable of recapitulating the tumor in immunodeficient mice
were studied for STAT3 activation. RESULTS: Glioma-derived CSC showed STAT3 phosphorylation at both serine andtyrosine sites by immunocytochemistry and immunoblot. STAT3-S727 activation correlated with self-renewal capacity asassessed by sphere forming assay. As seen with neural stem cells, differentiation of CSC with retinoic acid or addition ofserum resulted in attenuation of STAT3-S727 phosphorylation, and loss of self-renewal capacity even in the presence of
STAT3-Y705 phosphorylation. To determine the identity of the upstream pathway responsible for the activation of
STAT3-S727 in CSC, we probed the Akt-mTOR pathway. However, persistent activation of STAT3-S727 was observed evenafter treatment with mTOR, PI3K, and EGFR inhibitors. CONCLUSIONS: STAT3-S727 activation may represent a marker ofglioma CSC stemness. This study suggests inhibition of growth pathway may be insufficient in preventing CSC selfrenewal. A differentiation-based therapeutic strategy may target the CSC population.

P230
ENHANCEMENT OF STEM-LIKE GLIOMA NEUROSPHERE RADIORESPONSE BY
GEFITINIB: BY INCREASED DNA DAMAGE AND REDUCED DNA REPAIR CAPACITY
Khong Bee Kang1, Congju Zhu1, Qiuhan Gao1, Meng Cheong Wong1
National Cancer Centre Singapore, Singapore

1

P231
Inhibition of tumor growth and angiogenesis by targeting CXCL12/CXCR4axis in stem cell-like glioma cells
Xiu-wu Bian1, Yi-fang Ping1, Jian-yong Jiang1, Lin-tao Zhao1, Xiao-hong Yao1
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University,
Chongqing, China

1

Stem cell-like glioma cells (SCLGCs), or glioma stem cells (GSCs), produce high levels of vascular endothelial growth factor(VEGF) with yet to be defined mechanisms. We hypothesized that the chemokine CXCL12 and its receptor CXCR4 might
participate in SCLGC-mediated tumor angiogenesis. We therefore isolated CD133+ cells from a human glioblastoma cell line
U87 and primary glioblastoma tissues with the properties of self-renewal, multi-potency and tumorigenicity. These CD133+
SCLGCs expressed more CXCR4 than their CD133- counterparts and were capable of forming tumorspheres in vitro.
Activation of CXCR4 in SCLGCs with the ligand CXCL12 induced calcium mobilization and increased VEGF production
through the PI3K/AKT pathway. Knock-down of CXCR4 by RNA interference or treatment with a CXCR4 antagonist
AMD3100 reduced the capacity of SCLGCs to form colonies in soft agar and inhibited the growth and angiogenesis oftumors grown in SCID mice. We further observed co-expression of CD133 and CXCR4 in tumor cells of surgically removed
human primary malignant gliomas and such cells were located adjacent to microvessels. These results suggest thatCXCL12/CXCR4 axis may play an important role in mediating the tumorigenesis and neovascularization initiated by SCLGCs.
Thus, CXCL12/CXCR4 axis constitutes a promising target for the development of novel anti-glioma therapeutic agents.

- 211 -­­

Poster Presentation (P)Brain tumor stem cells (BTSCs) have been identified as responsible for maintenance and growth of brain tumors, which
subsequently contributes to chemo- and radioresistance. In this study, we analyzed the effect of irradiation on glioma
neurospheres (that displayed BTSC characteristics) and differentiated glioma cells. We determined whether the tyrosine
kinase inhibitor gefitinib could enhance radiosensitivity of glioma neurospheres by increasing DNA damage and reducing
DNA repair capacity. Malignant glioma tissues were collected with informed consents from patients in accordance with
protocols approved by the institutional review board. Tissues were minced, trypsinized and cultured for growth ofneurospheres and differentiated glioma cells. Neurospheres were evaluated for BTSC characteristics, i.e. ability to selfrenew, multi-potentiality and tumorigenesis. Dose-dependent effects of irradiation alone, and combined effects of irradiationand gefitinib in neurospheres and differentiated glioma cells were analyzed for CD133+ (neural stem cell marker) cell
population, clonogenic formation, γ-H 2 AX (double-strand DNA break marker) immunostaining and DNA-PKcs protein
expression. Glioma neurospheres displayed characteristics of BTSCs to self-renew; differentiate into neurons,
oligodendrocytes and astrocytes; and induce growth of gliomas in NOD-SCID mice. Irradiation significantly increased
CD133+ cell population in neurospheres, but not in differentiated glioma cells. Irradiation did not affect clonogenic survivaland γ-H 2 AX immunostaining of glioma neurospheres, but dose-dependently reduced clonogenic survival and increased γ-H 2 AX immunostaining of differentiated glioma cells. Addition of gefitinib significantly inhibited clonogenic survival andincreased γ-H 2 AX immunostaining of irradiated-neurospheres, without affecting irradiated-differentiated glioma cells.
Irradiation inhibited DNA-PKcs expression in neurospheres, with further inhibition by combined gefitinib and irradiation. In
differentiated glioma cells, irradiation enhanced DNA-PKcs expression without further effect by combined gefitinib andirradiation. In summary, stem-like glioma neurospheres are resistant to irradiation-induced DNA damage, with greaterclonogenic survival following irradiation than differentiated glioma cells. Gefitinib enhances radiosensitivity of stem-likeglioma neurospheres by increasing DNA damage and reducing DNA repair capacity.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P232
Cultivation and identification of the cells from central nervous systemhemangioblastomas and its stem cells origin
Rong Xie1, Xing Hua Ding1, Xing Wu1, Jian Hong Zhu1, Ying Mao1, Liang Fu Zhou1
Department of Neurosurgery, Huashan Hospital, Fudan Univeristy, Shanghai, China

1

Objetive: To cultivate and identify the tumor cells from central nervous system hemangioblastomas(CNS HB) for illustrating
its histological origin and pathogenesis. Methods: 13 CNS HBs were primary and passaging cultured using enzyme
combined digestion. The cells were identified by morphological observation, immunofluorescence, ultramicrostructuralobservation, EPO and VEGF concentration measurement from culture fluid supernatant and CNS HB tissues
immunohistochemical stain. Results: 11 CNS HBs were successfully cultivated. The cells monolayer appeared after 3
weeks. The results of immunofluorescence showed Vimentin+, VEGF+, CD133+, Nestin+, EPO+, CD34-, SMA-, GFAP-.
EPO and VEGF concentration measurement showed the cells had the ability of exocrine EPO and VEGF. CNS HB tissues
immunohistochemical stain suggested the cells cultured actually were the stromal cells of CNS HBs. Conclusion: A novel
method was successfully created for attainment of the cells from CNS HB, and firstly demonstrated it may derived from thestem cells of mesoderm mesenchymal tissues.

P233
Screen and identify the critical proteins of central nervous systemhemangioblastoma tumor cells using on-line capillary 2D-HPLC
combined with LTQ-Orbitrap MS
Rong Xie1, Jian Hong Zhu1, Hang Liu1
Department of Neurosurgery, Huashan Hospital, Fudan Univeristy, Shanghai, China

1

Object: We carried out a pilot study in which we analyzed the proteomes of central nervous system hemangioblastoma(CNS HB) tumor cells by using on-line capillary 2D-HPLC combined with LTQ-Orbitrap ESI MS so as to screen and identify
the critical proteins related to CNS HB occurring. Methods: CNS HB cells were cultured and identified by enzyme digestion
from CNS HB tissues collected during operations. Normal human nerve cells were obtained as control. Total proteins ofcells were extracted and enzymolysed. And then LC packing Ultimate 2D-HPLC systemcombined with LTQ-Orbitrap hybrid
mass spectrometer were used to segregate and idenify the proteins of CNS HB tumor cells and normal human nerve cells.
And shot gun quantitating technique was used to compare the protein expressional abundance of CNS HB cells withnormal human nerve cells so as to screen the critical proteins. Results: 674 and 531 proteins were segregated andidentified in this study. Of the total proteins identified, 360 proteins were found exclusively in CNS HB tumor cells while 217
proteins were found only in normal human nerve cells. And 55 proteins including 30 up-regulated and 25 down-regulatedwith distinguished difference in proteins expressional abundance were found, too. The identified proteins according to theirfunctions could be divided into several groups. Some critical proteins related with CNS HB occurring such as 14-3-3,
vimentin, carbonic anhydrase were screened. Conclusions: The whole proteins of CNS HB tumor cells with distinguisheddifference from normal nerve cells suggests CNS HB tumor cells may not come from normal never cells but have a origin of
mesenchymal stem cells of brain. The process of CNS HB occurring is an intricate, multi-step processmediated by a varietyof important proteins.

Poster Presentation (P)P234
Notch1 induces more expression of DLL1 in U251MG glioma cell line
You P. You1
Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing , P. R. China

1

Notch signaling pathway takes part in coordinated regulation of cell growth, survival and differentiation. Notch receptors
cleave into Notch intracellular domain (NICD) and Notch extracellular domain (NECD) when Notch ligand binds membrane
receptors. NICD dissociates from NECD, translocates into the nucleus and binds to members of the CSL transcription
factor family. And then the CSL family member CBF-1/RBP-JK becomes transcriptional activator and activates large familyof &beta &beta helix loop helix (bHLH) transcription factors known as HES genes. The expression of Notch ligand as thefirst beginning of Notch signaling pathway is crucial for its activation. Previous findings have shown that Notch1 and Deltalike1 (DLL1) over express in many glioma cell lines and primary human gliomas. Down-regulation of DLL1 by RNA
interference inhibits proliferation and induces apoptosis in multiple glioma cell lines. On the other hand, previous studies
had found that the expression of Notch1 inhibited delta ligand of neighbors in the development of nervous system ofDrosophila and vertebrates. However in glioma, it is still unknown whether the secretion of Notch ligand is effected by
Notch signaling pathway. In this regard, we examined the expression of DLL1 after up-regulating Notch1 by transfecting
Notch1 expression plasmid and blocking Notch1 receptors by Notch1 antibody. We showed that Notch1 expression
plasmid induced more expression of DLL1 in U251MG glioma cell lines. Adversely the way of blocking Notch1 receptors
down-regulated the expression of DLL1 and induced apoptosis and growth inhibition in U251MG cells, which had no
statistical difference from the effect of knocking down DLL1 by siRNA. But jointing knocking down DLL1 and blocking
Notch1 receptors induced much more apoptosis and growth inhibition than sum of single factor. These results suggest that
Notch1 could induce more expression of DLL1 and there may be a potential positive feedback loop between Notch1 andDLL1 in U251MG glioma cells. And DLL1 and Notch1 may become joint therapeutic targets.Keywords: Notch signaling;
Glioma; Notch1; DLL1; Feedback loop; U251MG- 212 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP235
Hedgehog pathway and Gliomagenesis
Tatsuya Takezaki1,2, Hideichiro Taku1,2, Hideo Nakamura2, Jun-ichi Kuratsu2, Toru Kondo1
Laboratory for Cell Lineage Modulation, Center for Developmental Biology, RIKEN, Kobe, Japan. 2Department of
Neurosurgery, Faculty of Medical and Phamaceutical Sciences, Kumamoto University

1

Gliomas are one of the most malignant cancers for human. Malignant gliomas contain small fractions of cells which haveboth tumorigenicity and neural stem cell properties, such as self-renew, multipotent, so called Cancer Stem-like Cells(CSCs).
CSCs have features of radioresistance and chemoresistance, so they could be a crucial target for brain tumor therapy. We
have established two glioma stem-like cell(GSC) lines from fresh human glioma tissues. GSCs formed floating spheres inserum-free-medium containing bFGF, EGF and human LIF. They were multipotent, expressed a number of stem cellmarkers(by RT-PCR, immunocytochemistry, immunohistochemistry) and formed tumors when transplanted in nude mousebrains. We focused on three signaling pathways those activated by Notch, Hedgehog(Hh), Wnt/Frz, all of which are involvedin brain tumorigenesis. Cyclopamine, which is a Hh pathway inhibitor, blocked cell proliferation of GSCs, we considered that
Hh pathway was essential for proliferation of GSCs. We confirmed that Gli2 bind to the enhancer region of Sox2 promoter
and that dominant negative form of Gli2(dnGli2) suppressed Sox2 mRNA/protein level in NSCs in vitro and in vivo. When we
transfected the dnGli2 expressing vector to GSCs, dnGli2 also suppressed Sox2 expressions and cell proliferation in GSCs.
Inducible dnGli2 expressing GSCs prolonged mean survival times of transplanted nude mice, but broke the tumorigenicity invivo. As NSCs might be the origin of brain tumors, applying the principles of stem cell biology make it possible to conquer
malignant gliomas.

P236
The functional analysis of a novel KDR (VEGFR II)-PDGFR-alpha fusion genein glioblastoma: From discovery to clinical application
Tatsuya Ozawa1,2, Cameron W. Brennan2,3, Guillaume Normand4, Lu Wang5, Christophe Antczak4,
David Shum 4, Adesh Tandon6, Elena I. Fomchenko1,2, Massimo Squatrito1,2, Ross L. Levine7,
Marc Ladanyi5, Hakim Djaballah4, Eric C. Holland1,2,3
1
Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center 2Brain Tumor Center, Memorial
Sloan-Kettering Cancer Center 3Department of Surgery, Neurosurgery and Neurology, Memorial Sloan-Kettering
Cancer Center 4High-Throughput Drug Screening Facility, Sloan-Kettering Institute 5Department of Pathology, Human
Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center 6 Department of Neurosurgery,
Montefiore Medical Center, Albert Einstein College of Medicine 7Department of Medicine, Human Oncology andPathogenesis Program, Memorial Sloan-Kettering Cancer Center

P237
Isolation and Characterization of an N-Linked Oligosaccharide That Is
Increased in Glioblastoma Tissue and Cell Line.
Ryuya Yamanaka1, Naoto Tsuchiya2, Kazuhiro Ikenaka3
Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan 2Dept. of Neurosurgery, Brain
Reseach Institute, Niigata University 3Division of Neurobiology and Bioinformatics, National Institute for Physiological
Sciences, National Institutes of Natural Sciences,1

We have isolated and characterized N-linked oligosaccharides that are significantly increased in glioblastoma tissue and celllines. The structures of N-linked oligosaccharides present in 3 human normal brain tissues, 15 patients with glioblastoma
and 3 glioma cell lines were analyzed by partially automated technique for the isolation and fluorescent labeling of N-linked
sugar chains from glycoproteins. Characterization of the sugar chains was achieved with the use of a combination of HPLC
columns and a highly sensitive fluorescence detector at femtomole levels. By collecting peaks which accounted for 0.1 % or
more, sixteen different oligosaccharide structures were characterized from glioblastoma tissue and cell lines. The 16
oligosaccharide structures accounted for 48.9 % of the total N-linked oligosaccharides present in glioblastoma tissue. The
major components of total oligosaccharides were similar to those of normal brain tissue. The amount of a biantennarybigalactosylated structure with one core fucosylation (A2G2F) was present in increased levels in glioblastoma tissue (mean=
2.90 %) and glioma cell lines (mean= 5.60 %), while being less than 0.1% in normal brain tissues. Expression of highly
branched tetra-antennary N-glycans that are usually detected in lungs or hepatocellular cancer was not observed. Tissue
glioma cells and cultured cells also displayed strong LCA lectin binding, which binds to sugar chains with core fucose(including A2G2F), while normal brain tissue did not. Moreover, LCA lectin inhibited proliferation of glioma cells, and thisinhibition resulted from induction of apoptosis. A2G2F on glioma specimens may provide a novel marker and target for the
diagnosis and treatment of glioblastoma, respectively.

- 213 -­­

Poster Presentation (P)Chromosomal rearrangements leading to translocation and fusion gene are the most frequent form of cancer genes
discovered in hematological disorders and child sarcomas. Because gene rearrangements are harder to detect in solid
tumors, they are probably underestimated. Recent advances in array-based analysis have identified frequent gene fusions inprostate and lung cancer. Gene rearrangement in the form of intragenic deletion is the primary mechanism of oncogenic
mutation of EGFR and PDGFRα in gliomas, while the incidence of gene fusion is unknown. We applied an array-based
comparative genomic hybridization (aCGH) strategy and sequencing to identify gene rearrangements within tyrosine kinases
and identified the first case of fusion gene with oncogenic potential from a glioblastoma patient sample. This fusion contains
the 5, segment of the KDR gene and the 3, segment of the PDGFRα gene by a small interstitial inversion on chromosome
4q. When this KP (KDR-PDGFRα) fusion gene is introduced into NIH3T3 cells by retroviral infection, fusion gene producthas constitutively elevated tyrosine kinase activity in vitro originating from homodimerization in ligand-independent manner.
NIH3T3 cells expressing KP fusion have a transformed-phenotype in vitro and are tumor-forming in nude mice. The
transformed phenotype of these cells is reversed by PDGFR blockade. Subsequently, to identify novel phenotype reversing
drugs with potential use in the clinic, we performed high throughput (HTP) drug screening of the NIH3T3 cells expressing KP
fusion and found several promising candidates. HTP drug screening also indicated that Akt pathway is necessary for thetransformed phenotype. These results suggest that KP fusion gene behaves as a potent oncogene in a subset of gliomas
and can be used as a tool for drug development.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P238
Inhibition of glioma proliferation by modified p53 protein fused withprotein transduction domains
Hiroyuki Michiue1, Tomotsugu Ichikawa1, Kazuhito Tomizawa2, Kazuhiko Kurozumi1,
Hideki Matsui2, Isao Date1
Department of Neurosurgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences, Okayama, Japan 2Department of Physiology Okayama University Graduate School of Medicine, Dentistry,
and Pharmaceutical Sciences, Okayama, Japan,
1

Protein transduction domains (PTDs), short basic peptide sequences, in such as human immunodeficiency virus type 1 (HIV-1)encoded trans-activator TAT domain and artificial cell membrane permeable poly-Arginine (11R) domain are capable ofmediating proteins across the plasma membrane into nearly all eukaryotic cells.P53 protein is one of the altered proteins incancer cells, and is mutated or deleted in more than half of human tumors including malignant glioma. Therefore, tumor
suppressor protein therapy with wild-type p53 protein has been proposed as a possible therapy for malignancies lacking active
p53. However, the half-life of 11R-p53 is less than 24 hr. Therefore, repeated transduction of 11R-p53 is needed for the
inhibition of cell proliferation.In this study, we show that the COOH-terminal region of p53 modulates the susceptibility of p53 to
Mdm2-mediated degradation. Moreover, p53 mutant in which lysine residues 370, 372, 373, 381, 382 and 386 in the COOHterminal were replaced by arginine residues was resistant to ubiquitin-proteosome-mediated degradation, and that thetranscriptional activity was higher than that of wild-type p53. We investigate the effect of protein transduction therapy of themutated p53, which the multiple lysine residues were substituted by arginine on the stabilization of the protein and the inhibitionof the growth of malignant glioma cells. The p53 mutant proteins fused with 11R were effectively delivered in glioma cells andlocalized in nucleus. Moreover, the delivered proteins were resistant to Mdm2-mediated ubiquitination and the expressions of
11R-p53 mutant were more stable than those of wild-type 11R-p53. Finally, the mutant 11R-p53s displayed a higher
transcriptional activity and a more powerful inhibition of the proliferation of glioma cells compared with wild-type 11R-p53.

P239
Expression of the lysosomal-associated membrane protein-1 (LAMP-1) inastrocytomas
Stine S. Jensen1, Karina Christensen1, Charlotte Aaberg-Jessen1, Bjarne W. Kristensen1
Department of Clinical Pathology, University of Southern Denmark, Odense, Denmark

1

Poster Presentation (P)Targeting lysosomes is a novel approach in cancer therapy providing a possible way of killing the otherwise apoptosisresistant cancer cells. Recent research has thus shown that lysosome targeting compounds induce cell death in a cervix
cancer cell line. Tumor stem cells in glioblastomas have recently been suggested to possess innate resistance mechanisms
against radiation and chemotherapy possibly explaining the high level of therapeutic resistance of these tumors. Since thepresence and distribution of lysosomes in tumor cells and especially in tumor stem cells in astrocytomas is unknown, the aimof this study was to investigate the immunohistochemical expression of LAMP-1, a membrane bound protein in lysosomes, informalin fixed paraffin embedded tumor tissue from 23 diffuse astrocytomas, 17 anaplastic astrocytomas and 72
glioblastomas. The LAMP-1 expression was scored and compared with both tumor grade and patient survival. Moreover
double immunofluorescence stainings with LAMP-1 and the stem cell marker CD133 as well as the macrophage marker
CD68 were performed. The results showed that LAMP-1 was expressed in the vast majority of tumors being present in thecytoplasm of single tumor cells, cell clusters and in blood vessel endothelial cells. The LAMP-1 expression in glioblastomas
was significantly higher than in diffuse and anaplastic astrocytomas (p<0.001). No association between the expression of
LAMP-1 and patient overall survival was found. Double immunofluorescence staining with LAMP-1 and CD133 showed somedegree of coexpression both in niches and single cells but coexpression of LAMP-1 and CD68 was also found. In
conclusion, this study shows that lysosomes are widely distributed in astrocytomas, especially in glioblastomas. With thelocalization of LAMP-1 in CD133 positive putative tumor stem cells, these results suggest that targeting lysosomes may be a
promising strategy of improving astrocytoma treatment.

P240
EVALUATION OF ELK-1 ACTIVATION BY PHOSPHATIDYLINOSITOL 3-KINASE/AKT
PATHWAY IN GLIOBLASTOMA
Melike Mut1, Sevda Isik 2, Ozlem Demir3, Banu Peynircioglu2
1
Hacettepe University Department of Neurosurgery Ankara Turkey 2Hacettepe University Institute of Neurological
Sciences and Psychiatry 3Yeditepe University Department of Genetics and Bioengineering

Purpose: Glioblastoma multiforme is the most malignant tumor among the glial tumors. A survival transcription factor, Elk-1
has been shown to be in the downstream of MAPK and PKC pathways and these pathways exerts some of its proliferative
effect via Elk-1 activation in GBM. However, a possible interaction with Elk-1 and another major survival pathway PI3K has notbeen studied in GBM. Methods: Western blotting for phosphorylation of MAPK and PI3K pathways and Elk-1 in thedownstream, Egr-1 PCR and survival, proliferation and apoptosis assays were performed to evaluate the Elk-1 role upon
stimulation by EGF and TPA. Results: Elk-1 transcriptional activation was demonstrated after TPA or EGF stimulation of
MAPK, PI3K and PKC pathways in rat C6 and human U138 glioma cells as in vitro. Elk-1 transcriptional activity was parallel tothe phosphorylation of its serine 383 residue in response to EGF or TPA stimulation. This activation was blocked mainly by
UO 126, a MEK inhibitor. Inhibiting PI3K pathway with LY 294002 did not affect Elk-1 transcriptional activation but thephosphorylation of Elk-1 was blocked partially by LY 294002. EGF stimulated preferentially the PI3K pathway, while TPA did
so for MAPK pathway. PI3K had no direct effect in activation of Elk-1, rather interacted with MAPK to phosphorylate Elk-1.
Elk-1 activation did have a physiological corresponse in regard to viability, but not in proliferation and apoptosis. Conlusion:
Our results suggest that Elk-1 is activated after phosphorylation at serine 383 residue mainly by MAPK pathway and PI3K
pathway has an indirect role in Elk-1 activation via MAPK pathway. Elk-1 may be a survival factor in C6 rat and U138 humanglioma cells.

- 214 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP241
ANTINEOPLASTONS INHIBIT MCM COMPLEX IN GLIOBLASTOMA CELLS
Sonali Patil1, Stanislaw R. Burzynski1, Sridhar Chittur2, Emilia Mrowczynski1, Krzysztof Grela1
Burzynski Research Institute 2Microarray Core Facility, Center for Functional Genomics, One Discovery Drive, Rm
342G, Rensselaer, NY 12144

1

Phenylacetylglutaminate (PG) is an active ingredient of antineoplastons A10 and AS2-1 (ANP) and is also a metabolic
byproduct of phenylbutyrate (PB). Antineoplastons have recently been granted FDA orphan drug designation for thetreatment of gliomas. In the antineoplaston AS2-1, PG is used in combination with phenylacetate (PN), a histone deacetylase
inhibitor. The aim of this study is to further understand the mechanism of action of PG on brain tumor cells in vitro. We
performed a screen to detect changes in gene expression in response to PG and PN in U87 glioblastoma cells using theAffymetrix Human Genome plus 2.0 oligonucleotide arrays. Pathway analysis was performed using tools such as DAVID,
Onto-express, Genespring, and GeneMAPP to identify pathways that show fold enrichment of genes based on theexpression data. Antineoplastons appear to inhibit cancer cell proliferation by targeting multiple pathways in the cells. A total
human gene array study in glioblastoma cells showed that major metabolic pathways such as glycolysis and TCA are
downregulated. Many pro-apoptotic genes such as CASP3, CASP4, several TNFRs, TRAF3 are up-regulated. The cell cycle
is disrupted and major checkpoint proteins are suppressed leading to apoptosis of glioblastoma cells. The Minichromosome
Maintenance Complex (MCM) proteins are highly expressed in malignant human cells and pre-cancerous cells undergoing
malignant transformation. On the other hand they are not expressed in differentiated cells that have withdrawn from the cell
cycle. Therefore, these proteins are ideal diagnostic markers for cancer and promising targets for anti-cancer drug
development. All six genes of the MCM are markedly suppressed by PG and PN in our gene array study. We are currently
investigating the role of corresponding proteins in apoptosis of glioblastoma cells. In conclusion ANP inhibit MCM complex
in glioblastoma cells which may play important role in control of tumor growth.

P242
Enhanced expression of NADPH Oxidase Nox4 in human gliomas and its
roles in cell proliferation and survival
Tadahisa Shono1, Masahiro Mizoguchi1, Koji Yoshimoto1, Toshio Uesaka1, Tomio Sasaki1
Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

1[Purpose] Reactive oxygen species (ROS) has been attracting attention as a mediator of various cell signaling pathways.
Nox-family NADPH oxidases have been proven to be a major source of ROS production in various cell types and have crucial
roles in various physiological and phathological processes. In this study, we have evaluated expression of Nox-family genes
in various neuroepithelial tumors, and also analyzed its functions in cultured glioma cells. [Methods and Results] We foundthat Nox4, a homolog of gp91phox /Nox2 (a phagocytic NADPH oxidase catalytic subunit) is prominently expressed invarious neuroepithelial tumors by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemical
studies. We quantified Nox4 mRNA expression by real time PCR in specimens from 58 patients with astrocytic tumors, andfound that the expression levels of Nox4 mRNA in glioblastomas (WHO grade IV) were significantly higher than otherastrocytomas (WHO grade II and III). We also found that specific knockdown of Nox4 expression by RNA interference
resulted in cell growth inhibition and enhanced apoptosis induction by cisplatin in cultured glioma cell lines, KNS42 and 81.
[Conclusions] Based on these observations, enhanced expression of Nox4 appeared to be involved in cell growth andsurvival in glioma cells.

EXPRESSION PATTERN OF EGFRS, INTEGRINS, AND RELATED MOLECULES IN HUMANGLIOBLASTOMA VERSUS INTRACEREBRAL LUNG ADENOCARCINOMA METASTASIS
Almos Klekner1, Laszlo Bognar1, Gabor Hutoczki1, Gabor Mehes2, Imre Varga3
Department of Neurosurgery, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary,
Europe 2Department of Pathology, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary,4032, Nagyerdei krt. 98. 3Department of Pulmonology, University of Debrecen, Medical and Health Science Center,
Debrecen, Hungary, 4032, Nagyerdei krt. 98.

1

Glioblastoma is the most common and most malignant primary tumor of the central nervous system. The therapy of thesetumors is often ineffective mainly because of their invasive behavior. Contrarily, metastases of the highly dedifferentiatedanaplastic lung adenocarcinoma are well-circumscribed intracerebral lesions with a very moderate infiltration activity to theadjacent brain tissue. Epidermal growth factor receptors (EGFRs), integrins and their most important ligands: collagens,fibronectin and laminins play a pivotal role in the invasion process. To understand the background of the different invasion
activity of glioblastoma and adenocarcinoma metastasis, the expression of these molecules were determined and comparedto each other and to peritumoral brain. Neurosurgical tissue samples were investigated. The mRNS expression of 29
molecules was measured by QRT-PCR and immunohistochemical (IHC) investigation was also performed in the case of 9molecule. EGFR amplification by fluorescence in situ hybridization (FISH) and EGFRvIII mutation by IHC were also
determined. Significant difference was detected in the mRNA level 10 molecules in comparison of glioblastoma tometastasis. The EGFR was amplificated both in the glioblastoma and metastasis. EGFRvIII mutation was detected
predominantly in glioblastoma. ErbB2, 3, 4, laminin &alpha2, &alpha4, &beta1, integrin &alpha3, &alpha7, &alpha9 and&beta1 seem to play some role in the different invasion activity of glioblastoma and intracerebral adenocarcinoma
metastasis. These molecules might serve as possible targets for anti-invasive therapy.

- 215 -­­

Poster Presentation (P)P243

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P244
Inhibition of LRIG3 gene expression via RNA interference modulates theproliferation, cell cycle, cell apoptosis, adhesion and invasion ofglioblastoma cell
Dongsheng Guo1, Mingjun Cai1
Department of Neurosurgery, Tongji Hospital, Tongji Medical College, University of Science and Technology

1

Background LRIG3 (leucine-rich repeats and immunoglobulin-like domains, LRIG) gene is both under-and over-expressedin human cancers and its role on tumor growth is not fully clarified. This study was undertaken to explore the effects ofinhibition of the expression of LRIG3 gene on proliferation, apoptosis, adhesion and invasion of the human glioblastoma cellline (GL15) and explore possible mechanisms by using small interfering RNA (siRNA) targeting the LRIG3 gene.
Methods The plasmids pGenesil2-LRIG3-shRNA1 and pGenesil2-LRIG3-shRNA2 which containing U6 promoter andLRIG3-specific short hairpin RNA (shRNA) and the plasmid pGenesil2-negative-shRNA containing unspecific shRNA weretransfected into GL15 cells. Stable cell clones were selected by G418. The changes in LRIG3, EGFR and P-EGFR expression
levels were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot. Cell proliferation was
detected by MTT assay. The expression of PCNA and Ki-67 in GL15 cells were examined by SABC immunohistochemistry.
The apoptosis rate and cell cycle were analyzed by flow cytometry. The changes of the GL15 cells adhesive and invasive
ability were measured by cell adhesion assay and Transwell chamber.
Results Compared with those in control cells, the mRNA levels of LRIG3 transcripts were reduced by 52.4% and 63.8% inshRNA1- and shRNA2-transfected cells, respectively; its protein levels were reduced by 50.9% and 67.4%, respectively. The
EGFR and P-EGFR protein level in pGenesil2-LRIG3-shRNA (siRNA) transfected cells were significantly higher than that innegative shRNA (neg) transfected cells p&lt0.05. MTT showed that the LRIG3-specific siRNA cell had higher proliferation
rate than neg cell p&lt0.05. The positive rate of PCNA was significantly higher in shRNA1- and shRNA2-transfected cells thanin control cells [(72.13&plusmn5.64)% and (81.93&plusmn5.23)% vs. (35.40 &plusmn5.69)%, P &lt 0.01]. The positive rate of
Ki-67 was also significantly higher in shRNA1- and shRNA2-transfected cells than in control cells [(82.27&plusmn5.50)% and(88.67&plusmn3.52)% vs. (49.73&plusmn5.73)%, P &lt 0.01]. PCNA expression was positively correlated to Ki-67 expression(r =0.932, P&lt0.001). Cell cycle analysis showed that silencing LRIG3 increased the percentage of G2 / M phase cells andimproved the proliferation index significantly (p&lt0.01). Silencing LRIG3 can inhibit the apoptosis of GL15 cells p&lt0.05.
Treatment of GL15 cells with pGenesil2-LRIG3-shRNA can enhance adhesive and invasive ability p&lt0.05.
Conclusions Our results demonstrated that RNAi against LRIG3 could effectively down regulate LRIG3 gene expression,and then effects cell proliferation, apoptosis, adhesion and invasion on the human glioblastoma. LRIG3 might be involved in
the regulation of EGFR signaling, and serve as a tumor suppressor gene in the pathogenesis of glioma.

P245
Promyelocytic leukemia protein induces apoptosis by the repression of
NFκB activation in glioblastoma cells.
Kazuhito Matsuzaki1, Kazuyuki Kuwayama1, Yoshihumi Mizobuchi1, Hideo Mure1,
Keiko Kitazato1, Teruyoshi Kageji1, Shinji Nagahiro1
Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School,
Tokushima, Japan

1

Poster Presentation (P)Purpose: Promyelocytic leukemia (PML) protein plays an essential role in the induction of apoptosis; its expression is
reduced in various cancers. As the functional roles of PML in glioblastoma multiforme (GBM) have not been clarified, we
assessed the expression of PML protein in GBM tissues and explored the mechanisms of PML-regulated cell-death in GBM
cells.Experimental Design: We examined the PML mRNA level and the expression of PML protein in surgical GBM
specimens. PML-regulated apoptotic mechanisms in GBM cells transfected with plasmids expressing the PML gene were
examined.Results: The protein expression of PML was significantly lower in GBM- than non-neoplastic tissues;
approximately 10% of GBM tissues were PML-null. The PML mRNA levels were similar in both tissue types. The
overexpression of PML activated caspase-8 and induced apoptosis in GBM cells. In these cells, PML decreased theexpression of transactivated forms of NFκB/p65 and c-FLIP gene expression was suppressed. Therefore, PML-induced
apoptosis resulted from the suppression of the transcriptional activity of NFκB/p65. PML overexpression decreased
phosphorylated IκBα and nuclear NFκB/p65 and increased the expression of the suppressor of cytokine signaling(SOCS)-1. A proteasome inhibitor blocked the reduction of activated p65 by PML.Conclusions: The reduction of PML is
associated with the pathogenesis of GBM. PML induces caspase-8-dependent apoptosis via the repression of NFκB
activation by which PML facilitates the proteasomal degradation of activated p65 and the sequestration of p65 with IκBα inthe cytoplasm.This novel mechanism of PML-regulated apoptosis may represent a therapeutic target for GBM.

- 216 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP246
The cellular oncogene ets-1 counteracts p53 tumour suppressor
activity by affecting the level of p53 protein.
Ella L. Kim1, Sven Hanson1, Kiran Todkar2, Christoph Schmitz-Salue1, Gabriele Warnecke3,
Wolfgang Deppert3, Alf Giese1
Department of Neurosurgery, Georg-August University of Goettingen, Goettingen, Germany 2Department of
Neurosurgery, University of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany 3Department of Tumor Virology,
Heinrich-Pette-Institute, Hamburg, Germany
Study purpose
The proto-oncogenic factor ets-1 is often found overexpressed in malignant brain tumours and has been implicated inpromoting glioma invasion. We have previously shown that ets-1 transcriptional activity is negatively regulated by tumour
suppressor p53 via a direct physical interaction between the two proteins. In this study, we addressed the possibility of areciprocal relationship between ets-1 and p53 and investigated the impact of ets-1 on transcriptional activity of p53.
Methods
Transcriptional activity of endogenous or ectopically expressed recombinant p53 and ets-1 proteins was evaluated by semiquantitative RT-PCR or western blot analyses. Protein interaction was assessed by co-immunoprecipitation of endogenous
proteins or by performing pull-down assays with recombinant proteins expressed in insect cells. DNA binding of p53 wasassessed in vitro by gel shif assay (EMSA) or in vivo by chromatin immunoprecipitation (ChIP).
Results
We have identified a mutually antagonistic relationship between tumour suppressor p53 and the cellular oncogene ets-1. ets1 expression and transcriptional activity are inhibited in the presense of high levels of wtp53. However, the p53-mediatedinhibition of the ets-1 expression is overcome through the increase in ets-1 protein levels. Furthermore, the enhanced
expression of ets-1 leads to a reduction in the p53 protein levels and consequently, diminishes transcriptional response
mediated by p53. Our investigations revealed a previously unknown interaction between ets-1 and MDM2, a major regulatorof p53 stability. Our results strongly suggest that the ability of ets-1 to modulate p53 levels is mediated by the interaction of
ets-1 and MDM2.
Conclusion
Increased expression of ets-1 affects p53 at the protein level through an mdm2-dependent mechanism that may operate inglioma cells with wild type p53 to diminish its tumor suppressor function.
1

P247
Cooperative cytotoxicity by HDAC inhibitors and RTKIs: induction of Cx43
in GBM cells
Thomas Asklund1, Anna-Maria Marino2, Christofer C Juhlin3, Anastasios Sofiadis3,
Zahidul Khan2, Catharina Larsson3, Roger Henriksson1, Thomas J Ekstrom2
1
Dept of Radiation Sciences - Oncology 2Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden 3Molecular
Medicine and Surgery; Karolinska Institutet, Stockholm, Sweden

P248
A MDR1 (ABCB1) GENE SINGLE NUCLEOTIDE POLYMORPHISM PREDICTS OUTCOME OFTEMOZOLOMIDE TREATMENT IN GLIOBLASTOMA PATIENTS
Dietmar Krex1, Lydia Kestel2, Katja Robel1, Michael Kramer2, Markus Schaich2
Department of Neurosurgery, University Hospital C. G. Carus, Dresden, Germany 2Department of Medicine I,
University Hospital C. G. Carus, Dresden, Germany

1

Purpose: Some patients with glioblastoma multiform do not respond to temozolomide even though they have aberrant
promoter methylation of the DNA repair enzyme MGMT. This suggests that additional factors hamper temozolomide
cytotoxicity. We aimed to confirm first that temozolomide is a target for the multidrug-resistance transporter MDR1/ABCB1,
and second to investigate whether genetic variants of the MDR1 gene are associated with the survival of glioblastoma
patients treated with temozolomide.Methods: Temozolomide mediated cytotoxicity was determined by the colorimetric
methyl-thiazol-tetrazolium (MTT) assay in MDR-expressing and-non-expressing cell lines. Genotypes of three single
nucleotide polymorphisms of the MDR1 gene (C1236T, G2677T, and C3435T), MDR1 mRNA expression levels and the
MGMT promoter methylation status were analyzed in 112 glioblastoma patients who had been treated either by surgery plus
radiotherapy alone or by additional temozolomide chemotherapy. Results: In vitro analysis revealed that temozolomide
mediated cytotoxicity is dependent on MDR1 expression. Multivariate analysis of MDR1 genotypes showed that the C/Cvariant of the exon12 C1236T SNP is predictive for survival of patients treated with temozolomide. This effect was
independent of the MGMT methylation status. Patients with the C/C genotype had a 2-year overall survival of 37% compared
to 8% and 10% for patients with C/T and T/T genotypes, respectively (p=0.02). No influence was seen in the group ofpatients with radiotherapy only. Conclusion: The genotype of the MDR1 exon12 C1236T SNP is a novel independent
predictive factor for outcome of temozolomide treatment in glioblastoma patients- 217 -­­

Poster Presentation (P)Glioblastoma multiforme (GBM) display a remarkable biological heterogeneity and redundancy of tumour cells, most likely
explaining the poor effects of the present available treatment options. This necessitates development of new therapeuticstrategies. We have previously addressed this issue demonstrating induction of the gap junction protein and tumour
suppressor connexin 43 (Cx43) by the histone deacetylase inhibitor 4-phenylbutyrate (4-PB). Here we further evaluatedcombination treatments with 4-PB and the receptor tyrosine kinase inhibitors gefitinib (EGFR) and vandetanib(EGFR,VEGFR-2, RET). The present study demonstartes that gefitinib and vandetanib increase expression levels andrelocalizes Cx43, most likely also including a 20-25 kDa protein entity with similarity to the previously identified C-terminal of
Cx43. Cooperative cytotoxic effects were also evident when cells were subjected to combination treatment with 4-PB andgefitnib or vandetanib. It is suggested that this novel approach could be a possible strategy to overcome the dismal efficacy
in the treatment of GBM.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P249
Diversity of DNA damage response of astrocytes and glioblastoma celllines with various p53 status to treatment with etoposide andtemozolomide
Yuichi Sato1, Akira Kurose2, Takaaki Beppu1, Teruo Sasaki1, Takashi Sawai2, Kuniaki Ogasawara1
1
Department of neurosurgery, Iwate medical university school of medicine, Iwate, Japan 2Department of pathology,
Iwate medical university school of medicine, Iwate, Japan

Phosphorylation of histone H2AX is a sensitive marker of DNA damage, particularly of DNA double strand breaks. Using
multiparameter cytometry we explored effects of etoposide and temozolomide (TMZ) on three glioblastoma cell lines withdifferent p53 status (A172, T98G, YKG-1) and on normal human astrocytes (NHA) correlating the drug-induced
phosphorylated H2AX (γH2AX) with cell cycle phase and induction of apoptosis. Etoposide induced γH2AX in all phases of
the cell cycle in all three glioblastoma lines and led to an arrest of T98G and YKG-1 cells in S and G 2 /M. NHA cells werearrested in G1 with no evidence of γH2AX induction. A172 responded by rise in γH2AX throughout all phases of the cycle,
arrest at the late S- to G 2 /M- phase, and appearance of senescence features: induction of p53, p21, p16, and β-galactosidase, accompanied by morphological changes typical of senescence. T98G cells showed the presence of γH2AX
in S phase with no evidence of cell cycle arrest. A modest degree of arrest in G1 was seen in YKG-1 cells with no rise in γ
H2AX. While frequency of apoptotic cells in all four TMZ-treated cell cultures was relatively low it is conceivable that the cellswith extensive DNA damage were reproductively dead. The data show that neither the status of p53 (wild-type vs mutated,or inhibited by pifithrin-α) nor the expression of O6-methylguanine-DNA methyltransferase significantly affected the cell
response to TMZ. Because of diversity in response to TMZ between individual glioblastoma lines our data suggest that with
better understanding of the mechanisms, the treatment may have to be customized to individual patients.

P250
The decreased expression of GANP is associated with chromosomal
instability in malignant gliomas
Kazutaka Ohta1,2, Kazuhiko Kuwahara2, Keishi Makino1, Nobuo Sakaguchi2, Jun-ichi Kuratsu1
Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Department of Immunology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

1
2

Poster Presentation (P)Purpose: Malignant gliomas are highly proliferative and invasive, resulting in poor prognosis, which are associated withaneuploidy and chromosomal instability (CIN). GANP is a germinal center-associated nuclear protein containing a region
homologous to Saccharomyces Sac3, which is involved in mRNA export and the regulation of DNA recombination. GANP
expression was decreased in the advanced cases of human breast cancers. This observation was confirmed by experimental
mouse model of ganp-heterodeficiency, which caused mammary tumors with hyperploid cells at a high incidence. We studied
how GANP expression changes and associates with CIN in malignant gliomas. Materials and Methods: The ganp mRNA
was assessed by real-time PCR in 101 cases of adult malignant glioma including anaplastic astrocytoma (AA) and glioblastoma(GBM) by comparing with various clinicopathologic factors. We examined the cell cycle change of five human malignant glioma
cell lines by ganp RNA interference (RNAi)-transfection. The generation of CIN was examined after ganp RNAi-treatment ofglioma cell lines with various p53 mutations. Results: GBM showed a significantly lower level of ganp mRNA than those of AA.
We classified malignant gliomas into ganpLow and ganpHigh groups. The ganpLow group displayed more malignant character withloss of heterozygosity on chromosome 10 (LOH10) and EGFR gene amplification, and showed the significant poor prognosis.
Ganp RNAi caused hyperploidy of glioma cell lines by flow cytometric analysis, and caused CIN with multiplication ofchromosomes and the increase of EGFR gene in the fluorescence in situ hybridization (FISH). Conclusions: Malignant gliomasof the highly malignant character showed a significant decrease of GANP expression and caused hyperploidy and CIN.

P251
ELK4 NEUTRALISATION SENSITISES HIGH GRADE GLIOMA TO APOPTOSIS THROUGHDOWN REGULATION OF THE ANTI-APOPTOTIC PROTEIN MCL-1
Brett W Stringer1, Bryan W Day1, Mark D Spanevello1, Brent A Reynolds2, Jacinta C Carter1,
Joanne M Cox1, Vicky J Ellis3, Christopher L Brown3, David G Walker4, Jason D Lickliter5,
Andrew W Boyd1
Queensland Institute of Medical Research, Brisbane, Queensland, Australia 2McKnight Brain Institute, University of
Florida, Gainesville, Florida, USA 3The ESKITIS Institute for Cell and Molecular Therapies, Griffith University, Brisbane,
Queensland, Australia 4Department of Neurosurgery, Royal Brisbane and Womens Hospital, Brisbane, Queensland,
Australia 5Cancer Services, Peninsula Health, Frankston Hospital, Frankston, Victoria, Australia
1

Purpose: Bcl-2 family anti-apoptotic proteins are elevated in many human malignancies and are attractive therapeutic targets.
The purpose of this study was to measure anti-apoptotic Bcl-2 family expression in high grade glioma to investigate potential
targets for molecular therapy. Methods: Gene expression was investigated by QPCR and Western blot in 37 primary highgrade glioma surgical specimens and 12 GBM cell lines. Targeted reduction of gene expression was performed in GBM celllines using transfected siRNAs or plasmid-based shRNAs. Increased gene expression was achieved using plasmid-based
cDNAs. Spontaneous, ABT-737- or cisplatin-induced apoptosis was measured by FACS analysis of annexin V-stained cells.
Gene promoter function was analysed by luciferase reporter assay. Results: We found Mcl-1 to be the highest expressed antiapoptotic Bcl-2 family member in the majority of malignant gliomas. This was functionally important as neutralisation of Mcl-1
induced apoptosis and increased sensitivity to the BH3 mimetic ABT-737 or cisplatin treatment in GBM cells. Sequencing of theMcl-1 promoter identified a novel functional single nucleotide polymorphism (SNP) in a previously uncharacterised consensus
ETS transcription factor binding site. We identified the ETS domain transcription factor ELK4 as a key regulator of Mcl-1 inglioma, since ELK4 down regulation was shown to reduce Mcl-1 expression. Importantly the presence of the SNP, which
ablated ELK4 binding, whilst uncommon in gliomas, was associated with low Mcl-1 levels and greater susceptibility toapoptosis following chemotherapy treatment. Furthermore, down regulation of ELK4 by siRNA, resulting in loss of Mcl-1
expression, increased sensitivity to ABT-737 and cisplatin treatment. Conversely, ELK4 overexpression increased Mcl-1 levels
and this was shown to be protective against higher concentrations of the chemotherapy agent cisplatin. Conclusions: Thesefindings demonstrate ELK4 to be a critical regulator of Mcl-1 expression in GBM and highlight both ELK4 and Mcl-1 as
molecular therapeutic targets in high grade glioma.

- 218 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP252
xCT as a potential molecular target in glioblastoma multiforme
Hiroshi Nawashiro1, Terushige Toyooka1, Nariyoshi Shinomiya2, Hideo Osada1, Youichi Uozumi1,
Hirotaka Matsuo2, Katsuji Shima1
1
Department of Neurosurgery, National Defense Medical College, Tokorozawa, Japan 2Department of Integrative
Physiology and Bio-Nano Medicine, National Defense Medical College

xCT is a light chain of the cystine/glutamate antiporter system xc-, and its expression is correlated with the system xcactivity. Cystine taken up by the cell via system xc- is rapidly reduced to cysteine, which is incorporated into glutathione. At
the same time, released glutamate promote killing of surrounding neurons. Recent studies have suggested the important roleof glutamate transporters and exchangers in glioblastoma multiforme (GBM). We have investigated the expression of xCT in
38 patients with newly diagnosed GBM. Expression of glial glutamate transporter GLT-1(EAAT2) was also investigated. All
patients were treated by temozolomide plus radiation therapy. xCT expression was determined by immunohistochemical
staining with an antibody against xCT (PA1-16893, Affinity BioReagents, CO). Immunoreactivity was graded and determined
as weak or strong. xCT protein expression level was also investigated in 18 patients using semiquantitative western blotting.
In the normal brain area, weak staining for xCT was observed in the leptomeningeal cells. No significant immunostaining inneurons or astrocytes was seen in the uninvolved normal brain. The result of immunohistochemical staining was tightly
correlated with the result obtained by western blotting. Kaplan-Meier analysis of progression-free survival showed astatistically significant association between strong xCT exprssion and poor outcome (log-rank, p<0.05). Median progressionfree survival was 11.1 months (weak xCT expression: n=10) versus 5.7 months (strong xCT expression: n=28). Cox
regression analyses demonstrated that xCT expression was one of significant predictors, independent of other variables.
GLT-1(EAAT2) expression was invariably very weak in GBM. These findings suggest that xCT could be one of the moleculartargets in therapy for GBM. Sulphasalazine is known to inhibit the activity of system xc-. We have initiated a phase I/II trial ofradiotherapy with concomitant temozolomide plus sulfasalazine for newly diagnosed GBM.

P253
A novel MMAC/PTEN gene mutation in a GBM patient
Gulsah Cecener1, Berrin Tunca1, Ahmet Bekar2, Unal Egeli1, Ozgur Vatan3, Sahsene Tolunay4
1
Department of Medical Biology, School of Medicine, Uludag University, Bursa, Turkey 2Department of Neurosurgery,
School of Medicine, Uludag University, Bursa, Turkey 3Department of Biology, Faculty of Science, Uludag University,
Bursa, Turkey 4Department of Pathology, School of Medicine, Uludag University, Bursa, Turkey

The MMAC/PTEN tumor suppressor gene has an essential biological role in the formation of Glioblastoma multiforme (GBM).
It is known that there are variations in genetic alterations in tumors that develop in patients with different ethnic backgrounds
so, we aimed to evaluate the presence of MMAC/PTEN mutations and protein expressions in Turkish patient with GBM. We
investigated mutations of the MMAC/PTEN gene using single strand conformational polymorphism (SSCP) method followed
by DNA sequencing. Additionally the level of MMAC / PTEN protein expression in tumor was assessed byimmunohistochemistry (IHC). As a result of our investigation, a novel MMAC/PTEN sequence variant was identified: it was G
deletion at codon 159. This frameshift mutation was caused premature stop codon at downstream 7 codons. Moreover, it
was observed that MMAC/PTEN protein expression was highly reduced in Turkish patient with GBM. Keywords: GBM;
MMAC/PTEN; IHC; novel mutation; Turkish population

Attraction of hematopoietic progenitor cells by experimental gliomas invivo: Towards a cell-based therapy for malignant gliomas?
Ghazaleh Tabatabai1,2, Caroline Herrmann1, Gabriele von Kuerthy1,2, Wolfgang Wick1,3,
Michael Weller1,2
Department of General Neurology, University of Tuebingen, Tuebingen, Germany 2Department of Neurology,
University of Zurich, Zurich, Switzerland 3Clinical Cooperation Unit, German Cancer Center, Heidelberg, Germany

1

Adult progenitor and stem cells are novel candidates for a cell-based gene delivery to cancers. Hematopoieitc progenitor
and stem cells (HPC) are an easily accessible cell population. Thus, we investigated their potential as autologous cellularvehicles in the treatment of malignant gliomas. Experimental gliomas attracted HPC in vivo by a transforming growth factor(TGF)-beta-regulated CXC chemokine ligand (CXCL) 12-dependent pathway. Irradiation and non-lethal hypoxia promoted
attraction of HPC by a hypoxia-inducible factor (HIF-)1-alpha-dependent induction of CXCL12. Next, we studied the role ofadhesive interactions for the glioma tropism of HPC. Exposure of human cerebral endothelial cells (SV-HCEC) to
supernatants of glioma cells induced CD62E expression. Transendothelial migration assays showed enhanced HPC
migration after CD62E induction which was impaired by neutralizing CD62E antibodies. Tissue microarrays containing
human glioblastoma and normal brain samples showed CD62E expression on glioblastoma vessels. Glioma supernatantmediated induction of CD62E on endothelial cells required TGF-beta signaling in glioma cells as well as vascular endothelial
growth factor receptor 2 (VEGF-R2) signaling in endothelial cells. Genetic modification of HPC by lentiviral transduction exvivo did not interfere with the glioma tropism of HPC in vitro or in vivo. Importantly, lentivirally transduced HPC were nottumorigenic.These data suggest that HPC might be promising vectors in the treatment of experimental gliomas. Given theessential roles of TGF-beta and VEGF-A, a potential HPC-based therapy might not work in combination with TGF-betaantagonistic strategies or VEGF-A neutralizing approaches. Instead, HPC-based therapy might be compatible with irradiationand chemotherapy.

- 219 -­­

Poster Presentation (P)P254

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)P255
OLIGODENDROGLIOMAS WITH LOH 1P/19Q: IDENTIFYING GENES ASSOCIATED WITH
THERAPEUTIC SENSITIVITY
Cathy A Payne1,2, Jonathon Parkinson3, Ray Cook4, Helen Wheeler5, Bruce Robinson1,2,
Kerrie McDonald1,2
Kolling Institute of Medical Research, St Leonards, Australia 2University of Sydney, NSW, Australia 3Prince of Wales
Hospital, Randwick, NSW, Australia 4Neurosurgery, Royal North Shore Hospital, NSW, Australia 5Neurooncology, RoyalNorth Shore Hospital, NSW, Australia
1

Background: Loss of heterozygosity of chromosomes 1p and 19q occurs in approximately 70% of oligodendrogliomas andis associated with therapeutic sensitivity and better overall survival. The precise genetic contributors to the improved
outcome for patients with LOH of 1p and 19q are unknown.
Aim: To use microarray profiling to compare gene expression in oligodendrogliomas with LOH of 1p and 19q to those
without, in order to identify genes that are implicated in the improvement in outcome for patients with LOH, then investigate
the role of these genes in chemosensitivity, tumorigenesis and survival in the biology of gliomas.
Methods: Exon microarrays were used to identify differential expression patterns of genes located on the 1p and 19q
chromosomes. Genes located throughout the rest of the genome were also screened in order the ascertain whether thesechromosomal aberrations may mediate therapeutic responsiveness or simply act as genetic markers for chemosensitive
tumours due to other genetic alterations. qPCR and immunohistochemistry was performed to validate the differential
expression of these genes in a larger sample set.
Results: PLAG1, IGF2, IQGAP1 and CHI3L1 genes were all found to be have low expression in oligodendrogliomas with
LOH of 1p and 19q compared to those without LOH. Interestingly, these genes have also been reported to be aberrant inglioblastomas. Thus, underexpression of these genes in oligodendrogliomas with LOH of 1p and 19q may contribute to amore favourable prognosis seen in these patients.
Conclusions: The genes identified by this study are potentially associated with the improved response to therapy andsurvival seen in oligodendrogliomas with LOH of 1p and 19q. Further investigation into the function of these genes could
ultimately lead to improved efficacy of therapy in the majority of gliomas that retain the 1p and 19q chromosomes.

P256
ASSOCIATION OF 7q34 COPY NUMBER GAINS AND KIAA1549-BRAF GENE FUSIONSWITH JUVENILE PILOCYTIC ASTROCYTOMA
J. Graeme Hodgson1, Scott R. VandenBerg1, C. David James1, Arrie Perry3, David Gutmann3,
Paul Fisher2, James Ford2, Hanlee Ji2, Joshua Schiffman2
1
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 2Stanford University,
Palo Alto, CA 3Washington University, St. Louis, MO

Poster Presentation (P)PURPOSE: The purpose of this study was to determine whether specific genomic and transcriptional alterations areassociated with specific pediatric astrocytoma malignancy grades . METHODS: DNAs and RNAs were extracted frompediatric astrocytomas. DNA copy number aberrations (CNAs) were determined using a customized molecular inversion
probe (MIP) panel. Gene expression and fusion gene detection were determined by RT-PCR. RESULTS: MIP profiling was
conducted on 10 previously diagnosed grade II tumors and 22 WHO-III and WHO-IV tumors. Among the grade II tumors,
7q34 duplications, involving the BRAF oncogene, were observed in 3/10 cases. Review of these 10 cases revealed two of
three with BRAF duplications as having histopathologic features associated with juvenile pilocytic astrocytoma (JPA), withclassification of the third BRAF duplication case being uncertain due to insufficient archival material. Subsequently weacquired 6 and 5 additional, histopathologically verified JPAs (WHO grade I) and grade II tumors, respectively, and identified
BRAF gene duplications in all grade I cases, but in none of the grade II diffuse-type astrocytomas. RNAs from all grade I-II
tumors were examined by RT-PCR for determination of KIAA1549-BRAF fusion transcripts. The results showed that all
tumors with BRAF gene duplications had detectable fusion transcripts (9/9), whereas none of the 12 grade II tumors showed
evidence of this fusion product. Analysis of the expression profiles from Grade I and II tumors revealed that tumors withKIAA1549-BRAF fusion transcripts expressed elevated PDGFRA, and this observation was supported by quantitative RTPCR analysis which revealed significantly increased PDGFRA expression in tumors with single copy gain of BRAF (p = 0.02).
CONCLUSIONS: Our results indicate a complete concordance between the detection of BRAF gene duplications and
KIAA15449-BRAF fusion transcripts in pediatric low grade malignancy astrocytomas, and that detection of either alteration isstrongly correlated with, and perhaps indicative of, WHO grade I JPA.

- 220 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP257
IDH-1 mutations are frequent in low grade glioma and do not correlatewith outcome to temozolomide chemotherapy
Erik-Jan Dubbink1, Walter Taal2, R v Marion1, Floris Groenendijk1, J Max Kros1, Winand Dinjens1,
Martin J van den Bent2
1
Dept Pathology Erasmus University Hospital Rotterdam, the Netherlands 2Dept Neuro-Oncology, Daniel den Hoed
Cancer Center/Erasmus University Hospital Rotterdam, the Netherlands

Introduction. Mutations in the IDH-1 gene have recently been described to occur infrequently in glioblastoma, and havebeen reported to occur more frequently in low grade astrocytoma, oligodendroglial tumors and secondary glioblastoma. We
analysed a series of 70 low grade astrocytoma cases treated with temozolomide for the presence of IDH-1 mutations.
Methods. A consecutive series of patients with at central pathology review histologically confirmed progressive low grade
astrocytoma after radiation therapy treated with temozolomide chemotherapy were analysed for IDH-1 mutations. Response
was assessed using Macdonalds criteria. The presence of IDH-1 alterations in the mutational hotspot codon R132 wasassessed by sequencing analysis of DNA isolated from formalin fixed paraffin embedded material. TP53 mutation status wasassessed by sequence analysis of exons 4-9. A series of 30 pheochromocytoma was also analysed for the presence of IDH1 mutations. Results. From 48 patients material was available for molecular analysis, from 27 patients material from twoconsecutive operations was available. IDH-1 mutations were present in 85% of samples. No IDH-1 mutations were found in
the pheochromocytoma. In 6 of the paired samples results of the two samples were different (different mutation (n = 3),
appearance or disappeareance of a mutation. In 72% of samples a TP53 mutations was found. Six tumors showed no TP53
mutations but a IDH-1 mutations, in 4 a TP53 mutation was found but no IDH-1 mutation. Nineteen of the 43 (44%) evaluable
patients responded to temozolomide. No clear difference in outcome to temozolomide treatment was observed.
Conclusion. IDH-1 mutations are frequent in low grade glioma. No correlation was found between IDH-1 mutations andTP53 mutations. No significant difference in outcome to temozolomide treatment was observed. IDH-1 mutations may be an
early event in the gliomatogenesis. More data will be presented on oligodendroglioma.

P258

PPAR-γ activators : Off-target against TGF-β mediated glioma cell
migration and brain invasion
Sebastian M. Seufert1, Roland Coras2, Ingmar Bluemcke2, Ilker Y Eyuepoglu3, Eric Hahnen1
Institute of Human Genetics, Institute of Genetics, and Center for Molecular Medicine Cologne (CMMC), Cologne,
Germany 2Department of Neuropathology, University of Erlangen-Nuremberg, Erlangen, Germany 3Department of
Neurosurgery, University of Erlangen-Nuremberg, Erlangen, Germany

1

P259
Tight junction protein Occludin in human brain tumors: Radiologicalcorrelation and prognostic implication on the survival
Choong-Hyun Kim1, Hyun-Jong Hong1,Jin-Hwan Cheong1, Jae-Min Kim1, Suck-Jun Oh1
Department of Neurosurgery, Hanyang University, Seoul, Korea

1

Cerebral edema develops in the brain tumors by loosening of the endothelial tight junction. The development of peritumoral
brain edema (PTBE) is influenced by many factors including tight junction proteins, such as occludin. We studied thecorrelation with PTBE volume and survival outcome related to occludin expression. Sixty fresh-frozen specimens frompatients with brain tumor were obtained during surgery and confirmed pathologically. Occludin expression was investigatedby Western blot analysis. PTBE volume was measured by using preoperative magnetic resonance image (MRI) and survival
time in each patient was also estimated retrospectively. Occludin was detected in 41 (68.3%) brain tumors and the other 19(31.7%) was not. Although its expression was variable according to pathology of brain tumors (p > 0.05), high grade glioma(1/4 = 25.0%) exhibited lower expression rate of occludin than low grade one (7/10 = 70.0%). The difference of PTBE volume
between occludin-positive and negative brain tumors was significant (p = 0.002). The mean survival time was prolonged in
occludin-positive tumors comparable to negative one (p = 0.001). This study suggests that occludin expression is wellcorrelated to the radiological finding of PTBE development in brain tumors and might be a prognostic indicator for survival ofpatients.

- 221 -­­

Poster Presentation (P)Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant
entity. Rapid proliferation and diffuse brain invasion of these tumors are likely to determine the unfavourable prognosis.
Considering its pro-migratory properties, the transforming growth factor β (TGF-β) signaling pathway has become a major
therapeutic target. Analyses of resected glioma tissues revealed an intriguing correlation between tumor grade and theexpression of TGF-β 1-3. Using an organotypic glioma invasion model, we identified the peroxisome proliferator-activatedreceptor γ (PPAR-γ) agonist troglitazone (TRO), which has been developed for the treatment of type II diabetes mellitus, asa potent inhibitor of TGF-β mediated glioma migration and brain invasion. The anti-migratory property of TRO occurred atclinically achievable levels resulting in dramatically reduced levels TGF-β released by glioma cells. Thus, TRO may represent
a promising drug for adjuvant glioma therapy. Here, we show that the PPAR-γ inactive TRO-derivative delta2-TRO
antagonized TGF-β signaling and glioma cell migration in a variety of glioma cell lines as well as ex vivo glioma progression,
giving clear evidence that the anti-glioma properties of TRO occur in a PPAR-γ independent manner. Based on thepromising in vitro and ex vivo anti-glioma activities of TRO and delta2-TRO, respectively, in vivo studies have been initiated.
Moreover, the identification of the yet unknown target protein(s) of delta2-TRO may provide new therapeutic strategies forgliomas and other highly migratory tumor entities.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P260
Expression of the TIMP-1 interacting cell surface protein CD63 inastrocytomas
Charlotte Aaberg-Jessen1, Henrik D. Schroeder1, Steinbjoern Hansen2, Nils Brunner3,
Bjarne W. Kristensen1
Department of Pathology, Odense University Hospital, Odense, Denmark 2Department of Oncology, Odense
University Hospital, Odense, Denmark 3Department of Veterinary Pathobiology, University of Copenhagen,Copenhagen, Denmark

1

Recent research has suggested that the cell surface protein CD63 is a new TIMP-1 (tissue inhibitor of metalloproteinases-1)
interacting protein or even a TIMP-1 receptor. Since TIMP-1 has been shown to be a negative prognostic marker in different
cancers including breast cancer and colorectal cancer, CD63 might also represent a new important biomarker. In a study,
using human breast epithelial cells it was demonstrated that TIMP-1 interacts with CD63 and this interaction was shown tobe necessary for the TIMP-1 anti-apoptotic pathway. We have recently shown that the TIMP-1 immunohistochemical
expression increased with tumor grade in astrocytomas and furthermore, a high TIMP-1 protein expression in glioblastomas
was associated with a shorter overall patient survival suggesting TIMP-1 and possibly also CD63 as new biomarkers inglioblastomas. In the present study, we therefore investigated the immunohistochemical expression of CD63 in 112 formalin
fixed paraffin embedded astrocytomas. The CD63 immunostainings were scored according to the percentage and staining
intensity of CD63 positive tumor cells and blood vessels for comparison with tumor grade and overall patient survival. In
addition, CD63 scores were compared to TIMP-1 scores obtained from the same tumors in a previous study. The CD63
protein was detected in both tumor cells and blood vessels in the vast majority of the astrocytomas, with the highest intensity
found in tumor cells. The total staining score increased from the mean total score 5.6 in diffuse and anaplastic astrocytomas
to the mean total score 7.5 in glioblastomas. There was no association between the CD63 protein expression and the overallpatient survival and no correlation was found between TIMP-1 and CD63 immunohistochemical scores. In conclusion, thisstudy showed that the CD63 immunohistochemical expression in astrocytomas increased with tumor grade but was without
association with overall survival in these tumors.

P261
Molecular Variations in Tumor-Host Interactions between Invasive andAngiogenic Phenotype in High Grade Gliomas
Uros Rajcevic1,6, Kjell Petersen3, Jaco C. Knol2,Maarten Loos4, Sebastien Bougnaud1, Hrvoje
Miletic5, Jian Wang5, Rolf Bjerkvig1,5, Connie R. Jimenez2, Simone P. Niclou1
1
NorLux Neuro-Oncology, CRP-Sante, Luxembourg 2OncoProteomics Laboratory, VU University Medical Center,
Amsterdam, The Netherlands 3Computational Bilogy Unit, BCCS, UiB, Bergen, Norway 4Department od Neurobiology,
VU, Amsterdam, The Netherlands 5Department of Biomedicine, UiB, Bergen Norway 6National Institute of Biology,
Department of Tumor Biology, Ljubljana, Slovenia

Poster Presentation (P)In solid tumor growth, a crucial turning point is the transition from the avascular to the vascular phase, leading to a moreaggressive tumor growth. Antiangiogenesis therapy is a powerful approach aimed at blocking/reducing tumor growth. The
identification of novel angiogenesis specific proteins is crucial for the development of new antiangiogenic therapies, and suchproteins are potential new biomarkers in cancer. A xenograft animal model of human glioblastoma multiforme (GBM) has
been developed in our lab. The model includes 4 generations of rats with the GBM tumor phenotype varying from very
invasive, nonangiogenic in the first to less invasive, fully angiogenic in the last generation rat. The objective of our study was
to explain the molecular background of the phenotypic change, the angiogenic switch, at the protein level and to identify
potential biomarker and target candidates we applied quantitative proteomics based on iTRAQ 2DLC MALDI TOFTOF andbioinformatics on a membrane enriched fractions of the tumors. In four generations of tumors, we identified 1038
nonredundant, host or tumor specific proteins (C.I. >= 95%). Species specific separation of the proteins allowed tumor hostinteraction studies at the proteome level and may reveal novel biomarkers involved in the angiogenic switch. Bioinformatic
analyses over four tumor phenotypes revealed distinct groups of proteins with specific expression profiles that may be
involved in the angiogenic switch and tumor angiogenesis. It appears from these profiles that many of the regulated proteins
are involved in alternative tumor specific metabolic pathways for energy production. The expression of particular proteinsrepresenting these profiles was validated by non-proteomic methods (e.g. GBM tissue arrays) as well as by functional assays
using a novel GFP expressing NOD/Scid mouse model, recently developed in our laboratory, which will allow us to confirm
the tumor/host interactions involved in the angiogenic switch.

- 222 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP262
MULTI-MODAL IMAGING OF ACUTE AND CHRONIC UP-REGULATION OF HYPOXIAINDUCIBLE FACTOR-1 (HIF-1) IN TUMORS
Tadashi Miyagawa1, Ronald G. Blasberg2, Hiroki Namba1
Department of Neurosurgery, Hamamatsu University School of Medicine 2Memorial Sloan-Kettering Cancer Center

1

Objective: Detection and assessment of tumor hypoxia, blood flow dependent hypoxia (acute) and oxygen diffusion
dependent hypoxia (chronic), are important to understand tumor biology. This study addresses whether in vivo multi-modal
imaging systems can be used for assessment of acute and chronic up-regulation of hypoxia-inducible factor-1 (HIF-1) intumors. Methods: A multimodality reporter gene system for radionuclide, fluorescence, and bioluminescence (BLI) imaging
was developed and placed under the control hypoxia responsive elements (HRE/TGL), and transduced to C6 and RG2 cells.
HRE/TGL-RG2 and -C6 were implanted subcutaneously in mice. Constitutively expressing TGL and wild-type tumor cells
were also implanted in the same animals as positive and negative controls, respectively. Acute tumor hypoxia was induced
by injection of Hydralazine (HYZ). To investigate the feasibility of BLI to image acute up-regulation of HIF-1, sequential BLI
was performed with or without HYZ treatment. Thereafter, autoradiographic imaging was performed following [18F]-FDG,[3H]-Xanthine and [14C]-FIAU administration to investigate the quantitative and spatial relationship between glucose
metabolism, tumor blood flow and HIF-1 expression, respectively. Results: HYZ treatment significantly increased BLI photon
emission intensity in the HRE/TGL tumors, but not in positive and negative control tumors. Radiotracer evaluations revealed
that HYZ reduced tumor blood flow from 0.36 to 0.10 (ml/min/g), suggesting that HYZ can induce acute tumor hypoxia bydecreasing blood flow. Autoradiographic images showed a good spatial relationship between FDG and FIAU uptake in viable
portions of the tumors, indicating enhanced glucose metabolism in the same tumor regions with up-regulation of HIF-1
expression. Conclusion: The multimodality HRE/TGL reporter system can be used to visualize hypoxic conditions byfluorescence, BLI and radiotracer imaging. BLI appears to be very sensitive to changes induced by acute hypotension, andto chronic hypoxic conditions in large tumors. HIF-1 expression in tumors, as assessed by FIAU uptake, occurred in a blood
flow-dependent manner.

P263
Relationship between ABC transporter proteins and vasculogenesis inglioblastomas
Keisuke Miyake1, Shuichi Ohkubo1, Masaki Okada1, Takashi Tamiya1
Department of Neurological Surgery, Kagawa University Faculty of Medicine, Kagawa, Japan

1

P264
Histone deacetylase inhibitor, valproic acid inhibits glioma angiogenesis
in vitro and in vivo in the brain
Satoru Osuka1, Shingo Takano1, Tetsuya Yamamoto1, Eiichi Ishikawa1, Akira Matsumura1
Department of Neurosurgery, Institute of Clinical medicine, University of Tsukuba, Tsukuba, Japan

1

Valproic acid (VPA) is one of the histone deacetylase inhibitors and now under the clinical trial for anticancer drug including
glioma. We investigate the antiangiogenic action of VPA in glioma cells and endothelial cells in vitro and glioma in vivo in thebrain. In vitro, the anti-proliferative effect of VPA on human glioblastoma U87MG cells, rat glioma C6 cells and endothelial
cells was assessed by cell proliferation assay. We investigated the effects of VPA on the expression of vascular endothelial
growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) by glioma cells under normoxic and hypoxic condition. The effectof VPA to inhibit for tube formation in human umbilical vein endothelial cell was assessed by angiogenesis kit. In vivo, a brain
tumor model of malignant glioma with Wister rat was used. After administration of VPA and CPT-11 to rat, angiogenic statusof tumor tissues were assessed by vessel densities and the expression of VEGF and HIF-1. In vitro, VPA inhibited theproliferation of human endothelial cells preferably compared to glioma cells. VPA reduced VEGF secretion into conditioned
media and VEGF mRNA expression of glioma cells under normoxic and hypoxic condition. VPA was also found to inhibit
tube formation. In vivo, treatment with either VPA and CPT-11 reduced VEGF mRNA expression and CD31 expression as
vessel densities in vivo in the brain tumor. In conclusion, VPA inhibit glioma angiogenesis by mechanisms involving adecrease in VEGF expression and inhibition of tube formation. VPA would be useful as an adjuvant medicine for malignant
gliomas through its anti-angiogenic action.

- 223 -­­

Poster Presentation (P)(BACKGROUND) Glioblastoma patients have a median survival of approximately 15 months following surgical resection,
radiotherapy and temozolomide. However, as with other regimens, it does not lead to cure, because the blood brain barrier(BBB) is one of the problems in chemotherapy for the central nervous system (CNS). BBB forms a very effective barrier tothe free diffusion of many polar solutes into the brain. Many metabolites that are polar have their brain entry facilitated by
specific inwardly-directed transport mechanisms. These molecules are substrated for the ABC (ATP-binding cassette)
transporter proteins which are present in BBB, and the activity of these transporters very efficiently removes the drug from
CNS. By the way, glioblastomas are among the highest vascularized tumors. Neovascularization encompasses bothangiogenesis and vasculogenesis. In the process of vasculogenesis, de novo formation of blood vessels from bone marrowderived endothelial progenitor cells (EPCs) takes place. So, we hypothesized that glioblastoma patients have increased levelsof EPCs involved in vasculogenesis because the increased EPCs and amplified ABC transporter proteins play importantroles in cancer chemotherapy problems. (METHODS) We investigated the ABC transporter proteins (MDR1, MRP1, MRP2
and ABCG2) and surface markers of primitive EPCs (CD133 and VEGFR) in 25 glioblastoma specimens using RT-PCR assay
and immunohistochemical staining. (RESULTS) We observed overexpression of CD133 and VEGFR with ABCG2
amplification in the microvessel endothelium. Glioblastomas with MDR1, ABCG2, CD133 and VEGFR amplification have amedian progression free survival (PFS) of approximately 4.6 months, but glioblastomas with no amplification of CD 133 and
VEGFR have a median PFS of 8 months. (CONCLUSIONS) Glioblastomas with MDR1, ABCG2, CD133 and VEGFR
amplification tend to have a shorter median PFS. The increased EPCs and amplified ABC transporter proteins probably resist
cancer chemotherapy with consequent poor outcomes in glioblastomas.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P265
The p14ARF tumor suppressor inhibits Glioma-Induced Angiogenesis by a
Novel Mdm2/Sp1/Timp3 Signaling Axis
Abdessamad Zerrouqi1, Beata Pyrzynska1, Maria Febbraio2, Daniel J Brat3,5, andErwin G Van Meir1,4,5.
Institution:
Laboratory of Molecular Neuro-Oncology, Departments of Neurosurgery1, Pathology and Laboratory Medicine3,
Hematology and Medical Oncology4, and Winship Cancer Institute5, Emory University School of Medicine, Atlanta,
Georgia, USA. Lerner Research Institute2, the Cleveland Clinic, Cleveland, Ohio.
The Ink4a/Arf locus on chromosome 9p21 is frequently inactivated in the progression of malignant astrocytoma suggesting
its role in tumor suppression. This locus encodes two tumor suppressor proteins, the p16INK4A cell cycle inhibitor and thealternative reading frame product, p14ARF, which can activate p53 by blocking mdm2 function. The importance of ARF loss
in glioma formation is further underscored by the fact that it leads to glioma formation in knockout mice and theastrocytoma-melanoma syndrome in humans. The mechanisms on how p14ARF loss facilitates the development ofmalignant gliomas is poorly understood, especially in p53 mutated tumors. It is noteworthy that this genetic alteration occurs
with the transition from WHO grade III to IV, and coincides with the associated pathological feature of dramaticallyincreased neovascularization. Here, we present a novel p53-independent tumor suppressor function for ARF as an
inhibitor of glioma-induced angiogenesis. We demonstrate that ARF restoration in glioma cells induces the secretion of
an inhibitor of angiogenesis and identified this inhibitor as tissue inhibitor of metalloproteinase-3 (TIMP3), a negative regulatorof proteolytic activities required for vascular remodeling. We show that ARF-induced expression of TIMP3 inhibits endothelial
cell migration and vessel formation in vitro and in vivo in response to angiogenic stimuli produced by cancer cells. We further
investigated the mechanism connecting ARF to TIMP3, and found that ARF induces the transcription of the TIMP3 gene byactivating the binding of transcription factor SP1 to the promoter. ARF does this indirectly, by relieving Sp1 from an inhibition
by MDM2, allowing it to activate Timp3 expression. The discovery of this novel angiogenesis regulatory axis provides new
insights into p53-independent-ARF tumor suppressive mechanisms that have implications for the development of novel
therapies directed at malignant gliomas and other diseases characterized by vascular pathology.

P266
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer
cells to cytotoxic T-lymphocytes by down-regulating ICAM-1 expression
Ryo Ueda1,2, Gary Kohanbash2, Kotaro Sasaki3, Mitsugu Fujita1,2, Xinmei Zhu1,2, Edward R.
Kastenhuber2, Heather A. McDonald2, Douglas M. Potter4, Michael T. Lotze5, Saleem A. Khan6,
Robert W. Sobol7, Hideho Okada1,2,5
1Department of Neurological Surgery, University of Pittsburgh School of Medicine 2Brain Tumor Program, University ofPittsburgh Cancer Institute 3Department of Dermatology and Immunology, University of Pittsburgh School of Medicine
4
Biostatistics Department, Graduate School of Public Health, University of Pittsburgh and Biostatistics Facility
5
Department of Surgery, University of Pittsburgh School of Medicine 6Department of Microbiology and Molecular
Genetics, University of Pittsburgh School of Medicine 7Department of Pharmacology and Chemical biology, Universityof Pittsburgh School of Medicine

Poster Presentation (P)The RNase III endonuclease Dicer plays a key role in generation of microRNAs (miRs) in cells. We hypothesized that Dicer
regulates cancer cell susceptibility to immune-surveillance through miR processing. Indeed, Dicer disruption up-regulated
intercellular cell adhesion molecule (ICAM)-1, and enhanced the susceptibility of tumor cells to antigen-specific lysis bycytotoxic T-lymphocytes (CTLs), while expression of other immuno-regulatory proteins examined was not affected.
Blockade of ICAM-1 inhibited the specific lysis of CTLs against Dicer-disrupted cells, indicating a pivotal role of ICAM-1 in theinteraction between tumor cells and CTL. Both miR-222 and -339, are down-regulated in Dicer-disrupted cells and directlyinteracted with the 3' untranslated region (UTR) of ICAM-1 mRNA. Modulation of Dicer or these miRs inversely correlatedwith ICAM-1 protein expression and susceptibility of U87 glioma cells to CTL-mediated cytolysis, while ICAM-1 mRNA levels
remained stable. Immunohistochemical and quantitative RT-PCR analyses of 30 primary glioblastoma tissues demonstrated
that expression of Dicer or miR-222 was inversely associated with ICAM-1 expression. Taken together, Dicer is responsible
for the generation of the mature miR-222 and -339, which suppress ICAM-1 expression on tumor cells, thereby downregulating the susceptibility of tumor cells to CTL-mediated cytolysis. This study suggests development of novel miRNAtargeted therapy to promote cytolysis of tumor cells.

- 224 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P267
Hypoxia-induced Stat3 activity contributes the HIF-1, VEGF, MMP2 and TWIST
expression in human glioblastoma, which induce angiogenesis and cell
migration.

CancelledP268
NOVEL MONOCLONAL ANTIBODY 13R2.C3 AGAINST IINTERLEUKIN 13 RECEPTOR
ALPHA-2 REVEALS A SPECIFIC AND MORE WIDE-SPREAD EXPRESSION OF THE
RECEPTOR IN VARIOUS BRAIN TUMORS
Waldemar Debinski1, Peter Dickinson2, Denise M. Gibo1
Brain Tumor Center of Excellence, Wake Forest University, Winston Salem, NC, USA 2University of California at Davis

1

Purpose. Interleukin 13 receptor alpha 2 (IL-13Rα2), an IL-13 plasma membrane receptor, is over-expressed in a vast
majority of patients with glioblastoma multiforme (GBM) and also in dogs with malignant gliomas. We have thus decided togenerate monoclonal antibody against the human receptor that would cross-react with the canine receptor. Methods. A
15-amino acid peptide spanning from residue 86 to 101 and located within D1 region of the extracellular portion of human IL13Rα2 was synthesized as immunogen for the study. The peptide has 100% homology between human and canine
receptors. A standard protocol was used for generation and purification of monoclonal antibody. Selected clone, 13R2.C3,
was used for Western blot analysis of human and canine tumor lysates.Results. 13R2.C3 antibody revealed a single proteinband of expected molecular size for IL-13Rα2 in Western blots of cell and tissue lysates. IL-13Rα2 protein was readily
detected in human GBM with 9/14 showing high and 4/14 moderate over-expression. This is higher than seen in studies
using a polyclonal antibody (CCR 14:199-208, 2008). All (6/6) canine GBMs tumor were positive for IL13Rα2 with 50%
exhibiting high over-expression. Human and canine astrocytomas and oligodendrogliomas were all positive for IL-13Rα2 tovarious degrees. Interestingly, human meningiomas exhibited strong positivity (5/6). In addition, IL-13Rα2 was highly
expressed in canine choroid plexus papillomas. Normal human and canine brain samples were negative for IL-13Rα2 with
13R2.C3 antibody. Conclusions. We have obtained a monoclonal antibody against IL-13Rα2 cross-reacting with humanand canine receptors. 13R2.C3 antibody detects immunoreactive IL-13Rα2 in up to 90% of human GBM. In addition, otherbrain tumors, such as high grade oligodendrogliomas, meningiomas and canine choroid plexus papillomas, appear to
express the receptor at high levels and thus may be appropriate candidates for IL-13Rα2-targeted therapies.

P269

Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan 2Toray Medical Co., Ltd.,Tokyo, Japan 3Proteios Research, Inc., c/o Toray Basic Research Laboratories, Kamakura, Kanagawa, Japan
4
Department of Medical Genome Science, Graduate School of Frontier Science, The University of Tokyo, Kashiwa,
Chiba, Japan1

IFN-β is known to display pleiotrophic biological activities including antitumor effects. On the other hand, TMZ has
demonstrated efficacy and become a key agent in patients with malignant gliomas; however, its survival benefit remains
unsatisfactory. More recent studies have indicated that there might be favorable therapeutic interactions between IFN-β and
TMZ, although the therapeutic advantages of such a combination have not yet been fully explored. The aim of the present
study was to elucidate whether an antitumor effect could be potentiated by a combination of human IFN-β and TMZ.The
antitumor effect of and cell sensitivity to IFN-β and TMZ, and the synergistic potential of IFN-β and TMZ in combination, were
evaluated in malignant glioma cell lines. The correlations among the MGMT methylation status, quantitative level of MGMT
mRNA, MGMT protein expression, and antitumor effect of these agents were also evaluated, since one of the most prominent
resistance mechanisms to TMZ involves MGMT.Cell growth inhibitory effects of IFN-β and TMZ on all tumor cell lines wereobserved in a dose-dependent manner, and the human malignant glioma derived cell lines differed in their sensitivity to TMZ.
MGMT status, including promoter hypermethylation, quantitative mRNA expression, and protein expression, was strongly
correlated with TMZ sensitivity. A synergistic cell growth inhibitory effect and down-regulated MGMT mRNA levels weresignificantly observed when a clinically achievable CNS dose of IFN-β was combined with TMZ, as compared to treatment
with IFN-β or TMZ alone in TMZ resistant T98G cells.These results suggest that the clinical therapeutic efficacy of TMZ might
be improved by combination with IFN-β in malignant gliomas unmethylated at the MGMT gene. The data provide anexperimental basis for future strategies in TMZ chemotherapy, although further studies are needed to determine the detailedrole of combined IFN-β and TMZ chemotherapy in increasing tumor sensitivity.

- 225 -­­

Poster Presentation (P)Synergistic effect of human IFN-beta and TMZ on malignant glioma celllines
Atsuo Yoshino1, Akiyoshi Ogino1, Takashi Ohta1, Takao Fukushima1, Takao Watanabe1,
Yoichi Katayama1, Yutaka Okamoto2, Norio Naruse3, Emiko Sano4

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P270
The role of chemokine SDF-1/CXCR4/CXCR7 for glioblastoma angiogenesis
and glioblastoma derived endothelial cells
Shingo Takano1,2, Toshio Yamashita2, Masumi Nagano2, Ryota Mashiko1, Tetsuya Yamamoto1,
Eiichi Ishikawa1, Satoru Ohsuga1, Akira Matsumura1, Osamu Ohneda2
1
Department of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan 2Regenerative
Medicine/Stem Cell Biology, Institute of Basic Medical Science, University of Tsukuba, Ibaraki, Japan

Glioma cells and tumor endothelial cells (ECs) in hypoxic area obtain prominent angiogenesis and invasiveness, resulting inresistance to radiation and chemotherapy. We investigate the role of SDF-1α/CXCR4 and CXCR7 in glioma angiogenesis
and invasiveness both for tumor cells and tumor derived ECs under normoxic and hypoxic condition in order to suggest newtreatment strategy for gliomas.Immunohistochemical detection of SDF-1, CXCR4, CXCR7 were obtained in 54 astrocytic
tumors. SDF-1 was strongly positive in high grade tumor cells and endothelial cells and CXCR7 was constantly positive inhigh grade endothelial cells. Four ECs from 13 glioblastoma patients were isolated and cultured with endothelial growth
medium (GBMEC-1, 3, 7, 8). SDF-1α/CXCR4/CXCR7 mRNA expression in vitro were different between normal (HUVEC) andglioma derived ECs (GBMEC). GBMEC showed strong expression of VEGF, up-regulation of SDF-1α; expression withhypoxia, no expression of CXCR4, and constant expression of CXCR7. GBMECs that secreted a large amount of SDF-1 into
the conditioned medium migrated well and their tube formation was inhibited by AMD3100. Also glioma cell expressed SDF1 under hypoxic condition and their invasiveness was inhibited by AMD3100. In conclusion, SDF-1α/CXCR4/CXCR7 were
key target molecules in glioma angiogenesis and invasiveness. The characteristics of glioma derived ECs were completely
different from those of normal ECs. GBMECs secrete SDF-1 and VEGF, resulting enhancement of autocrine angiogenesis
through VEGFR and CXCR7 as well as paracrine glioma invasiveness. In order to inhibit glioma angiogenesis andinvasiveness, glioma derived ECs should be targeted, for example by antagonizing SDF-1α or CXCR7 expression.

P271
Soluble CD70 Confers an Immune-Mediated Survival Advantage inExperimental Glioblastoma
James Miller1, Guenter Eisele2, Ghazaleh Tabatabai1, Steffen Aulwurm1, Patrick Roth2, Gabriele
von Kurthy1, Lothar Stitz3, Michael Weller2
Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany 2Department of Neurology,
Laboratory of Molecular Neurooncology, University Hospital Zurich, Zurich, Switzerland 3Friedrich-Loeffler Institute,
Institute of Immunology, Tuebingen, Germany
1

Poster Presentation (P)Purpose of the study: Expression of CD70 on the surface of glioma cells was shown to induce a potent anti-tumor immune
response in a murine glioma model in vivo. There is evidence that also the soluble form of CD70 is active in vivo. A soluble
co-stimulatory ligand is attractive as it might have a wider distribution into the tissue surrounding the tumor in vivo. Methods:
The murine glioma cell line SMA-560 was engineered to produce a soluble from of CD70 (sCD70). The expression of sCD70
was confirmed by immunoblot.. Markers of immune cells were assessed by flow cytometry. The proliferation of immune cells
was investigated in a 3H-Thymidine assay. The secretion of IL-2 and IFN-γ was assessed by ELISA. SMA-560 cells were
implanted stereotactically in the right striatum of syngeneic VM/Dk mice. The infiltration of immune cells in gliomas wasassessed by immunohistochemistry. CD8+ or NK cells were depleted by the injection of appropriate antibodies
intraperitoneally. Results: In vitro expression of sCD70 enhances proliferation of syngeneic splenocytes and their secretion of
IL-2 and IFN-γ. In syngeneic VM/Dk mice bearing intracranial gliomas, sCD70 enhances the survival rate. The infiltration of
CD8+ cells is enhanced compared to controls. Depletion of CD8+ cells abrogates the survival advantage. Conclusion:
These data suggest that sCD70 is a potent stimulator of anti-glioma immune response with cytotoxic CD8+ T-cells playing amajor role.

P272
Aberrant Hypermethylation of CpG islands Profile of Cell Cycle
Regulatory Genes in Malignant Astrocytomas
Takashi Ohta1, Kazunari Yachi1, Akiyoshi Ogino1, Takao Fukushima1, Takao Watanabe1,
Atsuo Yoshino1, Yoichi Katayama1
Department of Neurological Surgery Division of Neurologicalsurgery, Nihon University School of Medicine, Tokyo,
Japan

1

Purpose: Aberrant hypermethylation of CpG islands in the promoter region plays a casual role in the inactivation of various
key genes involved cell cycle regulatory cascade, which could result in loss of cell cycle control. The aim of the present
study was to investigate the role of promoter methylation of genes with a proven role of the cell cycle regulation in malignant
astrocytomas. Experimental Design: We profiled the CpG island methylation status of RB1, p14ARF, p15INK4b, p16INK4a,
p21Waf1/Cip1, p27Kip1, and p73 genes by methylation-specific polymerase chain reaction assay in a homogeneous cohortof patients with malignant astrocytomas, and assessed their relationships with clinical behavior. Results: Promoter
hypermethylation of the RB1, p14ARF, p15INK4b, p16INK4a, p21Waf1/Cip1, p27Kip1, and p73 genes was detected in 4 (4%),
3 (7%), 2 (5%), 6 (5%), 6 (8%), 7 (7%), and 11 samples (22%) of the 53 newly diagnosed malignant astrocytomas,
respectively. A total of 50% of the cases carried methylation of at least one gene, and only 20% of the cases displayedconcordant hypermethylation of two gene. None of the tumors disclosed three or more methylated loci. The presence of
methylation of these genes or a group of genes was not associated with any distinct clinicopathological characteristics
including tumor grade, proliferation activity, responsiveness to adjuvant therapy, and patient survival. p73 protein
accumulation examined by immunohistochemical staining was found in 6 (23%) of the 40 samples examined, with nosignificant association with the methylation status of p73 and any of the clinicopathological parameters tested. Conclusions:
Aberrant hypermethylation of the key cell cycle regulatory genes occurs at a relatively high frequency in malignant
astrocytomas, independent of each other methylation and clinicopathological parameters. This epigenetic change may be
an important early event during the pathogenesis of malignant astrocytomas.

- 226 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP273
An in vitro study of selected synthetic chalcone analogues activity
against Ben-Men-1 meningioma cell line
Igor Sulla1, Marek Sarissky2, Igor J. Sulla3
1
Department of Anatomy, Histology and Physiology, UVM, Kosice, Slovakia 2Department of Pharmacology, Safarik
University School of Medicine, Kosice, Slovakia 3Department of Neurosurgery, Safarik University School of Medicine,
Kosice, Slovakia

Introduction: Ben-Men-1 is a human benign meningioma cell line established from meningothelial meningioma cells
immortalised by retroviral transduction of hTERT. The cells display monosomy 22 typical for WHO gr.I tumours. Despite theirbenign nature, 20-25% of these neoplasms recur within 10 years after initial therapy. This fact inspired authors to study
potential anti-meningioma effects of selected synthetic analogues of chalcones, intermediates in the biosynthesis offlavonoids with relatively well-characterised anticancer properties. Material and Methods: Cytotoxic effects of Q-510 (E-2(4-methoxybenzylidene)-1-benzosuberone), Q-705 (E-2-(2,4-dimethoxybenzylidene)-1-tetralone and Q-766 (E-2-(4hydroxybenzylidene)-1-benzosuberone) on Ben-Men-1 cells were assessed using the colorimetric MTT assay. Apoptotic
activities of the tested agents were analysed by flow cytometry using Annexin V/PI staining and DNA cell cycle analysis.
Results: Of the tested chalcone analogues, Q-510 displayed a significant cytotoxic effect on Ben-Men-1 cells in aconcentration-dependent manner with an EC50 of 2.682 ± 1.999 microM. At 1 microM, Q-510 induced apoptosis in BenMen-1 cells increasing significantly the percentage of both apoptotic (AnnexinV+/PI-) and necrotic (AnnexinV+/PI+) cells from
1.0 ± 0.4% to 7.6 ± 2.6% and from 2.5 ± 0.9% to 4.3 ± 0.5% in untreated vs. treated cells, respectively. A similar increase
was also observed in the percentage of sub-G0/G1 cells: from 2.6 ± 3.4% in untreated cells to 21.3 &plusmn 9.7% in cells
treated with 1 microM Q-510 for 72 hours. For Q-705 and Q-766, no cytotoxic or apoptotic activities against meningioma
cells were observed. Conclusion: Q-510, a synthetic chalcone analogue, possesses a significant anti-meningioma activity at
micromolar concentrations. Further studies are necessary to elucidate its mechanism of action as well as its potential utility inthe treatment of recurring benign or anaplastic/malignant meningiomas.Acknowledgement: This work was supported by the
Slovak Research and Development Agency under the contract No. APVT-20-032504, APVV-20-052005 and VEGA grant
1/3361/06.

P274
New CCM1 gene mutations in Chinese sporadic intracranial cavernous
angioma patients
Rong Xie1, Xian Cheng Chen1
Department of Neurosurgery, Huashan Hospital, Fudan Univeristy, Shanghai, China

1- 227 -­­

Poster Presentation (P)Objectives: To detect and analyze the CCM1 gene (7q11.2-q22) mutations in Chinese sporadic intracranial Cavernous
Angioma (CA) patients which may be the cause of CA occurring. Methods: The sporadic CA group included nineteen
unrelated patients of Han people with CA confirmed by postoperation pathology and treated at Department of Neurosurgery,
HuaShan Hospital, FuDan University during 2005-2007, and the study was approved by the local ethics committee. Thirty
healthy people were enrolled as the control group. Genomic DNA was extracted from the peripheral blood. Exon 8, 9, 11, 12,
13, 15, 16, 17 and 18 of CCM1 and part of intervening sequences near both sides of these exons were amplified by PCR.
The PCR products were sequenced directly and then compared with reference sequences from GeneBank. Results: Four
exclusive mutation sites of CCM1 gene were detected from 11 Chinese sporadic CA patients. Total mutational rate of CCM1
was 31.6/100. Among the four exclusive mutations, there were one missense mutation: exon12, 1172C to T(S391F), one
insertion mutation: exon8, 704insT(K246stop), one intervening sequence mutation: IVS12-4C to T, and one synonymous
mutation: 1875C to T(F625F). No any mutations were detected in the control group. Conclusion: There are CCM1 genemutations in Chinese sporadic CA, which lead to functional loss or changes of the encoding KRIT1 protein and are relatedwith the sporadic CA occurring.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P275
The functional role of eIF4E in primary central nervous systemlymphoma
Daisuke Muta1, Keishi Makino1, Hideo Nakamura1, Mareina Kudo1, Jun-ichi Kuratsu1
Department of Neurosurgery, Kumamoto University School of Medicine, Kumamoto, Japan

1

Background and objects
Primary central nervous system malignant lymphoma (PCNSL) is defined as a diffuse lymphoma presenting in the brain or
spinal cord without systemic lymphoma. Although the incidence of PCNSL has increased among both immunocompetentand immunodeficient patients, the pathogenesis and histogenetic origin of PCNSL is poorly understood. The mRNA capbinding protein, eukaryotic initiation factor 4E (eIF4E), plays an important role in mRNA translation and its activity isimplicated in cell growth and proliferation. Increased eIF4E expression has been associated with tumor formation andprogression in human malignancies including leukemias, lymphomas and several types of cancer. Moreover, eIF4E is known
to be activated by MAP kinase-interacting kinase-1 (Mnk-1), which attracts the attention as a molecule related to cellproliferation. Therefore, we investigated the participation of eIF4E in PCNSL.
Methods
The expression of eIF4E in the specimens from PCNSL was examined by immunohistochemical analysis using anti-eIF4E
and anti-phospho-eIF4E Ab. In order to examine the physiological role of eIF4E in PCNSL cells, we used a cell line derived
from human brain malignant lymphoma (HKBML).
Results(1) We observed the overexpression of eIF4E and phosphorylated eIF4E in the specimens from the PCNSL patients. (2)Western blotting analysis showed that eIF4E was activated in HKBML, (3) the activation of eIF4E wasn't inhibited by the
inhibitors of MAPK (PD98059) and p38MAPK (SB203580). However, Mnk-1 inhibitor (CGP57380) could inhibit the activationof eIF4E. (4) Furthermore, CGP57380 inhibited the cell proliferation and induced a G1 arrest and apotosis in HKBML cells.
Conclusions
These data suggest that Mnk-1/eIF4E pathway plays an important role in pathogenesis of PCNSL. The inhibition of the signal
pathway may provide a basis for developing a novel therapeutic approach in PCNSL.

P276
Is it Total removal of glioblastoma possible? - tumor cell infiltrationfrom autopsy brain
Yoshihiro Numa1, Takahiro Yamahara1, Tetsuya Oishi1, Takuya Kawaguchi1, Toshitaka Seno1,
Yasuo Sakurai1, Yasuo Yamanouchi1, Akio Asai1, Keiji Kawamoto1
Department of Neurosurgery, Kansai Medical University, Osaka, Japan

1

Poster Presentation (P)Even if glioblastoma can do total extirpation by an operation macroscopically, it recurs by all means. [Materials andmethods] We reviewed an infiltrate of tumor cells from autopsy brain in a tumor peripheral zone. We compared it with animage from autopsy brain of 6 examples and reviewed cell infiltration by mapping of tumor cells by form and FCM. Autopsy
brain did a horizontal plane in 10mm slice in parallel with OM line and compared it with an image (CT, MRI). The other sidemade a graft to the homonymous brain surface mainly on a tumor, too, and the autopsy brain dyed HE and VEGF. We
compare a peripheral zone from a tumor edge contrasted from an image by contrast media with autopsy brain, and it isnumber of the cellular infiltrate (A: 100-60%, B: 60-20%, C: We measured less than 20%) and, from autopsy brain (3examples) at the time of autopsy, obtained tissue according to a part of a tumor and analyzed DNA contents by FCM.
[Results] Autopsy brain was easy to grasp the tumor more macroscopically than fixed autopsy brain. (1)In MRI, an infiltrateof tumor cells was present in high signal with brain edema (2)It extended over 3-13mm from tumor border, and the tumor
cells of an A domain accepted an infiltrate. (3)The tumor had few infiltrates so that in T2 WI hyperintense area around atumor was small. (4)The DNA index, the proliferating index related to morphologic cell infiltration from tumor border by FCM
in a peripheral zone. [Conclusion] In an operation of glioblastoma, it was thought that we were insufficient in macroscopical
total extirpation of tumor contrast enhanced area in MRI.

P277
Clinical significance of vasculogenic mimicry in human gliomas
Zhongping Chen1, Xiaomei Liu1
Department of Neurosurgery, Cancer Center,SunYat-sen University, Guangzhou, China

1Introduction: Vasculogenic mimicry (VM) is a newly recongnized phenomina in many malignancies. However, we do notknow its clinical significance in gliomas. This study was designed to investigate VM in gliomas and compare clinical data of
the patients. Methods: One hundred and nine glioma specimens were collected for immunohistochemical staining of CD34
and PAS staining (dual staining) to verify existing of VM. The clinical data of those glioma patients were collected andanalyzed with existence of VM. Results: The VM has been considered for those stained positively for PAS, but negatively forendothelial marker-CD34. There were 13 out of the 109 specimens found VM phenotype (11.9%). Most of the VM were foundin higher grade gliomas: 8 of 27 grade IV(29.6%), 3 of 41 grade III (7.3%), and 2 of 36 grade II(5.5%). While there was no VM
found in grade I gliomas. The higher grade gliomas had higher incidence of VM than that of lower grade gliomas (P=0.012).
There was no any association between existence of VM and the sex, age and preoperative epilepsy of the patients. However,the patients, who’s tumor with VM, survived short than that of without VM (P=0.031). Conclusions: The VM exists ingliomas, and the higher grade gliomas exhibit more VM than the lower grade gliomas. The glioma patients with VM may havepoorer prognosis.Key words: Glioma, Vasculogenic mimicry- 228 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P278
Validation of prognostic and therapeutic worth of molecular markers
by routine tools in diagnostic and clinical neuropathology: a study of
193 glioblastomas.
Bianca Pollo1, Emanuela Maderna1, Sara Guzzetti1, Ilaria Grecchi1, Rita Farina1,
Gaetano Finocchiaro1, Andrea Salmaggi1
Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy

1

The application of molecular biology technologies to cerebral tumours have permitted the identification of genetic andmolecular alterations specific for some oncotypes, allowing indications on tumour biological behaviour and to suggest new
therapeutic strategies. This issue has changed the clinical management of the patients and has required the implementationof some biomarkers to routine laboratory. In order to give early information about biomarkers, aim of this study was to verify
the transferability of molecular biology data to routine diagnosis performing an immunohistochemical study on surgical
specimens from 193 glioblastoma patients: 64 female, 129 male with median age 58 years. The results were related to theclinical data obtained from the Tumour Register and, in some cases, compared to the molecular biology tests. The
specimens were fixed in Carnoy alcohol-based fixative, processed for histology and immunhistochemistry for EGFR, P53,
MGMT, PTEN and YKL-40. Immunohistochemical results showed a different expression pattern: PTEN was positive in 58%
of cases, EGFR in 32%, p53 in 37% and YKL-40 in 60%. A correlation of EGFR and YKL-40 expression to shorter time totumour progression was found. MGMT was considered as positive when more than 20% of neoplastic cells were
immunostained: 65% of glioblastomas showed positivity. A correlation to molecular data by methylation-specific PCR wasassessed on 100 cases with 90% of correspondence. The immunohistochemical profile of diagnostic, prognostic andpredictive biomarkers in glioblastoma patients could be, with adequate technical handling and knowledge, a useful, easy andfast tool for pathologist in routine clinical practice, supporting oncologists to make treatment decisions.

P279
OLIGODENDROGLIAL TUMOR CLASSIFICATION: PHENOTYPE vs GENETIC SIGNATURE
Horacio Martinetto1, Ruben Ferrer-Luna2, Manuel Mata2, Lina Nunez1, Eugenia Arias1, Andres
Cervio4, Miguel Riudavets1, Naomi Arakaki1, Gustavo Sevlever1, Bernardo Celda2,3
Department of Neuropathology, FLENI, Buenos Aires, Argentina 2Universitat de Valencia (UVEG), Valencia, Spain
CIBER Bioengineering, Biomaterials and Nanomedicine, ISC-III, Valencia, Spain 4Department of Neurosurgery, FLENI,
Buenos Aires, Argentina

1
3

P280
HISTOLOGIC ANAPLASIA IN SPORADIC AND NF1-ASSOCIATED PILOCYTICASTROCYTOMAS PREDICTS UNFAVORABLE BEHAVIOR
Fausto J. Rodriguez1, Bernd W. Scheithauer1, Peter C. Burger3, Sarah Jenkins2,
Caterina Giannini1
1
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine 2Division of Biostatistics, Mayo
Clinic College of Medicine 3Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD

The clinical significance of histologic anaplasia in pilocytic astrocytoma (PA), a rare event, is not fully established. We
reviewed 37 histologically anaplastic PA among approximately 2,200 PA cases from the Mayo Clinic file (1.7%), including 22
males and 15 females, with a median age of 36 years (range 5-75). All tumors had either previously documented (n=10)(27%) or coexistent PA precursors (n=17)(46%), or exhibited typical pilocytic features in an otherwise anaplastic
astrocytoma (n=10)(27%). Most were located in the cerebellum (54%). Clinical features of NF1 were present in 22%, and ahistory of radiation for a PA precursor in 11%. Histologically, the anaplastic components were classified as pilocytic-like(38%), small cell (35%), fibrillary (14%) or epithelioid in appearance (14%). Median overall and progression-free survival for
the whole group was 24 and 14 months, respectively. Overall and progression-free survival was shorter when there was ahistory of radiation (p=0.0069, 0.0283), increasing levels of mitotic activity (p=0.0344, 0.0188), and necrosis (p=0.0226,
0.0242). When compared to historical cohorts of St. Anne-Mayo graded infiltrating astrocytomas, overall survival rates ofanaplastic PA was similar to that of infiltrative astrocytomas grade 2 and 3, depending on the absence/presence of necrosis
respectively. In summary, anaplastic PA exhibits a spectrum of morphologies and is associated with decreased survival
compared to typical PA.

- 229 -­­

Poster Presentation (P)PURPOSE : Oligodendroglial Tumors ( OT ) are constituted by Oligodendrogliomas or pure tumors ( OD ), andOligoastrocytomas or mixed tumors (OA) and their respective anaplastic grades. Oligodendrogliomas are one of the mostchemosensitive solid tumors and loss of chromosome (LOH) 1p is tightly associated with response to chemotherapy.We
have previously developed a molecular classification for oligodendroglial tumors and the purpose of this study was tocompare it to a histology-based classification. METHODS: Microarray analysis was used to study a set of 19 OD and 10 OA.
Supervised learning approaches were used to build a two-class prediction model based on the histological class. We
performed an evaluation of 3 algorithms (DLDA, 1-NN, and PAM) and 8 different prediction models were built in each one (2,5, 10, 20, 35, 50, 75, 100 features). The training error of this prediction models were determined using CV-10, and LOO.
Finally we selected the best number of genes that result in the smallest cross-validation error. RESULTS: No Gene-Ontology
based functional enrichment was found in 94 more significant and differentially expressed genes among defined histologicalclasses. We identified 72 features frequently used by predictors. To assess the usefulness of both classifiers in terms ofprognosis, we next performed a supervised analysis of genes involved in chemoresistance; groups defined by molecularclassification showed differences in the expression of this set of genes which could not be detected considering histologicalclasses. A similar result was obtained when the expression of several genes linked to proliferation and stemness wasinspected. CONCLUSION: More functionally significant and differentially expressed genes were detected among molecular
status than defined histological classes. Gene expression profile was decisively conditioned by 1p/19q allelic deletions.
Molecular predictors seem to be more efficient in prognosis and could be complementary to pathological diagnosis.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P281
APPLICATION OF A CYTOGENETC PROGRESSION SCORE (GPS), TUMOR LOCATIONAND GENETIC PROGRESSION IN MENINGIOMAS: HACETTEPE EXPERIENCE
Melike Mut1, Dilek Aktas2, Mehmet Alikasifoglu2, Tuncalp Ozgen1
Hacettepe University, Department of Neurosurgery, Ankara, Turkey 2Hacettepe University Department of Genetics

1

Purpose of the study: Meningioma is a common intracranial tumor. Monosomy 22 or loss of 22q are the most frequently
and early detected abnormality, especially in WHO Grade I tumors. Partial or complete loss of chromosome1 or 1p has beensuggested as a significant event in the initiation and progression of meningiomas. Recently, a sophisticated cytogenetic
progression model for meningiomas and the relationship between tumor location and genetic progression has been
proposed. According to genetic progression score (GPS), in the Group O, no monosomy 22 was detected. Monosomy 22
was observed in the Group I and lost of chromosome 1p was also found in the Group 2 as well as monosomy 22. We
investigated the karyotypes associted with multiple and atypical/malignant meningiomas. Methods: Tissue cultures frommeningioma biopsies and chromosome preparations with Giemsa banding were carried out according to standard
procedure. Results: None of the patients had NF2. One of two grade II chondroid meningioma was GPS Group 2(monosomy 22 and loss of 1p). Other WHO Grade II had 46 XX (GPS Group 0). A multiple meningioma patient hadmonosomy 22 (GPS group I) although the lesion was graded as WHO Grade I. Two giant meningiomas (parafalcine andtentorial) with atypical radiological features showed multiplex trisomy (GPS group 0) and monosomy 22 (GPS group I),
respectively. Conclusion: The GPS as a quantitative measure allow us for a more precise assesment of the prognosis of
menigiomas than classical cytogenetic markers.

P282
Targeting the tumor stroma a novel therapeutic strategy based on
separate analysis of the malignant and stromal cell compartments inbrain tumors
Jian Wang1, Oleg Tsinkalovsky2, Peng Zhao3, Lars Prestegarden1, Xingang Li3, Emmet Cormark4,
Bjorn Tore Gjertsen4, Rolf Bjerkivg1,5, Per Oyvind Enger1,6
Department of Biomedicine, University of Norway, Bergen, Norway 2The Gade Institute, University of Bergen, Bergen,
Norway 3Department of Pathology, University of Bergen, Bergen, Norway 4Department of Internal medicine,
Hematology Section, Haukeland University Hospital, Bergen, Norway 5NorLux Neuro-Oncology, Centre Recherche de
Public Sante, Luxembourg 6Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway

1

Poster Presentation (P)The recruitment of host vasculature and the infiltrative behaviour of gliomas underscore the significance of tumor-stromainteractions in brain tumor pathogenesis. The aim of this project is to identify cancer-related changes in the stroma during
brain tumor progression that can be targeted therapeutically. However, targeting tumor-activated stromal cells require further
insight into the mechanisms that regulate the tumor-stroma interplay. Since, any tumor biopsy contains a mixture of cancer
cells and stromal cells, we are unable to determine whether a given gene expression profile or protein signature is derived
from stromal or cancer cells. For the same reason, we are also unable to specify the directions of cross-talk between
compartments; whether an influence is excerted upon the tumor by the surrounding stroma, or vice versa. In this project, wehave generated a green fluorescent protein (GFP)-expressing on the nude rat by crossing nude rat with a transgenic GFPexpressing line. We implant human glioma biopsies in green-fluorescent (GFP) immunodeficient rats. The resulting xenograft
tumors are dissociated into a cell suspension and FACS-sorted into GFP-positive stromal cells and GFP-negative tumor
cells. We also obtained cell suspensions of stromal cells from normal brain. Human specific nuclei antibody staining has
confirmed that sufficient purity of the sorted cells. Using this tool, we intend to delineate the gene expression profiles andprotein signatures unique to the tumor-activated stromal cells. This information will subsequently be used to tailor drug
regimens that target tumor-activated stroma and tumor-stroma interactions.

P283
Therapeutic efficacy of a polymeric micellar doxorubicin infused byconvection-enhanced delivery against intracranial 9L brain tumor
modelsYoji Yamashita1, Tomoo Inoue1, Masamichi Nishihara2, Shin-ichiro Sugiyama1, Yukihiko Sonoda1,
Toshihiro Kumabe1, Masayuki Yokoyama2, Teiji Tominaga1
Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan 2Yokoyama Nanomedical Polymers Project, Kanagawa Academy of Science and Technology, Kawasaki, Japan

1

Convection-enhanced delivery (CED) with various drug carrier systems has recently emerged as a novel chemotherapeutic
method to overcome the problems of current chemotherapies against brain tumors. Polymeric micelle systems haveexhibited dramatically higher in vivo antitumor activity in systemic administration. This study investigated the effectiveness of
CED with polymeric micellar doxorubicin (micellar DOX) in a 9L syngeneic rat model. Distribution, toxicity, and efficacy offree, liposomal, and micellar DOX infused by CED were evaluated. Micellar DOX achieved much wider distribution in brain
tumor tissue and surrounding normal brain tissue compared to free DOX. Tissue toxicity increased at higher doses, but rats
treated with micellar DOX showed no abnormal neurological symptoms at any dose tested (0.1-1.0 mg/mL). Micellar DOX
infused by CED resulted in prolonged median survival (36 days) compared to free DOX (19 days; P=0.0173) and liposomal
DOX (16 days; P=0.0007) at the same dose (0.2 mg/mL). This study indicates the potential of CED with the polymeric micelledrug carrier system for the treatment of brain tumors.

- 230 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP284
Label-free Differentiation of individual human glioma cells by optical
FTIR spectroscopic imaging
Matthias Kirsch1, Saskia Kuechler1, Reiner Salzer3, Gabriele Schackert1, Gerald Steiner2
Neurosurgery, Carl Gustav Carus University Hospital, Technical University Dresden 2Clinical Sensoring andMonitoring, University Hospital Carl Gustav Carus, Technical University of Dresden 3Bioanalytical Chemistry, Technical
University of Dresden

1

The discrimination of cell types at different stages of development is a crucial task in cell biology. Available techniques,
based on an irreversible treatment of the cells, do not allow a sensitive label free characterization under in situ conditions.
The purpose of this study is to evaluate the ability of infrared spectroscopic imaging (IRSpec) to differentiate individual cells
between different glioma cell populations. Methods : Monolayers of cultivated U343, T1115 and T508 human glioma cells
were characterized using IRSpec. A classification algorithm based on linear discriminant analysis was developed to
distinguish different cells without labeling. The classification is based upon specific spectral patterning. Results : An
accuracy of 91% and 84% was obtained for U343 and T1115 cells. T508 cells exhibit some misclassifications resulting in alower accuracy rate of 73%. However, even different mixtures of these cell types were recognized and correctly classified.
Conclusions : As demonstrated, the potential of IRSpec to assess the overall molecular composition of cells in a nondestructive manner opens the possibility to characterize cells on a molecular level without labels or an irreversible treatment.
Many different aspects with regards to treatment response and differentiation are now open for nondestructive analysis.

P285
Application of multiple-stage tandem imaging mass spectrometry to theevaluation of lipids in a rat brain C6 glioma model
Shinichiro Koizumi1, Takahiro Hayasaka2, Naoko Goto-Inoue2, Koji Ikegami2, Mitsutoshi Setou2,
Hiroki Namba1
1
Department of Neurosurgery, Hamamatsu University School of Medicine, Shizuoka, Japan 2Department of Molecular
Anatomy, Hamamatsu University School of Medicine, Shizuoka, Japan

P286
Spectroscopic imaging of cerebral micrometastases in a murine model
Matthias Kirsch1, Claudia Beleites2, Reiner Salzer1,2, Gabriele Schackert1,2, Christoph Krafft2
Neurosurgery, Carl Gustav Carus University Hospital, Technical University Dresden 2Bioanalytical Chemistry,
Technical University Dresden

1

Optical spectroscopic imaging has the potential to be introduced into the surgical microscope. Both Raman and Fouriertransformed infrared spectroscopy (RSpec and IRSpec) detect the complete biochemical information. The purpose of thisstudy was to evaluate a murine model of brain metastases with regards to morphological mapping and detection ofmetastases. Methods Hematogenous brain metastases of a malignant melanoma cell line were induced in one brain
hemisphere while the other hemisphere remained tumor free. Dried, thin sections for IRSpec, hematoxylin and eosin-stained
thin sections for histopathological assessment, and pristine, 2-mm thick sections for RSpec were prepared. IRSpec images
were recorded using a multi-channel detector. Raman maps were collected serially using a spectrometer coupled to a fiberoptic probe. The images/maps were segmented by cluster analysis. Results The clusters coincided well with themorphology of mouse brains in stained tissue sections. More details in less time were resolved with IRSPec (25 μm
resolution) than RSpec (60 μm). The spectral contributions of melanin in tumor cells were resonance enhanced in RSpec
which enabled their sensitive detection in Raman maps. Conclusions FTIR and Raman spectrsocopic imaging havesensitive mapping capabilities but reveal different specificities to detect metastatic melanoma cells in murine brain.

- 231 -­­

Poster Presentation (P)Background: Direct molecular analysis of biological tissue using mass spectrometry (MS) is a subject of much interest in thefield of metabolomics. Furthermore, MS on 2D samples, also known as is imaging mass spectrometry (IMS) allows
visualization of molecular distributions on a tissue surface. This technology has been developed using matrix-assisted laser
desorption/ionization time-of-flight mass spectrometers (MALDI-TOF MS). Lipids can perform both structural and functionalroles within the body and are known to be important mediators of cell signaling, acting as second messengers in cellular
events. Many previous experiments using IMS to image samples have focused on measuring the distribution of elements andsmall molecules in normal rat brain sections.
Purpose: This study focuses on mapping the lipid distribution in rat brain tissue sections of a C6 glioma model, forcomparison with the normal cerebral area.
Methods: 1x105 C6 glioma cells were infused into the brains of Sprague-Dawley rats. The rats were killed on day 21, andtheir brains were removed and sliced at a 7μm thickness, then placed directly onto plate inserts. MS and IMS analyses wereacquired using MALDI-TOF MS (QSTAR XL, Applied Biosystems) in positive ion mode.
Results: Relative intensities of the ion signal of m/z 798.5 [phosphatidylcholine (PC) 16:0/18:1 + K]+ were reduced in thetumor area as compared with the normal cerebral area. However, relative intensities of the ion signal of m/z 741.4[sphingomyelin (SM) d18:1/16:0 + K]+ were increased in the tumor area. The decreased PC ion signal in the tumor areasuggests the collapse of normal tissue while the increased SM ion signal is regarded as having a tumor cell origin.
Conclusions: Direct molecular analysis using IMS in the rat brain C6 glioma model was performed. The results raise
possibility of analyzing brain tumor tissues using this novel approach combining IMS with other imaging methods.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P287
Significance of NMR based metabolomics (metabolome) for the predictionof malignant type meningioma using the analysis of water and lipidsoluble metabolites
Hiroshi Takahashi1, Keiko Hirakawa2,Youkichi Ohno2, Akira Teramoto3, Kohtaro Yuta4
Department of Neurosurgery, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan 2NMR Laboratory /Department of Legal Medicine, Nippon Medical School 3Department of Neurosurgery, Nippon Medical School Hospital
4
Bio-IT Group, Fujitsu Co. Ltd
1[Purpose] In meningiomas which are considered to be benign brain tumors, there are malignant type tumors. Most of thesemalignant type meningiomas are histologically diagnosed anaplastic or atypical ones. However, some of malignant typemeningiomas show poor clinical courses, although histological diagnoses are benign. It is difficult to distinguish this specificgroup from usual benign type meningioma. Therefore, we tried to gain characteristic extraction by the metabolite expression
profiling using NMR based metabolomics (comprehensive metabolite analysis). [Methods] We extracted water and lipidsoluble metabolites from recent frozen surgical specimens which are 31 meningiomas including 2 anaplastic, 1 atypical and2 malignant type cases, and measured 1H-NMR spectra. And then, we did analysis by data processing software Alice2 formetabolomeTM ver1.0 (JEOL DATUM) and ADOMEWORKS / ModelBuilderTM ver3.1 (Fujitsu). Finally, we searched for theparameters which characterized malignancy in loading plot. [Results] Water-soluble metabolites: Surgical specimens were
distributed to almost two domains (grade 1 and grade 2/3 domains). Two anaplastic and 1 atypical meningiomas were
distributed in the same domain, and 2 malignant type meningiomas were distributed over extremely near location in thegrade 2/3 domain. Lipid-soluble metabolites: Malignant type meningiomas were distributed near location in the grade 3
domain. However, grade 2 domain was isolated.[Conclusion] This study suggests that NMR based metabolomics are very
useful for prediction of malignant type meningiomas which were histologically benign.

P288
Role of Proteomic study of CSF as a diagnostic tool in the patients withmeningiomas
Jae ho Kim1, sang kawang lee2, young tae kim2, young mok park 2, kyung G cho1
Department of neurosurgery, Ajou University School of Medicine 2Korea Basic Science Institute1

Poster Presentation (P)Object: Meningiomas are common intracranial tumors and have been considered as benign because of their slow growth
rates and the feasibility of surgical cure and meningiomas represent the second most common central nervous system
neoplasms in adults and account for 26% of all primary brain tumors. Even Most meningiomas can be graded into WHO
grade 1 some of them are classified atypical(grade 2), and anaplastic meningiomas(grade 3). Cerebrospinal fluid contains arich proteins source of biomarker and has a potential to be used as diagnostic and prognostic indicators for brain tumors.
We tried to evaluate possibility of new diagnostic tools from the CSF in patients with meningioma. Methods: Proteome
profiling patterns were compared in 10 human CSF samples: 5 meningiomas, 5 non-brain tumors CSF. We could completely
differentiate specific proteins in CSF associated with human meningioma using the 2-D difference gel electrophoresis
analysis and thereafter identified specific proteins by mass spectrometry for ESI-Q-TOF. These proteins were verified withwestern blotting and immunohistochemistry method. Results: There were 10 proteins more than 2-folds differentiallyexpressed between meningioma and non-brain tumor including abundant proteins. 7 proteins (Apo E, Apo J, AAT) wereincreased in meningoma whereas 3 proteins (PTGDs, TTR, beta-2-microglobulin) were decreased. Through the western
blotting method and immunohistochemistry we identified similar pattern with 2-dimensional electrophoresis. Conclusions:
The goal of our study was to identify for the first time, from the CSF of patients with meningioma by 2-DE method andresulting pattern was confirmed by using western blotting and IHC. These proteins showed the possibility for candidate
biomarker for meningoma. These results may provide useful information with respect to preclinical research of diagnostic
tools for brain tumor.

P289
IL-6 in meningioma; Expression is correlated with peritumoral edema and
VEGF

Cancelled- 232 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP290
Antitumor effect of humanized anti-IL-6 receptor antibody (tocilizumab)
on glioma cell proliferation
Mareina Kudo1,2, Hirofumi Jono2, Satoru Shinriki2, Shigetoshi Yano1, Hideo Nakamura1,
Keishi Makino1, Takuichiro Hide1, Daisuke Muta1, Mitsuharu Ueda2, Kazutoshi Ota2,
Yukio Ando2, Jun-ichi Kuratsu1
Departments of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

1
2

Objective: Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates diverse physiological functions, including cellproliferation and survival. Recent studies showed that IL-6 expression was often elevated in response to several types ofcancers and tumors, including glioma. Although IL-6 is known to play an important role in glioma, the involvement of IL-6
signaling has been quite controversial. The aim of this study was to evaluate the involvement of IL-6 signaling in glioma andthe inhibitory effect of IL-6 signaling on glioma tumor proliferation. Methods: The expression of IL-6 receptor (IL-6R) was
evaluated in glioma tissues by immunohistochemistry and also the involvement of IL-6 signaling in glioblastoma U87MG cellproliferation was determined. In addition, to examine the inhibitory effect of IL-6 signaling on glioma cell proliferation, weinvestigated the effects of IL-6- and IL-6R-specific siRNA and AG490, a specific inhibitor of JAK2 phosphorylation in U87MG
cells. Furthermore, we investigated the effects of tocilizumab, a clinically developed humanized anti-human IL-6 receptor
antibody in U87MG cells. Results: Increased immunoreactivity for IL-6R was predominantly found in the cytoplasm ofendothelial cells in all glioblastoma samples. Inhibition of IL-6 signaling by IL-6 and IL-6R -specific siRNA and AG490
suppressed glioma cell proliferation, respectively. Furthermore, tocilizumab exerted the anti-proliferative effect on
glioblastoma cell line U87MG via IL-6R-dependent JAK-STAT3 pathway. Conclusions: IL-6 signaling pathway plays animportant role in glioma cell proliferation, and that tocilizumab exerts anti-tumor effect in U87MG glioma cells. These results
may bring a new insight into molecular pathogenesis of glioma and may lead to a new therapeutic intervention.

P291
The Plasma Concentration of ET-1 in the Brain Tumors
Ann-Shung Lieu1, Shen-Long Howng1
The Department of Neurosurgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

1

P292
Plasma Ig E levels correlate with diagnosis and response to therapy inglioma patients
Yi Lin1, Tao Jiang1, Baoshi Chen1, Jian Xie1, Xiaoguang Qiu1
Glioma Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

1

Objective: To determine the plasma IgE levels in different grades of glioma patients and its relationship with therapy
response. Methods: Enzyme-linked immunosorbance assay (ELISA) was employed to determine the plasma IgE levels of 25
normal subjects and 155 glioma patients (including 52 grade II glioma patients, 31 grade III glioma patients and 72 GBM
patients).We also compared the plasma IgE levels of 30 GBM patients who are receiving chemotherapy after operation
without signs of recurrence and 16 GBM patients who have a recurred disease after operation. Results: Plasma IgE level innormal subjects and glioma patients were 429.3+/-162.9ng/ml and 320.9+/-193.2ng/ml respectively. Plasma IgE level was
significantly lower in glioma patients(t=2.60,p=0.01). Plasma IgE level in the low-grade glioma patients (269.6+/-203.2ng/ml)
was significantly lower than that in the high-grade glioma patients(grade III and GBM,346.8+/-183.6ng/ml)(t=2.39,p=0.018).
No significant differences were observed from the plasma IgE levels within the high-grade glioma patients(p=0.74). Plasma
IgE increased(t=4.92,p<0.001) after successful removal of the tumor(572.7+/-249.0ng/ml).But did not decrease afterrecurrence(p=0.903). Conclusions: Plasma IgE levels of the glioma patients especially the low-grade glioma patients weresignificantly lower than the normal subjucets. Plasma IgE levels increased after successful tumor removal in the high-grade
glioma patients.

- 233 -­­

Poster Presentation (P)ET-1is produced by a large variety of cells from a wide rang of mammalian species, and has been identified in plasma. The
difference between plasma concentrations of ET-1 in prostate cancer patients, as compared to those without prostatecancer has been reported. To our knowledge, the plasma concentrations of ET-1 in different types of brain tumor have notbeen reported. If the different types of brain tumor express significantly various concentration of plasma ET-1, endothelin
receptor antagonists can be administered to inhibit proliferation of tumor cells. Therefore in this study, we test the differenceof serum concentrations of ET-1 in brain tumor.The plasma concentrations of ET-1 in different brain tumors were as following:
control: 8.0 ±1.953 pg/ml, meningioma: 8.8 ± 2.521 pg/ml, brain metastasis: 8.6 ± 3.098 pg/ml, glioblastoma multiforme:
5.0 ± 2.133 pg/ml, and pituitary adenoma: 8.4 ± 1.980 pg/ml. There were no significant differences among the subtypes ofmeningioma. Among the brain metastasis group, the plasma concentration of ET-1 of the lung carcinoma with brain
metastasis showed high level concentration (9.1 ± 3.650 pg/ml). There were no significant differences between the subgroupof metastasis except the colon carcinoma. The concentration of ET-1 in the meningioma and brain metastasis group issignificantly higher than that of glioblastoma multiforme group(p<0.001). The cause of different plasma concentration of ET-1
may be the different blood supply system. Most meningiomas are feeded from extracranial blood system and brain
metastasis is seeded from systemic blood supply. The glioblastoma multiforme is feeded via local brain blood supply.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P293
DELETION OF PTEN IN CLIVAL CHORDOMAS
Dae-Hee Lee1, Amin B. Kassam1,2, Craig Horbinski3, Paul Gardner2, Daniel M. Prevedello2,
Akio Soeda1, Carl Snyderman4, Ricardo Carrau4, Frank Lieberman1,5, Ronald L. Hamilton3,
Deric M. Park1,2,5
University of Pittsburgh Cancer Institute, Pittsburgh, PA 2Department of Neurological Surgery, University of Pittsbugh
Department of Pathology, University of Pittsburgh 4Department of Otolaryngology, University of Pittsburgh
5
Department of Medicine (Oncology), University of Pittsburgh
1
3

PURPOSE: Chordoma is a bone cancer restricted to the axial skeleton and believed to arise from the remnants of thenotochord. Clinical disease recurrence is characterized by invasion into surrounding structures by incompletely removed
cancer cells. Accepted treatment regimen consists of surgery followed by radiation therapy. A phase II clinical trial revealed
that use of imatinib may be warranted in chordomas with activated platelet-derived growth factor receptor (PDGFR).
Because this clinical experience and our in vitro observations demonstrated inconsistent response to PDGFR inhibition, weinvestigated the downstream signaling pathway in chordoma cells. METHODS: We performed detailed molecularpathologic analyses on 15 chordoma specimens from 12 patients, and established primary cultures from acutely resected
chordoma tissue for in vitro experiments. DNA isolated from manually microdissected tumor tissue was used to performpolymerase chain reaction-based loss of heterozygosity (LOH) analysis for the phosphatase and tensin homolog (PTEN)
gene (10q23). Primary cultures were established by mechanical dissociation of chordoma tissue and propagated in both
serum-free and serum-containing conditions at 5% and 20% oxygen tensions. RESULTS: LOH at the PTEN locus wasobserved in 2 specimens (17%). This was confirmed at the protein level by Western blot analysis. Cell culture studies
showed increased proliferative rate of PTEN deficient tumors compared to PTEN wild-type chordoma specimens. In
addition, chordoma cells derived from PTEN deficient tumors were less responsive to PDGFR tyrosine kinase inhibition.
CONCLUSIONS: To our knowledge, this is the first report of PTEN deletion in chordomas. Because patients with PTEN
deleted chordomas may be refractory to PDGFR inhibition, screening tumor tissue may be of value prior to initiating therapy.

P294
Promoter methylation profiles of six tumor-related genes in various
brain tumors
Lu-Ting Kuo1, Kuang-Ting Kuo2, Jui-Chang Tsai3, Ham-Min Tseng3, Yong-Kwang Tu3
Division of Neurosurgery, National Taiwan University Hospital, Yun-Lin branch, Yun-Lin county, Taiwan 2Department of
Pathology, National Taiwan University Hospital, Taipei, Taiwan 3Division of Neurosurgery, National Taiwan University
Hospital, Taipei, Taiwan
1

Poster Presentation (P)BACKGROUND: Hypermethylation of tumor-related genes represents a primary mechanism in the inactivation of this gene.
In this study, we investigated the methylation status of the promoter of six genes in human brain tumors. METHODS:
Genomic DNA was isolated from formalin-fixed paraffin sections of 279 brain tumors, including 58 oligodendroglial tumors,
56 ependymomas, 114 astrocytomas, 14 central neurocytomas and 37 chordomas, and then bisulfite-converted, andanalyzed by methylation-specific polymerase chain reaction. RESULTS: Among the brain tumor samples, 81.4% (227/279)
revealed hypermethylation in at least one gene analyzed. Especially in oligendroglial tumors, all but one sample (98.3%)
displayed anomalies in at least one gene. RASSF1A was hypermethylated in more than half of the tumors in eachclassification except in chordoma. P16 was the least frequently hypermethylated gene in this study, showing no methylationin central neurocytomas and chordomas. MGMT was more commonly methylated in gliomas, including 55.1% in
oligodendroglioma, 66.1% in ependymoma, and 31.6% in astrocytomas, in contrast to the 7.1% in central neurocytoma and
0% in chordoma. CONCLUSION: The major subtypes of brain tumors display differential aberrant promoter methylation
profiles. Such information may have substantial diagnostic and prognostic value.

P295
SHORT COURSE OF RADIOTHERAPY AND CONCOMITANT TEMOZOLOMIDE IN
PATIENTS AFFECTED WITH GLIOBLASTOMA WITH V-VI PROGNOSTIC CLASSES. A PILOT
STUDYSalvador Villa1, Anabel Manes1, Cristina Hostalot1, Jaume Capellades1, Emma Costas1,
Oria Rosinol1, Carolina Sanz1, Rafael Rosell1, Carme Balana1
Catalan Institute of Oncology and HU Germans Trias. Badalona. Barcelona

1

Purpose: To evaluate the outcome and toxicity profile of glioblastoma patients treated with hypofractionated radiotherapy(HPF) (Roa 2004) and concomitant Temozolomide (TMZ) (Stupp 2005) in unfavorable V and VI prognostic classes(Mirimanoff 2006). Materials and Methods: We are monitoring clinical outcome, survival, and acute and long term toxicitiesof patients treated with HPF scheme (40 Gy in 15 fractions) concomitantly with TMZ (75 mg/m2 for 2 patients and 85 mg/m2
for 5 patients) (21 days in total), followed by adjuvant TMZ (150-200 mg/m2). MST is calculated from surgical procedure.
Dexamethasone and neurological status are being registered. Results: Eight patients have been recruited till 12/2008, 7 ofthem are able to be validated (4 men and 3 women; median age of 69 years). Classification according to the RTOG/EORTC
recursive partitioning analysis was as follows: class V for 3 patients and class VI for 4 patients. Surgery consisted of partial
resection (n=2) or only biopsy (n=5). Median survival time was 24 weeks (4.5-63) for the whole group, but some differenceswere found by 3 class V patients (4.5, 54, 63 w) and 4 class VI patients (8, 13, 24, 58 w). In 3 patients MGMT gene promoter
was methylated. Main acute toxicity was asthenia and thrombocytopenia, with one case of pneumonia. Two patients diedduring treatment because progression. No long term neurological complications have been found. No steroid dependence
was observed in 2 patients. After progression, 3 patients were entered in schedule of CPT-11 and bevacizumab, with MRI
and SPECT monitoring. Conclusions: Hypofractionated Radiotherapy concomitant with Temozolomide can be used forselected poor prognostic GBM patients to reduce the overall treatment time, without apparent increased toxicity.

- 234 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P296
Assessment of 11C-methionine PET Changes for Monitoring Therapeutic
Response Following Simultaneous Integrated Boost Technique for
Glioblastoma Multiforme
Kazuhiro Miwa1, Masayuki Matsuo2, Jun Shinoda1, Syunsuke Takenaka1, Takeshi Ito1,
Yoshitaka Asano1, Mikito Yamada3, Kazutoshi Yokoyama3, Jitsuhiro Yamada3, Hirihito Yano4,
Toru Iwama4
Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, Gifu, Japan
Department of Radiao-oncology, Kizawa Memorial Hospital, Gifu, Japan 3Department of Neurosurgery, Kizawa
Memorial Hospital, Gifu, Japan 4Department of Neurosurgery, Gifu University School of Medicine, Gifu, Japan
1
2

Purpose We developed simultaneous integrated boost technique (SIB) planned by 11C-methionine (MET)-PET, andquantified the effect of MET-PET in monitoring the response to radiation for SIB with chemotherapy. Methods We performed
SIB in 17 patients with GBM with subtotal resection. GTV-1 was defined as the area of intensive MET uptake. GTV-2 wasdefined as the area of mild MET uptake. PTV-1 encompassed GTV-1 plus 5 mm margin, and PTV-2 encompassed GTV-2
plus 2 mm margin. SIB was performed in 8 fractions, planning the dose for GTV-1 at 68 Gy, PTV-1 at 56 Gy and PTV-2 at 40
Gy with concurrent temozolomide at a dose of 75mg/m2. Each patient underwent a series of MET-PET exams: baseline prior
to SIB, 3 months following SIB and 6 months following SIB. The change of MET uptake value in the PTV-1 and PTV-2 (PTVs)
after SIB was investigated. Results MET-PET exams were performed in all 17 patients 3 months after SIB and in 10 patients
6 months after SIB. At 3 months following SIB, MET uptake value in the PTV-1 was reduced in all 17 patients (average
32.3%). The uptake value in the PTV-2 was reduced in 14 of 17 patients (average 22.8%), and increased in three patients(average 14.6%). At 6 months following SIB, the uptake value in the PTV-1 was reduced in all 10 patients (average 35.4%).
The uptake value in the PTV-2 was also reduced in all 10 patients (average 25.3%). In three of those 10 patients, newabnormal MET uptake at the outside of PTVs was seen. Conclusion Preliminary results demonstrated that the uptake valueof MET decreases after SIB at the PTV-2, as well as at the PTV-1 in the majority of patients. In some cases, however, it isdifficult to prevent tumor recurrence at the outside of PTVs.

P297
RECURRENCE PATTERN AFTER [(18)F]FLUOROETHYLTYROSINE- POSITRON EMISSIONTOMOGRAPHY-GUIDED RADIOTHERAPY FOR HIGH-GRADE GLIOMA.

Cancelled

P298

Mayo Clinic College of Medicine, Rochester, Minnesota, USA

1

Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of benign tumors of
the peripheral and central nervous system (CNS) including schwannomas, meningiomas, and ependymomas. The gene
responsible for the development of NF2 (schwannomin or merlin) acts as a tumor suppressor gene. Disease expression isquite variable resulting in a spectrum of different phenotypes. While there is an association between NF1 and malignant
neurofibroma, the development of malignant tumors is not considered a feature of NF2.The hallmark of NF2 is developmentof bilateral vestibular schwannomas with a consequent hearing loss. Patients often have a large burden of intracranialtumors, particularly meningiomas, and require frequent interventions. Surgery has been a standard therapy, but stereotactic
radiotherapy (SRT) has been increasingly used for the management of these tumors. It offers some enticing advantages oversurgery particularly in regards to short-term risk. Because of the high frequency of multiple intracranial tumors in NF2
patients, SRT is an attractive option in this patient group. Common long-term complications of radiosurgery include cranial
neuropathies, and less commonly vasculopathy, while the risk for malignancy after SRT is not well delineated. While there are
no known instances of spontaneous malignant degeneration of tumors in NF2 patients, there are a few reports of malignant
schwannoma, meningioma and ependymoma after the SRT. We present the first documented case of rhabdomyosarcoma
following SRT for a NF2-associated vestibular schwannoma. Patients with NF2 have a tumor suppressor gene defect andmay be more vulnerable for development of secondary malignancy after treatment involving radiation, when compared topatients with isolated tumors. Decision about selection of therapy in NF2 patients, particularly ones in young age, must
include consideration of long term complications, particularly radiation-induced malignancies.

- 235 -­­

Poster Presentation (P)Rhabdomyosarcoma as a late complication of Stereotactic Radiotherapy
in the patient with Neurofibromatosis Type 2
Dusica Babovic-Vuksanovic1, Matthew L Carlson1, Bernd Scheithauer1, Brian A Neff1,
Michael J Link1

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P299
RADIATION-INDUCED CEREBRAL CAVERNOUS HEMANGIOMAS IN ADULTS.
Alexander Lossos1, Edna Shalom1, Eduard Linetsky1, Natalia Aizikovich1, J. Moshe Gomori2,
Tali Siegal1
Gaffin Center for Neuro-Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 2Department ofRadiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

1

Background: Cerebral cavernous hemangiomas are a documented delayed complication of cranial irradiation in pediatricprimary brain tumors. They are considered rare in adults and only sporadic cases have been described. Objective: To
evaluate the frequency of radiation-induced cerebral cavernous hemangiomas (RICH) in routine surveillance imaging of adultlong-term survivors of brain tumors therapy. Methods: Neuro-oncology patients with RICH detected on routine surveillance
MRI within a period of 12 months in our service were retrospectively analyzed . Early CT studies were retrospectively
reviewed as well as recent MRI, with particular attention to T2-weighted gradient echo (T2GE) and susceptibility-weighted(SWI) sequences. Results: We identified 15 patients (6 men and 9 women) with RICH diagnosed after a mean period of 8
years (range: 5-13) following external beam cranial irradiation delivered as treatment for high grade glioma (5),medulloblastoma (5) ependymoma (2), and either germinoma, pituitary adenoma and meningioma (1 each). The mean ageof patients at the time of this analysis is 43 years (range:24-66). The mean cumulative radiation dose was 48Gy
(range:40-60) with mean daily fractions of 1.8Gy (range:1.6-2). Characteristically, multiple (3 or more) RICH are detected
within the radiation field either supra- or infratentorially. It appears as multifocal areas of round hypointensity on T2GE and
SWI images. The lesions are asymptomatic in 10 patients, associated with seizures in 2, recurrent headaches in 2, and acuteintracerebral hemorrhage in 1. No specific treatment was given to RICH . Conclusions: RICH may be more common than iscurrently appreciated in adult long-term survivors of brain tumor therapy . The clinical and imaging features are similar to
RICH in children. Based on these findings, a prospective analysis of RICH seems warranted in order to evaluate its incidence,prevalence, associated morbidity and risk of bleeding.

P300
Hematotoxicity of craniospinal irradiation in adult patients
Katarzyna Elandt1, Gabriele Altorjai2, Andrea Rottenfusser2, Wolfgang Dietrich3,
Matthias Preusser1, Karin Dieckmann2, Christine Marosi1
Department of Internal Medicine I, Oncology, MUW, Vienna 2Department of Radiotherapy, MUW, Vienna 3Departmentof Neurosurgery, MUW, Vienna
Background: Craniospinal irradiation (CSI) is part of the standard care in patients with malignant embryonal brain tumours
as medulloblastomas, intracranial primitive neuroectodermal tumours (PNETs) and ependymoblastomas. As the radiation
field covers large parts of the haematopoietic bone marrow bone marrow depletion is a common side effect of CSI.
Methods: The incidence, grade and duration of bone marrow depletion in adults treated at our institution with CSI for anembryonal brain tumour during the last 10 years was investigated retrospectively. Results: Thirty patients, 12 women and 18
men, aged 23 to 64 years were treated with CSI. Radiation therapy consisted of 1.8 Gy/5 fractions per week to a dose of 36
Gy to the skull and the spinal axis followed by a boost of 18.8 Gy in 10 fractions to the posterior fossa (up to a total of 54.8
Gy). Twenty-two (73%) patients developed aplasia during or shortly after the CSI, with a median duration time of 136 days
(range 32 to 480 days). Most common hemato-toxicity (HT) of WHO Grade III or IV was thrombocytopenia (15/30; 50%) andleukocytopenia (19/30; 63.3%), which caused limitations to eventual subsequent chemotherapy (CHT). Granulocyte-colony
stimulated factor was used for more than 2 weeks in 23 (76.6%) patients. Further, ten (33.3%) patients presented HT of WHO
Grade I/II, for a median of 67 days. Anaemia requiring red blood cell transfusion was observed in seven (27%) patients. The
myelosuppression was associated with opportunistic infection, like fungal infection, herpes encephalitis or pneumonia. One
patient died of septicaemia. In ten cases, HT combined with infections resulted in interruption or stopping adjuvant CHT.
There was no gender or age specific difference in appearance of HT. Conclusions: The risk of significant bone marrow
depletion is high in adult patients treated with CSI for embryonal brain tumours.
1

Poster Presentation (P)- 236 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP301
Inspection about recurrence and progressing dementia after WBRT tometastatic brain tumor - Problem presentation against WBRT Hirokazu Takami, Akio Asai, Hideyuki Oshige, Tatsuro Uesaka, Junichi Takeda, Kunikazu
Yoshimura, Keiji Kawamoto1)
Department of Neurosurgery, Kansai Medical University Hirakata Hospital, Osaka, Japan1)
Department of Neurosurgery, Kansai Medical University Takii Hospital, Osaka, Japan(Background and Objective)
Streotactic radiosurgery has come to be used frequently as the initial therapy to metastatic brain tumors, but still whole brain
radiation therapy (WBRT) is the standard therapy after surgery. This report deals with cases of emergence of newmetastases after WBRT and cases of deterioration of QOL after WBRT, and aims to address issues about the timing and therole of WBRT.
(Cases discussed)
26 cases have been treated in our hospital for metastatic brain tumors during April 2006 and June 2008, and 17 cases ofthem were treated with surgery and WBRT as the initial therapy. Within these cases, there were 3 cases of recurrence as
new intracranial metastatic lesions (all of them were breast cancer), and one case of severe deterioration of QOL as a resultof severe brain atrophy and dementia. Representative cases are as follows; (Case 1) 58 year-old female patient with breast
cancer was diagnosed with single metastasis in the occipital lobe one year after the treatment of the original cancer.
Operation was performed, followed by 40 Gy (2 Gy times 20 fractions) of WBRT. 12 months later multiple small metastases
appeared, and cyberknife treatment was brought to those lesion. Since WBRT was administered before cyberknife
treatment, full dose could not be used. The patient died of uncontrollable intracranial tumors. (Case 2) 79 year-old malepatient with colon cancer was diagnosed with single brain metastasis in the superficial motor cortex 3 months after thetreatment of the original cancer. Operation followed by 30 Gy (3 Gy times 10 fractions) of WBRT was performed. 14 months
later brain atrophy progressed and dementia advanced. Deterioration of QOL led the patient to the state of cripple.
(Conclusion)
We propose, in cases that long course is expected and emergence of new metastatic lesion has high possibility like breast
cancer cases, and in cases of old age, WBRT after surgery should not be performed as a routine protocol. WBRT should be
limited to cases of multiple brain lesions which are intractable with operation or stereotactic radiosurgery.

P302
Novalis Shaped Beam Radiosurgery for cranial and spinal tumors: 8
years of experience in Korea
Hae-Won Gu1, Moon-Jun Sohn1, Dong-Joon Lee1, Chae Hueck Lee1, C. Jin Whang1
Department of Neurosurgery, Novalis Radiosurgery Center, Inje University Ilsan Paik Hospital, Goyang, Korea

1- 237 -­­

Poster Presentation (P)Objective: Our experience indicates that Novalis Shaped Beam Radiosurgery offers some distinct clinical advantages in thetreatment of a diverse range of cranial and spinal tumors. Over the past eight years we have focused on the development of
optimal treatment protocols for local tumor control with minimal collateral damage. In this paper we review 1,041 clinicalexperiences of cranial and spinal stereotactic radiosurgery(RS) and analyze the results. Methods: By April 2008, we hadcompleted 1041 cases of cranial and spinal RS. Of the cranial RS (795 cases), 59% were for malignant tumors and 34%
were for benign tumors while of the 245 cases of spinal RS most were for malignant tumors; 70% metastatic tumors with thebalance made up of benign tumors and AVM. We analyzed the treatment protocols used and the clinical outcomesaccording to the different dose-fraction regimes used, the patients' condition and the various stages of tumor development.
Results: Where we used single session cranial RS we were generally able to achieve excellent levels of local tumor control
for most types of benign and metastatic tumors. For more challenging cases involving limitations due to size, type of tumor,
dose restrictions and histology we were able to achieve positive outcomes using fractionation and intensity modulation.
Many of these tumors were large, glial or located close to critical structures such as the optic nerve or brainstem.
Conclusion: Hypofractionated schedules for treating sellar & parasellar tumors, multiple and large tumors have been appliedwith great success. Spinal Radiosurgery is now established as a clinically viable treatment option for a wide range ofchallenging lesions that previously required invasive surgical procedures. Further study is in progress to expand the range
and efficacy of our treatment protocols.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)P303
ULTRAFRACTIONATED RADIATION THERAPY (3 DOSES PER DAY) FOR INOPERABLEGLIOBLASTOMAS. A NEW AND PROMISING REGIMEN.
Patrick D Beauchesne1, Luc Taillandier1, Charlotte Carnin1, Valerie Bernier2, Remy Pedeux3
Neuro-Oncology, CHU de Nancy, Nancy, France 2Radiotherapy, Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France
INSERM U578, Groupe de Recherche sur le Cancer du Poumon, Institut Albert Bonniot, La Tronche, France.

1
3

Background: Ultrafractionation radiation therapy consists in irradiating cells or tumors several times daily, delivering low
doses at which hyperradiosensitivity occur. We recently reported the high efficiency of ultrafractionation radiotherapy inglioma cell lines and xenografts and are now conducting a phase II clinical trial to determine the effect of an ultrafractionation
regimen for glioblastoma patients. Methods: A prospective, multicenter, phase II study has opened for accrual in September
2003. Patients over 18 years of ages who are able to give informed consent and have histologically proven, newly diagnosed
and unresectable, supratentorial glioblastoma (WHO grade IV) are eligible. Three doses of 0.75Gy spaced by at least fourhours are delivered daily, five days a week for six consecutive weeks for a total of 67.5Gy. Conformal irradiation includes thetumor bulk including a margin of 2.5 cm. Tolerance and toxicity is the primary endpoints; survival and progression-freesurvival are secondary endpoints. Results: To date 31 patients have been enrolled in this study, 16 men and 15 women,
median age 58 (range 37 to 76), median Karnofsky performance status (80 range from 60 to 100). The median time between
histological diagnosis and the start of treatment is 6 weeks. The ultrafractionated radiation therapy has been well tolerated;no acute grade 3 and/or 4 CNS toxicity has been observed. Minor responses at the end of irradiation were seen in 5
patients. Median survival from initial diagnosis was 10 months, eight patients remain alive. Conclusions: Ultrafractionatedradiation therapy is safe and well tolerated. No acute CNS toxicitiy has been observed. Overall survival of over 10 months forpatients without prior debulking surgery compares favorably with other reports. Updated definitive results will be presented.

P304
STEREOTACTIC RADIOSURGERY (SRS) IN RECURRENT HIGH-GRADE GLIOMA
Felix Bokstein1, Deborah T Blumenthal1, Zvi Ram2, Benjamin W Corn3, Dany Shifter3,
Andrew A Kanner2
1
Neuro-Oncology Service,Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 2Department of Neurosurgery, Tel Aviv
Sourasky Medical Center, Tel Aviv, Israel 3Department of Radiation Oncology, Tel Aviv Sourasky Medical Center, TelAviv, Israel

Poster Presentation (P)Despite the failure of the RTOG 9305 randomized trial to demonstrate the efficacy of SRS in newly diagnosed glioblastoma,
this treatment was reported in several institutional series to be modestly effective, particularly in the setting of limited focallyrecurrent disease. The objective of the current presentation is to retrospectively analyze our experience with 17 patientstreated by SRS at the Tel Aviv Medical Center from 2004-2008. There were 9 patients with primary glioblastoma, 2 withsecondary glioblastoma, and 6 with anaplastic glioma. The median age was 52 (36-75); there were 8 males and 9 females.
The indication for use of SRS was rapidly progressing neurological deficit in 3 patients, and a new, asymptomatic, limited
enhancing focus on T1-contrast MRI in 14 patients. Two patients with anaplastic oligodendroglioma received SRS twice.
Three of 19 treatments resulted in immediate progression whereas in 16 other treatments (84%) stable disease or partial
responses were achieved. Median time to progression in responding patients was 5 months (1-51). Longstanding responses(> 12 months) were observed in 5 patients (3 with GBM and 2 with anaplastic gliomas). In one GBM patient with rapidly
progressing hemiparesis due to a new enhancing lesion in the internal capsule region, SRS resulted in significant
improvement of limb weakness within 2-3 weeks with clinical stabilization for two months. One patient with anaplastic
astrocytoma developed clinically significant radiation necrosis 3 months after SRS and required a palliative operation, butsince then has remained asymptomatic and without radiological evidence of active disease for more than 51 months. In theremainder of patients the treatment did not result in worsening of clinical symptoms and was not associated with significant
side effects. In conclusion, SRS may be considered an effective salvage procedure in selected patients with recurrent highgrade gliomas, providing long term responses in some cases.

P305
Treated with CyberKnife Stereotactic Radiosurgery: Two CyberKnife
Centers Experience
Da-Tong Ju1, Cheng-Ta Hsieh1, Jo-Ting Tsai2, Jia-Wei Lin3
1
Department of Neurological Surgery, Tri-Service General Hospital, Taipei, Taiwan, Republic of China 2Department ofRadiation Oncology, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan 3Department of Neurosurgery, Taipei
Medical University-Shuang Ho Hospital, Taipei, Taiwan

Background: The stereotactic radiosurgery such as Gamma-knife or linear accelerator radiosurgery has been showed toreduce the re-hemorrhage annual risk in patients with cavernous malformations. Cyberknife is a new frameless system andthe role of Cyberknife stereotactic radiosurgery in the management of cavernous malformations has not been discussed.
The authors present the 3-year results of cavernous malformation treated by Cyberknife stereotactic radiosurgery in two
medical centers.
Material and Methods: From September 2005 to September 2008, 14 patients with 17 cavernous malformations wereenrolled in this study. There were 6 men and 8 women with mean age of 40 years. Thirteen patients (93%) had only one
hemorrhagic episode in the pre-radiosurgery period. All patients were treated by Cyberknife stereotactic radiosurgery andfollowed at least more than one year. Magnetic resonance imaging was performed before and after treatment.
Results: The mean volume was 0.45 ml, whereas the mean maximal dose was 2203 cGy. The median marginal dose was1600 cGy. The mean prescribed isodose was 79%. The mean follow-up time was 21.5 months. Only two patients re-bled
after Cyberknife stereotactic radiosurgery. The annual re-hemorrhagic rate accounts for approximately 7.9%.
Conclusions: Cyberknife stereotactic radiosurgery seems to be effective in reducing annual rehemorrhagic risk in patientswith cavernous malformations in the 3 years follow-up. The long-term outcome should be investigated in the future.

- 238 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

P306
Peritumoral edema after Cyberknife radiosurgery for meningioma:
Report of two cases and Review of literature.
Cheng-Ta Hsieh1, Da-Tong Ju1, Jia-Wei Lin2, Jo-Ting Tsai3
1
Department of Neurological Surgery, Tri-Service General Hospital, Taipei, Taiwan, Republic of China 2Department of
Neurosurgery, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan 3Department of Radiation Oncology,
Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan

In the past decades, stereotactic radiosurgery including gamma-knife, linear accelerator or cyberknife becomes an effective
tool for patients with intracranial meningiomas, despite of primary or adjuvant therap. It can offer a noninvasive minimal
access, achieve a good tumor control rates and maintain the vital neurological functions. However, peritumoral edema
induced by radiosurgery during the treatment of intracranial meningioma has been reported in the literature and themechanism still remains unclear. Parasagittal meningioma has been described as a predisposing factor in developing
peritumoral edema after radiosurgery. In our presented cases, one parasagittal meningioma and one convexity meningioma
developed peritumoral edema at 6 and 7 months after Cyberknife stereotactic radiosurgery, respectively. The duration wascompatible with the findings of Kondziolka et al. (the peak time to edema was 6 to 8 months after treatment). The prescribeddosage has been suggested as a predisposing factor for peritumoral edema after radiosurgery. However, in our othersupratentorial meningioma cases, these tumors were all treated with a prescribed dose of 1800 cGy. The peritumoral edema
seems to be less likely related with the prescribed dosage. Otherwise, interestingly, although our second case was aconvexity meningioma, these two meningiomas were all located around the major draining sinus. Our results support the
hypothesis of peritumoral edema as a radiation side effect related to venous cause including damaging bridging veins
draining into the adjacent venous sinuses or thrombosis of circulation of sinus. It seems possible meningioma around the
major draining sinus may developed this complication after radiosurgery. Our cases provide an important formation that thepatient with meningioma around the drainage sinus treated by stereotactic radiosurgery should be followed closely. However,this phenomenon is rarely seen in other kind of brain tumors such as acoustic schwannoma or metastatic lesions. This also
should be investigated in further studies.

P307
Preliminary results of initially trated patients-FEASIBILITY OF APPLYINGTHE SYNERGY-S SYSTEM FOR STEREOTACTIC IRRADIATION SPINAL TUMORS
Andrew A. Kanner1
1
Stereotactic Radiosurgery Unit, Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv,
Tel Aviv Israel

P308
DOSE-VOLUME ANALYSIS OF WHOLE VENTRICULAR IRRADIATION BY PROTON BEAM
COMPARING WITH INTENSITY MODULATED RADIOTHERAPY AND STANDARD PHOTON
THERAPY
Hiroshi Fuji1, Yoko Nakasu2, Satoshi Horiguchi2, Koich Mitsuya2, Yuji Ishida3, Shigeyuki Murayama1
1
Proton Therapy Division, Shizuoka Cancer Center 2Division of Neurosurgery, Shizuoka Cancer Center 3Division of
Peadiatric, Shizuoka Cancer Center

Purpose: To assess the advantage of proton beam therapy (PBT) for whole ventricular irradiation (WVI), treatment plans with
proton beam therapy, intensity modulated radiotherapy (IMRT) and standard photon radiotherapy (SPR) were compared.
Methods: Computed tomography data set of a patient diagnosed germ cell tumor was utilized for the treatment planning.
Clinical target volume (CTV) were defined as the volume consisted of lateral ventricles, third ventricle and forth ventricle with
1 cm margins. Treatment plans with 24 GyE for CTV were performed with each treatment technique. Each treatment plan
included non-coplanner beams to reduce the dose to organ at risk. Inverse optimization was applied for treatment plan for
IMRT. On the treatment plans efficient dose deliveries in CTV were evaluated by the coverage and the homogeneity of doses
to the target. The mean dose of organ at risk including supratentorial and infratentorial brain, eyes and cochlea were
measured on the treatment plans. Results: Three treatment techniques achieved sufficient coverage to CTV. However, theinhomogeneity coefficient values for IMRT were higher than those of PBT and SPR. Mean dose of the supratentorial andinfratentorial brain with PBT was lower than those of IMRT and SPR. The doses to eyes and cochlea were decreased in PBTcomparing IMRT and SPR. Conclusion: Excellent conformality to target and homogenous dose deliver in target by proton
beam treatment enable to decrease doses to critical organs. Whole ventricular irradiation by proton beam expected toreduce the late toxicity after treatment of germinoma.

- 239 -­­

Poster Presentation (P)Background: Radiation treatment of spinal and paraspinal tumors has been limited by the tolerance of the spinal cord. As
such, therapeutic options are restricted to surgically accessible lesions or the use of sub-optimal dosing of external beamirradiation. During the last decade, several systems have been developed to implement extra-cranial stereotactic image
guided treatment delivering focused high dose radiation. Methods: Synergy-S (Elekta Corp, Crowley, UK) represents alinear accelerator based system that enables the delivery of sophisticated stereotactic-based treatment with high-resolution
multi-leaf collimation and volumetric image guidance. The system is predicated on rigid, reproducible, non-invasive body
fixation. We sought to determine the applicability of this system to the irradiation of spinal tumors within a busy universitybased practice. Results: Between November 2007 and June 2008 10 patients were treated for spinal tumors. Six patientswere female, median age was 50.2 years (39-79 years) and median KPS 85% (50-100). We treated metastases (renal cell
carcinoma, malignant melanoma, leiomyosarcoma and prostate cancer) and primary spinal tumors (malignant meningioma,
chondrosarcoma). The spinal levels included cervical (C1-2, C6-7), thoracic (T5), lumbar (L1-2, L2, L5) and sacral (S1). Fourcases were treated with radiosurgery (median 1550 cGy) and 3 were treated via fractionation (Median: 450 cGy x 5). All
patients tolerated therapy without acute complications. Local control has been achieved in all cases, albeit at short medianfollow-up time of 9.4 weeks (7.2 -27.1 weeks). Conclusions: The feasibility of delivering single and multiple fraction
stereotactic spinal irradiation has been demonstrated. No unique difficulties were encountered as a function of the level of
disease. Although a head-to-head comparison was not performed, this approach is considerably less time-consuming thanother image-guided systems (e.g., Cyberknife). Formal biologically-driven protocols are now in submission to the Institutional
Review Board to standardize this promising technology.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P309
IN VIVO BIODISTRIBUTION OF BORON AFTER INTRAVENOUS
4-DIHYDROXYBORYLPHENYLALANINE-FRUCTOSE (BPA-F) INFUSION IN MENINGIOMAAND SCHWANNOMA: A FEASIBILITY STUDY FOR BORON NEUTRON CAPTURE
THERAPY(BNCT)
Merja E Kallio1, Martti E Kulvik 2, Juha Laakso3, Jyrki Vahatalo4, Juha E Jaaskelainen5
1
Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland 2The Research Institute of the Finnish
Economy, Helsinki, Finland 3EVIRA, Finnish Food Safety Authority, Helsinki, Finland 4Finnish Maritime Administration,
Helsinki, Finland 5Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, University of Kuopio, Kuopio,
Finland

BNCT is an experimental neutron activated pharmacotherapy. The radiation energy is for the most part so high thatradioresistance does not play a significant role. BNCT is feasible for superficial tumors with high boron uptake. It is thus
attrac-tive to develop for inoperable meningiomas and Schwannomas in the elderly and in NF2 patients if sufficiently highand selective boron concentrations are achieved. As no data of boron uptake in vivo in the aforementioned tumors isavailable, we performed a feasibility study as part of the Finnish BNCT development project.Four meningioma and four
Schwannoma patients participated in the study. 100mg of BPA-F /kg of body weight of the patient was infused during 60
min prior to the operation. The tumor was then removed and sampled. The time to tumor removal varied, the earliest being
80 min after the start of infusion. Some of the Schwannomas were removed piecemeal, the last bits taken up to 300 min
from the start of the infusion. Boron was measured from tumor and from whole blood and plasma by a previously pub-lishedmethod utilizing atomic emission spectrometer. The mean tumor to whole blood boron concentration ratios was 3.6:1 formeningiomas and 2.4:1 for Schwannomas and respective tumor to plasma concentration ratios were 3.1:1 and 2.1:1. The
range of these ratios varied from 2:1 to 6:1.The data shows promising concentration ratios for boron uptake. Although theunavoidable manipulation of the samples in operation and other local factors may alter the concentrations somewhat we
believe the results are reliable, as the boron measurement methods have been tested previously. Our results motivate tocontinue developing BNCT for these difficult to treat tumors.

P310
Clinical Results of Modified Boron Neutron Capture Therapy for
Malignant Glioma
Shinji Kawabata1, Shin-Ichi Miyatake1, Ryou Hiramatsu1, Shiro Miyata1, Toshihiko Kuroiwa1,
Akira Maruhashi2, Koji Ono2, Mitsunori Kirihata3
1
Department of Neurosurgery, Oska Medical College, Osaka, Japan 2Particle Radiation Oncology, Kyoto University
Research Reactor Institute 3Department of Agriculture, Osaka Prefectural University

Poster Presentation (P)Boron neutron capture therapy (BNCT) is based upon the nuclear capture and fission reactions that occur when nonradioactive 10B is irradiated with low energy neutrons to produce high energy α particles (10B[n,α] 7 Li). In order for BNCT tobe successful a sufficient amount of 10B and neutrons must be delivered to the tumor. We utilized epithermal neutron fordeep penetration and simultaneous use of two dif ferent boron compounds, sodium borocaptate ( BSH ) andboronophenylalanine (BPA), with different accumulation mechanism. BNCT group including 21 newly histological confirmed
glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002 to 2006. Tenpatients were treated with BNCT only, and in the other 11 patients, 20 to 30 Gy fractionated external beam X-ray irradiation
was combined after BNCT. No chemotherapy was applied until tumor progression was observed. Treatments were welltolerated. Any kinds of acute systemic or local severe toxicity were not demonstrated. Median overall survival of the patientstreated by BNCT was 15.6 months with 2-years survival of 25%. Stratification by RPA criteria showed 6, 6, 8 and 1 patientsin class III to VI, respectively. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6
months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. BNCT
showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.

P311
BRAIN TUMORS BRACHYTHERAPY BY USING RIGID IR192 CATHETER
Arturas Sitkauskas1, Arvydas Burneckis2, Ieva Sataite1, Ingrida Sitkauskiene1, Egidijus
Jarzemskas1
Department Neurology and Neurosurgery, Vilnius University, Lithuania 2Vilnius University Oncology Institute1

AIM: To design a methodology of the insertion of the catheters into the tumor cavity. We used rigid Ir192 catheter with
VariSource system for high dose rate (HDR) brachytherapy in the different types brain tumours. Methods and Materials:
Over the year 12 patients were treated: six patients with recurrent glioblastoma multiforme (GBM), 2 patients with inoperative
anaplastic astrocitoma (AA), 3 patients with metastatic tumours (MTS) and 1 patient with recurrent meningioma. Minimum
three Ir192 catheters were placed in the resection cavity at the time of surgical resection. We used an original method toinsert and fix the catheters in the brain. For HDR brachitherapy we used VariSource workstation. Ir192 wire was delivered
into previously calculated and designed shape of tumour by VariSource system. Patients received radiation therapy: a meandose of 24Gy and a single local dose of 6Gy. Catheters were kept from 4 to 7 days depending the dose. All patients had
confirmed pathology of the tumour. The median Karnofsky performance status (KPS) was 80. Results: All patients were
followed-up over the year. At the time of analysis 3 (50%) patients with GBM, both with AA and one with MTS showed noradiological signs of tumour progression. Acute side effects were wound infection and liquorrhea in three cases. Two patients
got mild-nausea and/or headache. 2 incidents of symptomaticradiation necrosis with surrounding edema were observed.
Conclusions: We designed original safe system to use rigid IR192 wire for brachytherapy that allowed to create a precise
shape of radiation field and precisecalculated dose of radiation in functional sites of the brain. Treatment was generally welltolerated.

- 240 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP312
IMAGING FEATURES IN PARENCHYMAL LYMPHOMATOUS MASSES IN BRAIN: PRIMARY
CNS LYMPHOMA OR SYSTEMIC INVOLVEMENT OF THE BRAIN?
Melike Mut1, Kader Karli Oguz2, Selim Ayhan1, Figen Soylemezoglu3, Mustafa Berker1
Hacettepe University Department of Neurosurgery Ankara Turkey 2Hacettepe University Department of Radiology
Hacettepe University Department of Pathology

1
3

Purpose: We sought to determine whether there is any imaging features to enable differentiation of primary (group 1) andsecondary (Group 2) central nervous system (CNS) lymphoma. Material and methods: Computed tomography,
conventional MR imaging including Gadolinium enhanced series and diffusion-weighted MR imaging (DWI) findings of 19
patients, of which 12 were primary and 7 were secondary CNS lymphoma were re-evaluated. Pathological subtype of thetumours were diffuse large B cell in all primary and systemic tumours except 2 (1 lymphoblastic, 1 Burkitt type). Results: An
infiltrating lymphoma of butterfly pattern involvement were observed in three patients who had a history of extracranial
lymphomatous mass. None of the patients of group 1 had this type of involvement pattern.The lymphomatous lesions had
increased signal on DWI in 13 of 19 patients (8 in group 1, 5 in group 2) and decreased ADC values in all. There was nocorrelation between CT density values of the lesions and ADC values. In five patients (4 in Group 1) a very infiltrative pattern
was observed. In a background of profound vasogenic edema, scattered T2-hypointense nodules and stripes oriented
parallel to medullary veins suggesting perivascular infiltration were present. These T2-hypointense nodules and stripes
enhanced markedly on postcontrast T1-weighted series. In all four patients with infratentorial involvement either brain stem or
cerebellum were of primary CNS lymphoma group. The basal ganglia were involved in five patients in group 1 and none ingroup 2. Conclusion: Involvement of infratentorial structures and the basal ganglia, hemorrhagic lesions appreciated as T1
hyperintensity and T2-hypointense nodules and stripes probably showing perivenular infiltration and Gd enhancement along
the perivascular veins have been shown in primary CNS lymphomas. Bifrontal transcallosal lesions are suggestive of
secondary involvement of CNS by lymphoma.

P313
Long-term Survival in Primary CNS Lymphoma Treated by High-dose
Methotrexate Monochemotherapy: role of STAT6 Activation as
prognostic determinant
Seung-Ho Yang1, Kun Soo Lee2, Sang Won Lee1, Bum-Soo Kim3, So-Lyung Jung3, Sei-Chul Yoon4,
Youn-Soo Lee5, Yong-Kil Hong2
Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea 2Department of
Neurosurgery, Kangnam St. Mary’s Hospital, The Catholic University of Korea 3Department of Radiology, Kangnam St.
Mary’s Hospital, The Catholic University of Korea 4Department of Radiation Oncology, Kangnam St. Mary's Hospital,
The Catholic University of Korea 5Department of Hospital Pathology, St. Mary's Hospital, The Catholic University of
Korea
1

P314
Treatment for primary CNS lymphoma with high-dose MTX and salvage
therapy with ESHAP
Hiroshi Kanno1, Akimune Hayashi2, Hidemitsu Sato2, Kensuke Tateishi1, Nobutaka Kawahara1
1
Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan 2Kanagawa Cancer
CenterPrimary CNS lymphoma (PCNSL) is usually treated with high-dose methotrexate (MTX) which is mostly effective for PCNSL.
However, when use of high-dose MTX is repeated, MTX-resistant PCNSL gradually increases. In addition, high-dose MTX
therapy is not able to be applied for patients of poor renal function, and early recurrence after high-dose MTX therapy isoften encountered. Therefore, although the salvage therapy instead of high-dose MTX therapy is required, it has not been
established. Here, we show treatment outcome of high-dose MTX and salvage therapy with ESHAP (cisplatin, etoposide,
methypredonisolone and high-dose cytarabine). In 2002 to 2008, we have treated 30 patients bearing PCNSL (mean age,63.5 years; female, 8, male, 22) . Among them, 7 cases which showed good response for MTX were treated with high-dose
MTX, and the all cases have not recurred. Nineteen cases which lately showed resistance to MTX were initially treated withhigh-dose MTX but later with ESHAP, and among them 16 cases showed complete remission (CR) and progression freesurvival and the remaining cases showed partial remission. Three cases treated with ESHAP alone due to renal dysfunction
showed CR, but later the all cases recurred. In conclusions, high-dose MTX therapy is very useful for MTX-responsive
PCNSL, and ESHAP therapy is useful as a salvage therapy for the major of PCNSL that later show MTX-resistance.
Combination with high-dose MTX and salvage ESHAP therapy would overcome the problems high-dose MTX therapy andpossibly contribute to therapy for PCNSL.

- 241 -­­

Poster Presentation (P)We report a single-center experience of sixteen immunocompetent patients diagnosed with primary central nervous systemlymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy. MTX wasgiven at a dose of 8.0 g/m2 for induction and at a dose of 3.5-8.0 g/m2 for maintenance. There were eight complete
responses (CR), one partial response, one stable disease, and six patients whose tumors progressed in spite of thechemotherapy. At the final follow-up, five of 5 CRs were alive and well without radiotherapy, with a median follow-up of 26
months. Overall survival in 8 non-CRs treated with the subsequent radiotherapy was 36 months. In the immunohistochemical
study, STAT6 was positively expressed in eight out of 13 cases. They included all non-CRs and 2 CRs. This observationsuggests that STAT6 expression can be used as a prognostic determinant to the MTX chemotherapy.

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

P315
Treatment of Primary Central Nervous System Lymphoma withTemozolomide, Vincristine, Doxorubicin, Prednisone and Rituximab
Yi Lin1, Tao Jiang1, Baoshi Chen1
Glioma Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

1

Background: High-dose methotrexate is the mainstay of treatment for primary central nervous system lymphoma (PCNSL).
However, it can cause major toxicities. Materials and Methods: Four patients with PCNSL were treated with systemic
administration of temozolomide, vincristine, doxorubicin, prednisone and intravenous or intrathecal rituximab. Results:
Complete responses were achieved in all the patients. The mean follow up date of the patients is 18 months till 10/15/2008.
Grade I myelodepression was observed in all patients, but no other severe side effect manifested to date. The Karnofsky
Performance Scores were 100 throughout the treatment, and the MMSE scales did not decrease in all the patients during all
the cycles. Conclusions: The new combination has much less side effects compared to current standard therapy. Nearly
equal effect can be achieved. Further efforts are warranted to evaluate this regimen.

P316
Intravenous rituximab combined with temozolomide as a second line
therapy for CD20 positive primary central nervous system malignant
lymphomaAkira Matsuno1, Mineko Murakami1, Hiroshi Nakaguchi1, Mitsuyoshi Sasaki1, Takeshi Uno1,
Fuyuaki Ide1, Hideki Tanaka1, Takamitsu Fujimaki2
1
Department of Neurosurgery, Teikyo University Chiba Medical Center, Chiba, Japan 2Department of Neurosurgery,
Saitama Medical University, Saitama, Japan

Recently, the combination of rituximab and temozolomide is reported to have synergistic effect in the treatment of primarycentral nervous system (CNS) lymphomas (PCNSL). We experienced, as a second line therapy, combination of rituximab
and temozolomide in two patients with PCNSL. A 51-year-old man had a mass lesion in the left basal ganglia extending to
the left temporal lobe. The tumor was partially removed, and was diagnosed as malignant lymphoma, diffuse large B cell
type, CD20-immunopositive. High-dose methotrexate (MTX) chemotherapy followed by radiation therapy was carried out.
After 2 years, the tumor recurred, and the patient was started on oral temozolomide, 300 mg for 5 days per 4 weeks,
followed by intravenous administration of rituximab 540 mg. This combination of temozolomide and rituximab was repeatedfour times, and thereafter the patient was eight times on oral temozolomide, 300 mg for 5 days per 4 weeks. After thiscombination therapy, the tumor disappeared on MRI. A 65-year-old man had a mass lesion in the left basal ganglia
extending to the left temporal lobe. The tumor was partially removed, and was diagnosed as malignant lymphoma, diffuse
large B cell type, CD20-immunopositive. During high dose MTX chemotherapy, the tumor growth was progressive. Aftercompletion of radiotherapy, the patient was started on oral temozolomide, 300 mg for 5 days per 4 weeks, followed byintravenous administration of rituximab 540 mg. This combination of temozolomide and rituximab was repeated four times,
and thereafter the patient was eight times on oral temozolomide, 300 mg for 5 days per 4 weeks. After this combination
therapy, the tumor disappeared on MRI. The combination of temozolomide followed by rituximab demonstrated efficacy
against recurrent PCNSL and PCNSL resistant to high-dose MTX-based chemotherapy. This immunochemotherapy
combination can be a second line therapy for PCNSL.

Poster Presentation (P)P317
Maintenance therapy using rituximab for primary central nervous
system lymphoma
Tomotsugu Ichikawa1, Kazuhiko Kurozumi1, Isao Date1
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry andPharmaceutical Sciences, Okayama, Japan

1

Objective: The addition of high-dose methotrexate (MTX) to radiation has improved disease control and survival in patientswith primary central nervous system lymphoma (PCNSL). However, most of patients eventually relapse, and uncontrolled
PCNSL remains the primary cause of death. We designed a maintenance therapy using rituximab (anti-CD20 antibody) after
induction of complete remission to suppress recurrence. Methods: Preradiation chemotherapy consisted of MTX 3.5 g/m2
for a total of three to five doses. Cyclophosphamide, doxorubicin, vincristine and predonisone were given concomitantly witheach cycle of MTX. Chemotherapy was followed by 36-40 Gy of whole brain radiation. Older patients were given the optionof deferring radiation. Within 3 months after induction of complete remission, patients received multiple courses of rituximab;
each course consisted of rituximab 375mg/m2 given weekly for 4 consecutive weeks. Each course was repeated every 3months. Results: Nine patients with a median age of 65 years were included in this study between 2004 and 2008. Six
patients were older than 65 years-old. Median follow-up period was 21 months. All patients had histologic diagnosis ofdiffuse large B-cell lymphoma and positive immunohistochemical staining for anti-CD20 antibody. One patient died ofrecurrent disease, but 8 patients were alive (range, 18 to 38 months) and their Karnofsky performance status (KPS) were
kept higher than 80. Eight patients experienced recurrence. The median time-to-recurrence was 15 months (range 6-34
months). No toxicity was seen in association with rituximab. Conclusions: In this study, maintenance therapy with rituximab
did not suppress recurrence rate, however, it might prolong time-to-recurrence and suppress tumor growth rate, andeventually contribute to prolong overall survival. Complete remission was achieved in all patients who had recurrence. In
older patients, deferring whole brain radiation by retreatment with high-dose MTX and maintenance with rituximab did notcompromise overall survival but did reduce neurotoxicity.

- 242 -­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANP318
Diagnosis and Management of Spinal Extradural Non-Hodgkin
Lymphoma:Analysis of Three Cases and Review of the Literature
Chi-tun Tang1, Chung-Chiing Chia1, Hsin-I Ma1, Ming-Ying Liu1
The Department of Neurosurgery, National Defense Medical Center, Taipei, Taiwan

1

Non-Hodgkin lymphomas can involve central nervous system either primarily or secondarily. Spinal cord compression orneurolymphomatosis is reported in 0.1 to 10.2 % of patients, generally occurring late in the disease and often following an
aggressive course. We reported three cases with histologically confirmed spinal non-Hodgkin lymphoma. The three are offemale gender and median age at diagnosis is 54.3 years (range, 26-72 years); the time of symptom onset to the definite
diagnosis averaged 6.5 weeks. Two of them were of B-cell origin and presented with thoracic cord compression andprogressive paraplegia. The other sought treatment for axial neck pain and radiculopathy. Common neurologicalexaminations demonstrated a discrete sensory level, hyperreflexia and present pathological reflex(Hoffman or babinski sign).
Magnetic resonance imagings all revealed elongated intraspinal extradural tumors with good contrast enhancement but
absent bony destructions. Differential diagnoses include meningioma, schwannoma or meningeal infiltration by metastatic
tumors. All patients underwent a decompressive surgery(one corpectomy and two laminectomies) with instrumentation,
subtotal tumor resection and systemic chemotherapy with adjuvant spinal irradiation. Two are alive and well. A rapid
progressive spinal cord syndrome with consistent extradural compression and absent bony destruction on neuroimagings
should alert the possibility of spinal lymphoma. Surgery for this diagnosis followed by chemotherapy and spinal irradiation
could result in significant neurological improvement. The spinal non-Hodgkin lymphoma can be associated a favorable
outcome if diagnosed and treated early.

Poster Presentation (P)- 243 -­­

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

白ぺーじ- 244 -­­